PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Herman, J				Herman, J			Phantom limb: From medical knowledge to folk wisdom and back	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PAIN		Assia Community Hlth Ctr, IL-80200 Netivot, Israel		Herman, J (corresponding author), 24 Megadim St, IL-96185 Jerusalem, Israel.							BARON R, 1995, PAIN, V60, P223, DOI 10.1016/0304-3959(94)00188-K; BURR AR, 1929, W MITCHELL HIS LIFE; ENGEL GL, 1971, ANN INTERN MED, V74, P771, DOI 10.7326/0003-4819-74-5-771; Gallinek A, 1939, AM J PSYCHIAT, V96, P413, DOI 10.1176/ajp.96.2.413; HENDERSON WR, 1948, J NEUROL NEUROSUR PS, V11, P88, DOI 10.1136/jnnp.11.2.88; Herman J, 1997, SLEEP, V20, P577, DOI 10.1093/sleep/20.7.577; JENSEN TS, 1985, PAIN, V21, P267, DOI 10.1016/0304-3959(85)90090-9; JHEAD H, 1920, STUDIES NEUROLOGY, P606; KATZ J, 1992, J NEUROL NEUROSUR PS, V55, P811, DOI 10.1136/jnnp.55.9.811; KOLB LC, 1959, AM HDB PSYCHIAT, V66, P749; MELVILLE H, 1942, MOBY DICK, P435; MELZACK R, 1992, SCI AM, V266, P120, DOI 10.1038/scientificamerican0492-120; MICHAELS L, 1966, BRIT HEART J, V28, P258; Mitchell S. Weir, 1871, LIPPINCOTTS MAGAZINE, P563; MITCHELL SW, 1990, AUTOBIOGRAPHY QUACK, P115; Nikolajsen L, 1996, PAIN, V67, P69, DOI 10.1016/0304-3959(96)03080-1; PARE A, 1840, OEUVRES COMPLETES, V2, P221; Riddoch G, 1941, BRAIN, V64, P197, DOI 10.1093/brain/64.4.197; Romberg M.H., 1853, MANUAL NERVOUS DIS M, V1 and 2; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; SPRAGUE HB, 1966, ARCH ENVIRON HEALTH, V13, P4, DOI 10.1080/00039896.1966.10664500; STRONG JP, 1986, JAMA-J AM MED ASSOC, V256, P2863, DOI 10.1001/jama.256.20.2863; Taylor J, 1958, SELECTED WRITINGS JH; WASSERSTEIN AG, 1988, ANN INTERN MED, V109, P440, DOI 10.7326/0003-4819-109-5-440; 1993, COLUMBIA ENCY, P1975	25	14	14	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					76	78		10.7326/0003-4819-128-1-199801010-00029	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00029			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424997				2023-01-03	WOS:000071158000029
J	Tierney, JF; Stewart, LA; Parmar, MKB; Fletcher, CDM; Jones, G; Mosseri, V; Patel, M; deElvira, MCR; Souhami, RL; Sylvester, R; Tursz, T; Alvegard, TA; Sigurdsson, H; Antman, K; Bacchi, M; Baker, LH; Benjamin, RS; Brady, MF; Bramwell, V; Bui, BN; Edmonson, JH; Leyvraz, S; Omura, GA; Rouesse, J; Ryan, L; vanOosterom, AT; Yang, JC				Tierney, JF; Stewart, LA; Parmar, MKB; Fletcher, CDM; Jones, G; Mosseri, V; Patel, M; deElvira, MCR; Souhami, RL; Sylvester, R; Tursz, T; Alvegard, TA; Sigurdsson, H; Antman, K; Bacchi, M; Baker, LH; Benjamin, RS; Brady, MF; Bramwell, V; Bui, BN; Edmonson, JH; Leyvraz, S; Omura, GA; Rouesse, J; Ryan, L; vanOosterom, AT; Yang, JC			Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data	LANCET			English	Article							RANDOMIZED TRIAL; ONCOLOGY-GROUP; UTERINE SARCOMAS; ACTINOMYCIN-D; ADRIAMYCIN; DOXORUBICIN; CYCLOPHOSPHAMIDE; COMBINATION; EXTREMITIES; RECURRENCE	Background Individually, randomised trials have not shown conclusively whether adjuvant chemotherapy benefits adult patients with localised resectable soft-tissue sarcoma. Methods A quantitative meta-analysis of updated data from individual patients from all available randomised trials was carried out to assess whether adjuvant chemotherapy improves overall survival, recurrence-free survival, and local and distant recurrence-free intervals (RFI) and whether chemotherapy is differentially effective in patients defined by age, sex, disease status at randomisation, disease site, histology, grade, tumour size, extent of resection, and use of radiotherapy. Findings 1568 patients from 14 trials of doxorubicin-based adjuvant chemotherapy were included (median follow-up 9.4 years). Hazard ratios of 0.73 (95% CI 0.56-0.94, p=0.016) for local RFI, 0.70 (0.57-0.85, p=0.0003) for distant RFI, and 0.75 (0.64-0.87, p=0.0001) for overall recurrence-free survival, correspond to absolute benefits from adjuvant chemotherapy of 6% (95% CI 1-10), 10% (5-15), and 10% (5-15), respectively, at 10 years. For overall survival, the hazard ratio of 0.89 (0.76-1.03) was not significant (p=0.12), but represents an absolute benefit of 4% (1-9) at 10 years. These results were not affected by prespecified changes in the groups of patients analysed. There was no consistent evidence that the relative effect of adjuvant chemotherapy differed for any subgroup of patients for any endpoint. However, the best evidence of an effect of adjuvant chemotherapy for survival was seen in patients with sarcomas of the extremities. Interpretation The meta-analysis provides evidence that adjuvant doxorubicin-based chemotherapy significantly improves the time to local and distant recurrence and overall recurrence-free survival. There is a trend towards improved overall survival.	UNIV LUND HOSP, JUBILEUM INST, LUND, SWEDEN; COLUMBIA UNIV, COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; MASSACHUSETTS GEN HOSP, DANA FARBER CANC INST, BOSTON, MA 02114 USA; SIAK COORDINATING CTR, BERN, SWITZERLAND; UNIV MICHIGAN, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX USA; ROSWELL PK CANC INST, STAT OFF, GYNECOL ONCOL GRP, BUFFALO, NY USA; CHRISTIE HOSP, MANCHESTER, LANCS, ENGLAND; INST BERGONIE, BORDEAUX, FRANCE; MAYO CLIN, ROCHESTER, MN USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; HAMILTON REG CANC CTR, HAMILTON, ON L8V 1C3, CANADA; UNIV LAUSANNE HOSP, LAUSANNE, SWITZERLAND; SWISS GRP CLIN CANC RES, BERN, SWITZERLAND; INST CURIE, DEPT BIOSTAT, PARIS, FRANCE; UNIV ALABAMA, BIRMINGHAM, AL USA; CTR RENE HUGUENIN, ST CLOUD, FRANCE; UCL, EUROPEAN GRP BLOOD & MARROW TRANSPLANTAT, LONDON, ENGLAND; DANA FARBER CANC INST, STAT OFF, EASTERN COOPERAT ONCOL GRP, BOSTON, MA 02115 USA; UCL, SCH MED, DEPT ONCOL, LONDON W1N 8AA, ENGLAND; EORTC DATA CTR, METAANAL UNIT, BRUSSELS, BELGIUM; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; UNIV ZIEKENHUIZEN, DEPT ONCOL, LOUVAIN, BELGIUM; NCI, SURG BRANCH, BETHESDA, MD 20892 USA	Lund University; Skane University Hospital; Columbia University; NewYork-Presbyterian Hospital; Harvard University; Dana-Farber Cancer Institute; Massachusetts General Hospital; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; Roswell Park Cancer Institute; Christie NHS Foundation Trust; Christie Hospital; UNICANCER; Institut Bergonie; Mayo Clinic; Harvard University; Brigham & Women's Hospital; IRCCS Istituto Ortopedico Rizzoli; McMaster University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Group for Clinical Cancer Research (SAKK); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Alabama System; University of Alabama Birmingham; Rene Huguenin Hospital; University of London; University College London; Harvard University; Dana-Farber Cancer Institute; University of London; University College London; UCL Medical School; European Organisation for Research & Treatment of Cancer; UNICANCER; Gustave Roussy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			; Ryan, Louise/A-4562-2009	Stewart, Lesley/0000-0003-0287-4724; Tierney, Jayne/0000-0002-4734-3014; Ryan, Louise/0000-0001-5957-2490				ALVEGARD TA, 1989, J CLIN ONCOL, V7, P1504, DOI 10.1200/JCO.1989.7.10.1504; ANTMAN K, 1984, J CLIN ONCOL, V2, P601, DOI 10.1200/JCO.1984.2.6.601; BAKER L H, 1988, P130; BAKER LH, 1987, J CLIN ONCOL, V5, P851, DOI 10.1200/JCO.1987.5.6.851; BENJAMIN R S, 1975, Medical and Pediatric Oncology, V1, P63, DOI 10.1002/mpo.2950010109; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BORDEN EC, 1990, CANCER, V66, P862, DOI 10.1002/1097-0142(19900901)66:5<862::AID-CNCR2820660509>3.0.CO;2-R; BRAMWELL V, 1994, J CLIN ONCOL, V12, P1137, DOI 10.1200/JCO.1994.12.6.1137; CHANG AE, 1988, J CLIN ONCOL, V6, P1491, DOI 10.1200/JCO.1988.6.9.1491; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; Delaney T F, 1991, Oncology (Williston Park), V5, P105; Dickersin K, 1995, SYSTEMATIC REV, P17; Edmonson, 1985, CANCER TREAT S, V3, P89; EDMONSON JH, 1984, J CLIN ONCOL, V2, P1390, DOI 10.1200/JCO.1984.2.12.1390; EILBER FR, 1988, AM J CLIN ONCOL-CANC, V11, P39, DOI 10.1097/00000421-198802000-00009; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GHERLINZONI F, 1986, J CLIN ONCOL, V4, P552, DOI 10.1200/JCO.1986.4.4.552; GLENN J, 1985, SURGERY, V97, P316; GLENN J, 1985, CANCER, V55, P1206, DOI 10.1002/1097-0142(19850315)55:6<1206::AID-CNCR2820550612>3.0.CO;2-E; GOTTLIEB JA, 1975, CANCER CHEMOTH REP 3, V6, P271; Jones G.W., 1991, CLIN INVEST MED S19, V14, pA772; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINSELLA TJ, 1988, J CLIN ONCOL, V6, P18, DOI 10.1200/JCO.1988.6.1.18; LERNER HJ, 1987, J CLIN ONCOL, V5, P613, DOI 10.1200/JCO.1987.5.4.613; MCGRATH PC, 1995, CLIN PLAST SURG, V22, P21; MERTENS WC, 1995, HEMATOL ONCOL CLIN N, V9, P801, DOI 10.1016/S0889-8588(18)30072-8; OMURA GA, 1985, J CLIN ONCOL, V3, P1240, DOI 10.1200/JCO.1985.3.9.1240; PICCI P, 1988, P144; PINEDO HM, 1986, RADIOTHER ONCOL, V5, P193, DOI 10.1016/S0167-8140(86)80049-4; PIVER MS, 1988, J SURG ONCOL, V38, P233, DOI 10.1002/jso.2930380406; Ravaud A, 1990, ADJUVANT THERAPY CAN, P556; ROSENBERG SA, 1983, CANCER-AM CANCER SOC, V52, P424, DOI 10.1002/1097-0142(19830801)52:3<424::AID-CNCR2820520307>3.0.CO;2-8; Salmon SE., 1987, ADJUVANT THERAPY CAN, P735; Salmon SE., 1990, ADJUVANT THERAPY CAN, P529; SCHOENFELD DA, 1982, CANCER, V50, P2757, DOI 10.1002/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO;2-J; TIERNEY JF, 1995, BRIT J CANCER, V72, P469, DOI 10.1038/bjc.1995.357; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZALUPSKI MM, 1993, ADJUVANT THERAPY CAN, V7, P385	38	691	718	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1647	1654						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400508				2023-01-03	WOS:A1997YK21100008
J	Grotta, J				Grotta, J			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA - The best current option for most patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TISSUE-PLASMINOGEN-ACTIVATOR; URGENT THERAPY; MINUTES				Grotta, J (corresponding author), UNIV TEXAS,SCH MED,DEPT NEUROL,6431 FANNIN,SUITE 7044,HOUSTON,TX 77030, USA.		Grotta, James/AAH-7423-2021					Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; [Anonymous], 1996, NEUROLOGY, V47, P835; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1993, THROMBOLYTIC THERAPY, V2, P59; DONMAN GA, 1995, LANCET, V345, P578; *EUR COOP AC STROK, 1995, JAMA-J AM MED ASSOC, V274, P1017; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V335, P145; *MULT AC STROK TRI, 1995, LANCET, V346, P1509; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581	13	42	42	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1310	1313						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345085				2023-01-03	WOS:A1997YC92000013
J	Clark, F; Azen, SP; Zemke, R; Jackson, J; Carlson, M; Mandel, D; Hay, J; Josephson, K; Cherry, B; Hessel, C; Palmer, J; Lipson, L				Clark, F; Azen, SP; Zemke, R; Jackson, J; Carlson, M; Mandel, D; Hay, J; Josephson, K; Cherry, B; Hessel, C; Palmer, J; Lipson, L			Occupational therapy for independent-living older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SURVEY SF-36; QUALITY-OF-LIFE; SATISFACTION; PERFORMANCE; POPULATION; MACARTHUR; VALIDITY; OUTCOMES; SCIENCE; SERVICE	Context.-Preventive health programs may mitigate against the health risks of older adulthood. Objective.-To evaluate the effectiveness of preventive occupational therapy (OT) services specifically tailored for multiethnic, independent-living older adults. Design.-A randomized controlled trial. Setting.-Two government subsidized apartment complexes for independent-living older adults. Subjects.-A total of 361 culturally diverse volunteers aged 60 years or older. Intervention.-An OT group, a social activity control group, and a nontreatment control group, The period of treatment was 9 months. Main Outcome Measures.-A battery of self-administered questionnaires designed to measure physical and social function, self-rated health, life satisfaction, and depressive symptoms, Results.-Benefit attributable to OT treatment was found for the quality of interaction scale on the Functional Status Questionnaire (P=.03), Life Satisfaction Index-Z (P=.03), Medical Outcomes Study Health Perception Survey (P=.05), and for 7 of 8 scales on the RAND 36-item Health Status Survey, Short Form: bodily pain (P=.03), physical functioning (P=.008), role limitations attributable to health problems (P=.02), vitality (P=.004), social functioning (P=.05), role limitations attributable to emotional problems (P=.05), and general mental health (P=.02). Conclusions.-Significant benefits for the OT preventive treatment group were found across various health, function, and quality-of-life domains. Because the control groups tended to decline over the study interval, our results suggest that preventive health programs based on OT may mitigate against the health risks of older adulthood.	UNIV SO CALIF,SCH MED,STAT CONSULTAT & RES CTR,DEPT PREVENT MED,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT ECON & POLICY,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH MED,DEPT MED,DIV GERIATR MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California	Clark, F (corresponding author), UNIV SO CALIF,DEPT OCCUPAT SCI & OCCUPAT THERAPY,1540 ALCAZAR,CHP 133,LOS ANGELES,CA 90033, USA.			Jackson, Jeanne/0000-0001-5290-7382	NATIONAL INSTITUTE ON AGING [R01AG011810] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11810] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACHELDER JM, 1993, AM J OCCUP THER, V48, P73; BERKMAN LF, 1993, J CLIN EPIDEMIOL, V46, P1129, DOI 10.1016/0895-4356(93)90112-E; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; Carlson M, 1996, AM J OCCUP THER, V50, P89, DOI 10.5014/ajot.50.2.89; CLARK F, 1993, AM J OCCUP THER, V47, P1067, DOI 10.5014/ajot.47.12.1067; Clark F, 1996, AM J OCCUP THER, V50, P99, DOI 10.5014/ajot.50.2.99; Clark F., 1993, WILLARD SPACKMANS OC, P44; CLARK FA, 1991, AM J OCCUP THER, V45, P300, DOI 10.5014/ajot.45.4.300; Cohen J, 1987, STAT POWER ANAL BEHA; CRIMMINS EM, 1994, DEMOGRAPHY, V31, P159, DOI 10.2307/2061913; EBRAHIM S, 1995, SOC SCI MED, V41, P1383, DOI 10.1016/0277-9536(95)00116-O; Fisher BJ, 1995, INT J AGING HUM DEV, V41, P239, DOI 10.2190/HA9X-H48D-9GYB-85XW; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Gatz M, 1995, EMERGING ISSUES IN MENTAL HEALTH AND AGING, pR15; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HOPKINS HL, 1993, WILLARD SPACKMANS OC; Jackson J, 1996, OCCUPATIONAL SCI EVO; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; LARSON KO, 1996, ROTE ROLE OCCUPATION; LARUE A, 1979, J GERONTOL, V34, P687, DOI 10.1093/geronj/34.5.687; LEVINE RE, 1992, AM J OCCUP THER, V47, P147; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MURRELL SA, 1989, PSYCHOL AGING, V4, P166; ORY MG, 1994, SOC INDIC RES, V33, P89, DOI 10.1007/BF01078959; Pearlin LI, 1995, EMERGING ISSUES IN MENTAL HEALTH AND AGING, P97, DOI 10.1037/10179-004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Townsend E, 1996, OCCUP THER J RES, V16, P179, DOI 10.1177/153944929601600303; U. S. Bureau of the Census, 1996, STAT ABSTR US; *US BUR CENS, 1992, PUBL US BUR CENS; VERBRUGGE LM, 1993, SOC SCI MED, V38, P1; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465; YERXA E J, 1989, Occupational Therapy in Health Care, V6, P1; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zemke R., 1996, OCCUPATIONAL SCI EVO; [No title captured]	42	395	398	0	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1321	1326		10.1001/jama.278.16.1321	http://dx.doi.org/10.1001/jama.278.16.1321			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343462				2023-01-03	WOS:A1997YA90500032
J	Elliot, MJS				Elliot, MJS			Lower sodium for all	LANCET			English	Editorial Material							BLOOD-PRESSURE; HYPERTENSION; POPULATIONS; POTASSIUM; REDUCTION; SALT				Elliot, MJS (corresponding author), IMPERIAL COLL SCH MED,DEPT EPIDEMIOL & PUBL HLTH,ST MARYS CAMPUS,LONDON W2 1PG,ENGLAND.							APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; Cutler Jeffrey A., 1997, American Journal of Clinical Nutrition, V65, p643S, DOI 10.1093/ajcn/65.2.643S; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; GELEIJNSE JM, 1990, BMJ-BRIT MED J, V300, P899, DOI 10.1136/bmj.300.6729.899; Geleijnse JM, 1997, HYPERTENSION, V29, P913, DOI 10.1161/01.HYP.29.4.913; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; *INT COOP RES GROU, 1988, BRIT MED J, V297, P319; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; WHELTON PK, 1996, CIRCULATION S1, V94, P178	10	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					825	826		10.1016/S0140-6736(05)62026-0	http://dx.doi.org/10.1016/S0140-6736(05)62026-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310596				2023-01-03	WOS:A1997XX40100004
J	Levi, F; Zidani, R; Misset, JL				Levi, F; Zidani, R; Misset, JL			Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer	LANCET			English	Article							QUALITY-OF-LIFE; LIVER METASTASES; PHASE-II; INFUSION FLUOROURACIL; CIRCADIAN-RHYTHM; VENOUS INFUSION; BONE-MARROW; CHEMOTHERAPY; 5-FLUOROURACIL; MODULATION	Background The efficacy of chemotherapy may be affected by circadian rhythms. Therefore, we tested chronomodulated infusion (administered to coincide with relevant circadian rhythms) of oxaliplatin, fluorouracil, and folinic acid compared with a constant-rate infusion method. The combination of three drugs was delivered for 5-day courses with 16-day intervals. Methods We expected chronotherapy to increase objective response rate by 20% compared with constant-rate infusion. We tested this effect in a randomised multicentre trial involving patients with previously untreated metastases from colorectal cancer who were enrolled at nine institutions in three countries. 93 patients were asssigned chronotherapy and 93 were assigned constant-rate infusion via multichannel programmable ambulatory pumps. The trial was interrupted when a significant difference in main outcome was reached. All data were analysed by intention to treat. Findings On enrolment, we found significant imbalances in two characteristics-abdominal gland or bone metastases (constant-rate infusion two patients, chronotherapy ten patients) and relapse from surgically treated metastases (constant-rate infusion seven patients, chronotherapy 22 patients). An objective response was obtained in 47 (51%) of the chronotherapy group, and in 27 (29%) of the constant-rate group (difference 21.5% [95% CI 13.7-31.2], p=0003). Chronotherapy reduced five-fold the rate of severe mucosal toxicity (14% vs 76%, p<0.0001) and halved that of functional impairment from peripheral sensitive neuropathy (16% vs 31%, difference 15.0% [9.5-25.7], p<0.01). Median time to treatment failure was 6.4 months on chronotherapy and 4.9 months on constant-rate infusion (p=0.006), and 24% of the patients from the constant-rate infusion group received chronotherapy after failure. With a minimum follow-up of 3 years, median survival times and 3-year survival were similar in both groups (15.9 vs 16.9 months and 22% vs 21%, respectively). Interpretation Chronotherapy was significantly less toxic and more effective than constant-rate infusion. The results support the concept of temporal selectivity of cancer chemotherapy.			Levi, F (corresponding author), HOP PAUL BROUSSE,14 AVE PAUL VAILLANT COUTURIER,F-94807 VILLEJUIF,FRANCE.							ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; BertheaultCvitkovic F, 1996, J CLIN ONCOL, V14, P2950, DOI 10.1200/JCO.1996.14.11.2950; Bismuth H, 1996, ANN SURG, V224, P509, DOI 10.1097/00000658-199610000-00009; BOUGHATTAS NA, 1989, CANCER RES, V49, P3362; BUYSE M, IN PRESS BIOMETRICS; CAUSSANEL JP, 1990, J NATL CANCER I, V82, P1046, DOI 10.1093/jnci/82.12.1046; Cohen AM, 1993, CANC PRINCIPLES PRAC, P929; GLIMELIUS B, 1994, CANCER, V73, P556, DOI 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8; Hansen RM, 1996, J NATL CANCER I, V88, P668, DOI 10.1093/jnci/88.10.668; HARRIS BE, 1990, CANCER RES, V50, P197; HILL M, 1995, J CLIN ONCOL, V13, P2317, DOI 10.1200/JCO.1995.13.9.2317; HRYNIUK WM, 1987, SEMIN ONCOL, V14, P3; LEICHMAN CG, 1995, J CLIN ONCOL, V13, P1303, DOI 10.1200/JCO.1995.13.6.1303; LEVI F, 1992, CANCER, V69, P893, DOI 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X; LEVI F, 1993, EUR J CANCER, V29A, P1280, DOI 10.1016/0959-8049(93)90073-O; Levi F, 1997, HDB EXPT PHARM PHYSL, P299; LEVI F, 1997, P 33 ANN M AM SOC CL; LEVI FA, 1994, JNCI-J NATL CANCER I, V86, P1608, DOI 10.1093/jnci/86.21.1608; Levi Francis, 1996, Current Opinion in Oncology, V8, P334; Machover D, 1996, ANN ONCOL, V7, P95; METZGER G, 1994, CLIN PHARMACOL THER, V56, P190, DOI 10.1038/clpt.1994.123; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SMAALAND R, 1991, BLOOD, V77, P2603; SMAALAND R, 1992, BRIT J CANCER, V66, P39, DOI 10.1038/bjc.1992.213; STANGL R, 1994, LANCET, V343, P1405, DOI 10.1016/S0140-6736(94)92529-1	28	517	546	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					681	686		10.1016/S0140-6736(97)03358-8	http://dx.doi.org/10.1016/S0140-6736(97)03358-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291901				2023-01-03	WOS:A1997XU97700007
J	Kaplan, LD; Straus, DJ; Testa, MA; VonRoenn, J; Dezube, BJ; Cooley, TP; Herndier, B; Northfelt, DW; Huang, J; Tulpule, A; Levine, AM				Kaplan, LD; Straus, DJ; Testa, MA; VonRoenn, J; Dezube, BJ; Cooley, TP; Herndier, B; Northfelt, DW; Huang, J; Tulpule, A; Levine, AM			Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HOMOSEXUAL MEN; SYNDROME AIDS; REGIMEN CHOP; TRIAL; EXPERIENCE; NEOPLASIA	Background Reduced doses of cytotoxic chemotherapy or standard-dose therapy plus a myeloid colony-stimulating factor decreases hematologic toxicity and its complications in patients with non-Hodgkin's lymphoma associated with infection with the human immunodeficiency virus (HIV). However, the effect of reducing the doses of cytotoxic chemotherapeutic agents on clinical outcome is not known. Methods We randomly assigned 198 HIV-seropositive patients with previously untreated, aggressive non-Hodgkin's lymphoma to receive standard-dose therapy with methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) along with granulocyte-macrophage colony-stimulating factor (GM-CSF; n=94) or reduced-dose m-BACOD with GM-CSF administered only as indicated (n=98). Results A complete response was achieved in 39 of the 94 assessable patients assigned to low-dose therapy (41 percent) and in 42 of the 81 assessable patients assigned to standard-dose therapy (52 percent, P=0.56). There were no significant differences in overall or disease-free survival; median survival times were 35 weeks for patients receiving low-dose therapy and 31 weeks for those receiving standard-dose therapy (risk ratio for death in the standard-dose group, 1.17; 95 percent confidence interval, 0.84 to 1.63; P=0.25). Toxic effects of chemotherapy rated grade 3 or higher occurred in 66 of 94 patients assigned to standard-dose therapy (70 percent) and 50 of 98 patients assigned to low-dose treatment (51 percent, P=0.008). Hematologic toxicity accounted for the difference. Conclusions As compared with treatment with standard doses of cytotoxic chemotherapy (m-BACOD), reduced doses caused significantly fewer hematologic toxic effects yet had similar efficacy in patients with HIV-related lymphoma. Dose-modified chemotherapy should be considered for most HIV-infected patients with lymphoma. (C) 1997, Massachusetts Medical Society.	SAN FRANCISCO GEN HOSP, DEPT PATHOL, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV MED COLL, NEW YORK, NY USA; HARVARD UNIV, SCH PUBL HLTH, STAT & DATA ANAL CTR, BOSTON, MA 02115 USA; NORTHWESTERN UNIV, DEPT HEMATOL ONCOL, CHICAGO, IL 60611 USA; BETH ISRAEL DEACONESS MED CTR, BOSTON, MA USA; BOSTON MED CTR, DEPT MED, SECT HEMATOL, BOSTON, MA USA; BOSTON MED CTR, DEPT MED, SECT ONCOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; UNIV SO CALIF, NORRIS CANC HOSP, SCH MED, LOS ANGELES, CA 90089 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Harvard T.H. Chan School of Public Health; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Boston Medical Center; Boston Medical Center; Boston University; University of Southern California	Kaplan, LD (corresponding author), SAN FRANCISCO GEN HOSP, AIDS PROGRAM,DEPT MED,DIV ONCOL,WARD 84, 995 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.		Testa, Marianna/L-9768-2019	Cooley, Timothy/0000-0002-3373-1569	NCRR NIH HHS [GCRC-RR00533-28] Funding Source: Medline; NIAID NIH HHS [UO1-AI-27573, CFAR-P30 AI 27763] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, R01AI027573] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GILL PS, 1987, J CLIN ONCOL, V5, P1322, DOI 10.1200/JCO.1987.5.9.1322; GISSELBRECHT C, 1993, AM J MED, V95, P188, DOI 10.1016/0002-9343(93)90259-R; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; KAPLAN L D, 1989, Journal of the American Medical Association, V261, P719, DOI 10.1001/jama.261.5.719; KAPLAN LD, 1995, BLOOD, V85, P1727, DOI 10.1182/blood.V85.7.1727.bloodjournal8571727; KAPLAN LD, 1991, J CLIN ONCOL, V9, P929, DOI 10.1200/JCO.1991.9.6.929; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LEVINE AM, 1984, ANN INTERN MED, V100, P7, DOI 10.7326/0003-4819-100-1-7; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE AM, 1991, JAMA-J AM MED ASSOC, V266, P84, DOI 10.1001/jama.266.1.84; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; SERRAINO D, 1992, BRIT J CANCER, V66, P912, DOI 10.1038/bjc.1992.384; TESTA MA, 1995, AIDS CLIN TRIALS, P213; Vaccher E, 1996, J CLIN ONCOL, V14, P2217, DOI 10.1200/JCO.1996.14.8.2217; WALSH C, 1993, J ACQ IMMUN DEF SYND, V6, P265; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904	18	241	248	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1641	1648		10.1056/NEJM199706053362304	http://dx.doi.org/10.1056/NEJM199706053362304			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171066	Bronze			2023-01-03	WOS:A1997XC08600004
J	Lew, DP; Waldvogel, FA				Lew, DP; Waldvogel, FA			Osteomyelitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FOREIGN-BODY INFECTION; STAPHYLOCOCCUS-AUREUS; THERAPEUTIC CONSIDERATIONS; CLINICAL FEATURES; DIABETIC-PATIENTS; TOTAL HIP; BONE; FOOT; OSTEOPOROSIS; REPLACEMENT		UNIV HOSP GENEVA,DEPT MED,MED CLIN 2,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva	Lew, DP (corresponding author), UNIV HOSP GENEVA,DEPT MED,DIV INFECT DIS,24 RUE MICHELI DU CREST,CH-1211 GENEVA 14,SWITZERLAND.							Belmatoug N, 1996, J INFECT DIS, V174, P414, DOI 10.1093/infdis/174.2.414; Boxma H, 1996, LANCET, V347, P1133, DOI 10.1016/S0140-6736(96)90606-6; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; Charnley J, 1972, Clin Orthop Relat Res, V87, P167, DOI 10.1097/00003086-197209000-00020; CHUARD C, 1991, J INFECT DIS, V163, P1369; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; D'Hoore K, 1993, Acta Orthop Belg, V59, P306; DAROUICHE RO, 1994, ARCH INTERN MED, V154, P753, DOI 10.1001/archinte.154.7.753; DELLINGER EP, 1988, ARCH SURG-CHICAGO, V123, P333; DRANCOURT M, 1993, ANTIMICROB AGENTS CH, V37, P1214, DOI 10.1128/AAC.37.6.1214; ECKARDT JJ, 1994, CLIN ORTHOP RELAT R, V298, P229; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; FISCHER B, 1996, J ORTHOPAED RES, V14, P1914; GENTRY LO, 1991, ANN INTERN MED, V114, P986, DOI 10.7326/0003-4819-114-11-986; GOLD RH, 1991, AM J ROENTGENOL, V157, P365, DOI 10.2214/ajr.157.2.1853823; GOLD RH, 1995, SKELETAL RADIOL, V24, P563; GORDON L, 1988, J BONE JOINT SURG AM, V70A, P377, DOI 10.2106/00004623-198870030-00009; GRANINGER W, 1995, EUR J CLIN MICROBIOL, V14, P643, DOI 10.1007/BF01690746; GRAYSON ML, 1995, JAMA-J AM MED ASSOC, V273, P721, DOI 10.1001/jama.273.9.721; GREEN SA, 1991, ORTHOP CLIN N AM, V22, P515; Greene C, 1996, MICROBIOL-UK, V142, P2153, DOI 10.1099/13500872-142-8-2153; GRMEK M, 1983, MALADIES AUBE CIVILI, P190; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HERMANN M, 1988, J INFECT DIS, V158, P693; HILL C, 1981, LANCET, V1, P795; HOWARD CB, 1994, J BONE JOINT SURG BR, V76B, P311, DOI 10.1302/0301-620X.76B2.8113300; Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075; Jauregui, 1995, DIAGNOSIS MANAGEMENT; Klenerman L, 1991, Acta Orthop Belg, V57, P19; Lew D P, 1995, Drugs, V49 Suppl 2, P100; LEW DP, 1996, HOSP EPIDEMIOLOGY IN, P731; LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10; MACKOWIAK PA, 1978, JAMA-J AM MED ASSOC, V239, P2772, DOI 10.1001/jama.239.26.2772; MADER JT, 1992, CLIN INFECT DIS, V15, pS155, DOI 10.1093/clind/15.Supplement_1.S155; MANION SS, 1995, DIAGNOSIS MANAGEMENT, P325; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MATHES SJ, 1982, NEW ENGL J MED, V306, P294, DOI 10.1056/NEJM198202043060509; MORRISON WB, 1993, RADIOLOGY, V189, P251, DOI 10.1148/radiology.189.1.8204132; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; NELSON CL, 1993, CLIN ORTHOP RELAT R, V295, P96; NELSON JD, 1996, CLIN TOPICS INFECT D, V4, P64; NEWMAN LG, 1992, DIABETES CARE, V15, P1527, DOI 10.2337/diacare.15.11.1527; NORDEN C, 1992, CLIN INFECT DIS, V15, pS177, DOI 10.1093/clind/15.Supplement_1.S177; NORDEN CW, 1988, REV INFECT DIS, V10, P103; NORDEN CW, 1991, REV INFECT DIS, V13, pS842; OYEN WJG, 1990, J NUCL MED, V31, P403; PAPINEAU LJ, 1979, INT ORTHOP, V3, P165; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATZAKIS MJ, 1974, J BONE JOINT SURG AM, VA 56, P532, DOI 10.2106/00004623-197456030-00010; PIROFSKY JG, 1993, SPINE, V18, P1926, DOI 10.1097/00007632-199310000-00036; PROCTOR RA, 1995, CLIN INFECT DIS, V20, P95, DOI 10.1093/clinids/20.1.95; REESE JH, 1995, DIAGNOSIS MANAGEMENT, P425; SCHAAD HJ, 1994, ANTIMICROB AGENTS CH, V38, P1703, DOI 10.1128/AAC.38.8.1703; SOWA DT, 1987, ORTHOP CLIN N AM, V18, P257; TANG C, 1993, J INFECTION, V26, P89, DOI 10.1016/0163-4453(93)97064-5; TORDA AJ, 1995, CLIN INFECT DIS, V20, P320, DOI 10.1093/clinids/20.2.320; TUMEH SS, 1991, RHEUM DIS CLIN N AM, V17, P559; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406; WALDVOGEL FA, 1980, NEW ENGL J MED, V303, P360, DOI 10.1056/NEJM198008143030703; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P260, DOI 10.1056/NEJM197001292820507; WEILAND AJ, 1984, J BONE JOINT SURG AM, V66A, P181, DOI 10.2106/00004623-198466020-00004; WIDMER AF, 1992, CLIN INFECT DIS, V14, P1251, DOI 10.1093/clinids/14.6.1251; ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305	64	478	502	1	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					999	1007		10.1056/NEJM199704033361406	http://dx.doi.org/10.1056/NEJM199704033361406			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077380				2023-01-03	WOS:A1997WR38500006
J	Aggeli, A; Bell, M; Boden, N; Keen, JN; Knowles, PF; McLeish, TCB; Pitkeathly, M; Radford, SE				Aggeli, A; Bell, M; Boden, N; Keen, JN; Knowles, PF; McLeish, TCB; Pitkeathly, M; Radford, SE			Responsive gels formed by the spontaneous self-assembly of peptides into polymeric beta-sheet tapes	NATURE			English	Article							SUPRAMOLECULAR CHEMISTRY; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; PROTEIN; STABILITY; FILAMENTS; DOMAIN; ALPHA	Molecular self-assembly is becoming an increasingly popular route to new supramolecular structures and molecular materials(1-7). The inspiration for such structures is commonly derived from self-assembling systems in biology. Here we show that a biological motif, the peptide beta-sheet, can be exploited in designed oligopeptides that self-assemble into polymeric tapes and with potentially useful mechanical properties. We describe the construction of oligopeptides, rationally designed or based on segments of native proteins, that aggregate in suitable solvents into long, semi-flexible beta-sheet tapes. These become entangled even at low volume fractions to form gels whose viscoelastic properties can be controlled by chemical (pH) or physical (shear) influences. We suggest that it should be possible to engineer a wide range of properties in these gels by appropriate choice of the peptide primary structure.	UNIV LEEDS,CTR SELF ORGANISING MOL SYST,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,SCH CHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT PHYS,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND	University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Oxford; University of Oxford				McLeish, Tom/0000-0002-2025-0299; Radford, Sheena/0000-0002-3079-8039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aggeli A, 1996, BIOCHEMISTRY-US, V35, P16213, DOI 10.1021/bi960891g; BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; Berg RH, 1996, NATURE, V383, P505, DOI 10.1038/383505a0; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; CHIRGADZE YN, 1973, BIOPOLYMERS, V12, P1337, DOI 10.1002/bip.1973.360120610; Choo DW, 1996, MACROMOLECULES, V29, P355, DOI 10.1021/ma950703e; CLARK AH, 1987, ADV POLYM SCI, V83, P57; CLAUSEN TM, 1992, J PHYS CHEM-US, V96, P474, DOI 10.1021/j100180a086; Doi M., 1986, THEORY POLYM DYNAMIC; Ferry JD, 1970, J ELECTROCHEM SOC; GAY NJ, 1991, FEBS LETT, V291, P87, DOI 10.1016/0014-5793(91)81110-T; GEISLER N, 1993, J STRUCT BIOL, V110, P205, DOI 10.1006/jsbi.1993.1023; GUO H, 1994, J PHYS CHEM-US, V98, P7104, DOI 10.1021/j100080a002; HANABUSA K, 1994, J CHEM SOC CHEM COMM, P2683, DOI 10.1039/c39940002683; KAMLET MJ, 1983, J ORG CHEM, V48, P2877, DOI 10.1021/jo00165a018; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LOKEY RS, 1995, NATURE, V375, P303; Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Muller A, 1996, NATURE, V383, P296, DOI 10.1038/383296a0; Nyrkova IA, 1996, J PHYS II, V6, P1411, DOI 10.1051/jp2:1996139; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; STOCK HT, 1995, J CHEM SOC CHEM COMM, P2063, DOI 10.1039/c39950002063; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TAKUMI T, 1993, NEWS PHYSIOL SCI, V8, P175; Vegners R, 1995, J Pept Sci, V1, P371, DOI 10.1002/psc.310010604; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334	33	750	777	5	299	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					259	262		10.1038/386259a0	http://dx.doi.org/10.1038/386259a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069283				2023-01-03	WOS:A1997WP00300045
J	Lindner, KH; Dirks, B; Strohmenger, HU; Prengel, AW; Lindner, IM; Lurie, KG				Lindner, KH; Dirks, B; Strohmenger, HU; Prengel, AW; Lindner, IM; Lurie, KG			Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation	LANCET			English	Article							HIGH-DOSE EPINEPHRINE; ORGAN BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST	Background Studies in animals have suggested that intravenous vasopressin is associated with better vital-organ perfusion and resuscitation rates than is epinephrine in the treatment of cardiac arrest. We did a randomised comparison of vasopressin with epinephrine in patients with ventricular fibrillation in out-of-hospital cardiac arrest. Methods 40 patients in ventricular fibrillation resistant to electrical defibrillation were prospectively and randomly assigned epinephrine (1 mg intravenously; n=20) or vasopressin (40 U intravenously; n=20) as primary drug therapy for cardiac arrest, The endpoints of this double-blind study were successful resuscitation (hospital admission), survival for 24 h, survival to hospital discharge, and neurological outcome (Glasgow coma scale). Analyses were by intention to treat, Findings Seven (35%) patients in the epinephrine group and 14 (70%) in the vasopressin group survived to hospital admission (p=0.06). At 24 h, four (20%) epinephrine-treated patients and 12 (60%) vasopressin-treated patients were alive (p=0.02). Three (15%) patients in the epinephrine group and eight (40%) in the vasopressin group survived to hospital discharge (p=0.16). Neurological outcomes were similar (mean Glasgow coma score at hospital discharge 10.7 [SE 3.8] vs 11.7 [1.6], p=0.78). Interpretation In this preliminary study, a significantly larger proportion of patients treated with vasopressin than of those treated with epinephrine were resuscitated successfully from out-of-hospital ventricular fibrillation and survived for 24 h, Based upon these findings, larger multicentre studies of vasopressin in the treatment of cardiac arrest are needed.	UNIV ULM,DEPT ANESTHESIOL & CRIT CARE MED,ULM,GERMANY; UNIV MINNESOTA,DIV CARDIOVASC,DEPT MED,MINNEAPOLIS,MN 55455	Ulm University; University of Minnesota System; University of Minnesota Twin Cities								BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CUMMINS RO, 1993, ANN EMERG MED, V22, P37, DOI 10.1016/S0196-0644(05)80247-1; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; *EUR RES COUNC WOR, 1993, BRIT MED J, V306, P1589; LINDNER KH, 1993, ANESTH ANALG, V77, P427; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; LINDNER KH, 1990, CHEST, V97, P1458, DOI 10.1378/chest.97.6.1458; LINDNER KH, 1996, BRIT HEART J, V75, P145; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; TEASDALE G, 1974, LANCET, V2, P81; Woodhouse SP, 1995, RESUSCITATION, V30, P243, DOI 10.1016/0300-9572(95)00890-X	14	260	273	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					535	537		10.1016/S0140-6736(97)80087-6	http://dx.doi.org/10.1016/S0140-6736(97)80087-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048792				2023-01-03	WOS:A1997WJ51200011
J	John, LCH				John, LCH			''Phlebomania Hancocksia'': Prevalence of a previously undescribed psychomotor disturbance	BRITISH MEDICAL JOURNAL			English	Article							INHIBITION; HEPARIN				John, LCH (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CARDIOTHORAC SURG,LONDON EC1A 7BE,ENGLAND.							JOHN LCH, 1993, ANN THORAC SURG, V56, P899, DOI 10.1016/0003-4975(93)90352-I; JOHN LCH, 1993, J THORAC CARDIOV SUR, V105, P816; JOHN LCH, 1993, ANN THORAC SURG, V55, P1175, DOI 10.1016/0003-4975(93)90029-H	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1620	1620		10.1136/bmj.313.7072.1620	http://dx.doi.org/10.1136/bmj.313.7072.1620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991011	Green Published			2023-01-03	WOS:A1996VZ81100043
J	Morrison, RS; Meier, DE; Cassel, CK				Morrison, RS; Meier, DE; Cassel, CK			When too much is too little	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MECHANICAL RESTRAINTS; PHYSICAL RESTRAINTS; ELDERLY PATIENTS; MEDICAL-SCHOOLS; TERMINALLY ILL; DEATH; EDUCATION; NUTRITION; HYDRATION; CARE				Morrison, RS (corresponding author), CUNY MT SINAI SCH MED,HENRY L SCHWARTZ DEPT GERIATR & ADULT DEV,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.							Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; AHRONHEIM JC, 1994, ETHICS CLIN PRACTICE; AHRONHEIM JC, 1996, ARCH INTERN MED, V154, P2094; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Appelbaum PS, 1989, NEW ENGL J MED, V320, P748; BERRY ZS, 1993, JAMA-J AM MED ASSOC, V270, P221, DOI 10.1001/jama.270.2.221; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; DICKINSON GE, 1985, J MED EDUC, V60, P942; DUPONT EM, 1988, LOSS GRIEF CARE, V2, P33; Hansot E, 1996, ANN INTERN MED, V125, P149, DOI 10.7326/0003-4819-125-2-199607150-00016; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; *JOINT COMM ACCR H, 1996, STAND RESTR SECL JOI, P1; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; MACPHERSON DS, 1990, J AM GERIATR SOC, V38, P516, DOI 10.1111/j.1532-5415.1990.tb02400.x; MAHLER J, 1988, HOSP COMMUNITY PSYCH, V39, P856; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; McMillan A, 1990, Health Care Financ Rev, V12, P1; MEISEL A, 1989, RIGHT DIE; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; MION LC, 1989, J AM GERIATR SOC, V37, P949, DOI 10.1111/j.1532-5415.1989.tb07280.x; MION LC, 1990, J AM GERIATR SOC, V38, P181; MOSS RJ, 1991, HASTINGS CENT REP, V21, P22, DOI 10.2307/3563342; *NAT HOSP ORG, 1995, HOSP AM STAT PROF; National Center for Health Statistics, 1991, DHHS PUBL PHS, V2, P380; PRUITT JO, 1995, CRIT CARE NURS CLIN, V7, P363; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; RAPPAPORT W, 1993, SURGERY, V113, P163; SCOTT J, 1993, OXFORD TXB PALLIATIV, P761; SOUTHWICK F, 1993, ANN INTERN MED, V118, P146, DOI 10.7326/0003-4819-118-2-199301150-00011; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; Taggart J A, 1994, Dimens Crit Care Nurs, V13, P114, DOI 10.1097/00003465-199405000-00001; TAMLER MS, 1992, AM J PHYS MED REHAB, V71, P236, DOI 10.1097/00002060-199208000-00007; TINETTI ME, 1992, ANN INTERN MED, V116, P369, DOI 10.7326/0003-4819-116-5-369; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389	41	17	17	2	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1755	1759		10.1056/NEJM199612053352308	http://dx.doi.org/10.1056/NEJM199612053352308			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VW795	8929269				2023-01-03	WOS:A1996VW79500008
J	Girling, DJ; Thatcher, N; Clark, PI; Hopwood, P; Twiddy, S; Stephens, RJ; Bailey, AJ; Machin, D; Bleehen, NM; Bolger, JJ; Connolly, CK; Hasleton, PS; Macbeth, FR; Moghissi, K; Saunders, MI; White, RJ; Alcock, S; Burt, H; Crossley, E; Decker, E; English, J; Foster, G; Hannigan, K; Heron, D; Hutchinson, J; Lomax, L; Mercer, V; Page, S; Rothwell, T; Staines, K; TaylorNeal, P; Turnball, V; Axford, AT; Earl, HM; Glaholm, J; Falk, SJ; Graham, JD; Jones, DK; Coombes, RC; Epstein, RJ; Hanham, I; Lowdell, CP; Newlands, E; Smith, DB; Cookson, JB; Anderson, H; Gribbin, HR; Sinclair, DJM; Carmichael, J; Chan, SYT; Johnston, IDA; Morgan, SA; Dunn, KS; Manifold, IH; Radstone, DJ; Lamont, A; Robinson, ACR; Bissett, D; Nicolson, MC; Tang, OT; Sinnamon, DG; Varghese, G; Bibby, RJ; OReilly, JF; Bath, JCJ; Bredin, CP; Stewart, SJ; Whillis, D; Wiltshire, CR; McIllmurray, MB; Bond, MG; Wardman, AG; Bozzino, JM; Ferguson, GC; Macmillan, CH; Sugden, EM; Talbot, DC; Quigley, IG; Weatherstone, RM; Veale, D; ORegan, PF				Girling, DJ; Thatcher, N; Clark, PI; Hopwood, P; Twiddy, S; Stephens, RJ; Bailey, AJ; Machin, D; Bleehen, NM; Bolger, JJ; Connolly, CK; Hasleton, PS; Macbeth, FR; Moghissi, K; Saunders, MI; White, RJ; Alcock, S; Burt, H; Crossley, E; Decker, E; English, J; Foster, G; Hannigan, K; Heron, D; Hutchinson, J; Lomax, L; Mercer, V; Page, S; Rothwell, T; Staines, K; TaylorNeal, P; Turnball, V; Axford, AT; Earl, HM; Glaholm, J; Falk, SJ; Graham, JD; Jones, DK; Coombes, RC; Epstein, RJ; Hanham, I; Lowdell, CP; Newlands, E; Smith, DB; Cookson, JB; Anderson, H; Gribbin, HR; Sinclair, DJM; Carmichael, J; Chan, SYT; Johnston, IDA; Morgan, SA; Dunn, KS; Manifold, IH; Radstone, DJ; Lamont, A; Robinson, ACR; Bissett, D; Nicolson, MC; Tang, OT; Sinnamon, DG; Varghese, G; Bibby, RJ; OReilly, JF; Bath, JCJ; Bredin, CP; Stewart, SJ; Whillis, D; Wiltshire, CR; McIllmurray, MB; Bond, MG; Wardman, AG; Bozzino, JM; Ferguson, GC; Macmillan, CH; Sugden, EM; Talbot, DC; Quigley, IG; Weatherstone, RM; Veale, D; ORegan, PF			Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial	LANCET			English	Article							BIOAVAILABILITY; SCHEDULE	Background Single-drug oral etoposide daily for 5 days or more in 3 week cycles is commonly used as palliative chemotherapy for small-cell lung cancer (SCLC). However, there have been no randomised trials to compare this treatment with standard intravenous multidrug chemotherapy. Our objective was such a comparison in patients with poor performance status. However, before the planned intake of 450 patients had been completed the trial was stopped on the recommendation of an independent data monitoring committee, because of the inferiority of oral etoposide. We report the interim findings of the trial. Methods Patients of either sex and any age were entered into the trial if they had: previously untreated, microscopically confirmed SCLC; WHO grade performance status 2-4; no contraindications to either treatment regimen; normal renal function; and plasma bilirubin concentrations of less than 35 mu mol/L. Patients with grade 4 performance status were likely to benefit from chemotherapy. Between September, 1992, and August, 1995, 339 patients were randomly allocated four cycles of 50 mg oral etoposide twice daily for 10 days (171 patients) or a standard intravenous regimen of etoposide and vincristine (EV), or cyclophosphamide, doxorubicin, and vincristine (CAV, 168 controls). The intake was stopped in September, 1995. Patients were assessed by clinicians before the start of treatment, at each attendance for treatment, at 3 months after randomisation, every month to 6 months, every 2 months to 1 year, then every 3 months thereafter. The primary endpoint was the palliation of major symptoms at 3 months after randomisation-ie, a reduction in cough, pain, anorexia, and shortness of breath scores. Secondary endpoints were quality of life, clinical and radiographic tumour response, and survival. Findings The palliative effects of treatment were similar in the etoposide group and control group (41% vs 46%). Grade 2 or worse haematological toxicity occurred in 35 (29%) etoposide-treated patients and 26 (21%) controls. Controls had a higher overall response rate than etoposide-treated patients (51% vs 45%). There was a small disadvantage in survival associated with oral etoposide (hazard ratio 1.35 [95% CI 1.03-1.79], p=0.03). Median survival was 130 days in the etoposide group and 183 days in the controls; survival rates were 35% and 49% at 6 months and 11% and 13% at 12 months, respectively. Interpretation Oral etoposide 50 mg twice daily for 10 days every 3 weeks for four cycles is inferior to standard intravenous multidrug chemotherapy in the palliative treatment of patients with SCLC and poor performance status. Oral etoposide alone should no longer be used in the treatment of such patients.			Girling, DJ (corresponding author), MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BW,ENGLAND.		Varghese, George/AAQ-8219-2021	Coombes, Raoul Charles/0000-0002-4811-1100				[Anonymous], 1979, Br J Cancer, V40, P1; CLARK PI, 1992, SEMIN ONCOL, V19, P36; CLARK PI, 1989, P AN M AM SOC CLIN, V8, P257; DORWARD AJ, 1991, LUNG CANC S, V7, P111; HANDE KR, 1993, J CLIN ONCOL, V11, P374, DOI 10.1200/JCO.1993.11.2.374; HARVEY VJ, 1985, EUR J CANCER CLIN ON, V21, P1315, DOI 10.1016/0277-5379(85)90310-4; Ihde D C, 1984, Cancer, V54, P2722, DOI 10.1002/1097-0142(19841201)54:2+<2722::AID-CNCR2820541419>3.0.CO;2-P; MACHIN D, 1992, INTRO NEW TREATMENTS; MILLER AA, 1995, J CLIN ONCOL, V13, P1871, DOI 10.1200/JCO.1995.13.8.1871; RAWSON NSB, 1990, BRIT J CANCER, V61, P597, DOI 10.1038/bjc.1990.133; SLEVIN ML, 1989, J CLIN ONCOL, V7, P1333, DOI 10.1200/JCO.1989.7.9.1333; SOUHAMI RL, 1986, CANC ITS MANAGEMENT, P2126; STEPHENS RJ, 1994, LUNG CANCER-J IASLC, V11, P259, DOI 10.1016/0169-5002(94)90546-0; World Health Organization, 1979, WHO HDB REP RES CANC; 1996, BRIT J CANCER, V73, P406	15	166	167	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					563	566		10.1016/S0140-6736(96)02005-3	http://dx.doi.org/10.1016/S0140-6736(96)02005-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774567				2023-01-03	WOS:A1996VF18600008
J	Young, GP; Wagner, MB; Kellermann, AL; Ellis, J; Bouley, D				Young, GP; Wagner, MB; Kellermann, AL; Ellis, J; Bouley, D			Ambulatory visits to hospital emergency departments - Patterns and reasons for use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC EMERGENCY; TELEPHONE ADVICE; REFUSING CARE; MEDICAL-CARE; TRIAGE; NEED	Objectives.-To characterize the reasons ambulatory patients use hospital emergency departments (EDs) for outpatient care and to determine the proportion of ED patients who initially are assessed as having nonurgent conditions, but subsequently are hospitalized. Design.-Cross-sectional survey during a single 24-hour period of time. Setting.-Fifty-six hospital EDs nationwide. Patients or Other Participants.-Consecutive ambulatory patients presenting for care, Patients who arrived by ambulance were excluded. Results.-Of 6441 ambulatory patients (79% of all ED visits) who were eligible for study, interviews were obtained from 6187 (96%). A total of 5323 patients (86%) had clinical reasons or preferences for seeking care at an ED, including 2799 (45%) who thought they had an emergency or an urgent condition or were too sick to go elsewhere, Nineteen percent (n=1199) reported that they were sent to the ED by a health care professional. Patients with a regular clinician or with insurance cited similar reasons for seeking care at an ED. A total of 3062 patients (50%) cited 1 or more nonfinancial barriers to care as an important reason for coming to the ED, and 949 (15%) cited financial considerations, A total of 3045 patients (49% of ambulatory patients and 37% of total ED visits) were assessed at triage as having a nonurgent condition; 166 of them (5.5%; 95% confidence interval, 4.7%-6.3%) were admitted to the hospital. Conclusions.-Most ambulatory patients seek care in an ED because of worrisome symptoms or nonfinancial barriers to care. Although many ambulatory patients appear to have nonurgent conditions based on triage classification, a small but disturbing percentage of nonurgent patients are hospitalized.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; BETH ISRAEL HOSP,DIV EMERGENCY MED,BOSTON,MA 02215; EMORY UNIV,DEPT SURG,DIV EMERGENCY MED,ATLANTA,GA 30322	University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center; Emory University	Young, GP (corresponding author), HIGHLAND GEN HOSP,DEPT EMERGENCY MED,1411 E 31ST,OAKLAND,CA 94602, USA.							ALBIN SL, 1975, AM J PUBLIC HEALTH, V65, P1063, DOI 10.2105/AJPH.65.10.1063; *AM HOSP ASS, 1994, HOSP STAT EM TRENDS; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; BERMAN DA, 1989, ANN EMERG MED, V18, P141, DOI 10.1016/S0196-0644(89)80102-7; Birnbaum A, 1994, Acad Emerg Med, V1, P213; Brillman JC, 1996, ANN EMERG MED, V27, P493, DOI 10.1016/S0196-0644(96)70240-8; CHYBA MM, 1983, 2 NAT CTR HLTH STAT; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GADOMSKI AM, 1995, PEDIATRICS, V95, P170; GIFFORD MJ, 1980, ANN EMERG MED, V9, P502, DOI 10.1016/S0196-0644(80)80187-9; GLOTZER D, 1991, PEDIATRICS, V88, P674; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; GUTERMAN JJ, 1985, ANN EMERG MED, V14, P1191, DOI 10.1016/S0196-0644(85)81028-3; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; IGLEHART JK, 1993, NEW ENGL J MED, V328, P1208, DOI 10.1056/NEJM199304223281627; INGLEHART JK, 1992, NEW ENGL J MED, V327, P742; ISAACMAN DJ, 1992, PEDIATRICS, V89, P35; KELLERMANN A, 1993, VISITS HOSPITAL EMER; KELLERMANN AL, 1994, JAMA-J AM MED ASSOC, V271, P1953, DOI 10.1001/jama.271.24.1953; Lohr K N, 1986, Med Care, V24, pS1; LOWE RA, 1994, ANN EMERG MED, V23, P286, DOI 10.1016/S0196-0644(94)70042-7; McCaig L F, 1994, Adv Data, P1; Mills J, 1976, JACEP, V5, P877, DOI 10.1016/S0361-1124(76)80034-2; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; SHAW KN, 1990, ANN EMERG MED, V19, P59, DOI 10.1016/S0196-0644(05)82144-4; SHESSER R, 1991, ANN EMERG MED, V20, P743, DOI 10.1016/S0196-0644(05)80835-2; STEELE R, 1975, CAN MED ASSOC J, V112, P1096; Steinbrook R, 1996, NEW ENGL J MED, V334, P657, DOI 10.1056/NEJM199603073341010; *US DEP HHS, 1993, 069000181 US DEP HLT; *US DEP HHS, 1993, 069000180 US DEP HLT; *US GEN ACC OFF, 1993, HOSP EM DEP UN AFF G; VERDILE VP, 1989, ANN EMERG MED, V18, P278, DOI 10.1016/S0196-0644(89)80414-7; Warren B H, 1993, Arch Fam Med, V2, P523, DOI 10.1001/archfami.2.5.523; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007; WILSON LO, 1981, ANN EMERG MED, V10, P427, DOI 10.1016/S0196-0644(81)80311-3; 1996, C Q REP, V6, P1; 1994, NEW ENGL J MED, V330, P1426	39	197	199	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					460	465		10.1001/jama.276.6.460	http://dx.doi.org/10.1001/jama.276.6.460			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691553				2023-01-03	WOS:A1996VA86300033
J	Andrews, K; Murphy, L; Munday, R; Littlewood, C				Andrews, K; Murphy, L; Munday, R; Littlewood, C			Misdiagnosis of the vegetative state: Retrospective study in a rehabilitation unit	BRITISH MEDICAL JOURNAL			English	Article							PERSISTENT	Objective-To identify the number of patients who were misdiagnosed as being in the vegetative state and their characteristics. Design-Retrospective study of the clinical records of the medical, occupational therapy, and clinical psychology departments. Setting-20 bed unit specialising in the rehabilitation of patients with profound brain damage, including the vegetative state. Subjects-40 patients admitted between 1992 and 1995 with a referral diagnosis of vegetative state. Outcome measures-Patients who showed an ability to communicate consistently using eye pointing or a touch sensitive single switch buzzer. Results-Of the 40 patients referred as being in the vegetative state, 17 (43%) were considered as having been misdiagnosed; seven of these had been presumed to be vegetative for longer than one year, including three for over four years. Most of the misdiagnosed patients were blind or severely visually impaired. All patients remained severely physically disabled, but nearly all were able to communicate their preference in quality of life issues-some to a high level. Conclusions-The vegetative state needs considerable skill to diagnose, requiring assessment over a period of time; diagnosis cannot be made, even by the most experienced clinician, from a bedside assessment. Accurate diagnosis is possible but requires the skills of a multidisciplinary team experienced in the management of people with complex disabilities. Recognition of awareness is essential if an optimal quality of life is to be achieved and to avoid inappropriate approaches to the courts for a declaration for withdrawal of tube feeding.			Andrews, K (corresponding author), ROYAL HOSP NEURODISABIL,LONDON SW15 3SW,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Hagen C., 1980, REHABILITATION HEAD, P87; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; 1996, J R COLL PHYSICIANS, V30, P119; 1994, NEW ENGL J MED, V330, P1499; [No title captured]	11	558	572	2	40	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					13	16		10.1136/bmj.313.7048.13	http://dx.doi.org/10.1136/bmj.313.7048.13			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664760	Green Published			2023-01-03	WOS:A1996UW66700022
J	Emanuel, EJ; Fairclough, DL; Daniels, ER; Clarridge, BR				Emanuel, EJ; Fairclough, DL; Daniels, ER; Clarridge, BR			Euthanasia and physician-assisted suicide: Attitudes and experiences of oncology patients, oncologists, and the public	LANCET			English	Article							DEPRESSION; LIFE; CARE; END	Background Euthanasia and physician-assisted suicide are pressing public issues. We aimed to collect empirical data on these controversial interventions, particularly on the attitudes and experiences of oncology patients. Methods We interviewed, by telephone with vignette-style questions, 155 oncology patients, 355 oncologists, and 193 members of the public to assess their attitudes and experiences in relation to euthanasia and physician-assisted suicide. Findings About two thirds of oncology patients and the public found euthanasia and physician-assisted suicide acceptable for patients with unremitting pain. Oncology patients and the public found euthanasia and physician-assisted suicide least acceptable in vignettes involving ''burden on the family'' and ''life viewed as meaningless''. In no vignette-even for patients with unremitting pain-did a majority of oncologists find euthanasia or physician-assisted suicide ethically acceptable. Patients actually experiencing pain were more likely to find euthanasia or physician-assisted suicide unacceptable. More than quarter of oncology patients had seriously thought about euthanasia or physician-assisted suicide and nearly 12% had seriously discussed these interventions with physicians or others. Patients with depression and psychological distress were significantly more likely to have seriously discussed euthanasia, hoarded drugs, or read Final Exit. More than half of oncologists had received requests for euthanasia or physician-assisted suicide. Nearly one in seven oncologists had carried out euthanasia or physician-assisted suicide. Interpretation Euthanasia and physician-assisted suicide are important issues in the care of terminally ill patients and while oncology patients experiencing pain are unlikely to desire these interventions patients with depression are more likely to request assistance in committing suicide. Patients who request such an intervention should be evaluated and, where appropriate, treated for depression before euthanasia can be discussed seriously.	DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; UNIV MASSACHUSETTS,SURVEY RES CTR,BOSTON,MA 02125	Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Boston	Emanuel, EJ (corresponding author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,CTR OUTCOMES & POLICY RES,BOSTON,MA 02115, USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1993, J FAM PRACTICE, V37, P123; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; CLELLAND CS, 1989, ADV PAIN RES THER, V12, P391; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FOGEL BS, 1993, GEN HOSP PSYCHIAT, V15, P203, DOI 10.1016/0163-8343(93)90033-K; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; JACOBSON JA, 1995, J CLIN ETHIC, V6, P149; KINSELLA TD, 1993, CAN MED ASSOC J, V148, P1921; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MOINPOUR CM, 1989, J NATL CANCER I, V81, P485, DOI 10.1093/jnci/81.7.485; Owen C., 1994, PSYCHO-ONCOLOGY, V3, P1, DOI [10.1002/pon.2960030103, DOI 10.1002/PON.2960030103]; Quill TE, 1993, DEATH DIGNITY MAKING; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Ware J. E., 1993, SF 36 HLTH SURVEY MA, P11; Wentland E.J., 1993, SURVEY RESPONSES EVA; WINOKUR G, 1975, AM J PSYCHIAT, V132, P650	29	283	286	3	71	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1805	1810		10.1016/S0140-6736(96)91621-9	http://dx.doi.org/10.1016/S0140-6736(96)91621-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU469	8667927				2023-01-03	WOS:A1996UU46900014
J	Villanueva, C; Balanzo, J; Novilla, MT; Soriano, G; Sainz, S; Torras, Z; Cusso, Z; Guarner, C; Vilardell, F				Villanueva, C; Balanzo, J; Novilla, MT; Soriano, G; Sainz, S; Torras, Z; Cusso, Z; Guarner, C; Vilardell, F			Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSPECTIVE RANDOMIZED TRIAL; LONG-TERM MANAGEMENT; PORTAL-HYPERTENSION; ENDOSCOPIC SCLEROTHERAPY; CIRRHOTIC-PATIENTS; INJECTION SCLEROTHERAPY; ESOPHAGEAL-VARICES; ORAL PROPRANOLOL; HEMORRHAGE; ISOSORBIDE-5-MONONITRATE	Background. Patients who have bleeding from esophageal varices are at high risk for rebleeding and death. We compared the efficacy and safety of endoscopic sclerotherapy with the efficacy and safety of nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. Methods. Eighty-six hospitalized patients with cirrhosis and bleeding from esophageal varices diagnosed by endoscopy were randomly assigned to treatment with repeated sclerotherapy (43 patients) or nadolol plus isosorbide-5-mononitrate (43 patients). The primary outcomes were rebleeding, death, and complications. The hepatic venous pressure gradient was measured at base line and after three months. Results. Base-line data were similar in the two groups, and the median follow-up was 18 months in both. Eleven patients in the medication group and 23 in the sclerotherapy group had rebleeding. The actuarial probability of remaining free of rebleeding was higher in the medication group for all episodes related to portal hypertension (P = 0.001) and variceal rebleeding (P = 0.002). Four patients in the medication group and nine in the sclerotherapy group died (P = 0.07 for the difference in the actuarial probability of survival). Seven patients in the medication group and 16 in the sclerotherapy group had treatment-related complications (P = 0.03). Thirty-one patients in the medication group underwent two hemodynamic studies; 1 of the 13 patients with more than a 20 percent decrease in the hepatic venous pressure gradient had rebleeding, as compared with 8 of the 18 with smaller decreases in the pressure gradient (P = 0.04 for the actuarial probability of rebleeding at two years). Conclusions. As compared with sclerotherapy, nadolol plus isosorbide mononitrate significantly decreased the risk of rebleeding from esophageal varices.	HOSP SANTA CRUZ & SAN PABLO,SERV PATOL DIGEST,DEPT GASTROENTEROL,E-08025 BARCELONA,SPAIN					Soriano, German/0000-0002-9267-6811				ALEXANDRINO PT, 1988, J HEPATOL, V7, P175, DOI 10.1016/S0168-8278(88)80480-X; Armitage P., 1987, STAT METHODS MED RES; BALANZO J, 1990, SURG GYNECOL OBSTET, V171, P489; BALANZO J, 1989, ENDOSCOPY, V21, P251, DOI 10.1055/s-2007-1012963; BOSCH J, 1993, J HEPATOL, V17, pS41, DOI 10.1016/S0168-8278(05)80455-6; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; BURROUGHS AK, 1992, GASTROENTEROL CLIN N, V21, P119; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; DAMICO G, 1995, HEPATOLOGY, V22, P232; DAMICO G, 1990, GASTROENTEROLOGY, V99, P558; DASARATHY S, 1992, HEPATOLOGY, V16, P89, DOI 10.1002/hep.1840160116; DEFRANCHIS R, 1992, J HEPATOL, V15, P256, DOI 10.1016/0168-8278(92)90044-P; DOLLET JM, 1988, GASTROEN CLIN BIOL, V12, P234; FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3; FLEIG WE, 1987, HEPATOLOGY, V7, P355, DOI 10.1002/hep.1840070224; GARCIAPAGAN JC, 1990, HEPATOLOGY, V11, P230, DOI 10.1002/hep.1840110212; GARCIAPAGAN JC, 1991, ANN INTERN MED, V114, P869, DOI 10.7326/0003-4819-114-10-869; GARCIATSAO G, 1985, HEPATOLOGY, V5, P419, DOI 10.1002/hep.1840050313; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GATTA A, 1984, AM HEART J, V108, P1167, DOI 10.1016/0002-8703(84)90602-1; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; HENRIKSEN JH, 1993, HEPATOLOGY, V18, P688; IDEO G, 1988, HEPATOLOGY, V8, P6, DOI 10.1002/hep.1840080103; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; MCCORMICK PA, 1994, HEPATOLOGY, V20, pA106; MERKEL C, 1995, HEPATOLOGY, V22, P808, DOI 10.1016/0270-9139(95)90301-1; MORILLAS RM, 1994, HEPATOLOGY, V20, P1502, DOI 10.1002/hep.1840200620; POLIO J, 1986, SEMIN LIVER DIS, V6, P318, DOI 10.1055/s-2008-1040614; READY JB, 1989, DRUGS, V37, P13, DOI 10.2165/00003495-198900372-00004; ROSSI V, 1991, J HEPATOL, V12, P283, DOI 10.1016/0168-8278(91)90828-Y; SALMERON JM, 1993, HEPATOLOGY, V17, P800, DOI 10.1016/0270-9139(93)90155-G; SCHUMAN BM, 1987, AM J GASTROENTEROL, V82, P823; TERES J, 1993, GASTROENTEROLOGY, V105, P1508, DOI 10.1016/0016-5085(93)90158-9; VOROBIOFF J, 1993, HEPATOLOGY, V18, P477, DOI 10.1016/0270-9139(93)90344-M; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304	36	244	246	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1624	1629		10.1056/NEJM199606203342502	http://dx.doi.org/10.1056/NEJM199606203342502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628357				2023-01-03	WOS:A1996UQ70600002
J	Nightingale, SL				Nightingale, SL			Nicotine nasal spray approved for smoking cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2023-01-03	WOS:A1996UF47800007
J	Burt, RA				Burt, RA			The Supreme Court speaks - Not assisted suicide but a constitutional right to palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Burt, RA (corresponding author), YALE UNIV,SCH LAW,NEW HAVEN,CT 06520, USA.							Cherny N I, 1994, J Palliat Care, V10, P31; *INST MED, 1997, APPR DEATH IMPR CAR, P10; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; Pisano DJ, 1996, J LAW MED ETHICS, V24, P310, DOI 10.1111/j.1748-720X.1996.tb01872.x; Portenoy RK, 1996, J LAW MED ETHICS, V24, P296, DOI 10.1111/j.1748-720X.1996.tb01871.x	5	125	125	3	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1234	1236		10.1056/NEJM199710233371712	http://dx.doi.org/10.1056/NEJM199710233371712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9337388				2023-01-03	WOS:A1997YB71800012
J	Wardlaw, JM; Warlow, CP; Counsell, C				Wardlaw, JM; Warlow, CP; Counsell, C			Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke	LANCET			English	Article							ACUTE ISCHEMIC STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; STREPTOKINASE; TRIALS; INFARCTION	Background Recent trials of thrombolytic therapy in acute ischaemic stroke have given apparently conflicting results. Only one trial, the National Institute of Neurological Disorders and Stroke trial of tissue plasminogen activator (tPA), suggested that thrombolysis was definitely beneficial, To make sense of these results, we have done a systematic review of all available randomised trials of thrombolysis in acute ischaemic stroke. Methods From all available completed randomised trials of thrombolytic therapy compared with control in acute ischaemic stroke (with prerandomisation CT), we checked tabular data on deaths during roughly the first 2 weeks, deaths from all causes and functional outcome (disability) at the end of the trial follow-up period, and early symptomatic and fatal intracranial haemorrhages. Findings 12 trials included 3435 patients, of whom 694 (20%) were dead and 1001 (39%) of 2567 were functionally dependent at the end of follow-up (duration of follow-up varied between trials, but the longest was 6 months). 214 (6%) of the 3435 patients had early symptomatic or fatal intracranial haemorrhages. Thrombolytic therapy was associated with a significant excess of early deaths (91 per 1000 patients treated [95% CI 54-134]), and total deaths (37 per 1000 [20-83]), but there was nevertheless a significant reduction in the number of patients in the combined outcome of dead or dependent (65 fewer per 1000 patients treated [28-107]). There was a substantial and significant excess of symptomatic and fatal intracranial haemorrhages with thrombolysis-which was similar in all recent trials-of about 70 extra symptomatic intracranial haemorrhages per 1000 patients treated (of which 51 per 1000 were fatal), In the cohort of patients randomised within 3 h of stroke, there was a significant reduction in the number of patients who were dead or dependent al the end of follow-up (141 fewer dead or dependent per 1000 patients treated [75-206] and a non-significant increase in the number dead (nine per 1000 treated [-39 to 70]). There was significant heterogeneity between the trials for total deaths at the end of follow-up, which may be partly explained by differences in the use of antithrombotic drugs within the first 24 h of thrombolysis; the variation in severity of strokes included: the time window to thrombolytic treatment; and the dose of thrombolytic drug used. There were no direct comparisons of tPA with streptokinase or urokinase: much of the poor outcome in the streptokinase-treated patients might be explained by the inclusion of more severe strokes, greater use of antithrombotic drugs, higher doses, and the longer time to treatment compared with the trials that used tPA. Interpretation Thrombolysis requires further testing in large randomised trials because the risks seem substantial, and the benefit uncertain. The time window for effective treatment remains unclear. There is no objective evidence to suggest that tPA is safer than streptokinase; the apparent hazards and benefits may be similar when differences in trial design and baseline variables are accounted for.	UNIV EDINBURGH, DEPT CLIN NEUROSCI, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh			Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022	Wardlaw, Joanna M/0000-0002-9812-6642; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abe T, 1986, Folia Haematol Int Mag Klin Morphol Blutforsch, V113, P122; Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Araki G., 1985, CLIN EVAL, V13, P659; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; CANDELISE L, 1995, LANCET, V346, P1509; DAVIS SM, 1996, CEREBROVASC DIS, V6, P188; DELZOPPO G, 1996, CEREBROVASC DIS, V6, P184; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; *EMS BRIDG TRIAL I, 1996, CEREBROVASC DIS, V6, P184; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; Hommel M, 1996, NEW ENGL J MED, V335, P145; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MAST IT INV, 1996, CEREBROVASC DIS, V6, P183; MEYER JS, 1963, NEUROLOGY, V13, P927, DOI 10.1212/WNL.13.11.927; MEYER JS, 1964, JAMA-J AM MED ASSOC, V189, P373; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORRIS AD, 1995, QJM-MON J ASSOC PHYS, V88, P727; MOTTO C, 1996, CEREBROVASC DIS, V6, P129; Muir KW, 1996, LANCET, V347, P391, DOI 10.1016/S0140-6736(96)90568-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Naito I., 1981, BLOOD VESSELS, V12, P321, DOI 10.2491/jjsth1970.12.321; OHTOMO E, 1985, CLIN EVAL, V15, P711; PANG SQ, 1993, CHIN J NEUROL PSYCHI, V26, P229; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; Sandercock P, 1997, LANCET, V349, P1569; SHAHAR E, 1995, LANCET, V345, P578, DOI 10.1016/S0140-6736(95)90484-0; Sharp SJ, 1996, BRIT MED J, V313, P735; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SUSSMAN BJ, 1958, JAMA-J AM MED ASSOC, V167, P1705, DOI 10.1001/jama.1958.02990310011002; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; WARDLAW JM, 1994, J NEUROL NEUROSUR PS, V57, P255, DOI 10.1136/jnnp.57.2.255; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; WARDLAW JM, 1997, STROKE MODULE COCHRA; XIANG WH, 1995, P 4 CHIN STROK C CHE, P149; XIANG ZY, 1995, P 4 CHIN STROK C CHE, P44; Yamaguchi T., 1993, THROMBOLYTIC THERAPY, P59	40	218	230	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					607	614		10.1016/S0140-6736(97)03022-5	http://dx.doi.org/10.1016/S0140-6736(97)03022-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288042				2023-01-03	WOS:A1997XU28300007
J	Gerada, C; Ashworth, M				Gerada, C; Ashworth, M			Addiction and dependence .1. Illicit drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Review																		CHICK J, 1994, SEMINARS ALCOHOL DRU; *DEP HLTH, 1991, DRUG MIS DEP GUID CL; Russell J, 1993, GUIDELINES PREVENTIO; Williams H, 1996, BRIT J CLIN PRACT, V50, P94; WILLIAMS H, 1996, PREVENTION MENTAL IL, P223; 1997, DRUG THER B, V35, P18	6	35	35	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	1997	315	7103					297	300		10.1136/bmj.315.7103.297	http://dx.doi.org/10.1136/bmj.315.7103.297			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274553	Green Published			2023-01-03	WOS:A1997XP75000028
J	Winters, JC; Sobel, JS; Groenier, KH; Arendzen, HJ; MeyboomdeJong, B				Winters, JC; Sobel, JS; Groenier, KH; Arendzen, HJ; MeyboomdeJong, B			Comparison of physiotherapy, manipulation, and corticosteroid injection for treating shoulder complaints in general practice: Randomised, single blind study	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; TRIAL	Objective: To compare the efficacy of physiotherapy, manipulation, and corticosteroid injection for treating patients with shoulder complaints in general practice. Design: Randomised, single blind study. Setting: Seven general practices in the Netherlands. Subjects: 198 patients with shoulder complaints, of whom 172 were divided, on the basis of physical examination, into two diagnostic groups: a shoulder girdle group (n=58) and a synovial group (n=114). Interventions: Patients in the shoulder girdle group were randomised to manipulation or physiotherapy, and patients in the synovial group were randomised to corticosteroid injection, manipulation, or physiotherapy. Main outcome measures: Duration of shoulder complaints analysed by survival analysis. Results: In the shoulder girdle group duration of complaints was significantly shorter after manipulation compared with physiotherapy (P < 0.001). Also the number of patients reporting treatment failure was less with manipulation. In the synovial group duration of complaints was shortest after corticosteroid injection compared with manipulation and physiotherapy (P < 0.001). Drop out due to treatment failure was low in the injection group (17%) and high in the manipulation group (59%) and physiotherapy group (51%). Conclusions: For treating shoulder girdle disorders, manipulation seems to be the preferred treatment For the synovial disorders, corticosteroid injection seems the best treatment.	UNIV GRONINGEN,DEPT GEN PRACTICE,NL-9713 AW GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT REHABIL MED,NL-9700 RB GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen								Bakker JF, 1990, HUISARTS WETENSCHAP, V33, P196; CYRIAX J, 1984, TXB ORTHOPAEDIC MED, V1, P127; JONQUIERE M, 1986, THESIS ERASMUS U, P121; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; LACEY PH, 1984, EUR J RHEUMATOL INFL, V7, P95; LAMBERTS H, 1993, INT CLASSIFICATION P; ROY S, 1976, LANCET, V1, P1322; SOBEL JS, 1995, HUISARTS WET, V38, P342; STEINBROCKER O, 1974, ARCH PHYS MED REHAB, V55, P209; VANDERHEIJDEN BJM, 1992, NEDERLANDS TIJDSCHRI, V102, P38; VECCHIO PC, 1993, BRIT J RHEUMATOL, V32, P743; Winters JC, 1996, SCAND J REHABIL MED, V28, P163; WINTERS JC, 1955, HUISARTS WETENSCHAP, V38, P339; WINTERS JC, 1995, HUISARTS WETENSCHAP, V38, P347; Winters JC, 1995, HUISARTS WETENSCHAP, V38, P164	15	153	153	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1320	1325		10.1136/bmj.314.7090.1320	http://dx.doi.org/10.1136/bmj.314.7090.1320			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158469	Green Published			2023-01-03	WOS:A1997WX97500026
J	Farrell, AM				Farrell, AM			Acquired perforating dermatosis in renal and diabetic patients	LANCET			English	Editorial Material							COLLAGENOSIS; MELLITUS; PATHOGENESIS; ELIMINATION; FAILURE				Farrell, AM (corresponding author), CHURCHILL HOSP,DEPT DERMATOL,OXFORD OX3 7LJ,ENGLAND.							BAYOUMI AHM, 1978, BRIT J DERMATOL, V99, P611, DOI 10.1111/j.1365-2133.1978.tb07054.x; COCHRAN RJ, 1983, CUTIS, V31, P55; FAVER IR, 1994, J AM ACAD DERMATOL, V30, P575, DOI 10.1016/S0190-9622(94)70065-6; HAFTEK M, 1993, J CUTAN PATHOL, V20, P350, DOI 10.1111/j.1600-0560.1993.tb01274.x; Morton CA, 1996, BRIT J DERMATOL, V135, P671; PATTERSON JW, 1992, INT J DERMATOL, V31, P201, DOI 10.1111/j.1365-4362.1992.tb03937.x; POLIAK SC, 1982, NEW ENGL J MED, V306, P81, DOI 10.1056/NEJM198201143060206; ZELGER B, 1991, ARCH DERMATOL, V127, P695, DOI 10.1001/archderm.127.5.695	8	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					895	896		10.1016/S0140-6736(05)62693-1	http://dx.doi.org/10.1016/S0140-6736(05)62693-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093247				2023-01-03	WOS:A1997WR25400005
J	Kirwan, JF; Potamitis, T; ElKasaby, H; HopeRoss, MW; Sutton, GA				Kirwan, JF; Potamitis, T; ElKasaby, H; HopeRoss, MW; Sutton, GA			Lesson of the week - Microbial keratitis in intensive care	BRITISH MEDICAL JOURNAL			English	Review							EYE INFECTIONS		KINGSTON HOSP,ROYAL EYE UNIT,KINGSTON THAMES KT2 7QB,SURREY,ENGLAND; BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,W MIDLANDS,ENGLAND									Farrell M, 1993, Intensive Crit Care Nurs, V9, P137, DOI 10.1016/0964-3397(93)90055-3; HILTON E, 1983, LANCET, V1, P1318; KATZ J, 1977, ARCH OPHTHALMOL-CHIC, V95, P449; Liesegang T.J., 1988, CORNEA, P217; MILLIKEN J, 1988, CRIT CARE MED, V16, P233, DOI 10.1097/00003246-198803000-00005; OMMESLAG D, 1987, CRIT CARE MED, V15, P80, DOI 10.1097/00003246-198701000-00017	6	27	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					433	434		10.1136/bmj.314.7078.433	http://dx.doi.org/10.1136/bmj.314.7078.433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040392	Green Published			2023-01-03	WOS:A1997WH29500035
J	Houbiers, JGA; vandeWatering, LMG; vandeVelde, CHJ; Brand, A				Houbiers, JGA; vandeWatering, LMG; vandeVelde, CHJ; Brand, A			Postoperative injection after colorectal surgery	LANCET			English	Letter							COAT-DEPLETED BLOOD; CANCER		UNIV LEIDEN HOSP,BLOOD BANK,NL-2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT SURG,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Houbiers, JGA (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,POB 9600,NL-2300 RC LEIDEN,NETHERLANDS.							HEIS MM, 1994, LANCET, V344, P1430; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; HOUBIERS JGA, 1994, LANCET, V344, P1430; HOUBIERS JGA, IN PRESS TRANSFUSION; JENSEN LS, 1994, LANCET, V344, P1429	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1665	1666		10.1016/S0140-6736(05)65738-8	http://dx.doi.org/10.1016/S0140-6736(05)65738-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8962018				2023-01-03	WOS:A1996VX87600067
J	Arnott, SJ; Cunningham, D; Gallagher, J; Gray, R; Hardcastle, J; Houghton, J; James, RD; Lennon, TA; Meadows, HM; Mossman, J; Northover, JMA; Morgan, DAL; Plowman, PN; Slevin, M				Arnott, SJ; Cunningham, D; Gallagher, J; Gray, R; Hardcastle, J; Houghton, J; James, RD; Lennon, TA; Meadows, HM; Mossman, J; Northover, JMA; Morgan, DAL; Plowman, PN; Slevin, M			Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; CANAL CARCINOMA; RADIATION; CHEMOTHERAPY; THERAPY; MANAGEMENT; ANUS	Background Non-surgical management of anal cancer by radiotherapy alone or combined with chemotherapy has, in uncontrolled studies, yielded similar local tumour control and survival rates to surgery. However, whether the addition of chemotherapy improves outcome without adding to morbidity is not known. Our trial was designed to compare combined modality therapy (CMT) with radiotherapy alone in patients with epidermoid anal cancer. Methods From 856 patients considered for entry to our multicentre trial, 585 patients were randomised to receive initially either 45 Gy radiotherapy in twenty or twenty-five fractions over 4-5 weeks (290 patients) or the same regimen of radiotherapy combined with 5-fluorouracil (1000 mg/m(2) for 4 days or 750 mg/m(2) for 5 days) by continuous infusion during the first and the final weeks of radiotherapy and mitomycin (12 mg/m(2)) on day 1 of the first course (295 patients). We assessed clinical response 6 weeks after initial treatment: good responders were recommended for boost radiotherapy and poor responders for salvage surgery. The main endpoint was local-failure rate (greater than or equal to 6 weeks after initial treatment); secondary endpoints were overall and cause-specific survival. Analysis was by intention-to-treat. Findings In the radiotherapy and CMT arms, respectively, five and three were ineligible, and six and nine died 6 weeks after initial treatment. After a median follow-up of 42 months (interquartile range 28-62), 164 of 279 (59%) radiotherapy patients had a local failure compared with 101 of 283 (36%) CMT patients. This gave a 46% reduction in the risk of local failure in the patients receiving CMT (relative risk 0.54, 95% CI 0.42-0.69, p<0.0001). The risk of death from anal cancer was also reduced in the CMT arm (0.71, 0.53-0.95, p=0.02). There was no overall survival advantage (0.86, 0.67-1.11, p=0.25). Early morbidity was significantly more frequent in the CMT arm (p=0.03), but late morbidity occurred at similar rates. Interpretation Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin, with surgery reserved for those who fail on this regimen.	ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON,ENGLAND; ROYAL MARSDEN HOSP,LONDON,ENGLAND; CRC,CLIN TRIALS CTR,LONDON,ENGLAND; CLIN TRIAL SERV UNIT,OXFORD,ENGLAND; UNIV NOTTINGHAM HOSP,NOTTINGHAM,ENGLAND; CHRISTIE HOSP,MANCHESTER,LANCS,ENGLAND; UKCCCR,LONDON,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND	Imperial College London; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; University of Oxford; University of Nottingham; Christie NHS Foundation Trust; Christie Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital				Morgan, David/0000-0002-2291-1740; Gray, Richard/0000-0003-4440-574X; Cunningham, David/0000-0001-5158-1069				ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364; BOMAN BM, 1984, CANCER-AM CANCER SOC, V54, P114, DOI 10.1002/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P; CORTESE AF, 1975, CANCER, V36, P1869, DOI 10.1002/1097-0142(197511)36:5<1869::AID-CNCR2820360544>3.0.CO;2-2; CUMMINGS B, 1984, CANCER-AM CANCER SOC, V54, P2062, DOI 10.1002/1097-0142(19841115)54:10<2062::AID-CNCR2820541004>3.0.CO;2-T; CUMMINGS BJ, 1993, INT J RADIAT ONCOL, V27, P173, DOI 10.1016/0360-3016(93)90436-Y; CUMMINGS BJ, 1982, CANCER TREAT REV, V9, P125, DOI 10.1016/S0305-7372(82)80013-3; DIXON WJ, 1985, BMDP STATISTICAL SOF; DOBROWSKY W, 1992, INT J RADIAT ONCOL, V22, P875, DOI 10.1016/0360-3016(92)90782-D; FLAM MS, 1995, P AN M AM SOC CLIN, V14, P191; GABRIEL W., 1940, PROC ROY SOC MED, V34, P139; GERARD JP, 1991, LYON CHIR, V87, P74; GREEN JP, 1980, AM J SURG, V140, P151, DOI 10.1016/0002-9610(80)90432-8; GREENALL MJ, 1985, SURG GYNECOL OBSTET, V161, P509; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; JAMES RD, 1985, BRIT J SURG, V72, P282, DOI 10.1002/bjs.1800720411; JENSEN S, 1987, DIS COLON RECTUM, V31, P273; MADDEN MV, 1981, BRIT J SURG, V68, P287, DOI 10.1002/bjs.1800680420; NIGRO N, 1974, DIS COLON RECTUM, V15, P354; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; NIGRO ND, 1984, DIS COLON RECTUM, V27, P763, DOI 10.1007/BF02553933; PAPILLON J, 1983, CANCER, V51, P1830, DOI 10.1002/1097-0142(19830515)51:10<1830::AID-CNCR2820511013>3.0.CO;2-Z; PAPILLON J, 1987, DIS COLON RECTUM, V30, P324, DOI 10.1007/BF02555448; PAPILLON J, 1982, RECTAL ANAL CANCERS; PINTOR MP, 1989, BRIT J SURG, V76, P806, DOI 10.1002/bjs.1800760814; RICH TA, 1993, RADIOTHER ONCOL, V27, P209, DOI 10.1016/0167-8140(93)90076-K; ROELOFSON F, 1955, P AM SOC CLIN ONCOL, V14, P194; SPIESSL B, 1985, UICC TNM ATLAS ILLUS; TANNOCK IF, 1989, RADIOTHER ONCOL, V16, P83, DOI 10.1016/0167-8140(89)90025-X	28	772	788	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1049	1054						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874455				2023-01-03	WOS:A1996VM88600008
J	Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; Shen, H; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Vessey, M; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumcinda, K; Koetsawang, S; PiyaAnant, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Petitti, D; Perlman, J; Keleghan, J; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M				Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; Shen, H; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Vessey, M; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumcinda, K; Koetsawang, S; PiyaAnant, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Petitti, D; Perlman, J; Keleghan, J; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M			Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study	LANCET			English	Article							BLOOD-PRESSURE; CEREBROVASCULAR-DISEASE; RISK; AGE	Background The association between use of oral contraceptives (OCs) and cerebral infarction was established in studies from northern Europe and the USA during the 1960s and 1970s. Since then, the constituents of hormonal OCs have changed and now contain lower doses of oestrogen and progestagen. Current recommendations restrict OC use to younger women who do not have other risk factors for cardiovascular disease, in this international study we assessed the risk of CC-associated first stroke in women from Europe and other countries throughout Vie world. Methods In this hospital-based, case-control study, we assessed the risk of ischaemic stroke in association with current use of combined OCs in 697 cases, aged 20-44 years, and 1962 age-matched hospital controls in 21 centres in Africa, Asia, Europe, and Latin America. The diagnosis of ischaemic stroke was almost exclusively based on computed tomography (CT), magnetic resonance imaging (MRI), or cerebral angiography carried out within 3 weeks of the clinical event. Ail cases and controls were interviewed while in hospital with the same questionnaire, which included information on medical and personal history, details of lifetime contraceptive use, and blood-pressure measurements before the most recent episode of OC use. Findings The overall odds ratio of ischaemic stroke was 2 . 99 (95% CI 1 . 65-5 . 40) in Europe and 2 . 93 (2 . 15-4 . 00) in the non-European (developing) countries, Odds ratios were lower in younger women and those who did not smoke, and less than 2 in women who did not have hypertension and who reported that their blood pressure had been checked before the current episode of OC use. By contrast, among current OC users with a history of hypertension, the odds ratio was 10 . 7 (2 . 04-56 . 6) in Europe and 14 . 5 (5 . 36-39 . 0) in the developing countries. In Europe, the odds ratio associated with current use of low-dose OCs (<50 mu g oestrogen) was 1 . 53 (0 . 71-3 . 31), whereas for higher-dose preparations it was 5 . 30 (2 . 56-11 . 0). In the developing countries, there was no significant difference between overall estimates of risk associated with use of low-dose or higher-dose OCs (3 . 26 [2 . 19-4 . 86] vs 2 . 71 [1 . 75-4 . 19]), This differential effect of dose in Europe and the developing countries is likely to be due to different levels of other risk factors among users of low-dose and higher-dose OCs in the two groups of countries. There was no significant increase in odds ratios with increasing duration of OC use among current users; odds ratios were not significantly increased after cessation of OC use. Interpretation The incidence of ischaemic stroke is low in women of reproductive age and any risk attributable to OC use is small. The risk can be further reduced if users are younger than 35 years, do not smoke, do not have a history of hypertension, and have blood pressure measured before the start of QC use. In such women OC preparations with low oestrogen doses may be associated with even lower risk.	WHO, UNDP UNFPA WHO WORLD BANK SPECIAL PROGRAMME RES D, CH-1211 GENEVA 27, SWITZERLAND; ESCOLA PAULISTA MED, DEPT PREVENT MED, SAO PAULO, BRAZIL; UNIV CHILE, ESCUELA SALUD PUBL, SANTIAGO, CHILE; ESCUELA MED, DEPT SALUD PUBL, VALPARAISO, CHILE; NATL RES INST FAMILY PLANNING, BEIJING, PEOPLES R CHINA; SICHUAN FAMILY PLANNING RES INST, CHENGDU, PEOPLES R CHINA; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; ZENTRUM EPIDEMIOL & GESUNDHEITSFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, DEPT COMMUNITY MED, HONG KONG, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, DEPT OBSTET & GYNAECOL, SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; GRP INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REP, DURANGO, MEXICO; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, DEPT OBSTET & GYNAECOL, BANGKOK, THAILAND; SIRIRAJ HOSP, SIRIRAJ FAMILY HLTH RES CTR, BANGKOK, THAILAND; UNIV BELGRADE, SCH MED, BELGRADE, YUGOSLAVIA; UNIV LUSAKA, TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, DEPT MED, HARARE, ZIMBABWE; UCL, LONDON MED SCH, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; KAISER PERMANENTE, PASADENA, CA USA; NIH, BETHESDA, MD 20892 USA; UNIV AARHUS, DANISH EPIDEMIOL SCI CTR, AARHUS, DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	United Nations Population Fund; World Health Organization; Universidade Federal de Sao Paulo (UNIFESP); Universidad de Chile; National Research Institute for Family Planning - China; Universidad del Valle; University of Oxford; Chinese University of Hong Kong; Szeged University; University of Indonesia; University West Indies Mona Jamaica; Kenya Medical Research Institute; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Belgrade; University of Zimbabwe; University of London; University College London; University of Oxford; Kaiser Permanente; National Institutes of Health (NIH) - USA; Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Poulter, NR (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002914] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1995, J Clin Epidemiol, V48, P1513; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; ARBUCKLE DD, 1982, PUBLIC HEALTH, V96, P96, DOI 10.1016/S0033-3506(82)80102-9; BICKERSTAFF E, 1975, NEUROLOGICAL COMPLIC; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; CHANG KK, 1986, INT J GYNECOL OBSTET, V24, P421, DOI 10.1016/0020-7292(86)90032-9; FOGELHOLM R, 1973, ACTA NEUROL SCAND, V49, P415; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JICK H, 1978, ANN INTERN MED, V89, P58, DOI 10.7326/0003-4819-89-1-58; KAY CR, 1981, LANCET, V1, P541; LAYDE PM, 1983, J ROY COLL GEN PRACT, V33, P75; LIDEGAARD O, 1986, STROKE, V17, P670, DOI 10.1161/01.STR.17.4.670; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LORENTZ IT, 1962, BRIT MED J, P1191; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANN JI, 1976, BRIT J PREV SOC MED, V30, P94; MASI AT, 1970, ANN INTERN MED, V72, P111, DOI 10.7326/0003-4819-72-1-111; METTINGER KL, 1984, STROKE, V15, P795, DOI 10.1161/01.STR.15.5.795; METTINGER KL, 1984, ACTA NEUROL SCAND, V70, P415; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; RAMCHARAN S, 1981, CTR POPULATION RES M; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; Royal College of General Practitioners, 1974, OR CONTR HLTH; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; SHAH IH, 1994, WORLD HLTH STAT Q, V4, P1; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; WHELTON PK, 1994, TXB HYPERTENSION; IN PRESS J EPIDEMIOL	36	297	302	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	1996	348	9026					498	505						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757151				2023-01-03	WOS:A1996VD42700009
J	Tang, MX; Jacobs, D; Stern, Y; Marder, K; Schofield, P; Gurland, B; Andrews, H; Mayeux, R				Tang, MX; Jacobs, D; Stern, Y; Marder, K; Schofield, P; Gurland, B; Andrews, H; Mayeux, R			Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; PARADIGM-BASED DIAGNOSIS; E ALLELE EPSILON-4; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; DEMENTIA; RECEPTORS; NEURONS; WOMEN	Background Oestrogen use by postmenopausal women has many health benefits, but findings on the effect of oestrogen in Alzheimer's disease are conflicting. Oestrogen promotes the growth and survival of cholinergic neurons and could decrease cerebral amyloid deposition, both of which may delay the onset or prevent Alzheimer's disease. To investigate whether use of oestrogen during the postmenopausal period affects the risk of Alzheimer's disease, we studied 1124 elderly women who were initially free of Alzheimer's disease, Parkinson's disease, and stroke, and who were taking part in a longitudinal study of ageing and health in a New York City community. Methods Relative risks and age-at-onset distributions were calculated from simple and adjusted Cox proportional hazards models. Standard annual clinical assessments and criterion-based diagnoses were used in follow-up (range 1-5 years). Findings Overall, 156 (12.5%) women reported taking oestrogen after onset of menopause. The age at onset of Alzheimer's disease was significantly later in women who had taken oestrogen than in those who did not and the relative risk of the disease was significantly reduced (9/156 [5.8%] oestrogen users vs 158/968 [16.3%] non-users; 0.40 [95% CI 0.22-0.85], p<0.01), even after adjustment for differences in education, ethnic origin, and apolipoprotein-E genotype. Women who had used oestrogen for longer than 1 year had a greater reduction in risk; none of 23 women who were taking oestrogen at study enrolment has developed Alzheimer's disease. Interpretation Oestrogen use in postmenopausal women may delay the onset and decrease the risk of Alzheimer's disease. Prospective studies are needed to establish the dose and duration of oestrogen required to provide this benefit and to assess its safety in elderly postmenopausal women.	COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,TAUB CTR ALZHEIMERS DIS RES,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute			Schofield, Peter/J-7133-2013	Stern, Yaakov/0000-0001-7542-3241; Jacobs, Diane/0000-0003-0886-6784	NATIONAL INSTITUTE ON AGING [P50AG008702, R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG07232, AG08702, AG10963] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P205; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; COLLET D, 1994, MODELLING SUVIVAL DA, P153; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HERBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354; HIXSON J, 1991, J LIPID RES, V31, P545; HONJO H, 1995, HORM METAB RES, V27, P204, DOI 10.1055/s-2007-979941; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRANDA RC, 1993, MOL CELL NEUROSCI, V4, P510, DOI 10.1006/mcne.1993.1063; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SIMPKINS JW, 1994, NEUROBIOL AGING, V15, pS195; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Singh M., 1993, Society for Neuroscience Abstracts, V19, P1254; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009	28	1353	1393	2	88	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					429	432		10.1016/S0140-6736(96)03356-9	http://dx.doi.org/10.1016/S0140-6736(96)03356-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709781	Green Submitted, hybrid			2023-01-03	WOS:A1996VC67300009
J	Wachter, RM; Goldman, L				Wachter, RM; Goldman, L			The emerging role of ''hospitalists'' in the American health care system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; MEDICAL OUTCOMES; UNITED-STATES; HIV-INFECTION; PHYSICIANS; SPECIALIST; VOLUME; GENERALIST; MORTALITY; PATTERNS				Wachter, RM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P856; BRANDNER J, 1995, MANAGED CARE     JUL, P19; Donaldson M, 1994, DEFINING PRIMARY CAR; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; GIPE B, 1996, COST QUALITY, V2, P6; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; JAKLEVIC MC, 1994, MODERN HEALTHCA 0926, P64; Kassebaum DG, 1995, ACAD MED, V70, P1152, DOI 10.1097/00001888-199512000-00024; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KILGORE C, 1995, INTERNAL MED NE 0301, P1; KILGORE C, 1995, INTERNAL MED NE 0301, P33; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; Moore M J, 1995, Am J Surg, V170, P55; MOVSESIAN MA, 1990, NEW ENGL J MED, V322, P1602, DOI 10.1056/NEJM199005313222211; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Robins NS, 1995, GIRL WHO DIED TWICE; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; Starfield B., 1992, PRIMARY CARE CONCEPT; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER BJ, 1994, MED CARE, V32, P902, DOI 10.1097/00005650-199409000-00002; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; WEEKS WB, 1994, NEW ENGL J MED, V330, P1280, DOI 10.1056/NEJM199405053301807; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WINSLOW R, 1995, WALL STREET J   0721, pB1; WINSLOW R, 1995, WALL STREET J   0721, pB4; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; ZEIGER RS, 1992, J ALLERGY CLIN IMMUN, V90, P278; 1992, CRIT CARE MED, V20, P540	41	493	495	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					514	517		10.1056/NEJM199608153350713	http://dx.doi.org/10.1056/NEJM199608153350713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672160				2023-01-03	WOS:A1996VB84900013
J	Davenport, RJ; Dennis, MS; Warlow, CP				Davenport, RJ; Dennis, MS; Warlow, CP			Effect of correcting outcome data for case mix: An example from stroke medicine	BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE	Objective-To show the influence of variations in case mix on clinical outcome indicators for patients admitted to hospital with acute stroke. Design-''Before and after'' cohort study, with prospective, consecutive identification of patients and prospective follow up; multiple logistic regression analyses to correct for case mix variations. Setting-University teaching hospital. Subjects-216 patients with stroke identified before the introduction of an organised stroke service, and 252 patients with stroke identified after its introduction. Main outcome measures-Case fatality at 30 days and 12 months; for survivors at 12 months, proportions of patients who were independent (according to the Oxford handicap scale) and of those living at home. Results-Crude outcome data suggested that patients in the cohort identified after the introduction of the stroke service were significantly more likely to be alive, independent, and living at home than patients managed before the stroke service. After adjustment for age and sex these ''improvements'' were less impressive but still significant. After adjustment for many other possible prognostic indicators, however, the differences between the two groups for all four outcomes were non-significant, suggesting that the ''improvements'' may have been entirely due to differences in case mix between the two cohorts, rather than the new stroke service. Conclusions-Variations in case mix have a crucial influence on the interpretation of outcome data, and this is particularly important in non-randomised comparative studies. Such studies, comparing performance within and between different provider units, are likely to become increasingly common in the new reformed NHS. To allow meaningful interpretation, these studies must try to correct for case mix.			Davenport, RJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BION J, 1993, BRIT MED J, V307, P953, DOI 10.1136/bmj.307.6910.953; Carstairs V, 1991, DEPRIVATION HLTH; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; *SCOTT OFF, 1994, CLIN OUTC IND; *SCOTT OFF, 1995, CLIN OUTC IND; WARLOW C, 1995, STROKE MODULE COCHRA; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539	15	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1503	1505		10.1136/bmj.312.7045.1503	http://dx.doi.org/10.1136/bmj.312.7045.1503			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646140	Green Published			2023-01-03	WOS:A1996UR82300018
J	Dichter, MA; Brodie, MJ				Dichter, MA; Brodie, MJ			Drug therapy - New antiepileptic drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED CROSSOVER; RESISTANT PARTIAL SEIZURES; PARTIAL-ONSET SEIZURES; GABA UPTAKE INHIBITOR; GAMMA-VINYL-GABA; ADD-ON TREATMENT; DOUBLE-BLIND; CONTROLLED TRIAL; REFRACTORY EPILEPSY; FELBAMATE MONOTHERAPY		UNIV PENN, DEPT NEUROL, PHILADELPHIA, PA 19104 USA; UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, EPILEPSY RES UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND	University of Pennsylvania; University of Glasgow								AGOSTI R, 1990, EPILEPSY RES, V6, P166, DOI 10.1016/0920-1211(90)90092-A; ALLEN JW, 1983, BRIT MED J, V286, P1246, DOI 10.1136/bmj.286.6373.1246; ANDERSEN KE, 1993, J MED CHEM, V36, P1716, DOI 10.1021/jm00064a005; ANHUT H, 1994, EPILEPSIA, V35, P795, DOI 10.1111/j.1528-1157.1994.tb02513.x; [Anonymous], 1989, LANCET, V2, P196; [Anonymous], 1990, Lancet, V335, P1114; ASCONAPE JJ, 1994, EPILEPSIA S8, V35; BARDY AH, 1991, BRAIN DEV-JPN, V13, P174, DOI 10.1016/S0387-7604(12)80025-8; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; BOURGEOIS B, 1993, NEUROLOGY, V43, P693, DOI 10.1212/WNL.43.4.693; BRODIE M, 1994, LAMOTRIGINE NEW ADV, P83; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; BUCHANAN N, 1993, J ROY SOC MED, V86, P378; BUTLER WH, 1989, EPILEPSIA, V30, pS15, DOI 10.1111/j.1528-1157.1989.tb05827.x; CALLAGHAN N, 1988, EPILEPSIA, V29, pS29, DOI 10.1111/j.1528-1157.1988.tb05789.x; CHEUNG H, 1992, EPILEPSY RES, V13, P107; CHIRON C, 1991, J CHILD NEUROL, V6, pS52; Cocito L, 1992, Seizure, V1, P163, DOI 10.1016/1059-1311(92)90019-W; COSI V, 1988, EUR NEUROL, V28, P42, DOI 10.1159/000116227; COSI V, 1989, BRIT J CLIN PHARMACO, V27, pS61, DOI 10.1111/j.1365-2125.1989.tb03463.x; CRITCHLEY EMR, 1981, CLOBAZAM, V43, P159; DAM M, 1989, EPILEPSY RES, V3, P70; DICHTER MA, 1995, CURR OPIN NEUROL, V8, P95, DOI 10.1097/00019052-199504000-00001; DULAC O, 1991, J CHILD NEUROL, V6, pS30, DOI 10.1177/0883073891006002071; DULAC O, 1983, PRESSE MED, V12, P1067; FAUGHT E, 1993, NEUROLOGY, V43, P688, DOI 10.1212/WNL.43.4.688; FAUGHT E, IN PRESS NEUROLOGY; FEELY M, 1982, LANCET, V2, P71; FEELY M, 1984, J NEUROL NEUROSUR PS, V47, P1279, DOI 10.1136/jnnp.47.12.1279; French JA, 1996, NEUROLOGY, V46, P54, DOI 10.1212/WNL.46.1.54; FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; GRAHAM D, 1989, BRIT J CLIN PHARMACO, V27, pS43, DOI 10.1111/j.1365-2125.1989.tb03460.x; GRANT SM, 1992, DRUGS, V43, P873, DOI 10.2165/00003495-199243060-00007; GREENBLATT DJ, 1981, BRIT J CLIN PHARMACO, V12, P631, DOI 10.1111/j.1365-2125.1981.tb01281.x; Haefely W, 1975, Adv Biochem Psychopharmacol, P131; HAIGH JRM, 1987, BRIT J CLIN PHARMACO, V23, P213, DOI 10.1111/j.1365-2125.1987.tb03032.x; HAMMOND EJ, 1992, EPILEPSY RES, V12, P261, DOI 10.1016/0920-1211(92)90080-D; HELLER AJ, 1988, EPILEPSY RES, V2, P276, DOI 10.1016/0920-1211(88)90020-4; HILL DR, 1993, EUR J PHARM-MOLEC PH, V244, P303, DOI 10.1016/0922-4106(93)90156-4; HINDMARCH I, 1991, NEUROPSYCHOBIOLOGY, V24, P84, DOI 10.1159/000119466; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; KALVIAINEN R, 1991, J CHILD NEUROL S, V2; KILPATRICK E, IN PRESS EPILEPSIA; KOCSIS JD, 1994, NEUROSCI LETT, V169, P181, DOI 10.1016/0304-3940(94)90386-7; KOEPPEN D, 1987, EPILEPSIA, V28, P495, DOI 10.1111/j.1528-1157.1987.tb03678.x; LARKIN JG, 1991, BRIT J CLIN PHARMACO, V31, P65, DOI 10.1111/j.1365-2125.1991.tb03858.x; Leach John P., 1995, P889; LEPPIK IE, 1993, EPILEPSY RES, V14, P165, DOI 10.1016/0920-1211(93)90021-X; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; LIEGEOISCHAUVEL C, 1989, BRIT J CLIN PHARMACO, V27, pS69, DOI 10.1111/j.1365-2125.1989.tb03464.x; LIEGEOISCHAUVEL C, 1989, EPILEPSIA, V30, pS23, DOI 10.1111/j.1528-1157.1989.tb05829.x; LIPORACE J, 1994, EPILEPSIA S8, V35; LOISEAU P, 1990, EPILEPSY RES, V7, P136, DOI 10.1016/0920-1211(90)90099-H; MATSUO F, 1993, NEUROLOGY, V43, P2284, DOI 10.1212/WNL.43.11.2284; MCKEE PJW, 1993, EPILEPSIA, V34, P937, DOI 10.1111/j.1528-1157.1993.tb02115.x; MESSENHEIMER J, 1994, EPILEPSIA, V35, P113, DOI 10.1111/j.1528-1157.1994.tb02920.x; MILLER AA, 1986, EPILEPSIA, V27, P483, DOI 10.1111/j.1528-1157.1986.tb03572.x; MUMFORD JP, 1989, BRIT J CLIN PHARMACO, V27, pS101, DOI 10.1111/j.1365-2125.1989.tb03469.x; MUNN R, 1988, CAN J NEUROL SCI, V15, P406, DOI 10.1017/S0317167100028146; NIELSEN EB, 1991, EUR J PHARMACOL, V196, P257, DOI 10.1016/0014-2999(91)90438-V; OH DJ, 1994, EPILEPSIA, V35, P426, DOI 10.1111/j.1528-1157.1994.tb02455.x; OOMMEN K, 1993, NEUROLOGY, V43, P2292; PEDERSEN B, 1987, EPILEPSY RES, V1, P74, DOI 10.1016/0920-1211(87)90054-4; PETROFF OAC, 1995, EPILEPSIA, V36, P457, DOI 10.1111/j.1528-1157.1995.tb00486.x; PISANI F, 1991, J NEUROL NEUROSUR PS, V54, P845, DOI 10.1136/jnnp.54.9.845-a; PULLAR T, 1987, BRIT J CLIN PHARMACO, V24, P793, DOI 10.1111/j.1365-2125.1987.tb03247.x; RHO JM, 1994, ANN NEUROL, V35, P229, DOI 10.1002/ana.410350216; RICHENS A, 1995, EPILEPSY RES, V21, P37, DOI 10.1016/0920-1211(95)00006-V; RISNER M, 1994, EPILEPSIA, V31, P619; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; ROBERTSON MM, 1986, EPILEPSIA, V27, pS27, DOI 10.1111/j.1528-1157.1986.tb05730.x; ROCK DM, 1989, EPILEPSY RES, V3, P138, DOI 10.1016/0920-1211(89)90041-7; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; SANDER JWAS, 1990, EPILEPSY RES, V6, P221, DOI 10.1016/0920-1211(90)90077-9; SANDER JWAS, 1991, J NEUROL NEUROSUR PS, V54, P435, DOI 10.1136/jnnp.54.5.435; SCHAPEL GJ, 1993, J NEUROL NEUROSUR PS, V56, P448, DOI 10.1136/jnnp.56.5.448; SCHAUF CL, 1987, BRAIN RES, V413, P185, DOI 10.1016/0006-8993(87)90168-5; SCHMIDT D, 1993, EPILEPSY RES, V15, P67, DOI 10.1016/0920-1211(93)90011-U; SCHMIDT D, 1986, ARCH NEUROL-CHICAGO, V43, P824, DOI 10.1001/archneur.1986.00520080064023; SCOTT DF, 1988, ACTA NEUROL SCAND, V77, P498, DOI 10.1111/j.1600-0404.1988.tb05947.x; SEINO M, 1991, EPILEPSY RES, P169; SHANK RP, 1994, EPILEPSIA, V35, P450, DOI 10.1111/j.1528-1157.1994.tb02459.x; SIVENIUS J, 1993, EPILEPSIA, V34, P193, DOI 10.1111/j.1528-1157.1993.tb02398.x; SMITH D, 1993, EPILEPSIA, V34, P312, DOI 10.1111/j.1528-1157.1993.tb02417.x; STEINHOFF BJ, 1992, EPILEPSY RES, V11, P67, DOI 10.1016/0920-1211(92)90023-M; STEWART JA, 1991, EPILEPSIA, V32, P407; SUZUKI S, 1992, EPILEPSY RES, V12, P21, DOI 10.1016/0920-1211(92)90087-A; THEODORE WH, 1991, EPILEPSIA, V32, P392, DOI 10.1111/j.1528-1157.1991.tb04668.x; THOMPSON SM, 1992, J NEUROPHYSIOL, V67, P1698, DOI 10.1152/jn.1992.67.6.1698; VANAMELSVOORT T, 1994, EPILEPSIA, V35, P181; WAGNER JG, 1984, THER DRUG MONIT, V6, P277, DOI 10.1097/00007691-198409000-00004; WAMIL AW, 1994, EPILEPSY RES, V17, P1, DOI 10.1016/0920-1211(94)90074-4; WANG JJ, 1993, J EPILEPSY, V6, P180, DOI 10.1016/S0896-6974(05)80087-8; White H. Steve, 1994, Epilepsia, V35, P67; WHITE HS, 1992, EPILEPSIA, V33, P564, DOI 10.1111/j.1528-1157.1992.tb01711.x; WILDIN JD, 1990, BRIT J CLIN PHARMACO, V29, P169, DOI 10.1111/j.1365-2125.1990.tb03616.x; WOLFF DL, 1994, EPILEPSIA S8, V35; YAGI K, 1987, CLIN PSYCHIATR, V29, P111	101	229	238	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1583	1590		10.1056/NEJM199606133342407	http://dx.doi.org/10.1056/NEJM199606133342407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628341				2023-01-03	WOS:A1996UP66300007
J	Back, AL; Wallace, JI; Starks, HE; Pearlman, RA				Back, AL; Wallace, JI; Starks, HE; Pearlman, RA			Physician-assisted suicide and euthanasia in Washington State - Patient requests and physician responses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH; DECISIONS; LIFE	Objectives.-To estimate how often physicians receive requests for physician-assisted suicide and euthanasia and to describe a case series of patient requests for physician-assisted suicide and euthanasia, including physician responses to these requests. Design.-A mailed, anonymous two-part questionnaire. Participants.-A total of 828 physicians returned questionnaires sent to 1453 potential respondents, for a response rate of 57%. Questionnaires were mailed to a random sample (25%) of primary care physicians and all physicians in selected medical subspecialties in Washington State. Main Outcome Measures.-The frequency of explicit patient requests for physician-assisted suicide and euthanasia reported by physicians and individual case descriptions of patient characteristics, physician perceptions of patient concerns, and physician responses to patient requests. Results.-In the past year, 12% of responding physicians received one or more explicit requests for physician-assisted suicide, and 4% received one or more requests for euthanasia. These physicians provided 207 case descriptions. The diagnoses most often associated with requests were cancer, neurological disease, and the acquired immunodeficiency syndrome (AIDS). The patient concerns most often perceived by physicians were worries about loss of control, being a burden, being dependent on others for personal care, and loss of dignity, Physicians provided assistance more often to patients with physical symptoms. Physicians infrequently sought advice from colleagues, Of 156 patients who requested physician-assisted suicide, 38 (24%) received prescriptions, and 21 of these died as a result. Of 58 patients who requested euthanasia, 14 (24%) received parenteral medication and died. Conclusions.-Patient requests for physician-assisted suicide and euthanasia are not rare, As perceived by physicians, the most common patient concerns at the time these requests are made are nonphysical, Physicians occasionally provide these practices, even though they are currently illegal in Washington State. Physicians do not consult colleagues often about these requests. These findings raise the question of how to ensure quality in the evaluation of patient requests for physician-assisted death.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT HLTH SERV, SEATTLE, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Back, AL (corresponding author), VET AFFAIRS PUGET SOUND HLTH CARE SYST, MED SERV, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.				NIA NIH HHS [AG00615-02] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BATTIN MP, 1995, ACAD MED, V70, P583; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSELL EJ, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3563319; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FINS JJ, 1995, J AM GERIATR SOC, V43, P563, DOI 10.1111/j.1532-5415.1995.tb06107.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GIRSH FJ, 1992, WESTERN J MED, V157, P188; Humphry, 1991, FINAL EXIT PRACTICAL; JECKER NS, 1994, J AM GERIATR SOC, V42, P672, DOI 10.1111/j.1532-5415.1994.tb06869.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PEARLMAN RA, 1993, THEOR MED, V14, P197, DOI 10.1007/BF00995162; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PELLEGRINO ED, 1995, J CLIN ETHIC, V6, P161; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; *WA STAT DEP HLTH, 1994, WASH STAT VIT STAT; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, J AM GERIATR SOC, V43, P579	37	259	259	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					919	925		10.1001/jama.275.12.919	http://dx.doi.org/10.1001/jama.275.12.919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA563	8598619				2023-01-03	WOS:A1996UA56300031
J	Bond, CM; Bradley, C				Bond, CM; Bradley, C			Over the counter drugs - The interface between the community pharmacist and patients .3.	BRITISH MEDICAL JOURNAL			English	Article								Pharmacists play an important part in primary health care, and their accessibility is a key factor. Their NHS payments relate predominantly to the dispensing of prescribed medicines; to recognise the service element of their advisory role, an NHS funded professional fee could be built into the cost structure for pharmacy medicines. The increased number of medicines available over the counter has need for training for counter assistants; it will become compulsory in July 1996, and some family health services authorities are providing this. The shift to care in the community could mean that pharmacists will have an even greater role in the primary health care team. Encouraging the public to seek advice from the community pharmacist may lead to a greater proportion of visits to doctors resulting from referrals from the pharmacist. Joint development by pharmacists and doctors of guidelines for advice on, and recommendation of, over the counter medicines is needed.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Bond, CM (corresponding author), UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN,SCOTLAND.							BLENKINSOPP A, 1994, OTCS PRESCRIPTION HE; Bond C M, 1995, Health Bull (Edinb), V53, P26; Bond CM, 1995, INT J PHARM PRACT, V3, P85; BOND CM, 1992, PHARM J, V249, pR6; *COMM INQ PHARM, 1986, REP NUFF FDN; DARRACOTT R, 1995, PHARM J, V254, P497; Eaton G, 1979, Sociol Health Illn, V1, P69, DOI 10.1111/1467-9566.ep11006781; EVANS D, 1994, PHARM J, V252, P631; FLINT JF, 1995, PHARM J, V254, P28; GOODBURN E, 1991, BMJ-BRIT MED J, V302, P440, DOI 10.1136/bmj.302.6774.440; HARGIE ODW, 1987, INT PHARM J, V1, P175; Jepson M, 1991, CONSUMER EXPECTATION; KRSKA J, 1994, PHARM J, V252, P936; National Audit Office, 1992, COMM PHARM ENGL; *ROYAL PHARM SOC, 1992, PHARM CAR FUT ROL CO; TAPSTER JV, 1994, PHARM J, V253, P112; 1987, CM249	17	35	35	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					758	760						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605465				2023-01-03	WOS:A1996UC16600039
J	Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG				Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG			Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; EARLY ENDOSCOPY; SCORING SYSTEM; PEPTIC-ULCERS; MORTALITY; SIGNS; POPULATION	Context.-Upper gastrointestinal tract hemorrhage (UGIH) is a common and potentially life-threatening disorder. Resource utilization can vary without adverse effect on patient outcome. Clinical practice guidelines are a potential solution to reduce variation in practice while improving patient outcomes. Objective.-To validate prospectively the safety, acceptability, and impact of a clinical practice guideline defining the medically appropriate length of stay (LOS) for patients hospitalized with UGIH. Design.-Prospective, controlled time-series study with an alternate-month design. Outcome surveyors and patients were blinded to study group allocation. Guideline.-A retrospectively validated scoring system using 4 independent variables: hemodynamics, time from bleeding, comorbidity, and esophagogastroduodenoscopy (EGD) findings to predict risk of adverse events. The quantitative risk for the low-risk subset was 0.6% (95% confidence interval [CI], 0.0%-2.0%) for subsequent complications and 0% (95% CI, 0.0%-0.9%) for life-threatening complications from this retrospective evaluation. Setting.-A 1000-bed, not-for-profit, university-affiliate teaching hospital. Patients.-Consecutive adult patients hospitalized for acute UGIH. Intervention.-Concurrent feedback of guideline recommendation (same-day hospital discharge) to physicians caring for patients at low risk for complication. No risk information was provided during control months. Results.-Seventy percent (209/299) of UGIH patients achieved low-risk status according to the guideline and were therefore potentially suitable for early discharge from the hospital. Providing real-time quantitative risk information (intervention group only) was associated with an increase in guideline compliance from 30% to 70% (P<.001) and a decrease in mean (SD) LOS from 4.6 (3.5) days to 2.9 (1.3) days (mean reduction of 1.7 days per patient; P<.001). No differences in complications, patient health status, or patient satisfaction were found when measured 1 month after discharge. An independent variable predicting decreased hospital LOS for low-risk UGIH patients was early EGD. Conclusions.-Implementation of the clinical practice guideline safely reduced hospital LOS for selected low-risk patients with acute UGIH. Further prospective validation in other settings is warranted.	Healthcare Partners Med Grp, Pasadena, CA 91105 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Hlth Serv Res, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hay, JA (corresponding author), Healthcare Partners Med Grp, 55 E Calif Blvd, Pasadena, CA 91105 USA.							BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BORNMAN PC, 1985, BRIT MED J, V291, P245, DOI 10.1136/bmj.291.6490.245; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CARSTENSEN HE, 1980, SCAND J GASTROENTERO, V15, P103, DOI 10.3109/00365528009181439; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Cooper GS, 1996, GASTROENTEROLOGY, V111, P385, DOI 10.1053/gast.1996.v111.pm8690203; Dixon W.J, 1990, BMDP STAT SOFTWARE; EVERETT S, 1996, GUT               S1, V39, pA4; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P538; FLEISCHER DE, 1990, J CLIN GASTROENTE S2, V12, P41; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, P8; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; Hay JA, 1996, AM J MED, V100, P313, DOI 10.1016/S0002-9343(97)89490-9; HAY JA, 1995, AM J GASTROENTEROL, V90, P1661; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MORGAN AG, 1977, BRIT MED J, V2, P237, DOI 10.1136/bmj.2.6081.237; *NAT CTR HLTH STAT, 1991, VIT HLTH STAT, V13; *NIH CONS DEV PAN, 1990, GASTROINTEST ENDOS S, V36, P31; OSHITA Y, 1986, ENDOSCOPY, V18, P11, DOI 10.1055/s-2007-1018419; PANES J, 1987, LANCET, V2, P1292; PETERSON WL, 1981, NEW ENGL J MED, V304, P925, DOI 10.1056/NEJM198104163041601; PIMPL W, 1987, ENDOSCOPY, V19, P101, DOI 10.1055/s-2007-1013010; PROVENZALE D, 1987, AM J MED SCI, V294, P26, DOI 10.1097/00000441-198707000-00004; RICHTER JM, 1991, J CLIN GASTROENTEROL, V13, P268, DOI 10.1097/00004836-199106000-00005; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; SAEED ZA, 1995, GASTROINTEST ENDOSC, V41, P561, DOI 10.1016/S0016-5107(95)70191-5; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	34	136	137	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2151	2156		10.1001/jama.278.24.2151	http://dx.doi.org/10.1001/jama.278.24.2151			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417008				2023-01-03	WOS:000071022200030
J	Blum, RH				Blum, RH			Simplified vs complex adjuvant chemotherapy schedule for osteosarcoma	LANCET			English	Editorial Material											Blum, RH (corresponding author), ST VINCENTS COMPREHENS CANC CTR,NEW YORK,NY 10011, USA.							ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E	1	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					900	901		10.1016/S0140-6736(05)63262-X	http://dx.doi.org/10.1016/S0140-6736(05)63262-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314864				2023-01-03	WOS:A1997XY67200004
J	Minkoff, H; Bauer, T; Joyce, T				Minkoff, H; Bauer, T; Joyce, T			Welfare reform and the obstetrical care of immigrants and their newborns	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMPACT		NATL BUR ECON RES,NEW YORK,NY 10017	National Bureau of Economic Research	Minkoff, H (corresponding author), SUNY HLTH SCI CTR,BOX 24,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							*ASS AM MED COLL, 1997, AAMC FACT SHEET, V1; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BUESCHER PA, 1991, AM J PUBLIC HEALTH, V81, P1625, DOI 10.2105/AJPH.81.12.1625; CHAVEZ LR, 1986, WOMEN HEALTH, V11, P3, DOI 10.1300/J013v11n02_02; *DEP HLTH SERV, 1997, MED CAL FUND DEL 199; Halfon N, 1997, JAMA-J AM MED ASSOC, V277, P636, DOI 10.1001/jama.277.8.636; *MARCH DIM BIRTH D, 1995, FACTS MED PREGN WOM; Minkoff H, 1997, NEW ENGL J MED, V336, P1392, DOI 10.1056/NEJM199705083361916; *NAT GOV ASS, 1996, STAT MED COV PREGN W; Reichman NE, 1996, J HEALTH ECON, V15, P455, DOI 10.1016/S0167-6296(96)00491-2; SINGH S, 1994, FAM PLANN PERSPECT, V26, P31, DOI 10.2307/2136094	11	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					705	707		10.1056/NEJM199709043371011	http://dx.doi.org/10.1056/NEJM199709043371011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU349	9278471				2023-01-03	WOS:A1997XU34900011
J	Balas, EA; Jaffrey, F; Kuperman, GJ; Boren, SA; Brown, GD; Pinciroli, F; Mitchell, JA				Balas, EA; Jaffrey, F; Kuperman, GJ; Boren, SA; Brown, GD; Pinciroli, F; Mitchell, JA			Electronic communication with patients - Evaluation of distance medicine technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; FOLLOW-UP; COMPUTERIZED REMINDERS; APPOINTMENT REMINDERS; INFLUENZA VACCINATION; INCREASE COMPLIANCE; COST-EFFECTIVENESS; TELEPHONE PROGRAM; PRIMARY CARE	Objective.-To evaluate controlled evidence on the efficacy of distance medicin Data Sources.-Systematic electronic database and manual searches (1966-1996) were conducted to identify clinical trial reports on distance medicine applications. Study Selection.-Three eligibility criteria were applied: prospective, contemporaneously controlled clinical trial with random assignment of the intervention; electronic distance technology application in the intervention group and no similar intervention in the control group; and measurement of the intervention effect on process or outcome of care. Data Extraction.-Data were abstracted by independent reviewers using a standardized abstraction form and the quality of methodology was scored. Distance technology applications were described in 6 categories. computerized communication, telephone follow-up and counseling, telephone reminders, interactive telephone systems, after-hours telephone access, and telephone screening. Data Synthesis.-Of 80 eligible clinical trials, 61 (76%) analyzed provider-initiated communication with patients and 50 (63%) reported positive outcome, improved performance, or significant benefits, including studies of computerized communication (7 of 7), telephone follow-up and counseling (20 of 37), telephone reminders (14 of 23), interactive telephone systems (5 of 6), telephone access (3 of 4), and telephone screening (1 of 3). Significantly improved outcomes were demonstrated in studies of preventive care, management of osteoarthritis, cardiac rehabilitation, and diabetes care. Conclusions.-Distance medicine technology enables greater continuity of care by improving access and supporting the coordination of activities by a clinician, The benefits of distance technologies in facilitating communication between clinicians and patients indicate that application of telemedicine should not be limited to physician-to-physician communication.	UNIV MISSOURI, SCH MED, INTEGRATED TECHNOL SERV, COLUMBIA, MO 65211 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; POLITECN MILAN, I-20133 MILAN, ITALY	University of Missouri System; University of Missouri Columbia; Harvard University; Brigham & Women's Hospital; Polytechnic University of Milan	Balas, EA (corresponding author), UNIV MISSOURI, SCH MED, HLTH SERV MANAGEMENT PROGRAM, 324 CLARK HALL, COLUMBIA, MO 65211 USA.		Boren, Suzanne Austin/M-6589-2014	Boren, Suzanne Austin/0000-0003-4727-399X; Balas, Andrew/0000-0003-3535-8822; Kuperman, Gilad/0000-0002-4130-1577	NLM NIH HHS [LM05545] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM005545] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		*AD LITTL INC, 1992, TEL CAN IT HELP SOLV; AHRING KK, 1992, DIABETES CARE, V15, P971, DOI 10.2337/diacare.15.8.971; ALEMI F, 1995, MED CARE, V33, P227, DOI 10.1097/00005650-199503000-00002; Alto W A, 1994, J Am Board Fam Pract, V7, P472; BALAS EA, 1995, MED CARE, V33, P687, DOI 10.1097/00005650-199507000-00005; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; BALAS EA, 1995, J AM MED INFORM ASSN, V2, P307, DOI 10.1136/jamia.1995.96073833; BALAS EA, 1994, P 17 ANN S COMP APPL, P586; BECKIE T, 1989, HEART LUNG, V18, P46; BIGBY J, 1983, JAMA-J AM MED ASSOC, V250, P1742, DOI 10.1001/jama.250.13.1742; BILLIARD A, 1991, DIABETES CARE, V14, P130, DOI 10.2337/diacare.14.2.130; Blake R L Jr, 1990, Fam Med, V22, P365; BRENNAN PF, 1995, NURS RES, V44, P166; BRIGG EH, 1968, FAM COORD, V17, P41, DOI 10.2307/581971; BRIMBERRY R, 1988, J FAM PRACTICE, V26, P397; BRYCE RL, 1991, BRIT J OBSTET GYNAEC, V98, P1001, DOI 10.1111/j.1471-0528.1991.tb15338.x; CALLE EE, 1994, AM J PREV MED, V10, P361, DOI 10.1016/S0749-3797(18)30566-X; CAPONE RJ, 1988, AM HEART J, V116, P1606, DOI 10.1016/0002-8703(88)90749-1; CHANDE VT, 1994, PEDIATRICS, V93, P513; CHERRY R, 1994, EAR HEARING, V15, P256, DOI 10.1097/00003446-199406000-00006; *COMM EV CLIN APPL, 1996, TEL GUID ASS TEL HLT; Cummings K M, 1985, Am J Prev Med, V1, P54; DARNELL JC, 1985, MED CARE, V23, P20, DOI 10.1097/00005650-198501000-00003; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; ELDER JP, 1993, AM J PUBLIC HEALTH, V83, P1239, DOI 10.2105/AJPH.83.9.1239; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; FITZGERALD JL, 1985, J STUD ALCOHOL, V46, P418, DOI 10.15288/jsa.1985.46.418; FLETCHER EC, 1991, AM REV RESPIR DIS, V143, P936, DOI 10.1164/ajrccm/143.5_Pt_1.936; FRETWELL MD, 1990, J AM GERIATR SOC, V38, P1073, DOI 10.1111/j.1532-5415.1990.tb01368.x; Gerson L W, 1986, J Community Health, V11, P111, DOI 10.1007/BF01321512; GOODMAN C, 1990, SOC WORK, V35, P556, DOI 10.1093/sw/35.6.556; GOODMAN CC, 1990, GERONTOLOGIST, V30, P399, DOI 10.1093/geront/30.3.399; GORTNER SR, 1990, J ADV NURS, V15, P1132, DOI 10.1111/j.1365-2648.1990.tb01704.x; GROVER S, 1983, CAN MED ASSOC J, V129, P1101; HAGOPIAN GA, 1990, CANCER NURS, V13, P339; HARLOW BL, 1985, AM J EPIDEMIOL, V122, P335, DOI 10.1093/oxfordjournals.aje.a114105; HEATHER N, 1990, BRIT J ADDICT, V85, P1177; INFANTERIVARD C, 1988, J AM GERIATR SOC, V36, P306, DOI 10.1111/j.1532-5415.1988.tb02356.x; JONES PK, 1990, ANN EMERG MED, V19, P16, DOI 10.1016/S0196-0644(05)82133-X; JONES SL, 1988, MED CARE, V26, P1172, DOI 10.1097/00005650-198812000-00007; KING ES, 1994, AM J PUBLIC HEALTH, V84, P104, DOI 10.2105/AJPH.84.1.104; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; KIRSCHT JP, 1981, HEALTH EDUC QUART, V8, P261, DOI 10.1177/109019818100800303; KLUGER MP, 1983, COMMUNITY MENT HLT J, V19, P137, DOI 10.1007/BF00877606; LANDO HA, 1992, AM J PUBLIC HEALTH, V82, P41, DOI 10.2105/AJPH.82.1.41; LEIRER VO, 1991, GERONTOLOGIST, V31, P514, DOI 10.1093/geront/31.4.514; LEIRER VO, 1989, J AM GERIATR SOC, V37, P1147, DOI 10.1111/j.1532-5415.1989.tb06679.x; LERMAN C, 1992, J CLIN ONCOL, V10, P330, DOI 10.1200/JCO.1992.10.2.330; LEVY R, 1977, MED CARE, V15, P435, DOI 10.1097/00005650-197705000-00010; LINDBERG DAB, 1995, JAMA-J AM MED ASSOC, V273, P1667, DOI 10.1001/jama.273.21.1667; LINKINS RW, 1994, ARCH PEDIAT ADOL MED, V148, P908, DOI 10.1001/archpedi.1994.02170090022002; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MAYER JA, 1986, J BEHAV MED, V9, P179, DOI 10.1007/BF00848476; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; Mohler P J, 1995, Fam Med, V27, P117; Munro A J, 1994, Clin Oncol (R Coll Radiol), V6, P242, DOI 10.1016/S0936-6555(05)80294-8; NELSON EW, 1991, AM J DIS CHILD, V145, P440, DOI 10.1001/archpedi.1991.02160040098016; OCKENE JK, 1991, J GEN INTERN MED, V6, P1, DOI 10.1007/BF02599381; ODA DS, 1986, AM J PUBLIC HEALTH, V76, P1348, DOI 10.2105/AJPH.76.11.1348; PARKERSON GR, 1989, MED CARE, V27, P680, DOI 10.1097/00005650-198907000-00003; PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RICHARDSON A, 1994, AUST J PUBLIC HEALTH, V18, P290; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; RUSH JP, 1991, BIRTH-ISS PERINAT C, V18, P193, DOI 10.1111/j.1523-536X.1991.tb00101.x; SANMARTI LS, 1993, TUBERCLE LUNG DIS, V74, P217; SANMARTI LS, 1993, TUBERCLE LUNG DIS, V74, P28, DOI 10.1016/0962-8479(93)90065-6; SCHECTMAN G, 1994, ANN PHARMACOTHER, V28, P29, DOI 10.1177/106002809402800104; Schneider S J, 1993, Proc Annu Symp Comput Appl Med Care, P37; Schroeder S A, 1973, Med Care, V11, P75, DOI 10.1097/00005650-197301000-00010; SERWINT JR, 1991, PEDIATRICS, V88, P444; SHEPARD DS, 1976, MED CARE, V14, P268, DOI 10.1097/00005650-197603000-00008; SHESSER R, 1986, ANN EMERG MED, V15, P911, DOI 10.1016/S0196-0644(86)80674-6; Shultz E K, 1991, Proc Annu Symp Comput Appl Med Care, P53; SHULTZ EK, 1992, ANN NY ACAD SCI, V670, P141, DOI 10.1111/j.1749-6632.1992.tb26084.x; SIMKINS CV, 1986, DRUG INTEL CLIN PHAR, V20, P799, DOI 10.1177/106002808602001017; SORUM PC, 1994, JAMA-J AM MED ASSOC, V272, P1949, DOI 10.1001/jama.272.24.1949; SPARKS KE, 1993, HEART LUNG, V22, P298; STEHRGREEN PA, 1993, PUBLIC HEALTH REP, V108, P426; SWINSON RP, 1995, BEHAV RES THER, V33, P465, DOI 10.1016/0005-7967(94)00061-N; THOMPSON B, 1993, MONOGR NATL CANC I, V14, P105; THOMPSON RS, 1986, MED CARE, V24, P904, DOI 10.1097/00005650-198610000-00004; TURNIN MCG, 1992, DIABETES CARE, V15, P204, DOI 10.2337/diacare.15.2.204; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; WEINBERGER M, 1993, ARTHRITIS RHEUM, V36, P243, DOI 10.1002/art.1780360216; WEINBERGER M, 1994, J AM GERIATR SOC, V42, P1295, DOI 10.1111/j.1532-5415.1994.tb06515.x; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	93	186	190	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					152	159		10.1001/jama.278.2.152	http://dx.doi.org/10.1001/jama.278.2.152			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH667	9214532				2023-01-03	WOS:A1997XH66700037
J	Ramirez, A; House, A				Ramirez, A; House, A			ABC of mental health - Common mental health problems in hospital	BRITISH MEDICAL JOURNAL			English	Article									LAMBETH HEALTHCARE NHS TRUST,LONDON,ENGLAND; GEN INFIRM,DEPT LIAISON PSYCHIAT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	Ramirez, A (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.			House, Allan/0000-0001-8721-8026				Creed F., 1992, MED SYMPTOMS NOT EXP; House A, 1995, PSYCHIAT ASPECTS PHY; *ROYAL COLL PHYS R, 1995, PSYCHOL CAR MED PLAN; Royal College of Psychiatrists, 1994, GEN HOSP MAN AD DEL	4	8	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1679	1681		10.1136/bmj.314.7095.1679	http://dx.doi.org/10.1136/bmj.314.7095.1679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9193294	Green Submitted, Green Published			2023-01-03	WOS:A1997XD87400031
J	Meyboom, A; Maretzki, D; Stevens, PA; Hofmann, KP				Meyboom, A; Maretzki, D; Stevens, PA; Hofmann, KP			Reversible calcium-dependent interaction of liposomes with pulmonary surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SP-A; II CELLS; PHOSPHOLIPID-VESICLES; SECRETION; BINDING; LIPIDS; AGGREGATION; RHODOPSIN; RECEPTOR; DOMAINS	Surfactant protein A (SP-A) is crucial for lung function, including tubular myelin formation and lipid uptake by type II pneumocytes, Known properties of SP-A in vitro are its Ca2+-dependent interaction with phospholipids and its role in the aggregation of liposomes. To dissect and to analyze these processes, we have immobilized SP-A and measured binding of liposomes by the resonant mirror technique. Liposome aggregation was followed separately by kinetic light scattering in suspensions. It was found that SP-A-mediated binding and aggregation of liposomes have a common K-0.5 of 20 mu M for free Ca2+, independent of the species (sheep, rat, or cow) and of the phospholipid composition, and that both reactions exhibit the same high cooperativity (Hill coefficients of 6-9) for Ca2+ ions, However, binding of liposomes to SP-A is >10-fold faster than aggregation. Both processes are completely reversed by low Ca2+ concentrations, but liposomes dissociate from SP-A in <0.3 s, whereas disaggregation of the liposomes takes similar to 30 s. At equilibrium, the level of aggregation depends on the concentration of free SP-A. We interpret these results to be a rapid and reversible sequence of three reactions: (i) a cooperative Ca2+-dependent conformational change in SP-A, (ii) binding of Ca2+-bound SP-A to liposomes, and (iii) aggregation of the Ca2+/SP-A-bound liposomes.	HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,INST MED PHYS & BIOPHYS,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,ABT NEONATOL,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; EFRATI H, 1987, BIOCHEMISTRY-US, V26, P7986, DOI 10.1021/bi00398a066; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0; KING RJ, 1984, EXP LUNG RES, V6, P237, DOI 10.3109/01902148409109251; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; NIELSON DW, 1988, PEDIATR RES, V24, P322, DOI 10.1203/00006450-198809000-00009; OOSTING RS, 1991, AM J PHYSIOL, V261, pL77, DOI 10.1152/ajplung.1991.261.2.L77; ROSS GF, 1991, BIOCHEMISTRY-US, V30, P858, DOI 10.1021/bi00217a040; ROSS GF, 1986, J BIOL CHEM, V261, P14283; Ruano MLF, 1996, BIOCHEM J, V313, P683, DOI 10.1042/bj3130683; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SCHURCH S, 1992, AM J PHYSIOL, V263, pL210, DOI 10.1152/ajplung.1992.263.2.L210; SOHMA H, 1992, BIOCHIM BIOPHYS ACTA, V1159, P150, DOI 10.1016/0167-4838(92)90019-A; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; YINGST DR, 1983, ANAL BIOCHEM, V132, P431, DOI 10.1016/0003-2697(83)90031-3	32	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14600	14605		10.1074/jbc.272.23.14600	http://dx.doi.org/10.1074/jbc.272.23.14600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169419	hybrid			2023-01-03	WOS:A1997XC32700016
J	McLean, GR				McLean, GR			A case for goodwill	BRITISH MEDICAL JOURNAL			English	Article											McLean, GR (corresponding author), UNIV WITWATERSRAND,DEPT PHILOSOPHY,JOHANNESBURG,SOUTH AFRICA.			McLean, Graeme/0000-0003-3632-0906					0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					890	890						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093107				2023-01-03	WOS:A1997WQ02800040
J	Marion, DW; Penrod, LE; Kelsey, SF; Obrist, WD; Kochanek, PM; Palmer, AM; Wisniewski, SR; DeKosky, ST				Marion, DW; Penrod, LE; Kelsey, SF; Obrist, WD; Kochanek, PM; Palmer, AM; Wisniewski, SR; DeKosky, ST			Treatment of traumatic brain injury with moderate hypothermia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE HEAD-INJURY; FOREBRAIN ISCHEMIA; MILD HYPOTHERMIA; DAMAGE; RAT; ISOFLURANE; SCALE; MODEL	Background Traumatic brain injury initiates several metabolic processes that can exacerbate the injury. There is evidence that hypothermia may limit some of these deleterious metabolic responses. Methods In a randomized, controlled trial, we compared the effects of moderate hypothermia and normothermia in 82 patients with severe closed head in juries (a score of 3 to 7 on the Glasgow Coma Scale). The patients assigned to hypothermia were cooled to 33 degrees C a mean of 10 hours after injury, kept at 32 to 33 degrees C for 24 hours, and then rewarmed. A specialist in physical medicine and rehabilitation who was unaware of the treatment assignments evaluated the patients 3, 6, and 12 months later with the use of the Glasgow Outcome Scale. Results The demographic characteristics and causes and severity of injury were similar in the hypothermia and normothermia groups. At 12 months, 62 percent of the patients in the hypothermia group and 38 percent of those in the normothermia group had good outcomes (moderate, mild, or no disabilities). The adjusted risk ratio for a bad outcome in the hypothermia group was 0.5 (95 percent confidence interval, 0.2 to 1.2). Hypothermia did not improve the outcomes in the patients with coma scores of 3 or 4 on admission. Among the patients with scores of 5 to 7, hypothermia was associated with significantly improved outcomes at 3 and 6 months (adjusted risk ratio for a bad outcome, 0.2; 95 percent confidence interval, 0.1 to 0.9 at both intervals), although not at 12 months (risk ratio, 0.3; 95 percent confidence interval, 0.1 to 1.0). Conclusions Treatment with moderate hypothermia for 24 hours in patients with severe traumatic brain injury and coma scores of 5 to 7 on admission hastened neurologic recovery and may have improved the outcome. (C) 1997, Massachusetts Medical Society.	UNIV PITTSBURGH,MED CTR,BRAIN TRAUMA RES CTR,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021	Kochanek, Patrick/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; DeKosky, Steven/0000-0003-3743-2758	NINDS NIH HHS [NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS030318, P50NS030318] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERING EA, 1961, AM J PHYSIOL, V200, P417, DOI 10.1152/ajplegacy.1961.200.3.417; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BUCHAN A, 1990, J NEUROSCI, V10, P311; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; GELB AW, 1989, ANESTHESIOLOGY, V70, P678, DOI 10.1097/00000542-198904000-00023; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Mouritzen CV, 1966, J THORAC CARDIOVASC, V51, P579; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TEASDALE G, 1974, LANCET, V2, P81; THOMAS PD, 1988, J LAB CLIN MED, V111, P286; WARNER DS, 1986, ANESTHESIOLOGY, V64, P19, DOI 10.1097/00000542-198601000-00004; WORINGER E, 1954, Anesth Anal, V11, P34; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	39	939	984	1	63	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					540	546		10.1056/NEJM199702203360803	http://dx.doi.org/10.1056/NEJM199702203360803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023090				2023-01-03	WOS:A1997WJ24000003
J	Cragg, DK; McKinley, RK; Roland, MO; Campbell, SM; Van, F; Hastings, AM; French, DP; MankuScott, TK; Roberts, C				Cragg, DK; McKinley, RK; Roland, MO; Campbell, SM; Van, F; Hastings, AM; French, DP; MankuScott, TK; Roberts, C			Comparison of out of hours care provided by patients' own general practitioners and commercial deputising services: A randomised controlled trial .1. The process of care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOURS CALLS	Objective: To compare the process of out of hours care provided by general practitioners from patients' own practices and by commercial deputising services. Design: Randomised controlled trial. Setting: Four urban areas in Manchester, Salford, Stockport, and Leicester. Subjects: 2152 patients who requested out of hours care, and 49 practice doctors and 183 deputising doctors (61% local principals) who responded to those requests. Main outcome measures: Response to call, time to visit, prescribing, and hospital admissions. Results: 1046 calls were dealt with by practice doctors and 1106 by deputising doctors. Practice doctors were more likely to give telephone advice (20.2% v 0.72% of calls) and to visit more quickly than deputising doctors (median delay 35 minutes v 52 minutes). Practice doctors were less likely than deputising doctors to issue a prescription (56.1% v 63.2% of patients) or to prescribe an antibiotic (43.7% v 61.3% of prescriptions issued) and more likely to prescribe generic drugs (58.4% v 32.1% of drugs prescribed), cheaper drugs (mean cost per prescription pound 3.28 v pound 5.04), and drugs in a predefined out of hours formulary (49.8% v 41.1% of drugs prescribed. There was no significant difference in the number of hospital admissions. Conclusions: By contrast with practice doctors, deputising doctors providing out of hours care less readily give telephone advice, take longer to visit at home, and have patterns of prescribing that may be less discriminating.	UNIV LEICESTER, LEICESTER GEN HOSP, DEPT GEN PRACTICE & PRIMARY HLTH CARE, LEICESTER LE5 4PW, LEICS, ENGLAND; UNIV MANCHESTER, NATL PRIMARY CARE RES & DEV, MANCHESTER M13 9PL, LANCS, ENGLAND; UNIV MANCHESTER, DEPT GEN PRACTICE, RUSHOLME HLTH CTR, MANCHESTER M14 5NP, LANCS, ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Manchester; University of Manchester			McKinley, Robert Kee/H-9211-2013; French, David P/K-7283-2012	McKinley, Robert Kee/0000-0002-3684-3435; French, David P/0000-0002-7663-7804; Campbell, Stephen/0000-0002-2328-4136				ACHESON D, 1981, PRIMARY HLTH CARE IN; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; CRAGG D, 1994, BRIT MED J, V309, P1630; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; CROWE MGF, 1976, BRIT MED J, V1, P1582, DOI 10.1136/bmj.1.6025.1582; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; *DEP HLTH SOC SEC, 1984, GEN PRACT DEP SERV; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; *EL REF BALL SERV, 1992, YOUR CHOIC FUT SURV; GOLDSTEIN H, 1995, MULTILEEL STAT MODEL; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; HASTINGS A, 1996, PHARM J, V256, P900; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; McKinley RK, 1997, BMJ-BRIT MED J, V314, P190, DOI 10.1136/bmj.314.7075.190; NAZARETH I, 1993, BRIT MED J, V306, P1103, DOI 10.1136/bmj.306.6885.1103; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; Rasbash J., 1995, MLN COMMAND REFERENC; RIDSDILLSMITH RM, 1983, UPDATE, V26, P274; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; WHITBY M, 1989, PRACTITIONER, V233, P493; WILLIAMS BT, 1973, BRIT J PREV SOC MED, V27, P129	27	34	34	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					187	189		10.1136/bmj.314.7075.187	http://dx.doi.org/10.1136/bmj.314.7075.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022434	Green Published			2023-01-03	WOS:A1997WD91100029
J	Tesfaye, S; Watt, J; Benbow, SJ; Pang, KA; Miles, J; MacFarlane, IA				Tesfaye, S; Watt, J; Benbow, SJ; Pang, KA; Miles, J; MacFarlane, IA			Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy	LANCET			English	Article							BLOOD-FLOW; INTRACTABLE PAIN; EXPERIENCE	Background Conventional treatment for painful peripheral diabetic neuropathy is largely symptomatic and often ineffective, with unacceptable side-effects. We tested electrical spinal-cord stimulation for the management of chronic neuropathic pain, Methods Ten diabetic patients who did not respond to conventional treatment (mean age 51 [SD 9.3] years, six with type II diabetes, mean duration of diabetes 12 [6.3] years, mean duration of neuropathy 5 [2.1] years) were studied. The electrode was implanted in the thoracic/lumbar epidural space. Immediate neuropathic pain relief was assessed by visual analogue scale (VAS) after connecting the electrode, in a random order, to a percutaneous electrical stimulator or to a placebo stimulator, Exercise tolerance was assessed on a treadmill. Findings Eight subjects had statistically significant pain relief with the electrical stimulator (p<0.02) and were therefore converted to a permanent system, Statisically significant relief of both background and peak neuropathic pain was achieved at 3 months (n=7, p=0.016), at 6 months (n=7, p=0.03), and at the end of the study (14 months, n=7, background pain p=0.06, peak pain p=0.03). One patient died 2 months after the start of the study of unrelated cause while continuing to benefit from treatment and another patient ceased to benefit at 4 months. McGill pain questionnaire scores with the stimulator turned off did not change significantly from baseline scores, indicating that the severity of the underlying pain was unaltered. However, with the stimulator turned on, there was a statistically significant (p<0.05) improvement in all four components of the score, by the end of the study. At the end of the study, six patients continued to gain significant pain relief and used the stimulator as the sole treatment for their neuropathic pain. For example, median background and peak pain scores at the end of study, were, respectively, 77 and 81 with the stimulator off and 23 and 20 with the stimulator on. Exercise tolerance significantly improved at 3 months (n=7, median % increase 85 [IQR, 62-360], p=0.015) and at 6 months (n=6, 163 [61-425], p=0.0007). Electrophysiological tests, vibration perception-threshold, and glycaemic control were unchanged. Interpretation Electrical spinal-cord stimulation offers a new and effective way of relieving chronic diabetic neuropathic pain and improves exercise tolerance. The technique should be considered in patients with neuropathic pain who do not respond to conventional treatment.	WALTON DIABET CTR,LIVERPOOL,MERSEYSIDE,ENGLAND; WALTON HOSP,DEPT NEUROPHYSIOL,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND; PAIN RES INST,LIVERPOOL,MERSEYSIDE,ENGLAND	Walton Centre; University of Liverpool				Tesfaye, Solomon/0000-0003-1190-1472				BENBOW SJ, 1994, DIABETIC MED, V11, P17, DOI 10.1111/j.1464-5491.1994.tb00223.x; BOULTON AJM, 1982, DIABETES CARE, V5, P386, DOI 10.2337/diacare.5.4.386; CAMERON NE, 1993, DIABETIC MED, V10, P593, DOI 10.1111/j.1464-5491.1993.tb00131.x; CHAN A W, 1990, Pain Clinic, V3, P147; CHAN AW, 1988, J NEUROL NEUROSUR PS, V51, P688, DOI 10.1136/jnnp.51.5.688; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; DYCK PJ, 1988, MUSCLE NERVE, V11, P21, DOI 10.1002/mus.880110106; JACOBS MJHM, 1988, ANN SURG, V207, P179, DOI 10.1097/00000658-198802000-00011; Long D M, 1975, Surg Neurol, V4, P134; LONG DM, 1981, APPL NEUROPHYSIOL, V44, P207; *MCG PAIN QUEST, 1975, PAIN, V1, P277; NAUGHTON J, 1964, AM J CARDIOL, V14, P837, DOI 10.1016/0002-9149(64)90011-6; NORTH RB, 1993, NEUROSURGERY, V32, P384, DOI 10.1227/00006123-199303000-00008; RAY CD, 1988, LUMBAR SPINE SURG IN; SIMPSON BA, 1991, J NEUROL NEUROSUR PS, V54, P196, DOI 10.1136/jnnp.54.3.196; SIMPSON BA, 1994, PAIN REV, V1, P1999; TESFAYE S, 1993, DIABETOLOGIA, V36, P1266, DOI 10.1007/BF00400804; Tesfaye S, 1996, DIABETOLOGIA, V39, P1377, DOI 10.1007/s001250050586; TESFAYE S, 1994, DIABETES NUTR METAB, V7, P375; TESFAYE S, 1994, DIABETOLOGIA, V37, P847, DOI 10.1007/BF00400938; TESFAYE S, 1992, DIABETOLOGIA, V35, P155, DOI 10.1007/BF00402548; WATKINS ES, 1993, BRIT MED J, V307, P462, DOI 10.1136/bmj.307.6902.462; WATKINS PJ, 1984, BRIT MED J, V288, P168, DOI 10.1136/bmj.288.6412.168; 1985, LANCET, V1, P83	24	177	183	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1698	1701		10.1016/S0140-6736(96)02467-1	http://dx.doi.org/10.1016/S0140-6736(96)02467-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973433				2023-01-03	WOS:A1996VZ76600013
J	Kirkpatrick, AF				Kirkpatrick, AF			Role of the USA in shortage of food and medicine in Cuba	LANCET			English	Article							EPIDEMIC	For over 30 years an embargo by the USA has restricted Cuba's ability to purchase foods and medicines. In 1992, the USA enacted the Cuban Democracy Act (CDA), which ''exempted'' the sale of medicines from the embargo. However, the implementation of the CDA's requirements and the intensification of the embargo as a result of the passage of the Helms-Burton Act in March, 1996, have undermined the purpose of the medicine exemption. The resultant lack of food and medicine to Cuba contributed to the worst epidemic of neurological disease this century. The Inter-American Commission on Human Rights of the Organization of American States has informed the US Government that such activities violate international law and has requested that the US take immediate steps to exempt food and medicine from the embargo.			Kirkpatrick, AF (corresponding author), UNIV S FLORIDA,COLL MED,12901 BRUCE B DOWNS BLVD,BOX 59,TAMPA,FL 33612, USA.							*AM PUBL HLTH ASS, 1993, POL SUFF IMP US EMB; *AMN INT, 1995, US HUM RIGHTS VIOL S; BARRAL PE, 1990, 15 YEARS RESULTS PHA; CARTER T, 1995, WASHINGTON TIME 0730; *CUBA NEUR FIELD I, 1995, NEW ENGL J MED, V333, P1176; *HUM RIGHTS WATCH, 1995, CUB IMPR REF; Kirkpatrick AF, 1996, JAMA-J AM MED ASSOC, V275, P1633, DOI 10.1001/jama.1996.03530450023014; MONMANEY T, 1995, LOS ANGELES TIM 1120; *PHARM RES MAN AM, 1994, WORLD CLASS DRUGS OR; REDWOOD H, 1994, PRICE REGULATION PHA; ROMAN GC, 1995, ANN INTERN MED, V122, P530, DOI 10.7326/0003-4819-122-7-199504010-00009; ROMAN GC, 1994, NEUROLOGY, V44, P1784, DOI 10.1212/WNL.44.10.1784; WALTE J, 1995, USA TODAY       0307; 1995, USA TODAY       1025, pA3	14	27	31	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1489	1491		10.1016/S0140-6736(96)07376-X	http://dx.doi.org/10.1016/S0140-6736(96)07376-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942780				2023-01-03	WOS:A1996VV46300013
J	vanderWal, G; van der Maas, PJ; Bosma, JM; OnwuteakaPhilipsen, BD; Willems, DL; Haverkate, I; Kostense, PJ				vanderWal, G; van der Maas, PJ; Bosma, JM; OnwuteakaPhilipsen, BD; Willems, DL; Haverkate, I; Kostense, PJ			Evaluation of the notification procedure for physician-assisted death in the Netherlands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA	Background In the Netherlands, a notification procedure for physician-assisted death has been in use since 1991. it requires doctors to report each case to the coroner, who in turn notifies the public prosecutor. Ultimately, the Assembly of Prosecutors General decides whether to prosecute. Although physician-assisted death remains technically illegal, doctors are extremely unlikely to be prosecuted if they comply with the requirements for accepted practice. In 1995, the ministers of health and justice commissioned an evaluation to determine the adequacy of the notification procedure. Methods A random sample of 405 physicians were interviewed. We also interviewed 147 physicians who had reported cases of physician-assisted death and 116 coroners, and we reviewed 353 judicial files of reported cases. In addition, we interviewed 48 public prosecutors and reviewed the minutes of the Assembly of Prosecutors General for 1991 to 1995 and all published court decisions from 1981 through 1995. Results in 1995, about 41 percent of all cases of euthanasia and physician-assisted suicide were reported. There were no major differences between reported and unreported cases in terms of the patients' characteristics, clinical conditions, or reasons for the action. Most patients had cancer and were described as suffering ''unbearably'' and ''hopelessly.'' Of the 6324 cases reported during the period from 1991 through 1995, only 13 involved prosecution of the physician. The majority of respondents in the groups interviewed thought that all cases of physician-asssisted death should be reviewed, although most doctors thought the review should be performed by other doctors, and there was substantial concern about the burden associated with the reporting procedure. Conclusions Substantial progress in the oversight of physician-assisted death has been achieved in the Netherlands. The reporting procedure could be more streamlined and less threatening. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT GEN PRACTICE NURSING HOME & SOCIAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT EPIDEMIOL & BIOSTAT, NL-1081 BT AMSTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam								ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; Gardner M, 1989, BRIT MED J; Haverkate I, 1996, JAMA-J AM MED ASSOC, V275, P435, DOI 10.1001/jama.275.6.435; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, HLTH POLICY, V22; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346	10	160	160	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1706	1711						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8965876				2023-01-03	WOS:A1996VV93600035
J	Gear, RW; Miaskowski, C; Gordon, NC; Paul, SM; Heller, PH; Levine, JD				Gear, RW; Miaskowski, C; Gordon, NC; Paul, SM; Heller, PH; Levine, JD			Kappa-opioids produce significantly greater analgesia in women than in men	NATURE MEDICINE			English	Article							SEX-DIFFERENCES; SWIM ANALGESIA; PAIN; GENDER; PHARMACOKINETICS; PREGNANCY; MORPHINE; RECEPTOR; RATS; GONADECTOMY	Sex differences in human responses to nociceptive stimuli and painful pathological conditions have generally indicated that women report higher pain levels or exhibit less tolerance than men for given stimulus intensities (reviewed in ref. 1 and 2). However, studies have not evaluated sex differences in analgesic responses. We recently reported the opioid agonist-antagonist that pentazocine, which acts predominantly at kappa-receptors, produced significantly better postoperative analgesia in females than in males(3,4) in patients who underwent surgery for the removal of their third molars (wisdom teeth). In the current study, we evaluated the hypothesis that this sex difference is a characteristic of kappa-opioid agonism. In order to determine whether there are sex differences associated with kappa-opioid agonism, the analgesic efficacy of two other predominantly kappa-opioid analgesics, nalbuphine and butorphanol, was compared in males and females who underwent surgery for the removal of third molar teeth. We found that both nalbuphine and butorphanol produced significantly greater analgesia in females as compared with males. Considering our earlier findings, we conclude that kappa-opioid analgesia is greater in females than in males, probably reflecting a difference in kappa-opioid-activated endogenous pain modulating circuits.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV RHEUMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RESTORAT DENT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ORAL & MAXILLOFACIAL SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; KAISER FDN HOSP,HAYWARD,CA 94545	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente			Paul, Steve/ABE-5400-2020		NINR NIH HHS [NR 03923 T32-DE07204] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003923] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ALOISI AM, 1994, NEUROSCI LETT, V179, P79, DOI 10.1016/0304-3940(94)90939-3; BAAMONDE AI, 1989, NEUROPHARMACOLOGY, V28, P967, DOI 10.1016/0028-3908(89)90197-4; BEATTY WW, 1970, J COMP PHYSIOL PSYCH, V73, P446, DOI 10.1037/h0030216; CANDIDO J, 1992, PHARMACOL BIOCHEM BE, V42, P685, DOI 10.1016/0091-3057(92)90015-8; COGAN R, 1986, PAIN, V27, P63, DOI 10.1016/0304-3959(86)90223-X; COYLE DE, 1995, NEUROSCI LETT, V186, P135, DOI 10.1016/0304-3940(95)11304-F; DAWSONBASOA MB, 1993, BRAIN RES, V601, P241, DOI 10.1016/0006-8993(93)91716-6; DYRENFURTH I, 1974, BIORHYTHMS HUMAN REP, P171; FAUCETT J, 1994, J PAIN SYMPTOM MANAG, V9, P383, DOI 10.1016/0885-3924(94)90175-9; Fillingim RB, 1995, PAIN FORUM, V4, P209, DOI 10.1016/S1082-3174(11)80022-X; Gear RW, 1996, NEUROSCI LETT, V205, P207, DOI 10.1016/0304-3940(96)12402-2; GINTZLER AR, 1980, SCIENCE, V210, P193, DOI 10.1126/science.7414330; GORDON NC, 1995, NEUROSCIENCE, V69, P345, DOI 10.1016/0306-4522(95)00335-G; HALPERN SH, 1996, ANESTH ANALG, V82, pS159; JAILLON P, 1989, CLIN PHARMACOL THER, V46, P226, DOI 10.1038/clpt.1989.130; KEPLER KL, 1989, PHARMACOL BIOCHEM BE, V34, P119, DOI 10.1016/0091-3057(89)90363-8; KEPLER KL, 1991, PAIN, V45, P87, DOI 10.1016/0304-3959(91)90168-W; KEPLER KL, 1988, PHARMACOL BIOCHEM BE, V29, P83, DOI 10.1016/0091-3057(88)90278-X; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; MARKS HE, 1972, PHYSIOL BEHAV, V8, P1113, DOI 10.1016/0031-9384(72)90206-5; MUSACCHIO JM, 1990, NEUROPSYCHOPHARMACOL, V3, P191; Pande AC, 1996, CLIN NEUROPHARMACOL, V19, P92, DOI 10.1097/00002826-199619010-00009; PARE WP, 1969, J COMP PHYSIOL PSYCH, V69, P214, DOI 10.1037/h0028196; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; ROMERO MT, 1986, PHYSIOL BEHAV, V37, P893, DOI 10.1016/S0031-9384(86)80009-9; ROMERO MT, 1988, PHYSIOL BEHAV, V44, P257, DOI 10.1016/0031-9384(88)90147-3; SANDER HW, 1988, BRAIN RES, V474, P343, DOI 10.1016/0006-8993(88)90448-9; SHYU WC, 1994, EUR J CLIN PHARMACOL, V47, P57; UNRUH AM, 1993, PAIN, V65, P123; WILSON SJ, 1986, AM J OBSTET GYNECOL, V155, P340, DOI 10.1016/0002-9378(86)90822-7	31	341	351	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1248	1250		10.1038/nm1196-1248	http://dx.doi.org/10.1038/nm1196-1248			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898754				2023-01-03	WOS:A1996VQ10100042
J	vanBalen, FAM; deMelker, RA; TouwOtten, FWMM				vanBalen, FAM; deMelker, RA; TouwOtten, FWMM			Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice	LANCET			English	Article							SECRETORY OTITIS; DECONGESTANT-ANTIHISTAMINE; ANTIMICROBIAL THERAPY; CHILDREN; EFFICACY; ANTIBIOTICS; MANAGEMENT; PATHOGENS; STEROIDS; EAR	Background The treatment of persistent otitis media with effusion (OME) remains controversial, but this condition is the commonest reason for children to require ear, nose, and throat (ENT) surgery, Trials of antibiotics are inconclusive, are often weak methodologically, and have not been done in general practice. Our aim was a trial of an antibiotic for OME in such a population. Methods 433 children, aged 6 months to 6 years, with OME from 57 general practices entered a 3-month watchful waiting period. Of 223 (52%) with persistent bilateral OME, 162 were randomised double-blind to receive co-amoxiclav suspension (20 mg/kg amoxicillin, 5 mg/kg clavulanate potassium) or matching placebo, orally three times a day for 14 days. All cases also received xylometazoline 0.25% decongestant nosedrops thrice daily. Of the 61 not randomised, 13 children were referred to an ENT surgeon and parents refused consent in 48 cases. The main outcome measures were persistent OME in both ears and in one or both ears, as assessed clinically and by tympanometry. Analysis was by intention-to-treat. Findings 79 children in the treatment group and 70 in the placebo group were analysed for efficacy. 3 withdrew in the co-amoxiclav group (2 lost to follow-up, 1 due to side-effects); 6 withdrew in the placebo group (5 and 1, respectively). In addition, 4 tympanograms were uninterpretable in the controls. Compliance was over 90% in both groups, Persistent OME in both ears and in one or both ears were found at significantly lower rates in the co-amoxiclav group than in the controls at the 2-week followup: 53 vs 84% and 77 vs 93%, respectively, Odds ratios adjusted for sex, history of adenoidectomy, and upper respiratory tract infection at follow-up were 0.25 (95% CI 0.11, 0.58, p=0.001) and 0.30 (0.10, 0.89, p=0.03), respectively. Parents of children in the co-amoxiclav group reported significantly more side-effects than those of control children (44 vs 22%, p=0.03). Side-effects were mostly gastrointestinal and mild. Interpretation Our study in a general-practice setting confirmed the positive short-term effect of antibiotic treatment for persistent middle-ear infection. Before referral to an ENT surgeon, children with persistent OME presenting to general practitioners could be considered for such treatment, depending on the individual child and possible adverse sequelae.			vanBalen, FAM (corresponding author), UNIV UTRECHT,DEPT GEN PRACTICE,NL-3584 CG UTRECHT,NETHERLANDS.							BERMAN S, 1994, PEDIATRICS, V93, P353; BLUESTONE CD, 1992, CLIN INFECT DIS, V14, pS197, DOI 10.1093/clinids/14.Supplement_2.S197; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CANTEKIN EI, 1991, JAMA-J AM MED ASSOC, V266, P3309; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CORWIN MJ, 1986, INT J PEDIATR OTORHI, V11, P109, DOI 10.1016/S0165-5876(86)80005-2; DEMELKER RA, 1993, BRIT MED J, V306, P5, DOI 10.1136/bmj.306.6869.5; DIAMOND C, 1989, J LARYNGOL OTOL, V103, P369, DOI 10.1017/S0022215100108989; FADEN H, 1994, PEDIATR INFECT DIS J, V13, P609, DOI 10.1097/00006454-199407000-00005; FIELLAU-NIKOLAJSEN M, 1979, Scandinavian Audiology, V8, P181, DOI 10.3109/01050397909076319; FIELLAUNIKOLAJSEN M, 1983, ANN OTO RHINOL LARYN, V92, P172, DOI 10.1177/000348948309200215; GIEBINK GS, 1990, PEDIATR INFECT DIS J, V9, P33, DOI 10.1097/00006454-199001000-00008; HEALY GB, 1984, INT J PEDIATR OTORHI, V8, P13, DOI 10.1016/S0165-5876(84)80021-X; JERGER J, 1970, ARCHIV OTOLARYNGOL, V92, P311; KARMA P, 1988, ACTA OTOLARYNGOL STO, V449, P47; MAKININ ML, 1985, PEDIATRICS, V75, P329; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MOLLER P, 1990, J LARYNGOL OTOL, V104, P200, DOI 10.1017/S0022215100112277; PODOSHIN L, 1990, ARCH OTOLARYNGOL, V116, P1404; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; ROSENFELD RM, 1991, ARCH OTOLARYNGOL, V117, P984; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; SCHWARTZ RH, 1982, PEDIAT INFECT DIS, V5, P333; STOOL SE, 1994, AHCPR PUBLICATION; THOMSEN J, 1989, ARCH OTOLARYNGOL, V115, P447; TOS M, 1979, ARCH OTOLARYNGOL, V105, P582; *U LEEDS, 1992, U LEEDS B, V4; VANBALEN FAM, 1994, INT J PEDIATR OTORHI, V29, P219, DOI 10.1016/0165-5876(94)90168-6; VANDELISDONK EH, 1991, HUISARTS WET, V34, P426; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; ZIELHUIS G, 1989, LANCET, V11, P311; ZIELHUIS GA, 1990, INT J EPIDEMIOL, V19, P1037, DOI 10.1093/ije/19.4.1037	32	39	40	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					713	716		10.1016/S0140-6736(96)02511-1	http://dx.doi.org/10.1016/S0140-6736(96)02511-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806290				2023-01-03	WOS:A1996VG37400010
J	Barr, H; Shepherd, NA; Dix, A; Roberts, DJH; Tan, WC; Krasner, N				Barr, H; Shepherd, NA; Dix, A; Roberts, DJH; Tan, WC; Krasner, N			Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX	LANCET			English	Article							ESOPHAGUS; ADENOCARCINOMA; PHOTOSENSITIZATION; ABLATION; MUCOSA; CANCER; ACID	Background High-grade dysplasia in columnar-lined (Barrett's) oesophagus presents a difficult therapeutic dilemma. Choices for management are endoscopic surveillance to detect a cancer or oesophagectomy. One carries the risk of missing invasive cancer, the other carries worrying morbidity and mortality. We have used endoscopic photodynamic therapy to eradicate high-grade dysplasia. Methods After the oral administration of 5-aminolaevulinic acid, the accumulation of the endogenously generated photosensitiser protoporphyrin IX was measured with quantitative fluorescence microscopy. Five patients with histologically confirmed high-grade dysplasia were treated with endoscopic photodynamic therapy with 630 nm laser light to activate the photosensitiser. Findings Protoporphyrin IX accumulated in the dysplastic epithelium rather than the adjacent stroma. Selective necrosis of the dysplastic epithelium in columnar-lined oesophagus occurred after light activation. High-grade dysplasia was eradicated in all patients and squamous regeneration occurred after acid suppression with a proton-pump inhibitor. There were no complications or recurrence of dysplasia after 26-44 months' endoscopic and histological follow-up. In two cases we saw non-dysplastic Barrett's epithelium underneath regenerative squamous mucosa. Interpretation High-grade dysplasia in columnar-lined oesophagus can be eradicated by endoscopic photodynamic therapy with endogenously generated PpIX. Remaining non-dysplastic Barrett's epithelium will require surveillance, but overall the technique has interrupted or delayed the worsening of the dysplasia through to carcinoma. This technique may prevent the need for surgical excision in these patients.	UNIV LEEDS,CTR PHOTOBIOL & PHOTODYNAM THERAPY,LEEDS,W YORKSHIRE,ENGLAND; AINTREE HOSP,DEPT GASTROENTEROL,LIVERPOOL,MERSEYSIDE,ENGLAND	University of Leeds; Aintree University Hospitals NHS Foundation Trust	Barr, H (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTERSHIRE ROYAL & CRANFIELD UNIV INST MED SCI,GLOUCESTER GL1 3NN,ENGLAND.		Shepherd, Neil A/AAV-3565-2021					ALTORKI NK, 1991, AM J SURG, V161, P97, DOI 10.1016/0002-9610(91)90367-M; BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; GORE S, 1993, ALIMENT PHARM THERAP, V7, P923; GRANT WE, 1993, LANCET, V342, P147, DOI 10.1016/0140-6736(93)91347-O; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; LAUKKA MA, 1995, GASTROINTEST ENDOSC, V42, P59, DOI 10.1016/S0016-5107(95)70245-8; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Loh CS, 1996, GUT, V38, P71, DOI 10.1136/gut.38.1.71; MCFARLANE GJ, 1994, J R SOC MED, V78, P334; OVERHOLT BF, 1995, GASTROINTEST ENDOSC, V42, P64, DOI 10.1016/S0016-5107(95)70246-6; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67	12	280	285	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					584	585		10.1016/S0140-6736(96)03054-1	http://dx.doi.org/10.1016/S0140-6736(96)03054-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774572				2023-01-03	WOS:A1996VF18600013
J	MacDonagh, SE; Masters, J; Helps, BA; Tookey, PA; Ades, AE; Gibb, DM				MacDonagh, SE; Masters, J; Helps, BA; Tookey, PA; Ades, AE; Gibb, DM			Descriptive survey of antenatal HIV testing in London: Policy, uptake, and detection	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSMISSION				MacDonagh, SE (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Holland F J, 1994, J Med Screen, V1, P176	4	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					532	533						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789982				2023-01-03	WOS:A1996VF29400022
J	Keteyian, SJ; Levine, AB; Brawner, CA; Kataoka, T; Rogers, FJ; Schairer, JR; Stein, PD; Levine, TB; Goldstein, S				Keteyian, SJ; Levine, AB; Brawner, CA; Kataoka, T; Rogers, FJ; Schairer, JR; Stein, PD; Levine, TB; Goldstein, S			Exercise training in patients with heart failure - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							V-SLOPE METHOD; ANAEROBIC THRESHOLD; GAS-EXCHANGE; VENTRICULAR-FUNCTION; MUSCLE METABOLISM; PERFORMANCE; CAPACITY; DISEASE	Objective: To assess the benefit of exercise training in patients with heart failure caused by left ventricular systolic dysfunction and to further describe the physiologic changes associated with exercise training in these patients. Design: Randomized, controlled trial. Setting: Urban outpatient clinic. Patients: 40 men with compensated heart failure who were receiving standard medical therapy were randomly assigned to an exercise-training group or to a control group that did not exercise. Fifteen of the 21 patients assigned to exercise training and 14 of the 19 patients assigned to the control group completed the study. Intervention: Patients assigned to exercise training participated in a program of three exercise sessions per week for 24 weeks. Measurements: Symptom-limited exercise tests with gas exchange analysis done just before randomization, at week 12, and at week 24. Results: At week 24, the following changes (mean +/- SE) were seen in patients in the exercise group and patients in the control group, respectively: exercise duration, 2.8 +/- 0.6 minutes and 0.5 +/- 0.5 minutes; peak oxygen consumption (VO2), 231 +/- 54 L/min and 58 +/- 38 L/min; peak ventilation, 12 +/- 3 L/min and -4 +/- 3 L/min; peak heart rate, 10 +/- 4 beats/min and -2 +/- 4 beats/min; and peak power output, 20 +/- 6 W and 2 +/- 5 W. Differences between the increases occurring in the exercise group and the changes occurring in the control group were significant (P < 0.05). Among patients in the exercise group, 85% of the increase in peak VO2 occurred by week 12, and 46% of the increase in peak VO2 was caused by the increase in peak heart rate. Conclusions: Exercise training does not appear to be contraindicated in patients with compensated heart failure. Exercise training improved exercise tolerance, as measured by increases in peak VO2, exercise duration, and power output. This improved exercise tolerance was caused in part by an increase in peak heart rate.			Keteyian, SJ (corresponding author), HENRY FORD HOSP, HENRY FORD HEART & VASC INST, SUITE 1107, 2921 W GRAND BLVD, DETROIT, MI 48202 USA.		Brawner, Clinton A/K-6859-2019	Brawner, Clinton A./0000-0002-1705-6620				ADAMOPOULOS S, 1993, J AM COLL CARDIOL, V21, P1101, DOI 10.1016/0735-1097(93)90231-O; *AM COLL SPORTS ME, 1991, GUID EX TEST PRESCR, P148; ARVAN S, 1988, AM J CARDIOL, V62, P197, DOI 10.1016/0002-9149(88)90211-1; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; BULLER NP, 1990, BRIT HEART J, V63, P281; Chandrashekhar Y, 1993, Indian Heart J, V45, P493; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COHENSOLAL A, 1994, HEART FAILURE    APR, P46; DICKSTEIN K, 1990, AM J CARDIOL, V66, P1363, DOI 10.1016/0002-9149(90)91169-7; GELSSER S, 1958, ANN MATH STAT, V29, P885; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; JETTE M, 1991, CIRCULATION, V84, P1561, DOI 10.1161/01.CIR.84.4.1561; KETEYIAN S, 1991, J APPL PHYSIOL, V70, P2627, DOI 10.1152/jappl.1991.70.6.2627; KIILAVUORI K, 1995, EUR HEART J, V16, P490; KOCH M, 1992, CHEST, V101, pS231, DOI 10.1378/chest.101.5_Supplement.231S; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; LEE AP, 1979, CIRCULATION, V60, P1519, DOI 10.1161/01.CIR.60.7.1519; MANCINI DM, 1992, CIRCULATION, V85, P1364, DOI 10.1161/01.CIR.85.4.1364; MEYER TE, 1991, J INTERN MED, V230, P407, DOI 10.1111/j.1365-2796.1991.tb00465.x; MINOTTI JR, 1990, J CLIN INVEST, V86, P751, DOI 10.1172/JCI114771; MYERS J, 1991, ANN INTERN MED, V115, P377, DOI 10.7326/0003-4819-115-5-377; SCHNEIDER DA, 1993, MED SCI SPORT EXER, V25, P1180; SMITH RF, 1993, CIRCULATION, V87, P88; STRATTON JR, 1994, J APPL PHYSIOL, V76, P1575, DOI 10.1152/jappl.1994.76.4.1575; SUE DY, 1988, CHEST, V94, P931, DOI 10.1378/chest.94.5.931; SULLIVAN MJ, 1990, CIRCULATION, V81, P518, DOI 10.1161/01.CIR.81.2.518; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506	28	150	152	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1051	1057		10.7326/0003-4819-124-12-199606150-00004	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633818				2023-01-03	WOS:A1996UQ65800004
J	Hamblin, R; Harrison, A; Boyle, S				Hamblin, R; Harrison, A; Boyle, S			The supertanker's not for turning	LANCET			English	Editorial Material											Hamblin, R (corresponding author), KINGS FUND, LONDON W1M 0AN, ENGLAND.							APPLEBY J, 1994, HLTH SERVICE J, V104, P36; Dixon J, 1997, BRIT MED J, V314, P86, DOI 10.1136/bmj.314.7074.86; NEWTON JN, 1995, BRIT MED J, V311, P783, DOI 10.1136/bmj.311.7008.783; *NHS EX, 1997, EX LETT, V97, P42	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1493	1494		10.1016/S0140-6736(05)63937-2	http://dx.doi.org/10.1016/S0140-6736(05)63937-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388394				2023-01-03	WOS:A1997YH11500005
J	Katz, J				Katz, J			Phantom limb pain	LANCET			English	Editorial Material							REGIONAL ANALGESIA; AMPUTATION; BLOCK		TORONTO GEN HOSP,DEPT ANAESTHESIA,TORONTO,ON M5G 2C4,CANADA; MT SINAI HOSP,DEPT ANAESTHESIA,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,DEPT PUBL HLTH SCI,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto	Katz, J (corresponding author), TORONTO GEN HOSP,DEPT PSYCHOL,TORONTO,ON M5G 2C4,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; ELIZAGA AM, 1994, J REHABIL RES DEV, V31, P179; FISHER A, 1991, ANESTH ANALG, V72, P300; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; Katz J, 1997, LANCET, V349, P519, DOI 10.1016/S0140-6736(97)80081-5; Pinzur MS, 1996, J BONE JOINT SURG AM, V78A, P1501, DOI 10.2106/00004623-199610000-00007; SCHUG SA, 1995, REGION ANESTH, V20, P256; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023	8	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1338	1339		10.1016/S0140-6736(05)65130-6	http://dx.doi.org/10.1016/S0140-6736(05)65130-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365444				2023-01-03	WOS:A1997YE87200004
J	Regnard, C; Allport, S; Stephenson, L				Regnard, C; Allport, S; Stephenson, L			ABC of palliative care - Mouth care, skin care, and lymphoedema	BRITISH MEDICAL JOURNAL			English	Article											Regnard, C (corresponding author), ST OSWALD HOSPICE,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.								0	13	13	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1002	&		10.1136/bmj.315.7114.1002	http://dx.doi.org/10.1136/bmj.315.7114.1002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365302	Green Published			2023-01-03	WOS:A1997YC30700029
J	Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H				Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H			Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis	ANNALS OF INTERNAL MEDICINE			English	Article							NASAL VENTILATION; NATURAL-HISTORY; PREDICTION; DISEASE	Background: Noninvasive positive-pressure ventilation may benefit patients with amyotrophic lateral sclerosis and respiratory insufficiency. Objective: To determine 1) whether patients tolerant of noninvasive positive-pressure ventilation have better survival than intolerant patients and 2) whether bulbar symptoms account for intolerance of noninvasive positive-pressure ventilation. Design: Observational cohort study. Setting: Tertiary care referral center. Patients: 39 patients with amyotrophic lateral sclerosis who were treated with noninvasive positive-pressure ventilation. Intervention: Noninvasive positive-pressure ventilation was started for patients with new orthopnea, new hypercapnia, or both. Patients were divided into two groups: those tolerant of and those intolerant of noninvasive positive-pressure ventilation. Results: The risk for death from onset of respiratory insufficiency was higher for intolerant patients than for tolerant patients. (relative risk, 3.1 [95% CI, 1.8 to 9.6]). Moderate or severe bulbar symptoms were more prevalent among intolerant patients than among tolerant patients (67% compared with 33%; P = 0.04). Conclusions: Among patients with amyotrophic lateral sclerosis, those who are tolerant of noninvasive positive-pressure ventilation have better survival than do those who are intolerant. Bulbar symptoms partially account for intolerance of noninvasive positive-pressure ventilation.	WAYNE STATE UNIV, SCH MED, DETROIT, MI 48201 USA; CLEVELAND CLIN FDN, DEPT PULM & CRIT CARE MED, CLEVELAND, OH 44195 USA; CLEVELAND CLIN FDN, DEPT NEUROL, CLEVELAND, OH 44195 USA	Wayne State University; Cleveland Clinic Foundation; Cleveland Clinic Foundation			Aboussouan, Loutfi/O-2317-2019	Aboussouan, Loutfi/0000-0003-2716-0904				BACH JR, 1993, CHEST, V104, P1553, DOI 10.1378/chest.104.5.1553; BACH JR, 1994, LANCET, V344, P752, DOI 10.1016/S0140-6736(94)92242-X; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BROOKS BR, 1991, ADV NEUROL, V56, P521; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CROWLEY J, 1984, ANNU REV PUBL HEALTH, V5, P385; FALLAT RJ, 1979, ARCH NEUROL-CHICAGO, V36, P74, DOI 10.1001/archneur.1979.00500380044004; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; HILL NS, 1994, CHEST, V105, P337, DOI 10.1378/chest.105.2.337; HILLEL AD, 1989, NEUROEPIDEMIOLOGY, V8, P142, DOI 10.1159/000110176; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; JABLECKI CK, 1989, MUSCLE NERVE, V12, P833, DOI 10.1002/mus.880121008; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Oppenheimer Edward Anthony, 1993, Palliative Medicine, V7, P49; RAPHAEL JC, 1994, LANCET, V343, P1600	16	254	260	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					450	453		10.7326/0003-4819-127-6-199709150-00006	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313002				2023-01-03	WOS:A1997XV77900006
J	Guilhot, F; Chastang, C; Michallet, M; Guerci, A; Harousseau, JL; Maloisel, F; Bouabdallah, R; Guyotat, D; Cheron, N; Nicolini, F; Abgrall, JF; Tanzer, J				Guilhot, F; Chastang, C; Michallet, M; Guerci, A; Harousseau, JL; Maloisel, F; Bouabdallah, R; Guyotat, D; Cheron, N; Nicolini, F; Abgrall, JF; Tanzer, J			Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC GRANULOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; LOW-DOSE CYTARABINE; CHRONIC-PHASE; PROGNOSTIC DISCRIMINATION; CYTOGENETIC IMPROVEMENT; HEMATOLOGIC REMISSION; CYTOSINE-ARABINOSIDE; ALPHA; SURVIVAL	Background Treatment with interferon prolongs survival in chronic myelogenous leukemia. We conducted a clinical trial to assess the efficacy of treatment with a combination of interferon and cytarabine. Methods Previously untreated patients with chronic myelogenous leukemia were randomly assigned to receive either hydroxyurea (50 mg per kilogram of body weight per day) and interferon alfa-2b (5 million units per square meter of body-surface area per day), or hydroxyurea and interferon in the same dosages plus monthly courses of cytarabine (20 mg per square meter per day, for 10 days). The end points were overall survival, complete hematologic remission at 6 months, and major cytogenetic response (less than 35 percent Philadelphia chromosome-positive cells in the bone marrow) at 12 months. Results The trial was stopped when a sequential analysis showed a benefit of interferon and cytarabine. A significant improvement in survival was observed in the interferon-cytarabine group (360 patients) as compared with the interferon group (361 patients) (P=0.02; relative risk of death, 0.64; 95 percent confidence interval, 0.44 to 0.93). After three years, the survival rate was 85.7 percent with interferon and cytarabine and 79.1 percent with interferon alone. The rate of hematologic response was higher in the interferon-cytarabine group th an in the interferon group (P=0.003). Major cytogenetic responses were observed 12 months after randomization in 126 of 311 patients treated with interferon and cytarabine (41 percent) and in 75 of 314 patients treated with interferon only (24 percent, P<0.001). Conclusions The combination of interferon and cytarabine, as compared with interferon alone, increases the rate of major cytogenetic response and prolongs survival in patients in the chronic phase of chronic myelogenous leukemia. (C)1997, Massachusetts Medical Society.	HOP EDOUARD HERRIOT, LYON, FRANCE; HOP ST LOUIS, PARIS, FRANCE; HOP BRABOIS, VANDOEUVRE LES NANCY, FRANCE; HOP HOTEL DIEU, NANTES, FRANCE; HOP HAUTE PIERRE, STRASBOURG, FRANCE; INST J PAOLI I CALMETTES, F-13009 MARSEILLE, FRANCE; HOP NORD ST ETIENNE, ST ETIENNE, FRANCE; HOP ST ANTOINE, F-75571 PARIS, FRANCE; HOP MICHALON, GRENOBLE, FRANCE; HOP MORVAN, BREST, BELARUS; HOP LAPEYRONIE, LIMOGES, FRANCE; HOP LA BAUCHEE, ST BRIEUC, FRANCE; HOP REG, ANGERS, FRANCE; HOP HENRI MONDOR, F-94010 CRETEIL, FRANCE; HOP ROBERT DEBRE, REIMS, FRANCE; HOP BRETONNEAU, TOURS, FRANCE; HOP CLAUDE HURIEZ, LILLE, FRANCE; HOP JEAN BERNARD, POITIERS, FRANCE	CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; Nantes Universite; CHU de Nantes; CHU Strasbourg; UNICANCER; Institut Paoli-Calmette (IPC); CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU de Reims; CHU Tours; Universite de Lille - ISITE; CHU Lille; CHU Poitiers; Universite de Poitiers	Guilhot, F (corresponding author), HOP JEAN BERNARD, DEPT HAEMATOL & MED ONCOL, F-86021 POITIERS, FRANCE.			Guilhot, Francois/0000-0001-7222-487X				ALIMENA G, 1988, BLOOD, V72, P642; ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; [Anonymous], 1992, DESIGN ANAL SEQUENTI; COX DR, 1972, J R STAT SOC B, V34, P187; GOLDMAN JM, 1993, BLOOD, V82, P2235; GUILHOT F, 1991, LEUKEMIA LYMPHOMA, V4, P49, DOI 10.3109/10428199109107057; GUILHOT F, 1996, P AN M AM SOC CLIN, V15, P149; HEHLMANN R, 1995, BLOOD, V85, P3000, DOI 10.1182/blood.V85.10.3000.bloodjournal85103000; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; Imamishi J, 1984, Gan To Kagaku Ryoho, V11, P53; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KANTARJIAN HM, 1992, J CLIN ONCOL, V10, P772, DOI 10.1200/JCO.1992.10.5.772; KANTARJIAN HM, 1988, CANCER, V61, P1441, DOI 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; OHNISHI K, 1995, BLOOD, V86, P906; OZER H, 1993, BLOOD, V82, P2975; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTSON MJ, 1993, AM J HEMATOL, V43, P95, DOI 10.1002/ajh.2830430205; SILVER RT, 1990, P ASCO, V9, P209; SOKAL JE, 1987, CANCER, V59, P197, DOI 10.1002/1097-0142(19870101)59:1<197::AID-CNCR2820590137>3.0.CO;2-8; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; SOKAL JE, 1988, LEUKEMIA RES, V12, P453, DOI 10.1016/0145-2126(88)90110-5; SOKAL JE, 1985, BLOOD, V66, P1352; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TURA S, 1994, NEW ENGL J MED, V330, P820	28	455	472	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					223	229		10.1056/NEJM199707243370402	http://dx.doi.org/10.1056/NEJM199707243370402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227927				2023-01-03	WOS:A1997XL99400002
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 61-year-old man with psoriasis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		BAUGHMAN RD, 1996, JAMA-J AM MED ASSOC, V276, P1421; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228440				2023-01-03	WOS:A1997XL05900035
J	Kony, SJ; deVathaire, F; Chompret, A; Shamsaldim, A; Grimaud, E; Raquin, MA; Oberlin, O; Brugieres, L; Feunteun, J; Eschwege, F; Chavaudra, J; Lemerle, J; BonaitiPellie, C				Kony, SJ; deVathaire, F; Chompret, A; Shamsaldim, A; Grimaud, E; Raquin, MA; Oberlin, O; Brugieres, L; Feunteun, J; Eschwege, F; Chavaudra, J; Lemerle, J; BonaitiPellie, C			Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood	LANCET			English	Article							FAMILY HISTORY; BREAST-CANCER; RETINOBLASTOMA; SURVIVORS; CHILDREN; RADIOSENSITIVITY; RADIOTHERAPY; CHEMOTHERAPY; MUTATIONS; MORTALITY	Background Radiotherapy and chemotherapy are associated with an increased risk of second malignant neoplasm (SMN). An association between SMN and familial aggregation has also been shown. The aim of this study was to investigate the role of familial factors in the risk of SMM and their potential interaction with the effect of treatment. Methods We devised a case-control study of 25 children with SMN (cases) and 96 children with no SMN after a cancer treatment (controls), taken from a cohort of 649 children treated at our institution between 1953 and 1985. A complete family history was obtained for patients and controls and a familial index defined to evaluate the degree of familial aggregation. The radiation dose given at 151 sites in the body was estimated for each radiotherapy course for each child. Findings Among family members of the 25 SMN cases, there were ten with early-onset (less than or equal to 45 years) cancer, compared with eight among relatives of the 96 controls. Compared with patients who had no family history of early-onset cancer, those with one or more affected family members had an odds ratio of SMN of 4.7 (95% Cl 1.3-17.1; p=0.02). Adjustment for local radiation dose and exclusion of patients known to be predisposed to SMN (carriers of p53 mutation and those with Recklinghausen's disease) did not affect this risk substantially. Interpretation Both genetic factors and exposure to ionising radiation have independent effects on the risk of SMN. Follow-up of children treated for cancer should be especially vigilant when there is a family history of early-onset cancer.	INST GUSTAVE ROUSSY,INSERM,U351,RES UNIT CANC EPIDEMIOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PAEDIAT,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PHYS,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,LAB ONCOL GENET,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT RADIOTHERAPY,F-94805 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy			de Vathaire, Florent/L-2983-2016; Feunteun, Jean/AAZ-1267-2020	de Vathaire, Florent/0000-0002-8374-9281; Feunteun, Jean/0000-0003-1212-9189				BRESLOW NE, 1980, STATISTICAL METHODS; CHAKRABORTY R, 1995, RADIAT RES, V143, P293, DOI 10.2307/3579216; DARROUDI F, 1995, MUTAT RES-FUND MOL M, V328, P83, DOI 10.1016/0027-5107(95)00002-Z; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P792, DOI 10.1038/bjc.1989.165; Diallo I, 1996, RADIOTHER ONCOL, V38, P269, DOI 10.1016/0167-8140(96)01713-6; DORMAN JS, 1988, GENET EPIDEMIOL, V5, P305, DOI 10.1002/gepi.1370050502; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KERBER RA, 1995, GENET EPIDEMIOL, V12, P291, DOI 10.1002/gepi.1370120306; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; MALECOT E, 1948, MATH HEREDITE; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORRELL D, 1986, J NATL CANCER I, V77, P89; PARKINS DM, 1992, CANC INCIDENCE 5 CON, V6; SCHWARTZ AG, 1988, AM J EPIDEMIOL, V128, P524, DOI 10.1093/oxfordjournals.aje.a115000; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBER W, 1993, ANTICANCER RES, V13, P1197; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	28	105	106	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					91	95		10.1016/S0140-6736(97)01116-1	http://dx.doi.org/10.1016/S0140-6736(97)01116-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228960				2023-01-03	WOS:A1997XK11400008
J	Eisenberg, DM				Eisenberg, DM			Advising patients who seek alternative medical therapies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EOSINOPHILIA-MYALGIA-SYNDROME; HERBAL MEDICINES; CHIROPRACTIC MANIPULATION; SPINAL MANIPULATION; ADVERSE REACTIONS; CLINICAL-TRIALS; UNITED-STATES; CHINESE HERBS; CHRONIC PAIN; HEPATITIS-B	Alternative medical therapies, such as chiropractic, acupuncture, homeopathy, and herbal remedies, are in great public demand. Some managed care organizations now offer these therapies as an ''expanded benefit.'' Because the safety and efficacy of these practices remain largely unknown, advising patients who use or seek alternative treatments presents a professional challenge. A step-by-step strategy is proposed whereby conventionally trained medical providers and their patients can preactively discuss the use or avoidance of alternative therapies. This strategy involves a formal discussion of patients' preferences and expectations, the maintenance of symptom diaries, and follow-up visits to monitor for potentially harmful situations. In the absence of professional medical and legal guidelines, the proposed management plan emphasizes patient safety, the need for documentation in the patient record, and the importance of shared decision making.			Eisenberg, DM (corresponding author), BETH ISRAEL DEACONESS MED CTR, CTR ALTERNAT MED RES, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson IB, 1996, ANN INTERN MED, V124, P726, DOI 10.7326/0003-4819-124-8-199604150-00004; ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1988, HERBAL MED; ASSENDELFT WJJ, 1992, J MANIP PHYSIOL THER, V15, P487; BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BARRETT S, 1990, HLTH SCHEMES SCAMS F; BELLAVITE P, 1995, HOMEOPATHY FRONTIER; Bigos S, 1994, CLIN PRACTICE GUIDEL; BLUMENTHAL M, 1996, COMMISSION E MONOGRA; *BURT GOLDB GROUP, 1993, ALT MED DEF GUID; BUTLER K, 1992, CONSUMERS GUIDE ALTE; CARRON H, 1974, JAMA-J AM MED ASSOC, V228, P1552; Carton Barbara, 1995, WALL ST J       0116, pB1; CHAN TYK, 1993, LANCET, V342, P1532, DOI 10.1016/S0140-6736(05)80091-1; CHENG TO, 1989, AM J MED, V87, P489, DOI 10.1016/S0002-9343(89)80853-8; COLLINGE W, 1996, COMPLETE GUIDE ALTER; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Coulter ID, 1995, APPROPRIATENESS SPIN; COWLEY G, 1996, NEWSWEEK        0603, P60; DANDEKAR UP, 1992, J ETHNOPHARMACOL, V35, P285, DOI 10.1016/0378-8741(92)90026-N; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P. A. G. M., 1992, P1209; De Smet P. A. G. M., 1993, ADVERSE EFFECTS HERB; De Smet PAGM, 1992, TOXICOLOGICAL OUTLOO, P1; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; DESMET PAGM, 1991, J ETHNOPHARMACOL, V32, P43, DOI 10.1016/0378-8741(91)90102-J; DUNKIN A, 1995, BUSINESS WEEK   1127, P134; Egan Timothy, 1996, NY TIMES, pA6; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EISENBERG DM, 1996, HARVARD MED ALUMNI B, V70, P20; EPSTEIN WL, 1987, ANN EMERG MED, V16, P950, DOI 10.1016/S0196-0644(87)80739-4; FAST A, 1987, SPINE, V12, P840, DOI 10.1097/00007632-198711000-00003; FRIEDMAN RA, 1996, NY TIMES        0419, pA29; Fugh-Berman A., 1996, ALTERNATIVE MED WHAT; FUSHIMI R, 1989, LANCET, V1, P339, DOI 10.1016/S0140-6736(89)91361-5; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; GLOCK M, 1995, NIH PUBLICATION; GOLDMAN JA, 1991, ARTHRITIS RHEUM, V34, P1207, DOI 10.1002/art.1780340922; GOLEMAN D, 1993, MIND BODY MED HOW US; GORDON DW, 1995, JAMA-J AM MED ASSOC, V273, P489, DOI 10.1001/jama.273.6.489; HALDEMAN S, 1992, SPINE, V17, P1469, DOI 10.1097/00007632-199212000-00005; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HEWALL CA, 1996, HERBAL MED GUIDE HLT; HILTS PJ, 1995, NY TIMES        1227, pB10; HOGAN RP, 1983, JAMA-J AM MED ASSOC, V249, P2679, DOI 10.1001/jama.249.19.2679; Hurwitz EL, 1996, SPINE, V21, P1746, DOI 10.1097/00007632-199608010-00007; HUXTABLE RJ, 1990, DRUG SAFETY, V5, P126, DOI 10.2165/00002018-199000051-00020; JACKSON C, 1996, TAMPA TRIBUNE   0108, P8; James, 1995, ACUPUNCT MED, V13, P26, DOI [10.1136/aim.13.1.26, DOI 10.1136/AIM.13.1.26]; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Kaptchuk T.J., 1983, WEB HAS NO WEAVER; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KRAUSS C, 1996, NY TIMES        0524, pB1; LAGNADO L, 1996, WALL STREET J   1007, pB9; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; LERNER M, 1994, CHOICES HEALING INTE; Marti J, 1995, ALTERNATIVE HLTH MED; MICOZZI MS, 1996, FUNDAMENTALS COMPLEN; MOORE JS, 1993, CHIROPRACTIC AM HIST; NEFF R, 1995, BUSINESS WEEK   0130, P60; *NIH OFF ALT MED, 1994, ALT MED EXP MED HOR; OConnor Bonnie Blair, 1995, HEALING TRADITIONS A; OLIVER LD, 1984, TEX MED, V80, P40; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; PHALON R, 1993, FORBES          1220, P254; PIZZORNO JE, 1993, TXB NATURAL MED; POWELL FC, 1993, NEUROSURGERY, V33, P73; RASO J, 1993, MYSTICAL DIETS PARAN; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; RIDKER PM, 1989, LANCET, V1, P657, DOI 10.1016/S0140-6736(89)92154-5; ROBERTS IF, 1979, BRIT MED J, V1, P296, DOI 10.1136/bmj.1.6159.296; RUSSELL FE, 1975, JAMA-J AM MED ASSOC, V233, P341, DOI 10.1001/jama.233.4.341; RUSSELL S, 1996, SAN FRANCISCO C 0925, pA1; SALE JD, 1994, OVERVIEW LEGISLATIVE; SCHECK A, 1995, INVESTORS BUSIN 0620; SEGELMAN AB, 1976, JAMA-J AM MED ASSOC, V236, P477, DOI 10.1001/jama.236.5.477; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHERLOCK P, 1967, J AMER MED ASSOC, V199, P794, DOI 10.1001/jama.199.11.794; SLATER PE, 1988, EUR J EPIDEMIOL, V4, P322, DOI 10.1007/BF00148918; SMITH GW, 1993, BRIT J RHEUMATOL, V32, P87; STALKER D, 1989, EXAMINING HOLISTIC M; STRYKER WS, 1986, J FAM PRACTICE, V22, P155; TAI YT, 1992, LANCET, V340, P1254, DOI 10.1016/0140-6736(92)92951-B; TAYLOR GD, 1985, CAN MED ASSOC J, V133, P767; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; TRESOLINI CP, 1994, HLTH ED RELATIONSHIP; Tyler V. E., 1994, HERBS CHOICE THERAPE; Tyler VE, 1993, HONEST HERBAL SENSIB, V3rd; *US C, 1990, OTAH405; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; Vithoulkas G., 1980, SCI HOMEOPATHY; VITTECOQ D, 1989, NEW ENGL J MED, V320, P250; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WEINER M, 1982, COMPLETE BOOK HOMEOP; Werbach MR, 1994, BOT INFLUENCES ILLNE; *WHO, 1992, HERB MED CONT GERM W; WILKINSON JA, 1995, BRIT J PHYTOTHERAPY, V4, P34; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001; Zwicky JF, 1993, READERS GUIDE ALTERN; 1996, NY TIMES        1009, pA11; 1997, J MIND BODY HLTH, V13, P79; 1990, CAN MED ASSOC J, V143, P1009; 1995, MMWR-MORBID MORTAL W, V44, P41; 1997, INNOVIOSN COMMUNICAT, V3, P125; 1997, UPC C TRAIN SEM ALT, V3, P72; 1993, MMWR-MORBID MORTAL W, V42, P521	116	299	303	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					61	69		10.7326/0003-4819-127-1-199707010-00010	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214254				2023-01-03	WOS:A1997XG91400009
J	Smith, GK; Banks, S; Blumenkopf, TA; Cory, M; Humphreys, J; Laethem, RM; Miller, J; Moxham, CP; Mullin, R; Ray, PH; Walton, LM; Wolfe, LA				Smith, GK; Banks, S; Blumenkopf, TA; Cory, M; Humphreys, J; Laethem, RM; Miller, J; Moxham, CP; Mullin, R; Ray, PH; Walton, LM; Wolfe, LA			Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G AMIDASE CONJUGATE; MONOCLONAL-ANTIBODIES; CYTOSINE DEAMINASE; SEQUENCE-ANALYSIS; TARGETED ENZYMES; IMMUNE-RESPONSE; CANCER-THERAPY; CDNA CLONING; ACTIVATION; DOXORUBICIN	Antibody-directed enzyme prodrug therapy (ADEPT) has the potential of greatly enhancing antitumor selectivity of cancer therapy by synthesizing chemotherapeutic agents selectively at tumor sites, This therapy is based upon targeting a prodrug-activating enzyme to a tumor by attaching the enzyme to st tumor-selective antibody and dosing the enzyme-antibody conjugate systemically, After the enzyme-antibody conjugate is localized to the tumor the prodrug is then also dosed systemically, and the previously targeted enzyme converts it to the active drug selectively at the tumor, Unfortunately, most enzymes capable of this specific, tumor site generation of drugs are foreign to the human body and as such are expected to raise an immune response when injected, which will limit their repeated administration, Ne reasoned that with the power of crystallography, molecular modeling and site-directed mutagenesis, this problem could be addressed through the development of a human enzyme that is capable of catalyzing a reaction that is otherwise not carried out in the human body, This would then allow use of prodrugs that are otherwise stable in vivo but that are substrates for a tumor-targeted mutant human enzyme, We report here the first test of this concept using the human enzyme carboxypeptidase A1 (hCPA1) and prodrugs of methotrexate (MTX), Based upon a computer model of the human enzyme built from the well known crystal structure of bovine carboxypeptidase A, we have designed and synthesized novel bulky phenylalanine- and tyrosine-based prodrugs of MTX: that are metabolically stable in vivo and are not substrates for wild type human carboxypeptidases A, Two of these analogs are MTX-alpha-3-cyclobutylphenylalanine and MTX-alpha-3-cyclopentyltyrosine, Also based upon the computer model, we have designed and produced a mutant of human carboxypeptidase A1, changed at position 268 from the wild type threonine to a glycine (hCPA1-T268G), This novel enzyme is capable of using the in vivo stable prodrugs, which are not substrates for the wild type hCPA1, as efficiently as the wild type hCPA1 uses its best substrates (i.e. MTX-alpha-phenylalanine). Thus, the k(cat)/K-m value for the wild type hCPA1 with MTX-alpha-phenylalanine is 0.44 mu M-1 s(-1) and k(cat)/K-m values for hCPA1-T286G with MTX-alpha-3-cyclobutylphenylalanine and MTX-alpha-3-cyclopentyltyrosine are 1.8 and 0.16 mu M-1 s(-1) respectively, The cytotoxic efficiency of hCPA1-268G was tested in an in vitro ADEPT model, For this experiment, hCPA1-T268G was chemically conjugated to ING-1, an antibody that binds to the tumor antigen Ep-Cam, or to Campath-1H, an antibody that binds to the T and B cell antigen CDw52, These conjugates mere then incubated with HT-29 human colon adenocarcinoma cells (which express Ep-Cam but not the Campath. 1H antigen) followed by incubation of the cells with the in vivo stable prodrugs. The results showed that the targeted ING-1:hCPA1-T268G conjugate produced excellent activation of the MTX prodrugs to kill HT-29 cells as efficiently as MTX itself, By contrast, the enzyme-Campath 1H conjugate was without effect, These data strongly support the feasibility of ADEPT using a mutated human enzyme with a single amino acid change.			Smith, GK (corresponding author), GLAXO WELLCOME INC,RES & DEV,DEPT MOL BIOCHEM,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.							BAGSHAWE KD, 1988, BRIT J CANCER, V58, P700, DOI 10.1038/bjc.1988.293; BAGSHAWE KD, 1989, BRIT J CANCER, V60, P275, DOI 10.1038/bjc.1989.270; BIGNAMI GS, 1992, CANCER RES, V52, P5759; Blakey DC, 1996, CANCER RES, V56, P3287; BOSSLET K, 1994, CANCER RES, V54, P2151; CATASUS L, 1992, BIOCHEM J, V287, P299, DOI 10.1042/bj2870299; CATASUS L, 1995, J BIOL CHEM, V270, P6651, DOI 10.1074/jbc.270.12.6651; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; DUCH DS, 1993, CANCER RES, V53, P810; ECCLES SA, 1994, CANCER RES, V54, P5171; ENSMINGER WD, 1984, FOLATE ANTAGONISTS T, V2, P133; FOLK JE, 1963, J BIOL CHEM, V238, P3884; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; HAENSELER E, 1992, BIOCHEMISTRY-US, V31, P891, DOI 10.1021/bi00118a035; HAISMA HJ, 1992, BRIT J CANCER, V66, P474, DOI 10.1038/bjc.1992.298; HUENNEKENS FM, 1994, TRENDS BIOTECHNOL, V12, P234, DOI 10.1016/0167-7799(94)90122-8; JUNGHEIM LN, 1994, CHEM REV, V94, P1553, DOI 10.1021/cr00030a004; KERR DE, 1995, CANCER RES, V55, P3558; KERR DE, 1993, BIOCONJUGATE CHEM, V4, P353, DOI 10.1021/bc00023a008; KUEFNER U, 1989, BIOCHEMISTRY-US, V28, P2288, DOI 10.1021/bi00431a047; Laethem R. M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P467; Laethem RM, 1996, ARCH BIOCHEM BIOPHYS, V332, P8, DOI 10.1006/abbi.1996.0310; LEDERMANN JA, 1991, INT J CANCER, V47, P659, DOI 10.1002/ijc.2910470505; Liao S K, 1990, Hum Antibodies Hybridomas, V1, P66; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; Melton RG, 1996, JNCI-J NATL CANCER I, V88, P153, DOI 10.1093/jnci/88.3-4.153; MEYER DL, 1995, BIOCONJUGATE CHEM, V6, P440, DOI 10.1021/bc00034a014; MEYER DL, 1993, CANCER RES, V53, P3956; PAGE MJ, 1991, BIO-TECHNOL, V9, P64, DOI 10.1038/nbt0191-64; PETERSON LM, 1976, BIOCHEMISTRY-US, V15, P2501, DOI 10.1021/bi00657a001; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; REICHMANN L, 1988, NATURE, V332, P323; SELL S, 1985, MONOCLONAL ANTIBODIE; SENTER PD, 1990, FASEB J, V4, P188, DOI 10.1096/fasebj.4.2.2404820; SENTER PD, 1989, CANCER RES, V49, P5789; SENTER PD, 1991, BIOCONJUGATE CHEM, V2, P447, DOI 10.1021/bc00012a012; SENTER PD, 1993, BIOCONJUGATE CHEM, V4, P3, DOI 10.1021/bc00019a001; SHARMA SK, 1992, CELL BIOPHYS, V21, P109, DOI 10.1007/BF02789482; SMITH GK, 1995, Patent No. 9513095; SMITH GK, 1995, Patent No. 9402483; Springer C J, 1993, Cell Biophys, V22, P9; SVENSSON HP, 1995, CANCER RES, V55, P2357; TATTERSALL MHN, 1984, FOLATE ANTAGONISTS T, V2, P166; VITOLS KS, 1995, CANCER RES, V55, P478; VRUDHULA VM, 1993, J MED CHEM, V36, P919, DOI 10.1021/jm00059a018; WALLACE PM, 1991, BIOCONJUGATE CHEM, V2, P349, DOI 10.1021/bc00011a010; WANG SM, 1992, CANCER RES, V52, P4484; Wolfe L.a., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P467	50	55	57	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15804	15816		10.1074/jbc.272.25.15804	http://dx.doi.org/10.1074/jbc.272.25.15804			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188478	hybrid			2023-01-03	WOS:A1997XF32900038
J	Hendin, H; Rutenfrans, C; Zylicz, Z				Hendin, H; Rutenfrans, C; Zylicz, Z			Physician-assisted suicide and euthanasia in the Netherlands - Lessons from the Dutch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEATH		NEW YORK MED COLL,DEPT PSYCHIAT,NEW YORK,NY; DEPT JUSTICE,THE HAGUE,NETHERLANDS; HOSP ROSENHUYVEL,ROZENDAAL,NETHERLANDS	New York Medical College	Hendin, H (corresponding author), AMER FDN SUICIDE PREVENT,120 WALL ST,NEW YORK,NY 10005, USA.							ANGELL M, 1996, NEW ENGL J MED, V335, P1675; Bokhove J., 1996, BALANS REKENONDERWIJ; *BRIT MED ASS WORK, 1988, EUTHANASIA, P49; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; DORREPAAL KL, 1989, CANCER, V63, P593, DOI 10.1002/1097-0142(19890201)63:3<593::AID-CNCR2820630332>3.0.CO;2-5; *GEN BOARD ROYAL D, 1994, EUTHANASIA NETHERLAN; GOMEZ G, 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; Hendin H, 1997, NEW ENGL J MED, V336, P1385; HENDIN H, 1995, HASTINGS CENT REP, V25, P19, DOI 10.2307/3562109; Hendin H, 1996, Duquesne Law Rev, V35, P427; HENDIN H, 1996, SEDUCED DEATH DOCTOR; Keown J., 1995, EUTHANASIA EXAMINED; TENHAVE H, 1985, GENEESKUNDE TUSSEN D; Twycross R., 1995, EUTHANASIA EXAMINED; van der Maas P. J., 1992, EUTHANASIA OTHER MED; Van der Mass PJ, 1996, NEW ENGL J MED, V335, P1609; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; WALTON J, 1994, J ROY COLL PHYS LOND, V28, P235; Zylic Zbigniew, 1993, AM J HOSPICE PAL JUL, V30; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y	21	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1720	1722		10.1001/jama.277.21.1720	http://dx.doi.org/10.1001/jama.277.21.1720			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169901				2023-01-03	WOS:A1997XB08800035
J	Taylor, CJ; Threlfall, D				Taylor, CJ; Threlfall, D			Postural drainage techniques and gastrooesophageal reflux in cystic fibrosis	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX; INFANTS		UNIV SHEFFIELD, SHEFIELD CHILDRENS HOSP, DEPT PHYSIOTHERAPY, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield	Taylor, CJ (corresponding author), UNIV SHEFFIELD, SHEFIELD CHILDRENS HOSP, DEPT PAEDIAT, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND.							Button BM, 1997, ARCH DIS CHILD, V76, P148, DOI 10.1136/adc.76.2.148; CUCCHIARA S, 1991, ARCH DIS CHILD, V66, P617, DOI 10.1136/adc.66.5.617; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; MALFROOT A, 1991, ARCH DIS CHILD, V66, P1339, DOI 10.1136/adc.66.11.1339; MCVEAGH P, 1987, AM J DIS CHILD, V141, P917, DOI 10.1001/archpedi.1987.04460080103039; VANDENPLAS Y, 1991, PEDIATRICS, V88, P834; VANVANDENPLAS Y, 1987, J PEDIATR GASTR NUTR, V6, P220, DOI 10.1097/00005176-198703000-00010	7	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1567	1568		10.1016/S0140-6736(05)61626-1	http://dx.doi.org/10.1016/S0140-6736(05)61626-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174556				2023-01-03	WOS:A1997XB67300005
J	Covinsky, KE; Fortinsky, RH; Palmer, RM; Kresevic, DM; Landefeld, CS				Covinsky, KE; Fortinsky, RH; Palmer, RM; Kresevic, DM; Landefeld, CS			Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons	ANNALS OF INTERNAL MEDICINE			English	Article						depression; age factors; activities of daily living; outcome assessment (health care); health status	FUNCTIONAL STATUS; MAJOR DEPRESSION; DISABILITY; CARE; IMPACT; SYMPTOMATOLOGY; VALIDATION; MORBIDITY; MORTALITY; PATIENT	Background: Older patients often have poor health status outcomes after hospitalization. Symptoms of depression are common in hospitalized older persons and may be a risk factor for these poor outcomes. Objective: To determine whether symptoms of depression predict worse health status outcomes in acutely ill, older medical patients, independent of health status and severity of illness at hospital admission. Design: Prospective cohort study. Setting: Medical service of a teaching hospital. Patients: 572 hospitalized medical patients older than 70 years of age. Measurements: 15 symptoms of depression, health status, and severity of illness were measured at admission. The main outcome was dependence in basic activities of daily living at discharge and 30 and 90 days after discharge. Other outcome measures were dependence in instrumental activities of daily living, fair or poor global health status, and poor global satisfaction with life. Results: The median number of symptoms of depression on admission was 4. Patients with 6 or more symptoms on admission (n = 196) were more likely than patients with 0 to 2 symptoms (n = 181) to be dependent in basic activities of daily living (odds ratio, 2.47 [95% Cl, 1.58 to 3.86]) after controlling for demographic characteristics and severity of illness. At each subsequent time point, patients with more symptoms of depression on admission were more likely to be dependent in basic activities of daily living. This association persisted after adjustment for dependence in basic activities of daily living, severity of illness, and demographic characteristics on admission. The odds ratios comparing patients who had 6 or more symptoms with those who had 0 to 2 symptoms were 3.23 (Cl, 1.76 to 5.95) at discharge, 3.45 (Cl, 1.81 to 6.60) 30 days after discharge, and 2.15 (Cl, 1.15 to 4.03) 90 days after discharge. At each time point, patients with 6 or more symptoms of depression were more likely to have more dependence in instrumental activities of daily living, worse global health status, and less satisfaction with life. Conclusions: Symptoms of depression identified a vulnerable group of hospitalized older persons. The health status of patients with more symptoms of depression was after hospitalization. This association was not attributable to health status or severity of illness on admission. The temporal sequence and magnitude of this association, its consistency over time with different measures, and its independence from the severity of the somatic illness strongly support a relation between symptoms of depression on admission and subsequent health status outcomes.	VET AFFAIRS MED CTR, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Covinsky, KE (corresponding author), UNIV HOSP CLEVELAND, DIV GEN INTERNAL MED & HLTH CARE RES, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NIA NIH HHS [1K08AG00714-01, AG-10418-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010418, K08AG000714] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P323; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PSYCHIAT, V151, P716; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; Caine E.D., 1994, DIAGNOSIS TREATMENT, P21; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CRAIG TJ, 1983, AM J PSYCHIAT, V140, P598; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dunham N C, 1994, Arch Fam Med, V3, P676, DOI 10.1001/archfami.3.8.676; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GALLO JJ, 1994, J GERONTOL, V49, pP251, DOI 10.1093/geronj/49.6.P251; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORDON HS, 1995, ARCH INTERN MED, V155, P2465, DOI 10.1001/archinte.155.22.2465; GURLAND BJ, 1988, INT J GERIATR PSYCH, V3, P163, DOI 10.1002/gps.930030304; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; IMBODEN JB, 1961, JAMA-J AM MED ASSOC, V178, P1182, DOI 10.1001/jama.1961.73040520003003a; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOENIG HG, 1988, INT J PSYCHIAT MED, V18, P17; KOENIG HG, 1988, J AM GERIATR SOC, V36, P699, DOI 10.1111/j.1532-5415.1988.tb07171.x; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; MORLEY JE, 1988, ANN INTERN MED, V109, P890, DOI 10.7326/0003-4819-109-11-890; MOSSEY JM, 1990, J GERONTOL, V45, pM163, DOI 10.1093/geronj/45.5.M163; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; Sackett D.L., 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAS Institute, 1990, SAS PROC GUID VERS 6; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	42	162	163	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					417	+		10.7326/0003-4819-126-6-199703150-00001	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM530	9072926				2023-01-03	WOS:A1997WM53000001
J	Radler, JO; Koltover, I; Salditt, T; Safinya, CR				Radler, JO; Koltover, I; Salditt, T; Safinya, CR			Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes	SCIENCE			English	Article							SYNCHROTRON X-RAY; GENE-THERAPY; PHASE; TRANSFECTION; EXPRESSION; HUMANS	Cationic liposomes complexed with DNA (CL-DNA) are promising synthetically based nonviral carriers of DNA vectors for gene therapy. The solution structure of CL-DNA complexes was probed on length scales from subnanometer to micrometer by synchrotron x-ray diffraction and optical microscopy. The addition of either linear lambda-phage or plasmid DNA to CLs resulted in an unexpected topological transition from liposomes to optically birefringent liquid-crystalline condensed globules. X-ray diffraction of the globules revealed a novel multilamellar structure with alternating lipid bilayer and DNA monolayers. The lambda-DNA chains form a one-dimensional lattice with distinct interhelical packing regimes. Remarkably, in the isoelectric point regime, the lambda-DNA interaxial spacing expands between 24.5 and 57.1 angstroms upon lipid dilution and is indicative of a long-range electrostatic-induced repulsion that is possibly enhanced by chain undulations.	UNIV CALIF SANTA BARBARA, DEPT MAT, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOL BIOL PROGRAM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489				BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BOLTENHAGEN P, 1992, PHYS REV A, V46, pR1743, DOI 10.1103/PhysRevA.46.R1743; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DAN N, IN PRESS BIOPHYS J; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; Kamien RD, 1996, PHYS REV E, V53, P650, DOI 10.1103/PhysRevE.53.650; KEMWORTHY AK, 1995, BIOPHYS J, V68, P1921; KOLOVER I, UNPUB; LASIC D, IN PRESS ADV DRUG DE; LIGOURE C, 1993, PHYS REV LETT, V71, P3600, DOI 10.1103/PhysRevLett.71.3600; LIN AL, UNPUB; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; MANNING GS, 1969, J CHEM PHYS, V51, P924, DOI 10.1063/1.1672157; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MARSHALL E, 1995, SCIENCE, V270, P1751, DOI 10.1126/science.270.5243.1751; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048; RADLER JO, UNPUB; REICH Z, 1994, SCIENCE, V264, P1460, DOI 10.1126/science.8197460; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SAFINYA CR, 1989, NATO ADV SCI I B-PHY, V211, P249; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SELINGER JV, 1991, PHYS REV A, V43, P2922, DOI 10.1103/PhysRevA.43.2922; SINGHAL A, 1994, GENE THERAPEUTICS ME; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	38	1244	1293	4	277	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					810	814		10.1126/science.275.5301.810	http://dx.doi.org/10.1126/science.275.5301.810			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012343				2023-01-03	WOS:A1997WG77700054
J	Finucane, TE; Bynum, JPW				Finucane, TE; Bynum, JPW			Use of tube feeding to prevent aspiration pneumonia	LANCET			English	Review							SALIVA; INFECTION				Finucane, TE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BAYVIEW MED CTR,DEPT MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD 21224, USA.							*AM GASTR ASS, 1993, AGA HLTH CAR REF UPD, P1; BOSCOE MJ, 1984, BRIT MED J, V289, P1421, DOI 10.1136/bmj.289.6456.1421; CANEL D, 1987, J PEDIATR SURG, V22, P54; CIOCON JO, 1993, JPEN-PARENTER ENTER, V17, P230; COLE MJ, 1987, J CLIN GASTROENTEROL, V9, P90, DOI 10.1097/00004836-198702000-00023; CRAIG TJ, 1980, AM J PSYCHIAT, V137, P1366; DEPASO WJ, 1991, CLIN CHEST MED, V12, P269; EISELE DW, 1989, AM J SURG, V157, P230, DOI 10.1016/0002-9610(89)90534-5; EKBERG O, 1991, AM J ROENTGENOL, V156, P1181, DOI 10.2214/ajr.156.6.2028863; HORNER J, 1988, NEUROLOGY, V38, P1359; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; KOUFMAN JA, 1986, LARYNGOSCOPE, V96, P726; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; LEVY J, 1989, JPEN-PARENTER ENTER, V13, P228, DOI 10.1177/0148607189013003228; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; OLIVARES L, 1974, STROKE, V5, P654, DOI 10.1161/01.STR.5.5.654; OSTERBERG T, 1992, SCAND J DENT RES, V100, P340; SHIP JA, 1991, J AM DENT ASSOC, V122, P63, DOI 10.14219/jada.archive.1991.0098; SILVER KH, 1991, ARCH PHYS MED REHAB, V72, P902, DOI 10.1016/0003-9993(91)90009-8; Stoschus B., 1993, Dysphagia, V8, P154, DOI 10.1007/BF02266997; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TERPENNING M, 1993, CLIN INFECT DIS, V16, pS314, DOI 10.1093/clinids/16.Supplement_4.S314; THURN J, 1990, J HOSP INFECT, V15, P203, DOI 10.1016/0195-6701(90)90028-M; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; WADE DT, 1987, ACTA NEUROL SCAND, V76, P50, DOI 10.1111/j.1600-0404.1987.tb03543.x; WYNNE JW, 1977, ANN INTERN MED, V87, P466, DOI 10.7326/0003-4819-87-4-466	27	172	178	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1421	1424		10.1016/S0140-6736(96)03369-7	http://dx.doi.org/10.1016/S0140-6736(96)03369-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937283	hybrid			2023-01-03	WOS:A1996VU98600015
J	Hommel, M; Cornu, C; Boutitie, F; Boissel, JP; Viallet, F; BonnefoiKyriacou, D; Gayraud, D; Kiegel, P; Bissuel, JPB; Driencourt, JB; Ruel, H; Guillaume, L; Ruffie, C; Sirodot, M; Valon, P; MIchelBechet, L; Colin, B; Mourali, K; Olivier, P; Ziegler, B; Feissel, M; Cara, A; Faller, JP; Braun, JB; Chopard, JL; Berges, S; Berger, E; Rouanet, F; Orgogozo, JM; Devos, P; Testard, D; Bultel, J; Loubrieu, G; LeBolloch, A; Fallut, M; Bouniol, B; Pomet, E; Mocquard, Y; Rouhart, F; Diraison, P; Goas, JY; Zagnoli, F; Duriez, F; Riviere, B; Brault, JL; Colamarino, R; Claveloux, P; Deffond, D; Durieux, A; Tournilhac, M; Baldauf, E; RenglewiczDestgynder, C; Rondepierre, P; Brunet, JM; JulieCoaquette, V; Delefosse, F; Voisin, H; Alibert, M; Naviaux, S; Campagne, JB; Messin, R; Bakhache, E; Bouttement, C; Vanrenterghem, B; Masse, C; Lecat, N; Lenfant, F; Souyris, F; Lambert, P; Huttin, B; Gerard, D; Planque, E; Alexandre, JL; Gilet, B; Limousin, P; Kok, G; Lizeretti, J; Verier, A; Delisse, B; CaparrosLefebvre, D; DurieuCouade, I; Godefroy, O; Goldstein, P; Henon, H; Lestavel, P; Leys, D; Lucas, C; MounierVehier, F; Mathe, D; Clement, S; Ducluzeau, R; Meyran, S; Demaziere, J; Coppere, B; Ninet, J; Madoux, MHG; Gabollet, C; Laplace, S; Matas, O; Turkie, B; GavaudKennoz, C; Lafuma, H; Gallet, M; Lestrevel, M; Granger, J; Rozand, G; CrettetPousset, G; Savet, JF; Cavallaro, J; Mangola, B; Ribier, A; Rosolacci, T; Neuville, V; Chaussinand, JP; Chanwar, J; Courtois, S; Masson, C; Ille, O; Lees, KR; Woimant, F; Amarenco, P; Chabriat, H; Bousser, MG; Nouailhat, F; Outin, H; Merrer, J; Neau, JP; Tantot, AM; Visy, JM; Vaunaize, J; Pinel, JF; DeBrughgraeve, V; Deydier, A; Hermouet, M; AdnetBonte, C; Onnient, Y; GueganMassardier, E; Tardy, B; Bertrand, JC; Viallon, A; Lafond, P; Zeni, F; Page, Y; Cusey, I; Merienne, M; Legrand, S; Tranchant, C; Rodier, G; Faitg, R; Tavernier, D; Piot, P; Gillon, T; Sache, L; Schmidt, MH; Zerouali, Y; Feuchere, P; Chollet, F; GuiraudChaumeil, B; Saudeau, D; Devauchelle, H; Autret, A; Decombe, R; Rouques, C; Billaud, B; VanRechem, M; Kassiotis, P; LegalMeigne, B; BrunetBourgin, F; McInnes, GT; Muir, KW; Reid, JL; Semple, PF				Hommel, M; Cornu, C; Boutitie, F; Boissel, JP; Viallet, F; BonnefoiKyriacou, D; Gayraud, D; Kiegel, P; Bissuel, JPB; Driencourt, JB; Ruel, H; Guillaume, L; Ruffie, C; Sirodot, M; Valon, P; MIchelBechet, L; Colin, B; Mourali, K; Olivier, P; Ziegler, B; Feissel, M; Cara, A; Faller, JP; Braun, JB; Chopard, JL; Berges, S; Berger, E; Rouanet, F; Orgogozo, JM; Devos, P; Testard, D; Bultel, J; Loubrieu, G; LeBolloch, A; Fallut, M; Bouniol, B; Pomet, E; Mocquard, Y; Rouhart, F; Diraison, P; Goas, JY; Zagnoli, F; Duriez, F; Riviere, B; Brault, JL; Colamarino, R; Claveloux, P; Deffond, D; Durieux, A; Tournilhac, M; Baldauf, E; RenglewiczDestgynder, C; Rondepierre, P; Brunet, JM; JulieCoaquette, V; Delefosse, F; Voisin, H; Alibert, M; Naviaux, S; Campagne, JB; Messin, R; Bakhache, E; Bouttement, C; Vanrenterghem, B; Masse, C; Lecat, N; Lenfant, F; Souyris, F; Lambert, P; Huttin, B; Gerard, D; Planque, E; Alexandre, JL; Gilet, B; Limousin, P; Kok, G; Lizeretti, J; Verier, A; Delisse, B; CaparrosLefebvre, D; DurieuCouade, I; Godefroy, O; Goldstein, P; Henon, H; Lestavel, P; Leys, D; Lucas, C; MounierVehier, F; Mathe, D; Clement, S; Ducluzeau, R; Meyran, S; Demaziere, J; Coppere, B; Ninet, J; Madoux, MHG; Gabollet, C; Laplace, S; Matas, O; Turkie, B; GavaudKennoz, C; Lafuma, H; Gallet, M; Lestrevel, M; Granger, J; Rozand, G; CrettetPousset, G; Savet, JF; Cavallaro, J; Mangola, B; Ribier, A; Rosolacci, T; Neuville, V; Chaussinand, JP; Chanwar, J; Courtois, S; Masson, C; Ille, O; Lees, KR; Woimant, F; Amarenco, P; Chabriat, H; Bousser, MG; Nouailhat, F; Outin, H; Merrer, J; Neau, JP; Tantot, AM; Visy, JM; Vaunaize, J; Pinel, JF; DeBrughgraeve, V; Deydier, A; Hermouet, M; AdnetBonte, C; Onnient, Y; GueganMassardier, E; Tardy, B; Bertrand, JC; Viallon, A; Lafond, P; Zeni, F; Page, Y; Cusey, I; Merienne, M; Legrand, S; Tranchant, C; Rodier, G; Faitg, R; Tavernier, D; Piot, P; Gillon, T; Sache, L; Schmidt, MH; Zerouali, Y; Feuchere, P; Chollet, F; GuiraudChaumeil, B; Saudeau, D; Devauchelle, H; Autret, A; Decombe, R; Rouques, C; Billaud, B; VanRechem, M; Kassiotis, P; LegalMeigne, B; BrunetBourgin, F; McInnes, GT; Muir, KW; Reid, JL; Semple, PF			Thrombolytic therapy with streptokinase in acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CT; INFARCTION; SIGN	Background In patients with acute ischemic stroke, early treatment with thrombolytic agents is thought to permit reperfusion of ischemic neurons and to promote recovery of function. The Multicenter Acute Stroke-Trial - Europe (MAST-E) was designed to assess the efficacy and safety of streptokinase in patients with acute ischemic stroke. Methods Patients with moderate-to-severe ischemia in the territory of the middle cerebral artery were randomly assigned to receive streptokinase (1.5 million units over a period of one hour) or placebo within six hours after the onset of stroke. The primary efficacy outcome was a binary criterion combining mortality and severe disability at six months, with severe disability defined as a score of 3 or higher on the Rankin scale. The primary safety outcomes were mortality at 10 days and cerebral hemorrhage. Results All randomized patients (156 in the streptokinase group and 154 in the placebo group) were evaluated at six months. The incidence of the primary efficacy outcome was similar in the two groups (124 patients in the streptokinase group and 126 in the placebo group died or had a Rankin score greater than or equal to 3). However, the mortality rate at 10 days was significantly higher in the streptokinase group than in the placebo group (34.0 percent vs. 18.2 percent, P=0.002). The higher rate in the streptokinase group was mainly due to the hemorrhagic transformation of ischemic cerebral infarcts. At six months, more deaths had occurred in the streptokinase group than in the placebo group (73 vs. 59, P=0.06). Conclusions In patients with acute ischemic stroke, treatment with streptokinase resulted in an increase in mortality. The routine use of streptokinase cannot be recommended in acute ischemic stroke. (C) 1996, Massachusetts Medical Society.			Hommel, M (corresponding author), CHU GRENOBLE, NEUROL CLIN, STROKE UNIT, BP 217, F-38043 GRENOBLE 9, FRANCE.		Godefroy, Olivier/D-6117-2012; LEYS, Didier/G-2955-2016; Muir, Keith W/A-7670-2011; Chabriat, Hugues/G-5699-2010	LEYS, Didier/0000-0003-4408-4392; Muir, Keith W/0000-0001-9535-022X; Godefroy, Olivier/0000-0001-6789-6620; Chabriat, Hugues/0000-0001-8436-6074				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; BOISSEL JP, 1992, THROMB HAEMOSTASIS, V68, P752; CANDELISE L, 1995, LANCET, V346, P1509; CANDELISE L, 1994, CEREBROVASC DIS, V4, P341, DOI 10.1159/000108505; DONNAN GA, 1995, LANCET, V345, P578; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; HOMMEL M, 1994, EXPERT OPIN INV DRUG, V3, P1011; JAILLARDSERRADJ A, 1995, CEREBROVASC DIS, V5, P269; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MODAN B, 1992, STROKE, V23, P1230, DOI 10.1161/01.STR.23.9.1230; MOULIN T, 1994, EUR NEUROL, V34, P64; ORGOGOZO JM, 1992, STROKE, V23, P1678, DOI 10.1161/01.STR.23.11.1678; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; TOMSICK TA, 1990, AM J NEURORADIOL, V11, P473; TOMURA N, 1988, RADIOLOGY, V168, P463, DOI 10.1148/radiology.168.2.3393665; TRUWIT CL, 1990, RADIOLOGY, V176, P801, DOI 10.1148/radiology.176.3.2389039; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WAHLGREN NG, 1994, CEREBROVASC DIS, V4, P204, DOI 10.1159/000108483; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; 1994, STROKE, V25, P1317; 1994, CONTROL CLIN TRIALS, V15, P503; 1993, CLIN TRIALS METAANAL, V28, P329	25	447	454	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1996	335	3					145	150						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW790	8657211				2023-01-03	WOS:A1996UW79000001
J	Driver, J				Driver, J			Enhancement of selective listening by illusory mislocation of speech sounds due to lip-reading	NATURE			English	Article								MECHANISMS of human attention allow selective processing of just the relevant events among the many stimuli bombarding our senses(1). Most laboratory studies examine attention within just a single sense, but in the real world many important events are specified multimodally, as in verbal communication. Speech comprises visual lip movements as well as sounds, and lip-reading contributes to speech perception. even for listeners with good hearing, by a process of audiovisual integration(2). Such examples raise the problem of how we coordinate our spatial attention across the sensory modalities, to select sights and sounds from a common source for further processing. Here we show that this problem is alleviated by allowing some cross-modal matching before attentional selection is completed. Cross modal matching can lead to an illusion, whereby sounds are mislocated at their apparent visual source(3); this crossmodal illusion can enhance selective spatial attention to speech sounds.			Driver, J (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT PSYCHOL,MALET ST,LONDON WC1E 7HX,ENGLAND.		Driver, Jon/A-4779-2010					BERTELSON P, 1976, PERCEPT PSYCHOPHYS, V19, P531, DOI 10.3758/BF03211222; Blauert J., 1983, SPATIAL HEARING; CHERRY EC, 1953, J ACOUST SOC AM, V25, P975, DOI 10.1121/1.1907229; DRIVER J, 1994, ATTENTION PERFORM, V15, P311; MASSARO DW, 1995, CURR DIR PSYCHOL SCI, V4, P104, DOI 10.1111/1467-8721.ep10772401; MASSARO DW, 1987, PERSPECTIVES PERCEPT, P273; Massaro DW, 1987, SPEECH PERCEPTION EA; MCGURK H, 1976, NATURE, V263, P747; Naatanen R, 1992, ATTENTION BRAIN FUNC; RADEAU M, 1994, CAH PSYCHOL COGN, V13, P3; REISBERG D, 1978, ACTA PSYCHOL, V42, P331, DOI 10.1016/0001-6918(78)90007-0; WITKIN HA, 1952, J EXP PSYCHOL, V43, P58, DOI 10.1037/h0055889	12	197	200	1	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					66	68		10.1038/381066a0	http://dx.doi.org/10.1038/381066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UJ053	8609989				2023-01-03	WOS:A1996UJ05300056
J	Senard, JM; Montastruc, P; Herxheimer, A				Senard, JM; Montastruc, P; Herxheimer, A			Early warnings about drugs - From the stock market	LANCET			English	Editorial Material											Senard, JM (corresponding author), FAC MED TOULOUSE,SERV PHARMACOL MED & CLIN,TOULOUSE,FRANCE.			Senard, Jean-Michel/0000-0001-7679-1281				COSNARD D, 1993, ECHOS           1026, P12; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; NODELANGLOIS F, 1995, LIBERATION      0729, P20; 1995, SCRIP, V2048, P16; 1993, INVESTIR, V1032, P18; 1994, ECHOS           0817, P7; 1995, INVESTIR, V1095, P14	7	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					987	988		10.1016/S0140-6736(96)90141-5	http://dx.doi.org/10.1016/S0140-6736(96)90141-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606610				2023-01-03	WOS:A1996UF38000006
J	Beasley, BW				Beasley, BW			Whispering through the keyhole	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Beasley, Brent/AAE-9466-2021	Beasley, Brent/0000-0002-0997-9636					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2061	2061		10.1001/jama.278.23.2061	http://dx.doi.org/10.1001/jama.278.23.2061			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403410				2023-01-03	WOS:A1997YK98700019
J	Avgerinos, A; Nevens, F; Raptis, S; Fevery, J; Armonis, A; Manolakopoulos, S; Poulianos, G; Tzathas, C; Katsaros, D; Soutos, D; Zacharopoulose, A; Adler, M; Bourgeois, N; Bac, DJ; VanBuuren, HR; Decruyenaere, J; Elewaut, A; Deman, M; Lepoutre, L; VanderSpek, P; Hautekeete, M; Reynaert, H; Buyse, M; Ritter, L; Burtin, B; Darcis, T; Ioannou, J; Natens, J; Natens, O				Avgerinos, A; Nevens, F; Raptis, S; Fevery, J; Armonis, A; Manolakopoulos, S; Poulianos, G; Tzathas, C; Katsaros, D; Soutos, D; Zacharopoulose, A; Adler, M; Bourgeois, N; Bac, DJ; VanBuuren, HR; Decruyenaere, J; Elewaut, A; Deman, M; Lepoutre, L; VanderSpek, P; Hautekeete, M; Reynaert, H; Buyse, M; Ritter, L; Burtin, B; Darcis, T; Ioannou, J; Natens, J; Natens, O			Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial	LANCET			English	Article							ESOPHAGEAL-VARICES; INJECTION SCLEROTHERAPY; DOUBLE-BLIND; COMPARING SOMATOSTATIN; CIRRHOTIC-PATIENTS; BOLUS INJECTION; HEMORRHAGE; OCTREOTIDE; MANAGEMENT; TAMPONADE	Background Sclerotherapy is widely used for acute variceal bleeding, although in emergencies bleeding makes it difficult to obtain the clear view required for safe and effective treatment. We investigated whether early administration of somatostatin would improve the efficacy of sclerotherapy. Methods In this double-blind, prospective trial, patients who had cirrhosis with upper-gastrointestinal bleeding were randomly assigned natural somatostatin (6 mg per 24 h) or placebo for 120 h. In addition, intravenous bolus doses of somatostatin (250 mu g) or placebo were injected after the start of the infusion, before emergency endoscopy or sclerotherapy, and when active bleeding was observed. The primary endpoint was treatment failure, defined as the occurrence during the infusion period of at least one of: excess transfusion of blood products, haematemesis, haemodynamic instability, need for rescue therapy, or death. Findings: 205 patients were enrolled: 101 received somatostatin and 104 received placebo. Treatment failed in 35 somatostatin and 57 placebo recipients (p=0.004); death or use of rescue therapy occurred in nine and 19 patients, respectively (p=0.05). The mean quantity of blood products transfused over 120 h (adjusted for baseline haemoglobin) was 2.64 (SD 0.35) units in the somatostatin group versus 3.62 (0.35) units in the placebo group (p=0.05). At endoscopy, active bleeding from oesophageal varices was less frequent (27 vs 42 patients, p=0.012) and the sclerotherapy procedure was easier (2.8 vs 4.7 cm, p=0.0027) in the somatostatin than in the placebo group. Interpretation Early administration of natural somatostatin continued for 120 h, combined with additional bolus injections, is more effective than placebo in the overall control of acute variceal haemorrhage in patients with cirrhosis undergoing sclerotherapy.	UNIV ATHENS, EVANGELISMOS HOSP, DEPT INTERNAL MED 2, GR-10680 ATHENS, GREECE; UNIV HOSP GASTHUISBERG, DEPT LIVER & PANCREAT DIS, B-3000 LOUVAIN, BELGIUM; HELLEN RED CROSS HOSP, ATHENS, GREECE; FREE UNIV BRUSSELS, ERASME HOSP, B-1050 BRUSSELS, BELGIUM; AZ DIKZIGT, ROTTERDAM, NETHERLANDS; UNIV HOSP, GHENT, BELGIUM; ONZE LIEVE VROUW HOSP, AALST, BELGIUM; AZ JETTE VUB, JETTE, BELGIUM; D2, BRUSSELS, BELGIUM; UCB SA PHARMA SECTOR, BRAINE LALLEUD, BELGIUM	Evangelismos Hospital; National & Kapodistrian University of Athens; KU Leuven; University Hospital Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University Hospital; UCB Pharma SA	Avgerinos, A (corresponding author), UNIV ATHENS, EVANGELISMOS HOSP, DEPT GASTROENTEROL 2, GR-10680 ATHENS, GREECE.		Manolakopoulos, Spilios/AAD-7058-2019	Reynaert, Hendrik/0000-0002-2701-5777				[Anonymous], 1992, DESIGN ANAL SEQUENTI; AVGERINOS A, 1995, HEPATO-GASTROENTEROL, V42, P145; AVGERINOS A, 1995, J HEPATOL, V22, P379, DOI 10.1016/0168-8278(95)80295-9; AVGERINOS A, 1991, J HEPATOL, V13, P78, DOI 10.1016/0168-8278(91)90867-B; BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; BESSON I, 1995, NEW ENGL J MED, V333, P555, DOI 10.1056/NEJM199508313330904; BOSCH J, 1981, GASTROENTEROLOGY, V80, P518; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; Burroughs AK, 1996, HEPATOLOGY, V24, P737, DOI 10.1053/jhep.1996.v24.ajhep0240737; CIRERA I, 1995, HEPATOLOGY, V22, P106, DOI 10.1016/0270-9139(95)90360-7; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; DIMAGNO EP, 1985, MAYO CLIN PROC, V60, P149, DOI 10.1016/S0025-6196(12)60211-0; Feu F, 1996, GASTROENTEROLOGY, V111, P1291, DOI 10.1053/gast.1996.v111.pm8898643; GOMEZPAN RJ, 1974, LANCET, V1, P888; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; LEVACHER S, 1995, LANCET, V346, P865, DOI 10.1016/S0140-6736(95)92708-5; LO GH, 1992, GASTROINTEST ENDOSC, V38, P421, DOI 10.1016/S0016-5107(92)70469-6; MORETO M, 1988, SURG GYNECOL OBSTET, V167, P331; NEVENS F, 1994, J HEPATOL, V20, P27, DOI 10.1016/S0168-8278(05)80463-5; PANES J, 1994, HEPATOLOGY, V20, P336, DOI 10.1016/0270-9139(94)90183-X; PLANAS R, 1994, HEPATOLOGY, V20, P370, DOI 10.1016/0270-9139(94)90188-0; PRIMIGNANI M, 1995, HEPATOLOGY, V21, P1322, DOI 10.1016/0270-9139(95)90054-3; PRINDIVILLE T, 1987, AM J GASTROENTEROL, V82, P655; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219	28	178	180	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1495	1499		10.1016/S0140-6736(97)05099-X	http://dx.doi.org/10.1016/S0140-6736(97)05099-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388396				2023-01-03	WOS:A1997YH11500007
J	AuBuchon, JP; Birkmeyer, JD; Busch, MP				AuBuchon, JP; Birkmeyer, JD; Busch, MP			Safety of the blood supply in the United States: Opportunities and controversies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS IMMUNE GLOBULIN; COST-EFFECTIVENESS ANALYSIS; DETERGENT-TREATED PLASMA; FRESH-FROZEN PLASMA; RISK; INFECTION; TRANSFUSION; HEALTH	The risk for viral transmission by transfusion has been reduced dramatically through improved techniques for selecting and testing blood donors. Initiatives to further improve the safety of the blood supply, including more stringent donor qualifications, additional testing for infectious disease markers, viral inactivation processes, and refinement of transfusion decisions, are possible. However, because the risk for viral transmission by allogeneic transfusion is already low, additional measures will have limited yield and poor cost-effectiveness. Furthermore, unexpected side effects of some of these ''improvements'' may reduce the safety of the blood supply by introducing new risks. Cost-effectiveness analyses of blood safety initiatives have highlighted such successes as the introduction of virus-specific assays for screening donated blood and have identified other interventions that have poor cost-effectiveness estimates. They have also quantitated the threshold level at which the risks of an intervention outweigh its benefits. These analyses have had little effect on decisions about blood safety, possibly because of overwhelming fear of AIDS and difficulties in applying cost-effectiveness estimates to a politically and emotionally charged issue. Future interventions for improving blood supply safety must be evaluated thoroughly and chosen carefully so that the intended goals are met. Communication with the public should be undertaken so that the public understands that some of the desired measures may result in inefficient allocation of health care resources.	DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL & MED, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT SURG, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT COMMUNITY & FAMILY MED, LEBANON, NH 03756 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94118 USA	Dartmouth College; Dartmouth College; Dartmouth College; University of California System; University of California San Francisco	AuBuchon, JP (corresponding author), DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL, 1 MED CTR DR, LEBANON, NH 03756 USA.				NHLBI NIH HHS [N01-HB-47114] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, JAMA, V274, P1374; Au Buchon J. P., 1996, Transfusion (Bethesda), V36, p43S; AUBUCHON JP, 1994, JAMA-J AM MED ASSOC, V272, P1210, DOI 10.1001/jama.272.15.1210; AuBuchon JP, 1997, TRANSFUSION, V37, P45, DOI 10.1046/j.1537-2995.1997.37197176950.x; BASKETT TF, 1990, CAN MED ASSOC J, V142, P337; BenHur E, 1996, AIDS, V10, P1183, DOI 10.1097/00002030-199609000-00002; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; Busch M., 1996, Transfusion (Bethesda), V36, p59S; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1995, MOL GENETICS DIAGNOS; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; Evans RW, 1996, TRANSFUSION, V36, P671, DOI 10.1046/j.1537-2995.1996.36896374368.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HOROWITZ B, 1992, BLOOD, V79, P826; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; Kleinman S, 1996, CLIN PRACTICE TRANSF; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; Korelitz JJ, 1996, TRANSFUSION, V36, P232, DOI 10.1046/j.1537-2995.1996.36396182141.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Lefrere JJ, 1996, TRANSFUSION, V36, P394, DOI 10.1046/j.1537-2995.1996.36596282581.x; Leveton Lauren B., 1995, HIV BLOOD SUPPLY ANA, P49; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; Lynch TJ, 1996, TRANSFUSION, V36, P770, DOI 10.1046/j.1537-2995.1996.36996420751.x; MINTZ PD, 1992, AM J CLIN PATHOL, V98, P150, DOI 10.1093/ajcp/98.2.150; MORGAN MG, 1993, SCI AM, V269, P32, DOI 10.1038/scientificamerican0793-32; NELSON KE, 1995, INFECT DIS TESTING B; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SCHNEIDERMAN LJ, 1992, AM J PUBLIC HEALTH, V82, P584, DOI 10.2105/AJPH.82.4.584; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Shilts R., 1987, BAND PLAYED POLITICS; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WILLIAMSON LM, 1995, VOX SANG, V69, P159, DOI 10.1111/j.1423-0410.1995.tb02590.x	49	124	128	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					904	909		10.7326/0003-4819-127-10-199711150-00009	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382369				2023-01-03	WOS:A1997YF54500007
J	Marshall, A				Marshall, A			Laying the foundations for personalized medicines	NATURE BIOTECHNOLOGY			English	Article																		Kalow Werner, 1963, PHARMACOGENETICS HER; LICHTER J, 1995, CURR OPIN BIOTECH, V6, P715, DOI 10.1016/0958-1669(95)80117-0; MEYER UA, 1997, IN PRESS EVOLUTION H; MOTULSKY AG, 1957, JAMA-J AM MED ASSOC, V165, P835, DOI 10.1001/jama.1957.72980250010016; VESSELL E S, 1971, Clinical Pharmacology and Therapeutics, V12, P192; WEBER WW, 1997, PHARMACOGENETICS	6	47	53	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					954	957		10.1038/nbt1097-954	http://dx.doi.org/10.1038/nbt1097-954			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335043				2023-01-03	WOS:A1997XZ28500022
J	Fertleman, CR; Gallagher, A; Rossiter, MA				Fertleman, CR; Gallagher, A; Rossiter, MA			Evaluation of fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences	BRITISH MEDICAL JOURNAL			English	Article									N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND									BLACK J, 1986, LIVING SICKLE CELL D, P112; FRANCEDAWSON M, 1994, NURS STAND, V45, P25; Oppenheim A.N, 2000, QUESTIONNAIRE DESIGN	3	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					650	650		10.1136/bmj.315.7109.650	http://dx.doi.org/10.1136/bmj.315.7109.650			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310567	Green Published			2023-01-03	WOS:A1997XW69400020
J	Parikh, A; Gillam, EMJ; Guengerich, FP				Parikh, A; Gillam, EMJ; Guengerich, FP			Drug metabolism by Escherichia coli expressing human cytochromes P450	NATURE BIOTECHNOLOGY			English	Article						drug metabolism; cytochrome P450; NADPH-cytochrome P450; bicistronic constructs	REDUCTASE; PURIFICATION; RAT; 4-HYDROXYLATION; OXIDOREDUCTASE; HYDROXYLATION; DEBRISOQUINE; PROTEINS; P-450	The broad substrate specificity of the cytochrome P450 (P450) enzyme superfamily of heme-thiolate proteins lends itself to diverse environmental and pharmaceutical applications. Until recently, the primary drawback in using living bacteria to catalyze mammalian P450-mediated reactions has been the paucity of electron transport from NADPH to P450 via endogenous flavoproteins. We report the functional expression in Escherichia coli of bicistronic constructs consisting of a human microsomal P450 enzyme encoded by the first cistron and the auxiliary protein NADPH-P450 reductase by the second. Expression levels of P450s ranged from 35 nmol per liter culture to 350 nmol per liter culture, with expression of NADPH-P450 reductase typically ranging from 50% to 100% of that of P450. Transformed bacteria metabolized a number of typical P450 substrates at levels comparable to isolated bacterial membranes fortified with an NADPH-generating system. These rates compare favorably with those obtained using human liver microsomes as well as those of reconstituted in vitro systems composed of purified proteins, lipids, and cofactors.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; University of Queensland; Vanderbilt University			GILLAM, ELIZABETH/D-1011-2016	GILLAM, ELIZABETH/0000-0003-0378-793X	NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Blake JAR, 1996, FEBS LETT, V397, P210, DOI 10.1016/S0014-5793(96)01196-9; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243; BURKE MD, 1975, DRUG METAB DISPOS, V3, P245; CHOC MG, 1982, J BIOL CHEM, V257, P865; Chun YJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P48, DOI 10.1006/abbi.1996.0224; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; Dong JS, 1996, ARCH BIOCHEM BIOPHYS, V327, P254, DOI 10.1006/abbi.1996.0118; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; GOLD L, 1990, METHOD ENZYMOL, V185, P11; Guengerich F. Peter, 1995, P473; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1981, BIOCHEMISTRY-US, V20, P2379, DOI 10.1021/bi00512a003; Guengerich FP, 1996, METHOD ENZYMOL, V272, P35, DOI 10.1016/S0076-6879(96)72006-2; Guengerich FP, 1996, CRIT REV TOXICOL, V26, P551, DOI 10.3109/10408449609037477; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; JOSEPHY PD, 1995, CANCER RES, V55, P799; KNODELL RG, 1987, J PHARMACOL EXP THER, V241, P1112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARREY D, 1984, BIOCHEMISTRY-US, V23, P2787, DOI 10.1021/bi00307a039; LARSON JR, 1991, J BIOL CHEM, V266, P7321; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; Metz MZ, 1996, VIROLOGY, V217, P230, DOI 10.1006/viro.1996.0110; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; OMURA T, 1964, J BIOL CHEM, V239, P2370; Parikh A, 1997, PROTEIN EXPRES PURIF, V9, P346, DOI 10.1006/prep.1997.0721; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; Riley M., 1996, ESCHERICHIA COLI SAL, P2118; Sambrook J., 1989, MOL CLONING LAB MANU; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Shet MS, 1997, ARCH BIOCHEM BIOPHYS, V339, P218, DOI 10.1006/abbi.1996.9868; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; TARRAGONAFIOL A, 1992, GENE, V118, P239, DOI 10.1016/0378-1119(92)90194-T; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	41	267	276	3	28	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					784	788		10.1038/nbt0897-784	http://dx.doi.org/10.1038/nbt0897-784			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255795				2023-01-03	WOS:A1997XM70700032
J	Annas, GJ				Annas, GJ			Patients' rights in managed care - Exit, voice, and choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; ANNAS GJ, 1974, VANDERBILT LAW REV, V27, P243; *BNA, 1996, BNAS HLTH LAW R 1107, P1631; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; CHASE M, 1997, WALL ST J       0929, pB1; GAYNOR P, 1997, PITTSBURGH POST 0202, pC21; *HCFA, 1996, BNAS MANAGED CA 1211, P1159; HILTZIK MA, 1995, LOS ANGELES TIM 0827, pA1; Hirschman A. O., 1970, EXIT VOICE LOYALTY; Kinney ED, 1996, AM J LAW MED, V22, P301; Mariner WK, 1996, NEW ENGL J MED, V335, P1986, DOI 10.1056/NEJM199612263352610; RODWIN MA, 1996, HOUSTON LAW REV, V32, P1319; 1997, CHASREG, V62, P23368	13	38	39	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					210	215		10.1056/NEJM199707173370323	http://dx.doi.org/10.1056/NEJM199707173370323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219710	Green Published			2023-01-03	WOS:A1997XK81800030
J	vandeVen, CJM				vandeVen, CJM			Nasogastric enteral feeding in hyperemesis gravidarum!	LANCET			English	Editorial Material							HUMAN CHORIONIC-GONADOTROPIN; PREGNANCY; NAUSEA				vandeVen, CJM (corresponding author), UNIV MICHIGAN,CS MOTT CHILDRENS HOSP,DIV MATERNAL FETAL MED,ANN ARBOR,MI 48109, USA.							Barclay B A, 1990, Nutr Clin Pract, V5, P153, DOI 10.1177/0115426590005004153; GROSS S, 1989, AM J OBSTET GYNECOL, V160, P906, DOI 10.1016/0002-9378(89)90307-4; Hsu JJ, 1996, OBSTET GYNECOL, V88, P343, DOI 10.1016/0029-7844(96)00174-3; JARNFELTSAMSIOE A, 1983, GYNECOL OBSTET INVES, V16, P221; KAUPPILA A, 1979, BMJ-BRIT MED J, V1, P1670, DOI 10.1136/bmj.1.6179.1670; OBRIEN B, 1995, BIRTH-ISS PERINAT C, V22, P93, DOI 10.1111/j.1523-536X.1995.tb00566.x; SINGER AJ, 1991, AM J GASTROENTEROL, V86, P1695; SMITH CV, 1981, AM J OBSTET GYNECOL, V141, P180, DOI 10.1016/S0002-9378(16)32588-1; SOULES MR, 1980, OBSTET GYNECOL, V55, P696; Walsh JW, 1996, AM J PHYSIOL-GASTR L, V270, pG506, DOI 10.1152/ajpgi.1996.270.3.G506	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					445	446		10.1016/S0140-6736(05)61177-4	http://dx.doi.org/10.1016/S0140-6736(05)61177-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040568				2023-01-03	WOS:A1997WH38900003
J	Bates, DW; Spell, N; Cullen, DJ; Burdick, E; Laird, N; Petersen, LA; Small, SD; Sweitzer, BJ; Leape, LL				Bates, DW; Spell, N; Cullen, DJ; Burdick, E; Laird, N; Petersen, LA; Small, SD; Sweitzer, BJ; Leape, LL			The costs of adverse drug events in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADMISSIONS; MORBIDITY	Objective.-To assess the additional resource utilization associated with an adverse drug event (ADE). Design.-Nested case-control study within a prospective cohort study, Participants.-The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay. Main Outcome Measures.-Postevent length of stay and total costs. Methods.-Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges. Results.-During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was $3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and $5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were $2595 for all ADEs and $4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are $5.6 million and $2.8 million, respectively. Conclusions.-The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.	BRIGHAM & WOMENS HOSP, DIV GEN MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT ANESTHESIA, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, HLTH SERV RES & DEV, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University					AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM HOSP ASS, 1993, HOSP STAT; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CULLEN DJ, 1989, PROBL CRIT CARE, V3, P545; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KORIN J, 1993, HOSP FORMUL, V28, P59; KOSKA MT, 1989, HOSPITALS, V63, P24; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCKENNEY JM, 1976, AM J HOSP PHARM, V33, P792, DOI 10.1093/ajhp/33.8.792; *NAT ASS INS COMM, 1980, MED MALPR CLOS CLAIM; Rogowski J R, 1990, Health Care Financ Rev, V12, P87; SANDRICK K, 1995, HOSP HEALTH NETWORK, V69, P46; SANDRICK K, 1995, HOSP HEALTH NETWORK, V69, P36; *SAS, 1988, SAS PROC GUID REL 6; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; 1996, US NEWS WORLD R 0812, P67	24	1191	1230	2	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					307	311		10.1001/jama.277.4.307	http://dx.doi.org/10.1001/jama.277.4.307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC458	9002493				2023-01-03	WOS:A1997WC45800030
J	Salisbury, C				Salisbury, C			Observational study of a general practice out of hours cooperative: Measures of activity	BRITISH MEDICAL JOURNAL			English	Article							NORMAL WORKING HOURS; PRIMARY-CARE; DEPUTIZING SERVICES; TELEPHONE ADVICE; HOURS WORKLOAD; HOURS CALLS; ORGANIZATION; EMERGENCY; ACCIDENT; RATES	Objective: Tb evaluate an out of hours cooperative of Department of general practitioners compared with a deputising Primary Health service. Design: Observational study of two services in overlapping geographical areas. Setting: A general practice cooperative in Kensington, Chelsea, and Westminster and a deputising service operating in that area and the neighbouring area of Brent and Harrow. Subjects: All patients contacting a doctor at either service in an eight week period beginning 1 September 1995. Main outcome measures: Patients' age and sex; rates of home visiting, telephone advice, and attendance at a primary centre; hospital admission rates prescribing rates; times of patient calls; and response times. Results: Data were collected on 5812 patient contacts. Doctors from the cooperative visited 32.0% (1253/3920) of patients, offered telephone advice to 57.8% (2267), and saw 7.1% (278) of patients at the primary care centre. By contrast, the deputising service visited 76.3% (1444/1892) of patients and gave telephone advice to 19.3% (365). Doctors from the cooperative prescribed drugs to fewer patients (37.6%; 1473/3915) than did the deputising service (51.7%; 941/1821) (odds ratio 0.56 (95% confidence interval 0.50 to 0.63) adjusted for age and sex) and admitted 8.5% (339/3888) of patients to hospital compared with 6.8% (128/1889) from the deputising service (odds ratio 1.30 (1.05 to 1.61) adjusted for age and sex). Response times for the deputising service were faster (median time to visit 65 minutes) than for the cooperative (median time to visit 75 minutes) but the time to first contact with a doctor was shorter for the cooperative because most people initially received telephone advice. Conclusions: The cooperative in this study dealt with patient contacts very differently from the way the deputising service dealt with contacts, fewer patients being visited and fewer receiving prescriptions. The data presented enable other out of hours services to compare their own performance using a standard data collection and analysis program.			Salisbury, C (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,PRAED ST,LONDON W2 1PG,ENGLAND.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				ANDALO D, 1996, GEN PRACTITIONE 0614, P89; BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BARDSLEY M, 1995, 1 E LOND CIT HLTH AU; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; DALE J, 1992, BRIT J GEN PRACT, V42, P90; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; *DEP HLTH, 1984, HCFP842; *DEP HLTH, 1995, AM STAT FEES ALL OUT; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; *NAT HLTH SERV EX, 1996, 1994 5 HLTH SERV IND; *OFF POP CENS SURV, 1996, MID POP EST 1994 GOV; *OFF POP CENS SURV, 1993, 1994 CENS COUNT REP; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; REYNOLDS M, 1995, PULSE           0311, P48; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474	22	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					182	186		10.1136/bmj.314.7075.182	http://dx.doi.org/10.1136/bmj.314.7075.182			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022433	Green Published			2023-01-03	WOS:A1997WD91100028
J	Souba, WW				Souba, WW			Drug therapy - Nutritional support	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOTAL PARENTERAL-NUTRITION; BONE-MARROW TRANSPLANTATION; HUMAN GROWTH-HORMONE; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RANDOMIZED CONTROLLED TRIAL; GENERAL MEDICAL PATIENTS; MAJOR ABDOMINAL-TRAUMA; ACTIVE CROHNS-DISEASE; HEAD-INJURED PATIENTS; HUMAN SMALL-INTESTINE		MASSACHUSETTS GEN HOSP, NUTR SUPPORT SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Souba, WW (corresponding author), MASSACHUSETTS GEN HOSP, DIV SURG ONCOL, COX BLDG, RM 626, 100 BLOSSOM ST, BOSTON, MA 02114 USA.							ABEL RM, 1973, NEW ENGL J MED, V288, P695, DOI 10.1056/NEJM197304052881401; ALEXANDER JW, 1980, ANN SURG, V192, P505, DOI 10.1097/00000658-198010000-00009; [Anonymous], 1989, Ann Intern Med, V110, P734; BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BELLANTONE R, 1988, JPEN-PARENTER ENTER, V12, P195, DOI 10.1177/0148607188012002195; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; BOWER RH, 1995, CRIT CARE MED, V23, P436, DOI 10.1097/00003246-199503000-00006; BOWER RH, 1986, ARCH SURG-CHICAGO, V121, P1040; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; BYRNE TA, 1995, ANN SURG, V222, P243, DOI 10.1097/00000658-199509000-00003; CABRE E, 1990, GASTROENTEROLOGY, V98, P715, DOI 10.1016/0016-5085(90)90293-A; CERRA FB, 1985, JPEN-PARENTER ENTER, V9, P288, DOI 10.1177/0148607185009003288; CHANDRA RK, 1983, LANCET, V1, P688; CHRISTOU NV, 1995, ANN SURG, V222, P534; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CUNNINGHAM JJ, 1990, AM J CLIN NUTR, V51, P553, DOI 10.1093/ajcn/51.4.553; DALY JM, 1992, SURGERY, V112, P56; DECICCO M, 1993, JPEN-PARENTER ENTER, V17, P513, DOI 10.1177/0148607193017006513; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DICKINSON RJ, 1980, GASTROENTEROLOGY, V79, P1199; Doglietto GB, 1996, ANN SURG, V223, P357, DOI 10.1097/00000658-199604000-00003; DRISCOLL JM, 1972, J PEDIATR-US, V81, P145, DOI 10.1016/S0022-3476(72)80394-9; FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303; FEINSTEIN EI, 1981, MEDICINE, V60, P124, DOI 10.1097/00005792-198103000-00005; FONG YM, 1989, ANN SURG, V210, P449, DOI 10.1097/00000658-198910000-00005; GONZALEZHUIX F, 1993, GUT, V34, P778, DOI 10.1136/gut.34.6.778; GOODGAME JT, 1977, ANN SURG, V186, P651, DOI 10.1097/00000658-197711000-00018; GOUTTEBEL MC, 1986, DIGEST DIS SCI, V31, P718, DOI 10.1007/BF01296449; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; GRANT JP, 1984, ANN SURG, V200, P627, DOI 10.1097/00000658-198411000-00012; GREENBERG GR, 1988, GUT, V29, P1309, DOI 10.1136/gut.29.10.1309; GUEDON C, 1986, GASTROENTEROLOGY, V90, P373, DOI 10.1016/0016-5085(86)90935-2; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; HERRMANN FR, 1992, ARCH INTERN MED, V152, P125, DOI 10.1001/archinte.152.1.125; HEYLAND D, 1995, CRIT CARE MED, V23, P1055, DOI 10.1097/00003246-199506000-00010; Heymsfield SB, 1994, MODERN NUTR HLTH DIS, P812; INOUE Y, 1994, ANN SURG, V219, P715, DOI 10.1097/00000658-199406000-00016; INOUE Y, 1993, ANN SURG, V217, P604, DOI 10.1097/00000658-199306000-00002; KLEIN S, 1986, CANCER, V58, P1378, DOI 10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S; KLIDJIAN AM, 1980, BRIT MED J, V281, P899, DOI 10.1136/bmj.281.6245.899; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P1002, DOI 10.1016/S0272-6386(12)81075-4; Koretz R L, 1995, Gastroenterology, V109, P1713; KORETZ RL, 1995, AM J RESP CRIT CARE, V151, P570, DOI 10.1164/ajrccm.151.2.7842222; KOTLER DP, 1991, AM J CLIN NUTR, V53, P149, DOI 10.1093/ajcn/53.1.149; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; Kudsk KA, 1996, ANN SURG, V223, P629, DOI 10.1097/00000658-199606000-00001; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Lacey Janet M., 1996, Journal of Parenteral and Enteral Nutrition, V20, P74, DOI 10.1177/014860719602000174; Leonard C D, 1975, Urology, V6, P154, DOI 10.1016/0090-4295(75)90702-5; LI J, 1995, J TRAUMA, V39, P44, DOI 10.1097/00005373-199507000-00006; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; MESSING B, 1995, GASTROENTEROLOGY, V108, P1005, DOI 10.1016/0016-5085(95)90196-5; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MULLER JM, 1982, LANCET, V1, P68; MULLIGAN K, 1992, FASEB J, V6, pA1942; NASRALLAH SM, 1980, LANCET, V2, P1276; NAVEAU S, 1986, HEPATOLOGY, V6, P270, DOI 10.1002/hep.1840060219; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; NELSON J, 1995, NUTR CLIN PRACT, V4, P1; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; OMORAIN C, 1984, BRIT MED J, V288, P1859, DOI 10.1136/bmj.288.6434.1859; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROSE D, 1986, SURG GYNECOL OBSTET, V163, P345; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; SAVERYMUTTU S, 1985, GUT, V26, P994, DOI 10.1136/gut.26.10.994; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; SOETERS PB, 1979, ANN SURG, V190, P189, DOI 10.1097/00000658-197908000-00012; STEHLE P, 1989, LANCET, V1, P231; SUCHNER U, 1990, ARCH INTERN MED, V150, P1225, DOI 10.1001/archinte.150.6.1225; SZELUGA DJ, 1987, CANCER RES, V47, P3309; VALDIVIESO M, 1987, CANCER, V59, P362, DOI 10.1002/1097-0142(19870115)59:2<362::AID-CNCR2820590233>3.0.CO;2-J; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; VOERMAN HJ, 1992, ANN SURG, V216, P648, DOI 10.1097/00000658-199212000-00006; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418, DOI 10.1093/ajcn/32.2.418; WEISDORF SA, 1987, TRANSPLANTATION, V43, P833, DOI 10.1097/00007890-198743060-00012; WICKS C, 1994, LANCET, V344, P837, DOI 10.1016/S0140-6736(94)92824-X; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Wilmore DW, 1977, METABOLIC MANAGEMENT, P36; WINDSOR JA, 1988, ANN SURG, V208, P209, DOI 10.1097/00000658-198808000-00013; WOLFE RR, 1979, METABOLISM, V28, P1031, DOI 10.1016/0026-0495(79)90007-6; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; ZIEGLER TR, 1992, J CLIN ENDOCR METAB, V74, P865, DOI 10.1210/jc.74.4.865; ZIEGLER TR, 1991, J AM SOC NEPHROL, V2, P1130; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	90	198	207	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					41	48		10.1056/NEJM199701023360107	http://dx.doi.org/10.1056/NEJM199701023360107			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970939				2023-01-03	WOS:A1997WA49600007
J	Miller, FG; Fins, JJ				Miller, FG; Fins, JJ			A proposal to restructure hospital care for dying patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CORNELL UNIV,COLL MED,NEW YORK,NY 10021; UNIV VIRGINIA,CHARLOTTESVILLE,VA 22908; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; University of Virginia; Cornell University; NewYork-Presbyterian Hospital			Ram, Prem/K-4511-2012	Fins, Joseph/0000-0002-7221-0053				COLBURN D, 1995, WASHINGTON POST 1122, pA1; COLBURN D, 1995, WASHINGTON POST 1205, P7; COWLEY G, 1995, NEWSWEEK        1204, P74; Gilbert Susan, 1995, N Y Times Web, pC7; GOMEZ CF, 1996, CARING DYING IDENTIF, P27; GOODMAN E, 1995, JAMA-J AM MED ASSOC, V273, P1039; HORSBURGH CR, 1995, NEW ENGL J MED, V333, P735, DOI 10.1056/NEJM199509143331117; JAMES N, 1992, SOC SCI MED, V34, P1363, DOI 10.1016/0277-9536(92)90145-G; JECKER NS, 1991, J MED PHILOS, V16, P285, DOI 10.1093/jmp/16.3.285; Konner M., 1987, BECOMING DOCTOR JOUR; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MATHEWS JJ, 1991, WOMEN HEALTH, V17, P39, DOI 10.1300/J013v17n01_03; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; NULAND SB, 1994, HOW WE DIE RELFECTIO; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT JR, 1976, NEW ENGL J MED, V294, P1205, DOI 10.1056/NEJM197605272942203; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; STODDARD S, 1992, HOSPICE MOVEMENT; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WINSLOW R, 1995, WALL STREET J   0721, pB1; 1995, JAMA-J AM MED ASSOC, V274, P1591	24	57	57	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1740	1742		10.1056/NEJM199606273342612	http://dx.doi.org/10.1056/NEJM199606273342612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637523				2023-01-03	WOS:A1996UT40000012
J	Steadman, K; Franks, A				Steadman, K; Franks, A			A woman with malignant bowel obstruction who did not want to die with tubes	LANCET			English	Article									LEICESTERSHIRE HOSPICE, LEICESTER LE3 9QE, LEICS, ENGLAND									BAINES M, 1995, PALLIATIVE CARE TODA, V4, P4; Fallon MT, 1994, EUR J PALLIAT CARE, V1, P20; JOHNSON IS, 1994, ARTICLES SOMATOSTATI; Mercadante Sebastiano, 1993, Palliative Medicine, V7, P295; RIPAMONTI C, 1994, EUR J PALLIATIVE CAR, V1, P1	5	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					944	944		10.1016/S0140-6736(96)91418-X	http://dx.doi.org/10.1016/S0140-6736(96)91418-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598760				2023-01-03	WOS:A1996UD59100013
J	Tillman, JB; Dhahbi, JM; Mote, PL; Walford, RL; Spindler, SR				Tillman, JB; Dhahbi, JM; Mote, PL; Walford, RL; Spindler, SR			Dietary calorie restriction in mice induces carbamyl phosphate synthetase I gene transcription tissue specifically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PROTEIN-SYNTHESIS; MESSENGER-RNA LEVELS; UREA CYCLE ENZYMES; GROWTH FACTOR-I; RAT-LIVER; FOOD RESTRICTION; CARBAMOYLPHOSPHATE SYNTHETASE; MORRIS HEPATOMA-5123D; MITOCHONDRIAL ENZYME; HORMONAL-REGULATION	Dietary calorie restriction (CR) delays age-related physiologic changes, increases maximum life span, and reduces cancer incidence, Here, we present the novel finding that chronic reduction of dietary calories by 50% without changing the intake of dietary protein induced the activity of mouse hepatic carbamyl phosphate synthetase I (CpsI) 5-fold, In liver, CpsI protein, mRNA, and gene transcription were each stimulated by similar to 3-fold, Thus, CR increased both the rate of gene transcription and the specific activity of the enzyme. Short-term feeding studies demonstrated that higher cpsI expression was due to CR and not consumption of more dietary protein, Intestinal CpsI activity was stimulated 2-fold, while its mRNA level did not change, suggesting enzyme activity or translation efficiency was stimulated. CpsI catalyzes the conversion of metabolic ammonia to carbamyl phosphate, the rate-limiting step in urea biosynthesis, cpsI induction suggests there is a shift in the metabolism of calorie-restricted animals toward protein catabolism. CpsI induction likely facilitates metabolic detoxification of ammonia, a strong neurotoxin, Enhanced protein turnover and metabolic detoxification may extend life span. Physiologic similarities between calorie-restricted and hibernating animals suggest the effects of CR may be part of a spectrum of adaptive responses that include hibernation.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024	University of California System; University of California Riverside; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Tillman, John/0000-0003-2912-2370	NIA NIH HHS [AG00424] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; BALAGE M, 1990, HORM METAB RES, V22, P207, DOI 10.1055/s-2007-1004886; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CRAIK JD, 1979, BIOCHEM J, V182, P503, DOI 10.1042/bj1820503; DEGROOT CJ, 1984, BIOCHEM BIOPH RES CO, V124, P882, DOI 10.1016/0006-291X(84)91040-4; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARRIS SB, 1994, MECH AGEING DEV, V73, P209, DOI 10.1016/0047-6374(94)90053-1; HAYDEN JM, 1995, J ENDOCRINOL, V145, P397, DOI 10.1677/joe.0.1450397; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; Hochachka PW., 1987, METABOLIC ARREST CON; HURSTING SD, 1993, CANCER RES, V53, P2750; ISHIGAMI A, 1990, ARCH BIOCHEM BIOPHYS, V283, P362, DOI 10.1016/0003-9861(90)90655-I; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; JONES ME, 1965, ANNU REV BIOCHEM, V34, P381; KINGSLEY TR, 1991, J GERONTOL, V46, pB135, DOI 10.1093/geronj/46.4.B135; KITAGAWA Y, 1987, EUR J BIOCHEM, V167, P19, DOI 10.1111/j.1432-1033.1987.tb13299.x; KITAGAWA Y, 1985, BIOCHIM BIOPHYS ACTA, V825, P148, DOI 10.1016/0167-4781(85)90098-3; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361; KOIZUMI A, 1992, J NUTR, V122, P1446, DOI 10.1093/jn/122.7.1446; KOIZUMI A, 1989, AGE, V12, P93, DOI 10.1007/BF02432371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6; LIU RK, 1972, GERONTOLOGY, V18, P363, DOI 10.1159/000211944; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MARINEZRAMON A, 1990, J HISTOCHEM CYTOCHEM, V38, P371; MASORO EJ, 1989, J GERONTOL, V44, pB20, DOI 10.1093/geronj/44.1.B20; MASORO EJ, 1983, J NUTR, V113, P880, DOI 10.1093/jn/113.4.880; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOUSSEAU DD, 1994, P SOC EXP BIOL MED, V206, P329; Nuzum CT, 1976, UREA CYCLE, P325; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PALEKAR AG, 1985, ARCH BIOCHEM BIOPHYS, V237, P430, DOI 10.1016/0003-9861(85)90296-6; RAYMOND Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P111, DOI 10.1016/0005-2787(81)90033-2; ROZEN R, 1983, BIOCHIM BIOPHYS ACTA, V741, P47, DOI 10.1016/0167-4781(83)90008-8; RUGGERI BA, 1989, CANCER RES, V49, P4130; RYALL J, 1985, EUR J BIOCHEM, V152, P287, DOI 10.1111/j.1432-1033.1985.tb09196.x; RYALL J, 1984, J BIOL CHEM, V259, P9172; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; SCHIMKE RT, 1963, J BIOL CHEM, V238, P1021; SEILER N, 1993, NEUROCHEM RES, V18, P235, DOI 10.1007/BF00969079; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SPINDLER SR, 1990, J NUTR, V120, P1412, DOI 10.1093/jn/120.11.1412; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; SPINDLER SR, 1991, J GERONTOL, V46, pB233, DOI 10.1093/geronj/46.6.B233; STEINBERG RA, 1975, CELL, V5, P29, DOI 10.1016/0092-8674(75)90088-4; TAL M, 1990, J CLIN INVEST, V86, P986, DOI 10.1172/JCI114801; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TILLMAN JB, 1996, IN PRESS J NUTR; WALFORD RL, 1992, P NATL ACAD SCI USA, V89, P11533, DOI 10.1073/pnas.89.23.11533; WARD W, 1991, HEPATOLOGY, V14, P935, DOI 10.1002/hep.1840140529; WARD WF, 1988, J GERONTOL, V43, pB121, DOI 10.1093/geronj/43.5.B121; WARD WF, 1988, J GERONTOL, V43, pB50, DOI 10.1093/geronj/43.2.B50; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1988, RETARDATION AGING DI; WHITE BA, 1982, J BIOL CHEM, V257, P8569	63	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3500	3506						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631954	hybrid			2023-01-03	WOS:A1996TV72400028
J	McFarland, J; Menitove, J; Kagen, L; Braine, H; Kickler, T; Ness, P; Fuller, A; Slichter, S; Gernsheimer, T; Townsend-McCall, D; Kao, KJ; Noyes, W; Weiner, R; Hudson, S; Waldman-Slone, A; Schiffer, C; Lee, E; Norris, D; McCullough, J; Enright, H; Lennon, S; Clay, M; Woodson, R; Meisch, M; Noordsij, P; Davis, K; Mickel, M; Gillespie, MJ; Ng, G; Parker, S; Corley, S; Rodey, G; Kao, KJ; Sell, J; Nemo, G; Follmann, D; Hernandez, M; Hollingsworth, C; Klein, H; Dutcher, J; Fratantoni, J; Kruskall, M; Macklin, R; Strauss, R; Wittes, J				McFarland, J; Menitove, J; Kagen, L; Braine, H; Kickler, T; Ness, P; Fuller, A; Slichter, S; Gernsheimer, T; Townsend-McCall, D; Kao, KJ; Noyes, W; Weiner, R; Hudson, S; Waldman-Slone, A; Schiffer, C; Lee, E; Norris, D; McCullough, J; Enright, H; Lennon, S; Clay, M; Woodson, R; Meisch, M; Noordsij, P; Davis, K; Mickel, M; Gillespie, MJ; Ng, G; Parker, S; Corley, S; Rodey, G; Kao, KJ; Sell, J; Nemo, G; Follmann, D; Hernandez, M; Hollingsworth, C; Klein, H; Dutcher, J; Fratantoni, J; Kruskall, M; Macklin, R; Strauss, R; Wittes, J		Trial Reduce Alloimmunization Platelets Study	Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOSORBENT-ASSAY; PACKED RED-CELLS; HLA-ALLOIMMUNIZATION; THROMBOCYTOPENIC PATIENTS; BLOOD COMPONENTS; SINGLE-DONOR; DELAYED ALLOIMMUNIZATION; LYMPHOCYTOTOXIC ANTIBODY; GLYCOPROTEIN-IIIA; RANDOMIZED TRIAL	Background We conducted a multi-institutional, randomized, blinded trial to determine whether the use of platelets from which leukocytes had been removed by a filter or that had been treated with ultraviolet B irradiation would prevent the formation of antiplatelet alloantibodies and refractoriness to platelet transfusions. Methods Patients who were receiving induction chemotherapy for acute myeloid leukemia were randomly assigned to receive one of four types of platelet transfusions: unmodified, pooled platelet concentrates from random donors (control); filtered, pooled platelet concentrates from random donors (F-PC); ultraviolet B-irradiated, pooled platelet concentrates from random donors (UVB-PC); or filtered platelets obtained by apheresis from single random donors (F-AP). All patients received transfusions of filtered, leukocyte-reduced red cells. Results Of 530 patients with no alloantibodies at base line, 13 percent of those in the control group produced lymphocytotoxic antibodies and their thrombocytopenia became refractory to platelet transfusions, as compared with 3 percent in the F-PC group, 5 percent in the UVB-PC group, and 4 percent in the F-AP group (P less than or equal to 0.03 for each treated group as compared with the controls; there were no significant differences among the treated groups). Lymphocytotoxic antibodies were found in 45 percent of the controls, as compared with 17 to 21 percent in the treated groups (P<0.001 for each treated group as compared with the controls; there were no significant differences among the treated groups). Antibodies against platelet glycoproteins developed in 6 to 11 percent of the patients, with no significant differences among the four groups. Conclusions Reduction of leukocytes by filtration and ultraviolet B irradiation of platelets are equally effective in preventing alloantibody-mediated refractoriness to platelets during chemotherapy for acute myeloid leukemia. Platelets obtained by apheresis from single random donors provided no additional benefit as compared with pooled platelet concentrates from random donors. (C) 1997, Massachusetts Medical Society.	Puget Sound Blood Ctr, Div Res & Educ, Seattle, WA 98104 USA	Puget Sound Blood Center	Slichter, S (corresponding author), Puget Sound Blood Ctr, Div Res & Educ, 921 Terry Ave, Seattle, WA 98104 USA.			Corley, Scott/0000-0001-5288-9188	NHLBI NIH HHS [U01 HL42805, U01 HL42802, U01 HL42799] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL042805, U01HL042799, U01HL042802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREU G, 1990, TRANSFUSION, V30, P401, DOI 10.1046/j.1537-2995.1990.30590296370.x; ANDREU G, 1988, BLOOD, V72, P964; Andreu Georges, 1994, V60, P29; BISHOP JF, 1988, BLOOD, V71, P383; BLAJCHMAN MA, 1991, SEMIN HEMATOL, V28, P14; Blundell EL, 1996, TRANSFUSION, V36, P296, DOI 10.1046/j.1537-2995.1996.36496226140.x; BOWDEN RA, 1995, BLOOD, V86, P3598, DOI 10.1182/blood.V86.9.3598.bloodjournal8693598; BRAND A, 1988, VOX SANG, V54, P160, DOI 10.1111/j.1423-0410.1988.tb03892.x; BRAND A, 1978, BLOOD, V51, P781; CLAAS FHJ, 1981, EXP HEMATOL, V9, P84; COLLINS J, 1987, VOX SANG, V53, P157, DOI 10.1111/j.1423-0410.1987.tb04941.x; CORASH L, 1994, BLOOD, V84, pA530; CURTIS BR, 1994, BLOOD, V84, P176, DOI 10.1182/blood.V84.1.176.bloodjournal841176; DUQUESNOY RJ, 1977, AM J HEMATOL, V2, P219, DOI 10.1002/ajh.2830020303; Fish D., 1995, Blood, V86, p541A; FRIEDBERG RC, 1993, BLOOD, V81, P3428; FULLER TC, 1982, TRANSPLANTATION, V34, P24, DOI 10.1097/00007890-198207000-00005; FURIHATA K, 1987, J CLIN INVEST, V80, P1624, DOI 10.1172/JCI113250; GMUR J, 1983, BLOOD, V62, P473; Grass J., 1995, Blood, V86, p542A; GRIJZENHOUT MA, 1994, BRIT J HAEMATOL, V87, P598, DOI 10.1111/j.1365-2141.1994.tb08319.x; GRIJZENHOUT MA, 1994, BLOOD, V84, P3524; HOGGE DE, 1983, AM J HEMATOL, V14, P363, DOI 10.1002/ajh.2830140407; HOLOHAN TV, 1981, BLOOD, V58, P122; HOWE SE, 1984, TRANSFUSION, V24, P348, DOI 10.1046/j.1537-2995.1984.24484275580.x; KAO KJ, 1989, TRANSFUSION, V29, P774, DOI 10.1046/j.1537-2995.1989.29990070180.x; KAO KJ, 1995, TRANSFUSION, V35, P13, DOI 10.1046/j.1537-2995.1995.35195090653.x; KEKOMAKI R, 1991, J CLIN INVEST, V88, P847, DOI 10.1172/JCI115386; KICKLER T, 1990, TRANSFUSION, V30, P622, DOI 10.1046/j.1537-2995.1990.30790385520.x; KICKLER TS, 1985, TRANSFUSION, V25, P385, DOI 10.1046/j.1537-2995.1985.25485273823.x; KOOY MV, 1991, BLOOD, V77, P201; KRIPKE ML, 1984, IMMUNOL REV, V80, P87, DOI 10.1111/j.1600-065X.1984.tb00496.x; LEE EJ, 1987, BLOOD, V70, P1727; LINDAHLK.K, 1971, INT ARCH ALLER A IMM, V41, P670, DOI 10.1159/000230559; LUTZ P, 1993, TRANSFUSION, V33, P409, DOI 10.1046/j.1537-2995.1993.33593255602.x; MURPHY MF, 1986, BRIT J HAEMATOL, V62, P529, DOI 10.1111/j.1365-2141.1986.tb02965.x; Murphy S, 1996, TRANSFUSION, V36, P751, DOI 10.1046/j.1537-2995.1996.36896374382.x; NOROL F, 1994, BRIT J HAEMATOL, V86, P125, DOI 10.1111/j.1365-2141.1994.tb03262.x; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OKSANEN K, 1991, TRANSFUSION, V31, P588, DOI 10.1046/j.1537-2995.1991.31791368333.x; PAMPHILON DH, 1990, BRIT J HAEMATOL, V75, P240, DOI 10.1111/j.1365-2141.1990.tb02656.x; RUBINSTEIN LV, 1981, J CHRON DIS, V34, P469, DOI 10.1016/0021-9681(81)90007-2; SCHIFFER CA, 1983, BLOOD, V61, P311; SCHIFFER CA, 1986, BLOOD, V67, P1591; SCHIFFER CA, 1983, BLOOD, V62, P815; SHERMAN L, 1992, TRANSFUSION, V32, P402, DOI 10.1046/j.1537-2995.1992.32592327711.x; SINTNICOLAAS K, 1995, BLOOD, V85, P824, DOI 10.1182/blood.V85.3.824.bloodjournal853824; SINTNICOLAAS K, 1981, LANCET, V1, P750; SNIECINSKI I, 1988, BLOOD, V71, P1402; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103; VISENTIN GP, 1990, TRANSFUSION, V30, P694, DOI 10.1046/j.1537-2995.1990.30891020326.x; WILLIAMSON LM, 1994, BLOOD, V83, P3028, DOI 10.1182/blood.V83.10.3028.3028	52	569	577	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1861	1869						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9417523				2023-01-03	WOS:000071128200001
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			An 88-year-old woman facing the end of life, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2184	2184						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417014				2023-01-03	WOS:000071022200036
J	McLeish, T				McLeish, T			Polymer science - Fashioning flow by self-assembly	SCIENCE			English	Editorial Material											McLeish, T (corresponding author), UNIV LEEDS,DEPT PHYS & ASTRON,RES CTR POLYMER SCI & TECHNOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			McLeish, Tom/0000-0002-2025-0299				Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; Doi M., 1986, THEORY POLYM DYNAMIC; Lequeux F., 1997, THEORETICAL CHALLENG; MCLEISH T, 1995, PHYS WORLD, V8, P32; Sijbesma RP, 1997, SCIENCE, V278, P1601, DOI 10.1126/science.278.5343.1601	6	5	5	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1577	1578		10.1126/science.278.5343.1577	http://dx.doi.org/10.1126/science.278.5343.1577			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9411780				2023-01-03	WOS:A1997YJ87400026
J	Tinetti, ME; Williams, CS				Tinetti, ME; Williams, CS			Falls, injuries due to falls, and the risk of admission to a nursing home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; ELDERLY PEOPLE; OLDER PERSONS; FUNCTIONAL STATUS; COMMUNITY; POPULATION; ADULTS; EFFICACY; CARE; FEAR	Background Falls warrant investigation as a risk factor for nursing home admission because falls are common and are associated with functional disability and because they may be preventable. Methods We conducted a prospective study of a probability sample of 1103 people over 71 years of age who were living in the community. Data on demographic and medical characteristics, use of health care, and cognitive, functional, psychological, and social functioning were obtained at base line and one year later during assessments in the participants' homes. The primary outcome studied was the number of days from the initial assessment to a first longterm admission to a skilled-nursing facility during three years of follow-up, Patients were assigned to four categories during follow-up: those who had no falls, those who had one fall without serious injury, those who had two or more falls without serious injury, and those who had at least one fall causing serious injury. Results A total of 133 participants (12.1 percent) had long-term admissions to nursing homes. In an unadjusted model, the risk of admission increased progressively, as compared with that for the patients with no falls, for those with a single noninjurious fall (relative risk, 4.9; 95 percent confidence interval, 3.2 to 7.5), those with multiple noninjurious falls (relative risk, 8.5; 95 percent confidence interval, 3.4 to 21.2), and those with at least one fall causing serious injury (relative risk, 19.9; 95 percent confidence interval, 12.2 to 32.6). Adjustment for other risk factors lowered these ratios to 3.1 (95 percent confidence interval, 1.9 to 4.9) for one noninjurious fall, 5.5 (95 percent confidence interval, 2.1 to 14.2) for two or more noninjurious falls, and 10.2 (95 percent confidence interval, 5.8 to 17.9) for at least one fall causing serious injury, but the association between falls and admission to a nursing home remained strong and significant. The population attributable risk of long-term admission to a nursing home for these three groups (the proportion of admissions directly attributable to the three categories of falls) was 13 percent, 3 percent, and 10 percent, respectively. Conclusions Among older people living in the community falls are a strong predictor of placement in a skilled-nursing facility; interventions that prevent falls and their sequelae may therefore delay or reduce the frequency of nursing home admissions. (C) 1997, Massachusetts Medical Society.			Tinetti, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.				NIA NIH HHS [P60AG10487, R01 AG07447] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Dunn J E, 1993, J Aging Health, V5, P194, DOI 10.1177/089826439300500203; Foley D J, 1992, J Aging Health, V4, P155, DOI 10.1177/089826439200400201; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREENE VL, 1990, J GERONTOL, V45, pS250, DOI 10.1093/geronj/45.6.S250; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; JETTE AM, 1992, GERONTOLOGIST, V32, P634, DOI 10.1093/geront/32.5.634; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KIEL DP, 1991, MED CARE, V29, P221; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LIU K, 1991, MED CARE, V29, P125, DOI 10.1097/00005650-199102000-00005; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MURTAUGH CM, 1990, MED CARE, V28, P952, DOI 10.1097/00005650-199010000-00009; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Seeman T. E., 1993, J AGING HEALTH, V5, P455, DOI DOI 10.1177/089826439300500403; Spielberger C., 1983, STAI MANUAL; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; WOLINSKY FD, 1993, J GERONTOL, V48, pS93; WOLINSKY FD, 1992, MED CARE, V30, P587, DOI 10.1097/00005650-199207000-00002	37	921	943	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1279	1284		10.1056/NEJM199710303371806	http://dx.doi.org/10.1056/NEJM199710303371806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC920	9345078				2023-01-03	WOS:A1997YC92000006
J	Sykes, J; Johnson, R; Hanks, GW				Sykes, J; Johnson, R; Hanks, GW			ABC of palliative care - Difficult pain problems	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL ROYAL INFIRM & GEN HOSP,PAIN CLIN,BRISTOL,AVON,ENGLAND	Bristol Royal Infirmary	Sykes, J (corresponding author), CTY HOSP,HEREFORD HR1 2ER,ENGLAND.							GYBELS JM, 1989, NEUROSURGICAL TREATM; HANKS GW, 1997, OXFORD TXB PALLIATIV	2	16	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					867	869		10.1136/bmj.315.7112.867	http://dx.doi.org/10.1136/bmj.315.7112.867			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353510	Green Published			2023-01-03	WOS:A1997YA00700031
J	Nestler, EJ; Aghajanian, GK				Nestler, EJ; Aghajanian, GK			Molecular and cellular basis of addiction	SCIENCE			English	Review							MU-OPIOID-RECEPTOR; MESOLIMBIC DOPAMINE SYSTEM; LOCUS-CERULEUS NEURONS; VENTRAL TEGMENTAL AREA; OPIATE-DEPENDENT RATS; CYCLIC-AMP SYSTEM; LONG-TERM-MEMORY; BEHAVIORAL SENSITIZATION; NUCLEUS-ACCUMBENS; G-PROTEIN	Drug addiction results from adaptations in specific brain neurons caused by repeated exposure to a drug of abuse. These adaptations combine to produce the complex behaviors that define an addicted slate. Progress is being made in identifying such time-dependent, drug-induced adaptations and relating them to specific behavioral features of addiction. Current research needs to understand the types of adaptations that underlie the particularly long-lived aspects of addiction, such as drug craving and relapse, and to identify specific genes that contribute to individual differences in vulnerability to addiction. Understanding the molecular and cellular basis of addictive states will lead to major changes in how addiction is viewed and ultimately treated.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06508 USA; CONNECTICUT MENTAL HLTH CTR, NEW HAVEN, CT 06508 USA	Yale University	Nestler, EJ (corresponding author), YALE UNIV, SCH MED, DEPT PSYCHIAT, LAB MOL PSYCHIAT, 34 PK ST, NEW HAVEN, CT 06508 USA.							AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; AKAOKA H, 1991, J NEUROSCI, V11, P3830; ALREJA M, 1994, BRAIN RES, V639, P320, DOI 10.1016/0006-8993(94)91746-9; ALREJA M, 1993, J NEUROSCI, V13, P3525; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ATTALI B, 1989, J NEUROCHEM, V53, P1636, DOI 10.1111/j.1471-4159.1989.tb08562.x; Berhow MT, 1996, J NEUROSCI, V16, P4707; Berhow MT, 1996, J NEUROSCI, V16, P8019; BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3; Bonci A, 1997, J NEUROSCI, V17, P796; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Carlezon WA, 1996, J NEUROSCI, V16, P3112; Chen J. S., 1997, Society for Neuroscience Abstracts, V23, P410; Chen JS, 1997, J NEUROSCI, V17, P4933; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Crain SM, 1996, NEUROCHEM RES, V21, P1347, DOI 10.1007/BF02532375; CUNNINGHAM ST, 1993, J NEUROSCI, V13, P2342, DOI 10.1523/JNEUROSCI.13-06-02342.1993; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRAGO J, 1996, NEURON, V17, P747; ELLIOTT K, 1995, NEUROPSYCHOPHARMACOL, V13, P347, DOI 10.1038/sj.npp.1380294; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gold SJ, 1997, J NEUROSCI, V17, P8024; HENRY DJ, 1995, J NEUROSCI, V15, P6287; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; JEZIORSKI M, 1994, SYNAPSE, V16, P137, DOI 10.1002/syn.890160207; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; Jolas T., 1997, Society for Neuroscience Abstracts, V23, P124; KALIVAS PW, 1995, DRUG ALCOHOL DEPEN, V37, P95, DOI 10.1016/0376-8716(94)01063-Q; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; Kelley AE, 1997, SYNAPSE, V26, P46, DOI 10.1002/(SICI)1098-2396(199705)26:1<46::AID-SYN5>3.0.CO;2-E; KOGAN JH, 1992, EUR J PHARMACOL, V211, P47, DOI 10.1016/0014-2999(92)90261-2; Kolesnikov YA, 1997, P NATL ACAD SCI USA, V94, P8220, DOI 10.1073/pnas.94.15.8220; KOLESNIKOV YA, 1992, EUR J PHARMACOL, V221, P339; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A., 1997, Society for Neuroscience Abstracts, V23, P1769; Kreek MJ, 1996, MOL PSYCHIATR, V1, P232; Kuhar MJ, 1996, TRENDS PHARMACOL SCI, V17, P260, DOI 10.1016/S0165-6147(96)10024-9; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; Lu WX, 1997, SYNAPSE, V26, P269, DOI 10.1002/(SICI)1098-2396(199707)26:3<269::AID-SYN8>3.0.CO;2-5; Lucas JJ, 1997, MOL PHARMACOL, V51, P755, DOI 10.1124/mol.51.5.755; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; Maldonado R, 1997, NEUROSCI BIOBEHAV R, V21, P91, DOI 10.1016/0149-7634(95)00061-5; MALDONADO R, 1995, N-S ARCH PHARMACOL, V352, P565; Mandelzys A, 1997, J NEUROSCI, V17, P5407; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MISERENDINO MJD, 1995, BRAIN RES, V674, P299, DOI 10.1016/0006-8993(95)00030-T; Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Nye HE, 1996, MOL PHARMACOL, V49, P636; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; ORTIZ J, 1996, NEUROPSYCHOPHARMACOL, V14, P393; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PEI G, 1995, MOL PHARMACOL, V48, P173; Phillips TJ, 1997, CRIT REV NEUROBIOL, V11, P21, DOI 10.1615/CritRevNeurobiol.v11.i1.20; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Pich EM, 1997, SCIENCE, V275, P83; PUNCH L, IN PRESS J NEUROSCI; RASMUSSEN K, 1989, BRAIN RES, V505, P346, DOI 10.1016/0006-8993(89)91466-2; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Schoffelmeer ANM, 1996, NEUROCHEM RES, V21, P1417, DOI 10.1007/BF02532383; SEIF DW, 1995, ANNU REV NEUROSCI, V18, P463; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shaham Y, 1997, J NEUROSCI, V17, P2605; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Sim LJ, 1996, J NEUROSCI, V16, P2684; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; Spanagel R, 1996, J NEUROENDOCRINOL, V8, P93, DOI 10.1111/j.1365-2826.1996.tb00828.x; Spangler R, 1996, MOL BRAIN RES, V38, P71, DOI 10.1016/0169-328X(95)00319-N; STEKETEE JD, 1991, BRAIN RES, V545, P287, DOI 10.1016/0006-8993(91)91299-G; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; STRIPLIN CD, 1993, SYNAPSE, V14, P10, DOI 10.1002/syn.890140103; TAO PL, 1993, N-S ARCH PHARMACOL, V348, P504; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Tolliver BK, 1996, J PHARMACOL EXP THER, V278, P411; TRUJILLO KA, 1994, BRAIN RES, V633, P178, DOI 10.1016/0006-8993(94)91538-5; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Turgeon SM, 1997, BRAIN RES, V749, P120, DOI 10.1016/S0006-8993(96)01316-9; Uhl GR, 1997, P NATL ACAD SCI USA, V94, P2785, DOI 10.1073/pnas.94.7.2785; Uhl GR, 1996, CURR BIOL, V6, P935, DOI 10.1016/S0960-9822(02)00630-9; Unterwald EM, 1996, EUR J PHARMACOL, V318, P31, DOI 10.1016/S0014-2999(96)00841-2; Valverde O, 1996, EUR J NEUROSCI, V8, P2671, DOI 10.1111/j.1460-9568.1996.tb01562.x; VANVLIET BJ, 1993, EUR J PHARM-MOLEC PH, V245, P23, DOI 10.1016/0922-4106(93)90165-6; VAUPEL DB, 1995, NEUROPSYCHOPHARMACOL, V13, P315, DOI 10.1016/0893-133X(95)00138-4; Ventayol P, 1997, N-S ARCH PHARMACOL, V355, P491, DOI 10.1007/PL00004974; Wang XB, 1997, J NEUROSCI, V17, P5993; WERLING LL, 1989, P NATL ACAD SCI USA, V86, P6393, DOI 10.1073/pnas.86.16.6393; White F J, 1998, Adv Pharmacol, V42, P1006; WHITE FJ, 1995, J PHARMACOL EXP THER, V273, P445; Widnell KL, 1996, J PHARMACOL EXP THER, V276, P306; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; ZAMANILLO D, 1995, NEUROSCI LETT, V188, P183, DOI 10.1016/0304-3940(95)11428-Y; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	124	1042	1122	4	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					58	63		10.1126/science.278.5335.58	http://dx.doi.org/10.1126/science.278.5335.58			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311927				2023-01-03	WOS:A1997XZ12400032
J	Cappuccio, FP; Markandu, ND; Carney, C; Sagnella, GA; MacGregor, GA				Cappuccio, FP; Markandu, ND; Carney, C; Sagnella, GA; MacGregor, GA			Double-blind randomised trial of modest salt restriction in older people	LANCET			English	Article							BLOOD-PRESSURE; SODIUM RESTRICTION; FOOD-INDUSTRY; HYPERTENSION; REDUCTION; PREVENTION; TASTE	Background Stroke is directly related to blood pressure and treatment trials in older hypertensive individuals show a reduction in strokes. However, the majority of strokes occur in normotensive individuals in whom no attempt is made to lower blood pressure. We compared the effects of modest salt restriction on blood pressure in older hypertensive and normotensive people. Methods 47 untreated elderly people (24 men, age range 60-78 years; blood-pressure range 123-205 mm Hg systolic and 64-112 mm Hg diastolic) completed a 2-month double-blind randomised placebo-controlled crossover study of modest salt restriction with slow sodium and placebo to give a salt intake of either 10 g (equivalent to the normal amount for the UK population) or 5 g. Findings On the normal salt intake for the UK population, supine blood pressure was 163/90 (SD 21/10) mm Hg with urinary sodium excretion of 177 (49) mmol/day. With modest sodium restriction, blood pressure fell to 156/87 (22/9) mm Hg (p<0.001/0.004) with a urinary sodium excretion of 94 (50) mmol/day. A reduction in sodium intake of 83 mmol/day was associated with a reduction of 7.2/3.2 mm Hg. There was no significant difference in the blood-pressure fall between 18 normotensive and 29 hypertensive participants (8.2/3.9 vs 6.6/2.7 mm Hg). Interpretation A modest reduction in salt intake leads to a fall in blood pressure in both normotensive and hypertensive older people similar to that in outcome trials of thiazide-based treatment. Since the majority of strokes in older people occur below the current definition of hypertension, our results have important implications for the prevention of stroke.			Cappuccio, FP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND.		Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493				ADAMS SO, 1995, J AM DIET ASSOC, V95, P447, DOI 10.1016/S0002-8223(95)00120-4; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; BEAUCHAMP GK, 1983, ANN INTERN MED, V98, P763, DOI 10.7326/0003-4819-98-5-763; BERTINO M, 1982, AM J CLIN NUTR, V36, P1134, DOI 10.1093/ajcn/36.6.1134; Cappuccio FP, 1996, AM J CLIN NUTR, V63, P787; CAPPUCCIO FP, 1985, J HYPERTENS, V3, P243, DOI 10.1097/00004872-198506000-00008; FOTHERBY MD, 1993, J HYPERTENS, V11, P657, DOI 10.1097/00004872-199306000-00010; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; Godlee F, 1996, BRIT MED J, V312, P1239, DOI 10.1136/bmj.312.7041.1239; GREENFIELD H, 1984, HUM NUTR-APPL NUTR, V38A, P203; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; *PROSP STUD COLL, 1995, LANCET, V346, P1647; SWALES JD, 1995, GROWTH MED SCI LESSO, P1; SWALES JD, 1994, J HYPERTENS S10, V12, pS5; WHETON PK, 1996, CIRCULATION S1, V94, P78	20	128	130	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					850	854		10.1016/S0140-6736(97)02264-2	http://dx.doi.org/10.1016/S0140-6736(97)02264-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310603				2023-01-03	WOS:A1997XX40100011
J	Pui, CH; Boyett, JM; Hughes, WT; Rivera, GK; Hancock, ML; Sandlund, JT; Synold, T; Relling, MV; Ribeiro, RC; Crist, WM; Evans, WE				Pui, CH; Boyett, JM; Hughes, WT; Rivera, GK; Hancock, ML; Sandlund, JT; Synold, T; Relling, MV; Ribeiro, RC; Crist, WM; Evans, WE			Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; PNEUMOCYSTIS-CARINII PNEUMONITIS; ACUTE MYELOGENOUS LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; PHASE-III TRIAL; FACTOR G-CSF; CONGENITAL NEUTROPENIA; INTENSIVE INDUCTION; THERAPY	Background Recombinant human granulocyte colony-stimulating factor (G-CSF, or filgrastim) hastens the recovery from neutropenia after intensive chemotherapy, but its role in the management of childhood leukemia is unclear. Methods We randomly assigned 164 patients with acute lymphoblastic leukemia (age range, 2 months to 17 years) to receive placebo or G-CSF (10 mu g per kilogram of body weight per day subcutaneously), beginning one day after the completion of remission-induction therapy and continuing until the neutrophil count was greater than or equal to 1000 per cubic millimeter for two days. The clinical and laboratory effects of this therapy were documented for 21 days. The area under the plasma G-CSF concentration-time curve was measured on days 1 and 7 in both groups. Results Responses to the growth factor could be assessed in 148 patients (73 in the G-CSF group and 75 in the placebo group). G-CSF treatment did not significantly lower the rate of hospitalization for febrile neutropenia (58 percent in the G-CSF group vs. 68 percent in the placebo group; relative risk, 0.85; 95 percent confidence interval, 0.59 to 1.16), increase the likelihood of event-free survival at three years (83 percent in both groups), or decrease the number of severe infections (five in the G-CSF group vs. six in the placebo group). Patients treated with G-CSF had shorter median hospital stays (6 days vs. 10 days, P=0.011) and fewer documented infections (12 vs. 27, P=0.009). The median total costs of supportive care were similar in the G-CSF and placebo groups ($8,768 and $8,616, respectively). Among patients who did not have febrile neutropenia during the first week of G-CSF or placebo injections, higher systemic exposure to the growth factor on day 7 was significantly related to a lower probability of subsequent hospitalization (P=0.049). Conclusions G-CSF treatment had some clinical benefit in children who received induction chemotherapy for acute lymphoblastic leukemia, but it did not reduce the rate of hospitalization for febrile neutropenia, prolong survival, or reduce the cost of supportive care. (C)1997, Massachusetts Medical Society.	UNIV TENNESSEE, COLL MED, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, COLL PHARM, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), ST JUDE CHILDRENS RES HOSP, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658; Synold, Timothy/0000-0002-4075-2544				[Anonymous], 1994, J CLIN ONCOL, V12, P2471; BEKSAC M, 1992, BLOOD, V80, P2946; BONILLA MA, 1994, BRIT J HAEMATOL, V88, P723, DOI 10.1111/j.1365-2141.1994.tb05110.x; CLEVERLEY WHO, 1996, 1996 97 ALMANAC HOSP; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DARGENIO DZ, 1992, ADAPT 2 MATH SOFTWAR; DIBENEDETTO SP, 1995, EUR J HAEMATOL, V55, P93; DOMBRET H, 1995, NEW ENGL J MED, V332, P1678, DOI 10.1056/NEJM199506223322504; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; DREGER P, 1994, BRIT J HAEMATOL, V87, P609, DOI 10.1111/j.1365-2141.1994.tb08321.x; ESTEY E, 1994, J CLIN ONCOL, V12, P671, DOI 10.1200/JCO.1994.12.4.671; FURMAN WL, 1991, J CLIN ONCOL, V9, P1022, DOI 10.1200/JCO.1991.9.6.1022; GISSELBRECHT C, 1994, LANCET, V343, P696, DOI 10.1016/S0140-6736(94)91579-2; GISSELBRECHT C, 1994, LANCET, V343, P804; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HUGHES WT, 1992, CLIN INFECT DIS, V15, pS206, DOI 10.1093/clind/15.Supplement_1.S206; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; HUGHES WT, 1990, J INFECT DIS, V161, P1316; HUGHES WT, 1996, HOSP EPIDEMIOLOGY IN, P618; IMASHUKU S, 1995, BRIT J HAEMATOL, V89, P188, DOI 10.1111/j.1365-2141.1995.tb08928.x; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KANTARJIAN HM, 1993, CANCER-AM CANCER SOC, V72, P2950, DOI 10.1002/1097-0142(19931115)72:10<2950::AID-CNCR2820721015>3.0.CO;2-B; KITA K, 1993, LEUKEMIA, V7, P1184; KLUMPP TR, 1995, J CLIN ONCOL, V13, P1323, DOI 10.1200/JCO.1995.13.6.1323; KUBOTA M, 1995, PEDIATR HEMAT ONCOL, V12, P393, DOI 10.3109/08880019509029590; LARSON RA, 1994, P AN M AM SOC CLIN, V13, P305; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LINDEMANN A, 1989, BLOOD, V74, P2644; Locatelli F, 1996, BONE MARROW TRANSPL, V17, P31; MADERO L, 1995, BONE MARROW TRANSPL, V15, P349; MAYORDOMO JI, 1995, J NATL CANCER I, V87, P803, DOI 10.1093/jnci/87.11.803; MIKSITS K, 1993, BONE MARROW TRANSPL, V11, P375; MIRRO J, 1993, LEUKEMIA, V7, P1026; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; OHNO R, 1993, INT J HEMATOL, V58, P73; OHNO R, 1994, BLOOD, V83, P2086; OHNO R, 1990, NEW ENGL J MED, V323, P871, DOI 10.1056/NEJM199009273231304; OTTMANN OG, 1995, BLOOD, V86, P444, DOI 10.1182/blood.V86.2.444.bloodjournal862444; PETTENGELL R, 1992, BLOOD, V80, P1430; Pui CH, 1995, LEUKEMIA, V9, P1990; PUI CH, 1995, LEUKEMIA, V9, P1680; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; PUI CH, 1994, HAEMATOL BLOOD TRANS, V36, P307; Reisbach G, 1996, BRIT J HAEMATOL, V92, P907, DOI 10.1046/j.1365-2141.1996.434972.x; RIIKONEN P, 1995, STEM CELLS, V13, P289, DOI 10.1002/stem.5530130310; Saarinen UM, 1996, MED PEDIATR ONCOL, V26, P380, DOI 10.1002/(SICI)1096-911X(199606)26:6<380::AID-MPO2>3.0.CO;2-D; SANTANA VM, 1990, MED PEDIATR ONCOL, V18, P395; SCHERRER R, 1993, ANN HEMATOL, V66, P283, DOI 10.1007/BF01695970; SCHRIBER JR, 1994, BLOOD, V84, P1680; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; STAHEL RA, 1994, J CLIN ONCOL, V12, P1931, DOI 10.1200/JCO.1994.12.9.1931; STUTE N, 1992, BLOOD, V79, P2849; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; VEY N, 1994, BONE MARROW TRANSPL, V14, P779; WATARI K, 1989, BLOOD, V73, P117; Welte K, 1996, BLOOD, V87, P3143, DOI 10.1182/blood.V87.8.3143.bloodjournal8783143; 1996, J CLIN ONCOL, V14, P1957	59	115	118	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1781	1787		10.1056/NEJM199706193362503	http://dx.doi.org/10.1056/NEJM199706193362503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187068				2023-01-03	WOS:A1997XE48500003
J	Calvert, GA; Bullmore, ET; Brammer, MJ; Campbell, R; Williams, SCR; McGuire, PK; Woodruff, PWR; Iverson, SD; David, AS				Calvert, GA; Bullmore, ET; Brammer, MJ; Campbell, R; Williams, SCR; McGuire, PK; Woodruff, PWR; Iverson, SD; David, AS			Activation of auditory cortex during silent lipreading	SCIENCE			English	Article							PERCEPTION	Watching a speaker's lips during face-to-face conversation (lipreading) markedly improves speech perception, particularly in noisy conditions. With functional magnetic resonance imaging it was found that these linguistic visual cues are sufficient to activate auditory cortex in normal hearing individuals in the absence of auditory speech sounds. Two further experiments suggest that these auditory cortical areas are not engaged when an individual is viewing nonlinguistic facial movements but appear to be activated by silent meaningless speechlike movements (pseudospeech). This supports psycholinguistic evidence that seen speech influences the perception of heard speech at a prelexical stage.	UNIV OXFORD, WARNEFORD HOSP, DEPT EXPT PSYCHOL, OXFORD OX3 7JX, ENGLAND; INST PSYCHIAT, LONDON SE5 8AF, ENGLAND; UCL, DEPT HUMAN COMMUN SCI, LONDON WC1 1PG, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON SE5 8AZ, ENGLAND	University of Oxford; University of London; King's College London; University of London; University College London; University of London; King's College London	Calvert, GA (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND.		Bullmore, Ed/C-1706-2012; Campbell, Ruth/Y-4570-2019; David, Anthony S/C-1315-2011; Woodruff, Peter WR/B-5998-2009; Campbell, Ruth/K-5934-2012; David, Anthony/O-1750-2019; Williams, Steve C/D-6979-2011; Brammer, Michael J/B-7128-2012	Bullmore, Ed/0000-0002-8955-8283; David, Anthony S/0000-0003-0967-774X; Campbell, Ruth/0000-0001-7324-1313; David, Anthony/0000-0003-0967-774X; Williams, Steve C/0000-0003-4299-1941; Brammer, Michael J/0000-0001-9800-2052; Calvert, Gemma/0000-0002-5487-8076; opoku, anita/0000-0001-7243-8157; McGuire, Philip/0000-0003-4381-0532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; Blumstein Sheila E., 1995, P915; Bonda E, 1996, J NEUROSCI, V16, P3737; BRAMMER MJ, 1996, NEUROIMAGE, V3, P52; BULIMORE ET, 1996, NEUROIMAGE, V4, P16; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; David AS, 1996, NEUROREPORT, V7, P932, DOI 10.1097/00001756-199603220-00021; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Ekman Paul, 1973, DARWIN FACIAL EXPRES; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; GREEN KP, 1991, J EXP PSYCHOL HUMAN, V17, P278, DOI 10.1037/0096-1523.17.1.278; HABIB M, 1995, NEUROPSYCHOLOGIA, V33, P327, DOI 10.1016/0028-3932(94)00108-2; HECAEN H, 1979, STUDIES NEUROLINGUIS, V2, P269; Howard RJ, 1996, CURR BIOL, V6, P1015, DOI 10.1016/S0960-9822(02)00646-2; KUHL PK, 1982, SCIENCE, V218, P1138, DOI 10.1126/science.7146899; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; MASSARO DW, 1988, SPEECH PERCEPTION EA; McGuire PK, 1996, PSYCHOL MED, V26, P29, DOI 10.1017/S0033291700033699; MCGURK H, 1976, NATURE, V263, P747; Mellers JDC, 1995, NEUROREPORT, V7, P109, DOI 10.1097/00001756-199512000-00026; Papousek M., 1992, NONVERBAL VOCAL COMM; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Reisberg D., 1987, HEARING EYE PSYCHOL, P97; SUMBY WH, 1954, J ACOUST SOC AM, V26, P212, DOI 10.1121/1.1907309; SUMMERFIELD Q, 1984, Q J EXP PSYCHOL-A, V36, P51, DOI 10.1080/14640748408401503; Talairach I., 1988, COPLANAR STEREOTACTI; WATSON JD, 1994, CEREB CORTEX, V3, P79	28	695	709	5	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					593	596		10.1126/science.276.5312.593	http://dx.doi.org/10.1126/science.276.5312.593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110978				2023-01-03	WOS:A1997WV72100045
J	Lambert, H				Lambert, H			Popular therapeutics and medical preferences in rural north India	LANCET			English	Editorial Material							SYSTEMS; PERSPECTIVE				Lambert, H (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BANERJI D, 1973, EC POLIT WKLY, V8, P2261; Beals A., 1980, ASIAN MED SYSTEMS, P194; CHAVUNDUKA GL, 1986, PROFESSIONALIZATION; KLEINMAN A, 1980, COMP STUDIES HLTH SY, V3, P71; Kleinman A., 1980, COMP STUDIES HLTH SY; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; LAMBERT H, IN PRESS W MED CONTE; LAST M, 1981, SOC SCI MED-MED ANTH, V15, P387, DOI 10.1016/0160-7987(81)90064-8; LAST M, 1991, MED ANTHR CONT THEOR, P349; LESLIE C, 1980, SOC SCI MED-MED ANTH, V14, P191, DOI 10.1016/0160-7987(80)90044-7; LESLIE C, 1980, ASIAN MED SYSTEMS; LESLIE CM, 1992, PATHS ASIAN MED KNOW, P3; NICHTER M, 1980, SOC SCI MED-MED ANTH, V14, P225, DOI 10.1016/0160-7987(80)90048-4; NICHTER M, 1989, ANTHR INT HLTH S ASI; PRESS I, 1980, SOC SCI MED-MED ANTH, V14, P45, DOI 10.1016/0160-7987(80)90040-X; WAXLERMORRISON NE, 1988, SOC SCI MED, V27, P531, DOI 10.1016/0277-9536(88)90377-2; WORSLEY P, 1982, ANNU REV ANTHROPOL, V11, P315, DOI 10.1146/annurev.an.11.100182.001531; ZIMMERMAN F, 1987, JUNGLE AROMA MEATS E	18	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1706	1709		10.1016/S0140-6736(96)07135-8	http://dx.doi.org/10.1016/S0140-6736(96)07135-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973437				2023-01-03	WOS:A1996VZ76600017
J	Speroff, L; Rowan, J; Symons, J; Genant, H; Wilborn, W				Speroff, L; Rowan, J; Symons, J; Genant, H; Wilborn, W			The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study) - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; OSTEOPOROSIS; FRACTURE; MASS; WITHDRAWAL; PREVENTION; BENEFITS; ACETATE; RISKS	Objective.-To compare the effect of continuous norethindrone acetate (NA)-ethinyl estradiol (EE(2)) combinations with matching unopposed EE(2) or placebo. Design.-A 2-year, double-blind, placebo-controlled, parallel-group clinical trial. Setting.-Outpatients at 65 centers. Patients.-Asymptomatic or mildly symptomatic women aged 40 years or older who had undergone the onset of spontaneous menopause within the last 5 years and who had an intact uterus. Interventions.-Patients were equally randomized to placebo or 1 of 8 treatment groups: 0.2 mg of NA and 1 mu g of EE(2); 0.5 mg of NA and 2.5 mu g of EE(2); 1 mg of NA and 5 mu g of EE(2); 1 mg of NA and 10 mu g of EE(2); 1 mu g of EE(2); 2.5 mu g of EE(2); 5 mu g of EE(2); or 10 mu g of EE(2). Primary Outcome Measures.-Bone mineral density (BMD) measured by quantitative computed tomography, serum lipids, and endometrial effects as assessed by rate of hyperplasia and proliferative status. Results.-Twelve hundred sixty-five patients entered the study, Bone mineral density increased significantly from baseline (P<.001) in the 1 mg NA-5 mu g EE(2) and the 1 mg NA-10 mu g EE(2) treatment groups at each annual assessment. Among the unopposed EE(2) groups, only the 10-mu g group had increased BMD above baseline, but also was accompanied by an unacceptably high rate of endometrial hyperplasia. The NA-EE(2) treatment groups had a significant linear dose-response trend for increasing BMD. Increased endometrial proliferation and hyperplasia occurred with increasing unopposed estrogen doses, The combination of NA and EE(2) effectively protected the endometrium against hyperplasia. The percentage of change in the ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol was positive for all treatment groups; The increase in triglyceride levels associated with EE(2) was attenuated with NA-EE(2) treatment. Conclusions.-Daily treatment with NA-EE(2) was well tolerated and protected the endometrium from EE(2)-induced proliferation and hyperplasia, The NA-EE(2) treatments produced a dose-related significant increase in BMD that was not present with unopposed EE(2)treatment. The overall effect of NA-EE(2) treatments on lipid measures was favorable.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105; OREGON HLTH SCI UNIV,DEPT OBSTET & GYNECOL,PORTLAND,OR 97201; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; STRUCT RES CTR,MOBILE,AL	Pfizer; Oregon Health & Science University; University of California System; University of California San Francisco								ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; BARENTSEN R, 1993, EUR J OBSTET GYN R B, V51, P203, DOI 10.1016/0028-2243(93)90036-C; BARRETTCONNOR E, 1992, ANNU REV MED, V43, P239, DOI 10.1146/annurev.med.43.1.239; BLUNT BA, 1993, J BONE MINER RES, V8, pS356; CHRISTIANSEN C, 1981, LANCET, V1, P459; DELIGDISCH L, 1993, MODERN PATHOL, V6, P94; DELVA MD, 1993, CAN FAM PHYSICIAN, V39, P2149; EIKEN P, 1995, MATURITAS, V22, P97, DOI 10.1016/0378-5122(95)00921-7; ESTILO MJ, 1991, J BONE MINER RES  S1, V6, pS335; ETTINGER B, 1994, MENOPAUSE, V1, P19; Fleiss JL, 1986, DESIGN ANAL CLIN EXP; GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002-9378(89)80004-3; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; GLUER CC, 1993, OSTEOPOROSIS INT, V3, P227, DOI 10.1007/BF01623825; HAHN RG, 1984, J FAM PRACTICE, V18, P411; HANKEY BF, 1991, US DEP HHS PUBLICATI; HEMMINKI E, 1991, DICP ANN PHARMAC, V25, P418, DOI 10.1177/106002809102500416; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JENSEN GF, 1982, CLIN ORTHOP RELAT R, V166, P75; KROGER H, 1995, J BONE MINER RES, V10, P302; LAFFERTY FW, 1994, AM J MED, V97, P66, DOI 10.1016/0002-9343(94)90050-7; LAVALJEANTET AM, 1993, J COMPUT ASSIST TOMO, V17, P915, DOI 10.1097/00004728-199311000-00012; LINDSAY R, 1992, OSTEOPOROSIS INT, V2, P267; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471-0528.1992.tb13732.x; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WILLIAMS SR, 1990, AM J OBSTET GYNECOL, V162, P438, DOI 10.1016/0002-9378(90)90402-S; WREN BG, 1991, MATURITAS, V13, P17, DOI 10.1016/0378-5122(91)90281-T; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, JAMA-J AM MED ASSOC, V274, P1676	31	204	212	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1397	1403		10.1001/jama.276.17.1397	http://dx.doi.org/10.1001/jama.276.17.1397			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892714				2023-01-03	WOS:A1996VQ46400025
J	Grey, AB; Stapleton, JP; Evans, MC; Tatnell, MA; Reid, IR				Grey, AB; Stapleton, JP; Evans, MC; Tatnell, MA; Reid, IR			Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; UNTREATED PRIMARY HYPERPARATHYROIDISM; POPULATION-BASED COHORT; FOLLOW-UP; CONSERVATIVE TREATMENT; BREAST-CANCER; ESTROGEN; OSTEOPOROSIS; PARATHYROIDECTOMY; FRACTURES	Background: Most patients with primary hyperparathyroidism are postmenopausal women. The presence of osteopenia in persons with mild primary hyperparathyroidism is considered an indication for parathyroidectomy. No prospective, controlled trials have assessed medical therapies for osteopenia in primary hyperparathyroidism. Objective: To examine the effects of estrogen-progestin therapy (hormone replacement therapy) on bone mineral density and biochemical indices in postmenopausal women with mild primary hyperparathyroidism. Design: Double-blind, randomized, placebo-controlled trial. Setting: University teaching hospital. Patients: 42 postmenopausal women with mild primary hyperparathyroidism. Intervention: Patients were randomly assigned to receive either conjugated estrogens, 0.625 mg/d, and medroxyprogesterone, 5 mg/d, or placebo. Measurements: Bone mineral densities of the total body, lumbar spine, proximal femur (femoral neck, Ward triangle, trochanter), and proximal forearm were measured every 6 months using dual-energy x-ray absorptiometry. Biochemical indices of bone turnover and calcium metabolism were measured at baseline, 6 months, and 2 years. Results: In the placebo group, bone mineral densities of the total body and the proximal forearm decreased significantly from baseline (mean +/- SE, -2.3% +/- 0.7% [P = 0.005] and -3.5% +/- 1.2% [P = 0.01], respectively). At the other sites, bone mineral density also tended to decline. In the hormone replacement therapy group, bone mineral density increased from baseline in the total body (1.3% +/- 0.4%; P = 0.004), lumbar spine (5.2% +/- 1.4%; P = 0.002), and femoral neck (3.4% +/- 1.5%; P = 0.05). The between-group differences in bone mineral density at the end of the study ranged from 3.6% to 6.6% and were significant at all sites (P > 0.001 and P < 0.05) except for the Ward triangle (P = 0.06). In the hormone replacement therapy group, serum alkaline phosphatase levels decreased by 22% (P = 0.0004 compared with baseline), urinary hydroxyproline excretion decreased by 42% (P = 0.0004), urinary N-telopeptide excretion decreased by 54% (P = 0.001), and urinary calcium excretion decreased by 45% (P = 0.007). Hormone replacement therapy did not change levels of serum ionized calcium or intact parathyroid hormone. Conclusions: Although hormone replacement therapy has little effect on serum calcium levels, it suppresses bone turnover, reduces urinary calcium excretion, and increases bone mineral density throughout the skeleton in postmenopausal women with mild primary hyperparathyroidism. This therapy is thus an important management option for these patients.	UNIV AUCKLAND, DEPT MED, AUCKLAND 1, NEW ZEALAND; YALE UNIV, SCH MED, DEPT ENDOCRINOL, NEW HAVEN, CT 06520 USA	University of Auckland; Yale University								ALHAVA EM, 1988, ACTA CHIR SCAND, V154, P345; ANGUS RM, 1989, J AM DIET ASSOC, V89, P209; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BLOCK MA, 1989, SURGERY, V106, P1063; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CLYDE JW, 1992, NEW ZEAL MED J, V105, P71; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; DAUPHINE RT, 1975, ANN INTERN MED, V83, P365, DOI 10.7326/0003-4819-83-3-365; DAVIES M, 1992, CLIN ENDOCRINOL, V36, P325, DOI 10.1111/j.1365-2265.1992.tb01454.x; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; GALLAGHER JC, 1972, LANCET, V1, P503; GARTON M, 1995, CLIN ENDOCRINOL, V42, P493, DOI 10.1111/j.1365-2265.1995.tb02668.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREY AB, 1994, CLIN ENDOCRINOL, V40, P671, DOI 10.1111/j.1365-2265.1994.tb03020.x; GREY AB, 1994, ANN INTERN MED, V121, P745, DOI 10.7326/0003-4819-121-10-199411150-00003; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HOROWITZ M, 1987, ARCH INTERN MED, V147, P681, DOI 10.1001/archinte.147.4.681; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KOCHERSBERGER G, 1987, ARCH INTERN MED, V147, P1951, DOI 10.1001/archinte.147.11.1951; LAFFERTY FW, 1989, ARCH INTERN MED, V149, P789, DOI 10.1001/archinte.149.4.789; LARSSON K, 1993, J INTERN MED, V234, P585, DOI 10.1111/j.1365-2796.1993.tb01017.x; LEPPLA DC, 1982, INVEST RADIOL, V17, P604, DOI 10.1097/00004424-198211000-00013; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; MARTIN P, 1986, ARCH INTERN MED, V146, P689, DOI 10.1001/archinte.146.4.689; MAUTALEN C, 1986, ACTA ENDOCRINOL-COP, V111, P494, DOI 10.1530/acta.0.1110494; MCDERMOTT MT, 1994, J BONE MINER RES, V9, P509; MCKANE WR, 1995, J CLIN ENDOCR METAB, V80, P3458, DOI 10.1210/jc.80.12.3458; MELTON LJ, 1992, ARCH INTERN MED, V152, P2269, DOI 10.1001/archinte.152.11.2269; MOLE PA, 1992, BRIT J SURG, V79, P263, DOI 10.1002/bjs.1800790327; MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140-6736(80)91783-3; NORDIN BEC, 1991, J CLIN ENDOCR METAB, V72, P401, DOI 10.1210/jcem-72-2-401; PALMER M, 1988, EUR J CLIN INVEST, V18, P39, DOI 10.1111/j.1365-2362.1988.tb01163.x; PALMER M, 1987, LANCET, V1, P59; PARFITT AM, 1991, J BONE MINER RES, V6, P95; POTTS JT, 1990, J CLIN ENDOCR METAB, V70, P1489, DOI 10.1210/jcem-70-6-1489; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RICHARDSON ML, 1986, SKELETAL RADIOL, V15, P85, DOI 10.1007/BF00350200; RUDNICKI M, 1992, J INTERN MED, V232, P421, DOI 10.1111/j.1365-2796.1992.tb00608.x; SEIBEL MJ, 1992, J CLIN ENDOCR METAB, V74, P481, DOI 10.1210/jc.74.3.481; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723; SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; STEINICHE T, 1995, BONE, V16, pS214; STEVENSON JC, 1988, BRIT MED J, V296, P1016, DOI 10.1136/bmj.296.6628.1016-a; WARNER J, 1991, Journal of Bone and Mineral Research, V6, pS91; WILSON RJ, 1988, ANN INTERN MED, V109, P959, DOI 10.7326/0003-4819-109-12-959; WISHART J, 1990, ARCH INTERN MED, V150, P1329, DOI 10.1001/archinte.150.6.1329	55	133	136	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					360	368		10.7326/0003-4819-125-5-199609010-00002	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702086				2023-01-03	WOS:A1996VE07900002
J	Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Willett, WC; Rosner, B; Speizer, FE; Hennekens, CH				Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Willett, WC; Rosner, B; Speizer, FE; Hennekens, CH			Postmenopausal estrogen and progestin use and the risk of cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; MYOCARDIAL-INFARCTION; CORONARY-ARTERIES; FOLLOW-UP; WOMEN; COHORT; STROKE; REPRODUCIBILITY; LIPOPROTEINS; ACCUMULATION	Background Estrogen therapy in postmenopausal women has been associated with a decreased risk of heart disease. There is little information, however, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease. Methods We examined the relation between cardiovascular disease and postmenopausal hormone therapy during up to 16 years of follow-up in 59,337 women from the Nurses' Health Study, who were 30 to 55 years of age at base line. Information on hormone use was ascertained with biennial questionnaires. From 1976 to 1992, we documented 770 cases of myocardial infarction or death from coronary disease in this group and 572 strokes. Proportional-hazards models were used to calculate relative risks and 95 percent confidence intervals, adjusted for confounding variables. Results We observed a marked decrease in the risk of major coronary heart disease among women who took estrogen with progestin, as compared with the risk among women who did not use hormones (multivariate adjusted relative risk, 0.39; 95 percent confidence interval, 0.19 to 0.78) or estrogen alone (relative risk, 0.60; 95 percent confidence interval, 0.43 to 0.83). However, there was no significant association between stroke and use of combined hormones (multivariate adjusted relative risk, 1.09; 95 percent confidence interval, 0.66 to 1.80) or estrogen alone (relative risk, 1.27; 95 percent confidence interval, 0.95 to 1.69). Conclusions The addition of progestin does not appear to attenuate the cardioprotective effects of postmenopausal estrogen therapy. (C) 1996, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 30594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; COX DR, 1972, J R STAT SOC B, V34, P187; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GANGAR KF, 1991, LANCET, V338, P839; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PINES A, 1991, AM J OBSTET GYNECOL, V164, P806, DOI 10.1016/0002-9378(91)90520-2; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; Sarrel Philip M., 1994, P251; SARREL PM, 1992, AM J OBSTET GYNECOL, V167, P467, DOI 10.1016/S0002-9378(11)91431-8; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526; Walker AE, 1981, STROKE S1, V12, P13; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1971, IHD REG REP 5 WORK G; 1995, JAMA-J AM MED ASSOC, V273, P199	35	1090	1107	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					453	461		10.1056/NEJM199608153350701	http://dx.doi.org/10.1056/NEJM199608153350701			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672166				2023-01-03	WOS:A1996VB84900001
J	Wagner, M				Wagner, M			Midwife-managed care	LANCET			English	Editorial Material							BIRTH-CENTER; OUTCOMES; RATES											BARUFFI G, 1990, J NURSE-MIDWIFERY, V35, P274, DOI 10.1016/0091-2182(90)90080-O; BUTLER J, 1993, AM J OBSTET GYNECOL, V168, P5; Enkin M., 1995, GUIDE EFFECTIVE CARE; FELDMAN E, 1987, BIRTH-ISS PERINAT C, V14, P18, DOI 10.1111/j.1523-536X.1987.tb01444.x; ROOKS JP, 1989, NEW ENGL J MED, V321, P1804, DOI 10.1056/NEJM198912283212606; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683; STEPHENSON P, 1992, INT DIFFERENCES USE; 1986, LANCET, V2, P436	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					208	208		10.1016/S0140-6736(05)65538-9	http://dx.doi.org/10.1016/S0140-6736(05)65538-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ286	8684192				2023-01-03	WOS:A1996UZ28600002
J	Anderson, IB; Mullen, WH; Meeker, JE; KhojastehBakht, SC; Oishi, S; Nelson, SD; Blanc, PD				Anderson, IB; Mullen, WH; Meeker, JE; KhojastehBakht, SC; Oishi, S; Nelson, SD; Blanc, PD			Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature	ANNALS OF INTERNAL MEDICINE			English	Article						abortifacient agents; pennyroyal; medicine, herbal; acetylcysteine; poisoning	ACETAMINOPHEN OVERDOSE; HEPATOTOXICITY; MENTHOFURAN; PULEGONE; OIL; (R)-(+)-PULEGONE; R-(+)-PULEGONE; GLUTATHIONE; MOUSE	Background: Pennyroyal is a widely available herb that has long been used as an abortifacient despite its potentially lethal hepatotoxic effects. However, quantitative data for pennyroyal constituents and their metabolites in humans have not been previously reported. Objectives: To quantify pennyroyal metabolites in human overdose, to correlate these findings with clinical variables, and to place these findings in the context of previously reported cases of pennyroyal toxicity. Design: Clinical case series of pennyroyal ingestions; quantification of pennyroyal metabolites by gas chromatography and mass spectrometry; qualitative detection of protein-bound adducts of the metabolites of pennyroyal constituents in human liver by Western blot assay; and review of the literature based on a search of MEDLINE, Index Medicus, and the reference citations of all available publications. Results: We report four cases of pennyroyal ingestion. One patient died, one received N-acetylcysteine, and two ingested minimally toxic amounts of pennyroyal and were not treated with N-acetylcysteine. In the fatal case, postmortem examination of a serum sample, which had been obtained 72 hours after the acute ingestion, identified 18 ng of pulegone per mL and 1 ng of menthofuran per mL. In a serum sample from the patient treated with N-acetylcysteine, which had been obtained 10 hours after ingestion, the menthofuran level was 40 ng/mL. Review of 18 previous case reports of pennyroyal ingestion documented moderate to severe toxicity in patients who had been exposed to at least 10 mL of pennyroyal oil. Conclusion: Pennyroyal continues to be an herbal toxin of public health importance. Data on human metabolites may provide new insights into the toxic mechanisms and treatment of pennyroyal poisoning, including the potential role of N-acetylcysteine, Better understanding of the toxicity of pennyroyal may also lead to stricter control of and more restricted access to the herb.	UNIV CALIF SAN FRANCISCO, DIV ENVIRONM & OCCUPAT MED, SAN FRANCISCO, CA 94143 USA; INST FORENS SCI, TOXICOL LAB, OAKLAND, CA USA; UNIV WASHINGTON, SCH PHARM, DEPT MED CHEM, SEATTLE, WA 98195 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	Anderson, IB (corresponding author), SAN FRANCISCO GEN HOSP, SAN FRANCISCO BAY AREA REG POISON CONTROL CTR, ROOM 1E86, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.				NIGMS NIH HHS [GM32165, GM25418] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025418, P01GM032165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN WT, 1897, LANCET, P1022; Braithwaite PF, 1906, BRIT MED J, V2, P865; BUECHEL DW, 1983, J AM OSTEOPATH ASSOC, V82, P793; DERMARDEROSIAN A, 1988, NATURAL PRODUCT MED; EARLY DF, 1961, LANCET, V2, P580; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Flynn EF, 1893, BRIT MED J, V2, P1270; Girling J, 1887, BRIT MED J, V1, P1214, DOI [10.1136/bmj.1.1379.1214, DOI 10.1136/BMJ.1.1379.1214]; GORDON WP, 1987, DRUG METAB DISPOS, V15, P589; GORDON WP, 1982, TOXICOL APPL PHARM, V65, P413, DOI 10.1016/0041-008X(82)90387-8; GRIEVE M, 1981, MODERN HERBAL, V2, P624; Gunby P, 1979, JAMA, V241, P2246, DOI 10.1001/jama.241.21.2246; HOLLAND GW, 1902, VIRGINIA MED SEMIMON, V7, P319; HUXTABLE RJ, 1992, ANN INTERN MED, V117, P165, DOI 10.7326/0003-4819-117-2-165; JONES CO, 1913, BRIT MED J, P745; KIMBALLHW, 1898, ATLANTIC MED WEEKLY, P307; LIEHLAI MW, 1984, J PEDIATR-US, V105, P125, DOI 10.1016/S0022-3476(84)80376-5; LUST J, 1974, HERB BOOK; MADYASTHA KM, 1993, XENOBIOTICA, V23, P509, DOI 10.3109/00498259309059391; MADYASTHA KM, 1990, BIOCHEM BIOPH RES CO, V173, P1086, DOI 10.1016/S0006-291X(05)80897-6; MCCLANAHAN RH, 1989, CHEM RES TOXICOL, V2, P349, DOI 10.1021/tx00011a013; MCCLANAHAN RH, 1988, J AM CHEM SOC, V110, P1979, DOI 10.1021/ja00214a060; MCENVOY GK, 1995, AM HOSP FORMULARY SE; MOORTHY B, 1989, TOXICOLOGY, V55, P327, DOI 10.1016/0300-483X(89)90022-X; NELSON SD, 1983, J NAT PROD, V46, P71, DOI 10.1021/np50025a005; NELSON SD, 1992, ENVIR SCI R, V44, P287; OSOL A, 1955, DISPENSATORY US AM; ROSE J, 1972, HERBS THINGS; RUMACK BH, 1984, AM J DIS CHILD, V138, P428, DOI 10.1001/archpedi.1984.02140430006003; RUNNALLS HB, 1904, MED SENTINEL, V12, P325; *SAN FRANC BAY AR, 1993 1994 SAN FRANC; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SPOERKE DG, 1980, HERBAL MEDICATIONS; STEPHEN WH, 1994, PROVINCIAL MED J, V1, P466; SUDEKUM M, 1992, J AM VET MED ASSOC, V200, P817; SULLIVAN JB, 1979, JAMA-J AM MED ASSOC, V242, P2873; THOMASSEN D, 1991, DRUG METAB DISPOS, V19, P997; THOMASSEN D, 1988, J PHARMACOL EXP THER, V244, P825; THOMASSEN D, 1990, J PHARMACOL EXP THER, V253, P567; THOMASSEN D, 1992, CHEM RES TOXICOL, V5, P123, DOI 10.1021/tx00025a021; VALLANCE WB, 1955, ALNCET, V850; WILCOX WA, 1869, BOSTON MED SURGICAL, V79, P394; Wingate UOB, 1889, BOSTON MED SURG J, V120, P536, DOI 10.1056/NEJM188905301202206; 1992, LAWRENCE REV NATURAL; 1883, SO MED CLIN, V6, P323; 1978, MMWR-MORBID MORTAL W, V27, P511	46	178	183	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					726	+		10.7326/0003-4819-124-8-199604150-00004	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633832				2023-01-03	WOS:A1996UD93600004
J	Rebulla, P; Finazzi, G; Marangoni, F; Avvisati, G; Gugliotta, L; Tognoni, G; Barbui, T; Mandelli, F; Sirchia, G				Rebulla, P; Finazzi, G; Marangoni, F; Avvisati, G; Gugliotta, L; Tognoni, G; Barbui, T; Mandelli, F; Sirchia, G		Grp Italiano Malattie Ematologiche Maligne Adu	The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLICY; BLOOD	Background Prophylactic platelet transfusions are usually administered to patients receiving myelotoxic chemotherapy when their platelet count falls below 20,000 per cubic millimeter. Some observations suggest that lower platelet counts can be appropriate in patients in stable condition, but the safely of lower thresholds is uncertain. Methods We evaluated 255 adolescents and adults (age, 16 to 70 years) with newly diagnosed acute myeloid leukemia (but nor acute promyelocytic leukemia), who were treated in 21 centers. One hundred thirty-five patients were randomly assigned to receive a transfusion when their platelet count fell below 10,000 per cubic millimeter (or 10,000 to 20,000 per cubic millimeter in those with a temperature above 38 degrees C, with active bleeding, or a need for invasive procedures), and 120 patients were assigned to receive a transfusion when their platelet count was less than 20,000 per cubic millimeter. Results Patients in the group with a threshold of 10,000 platelets per cubic millimeter received 21.5 percent fewer platelet transfusions than the patients in the group with a threshold of 20,000 platelets per cubic millimeter (P = 0.001). The numbers of red-cell units transfused were not significantly different between groups. Major bleeding (defined as any bleeding more than petechiae or mucosal or retinal bleeding) occurred in 21.5 and 20 percent of patients, respectively (P = 0.41), and on 3.1 and 2.0 percent of the days of hospitalization. One episode of fatal cerebral hemorrhage occurred in the group with a threshold of 10,000 platelets per cubic millimeter; none occurred in the other group (P = 0.95). Actuarial estimates of survival during induction chemotherapy, actuarial estimates of the absence of major bleeding, and the length of hospital stay were not significantly different in the two groups. Conclusions The risk of major bleeding during induction chemotherapy in adolescents and adults with acute myeloid leukemia (except acute promyelocytic leukemia, which we did not study) was similar with platelet-transfusion thresholds of 20,000 per cubic millimeter and 10,000 per cubic millimeter (or 10,000 to 20,000 per cubic millimeter when body temperature exceeded 38 degrees C, there was active bleeding, or invasive procedures were needed). Use of the lower threshold reduced platelet use by 21.5 percent, (C) 1997, Massachusetts Medical Society.	Osped Maggiore, Ctr Trasfus & Immunol Trapianti, Ist Ricovero & Cura Carattere Sci, I-20122 Milan, Italy; Osped Riuniti Bergamo, Div Ematol, I-24100 Bergamo, Italy; Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Rome, Italy; Policlin S Orsola, Ist Ematol & Oncol Med L & A Seragnoli, Bologna, Italy; Ist Ric Farmacol Mario Negri, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedali Riuniti di Bergamo; Sapienza University Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rebulla, P (corresponding author), Osped Maggiore, Ctr Trasfus & Immunol Trapianti, Ist Ricovero & Cura Carattere Sci, Via F Sforza 35, I-20122 Milan, Italy.		Rebulla, Paolo/I-7684-2015	Rebulla, Paolo/0000-0002-3875-5754; Avvisati, Giuseppe/0000-0002-5027-5868				ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; ANDERSON KC, 1990, NEW ENGL J MED, V323, P1360; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERTOLINI F, 1989, TRANSFUSION, V29, P605, DOI 10.1046/j.1537-2995.1989.29789369678.x; BEUTLER E, 1993, BLOOD, V81, P1411; BEUTLER E, 1993, BLOOD, V82, P683; BISHOP JF, 1991, TRANSFUSION, V31, P392, DOI 10.1046/j.1537-2995.1991.31591263191.x; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; Friedman L, 1985, FUNDAMENTALS CLIN TR, P83; Gardner MJ, 1989, BRIT MED J LONDON; GilFernandez JJ, 1996, BONE MARROW TRANSPL, V18, P931; GMUR J, 1991, LANCET, V338, P1223, DOI 10.1016/0140-6736(91)92098-M; Hanseler E, 1996, AM J CLIN PATHOL, V105, P782; HANSON SR, 1985, BLOOD, V66, P1105; Heckman KD, 1997, J CLIN ONCOL, V15, P1143, DOI 10.1200/JCO.1997.15.3.1143; HEYMAN MR, 1990, SEMIN ONCOL, V17, P198; HEYMAN MR, 1996, PRINCIPLES TRANSFUSI, P263; KELLEHER JF, 1993, BLOOD, V82, P682; LAWRENCE JB, 1994, TRANSFUSION, V34, pS53; MCCULLOUGH J, 1988, JAMA-J AM MED ASSOC, V259, P2414, DOI 10.1001/jama.259.16.2414; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MURPHY WG, 1992, LANCET, V339, P120, DOI 10.1016/0140-6736(92)91025-4; *NIH CONS C, 1987, TRANSFUS MED REV, V1, P195; PISCIOTTO PT, 1995, TRANSFUSION, V35, P498, DOI 10.1046/j.1537-2995.1995.35695288769.x; Slichter Sherrill J., 1995, P1987; SLICHTER SJ, 1978, CLIN HAEMATOL, V7, P523; SLICHTER SJ, 1976, BRIT J HAEMATOL, V34, P395, DOI 10.1111/j.1365-2141.1976.tb03586.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; Wandt H., 1996, Blood, V88, p443A	29	399	412	2	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1870	1875		10.1056/NEJM199712253372602	http://dx.doi.org/10.1056/NEJM199712253372602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407153				2023-01-03	WOS:000071128200002
J	Quill, TE; Dresser, R; Brock, DW				Quill, TE; Dresser, R; Brock, DW			The rule of double effect - A critique of its role in end-of-life decision making	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA; PAIN; VIEWS; DEATH		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	University of Rochester; Case Western Reserve University; Brown University								*ABIM, 1996, ED RES DOC; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; [Anonymous], 1992, ANN INTERN MED, V117, P947; [Anonymous], 1985, MOD PEN COD COMM, P229; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BROCK DW, 1997, MED ETHICS, P363; BRODY H, 1993, J CLIN ETHIC, V4, P112; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Cherny N I, 1994, J Palliat Care, V10, P31; *COUNC ETH JUD AFF, 1992, JAMA-J AM MED ASSOC, V276, P2229; Donagan Alan, 1977, ETHICS; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; FOLEY KM, 1995, PAIN FORUM, V4, P163; FRIED C, 1978, RIGHT WRONG; GARCIA JLA, 1995, ENCY BIOETHICS, V2, P636; Graber MA, 1996, J GEN INTERN MED, V11, P71, DOI 10.1007/BF02599581; GRANFIELD D, 1971, ABORTION DECISION, P126; *HAST CTR, 1987, GUID TERM LIF SUST T; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; JOHNPAUL II, 1995, CATH C MARCH 30, P189; KASS LR, 1993, HASTINGS CENT REP, V23, P34, DOI 10.2307/3562279; Kenny A., 1973, ANATOMY SOUL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KUHSE H, 1987, SANCTITYY LIFE DOCRI; Mangan J., 1949, THEOL STUD, V10, P41, DOI DOI 10.1177/004056394901000102; MARQUIS DB, 1991, J MED PHILOS, V16, P515, DOI 10.1093/jmp/16.5.515; MEISEL A, 1995, RIGHT DIE; Nagel Thomas., 1986, VIEW NOWHERE; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Pellegrino E D, 1992, J Clin Ethics, V3, P95; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, IN PRESS JAMA; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; Ventafridda V, 1990, J Palliat Care, V6, P7; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	41	229	235	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1768	1771		10.1056/NEJM199712113372413	http://dx.doi.org/10.1056/NEJM199712113372413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK653	9392707				2023-01-03	WOS:A1997YK65300013
J	Krack, P; Pollak, P; Limousin, P; Benazzouz, A; Benabid, AL				Krack, P; Pollak, P; Limousin, P; Benazzouz, A; Benabid, AL			Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease	LANCET			English	Letter									CHRISTIAN ALBRECHTS UNIV KIEL,DEPT NEUROL,D-24105 KIEL,GERMANY	University of Kiel	Krack, P (corresponding author), UNIV GRENOBLE,DEPT CLIN & BIOL NEUROSCI,GRENOBLE,FRANCE.		Benabid, Alim L/Q-3506-2017; Benazzouz, Abdelhamid/E-5050-2016	Krack, Paul/0000-0002-3508-7295				BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3	5	138	141	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1675	1675		10.1016/S0140-6736(97)24049-3	http://dx.doi.org/10.1016/S0140-6736(97)24049-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400514				2023-01-03	WOS:A1997YK21100014
J	Fallon, M; ONeill, B				Fallon, M; ONeill, B			ABC of palliative care - Constipation and diarrhoea	BRITISH MEDICAL JOURNAL			English	Article									BRITISH MED ASSOC,LONDON,ENGLAND		Fallon, M (corresponding author), UNIV GLASGOW,WESTERN INFIRM,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND.			Fallon, Marie/0000-0001-9214-0091					0	39	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1293	1296		10.1136/bmj.315.7118.1293	http://dx.doi.org/10.1136/bmj.315.7118.1293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390060	Green Submitted, Green Published			2023-01-03	WOS:A1997YG64500030
J	Knopp, RH; Walden, CE; Retzlaff, BM; McCann, BS; Dowdy, AA; Albers, JJ; Gey, GO; Cooper, MN				Knopp, RH; Walden, CE; Retzlaff, BM; McCann, BS; Dowdy, AA; Albers, JJ; Gey, GO; Cooper, MN			Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men - The dietary alternatives study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; APOLIPOPROTEIN-B; ARTERY DISEASE; LIPID-LEVELS; PLASMA-LIPOPROTEINS; WEIGHT-LOSS; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE; CONSUMPTION	Context.-The long-term effect of aggressively vs moderately fat-restricted diets has not been studied extensively in free-living subjects with different types of hyperlipidemia. Objective.-To compare the cholesterol-lowering effects of 4 levels of dietary fat intake restriction after 1 year, Design.-Randomized, parallel, comparison trial. Setting.-Male employees of a large industry. Participants.-A total of 444 men had low-density lipoprotein cholesterol (LDL-C) levels above the 75th age-specific percentile, Subjects with triglyceride (TG) levels less than the 75th age-specific percentile were defined as hypercholesterolemic (HC) and those with TG levels at or above the 75th age-specific percentile were defined as combined hyperlipidemic (CHL). Interventions.-Hypercholesterolemic subjects were randomized to diets 1, 2, 3, and 4 taught to contain 30%, 26%, 22%, and 18% fat, and the CHL subjects were randomized to diets 1, 2, and 3, All 4 diets were taught to subjects and spouses or partners in a weekly 2-hour classes. Main Outcome Measures.-Plasma lipoprotein levels after 1 year. Results.-Fat intake after 1 year declined from a mean of 34% to 36% of energy to 27%, 26%, 25%, and 22% in the 4 HC diet groups and 28%, 26%, and 25% in the 3 CHL diet groups. Mean+/-SD percent LDL-C reductions were 5.3%+16.2%, 13.4%+/-12.6%, 8.4%+/-11.2%, and 13.0%+/-15.7% in the HC diet groups and 7.0%+/-16.2%, 2.8%+/-15.8%, and 4.6%+/-13.5% in the CHL diet groups (P<.01 in all but 1 instance). Apoprotein B levels decreased 8.6%, 10.7%, 4.3%, and 5.3% in the HC groups and 14.6%, 11.4%, and 9.9% in the CHL groups(P<.05-.01 in each instance). Triglyceride levels increased significantly in subjects following HC diets 3 and 4, 21.7% and 38.7% (P<.05 and .01), but not in any CHL subjects. High-density lipoprotein cholesterol decreased 2.8% and 3.2% in subjects on HC diets 3 and 4, respectively (P<.05 in both cases). Conclusions.-After 1 year, moderate restriction of dietary fat intake attains meaningful and sustained LDL-C reductions in HC subjects and apoprotein B reductions in both HC and CHL subjects. More extreme restriction of fat intake offers little further advantage in HC or CHL subjects and potentially undesirable effects in HC subjects.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104; UNIV WASHINGTON,CARDIOVASC BEHAV MED PROGRAM,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98104; BOEING MED DEPT,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Boeing	Knopp, RH (corresponding author), UNIV WASHINGTON,NW LIPID RES CLIN,BOX 359720,326 9TH AVE,SEATTLE,WA 98104, USA.		McCann, Barbara S./GPG-1789-2022	McCann, Barbara S./0000-0003-0384-8763	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, P30DK035816] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL28891] Funding Source: Medline; NIDDK NIH HHS [DK-35816, DK-17047] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADOLPHSON JL, 1989, J LIPID RES, V30, P597; ALBERS JJ, 1975, METABOLISM, V24, P1339, DOI 10.1016/0026-0495(75)90050-5; *AM DIAB ASS AM DI, 1986, EXCH LISTS MEAL PLAN; *AM HEART ASS, 1984, COUNS PAT HYP; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BERNARD JR, 1991, ARCH INTERN MED, V151, P1389; BOVBJERG VE, 1994, ANN BEHAV MED S, V16, P49; BOYD NF, 1990, AM J CLIN NUTR, V52, P470, DOI 10.1093/ajcn/52.3.470; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN GD, 1984, J AM DIET ASSOC, V84, P546; CHAIT A, 1993, CIRCULATION, V88, P3008, DOI 10.1161/01.CIR.88.6.3008; CHILDS MT, 1990, AM J CLIN NUTR, V52, P632, DOI 10.1093/ajcn/52.4.632; CLEVIDENCE BA, 1992, AM J CLIN NUTR, V55, P689, DOI 10.1093/ajcn/55.3.689; COMINACINI L, 1988, AM J CLIN NUTR, V48, P57, DOI 10.1093/ajcn/48.1.57; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DENNIS B, 1980, J AM DIET ASSOC, V77, P641; *EXP PAN, 1988, ARCH INTERN MED, V148, P36; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V269, P3015; GLATZ JFC, 1989, AM J CLIN NUTR, V49, P269, DOI 10.1093/ajcn/49.2.269; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GOTTO AM, 1984, CIRCULATION, V72, pA1067; GRUNDY SM, 1990, J LIPID RES, V31, P1149; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2351, DOI 10.1001/jama.256.17.2351; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KATZEL LI, 1995, METABOLISM, V44, P307, DOI 10.1016/0026-0495(95)90159-0; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P244; LAVIE CJ, 1994, AM J CARDIOL, V74, P1192, DOI 10.1016/0002-9149(94)90546-0; LICHTENSTEIN AH, 1994, ARTERIOSCLER THROMB, V14, P1751, DOI 10.1161/01.ATV.14.11.1751; *LIP RES CLIN, NIH PUBL, P1; *LIP RES CLIN, 1974, DHEW PUBL NIH, V1; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MCCANN BS, 1990, J AM DIET ASSOC, V90, P1408; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; RETZLAFF BM, 1995, AM J CLIN NUTR, V62, P988, DOI 10.1093/ajcn/62.5.988; RETZLAFF BM, 1991, AM J CLIN NUTR, V53, P890, DOI 10.1093/ajcn/53.4.890; RETZLAFF BM, 1995, J AM DIET ASSOC, V95, P1274, DOI 10.1016/S0002-8223(95)00335-5; ROMANO AT, 1973, CLIN CHEM, V19, P1152; Schaefer EJ, 1996, AM J CLIN NUTR, V63, P234, DOI 10.1093/ajcn/63.2.234; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; THUESEN L, 1986, AM J CLIN NUTR, V44, P212, DOI 10.1093/ajcn/44.2.212; TOOTHAKER LE, 1991, MULTIPLE COMP RES, P50; VESSBY B, 1974, ARTERY, V1, P63; WALDEN CE, 1991, J AM COLL NUTR, V10, P429; Warnick G R, 1986, Methods Enzymol, V129, P101; WARNICK GR, 1982, CLIN CHEM, V28, P1379	49	132	135	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1509	1515		10.1001/jama.278.18.1509	http://dx.doi.org/10.1001/jama.278.18.1509			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363971				2023-01-03	WOS:A1997YE44500035
J	Burkey, Y; Black, M; Reeve, H				Burkey, Y; Black, M; Reeve, H			Patients' views on their discharge from follow up in outpatient clinics: qualitative study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To discover the views of patients about their discharge from outpatient clinics, to detect any change in these perceptions over time, and explore how the discharge process might be improved for the patient. Design: A qualitative study comprising in-depth or semistructured interviews with patients 2 weeks and 3 months after discharge from an outpatient clinic. Subjects: 45 patients who had attended outpatient clinics on three or more occasions. Setting: Five general medical outpatient clinics from a Manchester provider trust. Main outcome measures: Aspects of the discharge consultation valued by patients included confidence that the doctor knew and understood their case; clarity of the discharge process; an explanation of the reasons for discharge; information about treatment, future care, and the mechanism for re-referral; and being seen by doctors who sought their views and allowed time for questions and reflection. Conclusions: Patients' views about their discharge changed over time and varied in relation to several factors, which included patients' perceptions of the discharge process, patients' expectations, the way in which the outpatient clinics were organised, and patients' relationships with, and confidence in, their general practitioners.	UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV SALFORD,PUBL HLTH RES & RESOURCE CTR,SALFORD M5 4QA,LANCS,ENGLAND; UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND	University of Manchester; University of Salford; University of Manchester								Burkey Y, 1997, FAM PRACT, V14, P29, DOI 10.1093/fampra/14.1.29; *DEP HLTH, 1995, OUTP WARD ATT ENGL F; FAULKNER A, 1993, EVALUATION DELIVERY; Fitzpatrick R., 1984, EXPERIENCE ILLNESS, P154; Horder J P, 1985, Health Trends, V17, P64; Lester J P, 1980, J R Coll Gen Pract, V30, P230; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Shaw C D, 1981, Health Trends, V13, P107; Stacey M, 1994, RES PEOPLES HLTH, P85; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008	10	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1138	1141						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374889				2023-01-03	WOS:A1997YE61500028
J	Linde, K; Clausius, N; Ramirez, G; Melchart, D; Eitel, N; Hedges, LV; Jonas, WB				Linde, K; Clausius, N; Ramirez, G; Melchart, D; Eitel, N; Hedges, LV; Jonas, WB			Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials	LANCET			English	Review							HOMEOPATHIC PREPARATION; RHEUMATOID-ARTHRITIS; PUBLICATION BIAS; COMPLEMENTARY MEDICINE; GENERAL-PRACTITIONERS; ALTERNATIVE MEDICINE; SYSTEMATIC REVIEWS; GALPHIMIA GLAUCA; ARNICA-MONTANA; POLLINOSIS	Background Homoeopathy seems scientifically implausible, but has widespread use. We aimed to assess whether the clinical effect reported in randomised controlled trials of homoeopathic remedies is equivalent to that reported for placebo. Methods We sought studies from computerised bibliographies and contacts with researchers, institutions, manufacturers, individual collectors, homoeopathic conference proceedings, and books. We included all languages. Double-blind and/or randomised placebo-controlled trials of clinical conditions were considered. Our review of 186 trials identified 119 that met the inclusion criteria. 89 had adequate data for meta-analysis, and two sets of trial were used to assess reproducibility. Two reviewers assessed study quality with two scales and extracted data for information on clinical condition, homoeopathy type, dilution, ''remedy'', population, and outcomes. Findings The combined odds ratio for the 89 studies entered into the main meta-analysis was 2.45 (95% CI 2.05, 2.93) in favour of homoeopathy. The odds ratio for the 26 good-quality studies was 1.66 (1.33, 2.08), and that corrected for publication bias was 1.78 (1.03, 3.10). Four studies on the effects of a single remedy on seasonal allergies had a pooled odds ratio for ocular symptoms at 4 weeks of 2.03 (1.51, 2.74). Five studies on postoperative ileus had a pooled mean effect-size-difference of -0.22 standard deviations (95% CI -0.36, -0.09) for flatus, and -0.18 SDs (-0.33, -0.03) for stool (both p<0.05). Interpretation The results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homoeopathy are completely due to placebo. However, we found insufficient evidence from these studies that homoeopathy is clearly efficacious for any single clinical condition. Further research on homoeopathy is warranted provided it is rigorous and systematic.	NIH,OFF ALTERNAT MED,BETHESDA,MD 20892; TECH UNIV MUNICH,MUNCHENER MODELL,CTR COMPLEMENTARY MED RES,D-8000 MUNICH,GERMANY; UNIV N TEXAS,HLTH SCI CTR,DEPT PUBL HLTH & PREVENT MED,FT WORTH,TX; UNIV MUNICH,CHIRURG KLIN & POLIKLIN INNENSTADT,MUNICH,GERMANY; UNIV CHICAGO,DEPT EDUC,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; Technical University of Munich; University of North Texas System; University of North Texas Health Science Center; University of Munich; University of Chicago				Linde, Klaus/0000-0002-2902-970X; Hedges, Larry/0000-0002-7531-0631				ALIBEU JP, 1990, PEDIATRIE, V45, P465; ALLBERTINI H, 1984, HOMEOPATHIE, V1, P47; ANDRADE LEC, 1991, SCAND J RHEUMATOL, V20, P204, DOI 10.3109/03009749109103022; [Anonymous], BIOLOGISCHE MEDIZIN; Aulagnier G, 1985, HOMEOPATHIE, V6, P42; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BEKKERING GM, 1993, HUISARTS WETENSCHAP, V36, P414; BENZECRI JP, 1991, CAHIERS ANAL DONNEES, V16, P389; BIGNAMINI M, 1991, BERL J RES HOM, V1, P286; BOHMER D, 1992, BIOL MED, V21, P260; Boissel JP, 1996, CRITICAL LIT REV EFF, V1996, P195; Bordes L., 1986, CAH OTORHINOLARINGOL, V21, P731; BOURGOIS JC, 1984, THESIS U PARIS NORD; Brigo B, 1991, BERL J RES HOM, V1, P98; Campbell A., 1976, BR HOMOEOPATH J, V65, P154; CAREY H, 1986, BR HOMOEOPATH RES GR, V15, P12; Carlini EA, 1987, REV ASSOC MED BRAS, V33, P83; CASANOVA P, 1981, UNPUB ESSAI CLIN PRO; Casanova P, 1992, BILAN 3 ANN ETUDES R, V1, P11; CHAPMAN EH, 1994, J AM I HOM, V87, P14; CHEVREL JP, 1984, PRESSE MED, V13, P883; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Consoli AM., 1987, BRIT HOM J, V76, P114; COUDERT M, 1981, THESIS U LIMOGES; DAVIES AE, 1971, BRIT HOMOEOPATHIC J, V60, P36; DAVIES AE, 1988, BR HOM RES GROUP COM, V18, P42; DEKLERK ESMD, 1994, BRIT MED J, V309, P1329; DELAUNAY M, 1985, MED DOUCE, V44, P34; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEXPERT M, 1987, HOMEOPATHIE FRANCAIS, V75, P353; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Dorfman P, 1992, CAHIERS BIOTHERAP, V114, P33; DORFMAN P, 1987, CAHIERS BIOTHERAP, V94, P77; Dorfman P, 1988, CAHIERS BIOTHERAPI S, V98, P77; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ENDLER PC, 1994, VET HUM TOXICOL, V36, P56; ENDLER PC, 1994, ULTRA HIGH DILUTION; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; Ernst E., 1990, PHLEBOLOGY, V5, P157; ERNST E, 1996, COMPLEMENTARY MED OB; ESTRANGIN M, 1983, THESIS U GRENOBLE; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; Ferley JP, 1987, IMMUNOLOGIE MED, V20, P22; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; Fisher P, 1986, BR HOM J, V75, P142; Fleiss JL, 1981, STAT METHODS RATES P; Freitas LA, 1995, REV HOMEOPATIA, V60, P26; Gaucher C, 1994, BR HOM J, V83, P132; GAUTHIER JE, 1983, THESIS U BORDEAUX; GIBSON J, 1991, BR HOM RES GROUP COM, V21, P34; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; GOTZSCHE PC, 1993, LANCET, V341, P1533; *GRECHO ARC GREPA, 1987, PRESSE MED, V16, P192; HAHNEMANN S, 1982, ULTRA HIGH DILUTION; Haltenhof H, 1995, Gesundheitswesen, V57, P192; HARDY J, 1984, BR HOM RES GROUP COM, V11, P75; HARIVEAU E, 1987, HOMEOPATHIE, V5, P55; HARIVEAU E, 1992, HOMEOPATH FRANCAISE, V80, P17; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Hedges LV, 1996, J EDUC BEHAV STAT, V21, P299, DOI 10.2307/1165338; Hedges LV, 1992, STAT SCI, V7, P246, DOI DOI 10.1214/SS/1177011364; HEDGES LV, 1994, HDB RES SYNTHESIS, P286; Heilmann A., 1992, BIOL MED, V21, P225; HILDEBRANDT G, 1983, 2 BEITR PHARM AD PRO; HILL M, 1993, SURFACES, V3, P4; HOFMEYR GJ, 1990, BRIT J CLIN PRACT, V44, P619; HOURST P, 1981, THESIS U P M CURIE; JACOBS J, 1994, PEDIATRICS, V93, P719; Jacobs J, 1993, BR HOM J, V82, P83; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JADAD AR, 1996, EDUC PSYCHOL MEAS, V17, P1; Jansen GRHJ, 1992, BR HOM J, V81, P132; KAZIRO GSN, 1984, BRIT J ORAL MAX SURG, V22, P42, DOI 10.1016/0266-4356(84)90007-X; KENNEDY CO, 1971, BRIT HOM J, V60, P120; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; KOHLER T, 1991, KASSENARZT, V13, P48; KUBISTA E, 1986, Gynaekologische Rundschau, V26, P65; Kurz C, 1993, Gynakol Geburtshilfliche Rundsch, V33 Suppl 1, P330; LABRECQUE M, 1992, CAN MED ASSOC J, V146, P1749; LEAMAN AM, 1989, ARCH EMERG MED, V6, P259; LECOCQ P, 1985, CAHIERS BIOTHERAPIE, V87, P65; LEPAISANT C, 1994, THESIS U CAEN; Lewis D, 1984, MIDLANDS HOMOEOPATHY, V11, P49; LIGHT RJ, 1984, SUMMING UP SCI REV R; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 1996, FORSCH KOMPLEMENTMED, V3, P148; LOKKEN P, 1995, BRIT MED J, V310, P1439, DOI 10.1136/bmj.310.6992.1439; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Master F.J., 1987, P 42 C LMHI ARL VIRG, P330; MICHAUD J, 1981, THESIS U NANTES; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOKKAPATTI R, 1992, BR HOMEOPATH J, V81, P22; MOSSINGER P, 1982, ZLLG HOMOOPATH ZTG, V227, P89; MOSSINGER P, 1984, HOMOOPATHIE NATURWIS, P165; MOSSINGER P, 1976, ALLG HOMOOPATH ZTG, V221, P177; MOSSINGER P, 1976, ALLG HOMOOPATH ZTG, V221, P26; MOSSINGER P, 1985, KINDERARZT, V16, P581; MOSSINGER P, 1990, ALLG HOMOOPATH ZTG, V225, P22; NOLLEVAUX MA, 1994, UNPUB KLIN STUDIE MU; OKEEFFE D, 1986, LANCET, V2, P1106; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157, DOI 10.2307/1164923]; Paterson J, 1943, BR HOM J, V33, P1; Pinsent RJ, 1986, BRIT HOMEOPATHIC RES, V15, P3; PONTI M, 1986, RECHERCHES HOMEOPATH, P71; RAHLFS VW, 1979, DEUT MED WOCHENSCHR, V104, P140, DOI 10.1055/s-0028-1103859; RAHLFS WV, 1976, ARZNEIMITTEL-FORSCH, V26, P2230; REIL GH, 1985, Z KARDIOL, V74, P65; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; RITTER H, 1966, HIPPOKRATES, V12, P472; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SainteLaudy J, 1997, INFLAMM RES, V46, pS27, DOI 10.1007/s000110050035; SAMPSON A, 1995, ALT THER, V1, P48; SARUGGIA M, 1992, BR HOM J, V81, P86; Savage R.H., 1977, BRIT HOMOEOPATHIC J, V66, P207; Savage R.H., 1978, BR HOM J, V67, P210; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHUPPEL R, 1994, FORTSCHR KOMPLEMENTA, V1, P177; SCHWAB G, 1990, LASST SICH WIRKUNG H; SHIPLEY M, 1983, LANCET, V1, P97; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SOMMER RG, 1987, THERAPEUTIKON, V1, P16; THIEL W, 1991, BIOL MED, V20, P506; TVEITEN D, 1991, Tidsskrift for den Norske Laegeforening, V111, P3630; USTIANOWSKI PA, 1974, BRIT HOMOEOPATHIC J, V63, P276; VALERO E, 1981, THESIS U MED GRENOBL; VEVEA JL, 1995, PSYCHOMETRIKA, V60, P419, DOI 10.1007/BF02294384; Walach H, 1997, CEPHALALGIA, V17, P119, DOI 10.1046/j.1468-2982.1997.1702119.x; Weiser M, 1994, FORSCH KOMPLEMENTMED, V1, P251, DOI 10.1159/000209924; WERK W, 1994, THERAPIEWOCHE, V44, P34; Whitmarsh TE, 1997, CEPHALALGIA, V17, P600, DOI 10.1046/j.1468-2982.1997.1705600.x; WHITMARSH TE, 1993, CEPHALAGIA, V13, P254; WIESENAUER M, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1745; WIESENAUER M, 1983, FORTSCHR MED, V101, P811; Wiesenauer M, 1995, PHYTOMEDICINE, V2, P3, DOI 10.1016/S0944-7113(11)80041-3; WIESENAUER M, 1989, ARZNEIMITTEL-FORSCH, V39-1, P620; WIESENAUER M, 1990, ALLERGOLOGIE, V13, P359; WIESENAUER M, 1991, AKTUEL RHEUMATOL, V16, P1, DOI 10.1055/s-2008-1047372; WIESENAUER M, 1996, KOMPLEMENTARMED, V3, P230; WIESENAUER M, 1992, 10 JAHR KARL VER CAR, P142; YAKIR M, 1994, P 8 GIRI M JER, P49; Zell J, 1988, Fortschr Med, V106, P96	145	602	616	6	207	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					834	843		10.1016/S0140-6736(97)02293-9	http://dx.doi.org/10.1016/S0140-6736(97)02293-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX401	9310601				2023-01-03	WOS:A1997XX40100009
J	Morgan, RO; Virnig, BA; DeVito, CA; Persily, NA				Morgan, RO; Virnig, BA; DeVito, CA; Persily, NA			The Medicare-HMO revolving door - The healthy go in and the sick go out	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OUTCOMES; DEMONSTRATIONS; DISENROLLEES; ISSUES; CARE	Background Enrollment in Medicare health maintenance organizations (HMOs) is encouraged because of the expectation that HMOs can help slow the growth of Medicare costs. However, Medicare HMOs, which are paid 95 percent of average yearly fee-for-service Medicare expenditures, are increasingly believed to benefit from the selective enrollment of healthier Medicare recipients. Furthermore, whether sicker patients are more likely to disenroll from Medicare HMOs, thus raising average fee-for service costs, is not clear. Methods We used Medicare enrollment and inpatient billing records for southern Florida from 1990 through 1993 to examine differences in the use of inpatient medical services by 375,406 beneficiaries in the Medicare fee-for-service system, 48,380 HMO enrollees before enrollment, and 23,870 HMO enrollees after disenrollment. We also determined whether these differences were related to demographic characteristics and whether the pattern of use after disenrollment persisted over time. Results The rate of use of inpatient services in the HMO-enrollment group during the year before enrollment was 66 percent of the rate in the fee-for-service group, whereas the rate in the HMO-disenrollment group after disenrollment was 180 percent of that in the fee-for-service group. Beneficiaries who disenrolled from HMOs re-enrolled at about the time that their level of use dropped to that in the fee-for-service group. Conclusions These data show marked selection biases with respect to HMO enrollment and disenrollment. These biases undermine the effectiveness of the Medicare managed-care system and highlight the need for longitudinal and population-based studies. (C)1997, Massachusetts Medical Society.	UNIV MIAMI,SCH MED,MIAMI,FL; VET AFFAIRS MED CTR,MIAMI,FL 33125; UNIV MIAMI,MICHAEL I ABRAMS HLTH POLICY RES CTR,PUBL HLTH TRUST,MIAMI,FL 33152; GEORGE WASHINGTON UNIV,SCH PUBL HLTH & HLTH SERV,WASHINGTON,DC	University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; George Washington University			Morgan, Robert/A-8577-2009					BROWN R, 1986, ENROLLMENT DISENROLL; BROWN RS, 1994, HMOS AND THE ELDERLY, P13; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; DOWD B, 1992, MILBANK Q, V70, P423, DOI 10.2307/3350130; Eggers P W, 1982, Health Care Financ Rev, V4, P55; Fleiss JL, 1981, STAT METHODS RATES P; *GAO, 1986, PUBL GAO; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; Hill JW, 1990, BIASED SELECTION TEF; *HLTH CAR FIN ADM, 1997, MAN CAR MED MED FACT; KOCH GG, 1986, ENCY STAT SCI, P7; MECHANIC D, 1983, MED CARE, V21, P338, DOI 10.1097/00005650-198303000-00006; *PHYS PAYM REV COM, 1996, 1996 ANN REP C, P255; PRELL FW, 1992, FACTORS ASS DISENROL; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RILEY G, 1989, MED CARE, V27, P337, DOI 10.1097/00005650-198904000-00002; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906	19	186	186	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					169	175		10.1056/NEJM199707173370306	http://dx.doi.org/10.1056/NEJM199707173370306			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219704				2023-01-03	WOS:A1997XK81800006
J	Fulcher, KY; White, PD				Fulcher, KY; White, PD			Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome	BRITISH MEDICAL JOURNAL			English	Article							FATIGUABILITY; FIBROMYALGIA; PERFORMANCE; ACTIVATION; STRENGTH; PROGRAM; HEALTH	Objective: To test the efficacy of a graded aerobic exercise programme in the Design: Randomised controlled trial with control treatment crossover after the first follow up examination. Setting: Chronic fatigue clinic in a general hospital department of psychiatry. Subjects: 66 patients with the chronic fatigue syndrome who had neither a psychiatric disorder nor appreciable sleep disturbance. Interventions: Random allocation to 12 weeks of either graded aerobic exercise or flexibility exercises and relaxation therapy Patients who completed the flexibility programme were invited to cross over to the exercise programme afterwards. Main outcome measure: The self rated clinical global impression change score, ''very much better'' or ''much better'' being considered as clinically important. Results: Four patients receiving exercise and three receiving flexibility treatment dropped out before completion. 16 of 29 patients rated themselves as better after completing exercise treatment compared with eight of 30 patients who completed flexibility treatment Analysis by intention to treat gave similar results (17/33 v 9/33 patients better). Fatigue, functional capacity, and fitness were significantly better after exercise than after flexibility treatment 12 of 22 patients who crossed over to exercise after flexibility treatment rated themselves as better after completing exercise treatment. 32 of 47 patients rated themselves as better three months after completing supervised exercise treatment 35 of 47 patients rated themselves as better one year after completing supervised exercise treatment. Conclusion: These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with the chronic fatigue syndrome.	ST BARTHOLOMEWS & ROYAL LONDON MED SCH, DEPT MED PSYCHOL, LONDON EC1A 7BE, ENGLAND; ST BARTHOLOMEWS & ROYAL LONDON MED SCH, NATL SPORTS MED INST, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London				White, Peter/0000-0002-8193-5355				[Anonymous], 1991, GUID EX TEST PRESCR; BLOMQVIST CG, 1983, ANNU REV PHYSIOL, V45, P169, DOI 10.1146/annurev.ph.45.030183.001125; BOMBARDIER CH, 1995, ARCH INTERN MED, V155, P2105, DOI 10.1001/archinte.155.19.2105; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BUCHWALD D, 1994, ARCH INTERN MED, V154, P2049, DOI 10.1001/archinte.154.18.2049; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Deale A, 1997, AM J PSYCHIAT, V154, P408; Feldman R M, 1987, Birth Defects Orig Artic Ser, V23, P335; Fleiss JL, 1981, STAT METHODS RATES P; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GIBSON H, 1993, J NEUROL NEUROSUR PS, V56, P993, DOI 10.1136/jnnp.56.9.993; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; LLOYD AR, 1991, BRAIN, V114, P85; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; McCully KK, 1996, SPORTS MED, V21, P35, DOI 10.2165/00007256-199621010-00004; MORGAN WP, 1994, MED SCI SPORT EXER, V26, P1071, DOI 10.1249/00005768-199409000-00001; MYLES WS, 1985, MED SCI SPORT EXER, V17, P580; Newham D, 1979, Physiotherapy, V65, P52; RILEY MS, 1990, BRIT MED J, V301, P953, DOI 10.1136/bmj.301.6758.953; RUTHERFORD OM, 1986, J NEUROL NEUROSUR PS, V49, P1288, DOI 10.1136/jnnp.49.11.1288; RUTHERFORD OM, 1991, J NEUROL NEUROSUR PS, V54, P961, DOI 10.1136/jnnp.54.11.961; Saltin B., 1968, CIRCULATION, V38, P1, DOI 10.1161/01.CIR.38.1.1; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Spitzer R.L., 1990, 1; STOKES MJ, 1988, BRIT MED J, V297, P1014, DOI 10.1136/bmj.297.6655.1014; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEYERER S, 1994, SPORTS MED, V17, P108, DOI 10.2165/00007256-199417020-00003; WHITE PD, 1995, PSYCHOL MED, V25, P917, DOI 10.1017/S0033291700037405; ZIGMOND A, 1983, ACTA PSYCHIAT SCAND, V87, P361	32	258	262	0	51	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1647	1652		10.1136/bmj.314.7095.1647	http://dx.doi.org/10.1136/bmj.314.7095.1647			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9180065	Green Published			2023-01-03	WOS:A1997XD87400022
J	Brody, H; Campbell, ML; FaberLangendoen, K; Ogle, KS				Brody, H; Campbell, ML; FaberLangendoen, K; Ogle, KS			Withdrawing intensive life-sustaining treatment - Recommendations for compassionate clinical management	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CRITICALLY ILL PATIENTS; TERMINALLY ILL; PALLIATIVE CARE; DEHYDRATION; DIALYSIS; DEATH; SUPPORT; DISCONTINUATION; PHYSICIANS; VECURONIUM		DETROIT RECEIVING HOSP & UNIV HLTH CTR, DETROIT, MI 48201 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Detroit Receiving Hospital & University Health Center; University of Minnesota System; University of Minnesota Twin Cities	Brody, H (corresponding author), MICHIGAN STATE UNIV, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022	Campbell, Margaret/0000-0003-4517-690X				ANDREWS M, 1993, POSTGRAD MED, V93, P201; Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN; Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; Campbell M L, 1992, Am J Crit Care, V1, P52; Campbell M L, 1996, Dimens Crit Care Nurs, V15, P4, DOI 10.1097/00003465-199601000-00002; Campbell M L, 1991, ANNA J, V18, P202; Campbell M L, 1993, Am J Crit Care, V2, P354; Campbell M L, 1996, Am J Crit Care, V5, P339; Carlson RW, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852-b; CARLSON RW, 1995, ARCH INTERN MED, V155, P13; CHERNOW B, 1994, PHARM APPROACH CRITI; CITRON ML, 1984, AM J MED, V77, P199, DOI 10.1016/0002-9343(84)90691-0; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; Daly B J, 1996, Am J Crit Care, V5, P331; Doyle D., 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; ELLERSHAW JE, 1995, J PAIN SYMPTOM MANAG, V10, P192, DOI 10.1016/0885-3924(94)00123-3; ENCK RE, 1994, MED CARE TERMINALLY; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FABERLANGENDOEN K, 1996, AM J RESP CRIT CARE, V153, pA365; GIANAKOS D, 1995, CHEST, V108, P1405, DOI 10.1378/chest.108.5.1405; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; *HAST CTR, 1987, GUID TERM LIF SUST T; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LO B, 1989, ARCH INTERN MED, V149, P1925, DOI 10.1001/archinte.149.9.1925; LUCE JM, 1991, RESP CARE, V109, P417; MAILLOUX LU, 1993, J AM SOC NEPHROL, V3, P1631; MALONE N, 1994, NURSING STANDAR 0720, P29; *MAN CANC PAIN GUI, 1994, AHCPR PUBL; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; *MULT TASK FORC PV, 1995, NEW ENGL J MED, V33, P130; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; ROUSSEAU PC, 1992, PATIENT CARE, V26, P71; Rushton C H, 1995, Am J Crit Care, V4, P112; SAUNDERS C, 1993, MANAGEMENT TERMINAL; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Shekleton M E, 1994, AACN Clin Issues Crit Care Nurs, V5, P523; Siegel MD, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852; SLOMKA J, 1995, ARCH INTERN MED, V155, P1258, DOI 10.1001/archinte.155.12.1258; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; TRUOG RD, 1994, J CLIN ETHIC, V5, P39; VACHON MLS, 1995, PALLIATIVE MED, V9, P91, DOI 10.1177/026921639500900202; Vachon MLS., 1987, OCCUPATIONAL STRESS; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weatherill G G, 1995, AACN Clin Issues, V6, P344, DOI 10.1097/00044067-199505000-00018; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	63	174	175	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					652	657		10.1056/NEJM199702273360910	http://dx.doi.org/10.1056/NEJM199702273360910			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK028	9032053				2023-01-03	WOS:A1997WK02800010
J	Goel, A; Kumar, G; Payne, GF; Dube, SK				Goel, A; Kumar, G; Payne, GF; Dube, SK			Plant cell biodegradation of a xenobiotic nitrate ester, nitroglycerin	NATURE BIOTECHNOLOGY			English	Article						phytoremediation; nitroglycerin; xenobiotic; nitrate ester; Beta vulgaris	GLUTATHIONE-S-TRANSFERASE; NITRIC-OXIDE FORMATION; GLYCERYL TRINITRATE; PHANEROCHAETE-CHRYSOSPORIUM; ORGANIC-CHEMICALS; NITROAROMATIC COMPOUNDS; METABOLIC-FATE; INVOLVEMENT; SYSTEMS; DEGRADATION	The ability of plants to metabolize the xenobiotic nitrate ester, glycerol trinitrate (GTN, nitroglycerin), was examined using cultured plant cells and plant cell extracts. Intact cells rapidly degrade GTN with the initial formation of glycerol dinitrate (GDN) and the later formation of glycerol mononitrate (GMN). A material balance analysis of these intermediates indicates little, if any, formation of reduced, conjugated or cell-bound carbonaceous metabolites. Cell extracts were shown to be capable of degrading GTN with the simultaneous formation of GDN in stoichiometric amounts. The intermediates observed, and the timing of their appearance, are consistent with a sequential denitration pathway that has been reported for the microbial degradation of nitrate esters. The degradative activities of plant cells are only tenfold less than those reported for bacterial GTN degradation. These results suggest that plants may serve a direct degradative function for the phytoremediation of sites contaminated by organic nitrate esters.	UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM ENGN,BALTIMORE,MD 21228; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland College Park								ANDERSON TA, 1993, ENVIRON SCI TECHNOL, V27, P2630, DOI 10.1021/es00049a001; BELLIN CA, 1990, J ENVIRON QUAL, V19, P598, DOI 10.2134/jeq1990.00472425001900030040x; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Bokern M, 1996, J AGR FOOD CHEM, V44, P1123, DOI 10.1021/jf950376+; BRIGGS GG, 1982, PESTIC SCI, V13, P495, DOI 10.1002/ps.2780130506; Cunningham SD, 1996, PLANT PHYSIOL, V110, P715, DOI 10.1104/pp.110.3.715; CUNNINGHAM SD, 1993, IN VITRO CELL DEV-PL, V29P, P207, DOI 10.1007/BF02632036; DUCROCQ C, 1989, FEMS MICROBIOL LETT, V65, P219, DOI 10.1111/j.1574-6968.1989.tb03625.x; DUCROCQ C, 1990, BIOTECHNOL APPL BIOC, V12, P325; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; HABIG WH, 1975, BIOCHEM BIOPH RES CO, V64, P501, DOI 10.1016/0006-291X(75)90349-6; HALL DR, 1992, TETRAHEDRON LETT, V33, P4811, DOI 10.1016/S0040-4039(00)61292-3; HARMS H, 1977, Z NATURFORSCH C, V32, P321; HARMS H, 1986, PLANT SCI, V45, P157, DOI 10.1016/0168-9452(86)90135-4; HARMS HH, 1992, PESTIC SCI, V35, P277, DOI 10.1002/ps.2780350313; Hegde RS, 1996, CHEMOSPHERE, V32, P2471, DOI 10.1016/0045-6535(96)00144-0; HILL KE, 1992, BIOCHEM PHARMACOL, V43, P561, DOI 10.1016/0006-2952(92)90579-8; HUGHES JB, IN PRESS ENV SCI TEC; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; INGERSOL LJC, 1996, PLANT CELL REP, V15, P836; KAPLAN DL, 1982, APPL ENVIRON MICROB, V43, P144, DOI 10.1128/AEM.43.1.144-150.1982; KOMOSSA D, 1992, PESTIC BIOCHEM PHYS, V43, P85, DOI 10.1016/0048-3575(92)90022-R; LANGEBARTELS C, 1985, ECOTOX ENVIRON SAFE, V10, P268, DOI 10.1016/0147-6513(85)90073-9; LAU DTW, 1990, DRUG METAB DISPOS, V18, P292; LEE I, 1992, PLANT CELL REP, V11, P97, DOI 10.1007/BF00235262; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MARVINSIKKEMA FD, 1994, APPL MICROBIOL BIOT, V42, P499; MENG M, 1995, APPL ENVIRON MICROB, V61, P2548, DOI 10.1128/AEM.61.7.2548-2553.1995; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAIR DR, 1993, J ENVIRON ENG, V119, P842, DOI 10.1061/(ASCE)0733-9372(1993)119:5(842); OCONNOR GA, 1990, J ENVIRON QUAL, V19, P113, DOI 10.2134/jeq1990.00472425001900010016x; PATERSON S, 1990, CHEMOSPHERE, V21, P297, DOI 10.1016/0045-6535(90)90002-B; PESARI H, 1993, BIOTECHNOL BIOENG, V41, P79, DOI 10.1002/bit.260410111; Ramos JL, 1996, NAT BIOTECHNOL, V14, P320, DOI 10.1038/nbt0396-320; RYAN JA, 1988, CHEMOSPHERE, V17, P2299, DOI 10.1016/0045-6535(88)90142-7; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SCHMIDT B, 1994, PESTIC SCI, V40, P231, DOI 10.1002/ps.2780400310; Schnoor J.L., 1995, ENV SCI TECH, V29, P318; SERVENT D, 1992, BIOTECHNOL APPL BIOC, V15, P257; SERVENT D, 1989, BIOCHEM BIOPH RES CO, V163, P1210, DOI 10.1016/0006-291X(89)91106-6; SERVENT D, 1991, BIOCHIM BIOPHYS ACTA, V1074, P320, DOI 10.1016/0304-4165(91)90170-L; SHIMP JF, 1993, CRIT REV ENV SCI TEC, V23, P41, DOI 10.1080/10643389309388441; SMETS BF, 1995, J ENERG MATS, V13, P385; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; Sun WQ, 1996, APPL MICROBIOL BIOT, V45, P525; TOPP E, 1986, ECOTOX ENVIRON SAFE, V11, P219, DOI 10.1016/0147-6513(86)90066-7; WALTON B T, 1992, Current Opinion in Biotechnology, V3, P267, DOI 10.1016/0958-1669(92)90102-O; WENDT TM, 1978, APPL ENVIRON MICROB, V36, P693, DOI 10.1128/AEM.36.5.693-699.1978; WETZEL A, 1994, ARCH BIOCHEM BIOPHYS, V314, P323, DOI 10.1006/abbi.1994.1449; White GF, 1996, APPL ENVIRON MICROB, V62, P637, DOI 10.1128/AEM.62.2.637-642.1996; WHITE GF, 1993, J GEN MICROBIOL, V139, P1947, DOI 10.1099/00221287-139-9-1947; WILKEN A, 1995, ENVIRON TOXICOL CHEM, V14, P2017, DOI [10.1897/1552-8618(1995)14[2017:MODPCI]2.0.CO;2, 10.1002/etc.5620141203]; YEATES RA, 1989, BIOCHEM PHARMACOL, V38, P1749, DOI 10.1016/0006-2952(89)90408-5	53	45	52	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					174	177		10.1038/nbt0297-174	http://dx.doi.org/10.1038/nbt0297-174			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035145				2023-01-03	WOS:A1997WE99800026
J	Radford, JA; Eardley, A; Woodman, C; Crowther, D				Radford, JA; Eardley, A; Woodman, C; Crowther, D			Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records	BRITISH MEDICAL JOURNAL			English	Article								Objective: To examine the effectiveness of routine clinic review in detecting relapse after treatment for Hodgkin's disease. Design: Review of hospital records. Setting: Regional centre for cancer treatment and research. Subjects: 210 patients with Hodgkin's disease recruited to a chemotherapy trial protocol between 1984 and the end of 1990 who had achieved a complete or partial remission after treatment. Main outcome measures: The number of clinic visits made by patients over the period of observation, the number of relapses occurring during that time, and the route by which relapse was detected. Results: The 210 patients generated 2512 outpatient reviews, and 37 relapses were detected. Thirty relapses (81%) were diagnosed in patients who described symptoms, which in 15 cases had resulted in an earlier appointment being arranged. In only four cases (11%; 95% confidence interval 4% to 25%) was relapse detected as a result of routine physical examination or investigation of a patient who did not have symptoms. Conclusions: Relapse of Hodgkin's disease after treatment is usually detected as a result of the investigation of symptoms rather than by routine screening of asymptomatic patients. It is therefore proposed that the frequency of routine follow up visits should be reduced and greater emphasis placed on patient education. This should underline the importance of symptoms and encourage patients to arrange an earlier appointment if these develop.			Radford, JA (corresponding author), CHRISTIE HOSP NHS TRUST,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M20 4BX,LANCS,ENGLAND.		Radford, John A/N-1331-2015	Radford, John A/0000-0001-7898-2786				ANDERSEN PK, 1993, SMOOTHING NELSON AAL, P229; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; RADFORD JA, 1995, J CLIN ONCOL, V13, P2379, DOI 10.1200/JCO.1995.13.9.2379; WEEKS JC, 1991, J CLIN ONCOL, V9, P1196, DOI 10.1200/JCO.1991.9.7.1196	4	81	81	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					343	346		10.1136/bmj.314.7077.343a	http://dx.doi.org/10.1136/bmj.314.7077.343a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040326	Green Published			2023-01-03	WOS:A1997WF86100032
J	Shen, WK; Hayes, DL; Hammill, SC; Bailey, KR; Ballard, DJ; Gersh, BJ				Shen, WK; Hayes, DL; Hammill, SC; Bailey, KR; Ballard, DJ; Gersh, BJ			Survival and functional independence after implantation of a permanent pacemaker in octogenarians and nonagenarians - A population-based study	ANNALS OF INTERNAL MEDICINE			English	Article							SICK SINUS SYNDROME; LONG-TERM SURVIVAL; ATRIOVENTRICULAR-BLOCK; HEART-BLOCK; FOLLOW-UP; PROGNOSIS; MODE; AGE	Background: The number of very elderly persons who are candidates for implantation of a permanent pacemaker is increasing, but the effect of cardiac pacing on long-term survival and functional variables has not been determined. Objective: To determine long-term survival after implantation of a permanent pacemaker in octogenarians and nonagenarians and to assess functional independence after such implantation. Design: Retrospective, population-based cohort study. Setting: Epidemiologic setting from an unselected population. Patients: 157 octogenarians and nonagenarians who initially received a pacemaker between 1962 and 1988 and were followed through 1992. Main Outcome Measures: Overall mortality rate, functional capabilities, and placement in a nursing home. Results: Observed survival in patients with heart disease was significantly worse than that in age- and sex-matched controls (P < 0.001). Observed survival in community residents without heart disease was similar to that in controls (P > 0.2). Multivariable analysis identified congestive heart failure, chronic obstructive pulmonary disease, old age, syncope, cancer, and atrioventricular block as independent predictors of increased mortality. Symptoms decreased in 118 patients (75%) after pacemaker implantation. After implantation, 70 patients (45%) were permanently placed in nursing homes; this number is similar to the estimated probability of lifetime use of nursing homes from the National Mortality Followback Survey. Dementia developed or worsened in 51 patients (32%), and orthopedic disability occurred in 41 patients (26%). Conclusions: Normal relative survival in octogenarians and nonagenarians without heart disease is reassuring; the poor prognosis in patients with heart disease warrants careful evaluation of the methods and indications for cardiac pacing. Permanent pacing alleviates bradycardia-related symptoms. Placement in a nursing home and development or worsening of cardiac, neurologic, or orthopedic disabilities frequently occur after implantation of a permanent pacemaker in the very elderly.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI, ROCHESTER, MN 55905 USA	Mayo Clinic	Shen, WK (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Ballard, David J/H-1062-2018					ALPERT MA, 1982, J CHRON DIS, V35, P341, DOI 10.1016/0021-9681(82)90005-4; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; [Anonymous], 1964, DIS HEART BLOOD VESS; BERGSTRALH EJ, 1988, CONDITIONAL PROBABIL, P1; BREIVIK K, 1984, ACTA MED SCAND, V216, P119; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; COX DR, 1972, J R STAT SOC B, V34, P187; EDHAG O, 1976, ACTA MED SCAND, V200, P457; ELIZABETH JE, 1991, POSTGRAD MED J, V67, P663, DOI 10.1136/pgmj.67.789.663; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GINKS W, 1979, BRIT HEART J, V41, P633; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; LINDEEDELSTAM C, 1992, PACE, V15, P304, DOI 10.1111/j.1540-8159.1992.tb06500.x; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; SHEN WK, 1994, AM J CARDIOL, V74, P560, DOI 10.1016/0002-9149(94)90744-7; STRAUSS HD, 1978, PACE, V1, P458, DOI 10.1111/j.1540-8159.1978.tb03507.x; TUNG RT, 1994, AM J CARDIOL, V74, P1016, DOI 10.1016/0002-9149(94)90851-6; VANHEMEL NM, 1981, PACE, V4, P8	20	38	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					476	480		10.7326/0003-4819-125-6-199609150-00008	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779460				2023-01-03	WOS:A1996VF88200009
J	Payne, K; Taylor, RM; Stocking, C; Sachs, GA				Payne, K; Taylor, RM; Stocking, C; Sachs, GA			Physicians' attitudes about the care of patients in the persistent vegetative state: A national survey	ANNALS OF INTERNAL MEDICINE			English	Article						knowledge, attitudes, practice; persistent vegetative state; ethics, medical; attitude toward death; life support care	COMA	Objective: To study the attitudes and beliefs of physicians who have experience caring for patients in the persistent vegetative state (PVS). Design: Mailed questionnaire survey. Participants: 500 physicians, 250 from the American Academy of Neurology and 250 from the American Medical Directors Association. Measurements: Physicians' beliefs about diagnosis of the PVS, patient awareness and suffering, treatment withdrawal, appropriate use of health maintenance and life-prolonging therapies, organ donation, lethal injection, and the treatment they would want if they were in the PVS. Results: 68% of surveyed neurologists and 60% of medical directors responded. Thirteen percent of responders believe that patients in the PVS have awareness and experience hunger and thirst; 30% believe they experience pain. Fewer than 9% believe that respiratory failure, cardiogenic shock, acute renal failure, or cancer should be aggressively treated. Eighty-nine percent believe that it is ethical to withdraw artificial hydration and nutrition. Almost two thirds of responders believe that it would be ethical to use the vital organs of patients in the PVS for transplantation, and 20% believe that it would be ethical to hasten the patient's death by lethal injection. Conclusions: When evaluating the appropriateness of treatments for patients in the PVS, neurologists and medical directors largely concur. Most physicians in both groups believe that patients in the PVS would be better off dead; that it is not necessary to provide aggressive therapeutic interventions; and that all therapeutic interventions, including artificial nutrition and hydration, can be withheld in certain circumstances. The areas of consensus are remarkable and suggest that-an ethical standard that physicians believe should be followed when caring for these patients may be emerging.	UNIV CHICAGO, MED CTR, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago Medical Center			Taylor, Robert/E-4181-2011		NIA NIH HHS [AG0048] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bernat J L, 1992, J Clin Ethics, V3, P21; BOYD K, 1991, LANCET, V337, P96; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; GALLUP G, 1991, GALLUP POLL NEWS SER, V55, P1; GERVAIS KG, 1985, REDEFINING DEATH; JENNETT B, 1972, LANCET, V1, P734; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNOX RA, 1991, BOSTON SUNDAY G 1103; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Plows CW, 1996, JAMA-J AM MED ASSOC, V275, P443, DOI 10.1001/jama.275.6.443; TRESCH DD, 1991, J AM GERIATR SOC, V39, P17, DOI 10.1111/j.1532-5415.1991.tb05900.x; Veatch R M, 1992, J Clin Ethics, V3, P181; 1996, NEUROLOGY, V45, P1015; 1990, JAMA-J AM MED ASSOC, V263, P426	19	83	85	2	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					104	+		10.7326/0003-4819-125-2-199607150-00004	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV921	8678363				2023-01-03	WOS:A1996UV92100007
J	Grubb, A; Walsh, P; Lambe, N; Murrells, T; Robinson, S				Grubb, A; Walsh, P; Lambe, N; Murrells, T; Robinson, S			Survey of British clinicians' views on management of patients in persistent vegetative state	LANCET			English	Article								Background The best care and management of patients in persistent vegetative slate (PVS) has been the subject of sustained moral and legal debate for a number of years. However, the views of clinicians in the UK involved in caring for patients in PVS are largely unknown. Methods A postal questionnaire was sent to 1882 consultant members of the British Association of Orthopaedic Surgeons, the Association of British Neurologists, the Society of British Neurosurgeons, and the British Society of Rehabilitation Medicine. Their views were sought on various aspects of the management and care of PVS, in particular the appropriateness of a decision not to treat and a decision to withdraw artificial nutrition and hydration (ANH). Findings 1027 doctors responded (55%) of whom 558 (54%) had experience of managing patients in PVS. Over 90% of responding doctors considered that it could be not to treat acute infections and other life-threatning conditions. 65% of doctors considered that withdrawal of ANH could be apporpriate. About two-thirds of doctors who thought treatment-limiting decisions could be appropriate thought that such decisions could be considered with the first 12 months of the patient being in PVS. Despite recent case law, less than half the doctors responding to the survey thought that an advance directive made by the patient should have a decisive influence in determining treatment-limiting decisions. Most doctors would like decisions about withdrawing ANH to be made in conjunction with family members and in accordance with agreed guidelines but without the need to go to court. Interpretation There is a broad consensus among doctors that treatment-limiting decisions are sometimes appropriate for patients in PVS, irrespective of whether they have experience of the condition or of the specialty to which they belong. However, two thirds of doctors said that such decisions can be considered al a time earlier than that recommended by the British Medical Association. It is not clear why some doctors thought a decision not to treat could be appropriate while a decision to withdraw ANH would not be.	UNIV LONDON KINGS COLL,NURSING RES UNIT,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	Grubb, A (corresponding author), UNIV LONDON KINGS COLL,CTR MED LAW & ETH,LONDON WC2R 2LS,ENGLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; ANDREWS K, 1993, BRIT MED J, V306, P1602; [Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1992, ANN NEUROL, V32, P570, DOI 10.1002/ana.410320414; *BRIT MED ASS, 1995, ADV STAT MED TREATM; CANTOR NL, 1989, AM J LAW MED, V15, P381; Cartwright A, 1983, HLTH SURVEYS PRACTIC; CELESIA GG, 1993, ANN NEUROL, V33, P391, DOI 10.1002/ana.410330410; Dworkin R., 1993, LIFES DOMINION; *GEZ, 1994, PUBL GEZ; GIACINO GT, 1995, J HEAD TRAUMA REHABI, V10, P40; HODGES MO, 1994, ARCH INTERN MED, V154, P1013, DOI 10.1001/archinte.154.9.1013; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; KENNEDY I, 1993, MED LAW REV, V1, P359; Kennedy I, 1991, TREAT ME RIGHT ESSAY; KENNEDY I, 1994, MED LAW; *LAW COMM ENGL WAL, 1995, 231 LAW COMM ENGL WA; RACHELS J., 1986, END LIFE EUTHANASIA; *SCOTT LAW COMM, 1995, 151 SCOTT LAW COMM; 1994, NEW ENGL J MED, V330, P1499; 1996, J R COLL PHYSNS, V30, P119; [No title captured]; [No title captured]; 1994, NEW ENGL J MED, V330, P1572	25	49	51	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					35	40		10.1016/S0140-6736(96)02030-2	http://dx.doi.org/10.1016/S0140-6736(96)02030-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691931				2023-01-03	WOS:A1996UV92300015
J	Sacks, SL; Aoki, FY; DiazMitoma, F; Sellors, J; Shafran, SD				Sacks, SL; Aoki, FY; DiazMitoma, F; Sellors, J; Shafran, SD			Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes - A randomized, double-blind multicenter trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIMPLEX VIRUS-INFECTION; ACYCLOVIR; SUPPRESSION; TYPE-2; PHARMACOKINETICS; PENCICLOVIR; ANTIBODIES; MODE	Objective.-To compare the efficacy and safety of episodic patient-initiated oral famciclovir with placebo in recurrent genital herpes. Design.-Randomized, double-blind, frequent-observation, dose-ranging study comparing twice-daily 125-mg, 250-mg, or 500-mg oral famciclovir with placebo. Patients initiated therapy after self-culturing, reported to the clinic within 12 hours, and were assessed twice daily for at least 5 days. Setting.-Fifteen Canadian university, private practice, or public outpatient clinics. Patients.-A total of 692 patients with culture-proven recurrent genital herpes were randomized; 467 patients experienced a symptomatic episode and commenced treatment. Main Outcome Measure.-Time to complete healing of all lesions. Results.-Famciclovir (all doses) was significantly more effective than placebo in reducing time to healing, time to cessation of viral shedding, and durations of lesion edema, vesicles, ulcers, and crusts. Times to cessation of all symptoms and of moderate to severe lesion tenderness, pain, and burning were also reduced. Patients who initiated famciclovir prior to viral shedding were more likely to not shed virus throughout. All doses were equally effective, safe, and well tolerated. Conclusions.-Oral famciclovir reduced the onset and duration of viral shedding, lesion persistence, and uncomfortable symptoms. Several individual symptoms and lesion stages were also reduced in duration by this episodic therapy. Additionally, our twice-daily observation trial design proved to be a helpful tool for studying recurrent disease. Episodic oral famciclovir provides a convenient and effective alternative for those patients with recurrent genital herpes whose frequency rates do not require continuous antiviral suppression.	UNIV BRITISH COLUMBIA,VANCOUVER HOSP & HLTH SCI CTR,DIV INFECT DIS,VANCOUVER,BC V5Z 1M9,CANADA; UNIV MANITOBA,WINNIPEG,MB,CANADA; HLTH SCI CTR HOSP,WINNIPEG,MB,CANADA; CHILDRENS HOSP EASTERN ONTARIO,OTTAWA,ON K1H 8L1,CANADA; MCMASTER UNIV,DEPT FAMILY MED,HAMILTON,ON L8S 4L8,CANADA; UNIV ALBERTA,DEPT MED,DIV INFECT DIS,EDMONTON,AB,CANADA	University of British Columbia; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Ottawa; Children's Hospital of Eastern Ontario; McMaster University; University of Alberta			Diaz-Mitoma, Francisco/AAA-2522-2019	Diaz-Mitoma, Francisco/0000-0003-0292-4859				BOYD MR, 1993, ANTIVIR CHEM CHEMOTH, V4, P3, DOI 10.1177/095632029300401S01; CHRISTENSON B, 1992, J INFECTION, V25, P147, DOI 10.1016/0163-4453(92)93943-K; COREY L, 1995, CLINICAL MANAGEMENT OF HERPES VIRUSES, P43; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM AL, 1993, MED J AUSTRALIA, V158, P525, DOI 10.5694/j.1326-5377.1993.tb121867.x; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; GOLD D, 1987, ANTIMICROB AGENTS CH, V31, P361, DOI 10.1128/AAC.31.3.361; GOLDBERG LH, 1993, ARCH DERMATOL, V129, P582, DOI 10.1001/archderm.129.5.582; HALSOS AM, 1985, ACTA DERM-VENEREOL, V65, P59; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; HODGE RAV, 1993, ANTIVIR CHEM CHEMOTH, V4, P67, DOI 10.1177/095632029300400201; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P223, DOI 10.1128/AAC.33.2.223; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MINDEL A, 1984, LANCET, V2, P57; NILSEN AE, 1982, LANCET, V2, P571; PUE MA, 1993, ANTIVIR CHEM CHEMOTH, V4, P47, DOI 10.1177/09563202930040S602; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; RUHNEKFORSBECK M, 1985, J ANTIMICROB CHEMOTH, V16, P621, DOI 10.1093/jac/16.5.621; SACKS SL, 1983, J VIROL METHODS, V7, P199, DOI 10.1016/0166-0934(83)90009-5; SACKS SL, 1990, J INFECT DIS, V161, P692, DOI 10.1093/infdis/161.4.692; SACKS SL, 1987, CAN MED ASSOC J, V136, P701; SACKS SL, 1988, SEX TRANSM DIS, V15, P58, DOI 10.1097/00007435-198801000-00013; SACKS SL, 1991, J INFECT DIS, V164, P665, DOI 10.1093/infdis/164.4.665; SACKS SL, 1995, CLINICAL MANAGEMENT OF HERPES VIRUSES, P55; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; STRAUS SE, 1986, ANTIVIR RES, V6, P151, DOI 10.1016/0166-3542(86)90009-4; [No title captured]; [No title captured]; [No title captured]; [No title captured]	31	129	136	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					44	49		10.1001/jama.276.1.44	http://dx.doi.org/10.1001/jama.276.1.44			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667538				2023-01-03	WOS:A1996UU43900026
J	Safrin, S; Finkelstein, DM; Feinberg, JD; Frame, P; Simpson, G; Wu, A; Cheung, T; Soeiro, R; Hojczyk, P; Black, JR				Safrin, S; Finkelstein, DM; Feinberg, JD; Frame, P; Simpson, G; Wu, A; Cheung, T; Soeiro, R; Hojczyk, P; Black, JR			Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS - A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine	ANNALS OF INTERNAL MEDICINE			English	Article						pneumonia, Pneumocystis carinii; trimethoprim-sulfamethoxazole combination; dapsone; clindamycin; primaquine	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PENTAMIDINE; THERAPY; QUESTIONNAIRE	Objective: To compare the tolerability and efficacy of three oral regimens for the treatment of patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia. Design: A randomized, double-blind study. Setting: 24 U.S. academic medical centers. Patients: 181 patients with morphologically confirmed P. carinii pneumonia and alveolar-arterial oxygen differences (PAO(2)-PaO2) of 45 mm Hg or less. Intervention: Patients were randomly assigned to receive trimethoprim-sulfamethoxazole, dapsone-trimethoprim, or clindamycin-primaquine for 21 days. Patients with a PaO2-PaO2 of 35 to 45 mm Hg at study entry also received prednisone. Measurements: Serial clinical and laboratory evaluations for therapeutic response and toxicity. Therapeutic failure at day 21 was defined by any of the following: increase in PAO(2)-PaO2 of greater than 20 mm Hg; no remission of baseline signs and symptoms; and change in antipneumocystis therapy for reasons other than toxicity, intubation, or death. Dose-limiting toxicity was defined as discontinuation of therapy by the primary physician because of one or more adverse reactions. Results: No statistically significant differences were seen among treatment groups in the proportions of patients who had dose-limiting toxicity (P = 0.2), therapeutic failure (P > 0.2), or a complete course of therapy (P > 0.2). Survival during therapy or for 2 months thereafter did not differ among the three groups (P > 0.2). However, elevation of serum aminotransferase levels to more than five times the baseline levels was more frequent in the trimethoprim-sulfamethoxazole group (P = 0.003), and one or more serious hematologic toxicities (neutropenia, anemia, thrombocytopenia, or methemoglobinemia) occurred more frequently in the clindamycin-primaquine group (P = 0.01). Conclusions: The rates of dose-limiting toxicity, therapeutic failure, and survival did not differ among patients with AIDS who were receiving oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, or clindamycin-primaquine for mild to moderate P. carinii pneumonia. However, the limited sample size prevents the unequivocal demonstration of the equality of these three regimens. Differences in expected categories of toxicities associated with each regimen should guide the clinician in choosing first-line therapy, particularly for patients with baseline hepatic insufficiency or myelosuppression.	HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02111 USA; UNIV CINCINNATI, HOLMES HOSP, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA; MT SINAI MED CTR, BALTIMORE, MD 21205 USA; ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; METHODIST HOSP INDIANA, INDIANAPOLIS, IN 46202 USA; FRONTIER SCI TECHNOL & RES FDN, AMHERST, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Indiana University System; Frontier Science Foundation					AHRQ HHS [HS07824] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLACK JR, 1994, CLIN INFECT DIS, V18, P905, DOI 10.1093/clinids/18.6.905; BOWDEN FJ, 1986, LANCET, V1, P853; GARAY SM, 1989, CHEST, V95, P769, DOI 10.1378/chest.95.4.769; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; KAY R, 1990, SOUTHERN MED J, V83, P403, DOI 10.1097/00007611-199004000-00010; KLEIN NC, 1992, AIDS, V6, P301, DOI 10.1097/00002030-199203000-00007; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; *NAT CTR INF DIS, 1994, HIV AIDS SURV REP, P1; QUEENER SF, 1988, ANTIMICROB AGENTS CH, V32, P807, DOI 10.1128/AAC.32.6.807; RIES PW, 1986, NATL HLTH SURVEY SER, V10; RUBIN HR, 1992, 8 INT C AIDS 3 STD W; RUF B, 1991, EUR J CLIN MICROBIOL, V10, P207, DOI 10.1007/BF01964466; SAFRIN S, 1994, J INFECT DIS, V170, P912, DOI 10.1093/infdis/170.4.912; SAFRIN S, 1994, PNEUMOCYSTIS CARINII, P2270; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SATTLER FR, 1994, J INFECT DIS, V170, P165, DOI 10.1093/infdis/170.1.165; STEVENS RC, 1991, ANTIMICROB AGENTS CH, V35, P1884, DOI 10.1128/AAC.35.9.1884; Stewart A. L., 1992, MEASURING FUNCTIONIN; TOMA E, 1991, EUR J CLIN MICROBIOL, V10, P210, DOI 10.1007/BF01964467; TOMA E, 1993, CLIN INFECT DIS, V17, P178, DOI 10.1093/clinids/17.2.178; TOMA E, 1989, LANCET, V1, P1046, DOI 10.1016/S0140-6736(89)92446-X; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011	28	131	137	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					792	+		10.7326/0003-4819-124-9-199605010-00003	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610948				2023-01-03	WOS:A1996UG25400003
J	Landi, G				Landi, G			No to DNR orders in acute stroke	LANCET			English	Editorial Material											Landi, G (corresponding author), OSPED MAGGIORE POLICLIN,MILAN,ITALY.							Alexandrov AV, 1996, STROKE, V27, P232, DOI 10.1161/01.STR.27.2.232; BURTIN P, 1994, INTENS CARE MED, V20, P32, DOI 10.1007/BF02425052; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					848	848		10.1016/S0140-6736(96)91342-2	http://dx.doi.org/10.1016/S0140-6736(96)91342-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622388				2023-01-03	WOS:A1996UC45000006
J	Krack, P; Limousin, P; Benabid, AL; Pollak, P				Krack, P; Limousin, P; Benabid, AL; Pollak, P			Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease	LANCET			English	Letter							GPI PALLIDOTOMY		CHRISTIAN ALBRECHTS UNIV KIEL,DEPT NEUROL,D-24105 KIEL,GERMANY	University of Kiel	Krack, P (corresponding author), UNIV GRENOBLE,DEPT CLIN & BIOL NEUROSCI,GRENOBLE 9,FRANCE.		Benabid, Alim L/Q-3506-2017	Krack, Paul/0000-0002-3508-7295				Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Krack P, 1997, ANN NEUROL, V42, P129, DOI 10.1002/ana.410420122; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; SHANNON KM, 1990, CLIN NEUROPHARMACOL, V13, P413, DOI 10.1097/00002826-199010000-00003	5	139	140	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1676	1676		10.1016/S0140-6736(05)64273-0	http://dx.doi.org/10.1016/S0140-6736(05)64273-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400515				2023-01-03	WOS:A1997YK21100015
J	Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM				Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM			Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							OPERATIONAL ASSESSMENT; ALGORITHM		ERASMUS UNIV ROTTERDAM,INST EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Mannesse, CK (corresponding author), UNIV HOSP ROTTERDAM DIJKZIGT,DEPT INTERNAL MED 1,DIV GERIATR MED,ROOM D442,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							*BRIT MED ASS ROYA, 1994, BRIT NAT FORM; Egberts TCG, 1996, BRIT MED J, V313, P530; HUTCHINSON TA, 1979, JAMA-J AM MED ASSOC, V242, P633, DOI 10.1001/jama.242.7.633; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; VANKRAAIJ DJW, 1994, NETH J MED, V44, P166	5	67	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1057	1058		10.1136/bmj.315.7115.1057	http://dx.doi.org/10.1136/bmj.315.7115.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366733	Green Published			2023-01-03	WOS:A1997YD44500023
J	Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J				Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J			Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		outcome and process assessment (health care); dialysis; cost-benefit analysis; kidney failure, acute; decision making	ACUTE-RENAL-FAILURE; CONVENIENT APPROXIMATION; REQUIRING DIALYSIS; LIFE EXPECTANCY; RISK-FACTORS; APACHE-II; SURVIVAL; SYSTEM; PROGNOSIS; SUPPORT	Background: Renal failure requiring dialysis in the setting of hospitalization for serious illness is a poor prognostic sign, and dialysis and aggressive care are sometimes withheld. Objective: To evaluate the clinical outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care for seriously ill hospitalized patients. Design: Prospective cohort study and cost-effectiveness analysis. Setting: Five geographically diverse teaching hospitals. Patients: 490 patients (median age, 61 years; 58% women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) in whom dialysis was initiated. Measurements: Survival, functional status, quality of life, and health care costs. Life expectancy was estimated by extrapolating survival data (up to 4.4 years of followup) using a declining exponential function. Utilities (quality-of-life weights) were estimated by using time-tradeoff questions. Costs were based on data from SUPPORT and published Medicare data. Results: Median duration of survival was 32 days, and only 27% of patients were alive after 6 months. Survivors reported a median of one dependency in activities of daily living, and 62% rated their quality of life as ''good'' or better. Overall, the estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128 200. For the 103 patients in the worst prognostic category, the estimated cost per quality-adjusted life-year was $274 100; for the 94 patients in the best prognostic category, the cost per quality-adjusted life-year was $61 900. Conclusions: For the few patients who survived, clinical outcomes were fairly good. With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating dialysis and continuing aggressive care far exceeded $50 000 per quality-adjusted life-year, a commonly cited threshold for cost-effective care.	UNIV TENNESSEE, CHATTANOOGA UNIV, CHATTANOOGA, TN 37403 USA; UNIV VIRGINIA, SCH MED, DEPT HLTH EVALUAT SCI, CHARLOTTESVILLE, VA 22908 USA; JOHNS HOPKINS UNIV, HLTH SERV RES CTR, BALTIMORE, MD 21205 USA; DUKE UNIV, SCH MED, DURHAM, NC 27710 USA; UNIV CINCINNATI, MED CTR, SECT OUTCOMES RES, CINCINNATI, OH 45267 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; DUKE UNIV, MED CTR, SCH MED, DURHAM, NC 27710 USA	University of Tennessee System; University of Tennessee at Chattanooga; University of Virginia; Johns Hopkins University; Duke University; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University	Hamel, MB (corresponding author), BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, LY-330, BOSTON, MA 02215 USA.		Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; GOLDMAN L, 1992, HEART DIS TXB CARDIO; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LOHR JW, 1988, AM J KIDNEY DIS, V11, P254, DOI 10.1016/S0272-6386(88)80158-6; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MAHER ER, 1989, Q J MED, V72, P857; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPURNEY RF, 1991, CRIT CARE MED, V19, P8, DOI 10.1097/00003246-199101000-00007; Torrance G W, 1972, Health Serv Res, V7, P118; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHEELER DC, 1986, Q J MED, V61, P977	29	165	166	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					195	+		10.7326/0003-4819-127-3-199708010-00003	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XN129	9245224				2023-01-03	WOS:A1997XN12900003
J	Edmonson, MB; Stoddard, JJ; Owens, LM				Edmonson, MB; Stoddard, JJ; Owens, LM			Hospital readmission with feeding-related problems after early postpartum discharge of normal newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM NEWBORN	Context.-Increasingly short postpartum hospital stays in the United States precipitated a policy debate that culminated in passage of the Newborns' and Mothers' Health Protection Act of 1996. The debate occurred without population-based evidence for adverse health effects in newborns who are discharged early. Objective.-To determine whether early postpartum hospital discharge of normal newborns increases their risk for hospital readmission with feeding-related problems. Design and Setting.-Nested case-control analysis of 1991 to 1994 Wisconsin birth certificate and hospital discharge data. Subjects.-A total of 210 readmitted case patients and 630 control subjects selected from a cohort of 120 290 normal newborns who weighed at least 2500 g, were delivered vaginally of mothers with uncomplicated medical and obstetrical histories, and were discharged from the hospital either early (day of life 1 or 2) or conventionally (day 3). Outcome Measure.-Readmission at age 4 to 28 days with discharge diagnoses indicating a primary feeding problem, secondary dehydration, or inadequate weight gain. Results.-Early discharges increased 3-fold (reaching 521/1000 discharges) during the study period, but feeding-related readmissions (1.7/1000) remained stable. Most readmitted newborns (53.8%) were 4 to 7 days old, many (34.3%) had concurrent dehydration and jaundice, and 29% were admitted through emergency departments. Readmitted newborns were significantly (P<.05) more likely to have been breast-fed, firstborn, or preterm or to have mothers who were poorly educated (<12th grade), unmarried, or receiving Medicaid. Readmission was not associated with early discharge (adjusted odds ratio, 1.05; 95% confidence interval, 0.71-1.53), Conclusion.-Although several neonatal and maternal factors increase the risk that a normal newborn will be rehospitalized with a feeding-related problem, early discharge following an uncomplicated postpartum hospital stay appears to have little or no independent effect on this risk.	UNIV WISCONSIN,CTR HLTH SCI,DEPT PREVENT MED,MADISON,WI 53792; WISCONSIN DEPT HLTH & SOCIAL SERV,CTR HLTH STAT,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison	Edmonson, MB (corresponding author), UNIV WISCONSIN,CTR HLTH SCI,DEPT PEDIAT,H6-440 CLIN SCI CTR,600 HIGHLAND AVE,MADISON,WI 53792, USA.							*AM AC PED COMM FE, 1995, PEDIATRICS, V96, P788; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; Center for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P335; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P700; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; Kini N, 1995, Wis Med J, V94, P143; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Margolis LH, 1995, CLIN PEDIATR, V34, P626, DOI 10.1177/000992289503401201; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; NEWMAN TB, 1992, PEDIATRICS, V89, P809; *OFF HLTH CAR INF, 1995, HLTH CAR DAT ANN REP; PARISI V, 1996, NEW ENGL J MED, V333, P1635; POSES RM, 1995, MED CARE, V33, pAS36; Public Health Service, 1988, INT CLASS DIS; *SAS I INC, 1990, SAS TECHN REP P 200, P175; SELBY JV, 1994, EPIDEMIOL REV, V16, P90, DOI 10.1093/oxfordjournals.epirev.a036148; Soskolne EI, 1996, ARCH PEDIAT ADOL MED, V150, P373, DOI 10.1001/archpedi.1996.02170290039006; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; *WI ASS PER CAR, 1993, INT C REP EARL DISCH, P1	22	93	98	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					299	303		10.1001/jama.278.4.299	http://dx.doi.org/10.1001/jama.278.4.299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228435				2023-01-03	WOS:A1997XL05900030
J	Edwards, DA; Hanes, J; Caponetti, G; Hrkach, J; BenJebria, A; Eskew, ML; Mintzes, J; Deaver, D; Lotan, N; Langer, R				Edwards, DA; Hanes, J; Caponetti, G; Hrkach, J; BenJebria, A; Eskew, ML; Mintzes, J; Deaver, D; Lotan, N; Langer, R			Large porous particles for pulmonary drug delivery	SCIENCE			English	Article							LEUPROLIDE ACETATE; SIZE; PHAGOCYTOSIS; AEROSOL; BIOAVAILABILITY; INTRATRACHEAL; MICROSPHERES; DEPOSITION; PROTEINS; PEPTIDE	A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; UNIV PARMA,DEPT PHARM,I-43100 PARMA,ITALY; PENN STATE UNIV,FENSKE LAB,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT ANIM SCI,UNIVERSITY PK,PA 16802; TECHNION ISRAEL INST TECHNOL,DEPT BIOMED ENGN,IL-32000 HAIFA,ISRAEL	Massachusetts Institute of Technology (MIT); University of Parma; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Technion Israel Institute of Technology	Edwards, DA (corresponding author), PENN STATE UNIV,DEPT CHEM ENGN,204 FENSKE LAB,UNIVERSITY PK,PA 16802, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026698] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29125] Funding Source: Medline; NIGMS NIH HHS [GM26698] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADJEI A, 1990, PHARMACEUT RES, V7, P565, DOI 10.1023/A:1015853824722; ADJEI A, 1994, INT J PHARM, V107, P57, DOI 10.1016/0378-5173(94)90302-6; BRAIN JD, 1985, RETICULOENDOTHELIAL, P315; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4; Einarsson O, 1995, ANN NY ACAD SCI, V762, P89; French DL, 1996, J AEROSOL SCI, V27, P769, DOI 10.1016/0021-8502(96)00021-3; Ganderton, 1992, GENERATION RESPIRABL; Gennaro, 2003, REMINGTON SCI PRACTI; GONDA I, 1992, TOPICS IN PHARMACEUTICAL SCIENCES 1991, P95; GONDA I, 1990, CRIT REV THER DRUG, V6, P4273; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; HRKACH JS, 1995, MACROMOLECULES, V28, P4736, DOI 10.1021/ma00117a055; Jeyanthi R, 1996, J CONTROL RELEASE, V38, P235, DOI 10.1016/0168-3659(95)00125-5; KAWAGUCHI H, 1986, BIOMATERIALS, V7, P61, DOI 10.1016/0142-9612(86)90091-8; KOMADA F, 1994, J PHARM SCI, V83, P863, DOI 10.1002/jps.2600830621; KRENIS LJ, 1961, P SOC EXP BIOL MED, V107, P748; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LECORRE P, 1994, INT J PHARM, V107, P41, DOI 10.1016/0378-5173(94)90300-X; Li WI, 1996, J AEROSOL SCI, V27, P1269, DOI 10.1016/0021-8502(96)00046-8; LIU FY, 1993, PHARMACEUT RES, V10, P228, DOI 10.1023/A:1018934810512; NIVEN RW, 1995, CRIT REV THER DRUG, V12, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20; PATTON JS, 1992, ADV DRUG DELIVER REV, V8, P179, DOI 10.1016/0169-409X(92)90002-8; PAVIA D, 1984, AEROSOLS LUNG CLIN E, P200; RUDT S, 1992, J CONTROL RELEASE, V22, P263, DOI 10.1016/0168-3659(92)90101-V; Sacchetti M., 1996, INHALATION AEROSOLS, P337; SMITH SJ, 1996, INHALATION AEROSOLS, P233; TOM JW, 1991, J AEROSOL SCI, V22, P555, DOI 10.1016/0021-8502(91)90013-8; VIDGREN MT, 1987, INT J PHARM, V35, P139, DOI 10.1016/0378-5173(87)90082-2; WARHEIT DB, 1993, MICROSC RES TECHNIQ, V26, P412, DOI 10.1002/jemt.1070260509	31	934	1023	8	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1868	1871		10.1126/science.276.5320.1868	http://dx.doi.org/10.1126/science.276.5320.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188534				2023-01-03	WOS:A1997XF10300051
J	Krumholz, HM; Murillo, JE; Chen, J; Vaccarino, V; Radford, MJ; Ellerbeck, EF; Wang, Y				Krumholz, HM; Murillo, JE; Chen, J; Vaccarino, V; Radford, MJ; Ellerbeck, EF; Wang, Y			Thrombolytic therapy for eligible elderly patients with acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORCESTER-HEART-ATTACK; AGE; MORTALITY	Objective.-To determine the correlates of thrombolytic therapy use in a population-based sample of elderly patients hospitalized with acute myocardial infarction who were eligible for the therapy on presentation. Design.-Retrospective cohort study using data from medical charts and administrative files. Setting.-All acute care, nongovernmental hospitals in Connecticut. Patients.-A cohort of 3093 patients aged 65 years and older with a discharge diagnosis of acute myocardial infarction covered by Medicare from May 1992 to May 1993. Results.-Among the 753 patients with ST-segment elevation of 1 mm or more in at least 2 contiguous leads, left bundle branch block not known to be old, and no absolute contraindications to thrombolytic therapy who were not referred for direct angioplasty or bypass surgery, 419 patients (56%) did not receive thrombolytic therapy. The strongest predictors of not receiving thrombolytic therapy included advanced age, absence of chest pain, presentation more than 6 hours after the onset of symptoms, left bundle branch block, total ST-segment elevation of 6 mm or less, presence of Q waves, ST-segment elevation in only 2 leads, and altered mental status. Physicians documented why they did not administer thrombolytic therapy in 19% of the charts, Delay in presentation and increased age were the most common reasons cited, Among the subset of 261 patients who presented with chest pain and within 6 hours of symptoms, 197 (75%) received thrombolytic therapy. Conclusions.-Many eligible and ideal patients for thrombolytic therapy are not treated. Physicians are less likely to use thrombolytic therapy in eligible patients with characteristics associated with an increased risk of bleeding, lower-risk infarction, less certain diagnosis, less certain efficacy, or altered mental status, These findings suggest that the lack of treatment represents a clinical judgment rather than an inadvertent omission. in some cases, such as the lower use of thrombolytic therapy with older age, these judgments are not consistent with the published literature and may represent opportunities to improve care.	YALE UNIV, SCH MED, DEPT MED, SECT CARDIOVASC MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, SECT CHRON DIS EPIDEMIOL, NEW HAVEN, CT 06520 USA; YALE NEW HAVEN MED CTR, CTR OUTCOMES RES & EVALUAT, NEW HAVEN, CT 06504 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT USA; UNIV CONNECTICUT, SCH MED, DEPT MED, DIV CARDIOL, FARMINGTON, CT USA; HLTH CARE FINANCING ADM, KANSAS CITY, MO USA	Yale University; Yale University; Yale University; University of Connecticut			Ellerbeck, Edward/I-8438-2014; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Radford, Martha/0000-0001-7503-9557				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Arnold AER, 1995, EUR HEART J, V16, P1502, DOI 10.1093/oxfordjournals.eurheartj.a060770; BAYER AJ, 1986, J AM GERIATR SOC, V34, P263, DOI 10.1111/j.1532-5415.1986.tb04221.x; COX DA, 1994, AM J CARDIOL, V73, P729, DOI 10.1016/0002-9149(94)90872-9; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; *GRP IT STUD STREP, 1986, LANCET, V1, P397; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; Gurwitz Jerry H., 1994, Archives of Internal Medicine, V154, P2202, DOI 10.1001/archinte.154.19.2202; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; *ISIS I COLL GROUP, 1988, LANCET, V2, P849; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; *US DEP HHS, 1988, INT CLASS DIS 9 REV; Vorchheimer David A., 1996, Journal of the American College of Cardiology, V27, p389A; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7	23	144	147	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1683	1688		10.1001/jama.277.21.1683	http://dx.doi.org/10.1001/jama.277.21.1683			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169894				2023-01-03	WOS:A1997XB08800028
J	McQuay, H; Moore, A; Justins, D				McQuay, H; Moore, A; Justins, D			Fortnightly review: Treating acute pain in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT; ANALGESIA		ST THOMAS HOSP, DEPT ANAESTHESIA, LONDON SE1 7EH, ENGLAND; CHURCHILL HOSP, PAIN RELIEF UNIT, OXFORD OX3 7LJ, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of Oxford								ATTARD AR, 1992, BRIT MED J, V305, P554, DOI 10.1136/bmj.305.6853.554; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRIDENBAUGH PO, 1988, NEURAL BLOCKADE CLIN, P695; BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; *BURF NURS DEV UN, 1984, NURS TIMES, V18, P94; Carroll D, 1997, BRIT J OBSTET GYNAEC, V104, P169, DOI 10.1111/j.1471-0528.1997.tb11039.x; Carroll D, 1996, BRIT J ANAESTH, V77, P798, DOI 10.1093/bja/77.6.798; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; JUSTINS DM, 1991, BRIT MED BULL, V47, P561, DOI 10.1093/oxfordjournals.bmb.a072493; KANE RE, 1981, ANESTH ANALG, V60, P150; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; MCGRATH PJ, 1993, PIAN MANAGEMENT NURS, P100; MCQUAY HJ, 1988, PAIN, V33, P291, DOI 10.1016/0304-3959(88)90287-4; MCQUAY HJ, 1995, ANN MED, V27, P249, DOI 10.3109/07853899509031967; MCQUAY HJ, 1994, TXB PAIN, P1025; Moore A, 1996, PAIN, V66, P229, DOI 10.1016/0304-3959(96)03032-1; MOORE A, IN PRESS PAIN; Moore RA, 1997, PAIN, V69, P287, DOI 10.1016/S0304-3959(96)03291-5; NAGLE C, 1990, CURR ANAESTH CRIT CA, V1, P247; PORTER J, 1980, NEW ENGL J MED, V302, P123; RAWAL N, 1994, PAIN, V57, P117, DOI 10.1016/0304-3959(94)90115-5; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; WATTS RW, 1995, ANAESTH INTENS CARE, V23, P564, DOI 10.1177/0310057X9502300506; *WORK PART PAIN SU, 1990, REP	31	82	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1531	1535		10.1136/bmj.314.7093.1531	http://dx.doi.org/10.1136/bmj.314.7093.1531			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183203	Green Published			2023-01-03	WOS:A1997XB48400030
J	Wilkinson, D; Sach, ME; Karim, SSA				Wilkinson, D; Sach, ME; Karim, SSA			Examination of attendance patterns before and after introduction of South Africa's policy of free health care for children aged under 6 years and pregnant women	BRITISH MEDICAL JOURNAL			English	Article									HLABISA HOSP,HLABISA,SOUTH AFRICA		Wilkinson, D (corresponding author), MRC,CTR EPIDEMIOL RES SO AFRICA,POB 658,ZA-3937 HLABISA,SOUTH AFRICA.		Karim, Salim Abdool/P-3117-2019; Karim, Salim Abdool/AAE-7118-2019; Wilkinson, David/A-6207-2008; Karim, Salim Safurdeen Abdool/N-5947-2013	Karim, Salim Abdool/0000-0002-4986-2133; Wilkinson, David/0000-0002-7265-9846; Karim, Salim Safurdeen Abdool/0000-0002-4986-2133				GILSON L, 1993, LANCET, V342, P800, DOI 10.1016/0140-6736(93)91560-9; WILKINSON D, IN PRESS S AFR MED	2	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					940	941		10.1136/bmj.314.7085.940	http://dx.doi.org/10.1136/bmj.314.7085.940			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099118	Green Published			2023-01-03	WOS:A1997WQ16900026
J	deKlerk, GJ; Nieuwenhuis, G; Beutler, JJ				deKlerk, GJ; Nieuwenhuis, G; Beutler, JJ			Lesson of the week - Hypokalaemia and hypertension associated with use of liquorice flavoured chewing pum	BRITISH MEDICAL JOURNAL			English	Article							LICORICE	Prolonged ingestion of substances containing glycyrrhizinic acid such as liquorice, is a well known cause of exogenously induced hypermineralocorticoidism. This is characterised by sodium retention, hypokalaemia, hypertension, metabolic alkalosis, and suppression of the renin-aldosterone system.(1) We describe two cases showing that hypokalaemia induced by glycyrrhizinic acid should be considered in patients with hypertension or oedema even if they have not eaten sweets that obviously contain liquorice.	UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,NL-3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center			de Klerk, Geert-Jan/AAL-4416-2021					BERNARDI M, 1994, LIFE SCI, V55, P863, DOI 10.1016/0024-3205(94)90042-6; BIJISMA JA, 1995, 348801005 U HOSP UTR; BLANCHLEY JD, 1980, NEW ENGL J MED, V302, P784; CLYBURN EB, 1995, SEMIN NEPHROL, V15, P72; FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; HERMESSE B, 1986, Archives Belges de Medecine Sociale Hygiene Medecine du Travail et Medecine Legale, V44, P60; MICHAUX L, 1993, REV MED INTERNE, V14, P121, DOI 10.1016/S0248-8663(05)81264-0; MOLHUYSEN JA, 1950, LANCET, V2, P381; ROSSEEL M, 1993, LANCET, V341, P175, DOI 10.1016/0140-6736(93)90036-G; SPINKS EA, 1990, FOOD ADDIT CONTAM A, V7, P769, DOI 10.1080/02652039009373939; STEWART PM, 1987, LANCET, V2, P821	12	67	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					731	732		10.1136/bmj.314.7082.731	http://dx.doi.org/10.1136/bmj.314.7082.731			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116553	Green Published			2023-01-03	WOS:A1997WM77600030
J	Kessler, RC; Frank, RG; Edlund, M; Katz, SJ; Lin, E; Leaf, P				Kessler, RC; Frank, RG; Edlund, M; Katz, SJ; Lin, E; Leaf, P			Differences in the use of psychiatric outpatient services between the United States and Ontario	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENTAL-HEALTH SERVICES; DISORDERS; CANADA; SYSTEM; CARE	Background The relation between health insurance and the use of mental health services is unclear. We compared the use of outpatient services for psychiatric problems in the United States and Ontario, Canada, among young and middle-aged adults according to self-reports of disorders listed in the Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) and to other indicators of need. Methods We analyzed two general-population surveys carried out separately in the United States and Ontario in 1990 that used identical assessments of need for services and questions about their use by persons 15 to 54 years of age. Results Respondents in the United States were significantly more likely than those in Ontario to report having had psychiatric disorders, poor mental health, or workdays lost or cut short because of psychiatric problems in the previous year. A significantly higher proportion of respondents in the United States (13.3 percent) than in Ontario (8.0 percent) had obtained outpatient treatment in the previous 12 months for psychiatric problems. However, an analysis of subgroups found that the higher probability of the use of services in the United States was confined to people with less severe mental illness. The average number of visits did not differ significantly between the two countries among patients who had similar numbers of psychiatric disorders over the same time periods. There was a stronger match in Ontario than in the United States between the use of services and the measures of perceived need we considered. Conclusions Although the mental health care system tem in the United States provides treatment to a larger proportion of the population than that in Ontario, the match between some measures of need and treatment is not as strong in the United States. Any plans to expand coverage for psychiatric disorders in the United States must address this problem. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI; UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON,CANADA; CLARKE INST PSYCHIAT,HLTH SYST RES UNIT,TORONTO,ON M5T 1R8,CANADA; JOHNS HOPKINS UNIV,DEPT MENTAL HLTH,BALTIMORE,MD	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Johns Hopkins University	Kessler, RC (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FL,BOSTON,MA 02115, USA.		KATZ, STEVEN/ABH-8886-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049098, R01MH052861] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46379, MH52861, MH49098] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*ALC DRUG RES FDN, 1994, INT PROF 1994 ALC OT; BARER ML, 1992, HEALTH AFFAIR, V11, P44, DOI 10.1377/hlthaff.11.1.44; BIGELOW DA, 1989, HOSP COMMUNITY PSYCH, V40, P805; Cannell C.F., 1981, SOCIOL METHODOL, V12, P389, DOI DOI 10.2307/270748; CANNELL CF, 1977, VITAL HLTH STATIST 2, V2; *CLARK I CONS GRP, 1994, EST UT INP BEDS REF; EVANS RG, 1992, J HEALTH POLIT POLIC, V17, P739, DOI 10.1215/03616878-17-4-739; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; FRANK RG, 1986, HEALTH SERV RES, V21, P241; FRANK RG, 1994, DHHS PUBLICATION, P8; FREEMAN SJJ, 1994, MENTAL HLTH CARE CAN, P11; FUCHS VR, 1992, JAMA-J AM MED ASSOC, V268, P916, DOI 10.1001/jama.268.7.916; GEORGE LK, 1985, HLTH SERVICES VALIDA; *HLTH WELF CAN, 1990, HLTH PERS CAN 1990; HOLLINGSWORTH EJ, 1992, J HEALTH POLIT POLIC, V17, P899, DOI 10.1215/03616878-17-4-899; JAHIEL RI, 1992, HOMELESSNESS PREVENT, P337; KATZ A, 1989, TALE 2 SYSTEMS COMP; KESSLER RC, 1995, EPIDEMIOL REV, V17, P192, DOI 10.1093/oxfordjournals.epirev.a036176; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KISH L, 1970, J AM STAT ASSOC, V65, P1071, DOI 10.2307/2284276; MACNAUGHTON E, 1991, COMMUNITY INVESTMENT, V2; Offord DR, 1994, MENTAL HLTH ONTARIO; Ontario Ministry of Health, 1993, PUTT PEOPL 1 REF MEN; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; ROBACK G, 1992, PHYSICIAN CHARACTERI; ROBINS LN, 1991, PSYCHIATRIC DISORDER; ROCHEFORT DA, 1992, HOSP COMMUNITY PSYCH, V43, P1083; ROOS LL, 1992, HEALTH AFFAIR, V11, P56, DOI 10.1377/hlthaff.11.2.56; *STAT CAN, 1994, SUIC RAT FIG 1950 19; *SUPPL SERV CAN, 1989, STAT CAN CAN YB 1990; *U MI I SOC RES, 1981, OSIRIS 7; US Census Bureau, 1994, STAT ABSTR US; WHO, 1990, COMP INT DIAGN INT C; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; WOODRUFF RS, 1976, J AM STAT ASSOC, V71, P315, DOI 10.2307/2285303; 1990, MENTAL HLTH SUBSTANC	36	158	159	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					551	557		10.1056/NEJM199702203360806	http://dx.doi.org/10.1056/NEJM199702203360806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WJ240	9023093	Green Published, Bronze			2023-01-03	WOS:A1997WJ24000006
J	Estrada, J; Boronat, M; Mielgo, M; Magallon, R; Millan, I; Diez, S; Lucas, T; Barcelo, B				Estrada, J; Boronat, M; Mielgo, M; Magallon, R; Millan, I; Diez, S; Lucas, T; Barcelo, B			The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; DIFFERENTIAL-DIAGNOSIS; ADENOMAS; MICROSURGERY; RADIOTHERAPY; THERAPY	Background Irradiation of the pituitary is widely considered the most appropriate treatment for patients with Cushing's disease in whom transsphenoidal microsurgery has been unsuccessful. However, there is little information about the long-term efficacy of this treatment. Methods We used external pituitary radiation to treat 30 adult patients with persistent or recurrent Cushing's disease after unsuccessful transsphenoidal surgery. The mean (+/-SD) dose of radiation was 50+/-1 Gy. Pituitary and adrenal function was assessed every six months after radiation therapy. Remission was defined as the regression of symptoms and signs of Cushing's syndrome, normal urinary cortisol excretion, and a low plasma cortisol concentration in the morning after the administration of 1 mg of dexamethasone at midnight. Results Twenty-five patients (83 percent) had remissions during a median follow-up of 42 months (range, 18 to 114). The remissions began 6 to 60 months after radiation therapy, but in most cases (22 patients) remission occurred during the first 2 years. None of the 25 patients had a relapse of Cushing's disease after remission was achieved. There was no relation between the response to radiotherapy and sex, age, urinary cortisol excretion before radiotherapy, the interval between surgery and radiotherapy, whether a pituitary adenoma was found by pathological examination, or tumor size. Seventeen patients had a deficiency of growth hormone after radiation therapy, 10 had a deficiency of gonadotropins, 4 had a deficiency of thyrotropin, and 1 had a deficiency of corticotropin. Conclusions Pituitary irradiation is an effective and well-tolerated treatment for patients with Cushing's disease in whom transsphenoidal surgery is unsuccessful. (C) 1997, Massachusetts Medical Society.	UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, DEPT RADIAT ONCOL, MADRID 28035, SPAIN; UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, DEPT BIOSTAT, MADRID 28035, SPAIN	Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Estrada, J (corresponding author), UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, SERV ENDOCRINOL, DEPT ENDOCRINOL, MADRID 28035, SPAIN.		Boronat, Mauro/I-2851-2017	Boronat, Mauro/0000-0001-8535-8543				BENEDETTI J, 1990, BMDP STATISTICAL SOF, V2, P739; BOCHICCHIO D, 1995, J CLIN ENDOCR METAB, V80, P3114, DOI 10.1210/jcem.80.11.7593411; BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x; BURCH WM, 1985, ARCH INTERN MED, V145, P1106, DOI 10.1001/archinte.145.6.1106; CARPENTER PC, 1988, ENDOCRIN METAB CLIN, V17, P445, DOI 10.1016/S0889-8529(18)30412-2; FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504; HOWLETT TA, 1989, CLIN ENDOCRINOL, V31, P309, DOI 10.1111/j.1365-2265.1989.tb01255.x; HUGHES MN, 1993, INT J RADIAT ONCOL, V27, P1035, DOI 10.1016/0360-3016(93)90520-6; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; LAMBERTS SWJ, 1995, J CLIN ENDOCR METAB, V80, P3111, DOI 10.1210/jc.80.11.3111; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LITTLEY MD, 1990, CLIN ENDOCRINOL, V33, P445, DOI 10.1111/j.1365-2265.1990.tb03883.x; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCCANCE DR, 1993, CLIN ENDOCRINOL, V38, P79, DOI 10.1111/j.1365-2265.1993.tb00976.x; MURAYAMA M, 1992, J CLIN ENDOCR METAB, V75, P935, DOI 10.1210/jc.75.3.935; NELSON JC, 1978, AM J MED SCI, V275, P165, DOI 10.1097/00000441-197803000-00006; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1992, NEW ENGL J MED, V326, P1172; ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; PIETERS GFFM, 1989, J CLIN ENDOCR METAB, V69, P1122, DOI 10.1210/jcem-69-6-1122; SCHTEINGART DE, 1980, ANN INTERN MED, V92, P613, DOI 10.7326/0003-4819-92-5-613; SHARPE GF, 1985, CLIN ENDOCRINOL, V22, P169, DOI 10.1111/j.1365-2265.1985.tb01078.x; TINDALL GT, 1990, J NEUROSURG, V72, P363, DOI 10.3171/jns.1990.72.3.0363; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x; TYRRELL JB, 1994, ENDOCRIN METAB CLIN, V23, P925, DOI 10.1016/S0889-8529(18)30075-6; TYRRELL JB, 1986, ANN INTERN MED, V104, P180, DOI 10.7326/0003-4819-104-2-180; VICENTE A, 1991, ACTA ENDOCRINOL-COP, V125, P470, DOI 10.1530/acta.0.1250470; YOUNG WF, 1988, MAYO CLIN PROC, V63, P256, DOI 10.1016/S0025-6196(12)65099-X	30	243	248	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					172	177		10.1056/NEJM199701163360303	http://dx.doi.org/10.1056/NEJM199701163360303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988897				2023-01-03	WOS:A1997WC26600003
J	Steele, A; Gowrishankar, M; Abrahamson, S; Mazer, CD; Feldman, RD; Halperin, ML				Steele, A; Gowrishankar, M; Abrahamson, S; Mazer, CD; Feldman, RD; Halperin, ML			Postoperative hyponatremia despite near-isotonic saline infusion: A phenomenon of desalination	ANNALS OF INTERNAL MEDICINE			English	Article							ANTI-DIURETIC HORMONE; PLASMA SODIUM CONCENTRATION; INAPPROPRIATE SECRETION; SURGERY; WOMEN	Background: It is widely presumed that the development of postoperative hyponatremia (which may be severe) results from administration of hypotonic fluids while antidiuretic hormone is acting. Objective: To show that hyponatremia would occur in patients 24 hours after surgery if only near-isotonic solutions are given and to evaluate the mechanisms responsible for hyponatremia in this setting. Design: Prospective cohort study. Setting: University medical center. Patients: 22 women who were having uncomplicated gynecologic surgery with infusion of near-isotonic solutions only (sodium chloride, 154 mmol/L, or Ringer lactate [sodium, 130 mmol/L, and potassium, 4 mmol/L]). Measurements: Plasma electrolyte levels were measured at the time of induction of anesthesia and 24 hours later. Data on the balance of water and electrolytes were obtained for the same 24-hour period. Results: At the time of induction of anesthesia, the plasma sodium concentration was 140 +/- 1 mmol/L; 24 hours later, it decreased in 21 of 22 patients (mean decrease, 4.2 +/- 0.4 mmol/L [P < 0.001]; lowest level, 131 mmol/L in 2 patients). The urine remained hypertonic (peak sodium plus potassium concentration in urine, 294 +/- 9 mmol/L) in all patients for the first 16 hours after induction of anesthesia. Conclusions: Postoperative hyponatremia occurred within 24 hours of induction of anesthesia when only near-isotonic fluids were infused. Hyponatremia was generally caused by generation of electrolyte-free water during excretion of hypertonic urine-a desalination process. This electrolyte-free water was retained in the body because of the actions of antidiuretic hormone. If the pathophysiology of this hyponatremic state is understood, recommendations for its prevention and treatment can be deduced.	UNIV TORONTO, ST MICHAELS HOSP, TORONTO, ON M5B 1A6, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto			Feldman, Ross/G-3293-2011	Mazer, Cyril David/0000-0003-2566-4308				ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; Ayus JC, 1996, NEUROLOGY, V46, P323, DOI 10.1212/WNL.46.2.323; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; COWLEY D M, 1988, Australian and New Zealand Journal of Surgery, V58, P485, DOI 10.1111/j.1445-2197.1988.tb06240.x; DECAUX G, 1980, AM J MED, V69, P99, DOI 10.1016/0002-9343(80)90506-9; DECAUX G, 1981, NEW ENGL J MED, V304, P329, DOI 10.1056/NEJM198102053040605; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; GOLDBERG M, 1981, MED CLIN N AM, V65, P251, DOI 10.1016/S0025-7125(16)31523-1; Gowrishankar M, 1996, KIDNEY INT, V50, P1490, DOI 10.1038/ki.1996.463; GOWRISHANKAR M, 1997, IN PRESS J AM SOC NE; GUY AJ, 1987, BRIT J SURG, V74, P1027, DOI 10.1002/bjs.1800741123; HALPERIN ML, 1985, AM J PHYSIOL, V248, pF607, DOI 10.1152/ajprenal.1985.248.4.F607; HALPERIN ML, 1986, AM J NEPHROL, V6, P241, DOI 10.1159/000167170; HANTMAN D, 1973, ANN INTERN MED, V78, P870, DOI 10.7326/0003-4819-78-6-870; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; IRVIN TT, 1972, LANCET, V2, P1159; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Oh MS, 1995, FLUID ELECTROLYTE AC, P1; Robertson Gary L., 1993, P99; ROSCOE JM, 1975, CAN MED ASSOC J, V112, P452; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; TINDALL SF, 1981, BRIT J SURG, V68, P639, DOI 10.1002/bjs.1800680911; WRIGHT HK, 1962, SURG GYNECOL OBSTET, V115, P553	26	182	192	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					20	25		10.7326/0003-4819-126-1-199701010-00003	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992919				2023-01-03	WOS:A1997WA16500003
J	Simini, B				Simini, B			Anaesthesia - Starved, sleepless, cold, and in pain	LANCET			English	Article																		Hirose M, 1996, ANESTH ANALG, V82, P1166, DOI 10.1097/00000539-199606000-00011; RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552, DOI 10.1093/bja/76.4.552; Russell GN, 1996, ANESTH ANALG, V83, P228, DOI 10.1097/00000539-199608000-00005; Sellden E, 1996, BRIT J ANAESTH, V76, P227, DOI 10.1093/bja/76.2.227; Tramer M, 1996, BRIT J ANAESTH, V76, P186, DOI 10.1093/bja/76.2.186	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII1	SII1						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973479				2023-01-03	WOS:A1996WA46300001
J	Laine, C; Davidoff, F; Lewis, CE; Nelson, EC; Nelson, E; Kessler, RC; Delbanco, TL				Laine, C; Davidoff, F; Lewis, CE; Nelson, EC; Nelson, E; Kessler, RC; Delbanco, TL			Important elements of outpatient care: A comparison of patients' and physicians' opinions	ANNALS OF INTERNAL MEDICINE			English	Article						quality of health care; ambulatory care; clinical competence; physician-patient relationships; patient education	MEDICAL-CARE; SATISFACTION; EMERGENCY	Objective: To compare patients' and physicians' opinions on the importance of discrete elements of health care as determinants of the quality of outpatient care. Design: Analysis of results of a mailed survey. Setting: Community-based internal medicine practices. Participants: 74 general internists and 814 patients randomly selected from the practices of these internists. Measures: 125 elements of care that covered nine domains were identified: physician clinical skill, physician interpersonal skill, support staff office environment, provision of information, patient involvement, nonfinancial access, finances, and coordination of care. Participants rated each element on its importance to high-quality care on a 4-point scale: 1 = not important; 2 = of medium importance; 3 = of high importance; and 4 = essential. Patients' and physicians' ratings were compared for individual elements of care and for elements aggregated into domains. Results: Survey response rates were 93% for physicians and 60% for patients. In an element-by-element comparison of ratings, ratings by the two groups differed substantially for 58% of the attributes. The most striking difference was seen in the domain of provision of information (median ratings, 3.56 for patients and 2.85 for physicians; P < 0.001). Ratings by the two groups also differed in the domains of clinical skill (3.75 for patients and 3.35 for physicians: P < 0.001), nonfinancial access (3.00 for patients and 2.87 for physicians; P < 0.001), and finances (3.00 for patients and 2.80 for physicians; P - 0.006). When relative rankings of the domains were compared, both groups agreed that clinical skill is most important; however, patients ranked provision of information second in importance whereas physicians ranked it sixth. Conclusions: Patients and physicians agreed that the most crucial element of outpatient care is clinical skill, but they disagreed about the relative importance of other aspects of care, particularly effective communication of health-related information. These differences in perception may influence the quality of interactions between physicians and patients.	AMER COLL PHYSICIANS, PHILADELPHIA, PA 19106 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, HLTH SCI CTR, DIV HLTH PROMOT & DIS PREVENT, LOS ANGELES, CA 90095 USA; DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH 03756 USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	American College of Physicians; University of California System; University of California Los Angeles; Dartmouth College; University of Michigan System; University of Michigan; Harvard University; Harvard Medical School	Laine, C (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, CTR RES MED EDUC & HLTH CARE, 1025 WALNUT ST, ROOM 119, PHILADELPHIA, PA 19107 USA.							Aharony L, 1993, Med Care Rev, V50, P49, DOI 10.1177/002570879305000104; Babbie E., 1989, PRACTICE SOCIAL RES; BAKER R, 1993, MEASUREMENT PATIENTS, P57; BURSCH B, 1993, ANN EMERG MED, V22, P586, DOI 10.1016/S0196-0644(05)81947-X; CARRHILL RA, 1992, J PUBLIC HEALTH MED, V14, P236; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; Donabedian A, 1992, Qual Health Care, V1, P247, DOI 10.1136/qshc.1.4.247; FLETCHER RH, 1983, MED CARE, V21, P234, DOI 10.1097/00005650-198302000-00010; GERTELS M, 1993, PATIENTS EYES; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; KAPLAN SH, 1989, PROVIDING QUALITY CA, P25; KRISHEL S, 1993, ANN EMERG MED, V22, P568, DOI 10.1016/S0196-0644(05)81943-2; Linder-Pelz S, 1985, J Community Health, V10, P42, DOI 10.1007/BF01321358; Robbins J A, 1993, Fam Med, V25, P17; STEIN MD, 1993, MED CARE, V31, P182, DOI 10.1097/00005650-199302000-00008; Strasser S, 1993, Med Care Rev, V50, P219, DOI 10.1177/107755879305000205; VONKORFF M, 1994, ANN INTERN MED, V121, P187, DOI 10.7326/0003-4819-121-3-199408010-00005; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006	19	203	206	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					640	+		10.7326/0003-4819-125-8-199610150-00003	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM889	8849148				2023-01-03	WOS:A1996VM88900005
J	Vandenbroucke, JP; Helmerhorst, FM				Vandenbroucke, JP; Helmerhorst, FM			Risk of venous thrombosis with hormone-replacement therapy	LANCET			English	Editorial Material									LEIDEN UNIV HOSP,DEPT OBSTET GYNAECOL & REPROD MED,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Vandenbroucke, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,NL-2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1995, LANCET, V346, P1575; GOLDHABER SZ, 1994, HAEMOSTASIS THROMBOS, V2, P1327; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VANDENBROUCKE JP, 1996, GYNECOL ENDOCRINOL, V10, P5; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; 1996, BRIT MED J, V312, P473	8	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					972	972		10.1016/S0140-6736(05)64918-5	http://dx.doi.org/10.1016/S0140-6736(05)64918-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855846				2023-01-03	WOS:A1996VM02700002
J	Walsh, TN; Noonan, N; Hollywood, D; Kelly, A; Keeling, N; Hennessy, TPJ				Walsh, TN; Noonan, N; Hollywood, D; Kelly, A; Keeling, N; Hennessy, TPJ			A comparison of multimodal therapy and surgery for esophageal adenocarcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL JUNCTION; PREOPERATIVE CHEMOTHERAPY; RADIATION-THERAPY; RESECTABLE ADENOCARCINOMA; NEOADJUVANT THERAPY; AUTOPSY FINDINGS; GASTRIC CARDIA; RESECTION; SURVIVAL	Background Uncontrolled studies suggest that a combination of chemotherapy and radiotherapy improves the survival of patients with esophageal adenocarcinoma. We conducted a prospective, randomized trial comparing surgery alone with combined chemotherapy, radiotherapy, and surgery. Methods Patients assigned to multimodal therapy received two courses of chemotherapy in weeks 1 and 6 (fluorouracil, 15 mg per kilogram of body weight daily for five days, and cisplatin, 75 mg per square meter of body-surface area on day 7) and a course of radiotherapy (40 Gy, administered in 15 fractions over a three-week period, beginning concurrently with the first course of chemotherapy), followed by surgery. The patients assigned to surgery had no preoperative therapy. Results Of the 58 patients assigned to multimodal therapy and the 55 assigned to surgery, 10 and 1, respectively, were withdrawn for protocol violations. At the time of surgery, 23 of 55 patients (42 percent) treated with preoperative multimodal therapy who could be evaluated had positive nodes or metastases, as compared with 45 of the 55 patients (82 percent) who underwent surgery alone (P<0.001). Thirteen of the 52 patients (25 percent) who underwent surgery after multimodal therapy had complete responses, as determined pathologically. The median survival of patients assigned to multimodal therapy was 16 months, as compared with 11 months for those assigned to surgery alone (P=0.01). At one, two, and three years, 52, 37, and 32 percent, respectively, of patients assigned to multimodal therapy were alive, as compared with 44, 26, and 6 percent of those assigned to surgery, with the survival advantage favoring multimodal therapy reaching significance at three years (P=0.01). Conclusions Multimodal treatment is superior to surgery alone for patients with resectable adenocarcinoma of the esophagus. (C) 1996, Massachusetts Medical Society.	ST JAMES HOSP,DEPT SURG,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; ST LUKES HOSP,DEPT RADIOTHERAPY,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT COMMUNITY HLTH,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT STAT,DUBLIN,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Walsh, Thomas N/E-9349-2013					ADELSTEIN DJ, 1994, AM J CLIN ONCOL-CANC, V17, P14, DOI 10.1097/00000421-199402000-00004; AJANI JA, 1993, J CLIN ONCOL, V11, P22, DOI 10.1200/JCO.1993.11.1.22; AJANI JA, 1990, J CLIN ONCOL, V8, P1231, DOI 10.1200/JCO.1990.8.7.1231; ANDERSON LL, 1982, CANCER, V50, P1587, DOI 10.1002/1097-0142(19821015)50:8<1587::AID-CNCR2820500820>3.0.CO;2-S; BEAHRS OH, 1988, MANUAL STAGING CANC, P63; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BOSCH A, 1979, ACTA RADIOL ONCOL, V18, P103, DOI 10.3109/02841867909128196; CAREY RW, 1991, CANCER, V68, P489, DOI 10.1002/1097-0142(19910801)68:3<489::AID-CNCR2820680307>3.0.CO;2-M; COIA LR, 1988, CANCER, V61, P643, DOI 10.1002/1097-0142(19880215)61:4<643::AID-CNCR2820610404>3.0.CO;2-4; DUHAYLONGSOD FG, 1995, ANN SURG, V221, P677, DOI 10.1097/00000658-199506000-00007; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GILL PG, 1990, BRIT J SURG, V77, P1020, DOI 10.1002/bjs.1800770922; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; HESKETH PJ, 1989, CANCER, V64, P526, DOI 10.1002/1097-0142(19890715)64:2<526::AID-CNCR2820640228>3.0.CO;2-B; HICKEY K, 1994, CANCER, V74, P1693, DOI 10.1002/1097-0142(19940915)74:6<1693::AID-CNCR2820740609>3.0.CO;2-#; HOFF SJ, 1993, ANN THORAC SURG, V56, P282, DOI 10.1016/0003-4975(93)91161-F; HUSEMANN B, 1989, BRIT J SURG, V76, P136, DOI 10.1002/bjs.1800760210; LEICHMAN L, 1984, J CLIN ONCOL, V2, P75, DOI 10.1200/JCO.1984.2.2.75; LUND O, 1989, BRIT J SURG, V76, P1301, DOI 10.1002/bjs.1800761227; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; PAPACHRISTOU DN, 1980, ANN SURG, V192, P58, DOI 10.1097/00000658-198007000-00010; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; ROSCH T, 1992, GASTROENTEROLOGIC EN, P45; STEWART JR, 1993, ANN SURG, V218, P571, DOI 10.1097/00000658-199310000-00017; URBA S, 1995, P AN M AM SOC CLIN, V14, P199; URBA SG, 1992, CANCER, V69, P285, DOI 10.1002/1097-0142(19920115)69:2<285::AID-CNCR2820690203>3.0.CO;2-E; WHITTINGTON R, 1990, INT J RADIAT ONCOL, V19, P593, DOI 10.1016/0360-3016(90)90485-3; WOLFE WG, 1993, J THORAC CARDIOV SUR, V105, P749	28	1553	1599	3	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					462	467		10.1056/NEJM199608153350702	http://dx.doi.org/10.1056/NEJM199608153350702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672151	Green Published			2023-01-03	WOS:A1996VB84900002
J	PascualLeone, A; Rubio, B; Pallardo, F; Catala, MD				PascualLeone, A; Rubio, B; Pallardo, F; Catala, MD			Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression	LANCET			English	Article								Background Lesion and neuroimaging studies suggest that left prefrontal lobe dysfunction is pathophysiologically linked to depression. Rapid-rate transcranial magnetic stimulation (rTMS) to prefrontal lateralised effect on mood In normal several preliminary studies suggest a beneficial effect of rTMS on depression. However, adequately controlled studies have not been conducted. Methods We have studied the effects of focal rTMS on the depressive symptoms in 17 patients with medication-resistant depression of psychotic subtype. The study was designed as a multiple cross-over, randomised placebo-controlled trial. Sham rTMS and stimulation of different cortical areas were used as controls. Findings Left dorsolateral prefrontal cortex rTMS resulted in a significant decrease in scores on the Hamilton depression rating scale HDRS (from 25.2 to 13.8) and the self-rated Beck questionnaire BQ (from 47.9 to 25.7). 11 of the 17 patients showed pronounced improvement that lasted for about 2 weeks after 5 days of daily rTMS sessions. No patient experienced any significant undesirable side-effects. Interpretation Our findings emphasise the role of the left dorsolateral prefrontal cortex in depression, and suggest that rTMS of the left dorsolateral prefrontal cortex might become a safe, non-convulsive alternative to electroconvulsive treatment in depression.	CSIC,INST RAMON Y CAJAL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)	PascualLeone, A (corresponding author), UNIV VALENCIA,DEPT FISIOL,UNIDAD NEUROBIOL,AVE BLASCO IBANEZ 17,E-46010 VALENCIA,SPAIN.		Pascual-Leone, Alvaro/AAC-5101-2019; Pallardo, Federico V./T-1156-2017	Pascual-Leone, Alvaro/0000-0001-8975-0382; Pallardo, Federico V./0000-0003-3715-1980; Rubio, Belen/0000-0003-0858-1842				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; GEORGE MS, 1994, CONVULSIVE THER, V10, P251; George MS, 1994, DEPRESSION, V2, P59; GRISARU N, 1994, EUR NEUROPSYCHOPHARM, V4, P287; HAMILTON M, 1961, BR J SOC CLIN PSYCHO, V4, P561; HOFLICH G, 1993, HUM PSYCHOPHARM CLIN, V8, P361, DOI 10.1002/hup.470080510; KOLBINGER HM, 1995, HUM PSYCHOPHARM CLIN, V10, P305, DOI 10.1002/hup.470100408; PascualLeone A, 1996, NEUROLOGY, V46, P499, DOI 10.1212/WNL.46.2.499; PASCUALLEONE A, 1994, NEUROREPORT, V5, P2517, DOI 10.1097/00001756-199412000-00028; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; PASCUALLEONE A, IN PRESS HDB NEUROPS, V10; PAZZAGLIA PJ, 1993, PSYCHIAT RES, V49, P257, DOI 10.1016/0165-1781(93)90066-P; ROTH BJ, 1991, ELECTROEN CLIN NEURO, V81, P47, DOI 10.1016/0168-5597(91)90103-5; SACKEIM HA, 1994, CONVULSIVE THER, V10, P255; TOFTS PS, 1990, PHYS MED BIOL, V35, P1119, DOI 10.1088/0031-9155/35/8/008; Wassermann EM, 1996, NEUROIMAGE, V3, P1, DOI 10.1006/nimg.1996.0001; WILLIAMS WA, 1995, NEUROLOGY S4, V5, pA168; 1985, JAMA-J AM MED ASSOC, V254, P2103	21	883	926	3	199	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					233	237		10.1016/S0140-6736(96)01219-6	http://dx.doi.org/10.1016/S0140-6736(96)01219-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684201				2023-01-03	WOS:A1996UZ28600012
J	Emi, Y; Ikushiro, S; Iyanagi, T				Emi, Y; Ikushiro, S; Iyanagi, T			Xenobiotic responsive element-mediated transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR AROMATIC-COMPOUNDS; INDUCIBLE EXPRESSION; PROMOTER REGION; HUMAN BILIRUBIN; P-450C GENE; AH RECEPTOR; RAT; CLONING; IDENTIFICATION; CELLS	We have isolated genomic DNA clones containing rat UDP-glucuronosyltransferase family 1 (UGT1) sequences and have shown drug-responsive and tissue-specific alternative expression of multiple first exons (Emi, Y., Ikushiro, S., and Iyanagi, T. (1995) J. Biochem. (Tokyo) 117, 392-399). The UGT1 locus encodes at least nine UGT1 isoforms. UGT1A1 is a major 3-methylcholanthene (MC)-inducible form in rat liver, In this report, we have identified a cis-acting element necessary for transcriptional activation of UGT1A1 in hepatocytes. A promoter region was fused to a chloramphenicol acetyltransferase gene, and the resultant construct was transiently transfected into hepatocytes. A DNA fragment carrying 1,100 nucleotides derived from the 5'-flanking region of the UGT1A1 gene was enough for MC induction. Unidirectional deletion of this region revealed that there existed one xenobiotic responsive element (XRE), TGCGTG, between -134 and -129, When a single base substitution was introduced into the XRE, MC-induced expression of the UGT1A1 gene was completely abolished. In addition, an XRE deleted construct failed to respond to MC. Gel mobility shift assays showed MC-inducible binding of the nuclear aromatic hydrocarbon receptor-ligand complex to this motif, Gel shift coupled DNase I protection analyses revealed that the GCGTG-core sequence was a target site of the liganded aromatic hydrocarbon receptor. These results suggest that the XRE participates in induction of the rat UGT1A1 gene by MC.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HIMEJI,HYOGO 67812,JAPAN	University of Hyogo								ALMB JG, 1994, BIOCHEMISTRY-US, V33, P10513; [Anonymous], 1980, GLUCURONIDATION DRUG; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; CLARKE DJ, 1992, FEBS LETT, V299, P183, DOI 10.1016/0014-5793(92)80243-A; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; EMI Y, 1990, P NATL ACAD SCI USA, V87, P9746, DOI 10.1073/pnas.87.24.9746; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; IYANAGI T, 1991, J BIOL CHEM, V266, P24048; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; KASPER CB, 1980, ENZYMATIC BASIS DETO, V2, P3; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LI Y, 1992, J BIOL CHEM, V267, P15097; Maniatis, 1989, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OWENS IS, 1977, J BIOL CHEM, V252, P2827; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SATO H, 1990, BIOCHEM BIOPH RES CO, V169, P260, DOI 10.1016/0006-291X(90)91462-2; SHEN ES, 1989, J BIOL CHEM, V264, P17754; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	38	123	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3952	3958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632018	hybrid			2023-01-03	WOS:A1996TV72400092
J	Hong, WK; Sporn, MB				Hong, WK; Sporn, MB			Recent advances in chemoprevention of cancer	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; 2ND PRIMARY TUMORS; CARDIOVASCULAR-DISEASE; MAMMARY-CARCINOMA; RETINOIC ACID; BETA-CAROTENE; LUNG-CANCER; VITAMIN-A; PREVENTION; RAT	Chemoprevention is the use of pharmacologic or natural agents that inhibit the development of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Recent advances in our understanding of the mechanisms of carcinogenesis have led to the synthesis of new drugs that can inhibit tumor development in experimental animals by selective action on specific molecular targets, such as the estrogen, androgen, and retinoid receptors or inducible cyclooxygenase. Several of these agents (including tamoxifen, 13-cis-retinoic acid, retinyl palmitate, and an acyclic retinoid) are clinically effective in preventing the development of cancer, particularly in patients who are at high risk for developing second primary tumors after surgical removal of the initial tumor.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,NORRIS COTTON CANC CTR,HANOVER,NH 03755	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Hong, WK (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC HEAD & NECK MED ONCOL,1515 HOLCOMBE BLVD,BOX 80,HOUSTON,TX 77030, USA.							*ALPH TOC BET CAR, 1994, OMEN, V330, P1029; Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123; Aquilina JW, 1997, JNCI-J NATL CANCER I, V89, P689, DOI 10.1093/jnci/89.10.689; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; Boolbol SK, 1996, CANCER RES, V56, P2556; CLARK WH, 1995, ACTA ONCOL, V34, P3, DOI 10.3109/02841869509093632; Cunha GR, 1996, ACTA ANAT, V155, P63; DELMAS PD, 1997, 79 ANN M END SOC MIN; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gottardis MM, 1996, CANCER RES, V56, P5566; GOTTARDIS MM, 1987, CANCER RES, V47, P4020; GOUVEIA J, 1983, LANCET, V1, P710; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; GREENWALD P, 1996, SCI AM, V275, P64; Gudas Lorraine J., 1994, P443; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Jordan VC, 1997, JNCI-J NATL CANCER I, V89, P747, DOI 10.1093/jnci/89.11.747; JORDAN VC, 1994, LONG TERM TAMOXIFEN, P257; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; KELLOFF GJ, 1994, CANCER RES, V54, pS2015; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOSARY CL, 1995, NIH PUBL; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LEE JS, 1994, J CLIN ONCOL, V12, P937, DOI 10.1200/JCO.1994.12.5.937; LIPPMAN SM, 1994, J CLIN ONCOL, V12, P851, DOI 10.1200/JCO.1994.12.4.851; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUCIA MS, 1995, CANCER RES, V55, P5621; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAO L, 1997, J NATL CANCER I, V89, P887; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAPADIMITRAKOPO.V, 1997, 33 ANN M AM SOC CLIN; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; POLLARD M, 1991, CANCER RES, V51, P3610; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; SHIN DM, 1957, 33 ANN M AM SOC CLIN; SPORN M, 1997, 88 ANN M AM ASS CANC; SPORN MB, 1991, CANCER RES, V51, P6215; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WATTENBERG LW, 1993, CANCER RES, V53, P5890; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	52	749	765	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1073	1077		10.1126/science.278.5340.1073	http://dx.doi.org/10.1126/science.278.5340.1073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353183				2023-01-03	WOS:A1997YE65200035
J	Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ				Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ			Pain and treatment of pain in minority patients with cancer - The Eastern Cooperative Oncology Group minority outpatient pain study	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT; SEVERITY	Background: Clinics that primarily see members of ethnic minority groups have been found to provide inadequate treatment of cancer-related pain. The extent of undertreatment of pain in these patients and the factors that contribute to undertreatment are not known. Objectives: To evaluate the severity of cancer-related pain and the adequacy of prescribed analgesics in minority outpatients with cancer. Design: Prospective clinical study. Setting: Eastern Cooperative Oncology Group. Patients: 281 minority outpatients with recurrent or metastatic cancer. Measurements: Patients and physicians independently rated severity of pain, pain-related functional impairment, and pain relief obtained by taking analgesic drugs. Analgesic adequacy was determined on the basis of accepted guidelines. Results: 77% of patients reported disease-related pain or took analgesics; 41% of patients reporting pain had severe pain. Sixty-five percent of minority patients did not receive guideline-recommended analgesic prescriptions compared with 50% of nonminority patients (P < 0.001). Hispanic patients in particular reported less pain relief and had less adequate analgesia. Conclusions: The awareness that minority patients do not receive adequate pain control and that better assessment of pain is needed may improve control of cancer-related pain in this patient population.	WESTAT CORP, ROCKVILLE, MD 20850 USA; SAN JUAN COMMUNITY CLIN ONCOL PROGRAM, SAN JUAN, PR 00936 USA; INDIANA UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; ST MARYS HOSP, DEPT MED, HEMATOL ONCOL UNIT, ROCHESTER, NY 14611 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	Westat; Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [U10CA023318, U10CA049883, U10CA021076] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21076, CA 49883, CA 23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1991, EFFECT CANC QUALITY; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; FORD ES, 1995, HEALTH SERV RES, V30, P237; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Raczynski James M., 1993, Ethnicity and Disease, V3, P290; SATARIANO ER, 1992, AM J PUBLIC HEALTH, V82, P195, DOI 10.2105/AJPH.82.2.195; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; TODD KH, 1994, JAMA-J AM MED ASSOC, V271, P925, DOI 10.1001/jama.271.12.925; *US DEP HHS PHS, 1994, AHCPR PUBL; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; World Health Organization,, 1986, CANC PAIN REL	17	380	385	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					813	816		10.7326/0003-4819-127-9-199711010-00006	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD898	9382402				2023-01-03	WOS:A1997YD89800005
J	Annas, GJ				Annas, GJ			The bell tolls for a constitutional right to physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; *NY STAT TASK FORC, 1997, DEATH IS SOUGHT ASS; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785	4	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1098	1103		10.1056/NEJM199710093371523	http://dx.doi.org/10.1056/NEJM199710093371523			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321541	Green Published			2023-01-03	WOS:A1997XZ84400032
J	Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF				Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF			Validation of preferences for life-sustaining treatment: Implications for advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article						advance directives; life support care; health status; treatment outcomes	STATES WORSE; DIRECTIVES; ATTITUDES; STABILITY; CHOICES; QUALITY; VALUES; DEATH	Background: Treatment preferences established before life-threatening illness occurs may differ from actual decisions because of changes in preferences or poor understanding of the link between prospective preferences and outcomes. Objective: To evaluate the validity of prospective treatment preferences by examining their concordance with ratings of health states. Design: Survey of seven cohorts of persons with diverse health status. Home-and hospital-based interviews were conducted at baseline and at 6, 18, and 30 months. Setting: The greater Seattle area. Participants: Younger and older well adults; persons with chronic conditions, terminal cancer, or AIDS; stroke survivors; and nursing home residents. Measurements: Concordance between six treatment preferences and five health state ratings (on a seven-point scale) was assessed by using logistic regression to measure the increase in odds of treatment refusal for each one-point change in health state ratings. Preferences were considered concordant if treatments were refused in health states rated as worse than death and were accepted in health states rated as better than death. Reasons for discordance were elicited at the final interview. Results: The probability of refusal of prospective treatment was strongly related to health state ratings. Odds ratios ranged from 1.7 to 1.9 (P < 0.001) for every treatment. When patients were shown their discordant preferences, they had a coherent explanation or changed their health state rating or treatment preference to make the two concordant. Conclusions: Prospective life-sustaining treatment preferences show high convergent validity. For most persons, treatment preferences are grounded in a consistent belief system. Concordance and discordance between treatment preferences and health state ratings offer clinicians the opportunity to explore patients' Values and reasoning.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Patrick, DL (corresponding author), UNIV WASHINGTON, DEPT HLTH SERV, BOX 357660, SEATTLE, WA 98195 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	AHRQ HHS [HS06343] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1994, ARCH INTERN MED, V154, P209, DOI 10.1001/archinte.1994.00420020131014; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; Patrick D. L., 1993, HLTH STATUS HLTH POL; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; Pearlman R. A., 1994, Journal of General Internal Medicine, V9, P97; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; PEARLMAN RA, 1995, PUBLICATION NAT TECH; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; Schonwetter RS, 1996, J AM GERIATR SOC, V44, P954, DOI 10.1111/j.1532-5415.1996.tb01867.x; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; *STAT CORP, 1993, STAT REF MAN; Sutherland H J, 1982, Med Decis Making, V2, P299, DOI 10.1177/0272989X8200200306; Tonelli MR, 1996, CHEST, V110, P816, DOI 10.1378/chest.110.3.816; TORRANCE GW, 1982, VALUES LONG TERM CAR; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	25	88	91	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					509	+		10.7326/0003-4819-127-7-199710010-00002	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY733	9313018				2023-01-03	WOS:A1997XY73300002
J	Billings, JA; Block, S				Billings, JA; Block, S			Palliative care in undergraduate medical education - Status report and future directions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1995 Annual Meeting of the Association-of-Canadian-Medical-Colleges / Association-of-Canadian-Teaching-Hospitals / Canadian-Association-for-Medical-Education	MAY 02, 1995	QUEBEC CITY, CANADA	Assoc Canadian Med Coll, Assoc Canadian Teaching Hosp, Canadian Assoc Med Educ			DEATH EDUCATION; STUDENTS; COMMUNICATION; PATIENT; SCHOOLS; SKILLS	Objective.-To describe the status of palliative care education in the under-graduate medical curriculum and to offer recommendations for improvement. Data Sources.-Review of literature on palliative care and of recently submitted grants on medical education for end-of-life care. Study Selection.-English-language reports of educational programs targeted toward medical students were examined, as well as surveys of medical schools. Data Extraction.-Studies were reviewed by the authors to assess the quality of the educational program, evaluation methodology, and conclusions. From over 9000 citations on palliative care and related topics that were retrieved from MEDLINE searches from 1980 through 1995, and from reviewing 14 palliative care journals published from 1985 through 1996, 310 articles were identified that addressed medical education for end-of-life care, and 180 were carefully examined. Data Synthesis.-While nearly all medical schools offer some formal teaching about end-of-life care, there is considerable evidence that current training is inadequate, most strikingly in the clinical years. Teaching about palliative care is received favorably by students, positively influences student attitudes, and enhances communication skills. However, curricular offerings are not well integrated; the major teaching format is the lecture; formal teaching is predominantly preclinical; clinical experiences are mostly elective; there is little attention to home care, hospice, and nursing home care; role models are few; and students are not encouraged to examine their personal reactions to these clinical experiences. Conclusions.-The increasing attention to palliative care education has created major opportunities for improving education about care at the end of life. Educational programs should be rigorously evaluated to identify best educational practices.	HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DIV PSYCHIAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, HARVARD PILGRIM HLTH CARE, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital	Billings, JA (corresponding author), MASSACHUSETTS GEN HOSP, PALLIAT CARE SERV, FOUNDERS HOUSE 600, 55 FRUIT ST, BOSTON, MA 02114 USA.		Van den Block, Lieve/D-1247-2011	Van den Block, Lieve/0000-0002-7770-348X	NATIONAL CANCER INSTITUTE [R25CA066818] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AD HOC COMM CANC, 1992, J CLIN ONCOL, V10, P1830; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; ANDERSON JL, 1982, MED EDUC, V16, P202, DOI 10.1111/j.1365-2923.1982.tb01249.x; [Anonymous], 1995, J Am Geriatr Soc, V43, P577; ARTISS KL, 1973, NEW ENGL J MED, V288, P1210, DOI 10.1056/NEJM197306072882305; BARTON D, 1972, J MED EDUC, V47, P945; BARTON D, 1972, J MED EDUC, V47, P169; BARTON D, 1975, OMEGA, V6, P243; BELANI CP, 1994, SUPPORT CARE CANCER, V2, P50, DOI 10.1007/BF00355239; Benoliel J Q, 1988, J Palliat Care, V4, P41; BERTMAN SL, 1985, MED EDUC, V19, P374, DOI 10.1111/j.1365-2923.1985.tb01340.x; BERTMAN SL, 1982, DEATH ED HLTH CARE P, P95; Billings J A, 1993, Hosp J, V9, P69, DOI 10.1300/J011v09n01_06; BILLINGS JA, 1985, J MED EDUC, V60, P855; BILLINGS JA, 1989, CLIN ENCOUNTER GUIDE; BLANCHARD CG, 1981, CANCER, V47, P2756, DOI 10.1002/1097-0142(19810601)47:11<2756::AID-CNCR2820471135>3.0.CO;2-G; BLANK LL, 1995, WESTERN J MED, V163, P297; BLOCH S, 1981, ED MED STUDENT THANA, P129; Block SD, 1996, ACAD PSYCHIATR, V20, P65, DOI 10.1007/BF03341552; BLOCK SD, 1997, HARVARD MED ALUMNI B, V70, P37; BLOCK SD, 1994, NEW PATHWAYS MED ED, P114; CALMAN KC, 1989, EDINBURGH S PAIN CON, P175; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSELL EJ, 1985, TALKING PATIENTS, V1; CASSELL EJ, 1985, TALKING PATIENTS, V2; CASSEM NH, 1978, HARVARD GUIDE MODERN; Cassileth B R, 1989, J Cancer Educ, V4, P261; CASSILETH BR, 1979, J MED EDUC, V54, P797; DICKINSON GE, 1976, J MED EDUC, V51, P134; DICKINSON GE, 1985, J MED EDUC, V60, P942; DIMAGGIO JR, 1993, GEN HOSP PSYCHIAT, V15, P166, DOI 10.1016/0163-8343(93)90120-D; DOYLE D, 1993, OXFORD TXB PALLIATIV, P3; DOYLE D, 1986, TERMINAL CARE, P207; DURLAK JA, 1991, DEATH STUD, V15, P39, DOI 10.1080/07481189108252408; DURLAK JA, 1979, OMEGA-J DEATH DYING, V9, P57, DOI 10.2190/1BQ0-HLTL-WL45-4QUV; EVANS BJ, 1991, MED EDUC, V25, P517, DOI 10.1111/j.1365-2923.1991.tb00105.x; FIELD MJ, 1992, APPROACHING DEATH IM; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Garvin D. A., 1991, ED JUDGMENT ARTISTRY, P3; Goldberg R, 1987, J Cancer Educ, V2, P159; GOODELL BW, 1982, DEATH EDUC, V5, P363; GROSSMAN SA, 1985, J MED EDUC, V60, P552; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; HOLLEMAN WL, 1994, TEACH LEARN MED, V6, P260; IRWIN WG, 1989, MED EDUC, V23, P387, DOI 10.1111/j.1365-2923.1989.tb01565.x; Itano J K, 1991, J Cancer Educ, V6, P219; Jacox A, 1994, AHCPR PUBLICATION; Kassirer JP, 1996, NEW ENGL J MED, V335, P507, DOI 10.1056/NEJM199608153350709; Kaye J M, 1991, J Cancer Educ, V6, P21; KITCHEN AD, 1986, J MED EDUC, V61, P760; KITCHEN AD, 1988, THANATOLOGY CURRICUL, P3; Kleinman A., 1988, ILLNESS NARRATIVES; Knight C F, 1992, Am J Hosp Palliat Care, V9, P23, DOI 10.1177/104990919200900104; KNOTT JE, 1982, THANATOPICS MANUAL S; Kubler-Ross Elisabeth, 1969, DEATH DYING; LATTANZI ME, 1983, HOSPICE CARE PRINCIP, P223; LINN BS, 1982, J MED EDUC, V57, P684; LISTON EH, 1973, J MED EDUC, V48, P577; LOCKARD BE, 1989, DEATH STUD, V13, P137, DOI 10.1080/07481188908252291; MacDonald N, 1993, J Cancer Educ, V8, P197; MacLeod R D, 1993, Hosp J, V9, P55, DOI 10.1300/J011v09n01_05; Maguire P, 1996, EUR J CANCER, V32A, P1486, DOI 10.1016/0959-8049(96)00059-7; MARKS SC, 1980, J MED EDUC, V55, P48; MARTIN RW, 1989, ACAD MED, V64, P413, DOI 10.1097/00001888-198907000-00018; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MASON C, 1986, MED EDUC, V20, P342, DOI 10.1111/j.1365-2923.1986.tb01377.x; MATHEW LM, 1983, J MED EDUC, V58, P772; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; McGrath PA, 1996, J PAIN SYMPTOM MANAG, V12, P87, DOI 10.1016/0885-3924(96)00099-1; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Mishler E.G., 1984, DISCOURSE MED DIALEC; OLIN HS, 1972, J MED EDUC, V47, P564; *PALL ONC ED SECT, 1996, J CANCER EDUC, V11, P7; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V12, P93, DOI 10.1016/0885-3924(96)00078-4; Qvarnstrom U, 1988, J Palliat Care, V4, P38; RAPPAPORT W, 1993, SURGERY, V113, P163; REULER JB, 1994, WESTERN J MED, V160, P335; SACK WH, 1984, PEDIATRICS, V73, P676; SANKAR A, 1985, J MED EDUC, V60, P308; SAUNDERS C, 1969, DEATH DYING, P59; Schmidt HG, 1996, ACAD MED, V71, P658, DOI 10.1097/00001888-199606000-00021; SCHMIDT HG, 1983, MED EDUC, V17, P11, DOI 10.1111/j.1365-2923.1983.tb01086.x; SCITOVSKY AA, 1994, MILBANK Q, V72, P561, DOI 10.2307/3350356; SMITH MD, 1980, J MED EDUC, V55, P844; Stedeford A, 1989, J Cancer Educ, V4, P103; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; Weissman D E, 1993, J Cancer Educ, V8, P191; WHITE LP, 1964, ANN NY ACAD SCI, V164, P822; WOLRAICH M, 1984, J MED EDUC, V59, P751; *WORK PART ASS PAL, 1992, ASS PALL MED GREAT B; YOUNG R, 1981, J MED EDUC, V56, P341	95	233	241	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					733	738		10.1001/jama.278.9.733	http://dx.doi.org/10.1001/jama.278.9.733			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XT709	9286833				2023-01-03	WOS:A1997XT70900026
J	Jeong, B; Bae, YH; Lee, DS; Kim, SW				Jeong, B; Bae, YH; Lee, DS; Kim, SW			Biodegradable block copolymers as injectable drug-delivery systems	NATURE			English	Article							CONTROLLED RELEASE; MEMBRANE; PH	Polymers that display a physicochemical response to stimuli are widely explored as potential drug-delivery systems(1-4), Stimuli studied to date include chemical substances and changes in temperature, pH and electric field, Homopolymers or copolymers of N-isopropylacrylamide(5,6) and poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (known as poloxamers)(7) are typical examples of thermosensitive polymers, but their use in drug delivery is problematic because they are toxic and nonbiodegradable, Biodegradable polymers used for drug delivery to date have mostly been in the form of injectable microspheres or implant systems, which require complicated fabrication processes using organic solvents(8). Such systems have the disadvantage that the use of organic solvents can cause denaturation when protein drugs are to be encapsulated. Furthermore, the solid form requires surgical insertion, which often results in tissue irritation and damage, Here we report the synthesis of a thermosensitive, biodegradable hydrogel consisting of blocks of poly(ethylene oxide) and poly(L-lactic acid), Aqueous solutions of these copolymers exhibit temperature-dependent reversible gel-sol transitions, The hydrogel can be loaded with bioactive molecules in an aqueous phase at an elevated temperature (around 45 degrees C), where they form a sol. In this form, the polymer is injectable. On subcutaneous injection and subsequent rapid cooling to body temperature, the loaded copolymer forms a gel that can act as a sustained-release matrix for drugs.	UNIV UTAH, CCCD PHARMACEUT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah			Jeong, Byeongmoon/AAB-1570-2021; LEE, DOO SUNG/D-3363-2011; Kang, Bo Kyung/F-6726-2015	Jeong, Byeongmoon/0000-0001-9582-1343; 				ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; MALSTOM M, 1992, MACROMOLECULES, V25, P5440; MORITZ AR, 1947, AM J PATHOL, V23, P695; Ronneberger B, 1996, J BIOMED MATER RES, V30, P31; THOMAS JL, 1995, J AM CHEM SOC, V117, P2949, DOI 10.1021/ja00115a039; Wout Z G, 1992, J Parenter Sci Technol, V46, P192; YOUXIN L, 1993, J CONTROL RELEASE, V27, P247; ZHU KJ, 1990, J APPL POLYM SCI, V39, P1, DOI 10.1002/app.1990.070390101	13	1744	1897	32	1253	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					860	862		10.1038/42218	http://dx.doi.org/10.1038/42218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278046				2023-01-03	WOS:A1997XT75400044
J	PowellTuck, J				PowellTuck, J			Glutamine supplementation in artificial nutritional support	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; TOTAL PARENTERAL-NUTRITION; DOUBLE-BLIND				PowellTuck, J (corresponding author), ROYAL LONDON HOSP,ST BARTHOLOMEWS & ROYAL LONDON HOSP SCH MED,RANK DEPT HUMAN NUTR,LONDON E1 1BB,ENGLAND.							Bozzetti F, 1997, NUTRITION, V13, P748, DOI 10.1016/S0899-9007(97)83038-9; GRIFFITHS RD, 1997, NUTRITION, V13, P302; JEBB SA, 1995, CLIN NUTR, V14, P143; Jensen GL, 1996, AM J CLIN NUTR, V64, P615, DOI 10.1093/ajcn/64.4.615; MORLION BJ, 1996, CLIN NUTR S1, V15, P48; ORIORDAIN MG, 1994, ANN SURG, V220, P212, DOI 10.1097/00000658-199408000-00014; POWELLTUCK J, 1997, NUTRITION, V13, P725; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					534	534		10.1016/S0140-6736(05)63136-4	http://dx.doi.org/10.1016/S0140-6736(05)63136-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284773				2023-01-03	WOS:A1997XT22100006
J	Price, H				Price, H			Deaths from venous thromboembolism associated with combined oral contraceptives	LANCET			English	Letter											Price, H (corresponding author), HM CORONER,EASTERN DIST GREATER LONDON,CORONERS COURT,LONDON E17 8QP,ENGLAND.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					450	450		10.1016/S0140-6736(05)64187-6	http://dx.doi.org/10.1016/S0140-6736(05)64187-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9289596				2023-01-03	WOS:A1997XQ24800074
J	vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA				vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA			Medical end-of-life decisions made for neonates and infants in the Netherlands	LANCET			English	Article							INTENSIVE-CARE; EUTHANASIA	Background Advances in neonatal intensive care have lowered the neonatal death rate. There are still some severely ill neonates and infants, however, for whom the application of all possible life-prolonging treatment modalities may be questioned. Methods We did two studies in the Netherlands. In the first we sent questionnaires to physicians who had attended 338 consecutive deaths (August-November, 1995) within the first year of life (death-certificate study), and in the second we interviewed 31 neonatologists or paediatric intensive-care specialists and 35 general paediatricians. The response rates were 88% and 99%, respectively. Findings in the death-certificate study, 57% of all deaths had been preceded by a decision to forgo life-sustaining treatment; this decision was accompanied by the administration of potentially life-shortening drugs to alleviate pain or other symptoms in 23%, and by the administration of drugs with the explicit aim of hastening death in 8%. A drug was given explicitly to hasten death to neonates not dependent on life-sustaining treatment in 1% of all death cases. No chance of survival was the main motive in 76% of all end-of-life decisions, and a poor prognosis was the main motive in 18%. The interview study showed that parents had been involved in making 79% of decisions, The physicians consulted colleagues about 88% of decisions, Most paediatricians favoured formal review of medical decisions by colleagues together with ethical or legal experts. Interpretation Death among neonates and infants is commonly preceded by medical end-of-life decisions. Most Dutch paediatricians seem to find prospects for survival and prognostic factors relevant in such decisions. Public control by a committee of physicians, paediatricians, ethicists, and legal experts is widely endorsed by paediatricians.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	vanderHeide, A (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							ANGELL M, 1986, NEW ENGL J MED, V314, P642, DOI 10.1056/NEJM198603063141010; BROUWERS HAA, 1995, OP GRENS LEVEN DOOD; CAMPBELL AGM, 1982, ARCH DIS CHILD, V57, P569, DOI 10.1136/adc.57.8.569; Cook L A, 1996, J Perinatol, V16, P133; de Kleine M J, 1993, Ned Tijdschr Geneeskd, V137, P496; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; EGANDERSEN G, 1989, ACTA PAEDIATR SCAND, P56; Frader JE, 1996, PEDIATRICS, V98, P149; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; LEENEN HJJ, 1994, HDB GEZONDHEIDSREC 1; LUCE JM, 1995, CRIT CARE MED, V23, P760, DOI 10.1097/00003246-199504000-00027; Nederlandse Vereniging voor Kindergeneeskunde, 1992, DOEN LAT GRENZ MED H; Rivers RPA, 1996, BRIT MED BULL, V52, P238; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WHITELAW A, 1986, LANCET, V2, P328	20	87	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 26	1997	350	9073					251	255		10.1016/S0140-6736(97)02315-5	http://dx.doi.org/10.1016/S0140-6736(97)02315-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242802	Green Submitted			2023-01-03	WOS:A1997XM86600012
J	McAllister, C; Fee, JPH				McAllister, C; Fee, JPH			Research into intensive-care admissions	LANCET			English	Editorial Material									ROYAL VICTORIA HOSP,REG INTENS CARE UNIT,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND		McAllister, C (corresponding author), CRAIGAVON AREA HOSP GRP TRUST,INTENS CARE UNIT,CRAIGAVON,NORTH IRELAND.							BION J, 1995, BMJ-BRIT MED J, V310, P682, DOI 10.1136/bmj.310.6981.682; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; *INT CAR SOC, 1990, INT CAR SERV UK; METCALFE MA, 1995, STUDY INTENSIVE CARE; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727	5	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					2	2		10.1016/S0140-6736(97)22027-1	http://dx.doi.org/10.1016/S0140-6736(97)22027-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217708				2023-01-03	WOS:A1997XH86900002
J	Benbow, SJ; Walsh, A; Gill, GV				Benbow, SJ; Walsh, A; Gill, GV			Diabetes in institutionalised elderly people: A forgotten population?	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,CLIN DEPT AINTREE,FAZAKERLEY HOSP,DIABET & ENDOCRINOL CLIN RES GRP,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	University of Liverpool	Benbow, SJ (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							SINCLAIR AJ, 1993, BRIT MED J, V306, P1142, DOI 10.1136/bmj.306.6886.1142; Sinclair AJ, 1996, POSTGRAD MED J, V72, P334, DOI 10.1136/pgmj.72.848.334; TATTERSALL RB, 1984, DIABETOLOGIA, V27, P167	3	59	59	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1868	1869		10.1136/bmj.314.7098.1868	http://dx.doi.org/10.1136/bmj.314.7098.1868			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224129	Green Published			2023-01-03	WOS:A1997XH73800023
J	Bishop, NJ; Morley, R; Chir, B; Day, JP; Lucas, A				Bishop, NJ; Morley, R; Chir, B; Day, JP; Lucas, A			Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS ENCEPHALOPATHY; PARENTERAL-NUTRITION; MILK FORMULAS; TOXICITY; OSTEODYSTROPHY; BONE	Background Aluminum, a contaminant of commercial intravenous-feeding solutions, is potentially neurotoxic. We investigated the effect of perinatal exposure to intravenous aluminum on the neurologic development of infants born prematurely. Methods We randomly assigned 227 premature infants with gestational ages of less than 34 weeks and birth weights of less than 1850 g who required intravenous feeding before they could begin enteral feeding to receive either standard or specially constituted, aluminum-depleted intravenous-feeding solutions. The neurologic development of the 182 surviving infants who could be tested was assessed by using the Bayley Scales of Infant Development at 18 months of age. Results The 90 infants who received the standard feeding solutions had a mean (+/- SD) Bayley Mental Development index of 95 +/- 22, as compared with 98 +/- 20 for the 92 infants who received the aluminum-depleted solutions (P=0.39). In a planned subgroup analysis of infants in whom the duration of intravenous feeding exceeded the median and who did not have neuromotor impairment, the mean values for the Bayley Mental Development Index for the 39 infants who received the standard solutions and the 41 infants who received the aluminum-depleted solutions were 92 +/- 20 and 102 +/- 17, respectively (P=0.2). The former were significantly more likely (39 percent, vs, 17 percent of the latter group; P=0.03) to have a Mental Development Index of less than 85, increasing their risk of subsequent educational problems. For all 157 infants without neuromotor impairment, increasing aluminum exposure was associated with a reduction in the Mental Development Index (P=0.03), with an adjusted loss of one point per day of intravenous feeding for infants receiving the standard solutions. Conclusions In preterm infants, prolonged intravenous feeding with solutions containing aluminum is associated with impaired neurologic development. (C) 1997, Massachusetts Medical Society.	MRC,DUNN NUTR UNIT,CAMBRIDGE CB4 1XJ,ENGLAND; UNIV CAMBRIDGE,DEPT PAEDIAT,CAMBRIDGE,ENGLAND; MRC,CHILDHOOD NUTR RES CTR,INST CHILD HLTH,LONDON,ENGLAND; UNIV MANCHESTER,DEPT CHEM,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Cambridge; University of London; University College London; University of Manchester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402; *AM AC PED COMM NU, 1986, PEDIATRICS, V78, P1150; AMIELTISON C, 1989, ARCH DIS CHILD-FETAL, V64, P496, DOI 10.1136/adc.64.4_Spec_No.496; Bayley N., 1969, BAYLEY SCALES INFANT; BETTINELLI A, 1987, INT J ARTIF ORGANS, V10, P131, DOI 10.1177/039139888701000214; BISHOP NJ, 1989, ARCH DIS CHILD, V64, P1316, DOI 10.1136/adc.64.9.1316; BOUGLE D, 1992, JPEN-PARENTER ENTER, V16, P157, DOI 10.1177/0148607192016002157; BOYCE BF, 1982, LANCET, V2, P1009; FAUGERE MC, 1986, J LAB CLIN MED, V107, P481; Gruskin A B, 1988, Adv Pediatr, V35, P281; KOO WWK, 1989, JPEN-PARENTER ENTER, V13, P516, DOI 10.1177/0148607189013005516; KOO WWK, 1992, PEDIATRICS, V89, P877; KOO WWK, 1986, J PEDIATR-US, V109, P877, DOI 10.1016/S0022-3476(86)80718-1; KOO WWK, 1988, J AM COLL NUTR, V7, P199, DOI 10.1080/07315724.1988.10720237; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; MCGRAW M, 1986, LANCET, V1, P157; MORENO A, 1994, ACTA PAEDIATR, V83, P25, DOI 10.1111/j.1651-2227.1994.tb12947.x; NATHAN E, 1980, ACTA PAEDIATR SCAND, V69, P793, DOI 10.1111/j.1651-2227.1980.tb07155.x; OHARE JA, 1983, MEDICINE, V62, P129, DOI 10.1097/00005792-198305000-00001; PUNTIS JWL, 1986, LANCET, V2, P1332; ROBINSON MJ, 1987, LANCET, V2, P1206; SALUSKY IB, 1991, MINER ELECTROL METAB, V17, P273; SEDMAN AB, 1985, NEW ENGL J MED, V312, P1337, DOI 10.1056/NEJM198505233122101; SEDMAN AB, 1984, J PEDIATR-US, V105, P836, DOI 10.1016/S0022-3476(84)80318-2; WARD MK, 1978, LANCET, V1, P841; WILLS MR, 1989, CRIT REV CL LAB SCI, V27, P59, DOI 10.3109/10408368909106590	26	174	183	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1557	1561		10.1056/NEJM199705293362203	http://dx.doi.org/10.1056/NEJM199705293362203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164811	Bronze			2023-01-03	WOS:A1997XB08700003
J	Miyagawa, K; Rosch, J; Stanczyk, F; Hermsmeyer, K				Miyagawa, K; Rosch, J; Stanczyk, F; Hermsmeyer, K			Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm	NATURE MEDICINE			English	Article							ORAL-CONTRACEPTIVES; POSTMENOPAUSAL WOMEN; RHESUS-MONKEYS; PROGESTERONE; PROGESTAGEN; DISEASE; THERAPY; RISK	Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17 beta in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.	OREGON HLTH SCI UNIV,OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT MED,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,CHARLES DOTTER INST INTERVENT RADIOL,PORTLAND,OR 97201; UNIV SO CALIF,SCH MED,WOMENS & CHILDRENS HOSP,LOS ANGELES,CA 90033	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Children's Hospital Los Angeles; University of Southern California					NHLBI NIH HHS [HL51723] Funding Source: Medline; NICHD NIH HHS [HD18185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams Michael R., 1994, P243; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; GILMORE JP, 1983, HDB PHYSL 2 2, V3, P885; Gorodeski George I., 1994, P199; HEALY B, 1995, JAMA-J AM MED ASSOC, V273, P240, DOI 10.1001/jama.273.3.240; HERMSMEYER K, IN PRESS J AM COLL C; HIROI M, 1975, STEROIDS, V26, P373, DOI 10.1016/0039-128X(75)90082-3; JIANG CW, 1992, EUR J PHARMACOL, V211, P163, DOI 10.1016/0014-2999(92)90524-8; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MEIRIK O, 1995, LANCET, V346, P1582; MILLER VM, 1991, AM J PHYSIOL, V261, pR1022, DOI 10.1152/ajpregu.1991.261.4.R1022; MISHRA SK, 1994, J CARDIOVASC PHARM, V24, P1, DOI 10.1097/00005344-199407000-00001; POULTER NR, 1995, LANCET, V346, P1575; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; RESKO JA, 1975, ENDOCRINOLOGY, V97, P425, DOI 10.1210/endo-97-2-425; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; Stanczyk Frank Z., 1994, P69; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILLIAMS CL, 1995, GOODMAN GILMANS PHAR, P1411; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199	23	225	231	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					324	327		10.1038/nm0397-324	http://dx.doi.org/10.1038/nm0397-324			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055861				2023-01-03	WOS:A1997WL30500035
J	McFarland, HF				McFarland, HF			Complexities in the treatment of autoimmune disease	SCIENCE			English	Editorial Material							GAMMA-INTERFERON; ENCEPHALOMYELITIS; RESPONSES; PROTEIN				McFarland, HF (corresponding author), NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892, USA.							Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Hemmer B, 1996, J NEUROSCI RES, V45, P852; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; Lee MS, 1996, J EXP MED, V183, P2663, DOI 10.1084/jem.183.6.2663; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LIDER O, 1989, J IMMUNOL, V142, P748; LINNINGTON C, 1988, AM J PATHOL, V130, P443; LUBLIN FD, 1993, AUTOIMMUNITY, V16, P267, DOI 10.3109/08916939309014645; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; RAMANATHAN S, 1996, J IMMUNOL, V157, P1767; TSUCHIDA T, 1994, P NATL ACAD SCI USA, V91, P10859, DOI 10.1073/pnas.91.23.10859	13	53	57	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2037	2038		10.1126/science.274.5295.2037	http://dx.doi.org/10.1126/science.274.5295.2037			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8984662				2023-01-03	WOS:A1996VY97400033
J	Gray, GC; Coate, BD; Anderson, CM; Kang, HK; Berg, SW; Wignall, FS; Knoke, JD; BarrettConnor, E				Gray, GC; Coate, BD; Anderson, CM; Kang, HK; Berg, SW; Wignall, FS; Knoke, JD; BarrettConnor, E			The postwar hospitalization experience of US veterans of the Persian Gulf War	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES-ARMY; NAVY PERSONNEL; DESERT-STORM; RECRUITS; HEALTH	Background Since the Persian Gulf War ended in 1991, many veterans of that conflict have reported diverse, unexplained symptoms. To evaluate the health of Gulf War veterans, we studied their postwar hospitalization experience and compared it with that of other military personnel serving at the same time who did not go to the Persian Gulf. Methods Using a retrospective cohort approach and data from Department of Defense hospitals, we studied hospitalizations of 547,076 veterans of the Gulf War who were serving in the Army, Navy, Marine Corps, and Air Force and 618,335 other veterans from the same era who did not serve in the Persian Gulf. Using multivariate logistic-regression models, we analyzed risk factors for hospitalization both overall and in 14 broad diagnostic categories during three periods from August 1991 through September 1993 (a total of 45 comparisons). Results After the war, the overall odds ratio for hospitalization of the Gulf War veterans was not higher than that of the other veterans, even after adjustment for selection effects related to deployment. In 16 of the 42 comparisons involving specific diagnoses, the risk of hospitalization among Gulf War veterans differed significantly from that among other veterans. Among these 16 comparisons, Gulf War veterans were at higher risk in 5: neoplasms (largely benign) during 1991, diseases of the genitourinary system during 1991, diseases of the blood and blood-forming organs (mostly forms of anemia) during 1992, and mental disorders during both 1992 and 1993. The differences were not consistent over time and could be accounted for by deferred care, postwar pregnancies, and postwar stress. Conclusions During the two years after the Persian Gulf War, there was no excess of unexplained hospitalization among Americans who remained on active duty after serving in that conflict. (C) 1996, Massachusetts Medical Society.	DEPT VET AFFAIRS,ENVIRONM EPIDEMIOL SERV,WASHINGTON,DC; USN,CTR ENVIRONM HLTH,NORFOLK,VA; NAVAL MED RES UNIT 2,JAKARTA,INDONESIA; UNIV CALIF SAN DIEGO,SCH MED,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); US Naval Medical Research Unit-2 (NAMRU-2); University of California System; University of California San Diego	Gray, GC (corresponding author), USN,HLTH RES CTR,DIV CLIN EPIDEMIOL,EMERGING ILLNESS RES TEAM,POB 85122,SAN DIEGO,CA 92186, USA.		Gray, Gregory C./ABF-1298-2020	Gray, Gregory/0000-0002-4628-5908				[Anonymous], 1995, Arch Intern Med, V155, P262; ARDAY DR, 1989, AM J PUBLIC HEALTH, V79, P471, DOI 10.2105/AJPH.79.4.471; BEST F, 1995, MED GULF WAR; BROWN D, 1994, WASHINGTON POST 0724; *C RES SERV, 1992, IR KUW CRIS CHRON EV; *COMM REV HLTH CON, 1995, HLTH CONS SERV PERS; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P572; COTTON P, 1992, JAMA-J AM MED ASSOC, V268, P2619, DOI 10.1001/jama.268.19.2619; COWLEY G, 1994, NEWSWEEK        1024, P56; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; DEFRAITES RF, 1992, INVESTIGATION SUSPEC; *DEP DEF, 1996, COMPR CLIN EV PROGR; *DHHS, 1989, DHHS PUBL; FLANDERS L, 1995, NATION          0123, P94; FRANCE D, 1994, REDBOOK          SEP, V114, P148; FUMENTO M, 1995, AM SPECTATOR     MAY, P28; GARLAND FC, 1990, AM J EPIDEMIOL, V132, P293, DOI 10.1093/oxfordjournals.aje.a115658; GRAY GC, 1990, PEDIATRICS, V86, P867; GRAY GC, 1994, AM J EPIDEMIOL, V139, P793, DOI 10.1093/oxfordjournals.aje.a117076; HELMKAMP JC, 1994, J OCCUP ENVIRON MED, V36, P609; HELMKAMP JC, 1992, MIL MED, V157, pA7, DOI 10.1093/milmed/157.3.A7; HOBFOLL SE, 1991, AM PSYCHOL, V146, P848; HOIBERG A, 1980, J OCCUP ENVIRON MED, V22, P685, DOI 10.1097/00043764-198010000-00017; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; HYAMS KC, 1995, CLIN INFECT DIS, V20, P1497, DOI 10.1093/clinids/20.6.1497; JEHL D, 1995, NY TIMES        0307, pA14; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KANG HK, 1995, HLTH SURVEILLANCE PE; MILNER UB, 1994, JAMA-J AM MED ASSOC, V271, P1661; *NAT I HLTH TECHN, 1994, JAMA-J AM MED ASSOC, V272, P391; NELSON S, 1995, NAVY TIMES      0704, P10; NELSON S, 1995, ARMY TIMES      0619; *OFF ASS SECR DEF, 1991, OCC CONV MAN ENL OFF; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P144; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; SUTKER PB, 1994, J TRAUMA STRESS, V71, P159; TIPPIT S, 1994, LADIES HOME J    JUN, V100, P148; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118; 1995, MMWR-MORBID MORTAL W, V44, P443; 1991, FED REGISTER, V156, P2663; 1995, PERSIAN GULF REV, P5	41	137	139	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1505	1513		10.1056/NEJM199611143352007	http://dx.doi.org/10.1056/NEJM199611143352007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT340	8890103				2023-01-03	WOS:A1996VT34000007
J	Herxheimer, A				Herxheimer, A			Euthanasia and palliative care: A pseudoconflict?	LANCET			English	Editorial Material																		*HOUS LORDS, 1994, REP SEL COMM MED ETH, V1; World Health Organization, 1996, CANC PAIN REL	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1187	1188		10.1016/S0140-6736(05)65478-5	http://dx.doi.org/10.1016/S0140-6736(05)65478-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898033				2023-01-03	WOS:A1996VQ46700006
J	Wolfe, S				Wolfe, S			Drug advertisements that go straight to the hippocampus	LANCET			English	Editorial Material											Wolfe, S (corresponding author), PUBL CITIZENS HLTH RES GRP,1600 20TH ST NW,WASHINGTON,DC 20009, USA.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; *HLTH CAR COMM, 1989, EFF J ADV MARK SHAR; KESSLER DA, 1992, ANN INTERN MED, V116, P950, DOI 10.7326/0003-4819-116-11-950; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912	4	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					632	632		10.1016/S0140-6736(05)65071-4	http://dx.doi.org/10.1016/S0140-6736(05)65071-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782751				2023-01-03	WOS:A1996VF60900006
J	Weaver, WD; White, HD; Wilcox, RG; Aylward, PE; Morris, D; Guerci, A; Ohman, M; Barbash, GI; Betriu, A; Sadowski, Z; Topol, EJ; Califf, RM				Weaver, WD; White, HD; Wilcox, RG; Aylward, PE; Morris, D; Guerci, A; Ohman, M; Barbash, GI; Betriu, A; Sadowski, Z; Topol, EJ; Califf, RM			Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEX-RELATED DIFFERENCES; GENDER DIFFERENCES; MORTALITY; PROGNOSIS; MORBIDITY; SURVIVAL; DISEASE; STROKE	Objective.-To compare baseline characteristics, complications, and treatment-specific outcomes of women and men with acute myocardial infarction treated with thrombolytic therapy. Design.-Randomized controlled trial. Patients and Setting.-A total of 10 315 women and 30 706 men with acute myocardial infarction treated in 1081 hospitals in 15 countries as part of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I). Intervention.-One of four thrombolytic regimens: (1) streptokinase with subcutaneous heparin; (2) streptokinase with intravenous heparin; (3) streptokinase plus alteplase (tissue-type plasminogen activator) with intravenous heparin; or (4) accelerated alteplase with intravenous heparin. Main Outcome Measures.-Mortality, stroke, and nonfatal complications during 30-day follow-up. Results.-Women were on average 7 years older than men and delayed 18 minutes (median) longer after symptom onset before presenting to the hospital. After adjustment for age, women more often had a history of diabetes, hypertension, and smoking than men. Time to treatment was significantly longer in women (1.2 vs 1.0 hours; P<.001). Women had more nonfatal complications after treatment, including shock (9% vs 5%; P<.001), congestive heart failure (22% vs 14%; P<.001), serious bleeding (15% vs 7%; P<.001), and reinfarction (5.1% vs 3.6%; P<.001). Women had twice as many total strokes as men (2.1% vs 1.2%; P<.001), secondary to their older age at presentation. The unadjusted mortality rate was twice as high in women as men (11.3% vs 5.5%; P<.001); the relative risk (RR) of death was greater among women than men after adjustment for differences in baseline characteristics (RR=1.15; 95% confidence interval, 1.0 to 1.31). Although women and men underwent angiography at similar rates, there were small but significant differences in their rates of revascularization procedures (angioplasty: 35% of women and 32% of men; bypass surgery: 7% of women and 9% of men; P<.001 for both). The higher rate of stroke in women after treatment with alteplase (2.0% vs 1.9% with streptokinase and intravenous heparin) was offset by a greater relative reduction in mortality (10.3% vs 11.1%). Conclusion.-Women who received thrombolytic therapy for treatment of acute myocardial infarction were at greater risk for both fatal and nonfatal complications than men.	GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 3, NEW ZEALAND; QUEENS MED CTR, DEPT MED, NOTTINGHAM NG7 2UH, ENGLAND; FLINDERS CARDIOVASC CTR, DEPT CARDIOVASC MED, ADELAIDE, SA, AUSTRALIA; EMORY UNIV, EMORY CLIN, ATLANTA, GA 30322 USA; ST FRANCIS HOSP, DEPT MED, ROSLYN, NY USA; DUKE UNIV, MED CTR, DIV CARDIOL, DURHAM, NC 27710 USA; TEL AVIV SOURASKY UNIV, MED CTR, DEPT MED, TEL AVIV, ISRAEL; HOSP CLIN 1, BARCELONA, SPAIN; INST KARDIOL, ISCHEM HEART DIS DEPT, WARSAW, POLAND; CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA	University of Nottingham; Emory University; Duke University; Tel Aviv University; Sackler Faculty of Medicine; Institute of Cardiology - Poland; Cleveland Clinic Foundation	Weaver, WD (corresponding author), UNIV WASHINGTON, MITI COORDINATING CTR, DIV CARDIOL RG22, 1910 FAIRVIEW AVE E, SUITE 205, SEATTLE, WA 98102 USA.			Aylward, Philip/0000-0002-5358-8552; Topol, Eric/0000-0002-1478-4729; Wilcox, Robert/0000-0001-9911-8743				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BEHAR S, 1992, EUR HEART J, V13, P45, DOI 10.1093/oxfordjournals.eurheartj.a060046; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HIGGINBOTHAM MB, 1984, CIRCULATION, V70, P357, DOI 10.1161/01.CIR.70.3.357; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MAYNARD C, 1993, CARDIOL ELDER, V1, P121; MAYNARD C, 1992, J MYOCARD ISCHEMIA, V4, P27; MAZEIKA PK, 1994, EUR HEART J, V15, P17, DOI 10.1093/oxfordjournals.eurheartj.a060373; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; Ridolfo Buno, 1993, Journal of the American College of Cardiology, V21, p238A; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOFLER GH, 1989, AM J CARDIOL, V64, P256, DOI 10.1016/0002-9149(89)90476-1; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEAVER WD, 1992, CIRCULATION, V86, P16; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097	29	206	213	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					777	782		10.1001/jama.275.10.777	http://dx.doi.org/10.1001/jama.275.10.777			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598594				2023-01-03	WOS:A1996TY88600025
J	Craft, N				Craft, N			Women's health - The childbearing years and after	BRITISH MEDICAL JOURNAL			English	Article											Craft, N (corresponding author), GOWER PL PRACTICE,LONDON WC1E 6BN,ENGLAND.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				BONITA R, 1995, 3 M WHO GLOB COMM WO; Craft N, 1997, BRIT MED J, V315, P1154, DOI 10.1136/bmj.315.7116.1154; Doyal L., 1995, WHAT MAKES WOMEN SIC; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; *INT PLANN PAR FED, 1995, WOM HLTH WOM RIGHTS; *INT PLANN PAR FED, 1997, REAL LIV; MEAGHER D, 1997, LANCET S, V349, P117; NEWNHAM HH, 1997, LANCET S, V349, P13; *OFF POPO CENS SUR, 1996, POP TRENDS 84; Peto R, 1996, JAMA-J AM MED ASSOC, V275, P1683, DOI 10.1001/jama.275.21.1683; SAUNDERS N, 1997, LANCET S, V349, P17; SYMKE P, 1991, WOMEN HLTH; *UN, 1995, LOOK BACK MOV FORW S; *UN, 1995, STAT WORLDS CHILDR; *UN, 1995, WORLDS WOM 1995 TREN; *UN FUND POP ASS, 1994, STAT WORLDS POP; vanWijk CMTG, 1996, SOC SCI MED, V43, P707, DOI 10.1016/0277-9536(96)00115-3; *WHO, 1991, WOM HLTH TOW BETT WO; *WHO, 1994, WOM AIDS AG ACT; *WHO, 1995, WOM HLTH IMPR OUR HL; *WHO, 1994, CHALL REPR HLTH RES, P120; *WHO, 1994, CREAT COMM GROUND AS; *WORLD BANK, 1993, WORLD DEV REP	23	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1301	1304		10.1136/bmj.315.7118.1301	http://dx.doi.org/10.1136/bmj.315.7118.1301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390062	Green Published			2023-01-03	WOS:A1997YG64500037
J	Ashcroft, GS; Dodsworth, J; vanBoxtel, E; Tarnuzzer, RW; Horan, MA; Schultz, GS; Ferguson, MWJ				Ashcroft, GS; Dodsworth, J; vanBoxtel, E; Tarnuzzer, RW; Horan, MA; Schultz, GS; Ferguson, MWJ			Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta 1 levels	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RAT BONE; CELLS; EXPRESSION; SKIN; QUANTITATION; FIBROBLASTS; CYTOKINES; HORMONE	The cellular and molecular mechanisms underlying the effects of aging on human cutaneous wound healing are poorly understood, and the possible role of reproductive hormones in this process has never been investigated. We report that aging in healthy females was associated with a reduced rate of cutaneous wound healing, but an improved quality of scarring both microscopically and macroscopically, and with reduced levels of transforming growth factor-beta 1 (TCF-beta 1) immunostaining and steady-state mRNA in the wound. These age-related changes were reversed by the systemic administration of hormone replacement therapy (HRT). Moreover, ovariectomized young female rodents exhibited a marked delay in repair of acute incisional wounds, which was reversed by the topical application of estrogen. The cellular mechanism underlying these changes appears to Involve an estrogen-induced increase in latent TCF-beta 1 secretion by dermal fibroblasts. These results suggest that both the rate and quality of wound healing depend on reproductive hormone levels.	UNIV MANCHESTER, SCH BIOL SCI, CELLS IMMUNOL & DEV DIV, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV S MANCHESTER HOSP, DEPT GERIATR MED, MANCHESTER M20 2LR, LANCS, ENGLAND; UNIV FLORIDA, DEPT OBSTET & GYNECOL, GAINESVILLE, FL 32610 USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; State University System of Florida; University of Florida				Tarnuzzer, Roy/0000-0002-3725-4173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashcroft GS, 1997, J INVEST DERMATOL, V108, P430, DOI 10.1111/1523-1747.ep12289705; ASHCROFT GS, 1995, J ANAT, V187, P1; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BOLOGNIA JL, 1995, AM J MED, V98, pS99, DOI 10.1016/S0002-9343(99)80066-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLETTA AA, 1991, J CLIN INVEST, V87, P277, DOI 10.1172/JCI114983; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; FrazierJessen MR, 1996, J IMMUNOL, V156, P3036; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MALET C, 1991, J CLIN ENDOCR METAB, V73, P8, DOI 10.1210/jcem-73-1-8; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; OVERALL CM, 1995, J CELL PHYSIOL, V164, P17, DOI 10.1002/jcp.1041640104; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PIERARD GE, 1995, J AM GERIATR SOC, V43, P662, DOI 10.1111/j.1532-5415.1995.tb07202.x; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; SCHMIDT JB, 1994, MATURITAS, V20, P25, DOI 10.1016/0378-5122(94)90097-3; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Tarnuzzer RW, 1996, BIOTECHNIQUES, V20, P670; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075	22	407	423	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1209	1215		10.1038/nm1197-1209	http://dx.doi.org/10.1038/nm1197-1209			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359694				2023-01-03	WOS:A1997YD89600028
J	Series, F; Marc, I				Series, F; Marc, I			Efficacy of automatic continuous positive airway pressure therapy that uses an estimated required pressure in the treatment of the obstructive sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; positive-pressure respiration; hypersomnia; sleep disorders; respiration disorders	DAYTIME SLEEPINESS; CLOSING PRESSURES; CPAP; NIGHT; COLLAPSIBILITY; REVERSAL	Background: Continuous positive airway pressure (CPAP) is effective therapy for the obstructive sleep apnea syndrome (OSAS). Automatic CPAP devices continuously adjust the positive pressure to the required levels. Objective: To determine the efficacy of an automatic CPAP machine used with an estimated reference pressure value. Design: A before-and-after, single-blind trial in which patients were randomly allocated to one of three modes of CPAP administration. Setting: Referral-based sleep center in a public health care institution. Patients: 36 outpatients with OSAS. Intervention: Continuous positive airway pressure was given at a conventional fixed pressure (group 1), automatic CPAP was given at a measured reference pressure (group 2), and automatic CRAP was given at an estimated reference pressure (group 3). In group 1, the effective pressure was determined during a titration sleep study. In groups 2 and 3, the pressure interval was allowed to vary from 4 cm H2O below reference pressure to 3 cm H2O above reference pressure. In group 3, the estimated value of the reference pressure was determined according to individual anthropometric characteristics. Measurements: Sleep studies were performed and measurements of diurnal sleepiness were obtained at each visit. Results: Sleep and breathing disorders and hypersomnolence were alleviated similarly in the three groups. The apnea + hypopnea index remained abnormal in one patient in group 3 for whom the reference pressure had been underestimated. A strong negative correlation was found between the percentage of time spent below reference pressure during CPAP and the difference between the effective and estimated pressures. Conclusion: Automatic CPAP can be used with an estimated reference pressure without doing a titration sleep study. The positive pressure trend can be used to determine whether treatment failure is caused by an inadequate pressure setting and to determine the amount of pressure to apply.			Series, F (corresponding author), HOP LAVAL, CTR PNEUMOL, 2725 CHEMIN ST FOY, Ste Foy, PQ G1V 4G5, CANADA.			Marc, Isabelle/0000-0001-6060-8550				[Anonymous], 1992, SLEEP, V15, P174; BERTHONJONES M, 1993, SLEEP, V16, pS120, DOI 10.1093/sleep/16.suppl_8.S120; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; FUJITA S, 1985, LARYNGOSCOPE, V95, P70; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; ISSA FG, 1984, J APPL PHYSIOL, V57, P520, DOI 10.1152/jappl.1984.57.2.520; ISSA FG, 1984, J APPL PHYSIOL, V57, P528, DOI 10.1152/jappl.1984.57.2.528; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; KALES A, 1985, J CHRON DIS, V38, P427, DOI 10.1016/0021-9681(85)90138-9; Kales A, 1968, NIH PUBLICATION, V204; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; MARRONE O, 1991, EUR RESPIR J, V4, P660; Meurice JC, 1996, AM J RESP CRIT CARE, V153, P794, DOI 10.1164/ajrccm.153.2.8564134; Meurice JC, 1996, AM J RESP CRIT CARE, V153, P255, DOI 10.1164/ajrccm.153.1.8542125; MILJETEIG H, 1993, AM REV RESPIR DIS, V147, P1526, DOI 10.1164/ajrccm/147.6_Pt_1.1526; MILLMAN RP, 1989, J CLIN PSYCHIAT, V50, P348; OSULLIVAN RA, 1995, AM J RESP CRIT CARE, V151, P194, DOI 10.1164/ajrccm.151.1.7812552; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; POCETA JS, 1992, CHEST, V101, P893, DOI 10.1378/chest.101.4.893; SANDERS MH, 1993, AM REV RESPIR DIS, V147, P1169, DOI 10.1164/ajrccm/147.5.1169; SFORZA E, 1990, AM REV RESPIR DIS, V141, P866, DOI 10.1164/ajrccm/141.4_Pt_1.866; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; SULLIVAN CE, 1981, LANCET, V1, P862; THUT DC, 1993, J APPL PHYSIOL, V75, P2084, DOI 10.1152/jappl.1993.75.5.2084; WASICKO MJ, 1990, AM REV RESPIR DIS, V141, P1569, DOI 10.1164/ajrccm/141.6.1569; YAMASHIRO Y, 1995, CHEST, V107, P62, DOI 10.1378/chest.107.1.62; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	28	64	64	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				588	+		10.7326/0003-4819-127-8_Part_1-199710150-00002	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341056				2023-01-03	WOS:A1997YB41900002
J	Koob, GF; LeMoal, M				Koob, GF; LeMoal, M			Drug abuse: Hedonic homeostatic dysregulation	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; STRESS-INDUCED SENSITIZATION; NUCLEUS-ACCUMBENS; ETHANOL WITHDRAWAL; ALCOHOL DEPENDENCE; EXTRACELLULAR DOPAMINE; MOLECULAR MECHANISMS; COCAINE WITHDRAWAL; RECEPTOR AGONISTS; OPIATE-WITHDRAWAL	Understanding the neurobiological mechanisms of addiction requires an integration of basic neuroscience with social psychology, experimental psychology, and psychiatry. Addition is presented as a cycle of spiralling dysregulation of brain reward systems that progressively increases, resulting in compulsive drug use and a loss of control over drug-taking. Sensitization and counteradaptation are hypothesized to contribute to this hedonic homeostatic dysregulation, and the neurobiological mechanisms involved, such as the mesolimbic dopamine system, opioid peptidergic systems, and brain and hormonal stress systems, are beginning to be characterized. This framework provides a realistic approach to identifying the neurobiological factors that produce vulnerability to addiction and to relapse in individuals with a history of addiction.	UNIV BORDEAUX 2, INSERM, U259, F-33077 BORDEAUX, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Koob, GF (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL CVN7, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		LE MOAL, Michel/B-5125-2008		NIAAA NIH HHS [AA06420, AA08459] Funding Source: Medline; NIDA NIH HHS [DA04043] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA008459, P50AA006420, R01AA008459, P60AA006420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004043] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahlstrom Sydney E., 1972, RELIG HIST AM PEOPLE; ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baumeister R.F., 1994, LOSING CONTROL WHY P, DOI 10.5860/choice.32-6508; Bergman J., 1990, Behav Pharmacol, V1, P355; Bindra D., 1976, THEORY INTELLIGENT B; Cabib S, 1996, PSYCHOPHARMACOLOGY, V128, P331, DOI 10.1007/s002130050142; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BRAIN RES, V692, P47; Carrera M. R. A., 1995, Society for Neuroscience Abstracts, V21, P725; CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407; CHEN JP, 1991, NEUROSCI LETT, V129, P136, DOI 10.1016/0304-3940(91)90739-G; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; COOLS AR, IN PRESS PHARM BIOCH; CRABBE JC, 1992, TRENDS PHARMACOL SCI, V13, P212, DOI 10.1016/0165-6147(92)90066-F; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401; DEROCHE V, 1992, BRAIN RES, V598, P343, DOI 10.1016/0006-8993(92)90205-N; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; ENGEL JA, 1992, NOVEL PHARM INTERVEN, P68; EPPINGJORDAN M, 1995, NEUR ABSTR, V21, P719; ETTENBERG A, 1982, PHYSIOL BEHAV, V28, P873, DOI 10.1016/0031-9384(82)90207-4; Gold LH, 1996, BEHAV PHARMACOL, V7, P589; HEIMER L, 1991, ADV EXP MED BIOL, V295, P1; HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74; HENRY DJ, 1992, ANN NY ACAD SCI, V654, P88, DOI 10.1111/j.1749-6632.1992.tb25958.x; Heyser C. J., 1995, Society for Neuroscience Abstracts, V21, P1698; HEYSER CJ, IN PRESS NEUROPSYCHO; Himmelsbach CK, 1943, FED PROC, V2, P201; HYYTIA P, 1995, EUR J PHARMACOL, V283, P151, DOI 10.1016/0014-2999(95)00314-B; Institute of Medicine, 1996, PATHW ADD; JAFFE J H, 1990, P522; Johnston JB, 1923, J COMP NEUROL, V35, P337, DOI 10.1002/cne.900350502; JUNG CG, 1969, PSYCHOL ENERGY MEANI, V8; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Koob George F., 1995, P759; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KOOB GF, 1993, SEMIN NEUROSCI, V5, P351; KOOB GF, 1987, BRAIN REWARD SYSTEMS, P35; KOOP GF, IN PRESS J PSYCHOPHA; Kreek M.J., 1987, PSYCHOPHARMACOLOGY 3, P1597; LAULIN JP, IN PRESS EUR J PHARM; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17; MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093; MURPHY JM, 1987, PHARMACOL BIOCHEM BE, V26, P389, DOI 10.1016/0091-3057(87)90134-1; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Piazza PV, 1996, P NATL ACAD SCI USA, V93, P8716, DOI 10.1073/pnas.93.16.8716; PIAZZA PV, IN PRESS BRAIN RES R; PICH EM, 1995, J NEUROSCI, V15, P5439; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Russell M. A. H., 1976, DRUGS DRUG DEPENDENC, P182; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Schulteis G, 1997, PSYCHOPHARMACOLOGY, V129, P56, DOI 10.1007/s002130050162; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shippenberg TS, 1996, J PHARMACOL EXP THER, V276, P545; SHIPPENBERG TS, 1992, ANN NY ACAD SCI, V654, P347, DOI 10.1111/j.1749-6632.1992.tb25980.x; Smith Devyn, COMMUNICATION; Solomon R.L, 1977, PSYCHOPATHOLOGY EXPT, P124; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Spanagel R, 1996, EUR J PHARMACOL, V305, P39, DOI 10.1016/0014-2999(96)00174-4; Sterling P., 1988, HDB LIFE STRESS COGN, P629; Stewart J., 1987, METHODS ASSESSING RE, P211; Tabakoff B., 1992, SUBSTANCE ABUSE COMP, P152; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; VOLPICELLI JR, 1986, LIFE SCI, V38, P841, DOI 10.1016/0024-3205(86)90601-6; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B; Weiss F, 1996, J NEUROSCI, V16, P3474; WHITE FJ, 1991, BIOL BASES DRUG TOLE, P153; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; World Health Organization, 1990, INT STAT CLASS DIS R; Zhou Y, 1996, EUR J PHARMACOL, V315, P31, DOI 10.1016/S0014-2999(96)00672-3; Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351	99	1797	1837	5	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					52	58		10.1126/science.278.5335.52	http://dx.doi.org/10.1126/science.278.5335.52			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311926				2023-01-03	WOS:A1997XZ12400031
J	Braveman, P; Kessel, W; Egerter, S; Richmond, J				Braveman, P; Kessel, W; Egerter, S; Richmond, J			Early discharge and evidence-based practice - Good science and good judgment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; MATERNAL CHILD & HLTH BUR,DIV SCI EDUC & ANAL,HLTH RESOURCES & SERV ADM,US DEPT DEF,WASHINGTON,DC; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115	University of California System; University of California San Francisco; United States Department of Defense; United States Health Resources & Service Administration (HRSA); Harvard University; Harvard Medical School	Braveman, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,500 PARNASSUS AVE,BOX 0900,MU-3E,RM 306,SAN FRANCISCO,CA 94143, USA.							*AM AC PED AM COLL, 1992, GUID PER CAR, P91; Braveman P, 1996, J Am Board Fam Pract, V9, P254; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; EGERTER S, IN PRESS CLIN PERINA; Institute of Medicine Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P293, DOI 10.1001/jama.278.4.293; RICHMOND JB, 1970, YALE J BIOL MED, V43, P137	8	36	39	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					334	336						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228442				2023-01-03	WOS:A1997XL05900037
J	Rafferty, T; WilsonDavis, K; McGavock, H				Rafferty, T; WilsonDavis, K; McGavock, H			How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY-CARE; COSTS; SCHEME	Objective: To compare prescribing patterns in general practices before and after the introduction of fundholding in April 1993 to determine whether fundholding changed prescribing patterns among practices that joined the scheme. Design: Analysis of prescribing data from the Drug Utilisation Research Unit's database for all practices in Northern Ireland during April 1989 to March 1996. Setting: Northern Ireland. Subjects: 23 first wave fundholders, 34 second wave fundholders, 9 third wave fundholders, and 268 non-fundholders. Main outcome measures: Prescribing costs per 1000 patients, prescription items per 1000 patients, average cost per item, and rate of generic prescribing. Results: Prescribing costs and frequency increased in all groups throughout the study. Among the fundholders the rate of increase in costs after fundholding was significantly lower than among non-fundholders. The rate of increase in cost per item fell, coinciding with a significant increase in the rate of generic prescribing. However, with regard to first wave fundholders, their yearly increase in costs in their third year as fundholders (1995-6) was similar to that of the non-fundholders. The earlier practices that joined the scheme seemed to differ in some important respects from those that joined later. Conclusions: After fundholders joined the fundholding scheme their patterns of prescribing changed compared with those of non-fundholders: the rate of increase in costs fell and there was a significant rise in the rate of generic prescribing.			Rafferty, T (corresponding author), QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,DRUG UTILISAT RES UNIT,WHITLA MED BLDG,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bloor K, 1996, BRIT MED J, V312, P1525, DOI 10.1136/bmj.312.7045.1525; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; *DEP HLTH, 1996, STAT B, V17, P24; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCGAVOCK H, 1994, HLTH TRENDS, V26, P22; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; WALLEY T, 1995, PHARMACOECONOMICS, V7, P320, DOI 10.2165/00019053-199507040-00006; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; WILSONDAVIS K, 1993, PRESCRIBER, V124, P61; [No title captured]	17	29	29	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					166	170		10.1136/bmj.315.7101.166	http://dx.doi.org/10.1136/bmj.315.7101.166			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251548	Green Published			2023-01-03	WOS:A1997XM32100023
J	Pearson, G; Shann, F; Barry, P; Vyas, J; Thomas, D; Powell, C; Field, D				Pearson, G; Shann, F; Barry, P; Vyas, J; Thomas, D; Powell, C; Field, D			Should paediatric intensive care be centralised? Trent versus Victoria	LANCET			English	Article							MORTALITY	Background The mortality rate is lower among children admitted to specialist paediatric intensive care units (ICUs) than among those admitted to mixed adult and paediatric units in non-tertiary hospitals. In the UC(, however, few children receive intensive care in specialist paediatric units. We compared the ICU mortality rate in children from the area of the Trent Health Authority, UK, with the rate in children from Victoria, Australia, where paediatric intensive care is highly centralised. Methods We studied all children under 16 years of age from Trent and Victoria who received intensive care between April 1, 1994, and March 31, 1995. Children younger than 1 month were excluded unless they had cardiac disorders. We developed a logistic regression model that used information gathered at the time of admission to ICU to adjust for risk of mortality. Findings The rates of admission of children to intensive care were similar for Trent and Victoria (1.22 and 1.18 per 1000 children per year), but the mean duration of an ICU stay was 3.93 days for Trent children compared with 2.14 days for children from Victoria. 74 (7.3%) of the 1014 children from Trent died, compared with 60 (5.0%) of the 1194 children from Victoria. With adjustment for severity of illness at the time of admission to ICU, the odds ratio for the risk of death for Trent versus Victoria was 2.09 (95% CI 1.37-3.19, p<0.0005). There were 31.7 (14.0-50.4) excess deaths in Trent children, which is equivalent to 42.8% of the deaths in ICU, and 11.1% of all deaths in children between the ages of 1 month and 16 years in Trent. Interpretation If Trent is representative of the whole country, there are 453 (200-720) excess deaths a year in the UK that are probably due to suboptimal results from paediatric intensive care. If the ratio of paediatric ICUs to children were the same in the UK as in Victoria, there would be only 12 paediatric ICUs in the country. Our findings suggest that substantial reductions in mortality could be achieved if every UK child who needed endotracheal intubation for more than 12-24 h were admitted to one of 12 large specialist paediatric ICUs.	BIRMINGHAM CHILDRENS HOSP,PAEDIAT INTENS CARE UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND; ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC,AUSTRALIA; UNIV LEICESTER,DEPT CHILD HLTH,LEICESTER LE1 7RH,LEICS,ENGLAND; LEICESTER ROYAL INFIRM,LEICESTER,LEICS,ENGLAND; QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; UNIV SHEFFIELD,DEPT PAEDIAT,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Birmingham; Royal Children's Hospital Melbourne; University of Leicester; University of Leicester; University of Nottingham; University of Sheffield			VYAS, Julian Ramesh/I-3603-2019; Shann, Frank/C-9510-2011					*BRIT PAED ASS, 1993, CAR CRIT ILL CHILDR; *BRIT PAED ASS, 1987, REP WORK PART PAED I; BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; Carnall D, 1996, BRIT MED J, V312, P655; Collett D., 1991, MODELLING BINARY DAT; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; GEMKE RJBJ, 1995, CRIT CARE MED, V23, P238, DOI 10.1097/00003246-199502000-00007; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; HALL JR, 1993, AM J DIS CHILD, V147, P102, DOI 10.1001/archpedi.1993.02160250104031; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LUFT HS, 1990, HOSPITAL VOLUME PHYS; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; SHANN F, 1993, LANCET, V342, P68, DOI 10.1016/0140-6736(93)91282-Q; THOMPSON DR, 1994, CRIT CARE MED, V22, P1306, DOI 10.1097/00003246-199408000-00015; ZWEIG MH, 1993, CLIN CHEM, V39, P561; [No title captured]	20	184	183	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1213	1217		10.1016/S0140-6736(96)12396-5	http://dx.doi.org/10.1016/S0140-6736(96)12396-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130943				2023-01-03	WOS:A1997WW71700011
J	Daly, E; Vessey, MP; Hawkins, MN; Carson, JL; Gough, P; Marsh, S				Daly, E; Vessey, MP; Hawkins, MN; Carson, JL; Gough, P; Marsh, S			Risk of venous thromboembolism in users of hormone replacement therapy	LANCET			English	Article							ESTROGEN REPLACEMENT; ORAL-CONTRACEPTIVES; POSTMENOPAUSAL WOMEN; DISEASE	Background The association between current use of oral contraceptives and increased risk of venous thromboembolism (VTE) has been firmly established. Although data-sheets for hormone replacement therapy (HRT) carry similar warnings as regards VTE, evidence of an association is inconclusive. We carried out a hospital-based case-control study to investigate whether current use of HRT is associated with VTE. Methods We screened all women aged 45-64 years admitted to hospitals in the area of the Oxford Regional Health Authority with a suspected diagnosis of VTE between February, 1993, and December, 1994. We recruited 81 cases of idiopathic VTE and 146 hospital controls with disorders of eyes, skin, ears, respiratory and alimentary tracts, kidneys, bones, and joints, and trauma; controls were matched to cases for age-group and date and district of admission. To increase the study power, an additional 22 cases of idiopathic VTE and 32 hospital controls admitted before February, 1993, were recruited retrospectively. Participants were questioned about medical and gynaecological history, use of oral contraceptives and HRT, use of other drugs within the previous 3 months, and lifestyle and socioeconomic characteristics. Detailed diagnostic data were extracted from the notes of eligible cases. Matched analyses, adjusted for body-mass index, socioeconomic group, and history of varicose veins, were undertaken by conditional logistic regression. Findings 44 (42 . 7%) cases and 44 (24 . 7%) controls were current users of HRT, The adjusted odds ratio for VTE in current users of HRT compared with non-users (never-users and past users combined) was 3 . 5 (95% CI 1 . 8-7 . 0; p<0 . 001). No association was found with past use, and risk appeared to be highest among short-term current users (adjusted likelihood ratio test of trend in odds ratios across different durations of current use, p=0 . 011). Interpretation Current HRT use is associated with risk of VTE, The increased risk may be concentrated in new users. The number of extra cases appears to be only about one in 5000 users per year. These findings need to be weighed against the probable benefits of long-term treatment, including reductions in risks of osteoporotic fracture and coronary heart disease, and the probable modest increase in risk of breast cancer.	CHILDRENS CANC RES GRP,OXFORD,ENGLAND	University of Oxford	Daly, E (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.							[Anonymous], 1974, N Engl J Med, V290, P15; [Anonymous], 1995, LANCET, V346, P1575; Banks E, 1996, BRIT MED J, V312, P638; Breslow N.E., 1980, STAT METHODS CANC RE, P192; *BRIT MED ASS ROYA, 1995, BRIT NATL FORM, V28; COMPSTON JE, 1992, BRIT MED BULL, V48, P309, DOI 10.1093/oxfordjournals.bmb.a072549; Daly E, 1996, MATURITAS, V23, P247, DOI 10.1016/0378-5122(95)00978-7; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; *OPCS, 1995, 1993 BAS SUBP PR PP3; *OPCS, 1990, STAND OCC CLASS, V1; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; RCOG, 1995, REP RCOG WORK PART P; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; 1995, JAMA-J AM MED ASSOC, V273, P199	21	665	675	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					977	980		10.1016/S0140-6736(96)07113-9	http://dx.doi.org/10.1016/S0140-6736(96)07113-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855852				2023-01-03	WOS:A1996VM02700008
J	Grodstein, F; Stampfer, MJ; Goldhaber, SZ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH				Grodstein, F; Stampfer, MJ; Goldhaber, SZ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH			Prospective study of exogenous hormones and risk of pulmonary embolism in women	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; ORAL-CONTRACEPTIVES; THROMBOEMBOLIC DISEASE; VENOUS THROMBOEMBOLISM; MENOPAUSAL WOMEN; PROGESTAGEN; COAGULATION; THROMBOSIS; SAFETY; DEATH	Background Current use of oral contraceptives (OCs) is a well-recognised risk factor for venous thrombosis and consequent pulmonary embolism (PE). Little is known about residual effects of past OC use. Furthermore, few epidemiological studies have assessed the relation between postmenopausal use of hormones and thrombotic disease. Methods in this prospective study information was obtained through questionnaires sent every 2 years (1976-92) to 112 593 women aged 30-55 in 1976, We excluded women with previously diagnosed cardiovascular disease or cancer in 1976 and at the beginning of each subsequent 2-year follow-up period. Findings From self-reports and medical records, we documented 123 cases of primary PE (no identified antecedent cancer, trauma, surgery, or immobilisation). Current users of postmenopausal hormones had an increased risk of primary PE (relative risk adjusted for multiple risk factors 2 . 1 [95% CI 1 . 2-3 . 8]). However, past use showed no relation to PE (1 . 3[0 . 7-2 . 4]). In current users of OCs the risk of primary PE was about twice that in non-users (2 . 2[0 . 8-5 . 9]), but this finding was based on only five cases who were current OC users. Users of OCs in the past had no increase in risk of PE (0 . 8[0 . 5-1 . 2]). These relations were consistent irrespective of cigarette-smoking status. Interpretation Primary PE was uncommon in this cohort. The risk was increased by current though not past use of postmenopausal hormones or OCs.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40935] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1974, N Engl J Med, V290, P15; [Anonymous], 1995, LANCET, V346, P1575; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; KOSTER T, 1995, J INTERN MED, V238, P31, DOI 10.1111/j.1365-2796.1995.tb00896.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LOBO RA, 1992, AM J MED, V92, P283, DOI 10.1016/0002-9343(92)90078-P; MEADE TW, 1988, AM J OBSTET GYNECOL, V158, P1646, DOI 10.1016/0002-9378(88)90203-7; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MELIS GB, 1988, MATURITAS S1, V10, P131; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOTELOVITZ M, 1983, OBSTET GYNECOL, V62, P596; NOTELOVITZ M, 1984, OBSTET GYNECOL, V63, P621; PETTITI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150; POLLER L, 1977, BRIT MED J, V1, P935, DOI 10.1136/bmj.1.6066.935; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; *ROYAL COLL GEN PR, 1974, OR CONTR HLTH; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1993, CARDIOVASCULAR HLTH, P175; STAMPFER MJ, 1992, CIRCULATION, V86, P1; STANGEL JJ, 1977, OBSTET GYNECOL, V49, P314; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, LANCET, V346, P1582	32	447	457	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					983	987		10.1016/S0140-6736(96)07308-4	http://dx.doi.org/10.1016/S0140-6736(96)07308-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855854				2023-01-03	WOS:A1996VM02700010
J	Jensen, LS; KissmeyerNielsen, P; Wolff, B; Qvist, N				Jensen, LS; KissmeyerNielsen, P; Wolff, B; Qvist, N			Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery	LANCET			English	Article							CANCER SURGERY; INFECTIOUS COMPLICATIONS; DELAYED-HYPERSENSITIVITY; RED-CELLS; RANITIDINE; INTERLEUKIN-2; FILTER; RISK	Background Allogeneic blood transfusion is associated with an increased frequency of postoperative infection. We studied whether such events can be avoided by the intraoperative and postoperative use of leucocyte-depleted blood. Methods 589 consecutive patients scheduled for elective colorectal surgery were randomised to receive buffy-coat poor (n=299) or filtered leucocyte-depleted red-cells (n=290) when transfusion was indicated. 260 patients actually received blood transfusion. Three patients were excluded from analysis. Findings The 142 patients randomised to and transfused with buffy-coat-poor blood had a significantly higher frequency of wound infections and intra-abdominal abscesses than the 155 patients who were allocated to this group but who were not transfused. (12 vs 1%, p<0.0001) and (5 vs 0%, p=0.005), respectively. Those receiving buffy-coat-poor blood also had a significantly higher frequency of wound infections and intra-abdominal abscesses than the 118 randomised to and receiving leucocyte-depleted blood (12 vs 0%, p<0.0001) and (5 vs 0%, p=0.017), respectively. Postoperative pneumonia occurred at a significantly higher rate in patients receiving buffy-coat-poor blood: 23 versus 3% in non-transfused patients (p<0.0001), and 23 versus 3% in patients transfused with leucocyte-depleted blood (p<0.001). The mortality rate between the groups was not statistically different. Interpretation Our data suggests that the association between allogeneic blood transfusion and postoperative infection is limited to allogeneic blood products that are not adequately depleted of immunosuppressive leucocytes. This undesirable effect can be reduced by leucocyte depletion with high-efficiency filters.	ODENSE UNIV HOSP, DK-5000 ODENSE, DENMARK	University of Southern Denmark; Odense University Hospital	Jensen, LS (corresponding author), AARHUS UNIV HOSP, DEPT SURG GASTROENTEROL, DK-8000 AARHUS C, DENMARK.			Qvist, Niels/0000-0002-1113-195X				AGARWAL N, 1993, ARCH SURG-CHICAGO, V128, P171; AKIYOSHI T, 1985, CLIN EXP IMMUNOL, V59, P45; BLUMBERG N, 1994, ARCH PATHOL LAB MED, V118, P371; EDNA TH, 1992, J TRAUMA, V33, P659, DOI 10.1097/00005373-199211000-00010; FERNANDEZ LA, 1992, AM J SURG, V163, P263, DOI 10.1016/0002-9610(92)90114-7; FRIEDMAN BA, 1979, TRANSFUSION, V19, P268, DOI 10.1046/j.1537-2995.1979.19379204208.x; GAFTER U, 1992, KIDNEY INT, V41, P143, DOI 10.1038/ki.1992.19; GIANOTTI L, 1993, TRANSFUSION, V33, P458, DOI 10.1046/j.1537-2995.1993.33693296806.x; HALLISSEY MT, 1992, ANN ROY COLL SURG, V74, P59; HAMMER JH, 1992, EUR SURG RES, V24, P133, DOI 10.1159/000129199; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; JENSEN LS, 1994, LANCET, V344, P1429; Jensen LS, 1996, BRIT J SURG, V83, P973, DOI 10.1002/bjs.1800830727; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; KAPLAN J, 1984, BLOOD, V64, P308; KOMAI H, 1994, ANN THORAC SURG, V57, P134, DOI 10.1016/0003-4975(94)90381-6; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MIHOLIC J, 1985, ANN THORAC SURG, V40, P224, DOI 10.1016/S0003-4975(10)60032-X; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; NIELSEN HJ, 1991, CAN J SURG, V34, P146; NIELSEN HJ, 1989, SURGERY, V105, P711; NIELSEN HJ, 1995, BRIT J SURG, V82, P582, DOI 10.1002/bjs.1800820505; NIELSEN HJ, 1994, BRIT J SURG, V81, P1747, DOI 10.1002/bjs.1800811213; RASMUSSEN LA, 1995, J AM COLL SURGEONS, V181, P138; SIRCHIA G, 1990, TRANSFUSION, V30, P30, DOI 10.1046/j.1537-2995.1990.30190117625.x; SPROGOEJAKOBSEN U, 1995, TRANSFUSION, V35, P421, DOI 10.1046/j.1537-2995.1995.35595259153.x; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; WENZ B, 1989, CONTROVERSIES LEUKOC, P27; WENZ B, 1989, ROLE LEUCOCYTE DEPLE, P83; WIDMANN FK, 1991, STANDARDS BLOOD BANK	32	314	318	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	1996	348	9031					841	845		10.1016/S0140-6736(96)06168-5	http://dx.doi.org/10.1016/S0140-6736(96)06168-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826808				2023-01-03	WOS:A1996VK03700008
J	Young, J				Young, J			Caring for older people - Rehabilitation and older people .10.	BRITISH MEDICAL JOURNAL			English	Article								Rehabilitation is concerned with lessening the impact of disabling conditions. These are particularly common in older people and considerable health gain can be achieved by successful rehabilitation. Hospital doctors and general practitioners should be aware of the core principles of rehabilitation, be able to recognise rehabilitation need in their patients, and have sufficient knowledge of their local rehabilitation services to trigger the referral process.			Young, J (corresponding author), ST LUKES HOSP,BRADFORD HOSP TRUST,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			young, john/0000-0003-4085-9306				MARTEN J, 1989, 1 OPCS; Travers AF, 1996, BRIT MED J, V313, P482	2	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					677	681						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811764				2023-01-03	WOS:A1996VH16500031
J	Levinsky, NG				Levinsky, NG			The purpose of advance medical planning - Autonomy for patients or limitation of care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NURSING-HOME RESIDENTS; CARDIOPULMONARY-RESUSCITATION; PREFERENCES; LIFE; DIRECTIVES; PHYSICIANS; DECISIONS				Levinsky, NG (corresponding author), BOSTON UNIV,MED CTR,88 E NEWTON ST,BOSTON,MA 02118, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROWN NK, 1979, NEW ENGL J MED, V300, P1246, DOI 10.1056/NEJM197905313002204; Callahan D., 1987, SETTING LIMITS MED G; CAPRON AM, 1994, HASTINGS CENT REP, V24, P42; Finucane TE, 1996, AM J MED, V100, P126, DOI 10.1016/S0002-9343(97)89449-1; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIESINGER GO, 1995, AM J MED, V99, P13, DOI 10.1016/S0002-9343(99)80098-9; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; HIRSCH CH, 1995, GERIATRICS, V50, P26; KONG D, 1995, BOSTON GLOBE    1120, P10; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; NOYES R, 1977, J AM GERIATR SOC, V25, P470, DOI 10.1111/j.1532-5415.1977.tb00810.x; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; RETTIG RA, 1991, KIDNEY FAILURE FEDER, P89; ROTHMAN D, 1991, STRANGERS BEDSIDE; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	42	42	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					741	743		10.1056/NEJM199609053351012	http://dx.doi.org/10.1056/NEJM199609053351012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VH266	8703178				2023-01-03	WOS:A1996VH26600012
J	LopezJaramillo, P; Teran, E; Molina, G; Rivera, J; Lozano, A				LopezJaramillo, P; Teran, E; Molina, G; Rivera, J; Lozano, A			Oestrogens and depression	LANCET			English	Letter											LopezJaramillo, P (corresponding author), CENT UNIV ECUADOR,FAC MED,MINERAL METAB UNIT,POB 17-21-1060,QUITO,ECUADOR.		Terán, Enrique/L-6000-2016; Lozano, Andres M/A-5058-2012	Terán, Enrique/0000-0001-6979-5655; 				Gregoire AJP, 1996, LANCET, V347, P930, DOI 10.1016/S0140-6736(96)91414-2; LopezJaramillo P, 1996, BRIT J OBSTET GYNAEC, V103, P33, DOI 10.1111/j.1471-0528.1996.tb09512.x; LOZANO A, 1993, REV MED COL MED IMBA, V2, P20; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; ROSELLI M, 1995, HYPERTENSION, V25, P845	5	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					135	136		10.1016/S0140-6736(05)64656-9	http://dx.doi.org/10.1016/S0140-6736(05)64656-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676707				2023-01-03	WOS:A1996UW67300065
J	Falk, S; Fallon, M				Falk, S; Fallon, M			ABC of palliative care - Emergencies	BRITISH MEDICAL JOURNAL			English	Review									UNIV GLASGOW,WESTERN INFIRM,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND	Beatson Oncology Centre; University of Glasgow	Falk, S (corresponding author), BRISTOL ONCOL CTR,BRISTOL,ENGLAND.			Fallon, Marie/0000-0001-9214-0091					0	15	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1525	1528		10.1136/bmj.315.7121.1525	http://dx.doi.org/10.1136/bmj.315.7121.1525			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420498	Green Published, Green Submitted			2023-01-03	WOS:A1997YK98600030
J	Meystre, CJN; Burley, NMJ; Ahmedzai, S				Meystre, CJN; Burley, NMJ; Ahmedzai, S			What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY-RESUSCITATION; CANCER; VIEWS		UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SECT PALLIAT MED,DEPT SURG & ANAESTHET SCI,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Meystre, CJN (corresponding author), LEICESTERSHIRE HOSPICE,LEICESTER LE3 9QE,LEICS,ENGLAND.			Ahmedzai, Sam/0000-0002-2028-8510				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; MORGAN R, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677a; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WHO, 1979, WHO HDB REP RES CANC	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1202	1203		10.1136/bmj.315.7117.1202	http://dx.doi.org/10.1136/bmj.315.7117.1202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393223	Green Published			2023-01-03	WOS:A1997YF25200020
J	Link, MP; Shuster, JJ; Donaldson, SS; Berard, CW; Murphy, SB				Link, MP; Shuster, JJ; Donaldson, SS; Berard, CW; Murphy, SB			Treatment of children and young adults with early-stage non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CANCER STUDY-GROUP; LYMPHOBLASTIC LYMPHOMA; RANDOMIZED TRIAL; THERAPY; CHILDHOOD; HISTOLOGY; LSA2-L2; COMP	Background Children and young adults with early-stage non-Hodgkin's lymphoma have an excellent prognosis, but treatment is prolonged and is associated with many side effects. We performed two studies to determine whether therapy could be simplified. Methods Between 1983 and 1991, we conducted two consecutive trials in children and young adults (age, <21 years) with early-stage non-Hodgkin's lymphoma. In the first trial, patients were treated for 9 weeks with induction chemotherapy consisting of vincristine, doxorubicin, cyclophosphamide, and prednisone, followed by 24 weeks of continuation chemotherapy with mercaptopurine and methotrexate. Half the patients were randomly assigned to receive involved-field irradiation. In the second trial, after the 9 weeks of induction chemotherapy, the patients were randomly assigned to receive 24 weeks of continuation chemotherapy or no further therapy. Results A total of 340 patients were enrolled in the two trials, 12 of whom did not have complete remissions. One hundred thirteen patients received nine weeks of chemotherapy without radiotherapy, 131 received eight months of chemotherapy without radiotherapy, and 67 received eight months of chemotherapy with radiotherapy. At five years, the projected rates of continuous complete remission were 89, 86, and 88 percent for the three groups, respectively. At five years, event-free survival among the patients with early-stage lymphoblastic lymphoma was inferior to that among the patients with other subtypes of lymphoma (63 percent vs. 88 percent, P<0.001). Continuation therapy was effective only in patients with lymphoblastic lymphoma. Conclusions A nine-week chemotherapy regimen without irradiation of the primary sites of involvement is adequate therapy for most children and young adults with early-stage, nonlymphoblastic non-Hodgkin's lymphoma. (C) 1997, Massachusetts Medical Society.	STANFORD UNIV, SCH MED, DEPT RADIAT ONCOL, STANFORD, CA 94305 USA; LUCILE SALTER PACKARD CHILDRENS HOSP, STANFORD, CA USA; UNIV FLORIDA, DEPT STAT, GAINESVILLE, FL 32611 USA; PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, MEMPHIS, TN USA; CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA	Stanford University; Lucile Packard Children's Hospital (LPCH); State University System of Florida; University of Florida; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	Link, MP (corresponding author), STANFORD UNIV, SCH MED, DEPT PEDIAT, 300 PASTEUR DR, STANFORD, CA 94305 USA.		Shuster, Jonathan/ABB-5773-2021	Shuster, Jonathan/0000-0001-9499-5616	NATIONAL CANCER INSTITUTE [U10CA033603, U10CA029139, U10CA031566] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33603, CA-31566, CA-29139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JR, 1993, J CLIN ONCOL, V11, P1024, DOI 10.1200/JCO.1993.11.6.1024; HVIZDALA EV, 1991, J CLIN ONCOL, V9, P1189, DOI 10.1200/JCO.1991.9.7.1189; HVIZDALA EV, 1988, J CLIN ONCOL, V6, P26, DOI 10.1200/JCO.1988.6.1.26; JENKIN RDT, 1984, J CLIN ONCOL, V2, P88, DOI 10.1200/JCO.1984.2.2.88; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LINK MP, 1990, NEW ENGL J MED, V322, P1169, DOI 10.1056/NEJM199004263221701; MAGRATH IT, 1984, BLOOD, V63, P1102; MEADOWS AT, 1989, J CLIN ONCOL, V7, P92, DOI 10.1200/JCO.1989.7.1.92; MURPHY SB, 1980, CANCER, V45, P630, DOI 10.1002/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5; MURPHY SB, 1989, J CLIN ONCOL, V7, P186, DOI 10.1200/JCO.1989.7.2.186; MURPHY SB, 1983, J CLIN ONCOL, V1, P326, DOI 10.1200/JCO.1983.1.5.326; MURPHY SB, 1980, SEMIN ONCOL, V7, P332; PATTE C, 1992, MED PEDIATR ONCOL, V20, P105, DOI 10.1002/mpo.2950200204; PATTE C, 1993, MED PEDIATR ONCOL, V21, P531; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; ROSENBERG SA, 1982, CANCER, V49, P2112; SULLIVAN MP, 1985, CANCER-AM CANCER SOC, V55, P323, DOI 10.1002/1097-0142(19850115)55:2<323::AID-CNCR2820550204>3.0.CO;2-9; TUBERGEN DG, 1995, J CLIN ONCOL, V13, P1368, DOI 10.1200/JCO.1995.13.6.1368; WEINSTEIN HJ, 1984, BLOOD, V64, P422	20	112	119	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1259	1266		10.1056/NEJM199710303371802	http://dx.doi.org/10.1056/NEJM199710303371802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345074				2023-01-03	WOS:A1997YC92000002
J	Campbell, AJ; Robertson, MC; Gardner, MM; Norton, RN; Tilyard, MW; Buchner, DM				Campbell, AJ; Robertson, MC; Gardner, MM; Norton, RN; Tilyard, MW; Buchner, DM			Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FICSIT TRIALS; OLDER ADULTS; RISK-FACTORS; TAI-CHI; COMMUNITY; BALANCE; INTERVENTION; STRENGTH	Objective: To assess the effectiveness of a home exercise programme of strength and balance retraining exercises in reducing falls and injuries in elderly women. Design: Randomised controlled trial of an individually tailored programme of physical therapy in the home (exercise group, n=116) compared with the usual care and an equal number of social visits (control group, n=117). Setting 17 general practices in Dunedin, New Zealand. Subjects: Women aged 80 years and older living in the community and registered with a general practice in Dunedin. Main outcome measures: Number of falls and injuries related to falls and time between falls during one year of follow up; changes in muscle strength and balance measures after six months. Results: After one year there were 152 falls in the control group and 88 falls in the exercise group. The mean (SD) rate of falls was lower in the exercise than the control group (0.87 (1.29) v 1.34 (1.93) falls per year respectively; difference 0.47; 95% confidence interval 0.04 to 0.90). The relative hazard for the first four falls in the exercise group compared with the control group was 0.68 (0.52 to 0.90). The relative hazard for a first fall with injury in the exercise group compared with the control group was 0.61 (0.39 to 0.97). After six months, balance had improved in the exercise group (difference between groups in change in balance score 0.43 (0.21 to 0.65). Conclusions: An individual programme of strength and balance retraining exercises improved physical function and was effective in reducing falls and injuries in women 80 years and older.	UNIV AUCKLAND, SCH MED, INJURY PREVENT RES CTR, AUCKLAND, NEW ZEALAND; UNIV OTAGO SCH MED, DUNEDIN SCH MED, DEPT GEN PRACTICE, DUNEDIN, NEW ZEALAND; VA PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA	University of Auckland; University of Otago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Campbell, AJ (corresponding author), UNIV OTAGO SCH MED, DUNEDIN SCH MED, DEPT MED, POB 913, DUNEDIN, NEW ZEALAND.		Robertson, Mary Clare/A-3964-2009					BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HU MH, 1994, J GERONTOL, V49, pM52, DOI 10.1093/geronj/49.2.M52; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; Myers AH, 1996, BONE, V18, pS87, DOI 10.1016/8756-3282(95)00384-3; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; Tinetti ME, 1996, AM J EPIDEMIOL, V144, P389; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x	24	730	755	2	99	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1065	1069		10.1136/bmj.315.7115.1065	http://dx.doi.org/10.1136/bmj.315.7115.1065			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD445	9366737	Green Published			2023-01-03	WOS:A1997YD44500027
J	LeBars, PL; Katz, MM; Berman, N; Itil, TM; Freedman, AM; Schatzberg, AF				LeBars, PL; Katz, MM; Berman, N; Itil, TM; Freedman, AM; Schatzberg, AF			A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; CLINICAL DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; FREE-RADICALS; RATING-SCALE; MULTICENTER; EFFICACY; TACRINE; RELIABILITY	Context.-EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders, Its use in dementias is based on positive results from only a few controlled clinical trials, most of which did not include standard assessments of cognition and behavior. Objective.-To assess the efficacy and safety of EGb in Alzheimer disease and multi-infarct dementia. Design.-A 52-week, randomized double-blind, placebo-controlled, parallel-group, multicenter study. Patients.-Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia, without other significant medical conditions. Intervention.-Patients assigned randomly to treatment with EGb (120 mg/d) or placebo, Safety, compliance, and drug dispensation were monitored every 3 months with complete outcome evaluation at 12, 26, and 52 weeks. Primary Outcome Measures.-Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC). Results.-From 309 patients included in an intent-to-treat analysis, 202 provided evaluable data for the 52-week end point analysis, In the intent-to-treat analysis, the EGb group had an ADAS-Cog score 1.4 points better than the placebo group (P=.04) and a GERRI score 0.14 points better than the placebo group (P=.004). The same patterns were observed with the evaluable data set in which 27% of patients treated with EGb achieved at least a 4-point improvement on the ADAS-Cog, compared with 14% taking placebo (P=.005); on the GERRI, 37% were considered improved with EGb, compared with 23% taking placebo (P=.003). No difference was seen in the CGIC, Regarding the safety profile of EGb, no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events. Conclusions.-EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.	ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT PSYCHIAT, NEW YORK, NY USA; HARBOR UCLA MED CTR, TORRANCE, CA 90509 USA; NEW YORK MED COLL, DEPT PSYCHIAT, VALHALLA, NY 10595 USA; HARVARD MED CTR, BOSTON, MA USA	Montefiore Medical Center; Yeshiva University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; New York Medical College; Harvard University; Harvard Medical School	LeBars, PL (corresponding author), NYU MED CTR, NEW YORK INST MED RES, DEPT PSYCHIAT, 150 WHITE PLAINS RD, TARRYTOWN, NY 10591 USA.							AGRESTI A, 1989, PSYCHOL BULL, V105, P290, DOI 10.1037/0033-2909.105.2.290; ANDERSON DK, 1994, INT ACAD B, V7, P119; ANTHONY JC, 1982, PSYCHOL MED, V12, P397, DOI 10.1017/S0033291700046730; BALDERESCHI M, 1994, NEUROLOGY, V44, P239, DOI 10.1212/WNL.44.2.239; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Cott J, 1995, PSYCHOPHARMACOL BULL, V31, P745; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DAHLKE F, 1992, PSYCHOPHARMACOL BULL, V28, P425; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEFEUDIS FV, 1991, GINKGO BILOBA EXTRAC, P7; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; HOFFERBERTH B, 1994, HUM PSYCHOPHARM CLIN, V9, P215, DOI 10.1002/hup.470090308; HUGUET F, 1992, J PHARM PHARMACOL, V44, P24, DOI 10.1111/j.2042-7158.1992.tb14357.x; Itil Turan M., 1996, Am J Ther, V3, P63, DOI 10.1097/00045391-199601000-00009; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; KATZMAN R, 1988, AGING BRAIN, P17; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KNOPMAN DS, 1994, NEUROLOGY, V44, P2315, DOI 10.1212/WNL.44.12.2315; KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458; Kristofikova Z, 1997, DEMENT GERIATR COGN, V8, P43; Leber P, 1996, ALZ DIS ASSOC DIS, V10, P31, DOI 10.1097/00002093-199601031-00009; Letzel H, 1996, J DRUG DEV CLIN PR, V8, P77; LOPEZ OL, 1994, NEUROLOGY, V44, P1240, DOI 10.1212/WNL.44.7.1240; Morich FJ, 1996, CLIN DRUG INVEST, V11, P185, DOI 10.2165/00044011-199611040-00001; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; OYAMA Y, 1994, BRAIN RES, V635, P125, DOI 10.1016/0006-8993(94)91431-1; PACKER L, 1995, ADV GINKGO, V4, P23; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; RICHARDSON JS, 1993, ANN NY ACAD SCI, V695, P73, DOI 10.1111/j.1749-6632.1993.tb23031.x; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SCHWARTZ GE, 1983, PSYCHOL REP, V53, P479, DOI 10.2466/pr0.1983.53.2.479; STERN RG, 1994, AM J PSYCHIAT, V151, P390; VICTOROFF J, 1995, AM J PSYCHIAT, V152, P1476; WARBURTON DM, 1986, PRESSE MED, V15, P1595; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016	42	764	796	0	93	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1327	1332		10.1001/jama.278.16.1327	http://dx.doi.org/10.1001/jama.278.16.1327			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343463				2023-01-03	WOS:A1997YA90500033
J	Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC				Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC			The effect of Medicare's payment system for rehabilitation hospitals on length of stay, charges, and total payments	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Medicare's system for the payment of rehabilitation hospitals is based on limits derived from a hospital's average allowable charges per patient discharged during a base year. Thereafter, payments are capped, but hospitals receive incentive payments if charges per patient are reduced in succeeding years. We hypothesized that per-patient charges would increase during the base year and then decrease in subsequent years. Hospitals would thus have higher reimbursement limits and receive incentive payments for reducing their charges. Methods We analyzed Medicare claims data for 190,921 discharges from 69 rehabilitation hospitals from 1987 through 1994. We compared total charges, length of stay, and interim payments before, during, and alter each hospital's base year. Results After we controlled for inflation and temporal and seasonal trends, mean charges per patient discharged increased from $25,131 for patients discharged before the base year to $32,167 for patients discharged in the base year (a 28 percent increase, P<0.001) and the mean length of stay increased from 22.1 to 26.7 days (a 21 percent increase, P<0.001). After the base year, mean charges decreased to $29,307 (a 9 percent decrease) and the mean length of stay decreased to 24.0 days (a 10 percent decrease) (P<0.001 for both comparisons). Analysis of data on patients according to diagnosis-for example, spinal cord injury, brain injury, stroke, amputation or deformity, hip fracture, and arthritis or other joint disorders-showed similar findings for each, with increases in charges and length of stay in the base year, followed by small reductions thereafter For-profit hospitals had greater increases than nonprofit hospitals in their per-patient charges (mean increase, $7,434 vs. $2,929; P<0.001) and length of slay (mean increase, 4.6 vs. 2.3 days, P<0.001) during the base year. Conclusions Although Medicare's reimbursement system far rehabilitation hospitals put an upper limit on total payments, its design was associated with substantial extra costs, including significantly increased payments to hospitals and doctors and increased numbers of hospital days for the average patient. (C) 1997, Massachusetts Medical Society.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chan, L (corresponding author), HLTH CARE FINANCING ADM,DIV CLIN STAND & QUAL,REG 10,MS-RX 40,2201 6TH AVE,SEATTLE,WA 98121, USA.							ALTMAN DG, 1991, PRACTICAL STAT MED R, P194; ARNOLD S, 1992, C9205 PROSP PAYM ASS, P16; *BUR LAB STAT, 1996, CPI DET REP DAT MARC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CROMWELL J, 1990, TEFRA PSYCH HOSP UNI; Davis L M, 1993, Adv Health Econ Health Serv Res, V14, P87; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Guterman S, 1988, Health Care Financ Rev, V9, P67; HARADA N, 1993, INQUIRY-J HEALTH CAR, V30, P54; HARROW B, 1990, IMPACT ANAL TEFRA SY; *HLTH CAR FIN ADM, 1994, MED PROV REIMB MAN 1, P30; *HLTH CAR FIN ADM, 1995, REG OFF MAN MED, pI25; HOSEK S, 1986, R3424HCFA RAND, P1; HSIA DC, 1990, NEW ENGL J MED, V322, P1540; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Langenbrunner J C, 1989, Health Care Financ Rev, V10, P91; *PROSP PAYM ASS CO, 1996, REP REC C MARCH 1 19; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Searle S.R., 1992, VARIANCE COMPONENTS, P168; 1993, FED REGISTER, V58, P63820	21	71	71	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					978	985		10.1056/NEJM199710023371406	http://dx.doi.org/10.1056/NEJM199710023371406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309104				2023-01-03	WOS:A1997XY42300006
J	Ball, S; Borman, N				Ball, S; Borman, N			Pharmacogenetics and drug metabolism	NATURE BIOTECHNOLOGY			English	Editorial Material									NOVARTIS PHARMACEUT,GEN & EXPT TOXICOL,E HANOVER,NJ 07936	Novartis	Ball, S (corresponding author), WYETH AYERST RES,DRUG METABOLISM,CN 8000,PRINCETON,NJ 08543, USA.							BALL SE, 1995, DRUG CHEM TOXICOL, V18, P1, DOI 10.3109/01480549509017855; DALY AK, 1995, J MOL MED-JMM, V73, P539; IDLE JR, 1979, DRUG METAB REV, V9, P301, DOI 10.3109/03602537908993896; Nebert DW, 1997, AM J HUM GENET, V60, P265; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; 1996, NAT BIOTECHNOL, V14, P1516	6	10	10	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					925	926		10.1038/nbt1097-925	http://dx.doi.org/10.1038/nbt1097-925			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335033				2023-01-03	WOS:A1997XZ28500003
J	Compston, JE				Compston, JE			Designer oestrogens: fact or fantasy?	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN; RISK; RALOXIFENE				Compston, JE (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Compston JE, 1997, DRUGS, V53, P727, DOI 10.2165/00003495-199753050-00001; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DELMAS PD, IN PRESS P ENDOCR SO; Draper MW, 1996, J BONE MINER RES, V11, P835; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	11	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					676	677		10.1016/S0140-6736(97)22036-2	http://dx.doi.org/10.1016/S0140-6736(97)22036-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291896				2023-01-03	WOS:A1997XU97700002
J	Breslin, PAS; Beauchamp, GK				Breslin, PAS; Beauchamp, GK			Salt enhances flavour by suppressing bitterness	NATURE			English	Letter							SODIUM-CHLORIDE; MIXTURES				Breslin, PAS (corresponding author), MONELL CHEM SENSES CTR, 3500 MARKET ST, PHILADELPHIA, PA 19104 USA.			Breslin, Paul/0000-0001-5988-8401				BRAND JG, 1992, IFT BAS SYM, V7, P517; Breslin PAS, 1996, TRENDS FOOD SCI TECH, V7, P390, DOI 10.1016/S0924-2244(96)10039-X; Breslin PAS, 1995, CHEM SENSES, V20, P609, DOI 10.1093/chemse/20.6.609; DEGRAAF C, 1989, CHEM SENSES, V14, P81; Denton D.A., 1982, HUNGER SALT; FORSYTHE RH, 1980, BIOL BEHAVIORAL ASPE, P221; GILLETTE M, 1985, FOOD TECHNOL-CHICAGO, V39, P47; KEMP SE, 1994, J FOOD SCI, V59, P682, DOI 10.1111/j.1365-2621.1994.tb05592.x; LAWLESS HT, 1979, J COMP PHYSIOL PSYCH, V93, P538, DOI 10.1037/h0077582; Michell A R, 1989, Nutr Res Rev, V2, P149, DOI 10.1079/NRR19890012; WOSKOW MH, 1969, FOOD TECHNOL-CHICAGO, V23, P1364	11	158	163	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					563	563		10.1038/42388	http://dx.doi.org/10.1038/42388			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177340				2023-01-03	WOS:A1997XC52200035
J	Pan, D; Hsu, K; Ray, SC				Pan, D; Hsu, K; Ray, SC			Ecchymoses and eschars at sites of injection	LANCET			English	Article							RENAL-FAILURE; CALCIPHYLAXIS; NECROSIS		JOHNS HOPKINS UNIV HOSP,DEPT MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine			Ray, Stuart C./B-7527-2008	Ray, Stuart C./0000-0002-1051-7260				GIPSTEIN RM, 1976, ARCH INTERN MED, V136, P1273, DOI 10.1001/archinte.136.11.1273; MEHTA RL, 1990, AM J MED, V88, P252, DOI 10.1016/0002-9343(90)90150-C; ROE SM, 1994, AM SURGEON, V60, P81; Ruggian JC, 1996, AM J KIDNEY DIS, V28, P409, DOI 10.1016/S0272-6386(96)90499-0; Selye H., 1962, CALCIPHYLAXIS, P48	5	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1364	1364		10.1016/S0140-6736(97)03156-5	http://dx.doi.org/10.1016/S0140-6736(97)03156-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149700				2023-01-03	WOS:A1997WY34200012
J	Dong, BJ; Hauck, WW; Gambertoglio, JG; Gee, L; White, JR; Bubp, JL; Greenspan, FS				Dong, BJ; Hauck, WW; Gambertoglio, JG; Gee, L; White, JR; Bubp, JL; Greenspan, FS			Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE; THERAPY; BIOAVAILABILITY; TABLET	Objective.-To compare relative bioavailability of Synthroid, Levoxine (Levoxine has been renamed Levoxyl), and 2 generic levothyroxine sodium preparations. Design.-Single-blind (primary investigators blinded), randomized, 4-way crossover trial. Setting.-Ambulatory care. Patients.-Twenty-two women with hypothyroidism who were clinically and chemically euthyroid and were receiving levothyroxine sodium, 0.1 or 0.15 mg. Interventions.-All patients received each of the 4 levothyroxine products for 6-week periods in the same dosage as their prestudy regimen with no washout period. The order of the drug sequences was randomly determined before study initiation. Main Outcome Measures.-Area under the curve, time to peak serum concentrations, and peak serum concentrations of thyroxine, triiodothyronine, and free thyroxine index for all 4 products. Results.-All data analyses were completed prior to unblinding of the product codes. No significant differences between the 4 products were found in area under the curve or peak serum concentrations of total thyroxine, total triiodothyronine, or free thyroxine index, Although Synthroid produced a more rapid rise in total serum triiodothyronine concentration and a higher total peak serum triiodothyronine concentration than the other products, these differences were not statistically significant (P=.08). The Food and Drug Administration criterion for relative bioequivalence within 90% confidence intervals (0.8-1.25) was demonstrated (P<.05) for all pairs of products, Relative bioequivalence of 0.95 to 1.07 was demonstrated, tighter than the current bioequivalence criterion for oral formulations. Conclusions.-The 4 generic and brand-name levothyroxine preparations studied are different but are bioequivalent by current Food and Drug Administration criteria and are interchangeable in the majority of patients receiving thyroxine replacement therapy. Further investigation is required to determine whether our results are equally applicable to all existing levothyroxine preparations.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT BIOSTAT & EPIDEMIOL,DIV BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Dong, BJ (corresponding author), UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT CLIN PHARM,MED CTR,C-152,521 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.							AIN KB, 1993, THYROID, V3, P81, DOI 10.1089/thy.1993.3.81; ANDERSON S, 1990, J PHARMACOKINET BIOP, V18, P259, DOI 10.1007/BF01062202; BERG JA, 1992, J CLIN PHARMACOL, V32, P1135; BERG JA, 1989, DICP ANN PHARMAC, V23, P812, DOI 10.1177/106002808902301018; BLOUIN RA, 1989, CLIN PHARMACY, V8, P588; BROWER JF, 1984, J PHARM SCI, V73, P1315, DOI 10.1002/jps.2600730937; CARMEYER NR, 1991, AM J HOSP PHARM, V48, P735; Chow S, 1992, DESIGN ANAL BIOAVAIL; Cochran W.G., 1957, EXPT DESIGNS, p[117, 132, 244]; CURRY SH, 1988, DRUG INTEL CLIN PHAR, V22, P589, DOI 10.1177/106002808802200715; DAVIS HA, 1962, BLOOD VOLUME DYNAMIC; Dong B J, 1991, J Am Board Fam Pract, V4, P167; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; HAUCK WW, 1992, INT J CLIN PHARM TH, V30, P181; HENNESSEY JV, 1985, ANN INTERN MED, V102, P770, DOI 10.7326/0003-4819-102-6-770; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; *IMS AM LTD, 1988, NAT PRESCR AUD BAS D; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; Neter J., 1974, J R STAT SOC C-APPL; SAWIN CT, 1984, ANN INTERN MED, V100, P641, DOI 10.7326/0003-4819-100-5-641; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TOFT AD, 1994, NEW ENGL J MED, V331, P174; *US PHARM, 1985, OFF MON LEV SOD LEV; Waterfield RL, 1931, J PHYSIOL-LONDON, V72, P110, DOI 10.1113/jphysiol.1931.sp002765; WESTLAKE WJ, 1981, BIOMETRICS, V37, P589	26	143	147	1	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1205	1213		10.1001/jama.277.15.1205	http://dx.doi.org/10.1001/jama.277.15.1205			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103344				2023-01-03	WOS:A1997WT40300031
J	Wilson, RPH; Hatcher, J; Barton, S; Walley, T				Wilson, RPH; Hatcher, J; Barton, S; Walley, T			Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: An observational study	BRITISH MEDICAL JOURNAL			English	Article							COSTS; ENGLAND	Objective-To investigate the variation in prescribing among general practices by examining the contribution to this variation of fundholding, training status, partnership status, and the level of deprivation in the practice population and to investigate the extent to which fundholding has been responsible for any changes in prescribing. Design-Analysis of prescribing data (PACT) for the years 1990-1 (before fundholding) and 1993-4 (after fundholding). Use of multiple linear regressions to investigate the variation among practices in total prescribing costs (net ingredient cost per prescribing unit), prescribing volume (items per 1000 prescribing units), and mean cost per item in each of the two years and also the change in these variables between years. Setting-Former Mersey region. Subjects-384 practices. Results-The models developed explained the variation in cost per item (43% of variation explained for 1990-1, 38% for 1993-4) and prescribing volume (34% for 1990-1, 38% for 1993-4) better than the variation in total prescribing costs (3% for 1990-1, 7% for 1993-4). The models developed to explain the change in these variables between years did not explain more than 10% of the variation. Most of the explained variation in the change in total prescribing costs was accounted for by fundholding. Of the pound 3.71 saved by first wave fundholders compared with non-fundholders pound 3.57 was attributable to fundholding alone. Conclusion-In neither year did fundholding make a major contribution to the variation in prescribing behaviour among practices, which was better explained by deprivation, training status, and partnership status, but it did seem largely responsible for differences in the rise of total prescribing costs between fundholders and non-fundholders.	UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool								*AUD COMM, 1996, WHAT DOCT ORD STUD G; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRITTEN N, 1995, BRIT MED J, V310, P1067, DOI 10.1136/bmj.310.6986.1067c; Department of Health, 1994, EV HOUS COMM HLTH CO; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GLENNERSTER H, 1994, EVALUATING NHS REFOR; *GOV STAT SERV, 1995, STAT B GOV  STAT SER; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HEALEY AT, 1994, HEALTH ECON, V3, P47, DOI 10.1002/hec.4730030107; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; LLOYD DCEF, 1995, BRIT MED J, V310, P1068, DOI 10.1136/bmj.310.6986.1068b; MARINKER M, 1994, CONTROVERSIES HLTH C; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; PRINGLE M, 1994, BR J GEN PRACT, V44, P543; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; Wilson R, 1995, LANCET, V346, P1710, DOI 10.1016/S0140-6736(95)92877-4; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; Wilson-Davis K, 1992, PHARMACOEPIDEM DR S, V1, P341, DOI [10.1002/pds.2630010606, DOI 10.1002/PDS.2630010606]; 1996, GP MAGAZINE      FEB	24	35	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					595	599						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806250				2023-01-03	WOS:A1996VG10800019
J	Orentlicher, D				Orentlicher, D			The legalization of physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DOCTORS; OREGON; KILL				Orentlicher, D (corresponding author), INDIANA UNIV, SCH LAW INDIANAPOLIS, CTR LAW & HLTH, 735 W NEW YORK ST, INDIANAPOLIS, IN 46202 USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1995, ETHICAL ISSUES SUICI, P206; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; generally, 1994, ISSUES LAW MED, V10, P91; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KASS LR, 1989, PUBLIC INTEREST, P25; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LESSENBERRY J, 1996, NY TIMES        0504, P10; LEWIN T, 1996, NY TIMES        0521, pA14; MCFADDEN RD, 1985, NY TIMES        0612, pA1; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RUBENFELD J, 1989, HARVARD LAW REV, V102, P737, DOI 10.2307/1341305; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, NY TIMES        1005, pD23	30	54	54	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					663	667		10.1056/NEJM199608293350912	http://dx.doi.org/10.1056/NEJM199608293350912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD425	8687525				2023-01-03	WOS:A1996VD42500012
J	deSmet, PAGM; vandenEertwegh, AJM; Sticker, BHC				deSmet, PAGM; vandenEertwegh, AJM; Sticker, BHC			Hepatotoxicity associated with herbal tablets	BRITISH MEDICAL JOURNAL			English	Letter									MERWEDE HOSP,DORDRECHT,NETHERLANDS; NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,RIJSWIJK,NETHERLANDS		deSmet, PAGM (corresponding author), ROYAL DUTCH ASSOC ADVANCEMENT PHARM,THE HAGUE,NETHERLANDS.							BISSET NG, 1994, HERBAL DRUGS PYTOPHA, P326; COX D, 1989, HUM TOXICOL, V8, P501, DOI 10.1177/096032718900800612; TAKEGOSHI K, 1986, Gastroenterologia Japonica, V21, P62	3	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					92	92		10.1136/bmj.313.7049.92	http://dx.doi.org/10.1136/bmj.313.7049.92			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688761	Green Published			2023-01-03	WOS:A1996UX69800024
J	Enderby, P; Emerson, J				Enderby, P; Emerson, J			Speech and language therapy: Does it work?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; DYSARTHRIC SPEAKER; APHASIA; CHILDREN; STROKE; TRIAL		FRENCHAY HOSP, SPEECH & LANGUAGE THERAPY RES UNIT, BRISTOL BS16 1LE, AVON, ENGLAND		Enderby, P (corresponding author), UNIV SHEFFIELD, NO GEN HOSP, DEPT HLTH CARE ELDERLY PEOPLE, COMMUNITY SCI CTR, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND.			Enderby, Pamela/0000-0002-4371-9053				ALBERY L, 1984, BRIT J DISORD COMMUN, V19, P115; ANDREWS G, 1980, J SPEECH HEAR DISORD, V45, P287, DOI 10.1044/jshd.4503.287; BASSO A, 1979, ARCH NEUROL-CHICAGO, V36, P190, DOI 10.1001/archneur.1979.00500400044005; BELLAIRE K, 1986, J COMMUN DISORD, V19, P271, DOI 10.1016/0021-9924(86)90033-X; BEUKELMAN DR, 1977, J SPEECH HEAR DISORD, V42, P265, DOI 10.1044/jshd.4202.265; BRYEN DN, 1985, J SPEC EDUC, V19, P7, DOI 10.1177/002246698501900103; CARDING PN, 1992, EUR J DISORDER COMM, V27, P137; DAVID RM, 1982, BRIT J DISORDERS COM, V14, P85; Dodd B., 1990, AUSTR J HUMAN COMMUN, V18, P29, DOI [10.3109/asl2.1990.18.issue-1.03, DOI 10.3109/ASL2.1990.18.ISSUE-1.03]; Eiserman WD., 1990, J EARLY INTERV, V14, P297, DOI [10.1177/105381519001400402, DOI 10.1177/105381519001400402]; Enderby P, 1992, Health Trends, V24, P61; ENDERBY P., 1995, DOES SPEECH LANGUAGE; ENDERBY P, 1989, RECENT ADV CLIN DYSA; LANCER JM, 1988, J LARYNGOL OTOL, V102, P423, DOI 10.1017/S0022215100105250; LINCOLN NB, 1984, LANCET, V1, P1197; MASTERSON JJ, 1993, AJSLT, V1, P5; MEIKLE M, 1979, BRIT MED J, V2, P87, DOI 10.1136/bmj.2.6182.87; OLSWANG LB, 1991, LANG SPEECH HEAR SER, V22, P255; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PEARSON VAH, 1995, PUBLIC HEALTH, V109, P143, DOI 10.1016/S0033-3506(05)80008-3; PERRY A, 1988, BRIT J DISORD COMMUN, V23, P23; ROBERTSON SJ, 1984, BRIT J DISORD COMMUN, V19, P213; ROULSTONE S, 1996, RCSLT B, V528, P16; ROY N, 1993, J VOICE, V7, P242, DOI 10.1016/S0892-1997(05)80333-9; SCARBOROUGH HS, 1990, J SPEECH HEAR RES, V33, P70, DOI 10.1044/jshr.3301.70; SCOTT S, 1983, J NEUROL NEUROSUR PS, V46, P140, DOI 10.1136/jnnp.46.2.140; SCOTT S, 1984, J NEUROL NEUROSUR PS, V47, P302, DOI 10.1136/jnnp.47.3.302; SHEWAN CM, 1984, BRAIN LANG, V23, P272, DOI 10.1016/0093-934X(84)90068-3; SUBBARAO SP, 1991, INDIAN J CANC, V28, P218; VANDEMARK DR, 1986, CLEFT PALATE J, V23, P215; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WERTZ RT, 1986, ARCH NEUROL-CHICAGO, V43, P653, DOI 10.1001/archneur.1986.00520070011008; WERTZ RT, 1987, TOP LANG DISORD, V8, P1, DOI 10.1097/00011363-198712000-00003; YAMAGUCHI H, 1993, J VOICE, V7, P250, DOI 10.1016/S0892-1997(05)80334-0	34	25	25	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	1996	312	7047					1655	1658		10.1136/bmj.312.7047.1655	http://dx.doi.org/10.1136/bmj.312.7047.1655			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV489	8664724	Green Published			2023-01-03	WOS:A1996UV48900030
J	Emanuel, EJ				Emanuel, EJ			Cost savings at the end of life - What do the data show?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; NATIONAL HOSPICE; CANCER-PATIENTS; CARE; DEATH; HOME; EXPENDITURES; SERVICES; TRIAL	Medical care at the end of life consumes 10% to 12% of the total health care budget and 27% of the Medicare budget. Many people claim that increased use of hospice and advance directives and lower use of high-technology interventions for terminally ill patients will produce significant cost savings. However, the studies on cost savings from hospice and advance directives are not definitive, The 3 randomized trials show no savings from these interventions, but either they are too small for confidence in their negative results or their intervention and cost accounting are flawed, The nonrandomized trials of hospice and advance directives show a wide range of savings, from 68% to none. Five methodological issues obscure the assessment of these studies: (1) selection bias in those patients who use hospice and advance directives, (2) the different time frames of assessing the costs, (3) the limited types of medical costs evaluated, (4) the variability of reporting the savings, and (5) the lack of generalizability of the findings to other patient populations, A more definitive study that assessed patients' end-of-life care preferences, use of hospice and advance directives, and direct and indirect costs would be desirable, In the absence of such a study, the existing data suggest that hospice and advance directives can save between 25% and 40% of health care costs during the last month of life, with savings decreasing to 10% to 17% over the last 6 months of life and decreasing further to 0% to 10% over the last 12 months of life. These savings are less than most people anticipate. Nevertheless, they do indicate that hospice and advance directives should be encouraged because they certainly do not cost more and they provide a means for patients to exercise their autonomy over end-of-life decisions.	HARVARD UNIV,SCH MED,DIV MED ETH,BOSTON,MA 02115	Harvard University; Harvard Medical School	Emanuel, EJ (corresponding author), DANA FARBER CANC INST,CTR OUTCOMES & POLICY RES,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.							Amado A, 1979, Nurs Outlook, V27, P522; Berwick DM, 1995, HASTINGS CENT REP, V25, pS21, DOI 10.2307/3527853; BILLINGS JA, 1995, HARV MED SCH DIV MED; BLOOM BS, 1980, MED CARE, V18, P560, DOI 10.1097/00005650-198005000-00009; BROOKS CH, 1984, MED CARE, V22, P691, DOI 10.1097/00005650-198408000-00002; CHAMBERS CV, 1994, ARCH INTERN MED, V154, P541, DOI 10.1001/archinte.154.5.541; CLEMENS SL, 1959, AUTOBIOGRAPHY, pCH29; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DORONZIO JC, 1993, NY TIMES        0608, pA25; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; EMANUEL EJ, 1994, NEW ENGL J MED, V331, P478; Emanuel LL, 1995, HASTINGS CENT REP, V25, pS14, DOI 10.2307/3527851; FAIRCLOUGH HR, 1929, SATIRES EPISTLES ARS, P246; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GRAY D, 1987, J CHRON DIS, V40, P801, DOI 10.1016/0021-9681(87)90132-9; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KANE RL, 1984, LANCET, V1, P890; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MAKSOUD A, 1993, ARCH INTERN MED, V153, P1249, DOI 10.1001/archinte.153.10.1249; MITCHELL A, 1994, NEW ENGL J MED, V331, P478; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; MOR V, 1985, HEALTH SERV RES, V20, P407; *NAT HOSP ORG, 1995, ANAL COST SAV MED HO; PAULOS JA, 1990, INNUMERACY MATH ILLI; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCITOVSKY AA, 1994, MILBANK Q, V72, P561, DOI 10.2307/3350356; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; TENO J, 1993, CLIN RES, V41, pA551; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Waldo D R, 1989, Health Care Financ Rev, V10, P111; WEEKS WB, 1994, ARCH INTERN MED, V154, P2077, DOI 10.1001/archinte.154.18.2077; 1996, JAMA-J AM MED ASSOC, V275, P1232; 1995, JAMA-J AM MED ASSOC, V274, P1591	43	188	189	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1907	1914		10.1001/jama.275.24.1907	http://dx.doi.org/10.1001/jama.275.24.1907			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UR975	8648872				2023-01-03	WOS:A1996UR97500037
J	Entwistle, VA; Watt, IS; Bradbury, R; Pehl, LJ				Entwistle, VA; Watt, IS; Bradbury, R; Pehl, LJ			Media coverage of the Child B case	BRITISH MEDICAL JOURNAL			English	Article								The case of a girl with leukaemia, known as Child B, hit the headlines in March 1995 when her father refused to accept the advice of doctors who counselled against further treatment and took Cambridge and Huntingdon Health Authority to court for refusing to fund chemotherapy and a second bone transplant for her in the private sector. British national newspapers varied greatly in the way they covered the case. Some paid little attention to clinical considerations and presented the case as an example of rationing based on financial considerations. Their selective presentations meant that anyone reading just one newspaper would have received only limited and partial information. If members of the public are to participate in debates about treatment decisions and health care rationing, means other than the media will need to be found to inform and involve them.			Entwistle, VA (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				ALLEN D, 1995, NEWS WORLD      0312, P20; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; ENTWISTLE VA, IN PRESS CONTROVERSI, V2; LEFANU J, 1995, DAILY TELEGRAPH 0311, P23; *NHS EX, 1995, PRIOR PLANN GUID 199; PALMER J, 1995, DAILY MIRROR    0313, P4; Sheldon T, 1993, RATIONING ACTION, P3; SMITH R, 1995, BRIT MED J, V310, P686, DOI 10.1136/bmj.310.6981.686; STUTTAFORD T, 1995, TIMES           0313, P3; WEALE S, 1995, GUARDIAN        0310, P1; 1995, DAILY EXPRESS   0311, P8; 1995, DAILY TELEGRAPH 0313, P20; 1995, TIMES           0311, P17	13	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1587	1591		10.1136/bmj.312.7046.1587	http://dx.doi.org/10.1136/bmj.312.7046.1587			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664671	Green Published			2023-01-03	WOS:A1996UU80600024
J	Hollenberg, SM; Parrillo, JE				Hollenberg, SM; Parrillo, JE			Critical care medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK SURGICAL PATIENTS; OXYGEN DELIVERY				Hollenberg, SM (corresponding author), RUSH MED COLL, CHICAGO, IL 60612 USA.		Hollenberg, Steven/AAR-4522-2020	Hollenberg, Steven/0000-0003-1293-8496				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; CIVETTA JM, 1990, ANN SURG, V212, P266, DOI 10.1097/00000658-199009000-00005; ESSERMAN L, 1995, JAMA-J AM MED ASSOC, V274, P1544, DOI 10.1001/jama.274.19.1544; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SUFFREDINI AF, 1994, CRIT CARE MED, V22, pS12; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; 1996, JAMA-J AM MED ASSOC, V275, P1232	16	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1799	1800		10.1001/jama.275.23.1799	http://dx.doi.org/10.1001/jama.275.23.1799			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642716				2023-01-03	WOS:A1996UQ15200015
J	Jacobson, BS; Stolz, DB; Schnitzer, JE				Jacobson, BS; Stolz, DB; Schnitzer, JE			Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease	NATURE MEDICINE			English	Editorial Material							DISCOIDEUM PLASMA-MEMBRANE; GEL-ELECTROPHORESIS; ANGIOGENESIS; CYTOSKELETON; VASCULATURE; INVITRO		UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Jacobson, BS (corresponding author), UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003, USA.							BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUCK CA, 1995, MOL BASIS CANC, P172; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; CHANEY LK, 1983, J BIOL CHEM, V258, P62; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; JACOBSON BS, 1992, EUR J CELL BIOL, V58, P296; JACOBSON BS, 1977, SCIENCE, V195, P302, DOI 10.1126/science.831278; PATTON WF, 1989, ANAL BIOCHEM, V179, P37, DOI 10.1016/0003-2697(89)90197-8; PATTON WF, 1989, J CELL SCI, V92, P85; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHWARTZ LM, 1995, METHOD CELL BIOL, V46, P107; SHIOZAWA JA, 1987, BIOCHEMISTRY-US, V26, P4884, DOI 10.1021/bi00389a041; STOLZ DB, 1991, IN VITRO CELL DEV B, V27, P169; STOLZ DB, 1992, J CELL SCI, V103, P53; STOLZ DB, IN PRESS CELL BIOL L	22	39	42	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1996	2	4					482	484		10.1038/nm0496-482	http://dx.doi.org/10.1038/nm0496-482			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UD314	8597963				2023-01-03	WOS:A1996UD31400056
J	Barer, D				Barer, D			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Barer, D (corresponding author), NEWCASTLE GEN HOSP,DEPT GERIATR MED,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.							BARER DH, IN PRESS EUROPEAN ME; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HORTON R, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92043-9; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7	5	2	2	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					391	392						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598712				2023-01-03	WOS:A1996TU69500039
J	Meier, DE; Morrison, RS; Cassel, CK				Meier, DE; Morrison, RS; Cassel, CK			Improving palliative care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CANCER PAIN MANAGEMENT; TERMINALLY ILL PATIENTS; PHYSICIAN ATTITUDES; MEDICAL-EDUCATION; ADVANCE DIRECTIVES; DYING PATIENT; UNITED-STATES; DEATH; HOSPICE; LIFE	Although most deaths in the United States occur in hospitals, data suggest that hospitals and physicians are not equipped to handle the medical and psychosocial problems of dying patients. In this article, we review the barriers to achieving a peaceful death, including inadequate medical professional education on palliative care, and public and professional uncertainty about the difference between forgoing life-sustaining treatment and active euthanasia, and health professionals' difficulty recognizing when patients are dying and the associated sense that death is a professional failure. Other barriers include fiscal constraints on the length of stay, the number of nurses available to care for dying patients, legal and regulatory constraints on obtaining opioid prescriptions, and a segregated system of hospice care that requires patients to be separated from familiar health care providers and settings in order to receive palliative care at the end of life. Identifying the opportunities that can improve the delivery of palliative care at the end of life is the first step toward developing corrective approaches. Strategies that enhance these opportunities are proposed.			Meier, DE (corresponding author), MT SINAI MED CTR, BOX 1070, NEW YORK, NY 10029 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AM MED ASS, 1993, ANN MED SCH QUEST 2; *AM SOC CLIN ONC A, 1992, J CLIN ONCOL, V10, P1976; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; ANGAROLO R, 1994, APS B, V4, P9; [Anonymous], 1994, AHCPR PUBL, V94-0592; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BERRY ZS, 1993, JAMA-J AM MED ASSOC, V270, P221, DOI 10.1001/jama.270.2.221; BLANK LL, 1995, WESTERN J MED, V163, P297; Byock I R, 1993, J Palliat Care, V9, P25; Byock I R, 1994, J Palliat Care, V10, P8; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CASSEL C, 1996, ACP OBSERVER     JUL, P2; CASSEL C, 1994, I MED WORKSH EX FEAS; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CHERNY NI, 1995, CANCER-AM CANCER SOC, V76, P2181, DOI 10.1002/1097-0142(19951201)76:11<2181::AID-CNCR2820761102>3.0.CO;2-F; CHERNY NI, 1994, P AMSLC CLIN ONCOL, V12, pA434; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1996, J GEN INTERN MED, V11, P422, DOI 10.1007/BF02600190; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DICKINSON GE, 1985, J MED EDUC, V60, P942; DIDICH J, 1989, CLEV CLIN J MED, V56, P762, DOI 10.3949/ccjm.56.8.762; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; FORD G, 1993, OXFORD TXB PALLIATIV, P43; GIANELLI D, 1996, AM MED NEWS     0916, P5; Gilligan T, 1996, ANN INTERN MED, V125, P137, DOI 10.7326/0003-4819-125-2-199607150-00010; GRAY D, 1987, J CHRON DIS, V40, P801, DOI 10.1016/0021-9681(87)90132-9; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; *HAST CTR, 1987, GUID TERM LIF SUST T; HERMAN TA, 1980, NEW YORK STATE J MED, V80, P200; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; JORANSON DE, 1994, J PAIN SYMPTOM MANAG, V9, P244, DOI 10.1016/0885-3924(94)90101-5; JORANSON DE, 1995, AM PAIN SOC B, V5, P1; KANE AC, 1986, OMEGA, V16, P11; Kane RS, 1996, J AM GERIATR SOC, V44, P321, DOI 10.1111/j.1532-5415.1996.tb00923.x; KIDDER D, 1992, HEALTH SERV RES, V27, P195; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lewin Tamar, 1996, N Y Times Web, pD20; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; LYNN J, 1995, WESTERN J MED, V163, P250; MacDonald N, 1993, J Cancer Educ, V8, P197; MACDONALD N, 1991, CANCER DETECT PREV, V15, P253; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MEIER DE, 1993, PHYSICIAN ASSISTED D; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; Morrison R S, 1995, Trends Health Care Law Ethics, V10, P91; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MORRISON RS, 1994, GENERATIONS, V18, P48; NARKIEWICZ R, 1986, AM J HOSP CARE, P12; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2; *NAT HOSP ORG, 1995, NAT HOSP ORG FACT SH; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT; OJIMCNAIR K, 1984, HLTH MARKETING Q, V2, P119; PERRONE C, 1995, 712901 NAT HOSP ORG; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Portenoy R K, 1990, J Pain Symptom Manage, V5, pS46; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; RAPPAPORT W, 1993, SURGERY, V113, P163; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT J, 1993, OXFORD TXB PALLIATIV; SCOTT RA, 1995, MILBANK Q, V73, P77, DOI 10.2307/3350314; SERAVALLI EP, 1988, NEW ENGL J MED, V319, P1728, DOI 10.1056/NEJM198812293192609; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; The Joint Commission on Accreditation of Healthcare Organizations, 1996, COMPR ACCR MAN HOSP; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TULSKY JA, 1996, J GEN INTERN MED, V156, P1285; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P449, DOI 10.1001/jama.274.6.449; vonGunten CF, 1996, NEW ENGL J MED, V335, P1766; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WALSH D, 1994, J PAIN SYMPTOM MANAG, V9, P109, DOI 10.1016/0885-3924(94)90163-5; WEISSMAN DE, 1993, J PAIN SYMPTOM MANAG, V8, P29, DOI 10.1016/0885-3924(93)90117-E; *WHO EXP COMM, 1990, TECHN REP SER WHO, V804; 1995, MED ETHICS ADVIS NOV, P143; 1996, UPDATE UPDATE CHOICE, P1	85	114	118	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					225	230		10.7326/0003-4819-127-3-199708010-00008	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245229				2023-01-03	WOS:A1997XN12900008
J	Savitz, AJ; Meyer, DI				Savitz, AJ; Meyer, DI			Receptor-mediated ribosome binding to liposomes depends on lipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; MEMBRANE INTERACTION; RAT-LIVER; MICROSOMAL-MEMBRANES; COMPONENTS; IDENTIFICATION	Ribosome binding to the endoplasmic reticulum has been traditionally studied using an in vitro assay in which potential ribosome receptors have been purified, incorporated into synthetic liposomes, and tested for activity, One such receptor (180 kDa; ''p180'') has been shown to bind ribosomes with high affinity in such a system when purified to homogeneity, This result has been challenged by data generated in other laboratories, and as a result, doubt has lingered as to the authen ticity of p180 as a ribosome receptor, The contribution of the major difference between these studies, the lipid composition of the liposomes used in the in vitro assays, was assessed when identical fractions of rough endoplasmic reticulum-specific membrane proteins were in corporated into liposomes composed of only phosphatidylcholine (as used in other laboratories), a 50:50 mix of phosphatidylcholine and phosphatidylserine (as used in our original studies), or lipids derived from canine pancreatic microsomes (as a physiologically relevant control). The presence of PS was found to be crucial for the incorporation into and ribosome binding activity of p180 in liposomes, These observations are compatible with published studies on the importance of acidic phos pholipids in ribosome binding to intact microsomes and reconcile the apparently conflicting in vitro results surrounding the assignment of p180 as a ribosome receptor.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; Blobel G., 1971, BIOMEMBRANE, P193; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HORTSCH M, 1985, EUR J BIOCHEM, V150, P559, DOI 10.1111/j.1432-1033.1985.tb09057.x; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; ICHIMURA T, 1993, FEBS LETT, V326, P241, DOI 10.1016/0014-5793(93)81799-6; ICHIMURA T, 1992, FEBS LETT, V296, P7, DOI 10.1016/0014-5793(92)80391-S; JOTHY S, 1975, CAN J BIOCHEM CELL B, V53, P1039, DOI 10.1139/o75-143; JOTHY S, 1973, BIOCHEM J, V132, P637, DOI 10.1042/bj1320637; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KRUPPA J, 1977, J CELL BIOL, V74, P414, DOI 10.1083/jcb.74.2.414; NEUHOF A, 1996, 1 CELL BIOL S MDC PR, P93; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; OHSUMI T, 1993, BIOCHEM J, V294, P465, DOI 10.1042/bj2940465; ROSBASH M, 1971, J MOL BIOL, V59, P227, DOI 10.1016/0022-2836(71)90048-9; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; YAMAGUCHI M, 1981, BIOCHEM J, V194, P907, DOI 10.1042/bj1940907; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	27	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13140	13145		10.1074/jbc.272.20.13140	http://dx.doi.org/10.1074/jbc.272.20.13140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148928	hybrid			2023-01-03	WOS:A1997WZ38400041
J	Hollingsworth, H				Hollingsworth, H			Preventing insect sting anaphylaxis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERSENSITIVITY				Hollingsworth, H (corresponding author), BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA.			Hollingsworth, Helen/0000-0001-9007-9012				Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; HOLLINGSWORTH HM, 1996, INTENS CARE MED, P2401; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; VALENTINE MD, 1992, JAMA-J AM MED ASSOC, V268, P2830, DOI 10.1001/jama.268.20.2830	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1196	1197		10.1001/jama.1997.03540390026016	http://dx.doi.org/10.1001/jama.1997.03540390026016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103334				2023-01-03	WOS:A1997WT40300015
J	Ettinger, WH; Burns, R; Messier, SP; Applegate, W; Rejeski, WJ; Morgan, T; Shumaker, S; Berry, MJ; OToole, M; Monu, J; Craven, T				Ettinger, WH; Burns, R; Messier, SP; Applegate, W; Rejeski, WJ; Morgan, T; Shumaker, S; Berry, MJ; OToole, M; Monu, J; Craven, T			A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis - The Fitness Arthritis and Seniors Trial (FAST)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEO-ARTHRITIS; DISABILITY; PERFORMANCE; MANAGEMENT	Objective.-To determine the effects of structured exercise programs on self-reported disability in older adults with knee osteoarthritis. Setting and Design.-A randomized, single-blind clinical trial lasting 18 months conducted at 2 academic medical centers, Participants.-A total of 439 community-dwelling adults, aged 60 years or order, with radiographically evident knee osteoarthritis, pain, and self-reported physical disability. Interventions.-An aerobic exercise program, a resistance exercise program, and a health education program. Main Outcome Measures.-The primary outcome was self-reported disability score (range, 1-5). The secondary outcomes were knee pain score (range, 1-6), performance measures of physical function, x-ray score, aerobic capacity, and knee muscle strength. Results.-A total of 365 (83%) participants completed the trial, Overall compliance with the exercise prescription was 68% in the aerobic training group and 70% in the resistance training group. Postrandomization, participants in the aerobic exercise group had a 10% lower adjusted mean (+/-SE) score on the physical disability questionnaire (1.71+/-0.03 vs 1.90+/-0.04 units; P<.001), a 12% lower score on the knee pain questionnaire (2.1+/-0.05 vs 2.4+/-0.05 units; P=.001), and performed better (mean [+/-SE]) on the 6-minute walk test (1507+/-16 vs 1349+/-16 ft; P<,001), mean (+/-SE) time to climb and descend stairs (12.7+/-0.4 vs 13.9+/-0.4 seconds; P=.05), time to lift and carry 10 pounds (9.1+/-0.2 vs 10.0+/-0.1 seconds; P<,001), and mean (+/-SE) time to get in and out of a car (8.7+/-0.3 vs 10.6+/-0.3 seconds; P<.001) than the health education group, The resistance exercise group had an 8% lower score on the physical disability questionnaire (1.74+/-0.04 vs 1.90+/-0.03 units; P=.003), 8% lower pain score (2.2+/-0.06 vs 2,4+/-0.05 units; P=.02), greater distance on the 6-minute walk (1406+/-17 vs 1349+/-16 ft; P=.02), faster times on the lifting and carrying task (9.3+/-0.1 vs 10.0+/-0.16 seconds; P=.001), and the car task (9.0+/-0.3 vs 10.6+/-0.3 seconds; P=.003) than the health education group. There were no differences in x-ray scores between either exercise group and the health education group, Conclusions.-Older disabled persons with osteoarthritis of the knee had modest improvements in measures of disability, physical performance, and pain from participating in either an aerobic or a resistance exercise program. These data suggest that exercise should be prescribed as part of the treatment for knee osteoarthritis.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT INTERNAL MED, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT RADIOL, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, DEPT HLTH & SPORT SCI, WINSTON SALEM, NC 27103 USA; UNIV TENNESSEE, DEPT INTERNAL MED, MEMPHIS, TN USA; UNIV TENNESSEE, DEPT PREVENT MED, MEMPHIS, TN USA; UNIV TENNESSEE, DEPT ORTHOPAED SURG, MEMPHIS, TN USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Monu, Johnny U. V./AAC-3030-2020	Monu, Johnny U. V./0000-0002-4600-9217	NCRR NIH HHS [M01-RR00211] Funding Source: Medline; NIA NIH HHS [P60AG10484] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG010484] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN RD, 1987, ARTHRITIS RHEUM-US, V30, P1214, DOI 10.1002/art.1780301103; Armstrong S J, 1993, Osteoarthritis Cartilage, V1, P89, DOI 10.1016/S1063-4584(05)80023-8; Berry MJ, 1996, MED SCI SPORT EXER, V28, P808, DOI 10.1097/00005768-199607000-00006; BRANDT KD, 1993, TXB RHEUMATOLOGY, P1385; Buchner DM, 1993, TOP GERIATR REHABIL, V8, P1; BUCKWALTER JA, 1995, J RHEUMATOL, V22, P13; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; DAVIS MA, 1991, J RHEUMATOL, V18, P591; Elward K, 1992, Clin Geriatr Med, V8, P35; ETTINGER WH, 1994, MED SCI SPORT EXER, V26, P1435; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P840, DOI 10.1016/0003-9993(93)90011-X; FISHER NM, 1994, ARCH PHYS MED REHAB, V75, P792; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hochberg M C, 1996, Arthritis Care Res, V9, P170, DOI 10.1002/1529-0131(199606)9:3<170::AID-ANR1790090304>3.0.CO;2-K; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; Jan M H, 1991, J Formos Med Assoc, V90, P1008; KING AC, 1991, JAMA-J AM MED ASSOC, V266, P1535, DOI 10.1001/jama.266.11.1535; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KUJALA UM, 1995, ARTHRITIS RHEUM, V38, P539, DOI 10.1002/art.1780380413; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LANE N, 1992, B RHEUM DIS, V41, P5; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; REJESKI WJ, 1995, J RHEUMATOL, V22, P1124; REJESKI WJ, 1995, OSTEOARTHR CARTILAGE, V3, P157, DOI 10.1016/S1063-4584(05)80050-0; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; VERBRUGGE LM, 1991, J GERONTOL, V46, pS71, DOI 10.1093/geronj/46.2.S71; WEINBERGER M, 1991, J RHEUMATOL, V18, P849; [No title captured]	34	971	986	2	160	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					25	31		10.1001/jama.277.1.25	http://dx.doi.org/10.1001/jama.277.1.25			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ767	8980206				2023-01-03	WOS:A1997VZ76700025
J	Aker, PD; Gross, AR; Goldsmith, CH; Peloso, P				Aker, PD; Gross, AR; Goldsmith, CH; Peloso, P			Conservative management of mechanical neck pain: Systematic overview and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; ACUTE WHIPLASH INJURIES; DOUBLE-BLIND; CERVICAL-SPINE; MANUAL THERAPY; ELECTROMAGNETIC THERAPY; GENERAL-POPULATION; EARLY MOBILIZATION; OUTCOME MEASURES; PERSISTENT BACK	Objective-To review the efficacy of conservative management of mechanical neck disorders. Methods-Published and unpublished reports were identified through computerised and manual searches of bibliographical databases, reference lists from primary articles, and letters to authors, agencies, foundations, and content experts. Selection criteria were applied to blinded articles, and selected articles were scored for methodological quality. Effect sizes were calculated from raw pain scores and combined by using meta-analytic techniques when appropriate. Results-Twenty four randomised clinical trials met the selection criteria and were categorised by type of intervention: nine used manual treatments; 12 physical medicine methods; four drug treatment; and three education of patients (four trials investigated more than one form of intervention). The intervention strategies were summarised separately. Pooling of studies was considered only within each category. Five of the nine trials that used manual treatment in combination with other treatments were combined. One to four weeks after treatment the pooled effect size was -0.6 (95% confidence interval -0.9 to -0.4), equivalent to an improvement of 16 (6.9 to 23.1) points on a 100 point scale. Sensitivity analyses on study quality, chronicity, and data imputation did not alter this estimate. For other interventions, studies could not be combined to arrive at pooled estimates of effect. Conclusions-There is little information available from clinical trials to support many of the treatments for mechanical neck pain. In general, conservative interventions have not been studied in enough detail to assess efficacy or effectiveness adequately.	CANADIAN MEM CHIROPRACT COLL, DIV GRAD STUDIES & RES, TORONTO, ON, CANADA; MCMASTER UNIV, CHEDOKE MCMASTER HOSP & SCH REHABIL SCI, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; UNIV SASKATCHEWAN, DEPT MED, SASKATOON, SK S7N 0W0, CANADA	McMaster University; McMaster University; University of Saskatchewan			salimi, mehdi/D-1192-2009	Gross, Anita R/0000-0001-5187-7484				BARRY M, 1995, BRIT MED J, V310, P183, DOI 10.1136/bmj.310.6973.183; BASMAJIAN JV, 1978, ARCH PHYS MED REHAB, V59, P58; BERCEL NA, 1977, CURR THER RES CLIN E, V22, P462; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; Breslow N, 1980, STATISTICAL METHODS, V32; BRODIN H, 1984, INT J REHABIL RES, V7, P190, DOI 10.1097/00004356-198406000-00008; BRODIN H, 1985, INT J REHABIL RES, V2, P18; CASSIDY JD, 1992, J MANIP PHYSIOL THER, V15, P570; CASSIDY JD, 1993, J MANIP PHYSIOL THER, V16, P279; COLETTA R, 1988, INT J CLIN PHARM RES, V8, P295; FOLEYNOLAN D, 1990, ORTHOPEDICS, V13, P445; FOLEYNOLAN D, 1992, SCAND J REHABIL MED, V24, P51; GOLDIE I, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P117; GROSS A, 1995, MUSCULOSKELETAL MODU; GROSS AR, 1996, ONLINE J CURR C 0730, P5; HEDGES LV, 1985, STAT METHODS METAANA, P27; HORAL J, 1969, ACTA ORTHOP SCAND S, V118, P42; HULT L, 1954, ACTA ORTHOP SCAND S, V16, P12; HULT L, 1954, ACTA ORTHOP SCAND, V17, P175; JADAD AR, 1994, THESIS U OXFORD OXFO; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; KAMWENDO K, 1991, SCAND J REHABIL MED, V23, P143; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; Koes BW, 1992, THESIS CIP GEGEVENS; KVARNSTROM S, 1983, SCAND J REHABIL MED, P1; LEVOSKA S, 1993, ARCH PHYS MED REHAB, V74, P425; LEWITH GT, 1981, ACUPUNCTURE ELECTRO, V6, P277, DOI 10.3727/036012981816952180; LOY TT, 1983, MED J AUSTRALIA, V2, P32, DOI 10.5694/j.1326-5377.1983.tb142083.x; MCKINNEY LA, 1989, BRIT MED J, V299, P1006, DOI 10.1136/bmj.299.6706.1006; MCKINNEY LA, 1989, ARCH EMERG MED, V6, P27; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; *MICR CORP, 1982, METANAL VERS 4 01; NORDEMAR R, 1981, PAIN, V10, P93, DOI 10.1016/0304-3959(81)90050-6; PENNIE BH, 1990, J BONE JOINT SURG BR, V72, P277, DOI 10.1302/0301-620X.72B2.2312568; PETRIE JP, 1983, CLIN EXP RHEUMATOL, V1, P333; RUSH PJ, 1994, BRIT J RHEUMATOL, V33, P566; SLOOP PR, 1982, SPINE, V7, P532, DOI 10.1097/00007632-198211000-00003; SNOW CJ, 1992, PHYSIOTHERAPY CANADA, V44, pS8; SPITZER WO, 1987, SPINE, V12, pS1; Thorsen H, 1991, Ugeskr Laeger, V153, P1801; THORSEN H, 1992, SCAND J RHEUMATOL, V21, P139, DOI 10.3109/03009749209095086; Tollison CD, 1992, PAINFUL CERVICAL TRA; VANDERDONK J, 1991, J RHEUMATOL, V18, P1884; VERNON HT, 1990, J MANIP PHYSIOL THER, V13, P13; WAYLONIS GW, 1988, ARCH PHYS MED REHAB, V69, P1017	48	231	233	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1996	313	7068					1291	1296						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942688				2023-01-03	WOS:A1996VV15300022
J	Hatsukami, DK; Fischman, MW				Hatsukami, DK; Fischman, MW			Crack cocaine and cocaine hydrochloride - Are the differences myth or reality?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FREE-BASE COCAINE; INTRAVENOUS COCAINE; USE PATTERNS; DRUG-USE; HUMANS; SMOKING; DEPENDENCE; ABUSERS; INTRANASAL; PYROLYSIS	Objective.-To review and discuss the differences and similarities between the use of crack cocaine and cocaine hydrochloride; and to determine how these findings might affect policies on the imprisonment and treatment of cocaine users. Data Sources.-English-language publications were identified through a computerized search (using MEDLINE) between 1976 and 1996 using the search terms ''smoked cocaine,'' ''crack cocaine,'' ''freebase,'' and ''cocaine-base.'' In addition, manual searches were conducted on references cited in original research articles, reviews, and an annotated bibliography, and on selected journals. Study Selection.-Only those articles that compared various routes of cocaine administration or types of cocaine (cocaine base or crack cocaine vs cocaine hydrochloride) were examined. Data Extraction.-Studies were reviewed to obtain information on the composition of the 2 forms of cocaine, and the prevalence, pharmacokinetics and pharmacodynamics, abuse liability, pattern of use, and consequences across the various routes of cocaine administration and forms of cocaine. Conclusion.-Cocaine hydrochloride is readily converted to base prior to use. The physiological and psychoactive effects of cocaine are similar regardless of whether it is in the form of cocaine hydrochloride or crack cocaine (cocaine base). However, evidence exists showing a greater abuse liability, greater propensity for dependence, and more severe consequences when cocaine is smoked (cocaine-base) or injected intravenously (cocaine hydrochloride) compared with intranasal use (cocaine hydrochloride). The crucial variables appear to be the immediacy, duration, and magnitude of cocaine's effect, as well as the frequency and amount of cocaine used rather than the form of the cocaine. Furthermore, cocaine hydrochloride used intranasally may be a gateway drug or behavior to using crack cocaine, Based on these findings, the federal sentencing guidelines allowing possession of 100 times more cocaine hydrochloride than crack cocaine to trigger mandatory minimum penalties is deemed excessive, Although crack cocaine has been linked with crime to a greater extent than cocaine hydrochloride, many of these crimes are associated with the addiction to cocaine. Therefore, those addicted individuals who are incarcerated for the sale or possession of cocaine are better served by treatment than prison.	NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY USA	New York State Psychiatry Institute; Columbia University	Hatsukami, DK (corresponding author), UNIV MINNESOTA, DEPT PSYCHIAT, DIV NEUROSCI, BOX 392, UMHC, MINNEAPOLIS, MN 55455 USA.							BALSTER R L, 1973, Pharmacology Biochemistry and Behavior, V1, P67, DOI 10.1016/0091-3057(73)90057-9; Belenko S, 1993, CRACK EVOLUTION ANTI; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; BROWER KJ, 1986, HOSP COMMUNITY PSYCH, V37, P1229; BUNT G, 1990, AM J PSYCHIAT, V147, P1542; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P989; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177; CAULKINS JP, 1993, RP193 RAND; CONE EJ, 1995, J ANAL TOXICOL, V19, P459, DOI 10.1093/jat/19.6.459; Cook CE, 1985, PHARMACOKINETICS PHA, P48; De Leon G, 1993, NIDA Res Monogr, V135, P163; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; EVANS SM, 1993, NATL I DRUG ABUSE RE, V132, P343; Fagan J, 1990, NIDA Res Monogr, V103, P8; FOLTIN RW, 1992, J PHARMACOL EXP THER, V261, P841; FOLTIN RW, 1991, J PHARMACOL EXP THER, V257, P247; Gawin F H, 1985, NIDA Res Monogr, V61, P182; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GOLD MS, 1987, MED TIMES, V115, P27; Goldstein P.J., 1989, CONTEMP DRUG PROBL, V16, P651; GORELICK DA, 1992, AM J DRUG ALCOHOL AB, V18, P13, DOI 10.3109/00952999209001607; GOSSOP M, 1994, BRIT J PSYCHIAT, V164, P660, DOI 10.1192/bjp.164.5.660; GRELLA CE, 1995, DRUG ALCOHOL DEPEN, V37, P15, DOI 10.1016/0376-8716(94)01059-T; HATSUKAMI DK, 1987, CLIN PHARMACOL THER, V41, P103, DOI 10.1038/clpt.1987.17; Helfrich A A, 1983, NIDA Res Monogr, V43, P343; HENDERSON DJ, 1994, RES NURS HEALTH, V17, P265, DOI 10.1002/nur.4770170405; HIGGINS ST, 1994, DRUG ALCOHOL DEPEN, V34, P87, DOI 10.1016/0376-8716(94)90128-7; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; HONER WG, 1987, LANCET, V2, P451; INCIARDI JA, 1994, J DRUG ISSUES, V24, P273, DOI 10.1177/002204269402400205; INCIARDI JA, 1991, J DRUG ISSUES, V21, P257, DOI 10.1177/002204269102100204; ISENSCHMID DS, 1992, J ANAL TOXICOL, V16, P311, DOI 10.1093/jat/16.5.311; JACOB P, 1990, J TOXICOL-CLIN TOXIC, V28, P121; JAVAID JI, 1983, BIOPHARM DRUG DISPOS, V4, P9, DOI 10.1002/bdd.2510040104; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; Johanson C E, 1988, NIDA Res Monogr, V88, P107; JOHNSON BD, 1994, J DRUG ISSUES, V24, P117, DOI 10.1177/002204269402400107; Jones R T, 1990, NIDA Res Monogr, V99, P30; KANDEL D, 1993, AM J PUBLIC HEALTH, V83, P851, DOI 10.2105/AJPH.83.6.851; Kandel DB, 1996, ARCH GEN PSYCHIAT, V53, P71; KHALSA HK, 1993, NATL I DRUG ABUSE RE, V135, P218; KLEINMAN PH, 1990, J NERV MENT DIS, V178, P442, DOI 10.1097/00005053-199007000-00005; Leukefeld C G, 1988, NIDA Res Monogr, V86, P236; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; MARTIN BR, 1989, J ANAL TOXICOL, V13, P158, DOI 10.1093/jat/13.3.158; Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507; Mieczkowksi T., 1990, CONTEMP DRUG PROBL, V17, P9; MILLER NS, 1994, INT J ADDICT, V29, P1069, DOI 10.3109/10826089409047928; NAKAHARA Y, 1991, J ANAL TOXICOL, V15, P105, DOI 10.1093/jat/15.3.105; NOVAK M, 1984, B NARCOTICS, V36, P79; PEREZREYES M, 1982, CLIN PHARMACOL THER, V32, P459, DOI 10.1038/clpt.1982.189; PETERS RH, 1992, AM J DRUG ALCOHOL AB, V18, P355, DOI 10.3109/00952999209026072; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; POTTIEGER AE, 1992, J PSYCHOACTIVE DRUGS, V24, P399, DOI 10.1080/02791072.1992.10471664; POTTIEGER AE, 1995, J PSYCHOACTIVE DRUGS, V27, P27, DOI 10.1080/02791072.1995.10471670; RESNICK RB, 1977, SCIENCE, V195, P696, DOI 10.1126/science.841307; REUTER P, 1988, PUBLIC INTEREST, P51; RICHARDSON GA, 1991, NEUROTOXICOL TERATOL, V13, P455, DOI 10.1016/0892-0362(91)90095-E; RINGWALT CL, 1989, ADOLESCENCE, V24, P851; ROUNSAVILLE BJ, 1991, ARCH GEN PSYCHIAT, V48, P43; Rydell CP, 1994, CONTROLLING COCAINE; Schnoll S H, 1985, NIDA Res Monogr, V61, P171; SCHWARCZ SK, 1992, SEX TRANSM DIS, V19, P7, DOI 10.1097/00007435-199201000-00002; Siegel R K, 1984, NIDA Res Monogr, V50, P92; SMART RG, 1991, AM J DRUG ALCOHOL AB, V17, P13, DOI 10.3109/00952999108992806; SMART RG, 1988, AM J EPIDEMIOL, V127, P1315, DOI 10.1093/oxfordjournals.aje.a114925; STRANG J, 1990, BRIT J ADDICT, V85, P193; TIMS FM, 1993, NATL I DRUG ABUSE RE, V135; TURNER CE, 1988, COCAINE ANNOTATED BI; *US DEP HLTH HUM S, 1995, NAT HOUS SURV DRUG A; *US DEP HLTH HUM S, 1993, NAT HOUS SURV DRUG A; *US DEP HLTH HUM S, 1994, NAT I DRUG AB SER, V1; *US DEP HLTH HUM S, 1988, NAT HOUS SURV DRUG A; *US DEP HLTH HUM S, 1994, NATL I DRUG AB SER, V1; *US SENT COMM, 1995, COC FED SENT POL; VEREBEY K, 1988, PSYCHIAT ANN, V18, P513, DOI 10.3928/0048-5713-19880901-06; Washton A M, 1984, NIDA Res Monogr, V49, P247; WASHTON AM, 1986, POSTGRAD MED, V80, P52, DOI 10.1080/00325481.1986.11699554; WASHTON AM, 1987, ADV ALCOHOL SUBST AB, V6, P31; WILKINSON P, 1980, CLIN PHARMACOL THER, V27, P386, DOI 10.1038/clpt.1980.52; Yawn B P, 1994, Arch Fam Med, V3, P520, DOI 10.1001/archfami.3.6.520; YOUNG SL, 1992, PHARMACOTHERAPY, V12, P2; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	85	188	198	3	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1580	1588						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT025	8918856				2023-01-03	WOS:A1996VT02500031
J	Manber, H; Kanzler, M				Manber, H; Kanzler, M			Consequences of cupping	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Manber, H (corresponding author), STANFORD UNIV HOSP,PALO ALTO,CA 94304, USA.								0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1281	1281		10.1056/NEJM199610243351705	http://dx.doi.org/10.1056/NEJM199610243351705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857008				2023-01-03	WOS:A1996VN59400005
J	Annas, GJ				Annas, GJ			The promised end - Constitutional aspects of physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Glantz L H, 1987, Law Med Health Care, V15, P231; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Preston T. A., 1996, J PHARM CARE PAIN SY, V4, P183; Sontag S, 1988, AIDS ITS METAPHORS; *STAT TASK FORC LI, 1994, DEATH SOUGHT ASS SUI; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1995, JAMA-J AM MED ASSOC, V274, P1591	12	36	36	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					683	687		10.1056/NEJM199608293350924	http://dx.doi.org/10.1056/NEJM199608293350924			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD425	8687526	Green Published			2023-01-03	WOS:A1996VD42500030
J	Stegeman, CA; Tervaert, JWC; deJong, PE; Kallenberg, CGM				Stegeman, CA; Tervaert, JWC; deJong, PE; Kallenberg, CGM			Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTICYTOPLASMIC AUTOANTIBODIES; DIAGNOSIS; ANTIBODIES; VASCULITIS; AGENTS	Background Respiratory tract infections may trigger relapses in patients with Wegener's granulomatosis in remission. Uncontrolled data have suggested that treatment with trimethoprim-sulfamethoxazole (co-trimoxazole) may be beneficial. Methods We conducted a prospective, randomized, placebo-controlled study of the efficacy of cotrimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months in preventing relapses in patients with Wegener's granulomatosis in remission during or after treatment with cyclophosphamide and prednisolone. Relapses and infections were assessed with predefined criteria based on clinical, laboratory, and histopathological findings. Patients were evaluated at least once every three months for signs of disease activity, compliance with the treatment regimen, side effects of the therapy, and evidence of infections. Titers of serum antineutrophil cytoplasmic antibodies were measured serially. Results Forty-one patients were assigned to receive co-trimoxazole, and 40 to receive placebo. In 8 of the 41 patients in the co-trimoxazole group (20 percent), the drug had to be stopped because of side effects. According to life-table analysis, 82 percent of the patients in the co-trimoxazole group remained in remission at 24 months, as compared with 60 per cent of those in the placebo group (relative risk of relapse, 0.40; 95 percent confidence interval, 0.17 to 0.98). There were fewer respiratory tract infections (P = 0.005) and non-respiratory tract infections (P = 0.05) in the co-trimoxazole group than in the placebo group. There were no significant differences in antineutrophil cytoplasmic antibody titers at any time. Proportional-hazards regression analysis identified treatment with co-trimoxazole as an independent factor associated with prolonged disease-free survival and a positive antineutrophil cytoplasmic antibody test at the sta rt of treatment as a risk factor for relapse. Conclusions Treatment with co-trimoxazole reduces the incidence of relapses in patients with Wegener's granulomatosis in remission. (C)1996, Massachusetts Medical Society.	UNIV GRONINGEN HOSP,DEPT MED,DIV CLIN IMMUNOL,9713 EZ GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DIV NEPHROL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen			tervaert, jan willem cohen/AAB-1111-2019	Stegeman, Coen/0000-0002-0224-0927				ARMITAGE P, 1987, STAT METHODS MED RES, P125; ARMITAGE P, 1987, STATISTICAL METHODS, P408; BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; BRADLEY JD, 1989, ARTHRITIS RHEUM, V32, P45, DOI 10.1002/anr.1780320108; BROUWER E, 1994, KIDNEY INT, V45, P1120, DOI 10.1038/ki.1994.149; COX DR, 1972, J R STAT SOC B, V34, P187; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GODMAN GC, 1954, AMA ARCH PATHOL, V58, P533; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; JAYNE D, 1990, NEPHROL DIAL TRANSPL, V5, P309; JUNG AC, 1994, ARCH INTERN MED, V154, P2402, DOI 10.1001/archinte.154.21.2402; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; MCRAE D, 1993, ARCH OTOLARYNGOL, V119, P103; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINCHING AJ, 1980, BRIT MED J, V281, P836, DOI 10.1136/bmj.281.6244.836; ROBERTS DE, 1990, ARTHRITIS RHEUM, V33, P1590, DOI 10.1002/art.1780331020; RUBIN RH, 1980, NEW ENGL J MED, V303, P426, DOI 10.1056/NEJM198008213030804; SAVAGE COS, 1987, LANCET, V1, P1389; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; STILLWELL TJ, 1988, ARTHRITIS RHEUM, V31, P465, DOI 10.1002/art.1780310402; TERVAERT JWC, 1989, ARCH INTERN MED, V149, P2461, DOI 10.1001/archinte.149.11.2461; TERVAERT JWC, 1990, LANCET, V336, P709; VALERIANOMARCET J, 1991, ARCH INTERN MED, V151, P1649, DOI 10.1001/archinte.151.8.1649; VANDERWOUDE FJ, 1985, LANCET, V1, P425; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; YUASA K, 1988, AM J MED, V84, P371, DOI 10.1016/0002-9343(88)90450-0	32	581	603	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					16	20		10.1056/NEJM199607043350103	http://dx.doi.org/10.1056/NEJM199607043350103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637536				2023-01-03	WOS:A1996UU47900003
J	Hickok, G; Bellugi, U; Klima, ES				Hickok, G; Bellugi, U; Klima, ES			The neurobiology of sign language and its implications for the neural basis of language	NATURE			English	Article								THE left cerebral hemisphere is dominant for language, and many aspects of language use are more impaired by damage to the left than the right hemisphere, The basis for this asymmetry, however, is a matter of debate; the left hemisphere may be specialized for processing linguistic information(1-3) or for some more general function on which language depends, such as the processing of rapidly changing temporal information(4) or execution of complex motor patterns(5). To investigate these possibilities, we examined the linguistic abilities of 23 sign-language users with unilateral brain lesions. Despite the fact that sign language relies on visuospatial rather than rapid temporal information, the same left-hemispheric dominance emerged. Correlation analyses of the production of sign language versus non-linguistic hand gestures suggest that these processes are largely independent, Our findings support the view that the left-hemisphere dominance for language is not reducible solely to more general sensory or motor processes.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92186	University of California System; University of California San Diego	Hickok, G (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BELIUGI U, 1989, TRENDS NEUROSCI, V10, P380; CHIARELLO C, 1982, BRAIN, V105, P29, DOI 10.1093/brain/105.1.29; Corina D., 1993, PHONOLOGY, V10, P165, DOI [10.1017/S0952675700000038, DOI 10.1017/S0952675700000038]; Corina David P., 1993, PHONETICS PHONOLOGY, P63; CORINA DP, 1992, SCIENCE, V255, P1258, DOI 10.1126/science.1546327; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; GOODGLASS H, 1976, ASSESSMENT APHASIA R; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; Kimura D., 1993, NEUROMOTOR MECH HUMA; Klima E.S., 1979, SIGNS LANGUAGE; Liddell S.K., 1980, AM SIGN LANGUAGE SYN, DOI 10.1515/9783112418260; Lillo-Martin Diane., 1991, UNIVERSAL GRAMMAR AM; PERLMUTTER DM, 1992, LINGUIST INQ, V23, P407; POIZNER H, 1993, ANN NY ACAD SCI, V682, P192, DOI 10.1111/j.1749-6632.1993.tb22969.x; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Rey A, 1944, ARCH PSYCHOL, V30, P206; Siple Patricia, 1990, THEORETICAL ISSUES S, V1, P191, DOI DOI 10.1007/978-94-011-3468-2; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; [No title captured]	19	114	116	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					699	702		10.1038/381699a0	http://dx.doi.org/10.1038/381699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649515				2023-01-03	WOS:A1996UR97900053
J	Gomaa, A; Shalaby, M; Osman, M; Eissa, M; Eizat, A; Mahmoud, M; Mikhail, N				Gomaa, A; Shalaby, M; Osman, M; Eissa, M; Eizat, A; Mahmoud, M; Mikhail, N			Topical treatment of erectile dysfunction: Randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate	BRITISH MEDICAL JOURNAL			English	Article							INTRACAVERNOUS SELF-INJECTION; THERAPEUTIC APPLICATIONS; FACILITATING DRUGS; VASOACTIVE DRUGS; IC INJECTIONS; IMPOTENCE; NITROGLYCERIN; PAPAVERINE; MANAGEMENT; EXPERIENCE	Objective-To examine the effectiveness in treating impotence of topically applied cream containing three vasodilators-aminophylline, isosorbide dinitrate, and co-dergocrine mesylate-which act by different mechanisms. Design-Randomised double blinded placebo controlled crossover trial over two weeks. Subjects-36 men with erectile dysfunction randomly allocated to two equal groups. Interventions-Active cream containing aminophylline 3%, isosorbide dinitrate 0.25%, and co-dergocrine mesylate 0.05% for one week and placebo for another. Main outcome measures-Patients' reported experience of penile responses and side effects of treatment in questionnaires. Penile tumescence and arterial Row in the laboratory. Results-21 patients reported full erection and satisfactory intercourse with the active cream. Three men reported full erection and satisfactory intercourse with either cream. The active cream was more effective in psychogenic than organic impotence (eight out of nine men with psychogenic impotence achieved a full erection zi four out of eight with neurogenic impotence and two out of seven with arterial insufficiency). No major side effects were reported. In the laboratory the active cream increased penile arterial flow (0.19 (SD 0.08) m/s v 0.02 (0.15) m/s with placebo) and induced tumescence in 24 patients. Conclusions-Topical treatment with a cream containing three different vasodilators might be considered before intracavernous injection of vasoactive agents, particularly in psychogenic impotence.	UNIV ASSIUT,FAC MED,DEPT UROL,ASSIUT,EGYPT; UNIV ASSIUT,FAC MED,DEPT NEUROL,ASSIUT,EGYPT; UNIV ASSIUT,FAC MED,DEPT COMMUNITY MED,ASSIUT,EGYPT	Egyptian Knowledge Bank (EKB); Assiut University; Egyptian Knowledge Bank (EKB); Assiut University; Egyptian Knowledge Bank (EKB); Assiut University	Gomaa, A (corresponding author), UNIV ASSIUT,FAC MED,DEPT PHARMACOL,ASSIUT,EGYPT.		Eissa, Mamdouh M/K-9774-2015; Eissa, M M/S-4230-2019; Gomaa, Adel Abdel-Wadood/E-7326-2010	Eissa, Mamdouh M/0000-0001-8688-0843; Eissa, M M/0000-0003-4723-6427; Gomaa, Adel Abdel-Wadood/0000-0002-6462-0917				ABOSEIF SR, 1989, BRIT J UROL, V64, P183, DOI 10.1111/j.1464-410X.1989.tb05985.x; ABOZEID M, 1987, J UROLOGY, V138, P1263, DOI 10.1016/S0022-5347(17)43581-6; BLUM MD, 1985, J UROLOGY, V134, P479, DOI 10.1016/S0022-5347(17)47248-X; BRINDLEY GS, 1983, BRIT J PSYCHIAT, V143, P332, DOI 10.1192/bjp.143.4.332; BUCH PA, 1992, J UROLOGY, V147, P1650; BUVAT J, 1989, J UROLOGIE, V95, P89; BUVAT J, 1989, J UROLOGIE, V95, P33; CARTWRIGHT RG, 1990, BRIT J CLIN PHARMACO, V29, P533, DOI 10.1111/j.1365-2125.1990.tb03676.x; CAVALLINI G, 1991, J UROLOGY, V146, P50, DOI 10.1016/S0022-5347(17)37712-1; CLASS H, 1989, UROL INT, V44, P309; CONNER D P, 1989, Skin Pharmacology, V2, P153; DONATUCCI GF, 1993, PENIS, P20; GASSER TC, 1987, J UROLOGY, V137, P678, DOI 10.1016/S0022-5347(17)44172-3; GERBER GS, 1991, J UROLOGY, V146, P786, DOI 10.1016/S0022-5347(17)37921-1; GILMAN AG, 1990, PHARMACOL BASIS THER, P939; GIRDLEY FM, 1988, J UROLOGY, V140, P972, DOI 10.1016/S0022-5347(17)41902-1; GOMAA AA, 1994, J EGYPTIAN ACAD SCI, V145, P150; GOMAA AA, 1994, EUR J CLIN PHARMACOL, V47, pA101; HANDLER CE, 1985, INT J CARDIOL, V7, P149, DOI 10.1016/0167-5273(85)90356-0; HASHMAT AI, 1993, PENIS, P222; HEATON JPW, 1990, J UROLOGY, V143, P729, DOI 10.1016/S0022-5347(17)40074-7; KIRBY RS, 1991, IMPOTENCE DIAGNOSIS, P149; KRANE RJ, 1989, NEW ENGL J MED, V321, P1648, DOI 10.1056/NEJM198912143212406; LUE TF, 1987, J UROLOGY, V137, P829, DOI 10.1016/S0022-5347(17)44267-4; MEYHOFF HH, 1992, BRIT J UROL, V69, P88, DOI 10.1111/j.1464-410X.1992.tb15466.x; MORALES A, 1988, CONT MANAGEMENT IMPO, P178; NEGELEV S, 1990, J UROLOGY, V143, P586, DOI 10.1016/S0022-5347(17)40030-9; OWEN JA, 1989, J UROLOGY, V141, P546, DOI 10.1016/S0022-5347(17)40888-3; SIDI AA, 1986, J UROLOGY, V135, P704, DOI 10.1016/S0022-5347(17)45825-3; VIRAG R, 1984, ANGIOLOGY, V35, P79, DOI 10.1177/000331978403500203; WALTERS GR, 1988, BR J UROL, V62, P143	31	23	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1512	1515		10.1136/bmj.312.7045.1512	http://dx.doi.org/10.1136/bmj.312.7045.1512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646143	Green Published			2023-01-03	WOS:A1996UR82300021
J	Kandela, P				Kandela, P			Exposing the abuse of Chinese orphans	BRITISH MEDICAL JOURNAL			English	Article																		1996, DEATH DEFAULT POLICY	1	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					495	496		10.1136/bmj.312.7029.495	http://dx.doi.org/10.1136/bmj.312.7029.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TX383	8597687	Green Published			2023-01-03	WOS:A1996TX38300033
J	Souhami, RL; Craft, AW; VanderEijken, JW; Nooij, M; Spooner, D; Bramwell, VHC; Wierzbicki, R; Malcolm, AJ; Kirkpatrick, A; Uscinska, BM; VanGlabbeke, M; Machin, D				Souhami, RL; Craft, AW; VanderEijken, JW; Nooij, M; Spooner, D; Bramwell, VHC; Wierzbicki, R; Malcolm, AJ; Kirkpatrick, A; Uscinska, BM; VanGlabbeke, M; Machin, D			Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup	LANCET			English	Article							ADJUVANT CHEMOTHERAPY; OSTEOGENIC-SARCOMA; NEOADJUVANT CHEMOTHERAPY; DOSE INTENSITY; YOUNG-ADULTS; METHOTREXATE; DOXORUBICIN; CHILDREN; TUMOR	Background A previous trial by the European Osteosarcoma Intergroup (EOI) suggested that a short intensive chemotherapy regimen with doxorubicin and cisplatin might produce survival of operable, non-metastatic osteosarcoma similar to that obtained with complex and longer-duration drug regimens based on the widely used T10 multi-drug protocol. We undertook a randomised multicentre trial to compare these two approaches. Methods 407 patients with operable, non-metastatic osteosarcoma were randomly assigned the two-drug regimen (six cycles [18 weeks] of doxorubicin 25 mg/m(2) on days 1-3 and cisplatin 100 mg/m(2) on day 1) or a multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin; this protocol took 44 weeks). Surgery was scheduled for week 9 for the two-drug group and week 7 for the multi-drug group. Analyses of survival and progression-free survival were by intention to treat. Findings Of 407 randomised patients, 391 were eligible and have been followed up for at least 4 years (median 5.6 years). Toxic effects were qualitatively similar with the two regimens. However, 188 (94%) of 199 patients completed the six cycles of two-drug treatment, whereas only 97 (51%) of 192 completed 18 or more of the 20 cycles of the multi-drug regimen. The proportion showing a good histopathological response (>90% tumour necrosis) to preoperative chemotherapy was about 29% with both regimens and was strongly predictive of survival. Overall survival was 65% at 3 years and 55% at 5 years in both groups (hazard ratio 0.94 [95% CI 0.69-1.27]). Progression-free survival at 5 years was 44% in both groups (hazard ratio 1.01[0.77-1.33]). Interpretation We found no difference in survival between the two-drug and multi-drug regimens in operable, non-metastatic osteosarcoma. The two-drug regimen is shorter in duration and better tolerated, and is therefore the preferred treatment. However, 5-year survival is still unsatisfactory and new approaches to treatment, such as dose intensification, are needed to improve results.	ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; ONZE LIEVE VROUW HOSP, AMSTERDAM, NETHERLANDS; ACAD HOSP LEIDEN, LEIDEN, NETHERLANDS; ROYAL ORTHOPAED HOSP, BIRMINGHAM B31 2AP, W MIDLANDS, ENGLAND; LONDON REG CANC CTR, LONDON, ON N6A 4L6, CANADA; CANC TREATMENT & RES FDN, HALIFAX, NS, CANADA; EORTC DATA CTR, BRUSSELS, BELGIUM; MRC, CANC TRIALS OFF, CAMBRIDGE, ENGLAND	Newcastle University - UK; Onze Lieve Vrouwe Gasthuis Hospital; Leiden University; Leiden University Medical Center (LUMC); Royal Orthopaedic Hospital; Western University (University of Western Ontario); European Organisation for Research & Treatment of Cancer	Souhami, RL (corresponding author), UCL, SCH MED, GOWER ST, LONDON WC1E 6BT, ENGLAND.							BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; Delepine N, 1996, CANCER-AM CANCER SOC, V78, P2127, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2127::AID-CNCR13>3.3.CO;2-Z; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; *EUR OST INT, 1993, 80931 EORTC EUR OST; GRAF N, 1994, J CLIN ONCOL, V12, P1443, DOI 10.1200/JCO.1994.12.7.1443; GREM JL, 1988, JNCI-J NATL CANCER I, V80, P626, DOI 10.1093/jnci/80.9.626; LANGE B, 1982, CANCER TREAT REP, V66, P1699; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5; MISER JS, 1987, J CLIN ONCOL, V5, P1191, DOI 10.1200/JCO.1987.5.8.1191; ORNADEL D, 1994, J CLIN ONCOL, V12, P1842, DOI 10.1200/JCO.1994.12.9.1842; Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76; ROSEN G, 1982, CANCER TREAT REP, V66, P1687; ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E; SMITH MA, 1991, JNCI-J NATL CANCER I, V83, P1460, DOI 10.1093/jnci/83.20.1460; WINKLER K, 1984, J CLIN ONCOL, V2, P617, DOI 10.1200/JCO.1984.2.6.617; WINKLER K, 1988, J CLIN ONCOL, V6, P329, DOI 10.1200/JCO.1988.6.2.329	17	290	303	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					911	917		10.1016/S0140-6736(97)02307-6	http://dx.doi.org/10.1016/S0140-6736(97)02307-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314869				2023-01-03	WOS:A1997XY67200009
J	Rackoff, P; Feldman, T				Rackoff, P; Feldman, T			Total lymphoid irradiation - not for rheumatoid arthritis	LANCET			English	Editorial Material							TERM FOLLOW-UP				Rackoff, P (corresponding author), BETH ISRAEL MED CTR,DIV RHEUMATOL,NEW YORK,NY 10003, USA.			Rackoff, Paula/0000-0002-4669-2116				HUBERT G, 1985, ARTHRITIS RHEUM, V28, P1205; SODEN M, 1989, ARTHRITIS RHEUM, V32, P523, DOI 10.1002/anr.1780320503; TANAY A, 1987, ARTHRITIS RHEUM-US, V30, P1, DOI 10.1002/art.1780300101; TRENTHAM DE, 1987, ARTHRITIS RHEUM, V30, P980, DOI 10.1002/art.1780300904; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; Westhovens R, 1997, ARTHRITIS RHEUM, V40, P426, DOI 10.1002/art.1780400306	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					752	753		10.1016/S0140-6736(97)22037-4	http://dx.doi.org/10.1016/S0140-6736(97)22037-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297989				2023-01-03	WOS:A1997XW28200004
J	Spencer, CP; Cooper, AJ; Whitehead, MI				Spencer, CP; Cooper, AJ; Whitehead, MI			Fortnightly review - Management of abnormal bleeding in women receiving hormone replacement therapy	BRITISH MEDICAL JOURNAL			English	Review							POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; MEDROXYPROGESTERONE ACETATE; PROGESTOGEN THERAPY; VABRA ASPIRATOR; BREAST-CANCER; TAMOXIFEN; ESTROGEN; SONOHYSTEROGRAPHY; PATTERNS				Spencer, CP (corresponding author), UNIV LONDON KINGS COLL HOSP,MENOPAUSE CLIN,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							AKKAD AA, 1995, OBSTET GYNECOL, V86, P330, DOI 10.1016/0029-7844(95)00172-N; ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; BORNSTEIN J, 1994, J REPROD MED, V39, P674; BROOKS PG, 1992, J REPROD MED, V37, P682; BRYCE FC, 1990, EUR J OBSTET GYN R B, V37, P55, DOI 10.1016/0028-2243(90)90095-I; COHEN JR, 1994, ULTRASOUND OBST GYN, V4, P227, DOI 10.1046/j.1469-0705.1994.04030227.x; DOWNES E, 1993, BRIT J OBSTET GYNAEC, V100, P1148, DOI 10.1111/j.1471-0528.1993.tb15187.x; EVANS MP, 1995, MAYO CLIN PROC, V70, P800, DOI 10.4065/70.8.800; FRIEDL A, 1994, BREAST CANCER RES TR, V31, P27, DOI 10.1007/BF00689674; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GAUCHERAND P, 1995, J CLIN ULTRASOUND, V23, P339, DOI 10.1002/jcu.1870230603; GIMPELSON RJ, 1988, AM J OBSTET GYNECOL, V158, P489, DOI 10.1016/0002-9378(88)90011-7; GOLDSTEIN SR, 1994, AM J OBSTET GYNECOL, V170, P447, DOI 10.1016/S0002-9378(94)70209-8; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; HAHN RG, 1984, J FAM PRACTICE, V18, P411; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; HILLARD TC, 1992, AM J OBSTET GYNECOL, V167, P1; INDMAN PD, 1993, OBSTET GYNECOL, V81, P716; ISMAIL SM, 1994, J CLIN PATHOL, V47, P827, DOI 10.1136/jcp.47.9.827; KAUNITZ AM, 1988, J REPROD MED, V33, P427; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; MAGOS AL, 1985, OBSTET GYNECOL, V65, P496; MARSH MS, 1993, BAILLIERE CLIN ENDOC, V7, P183, DOI 10.1016/S0950-351X(05)80275-7; MARSH MS, 1992, BRIT MED BULL, V48, P426, DOI 10.1093/oxfordjournals.bmb.a072554; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; PARSONS AK, 1993, J CLIN ULTRASOUND, V21, P87, DOI 10.1002/jcu.1870210203; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P55, DOI 10.1016/S0002-9378(12)90884-4; ROSENFELD JA, 1994, AM J OBSTET GYNECOL, V50, P510; ROSS D, 1995, CURR OPIN OBSTET GYN, V7, P63; RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471-0528.1992.tb13732.x; RYMER J, 1994, BRIT J OBSTET GYNAEC, V101, P53; SPAULDING LB, 1994, FERTIL STERIL, V62, P1181; SPORRONG T, 1992, BRIT J OBSTET GYNAEC, V99, P399, DOI 10.1111/j.1471-0528.1992.tb13757.x; THORNEYCROFT IH, 1995, PROG CARDIOVASC DIS, V38, P243, DOI 10.1016/S0033-0620(95)80015-8; UDOFF L, 1995, OBSTET GYNECOL, V86, P306, DOI 10.1016/0029-7844(95)00115-8; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701	39	20	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					37	42		10.1136/bmj.315.7099.37	http://dx.doi.org/10.1136/bmj.315.7099.37			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233327	Green Published			2023-01-03	WOS:A1997XJ94700031
J	Martensen, RL; Jones, DS				Martensen, RL; Jones, DS			When US medicine became imperial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,CAMBRIDGE,MA 02138	Harvard University	Martensen, RL (corresponding author), UNIV KANSAS,SCH MED,DEPT HIST & PHILOSOPHY MED,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.							BANISTER JM, 1906, J ASS MILIT SURG US, V18, P148; BANISTER JM, 1906, J ASS MILIT SURG US, V18, P258; DEKRUIF P, 1954, MICROBE HUNTERS, P286; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; LEIGH JG, 1905, LANCET, V71, P1597; LEIGH JG, 1905, LANCET, V71, P1726; LEIGH JG, 1905, LANCET, V71, P1530; LUGOVINA J, 1903, J ASS MILIT SURG US, V18, P150; MAXWELL GT, 1896, SANITARIAN, V36, P97; MENZIES R, 1993, TUBERCLE LUNG DIS, V74, P32, DOI 10.1016/0962-8479(93)90066-7; Reed CAL, 1905, JAMA-J AM MED ASSOC, VXLIV, P812	11	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1917	1917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200618				2023-01-03	WOS:A1997XF08700002
J	Bone, RC				Bone, RC			Critical care medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL SINUSITIS; PNEUMONIA; MORTALITY; UNIT				Bone, RC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BERT F, 1995, J INFECTION, V31, P5, DOI 10.1016/S0163-4453(95)91147-2; BERT F, 1995, AM J RESP CRIT CARE, V152, P1424, DOI 10.1164/ajrccm.152.4.7551404; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; Chatila W, 1996, CHEST, V109, P1577, DOI 10.1378/chest.109.6.1577; Hund EF, 1996, CRIT CARE MED, V24, P1328, DOI 10.1097/00003246-199608000-00010; KIRTON OC, 1995, CHEST, V108, P1021, DOI 10.1378/chest.108.4.1021; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Latronico N, 1996, LANCET, V347, P1579, DOI 10.1016/S0140-6736(96)91074-0; Linden PK, 1996, CLIN INFECT DIS, V22, P663, DOI 10.1093/clinids/22.4.663; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; Stein PD, 1996, CHEST, V109, P78, DOI 10.1378/chest.109.1.78	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1847	1848						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185794				2023-01-03	WOS:A1997XD54400013
J	Butterfield, L; Storey, B; Maas, L; Heasley, LE				Butterfield, L; Storey, B; Maas, L; Heasley, LE			c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; IONIZING-RADIATION; TYROSINE KINASE; UV RESPONSE; LINES; PHOSPHORYLATION; GENE; EXPRESSION	Exposure of cultured small cell lung cancer (SCLC) cells to UV radiation induces apoptosis. We observed that the UV sensitivity of a panel of SCLC lines and the activation of c-Jun NH2-terminal kinases (JNKs) by UV in the individual SCLC lines, assessed by binding and phosphorylation of glutathione S-transferase (GST)-c-Jun fusion proteins, ranged widely. In fact, increased JNK activity in this assay was closely correlated with decreased sensitivity to apoptosis following UV irradiation. Increased JNK activity was also detected in anti-JNK1 immune complexes collected from UV-irradiated SCLC cells, although the level of activity was similar among the various SCLC lines and correlated poorly with UV sensitivity. Immunoblot analysis of JNK polypeptides that bound to GST c-Jun revealed at least two JNK polypeptides, one of which appeared only in extracts from UV-irradiated SCLC. To test the role of JNKs in UV-induced apoptosis, nonphosphorylatable mutants of JNK1 or JNK2 in which the phosphorylation site Thr-Pro-Tyr is changed to Ala-Pro-Phe (JNK-APF) and are predicted to behave as competitive inhibitors were stably expressed in SCLC. Expression of JNK1-APF or JNK2-APF significantly reduced UV-stimulated JNK activity. However, JNK1-APF markedly increased the resistance of the cells to UV-induced apoptosis, while JNK2-APF did not influence SCLC sensitivity to UV. The findings suggest that UV-stimulated JNK1 activation promotes UV-induced SCLC apoptosis, while a JNK isoform that is variably activated among the SCLC lines may signal a UV-protective response. We hypothesize that integration of distinct JNK activities dictates the relative responsiveness of SCLC to UV and ionizing radiation.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV RENAL MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Butterfield, Lisa H./W-1564-2019	Butterfield, Lisa H./0000-0002-3439-9844	NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline; NIGMS NIH HHS [GM 48826] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BRENNAN J, 1991, CANCER RES, V51, P1708; BUSCHER M, 1988, ONCOGENE, V3, P301; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARMICHAEL J, 1989, EUR J CANCER CLIN ON, V25, P527, DOI 10.1016/0277-5379(89)90266-6; CARMICHAEL J, 1988, BRIT J CANCER, V58, P437, DOI 10.1038/bjc.1988.236; Carmichael J., 1985, BRIT J CANCER, V57, P540, DOI DOI 10.1038/bjc.1988.125; CARNEY DN, 1983, CANCER RES, V43, P2806; CARNEY DN, 1985, CANCER RES, V45, P2913; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAI TN, 1995, ONCOGENE, V10, P849; DAMICO D, 1992, ONCOGENE, V7, P339; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GAZDAR AF, 1985, CANCER RES, V45, P2924; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JENSEN GL, 1983, P NATL ACAD SCI-BIOL, V80, P4714, DOI 10.1073/pnas.80.15.4714; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIM CY, 1992, BRIT J CANCER, V66, P844, DOI 10.1038/bjc.1992.371; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUZUKI K, 1992, RADIAT RES, V129, P157, DOI 10.2307/3578152; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	55	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10110	10116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092556				2023-01-03	WOS:A1997WU03900075
J	Spector, MS; Schnur, JM				Spector, MS; Schnur, JM			DNA ordering on a lipid membrane	SCIENCE			English	Editorial Material							TRANSFECTION				Spector, MS (corresponding author), USN,RES LAB,CTR BIOMOL SCI & ENGN,WASHINGTON,DC 20375, USA.							[Anonymous], 1988, LIPOSOMES DRUG CARRI; Dan N, 1996, BIOPHYS J, V71, P1267, DOI 10.1016/S0006-3495(96)79326-8; FANG Y, IN PRESS J PHYS CHEM; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; Lasic D. D., 1996, HDB NONMEDICAL APPL; Lasic DD, 1996, ADV DRUG DELIVER REV, V20, P221, DOI 10.1016/0169-409X(96)00002-6; *NAT RES COUNC, 1996, BIOM SELF ASS MAT; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; RICH A, 1993, GENE, V135, P99, DOI 10.1016/0378-1119(93)90054-7	11	39	41	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					791	792		10.1126/science.275.5301.791	http://dx.doi.org/10.1126/science.275.5301.791			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9036545				2023-01-03	WOS:A1997WG77700046
J	Laureno, R; Karp, BI				Laureno, R; Karp, BI			Myelinolysis after correction of hyponatremia	ANNALS OF INTERNAL MEDICINE			English	Article							CENTRAL PONTINE MYELINOLYSIS; BLOOD-BRAIN-BARRIER; RAPID CORRECTION; EXTRAPONTINE MYELINOLYSIS; LIVER-TRANSPLANTATION; SERUM SODIUM; RATS; DEMYELINATION; MANAGEMENT; DIAGNOSIS	Myelinolysis is a neurologic disorder that can occur after rapid correction of hyponatremia. Initially named ''central pontine myelinolysis,'' this disease is now known to also affect extrapontine brain areas. Manifestations of myelinolysis usually evolve several days after correction of hyponatremia. Typical features are disorders of upper motor neurons, spastic quadriparesis and pseudobulbar palsy, and mental disorders ranging from mild confusion to coma. Death may occur. The motor and localizing signs of myelinolysis differ from the generalized encephalopathy that is caused by untreated hyponatremia. Experiments have duplicated the clinical and pathologic features of myelinolysis by rapidly reversing hyponatremia in animals. Myelinolysis is more likely to occur after the treatment of chronic rather than acute hyponatremia and is more likely to occur with a rapid rate of correction. The exact pathogenesis of myelinolysis has not been determined. Optimal management of hyponatremic patients involves weighing the risk for illness and death from untreated hyponatremia against the risk for myelinolysis due to correction of hyponatremia. Experiments in animals and clinical experience suggest that correction of chronic hyponatremia should be kept at a rate less than 10 mmol/L in any 24-hour period.	NINCDS, NIH, OFF CLIN DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Laureno, R (corresponding author), WASHINGTON HOSP CTR, ROOM 2A44, 110 IRVING ST NW, WASHINGTON, DC 20010 USA.							ADAMS DH, 1987, LANCET, V1, P949; ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154, DOI 10.1001/archneurpsyc.1959.02340140020004; ADLER S, 1994, J AM SOC NEPHROL, V5, P935; BURCAR PJ, 1977, NEUROLOGY, V27, P223, DOI 10.1212/WNL.27.3.223; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; ESTOL CJ, 1989, NEUROLOGY, V39, P493, DOI 10.1212/WNL.39.4.493; FERRIRO JA, 1992, ACTA NEUROPATHOL, V84, P1, DOI 10.1007/BF00427209; GRAFTON ST, 1988, J NEUROL NEUROSUR PS, V51, P1354, DOI 10.1136/jnnp.51.10.1354; GRAY DS, 1987, CAN J NEUROL SCI, V14, P243; ILLOWSKY BP, 1987, BRAIN, V110, P855, DOI 10.1093/brain/110.4.855; INGRAM DA, 1986, J NEUROL, V233, P23, DOI 10.1007/BF00313986; KARP BI, 1993, MEDICINE, V72, P359, DOI 10.1097/00005792-199311000-00001; KLEINSCHMIDTDEMASTERS BK, 1982, J NEUROPATH EXP NEUR, V41, P67, DOI 10.1097/00005072-198201000-00007; KLEINSCHMIDTDEMASTERS BK, 1981, SCIENCE, V211, P1068, DOI 10.1126/science.7466381; KURTZ I, 1995, J CLIN INVEST, V95, P441, DOI 10.1172/JCI117681; LAURENO R, 1981, T AM NEUROL ASSOC, V106, P98; Laureno R, 1980, Trans Am Neurol Assoc, V105, P354; LAURENO R, 1983, ANN NEUROL, V13, P232, DOI 10.1002/ana.410130303; MASCALCHI M, 1993, CLIN RADIOL, V47, P137, DOI 10.1016/S0009-9260(05)81191-2; MICKEL HS, 1990, BIOCHEM BIOPH RES CO, V172, P92, DOI 10.1016/S0006-291X(05)80177-9; MORLAN L, 1990, EUR NEUROL, V30, P149, DOI 10.1159/000117333; NORENBERG MD, 1984, ANN NEUROL, V15, P544, DOI 10.1002/ana.410150606; NORENBERG MD, 1982, ANN NEUROL, V11, P128, DOI 10.1002/ana.410110204; RAGLAND RL, 1989, J COMPUT ASSIST TOMO, V13, P316, DOI 10.1097/00004728-198903000-00025; RIGGS JE, 1989, ARCH PATHOL LAB MED, V113, P1386; ROJIANI AM, 1994, ACTA NEUROPATHOL, V88, P287; ROSENBLOOM S, 1984, AM J NEURORADIOL, V5, P110; SCHROTH G, 1984, NEURORADIOLOGY, V26, P149, DOI 10.1007/BF00339865; SINGH N, 1994, MEDICINE, V73, P110, DOI 10.1097/00005792-199403000-00004; SOUPART A, 1994, J AM SOC NEPHROL, V5, P374; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P594, DOI 10.1097/00005072-199605000-00011; SOUPART A, 1994, KIDNEY INT, V45, P193, DOI 10.1038/ki.1994.23; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011; STERNS RH, 1993, AM J PHYSIOL, V264, pF833, DOI 10.1152/ajprenal.1993.264.5.F833; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; STERNS RH, 1994, J AM SOC NEPHROL, V4, P1522; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; THOMPSON AJ, 1988, NEURORADIOLOGY, V30, P175, DOI 10.1007/BF00395621; TOMLINSON BE, 1976, Q J MED, V45, P373; TREIG T, 1988, Neurology, V38, P333; VERBALIS JG, 1993, BRAIN RES, V606, P19, DOI 10.1016/0006-8993(93)91564-9; VERBALIS JG, 1988, KIDNEY INT, V34, P351, DOI 10.1038/ki.1988.188; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; VERBALIS JG, 1991, KIDNEY INT, V39, P1274, DOI 10.1038/ki.1991.161; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; WIJDICKS EFM, 1994, ANN NEUROL, V35, P626, DOI 10.1002/ana.410350520; WRIGHT DG, 1979, BRAIN, V102, P361, DOI 10.1093/brain/102.2.361; WSZOLEK ZK, 1989, TRANSPLANTATION, V48, P1006, DOI 10.1097/00007890-198912000-00023; Wu Chia-Lun, 1992, Journal of the Formosan Medical Association, V91, P1013	49	259	272	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					57	62		10.7326/0003-4819-126-1-199701010-00008	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992924				2023-01-03	WOS:A1997WA16500008
J	Stenson, B				Stenson, B			Promoting attachment, providing memories	BRITISH MEDICAL JOURNAL			English	Article											Stenson, B (corresponding author), ROYAL EDINBURGH INFIRM,SIMPSON MEM MATERN PAVIL,NEONATAL UNIT,EDINBURGH EH3 9YN,MIDLOTHIAN,SCOTLAND.								0	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1615	1615		10.1136/bmj.313.7072.1615	http://dx.doi.org/10.1136/bmj.313.7072.1615			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991007	Green Published			2023-01-03	WOS:A1996VZ81100038
J	Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG				Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG			Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study	LANCET			English	Article							CEREBROVASCULAR-DISEASE; SUBARACHNOID HEMORRHAGE; EPIDEMIOLOGY; SMOKING; AGE	Background The risk of haemorrhagic stroke associated with use of oral contraceptives (OCs) is less well-established than that for ischaemic stroke. We assessed the risk of haemorrhagic stroke associated with current use of modern OCs as now used throughout the world. Methods In this WHO collaborative, case-control study, we assessed the association between risk of haemorrhagic stroke and use of combined OCs in 1068 cases, 20-44 years, and 2910 age-matched controls. We also assessed risks for all strokes combined (haemorrhagic, ischaemic, and unclassified) based on 2198 cases and 6086 controls. Findings Overall, current use of combined OCs was associated with slightly increased risk of haemorrhagic stroke; the increase was significant in the developing countries (odds ratio 1 . 76 [95% CI 1 . 34-2 . 30]) but not in Europe (1 . 38 [0 . 84-2 . 25]). Use of OCs in women younger than 35 years did not affect risk of haemorrhagic stroke in either group of countries, whereas in women aged older than 35 years, odds ratios were greater than 2. Women who were current users of OCs and had a history of hypertension (detected before current episode of OC use, but not during pregnancy) had a substantially increased risk (ten-fold to 15-fold) of haemorrhagic stroke compared with women who did not use OCs and had no history of hypertension. Odds ratios among current OC users who were also current cigarette smokers were greater than 3. In both groups of countries, past use of OCs, dose of oestrogen, and dose and type of progestagen had no effect on risk, and risks were similar for subarachnoid and intracerebral haemorrhage. The odds ratios for any type of stroke associated with current use of low-dose (<50 mu g oestrogen) and higher-dose OCs were 1 . 41 (0 . 90-2 . 20) and 2 . 71 (1 . 70-4 . 32), respectively, in Europe and 1 . 86 (1 . 49-2 . 33) and 1 . 92 (1 . 48-2 . 50) in the developing countries. From these data we estimated that about 13% and 8% of all strokes in women aged 20-44 in Europe and the developing countries, respectively, are attributable to the use of OCs. Interpretation The risk of haemorrhagic stroke attributable to OC use is not increased in younger women and is only slightly increased in older women. The estimated excess risk of all stroke types associated with use of low-oestrogen and higher-oestrogen dose OCs in Europe was about two and eight, respectively, per 100 000 woman-years of OC use. However, findings need to be considered in the context of other risks and benefits associated with OC use, as well as those associated with the use of other forms of contraception.	WHO, UNDP UNFPA WHO WORLD BANK SPECIAL PROGRAMME RES D, CH-1211 GENEVA 27, SWITZERLAND; ESCOLA PAULISTA MED, DEPT PREVENT MED, SAO PAULO, BRAZIL; UNIV CHILE, ESCUELA SALUD PUBL, SANTIAGO, CHILE; ESCUELA MED, DEPT SALUD PUBL, VALPARAISO, CHILE; NATL RES INST FAMILY PLANNING, BEIJING, PEOPLES R CHINA; SICHUAN FAMILY PLANNING RES INST, CHENGDU, PEOPLES R CHINA; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; ZENTRUM EPIDEMIOL & GESUNDHEITSFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, DEPT COMMUNITY MED, HONG KONG, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, DEPT OBSTET & GYNAECOL, H-6701 SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; GRP INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REP, DURANGO, MEXICO; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, DEPT OBSTET & GYNAECOL, BANGKOK, THAILAND; SIRIRAJ HOSP, SIRIRAJ FAMILY HLTH RES CTR, BANGKOK, THAILAND; UNIV BELGRADE, SCH MED, BELGRADE, YUGOSLAVIA; UNIV LUSAKA, TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, DEPT MED, HARARE, ZIMBABWE; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; KAISER PERMANENTE, PASADENA, CA USA; NIH, BETHESDA, MD 20892 USA; UNIV AARHUS, DANISH EPIDEMIOL SCI CTR, AARHUS, DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	United Nations Population Fund; World Health Organization; Universidade Federal de Sao Paulo (UNIFESP); Universidad de Chile; National Research Institute for Family Planning - China; Universidad del Valle; University of Oxford; Chinese University of Hong Kong; Szeged University; University of Indonesia; University West Indies Mona Jamaica; Kenya Medical Research Institute; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Belgrade; University of Zimbabwe; University of Oxford; Kaiser Permanente; National Institutes of Health (NIH) - USA; Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Poulter, NR (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CHANG KK, 1986, INT J GYNECOL OBSTET, V24, P421, DOI 10.1016/0020-7292(86)90032-9; FISCH IR, 1974, WALNUT CREEK CONTRAC, V1, P105; FOGELHOLM R, 1973, ACTA NEUROL SCAND, V49, P415; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1979, BRIT MED J, V2, P1468, DOI 10.1136/bmj.2.6203.1468; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JICK H, 1978, ANN INTERN MED, V89, P58, DOI 10.7326/0003-4819-89-1-58; KAY CR, 1981, LANCET, V1, P541; LAYDE PM, 1983, J ROY COLL GEN PRACT, V33, P75; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; METTINGER KL, 1984, STROKE, V15, P795, DOI 10.1161/01.STR.15.5.795; METTINGER KL, 1984, ACTA NEUROL SCAND, V70, P415; PETITTI DB, 1978, LANCET, V2, P234; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; PRENTICE RL, 1988, AM J EPIDEMIOL, V127, P213, DOI 10.1093/oxfordjournals.aje.a114797; RAMCHARAN S, 1981, CTR POPULATION RES M; RAMCHARAN S, 1976, WALNUT CREEK CONTRAC, V2, P1; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; Schlesselman JJ, 1982, CASE CONTROL STUDIES; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VESSEY MP, 1990, ORAL CONTRACEPTIVES; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEIR RJ, 1994, TXB HYPERTENSION; 1977, LANCET, V2, P727; 1995, J CLIN EPIDEMIOL S12, V48, P1513	32	181	183	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	1996	348	9026					505	510						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757152				2023-01-03	WOS:A1996VD42700010
J	Lyons, SF				Lyons, SF			Shadow bands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					98	98						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656519				2023-01-03	WOS:A1996UV48500009
J	Okada, F				Okada, F			Kampo medicine, a source of drugs waiting to be exploited	LANCET			English	Editorial Material											Okada, F (corresponding author), OKAJIMA NEUROPSYCHIAT CLIN,HIGASHI KU,SAPPORO,HOKKAIDO 065,JAPAN.							BABA S, 1995, CLIN OTOLARYNGOL, V88, P389; HIRAYAMA C, 1989, Gastroenterologia Japonica, V24, P715; HIZAWA N, 1994, INTERNAL MED, V33, P337, DOI 10.2169/internalmedicine.33.337; *JAP MIN HLTH WELF, 1992, STAT PROD PHARM IND; *JAP MIN HLTH WELF, 1992, 15 JAP MIN HLTH WELF; KIMURA I, 1993, ANN NY ACAD SCI, V685, P529, DOI 10.1111/j.1749-6632.1993.tb35916.x; Miyoshi A, 1994, GASTROENTEROLOGY, V18, P299; WOMIOKA H, 1992, SAISHIN IGAKU, V47, P1342; 1991, NIHON KEIZAI SH 1214	9	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					5	6		10.1016/S0140-6736(05)64351-6	http://dx.doi.org/10.1016/S0140-6736(05)64351-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691936				2023-01-03	WOS:A1996UV92300006
J	Dennehy, JA; Appleby, L; Thomas, CS; Faragher, EB				Dennehy, JA; Appleby, L; Thomas, CS; Faragher, EB			Case-control study of suicide by discharged psychiatric patients	BRITISH MEDICAL JOURNAL			English	Article							RISK		UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV S MANCHESTER HOSP,MANCHESTER,LANCS,ENGLAND	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; *DEP HLTH, 1992, HLTH NAT; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; WILLIAMS P, 1986, SOC PSYCH PSYCH EPID, V21, P89, DOI 10.1007/BF00578748	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1580	1580		10.1136/bmj.312.7046.1580	http://dx.doi.org/10.1136/bmj.312.7046.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU806	8664668	Green Published			2023-01-03	WOS:A1996UU80600020
J	Jeevaratnam, DR; Menon, DK				Jeevaratnam, DR; Menon, DK			Survey of intensive care of severely head injured patients in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL PERFUSION-PRESSURE; RANDOMIZED CLINICAL-TRIAL; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; BRAIN INJURY; BLOOD-FLOW; MANAGEMENT; HYPERVENTILATION; STEROIDS	Objectives-To study practice in intensive care of patients with severe head injury in neurosurgical referral centres in United Kingdom. Design-Structured telephone interview of senior nursing staff in intensive care unit of adult neurosurgical referral centre. Setting-39 intensive care units in hospitals that accepted acute head injuries for specialist neurosurgical management, identified from Medical Directory and information from professional bodies. Main outcome measures-Details of organisation and administration of intensive care and patterns of monitoring and treatment for patients admitted with severe head injury. Results-Patients were managed in specialist neurosurgical intensive care units in 21 of the centres and in general intensive care units in 18. Their intensive care was coordinated by an anaesthetist in 25 units and by a neurosurgeon in 12. Annual caseload varied between units: 20 received >100 patients, 12 received 50-100, and seven received 25-49. Monitoring and treatment varied considerably between centres. Invasive arterial pressure monitoring was used routinely in 36 units, but central venous pressure monitoring was routinely used in 24 and intracranial pressure was routinely monitored in only 19. Corticosteroids were used to treat intracranial hypertension in 19 units. Seventeen units routinely aimed for arterial carbon dioxide pressure of 3.3-4.0 kPa, and one unit still used severe hyperventilation to a pressure of <3.3 kPa. Conclusion-The intensive care of patients with acute head injuries varied widely between the centres surveyed. Rationalisation of the intensive care of severe head injury with the production of widely accepted guidelines ought to improve the quality of care.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT ANAESTHESIA,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Jennett B., 1981, MANAGEMENT HEAD INJU; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Young B, 1991, Neurosurg Clin N Am, V2, P301	29	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					944	947						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616307				2023-01-03	WOS:A1996UF65900019
J	Rettig, RA				Rettig, RA			The social contract and the treatment of permanent kidney failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Rettig, RA (corresponding author), RAND CORP, 2100 M ST NW, WASHINGTON, DC 20037 USA.							BRADSHER K, 1995, NY TIMES        0417, pA1; BURTON TM, 1996, WALL STREET J   0205, pA3; DAMICO G, 1995, AM J KIDNEY DIS, V25, P113, DOI 10.1016/0272-6386(95)90637-1; EICHENWALD K, 1996, NY TIMES        1116, pA1; EICHENWALD K, 1995, NY TIMES        1204, pA1; FARLEY DO, 1994, DESIGNING CAPITATION; Friedman E, 1993, Nephrol News Issues, V7, P41; Friedman EA, 1996, JAMA-J AM MED ASSOC, V275, P1118, DOI 10.1001/jama.275.14.1118; HAKIM RM, 1992, AM J KIDNEY DIS, V20, P107, DOI 10.1016/S0272-6386(12)80538-5; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HELD PJ, 1994, DEV NEPHROL, V35, P13; HELD PJ, 1992, KIDNEY INT, V42, pS16; *HLTH CAR FIN ADM, 1994, HLTH CAR FIN RES REP; KJELLSTRAND CM, 1994, DEV NEPHROL, V35, P55; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; LIPIN S, 1996, WALL STREET J   0202, pA3; MALLICK MB, 1995, AM J KIDNEY DIS, V25, P176; MCCLELLAN WM, 1992, ANN INTERN MED, V117, P332, DOI 10.7326/0003-4819-117-4-332; Moss A H, 1995, Adv Ren Replace Ther, V2, P175; PARKER TF, 1994, AM J KIDNEY DIS, V24, P981, DOI 10.1016/S0272-6386(12)81073-0; RETTIG RA, 1991, DECISION MAKING SCI; Rettig RA, 1991, KIDNEY FAILURE FEDER; *US GEN ACC OFF, 1995, MED ENR GROWTH PAYM; *US REN DAT SYST, 1991, 1991 USRDS NIH NAT I; *US REN DAT SYST, 1990, 1990 USRDS NIH NAT I; *US REN DAT SYST, 1992, 1992 USRDS NIH NAT I; *US REN DAT SYST, 1993, 1993 USRDS NIH NAT I; *US REN DAT SYST, 1989, 1989 USRDS NIH NAT I; *US REN DAT SYST, 1995, 1995 USRDS NIH NAT I; *US REN DAT SYST, 1994, 1994 USRDS NIH NAT I; WOLFE RA, 1991, KIDNEY FAILURE FEDER, P353	31	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1123	1126		10.1001/jama.275.14.1123	http://dx.doi.org/10.1001/jama.275.14.1123			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601933				2023-01-03	WOS:A1996UD02700030
J	Haverkate, I; vanderWal, G				Haverkate, I; vanderWal, G			Policies on medical decisions concerning the end of life in Dutch health care institutions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe the prevalence and some features of policies on medical decisions concerning the end of life (MDELs) in Dutch hospitals, nursing homes, and institutions for the mentally disabled. Design.-A cross-sectional descriptive postal survey of 558 Dutch health care institutions. Setting.-All Dutch hospitals, nursing homes, and general institutions for the mentally disabled. Participants.-Directors of patient care of the institutions. Main Outcome Measures.-Respondents' reports on the existence of policies and guidelines on the following MDELs: euthanasia/assisted suicide (EAS), life-terminating acts without explicit request of the patient, refusal of treatment by patient, withholding or withdrawing treatment, symptom and pain control, and do-not-resuscitate (DNR) decisions. Results.-Of 558 health care institution managers, 86% responded. Most of the hospitals (69.2%) and nursing homes (73.9%) but only 16.3% of the institutions for the disabled had a written EAS policy. Nursing homes with a ban on EAS often had religious affiliations. In 37% of nursing homes, 15% of hospitals, and 15% of institutions for the disabled, the management had written policies on terminating life without request. Sixty percent of the hospitals, 35% of the nursing homes, and 17% of the institutions for the disabled had guidelines for one or more of four other distinct MDELs. Forty-five percent, 20%, and 8% of hospitals, nursing homes, and institutions of mentally disabled, respectively, had guidelines on DNR decisions. The management of 89% of the hospitals and 94% of the nursing homes communicated their policies on EAS to physicians and nurses in their institutions without being asked. Far fewer of these hospitals (3.9%) and nursing homes (30.5%) made their policies on EAS known to patients without being asked. Conclusions.-This study indicates that an important step toward policy development on EAS has been made by Dutch hospitals and nursing homes. Particularly with respect to policies on such decisions as withholding or withdrawing treatment, symptom and pain control, and DNR orders, an unexplored field is open to management for policy development in the Netherlands.	VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,DEPT GEN PRACTICE NURSING HOME & SOCIAL MED INSPE,AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam								BASTELS LP, 1995, I INTRAMURAL HLTH CA; BRUNETTI LL, 1990, ARCH INTERN MED, V150, P121, DOI 10.1001/archinte.150.1.121; CHOUDHRY NK, 1994, J AM GERIATR SOC, V42, P1150, DOI 10.1111/j.1532-5415.1994.tb06980.x; KLEEMANS CHM, 1992, ZIEKENHUIS, V9, P438; KORTMAN FAM, 1993, MAANDBLAD GEESTELIJK, P787; MILES SH, 1985, J AM GERIATR SOC, V33, P707, DOI 10.1111/j.1532-5415.1985.tb01780.x; MILES SH, 1989, PROTOCOLS ELECTIVE U; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; RASOOLY I, 1994, CAN MED ASSOC J, V150, P1265; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDEBUNT C, 1995, REQUEST EUTHANASIA N; VANWIJMEN FCB, 1986, MED CONTACT, V41, P1065; 1992, 2ND CHAMB DUTCH PARL; 1992, MED CONTACT, V47, P29; 1987, BIOETHICS, V1, P163	15	28	28	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					435	439		10.1001/jama.275.6.435	http://dx.doi.org/10.1001/jama.275.6.435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU638	8627954				2023-01-03	WOS:A1996TU63800013
J	Sheldon, T				Sheldon, T			Dutch and Swiss support heroin on prescription	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					835	835						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353501				2023-01-03	WOS:A1997YA00700015
J	Jonas, WB				Jonas, WB			Researching alternative medicine	NATURE MEDICINE			English	Editorial Material							COMPLEMENTARY MEDICINE; RHEUMATOID-ARTHRITIS; METAANALYSIS; TRIAL				Jonas, WB (corresponding author), NIH,OFF ALTERNAT MED,9000 ROCKVILLE PIKE,BLDG 31,ROOM 5B35,MSC 2182,BETHESDA,MD 20892, USA.							Ader R, 1985, PLACEBO THEORY RES M, P306; Altman Roy D., 1994, Seminars in Arthritis and Rheumatism, V23, P25, DOI 10.1016/S0049-0172(10)80023-X; ANDERSON WH, 1993, AIDS, V74, P561; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BERMAN BM, 1995, OSTEOARTHR CARTILAGE, V3, P139, DOI 10.1016/S1063-4584(05)80046-9; Blumberg D L, 1995, Altern Ther Health Med, V1, P31; Boissel JP, 1996, CRITICAL LIT REV EFF; BRAUD WG, 1992, SUBTLE ENERGIES, V2, P1; CARLSTON M, 1997, IN PRESS FAM MED; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; Dowie J, 1996, BRIT MED J, V313, P170, DOI 10.1136/bmj.313.7050.170a; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; HALLIDAY J, 1993, COMPLEMENTARY THER S, V1, P32; Jonas WB, 1996, INFLAMM RES, V45, P330, DOI 10.1007/BF02252945; KJELDSENKRAGH J, 1995, SCAND J RHEUMATOL, V24, P85, DOI 10.3109/03009749509099290; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; Lavigne J V, 1992, Arthritis Care Res, V5, P101, DOI 10.1002/art.1790050209; LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Neil Andrew, 1994, Current Opinion in Lipidology, V5, P6, DOI 10.1097/00041433-199402000-00002; RADIN DI, 1989, FOUND PHYS, V19, P1499, DOI 10.1007/BF00732509; TAO XL, 1987, CHIN J MED, V26, P399; TAO XL, 1987, CHUNG HUA NEI KO TSA, V26, P444; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; 1997, INT J TECH ASSESS HL, V13, P111; [No title captured]; 1997, ALTERNATIVE THERAPIE, V3, P49	35	28	28	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					824	827		10.1038/nm0897-824	http://dx.doi.org/10.1038/nm0897-824			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256264				2023-01-03	WOS:A1997XP01400015
J	Collins, JJ; Brennan, FT				Collins, JJ; Brennan, FT			Euthanasia and the potential adverse effects for Northern Territory Aborigines	LANCET			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; PAIN		AUSTRALIAN NATL UNIV,RES SCH SOCIAL SCI,CANBERRA,ACT 2600,AUSTRALIA	Australian National University	Collins, JJ (corresponding author), MEM SLOAN KETTERING CANC CTR,PAIN & PALLIAT CARE SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.							ALCORN G, 1996, SYDNEY MORNING  0823; AUSTIN N, 1996, LETS MEET HALF WAY P; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; *CANC PAIN REL PAL, 1990, WHO TECHN REP SER, V804; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; CHASSIN MR, 1994, WHEN DEATH IS SOUGHT; CORDNER S, 1995, LANCET, V346, P692, DOI 10.1016/S0140-6736(95)92295-4; Cunningham J, 1996, MED J AUSTRALIA, V165, P309, DOI 10.5694/j.1326-5377.1996.tb124987.x; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1995, PAIN FORUM, V4, P163; HARRISON B, 1994, DEMOGRAPHY NO TERRIT; Hoy WE, 1996, MED J AUSTRALIA, V165, P126, DOI 10.5694/j.1326-5377.1996.tb124882.x; Maguire GP, 1996, MED J AUSTRALIA, V164, P721, DOI 10.5694/j.1326-5377.1996.tb122270.x; MCLENNON W, 1994, DEATHS AUSTR; MOBBS R, 1994, HLTH ABORIGINAL AUST, P292; PORTENOY RK, IN PRESS PSYCHOSOMAT; REID J, 1994, HLTH ABORIGINAL AUST, pR11; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; 1997, SYDNEY MORNING  0116	19	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1907	1908		10.1016/S0140-6736(96)12388-6	http://dx.doi.org/10.1016/S0140-6736(96)12388-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217772				2023-01-03	WOS:A1997XG41700043
J	Davis, KD; Taub, E; Houle, S; Lang, AE; Dostrovsky, JO; Tasker, RR; Lozano, AM				Davis, KD; Taub, E; Houle, S; Lang, AE; Dostrovsky, JO; Tasker, RR; Lozano, AM			Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms	NATURE MEDICINE			English	Article							POSTEROVENTRAL PALLIDOTOMY; NEURONAL-ACTIVITY; DISEASE; SUPPLEMENTARY; APOMORPHINE; TREMOR; AREA	Studies of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in monkeys(1,2) suggest that excessive inhibitory outflow from the internal segment of the globus pallidus (GPi) suppresses the motor thalamus, which reduces activation of the cerebral cortex motor system, resulting in the slowness and poverty of movement of Parkinson's disease (PD)(3). This hypothesis is supported by reports of high rates of spontaneous neuronal discharges and hypermetabolism in GPi (ref. 4-7) and impaired activation of the supplementary motor area (SMA) and dorsolateral prefrontal regions(8,9) in PD patients. Furthermore, lesion or chronic high-frequency electrical (likely inactivating) stimulation of GPi (ref. 10-14) is associated with marked improvements in akinesia and rigidity, and the impaired activation of SMA is reversed when the akinesia is treated with dopamine agonists's. To test whether improvement in motor function with pallidal surgery can be attributed to increased activity in premotor cortical regions, we assessed the changes in regional cerebral blood flow (rCBF) and parkinsonian symptoms during disruption of GPi activity with high-frequency stimulation delivered through implanted brain electrodes. Positron emission tomography (PET) revealed an increase in rCBF in ipsilateral premotor cortical areas during GPi stimulation, which improved rigidity and bradykinesia. These results suggest that disrupting the excessive inhibitory output of the basal ganglia reverses parkinsonism, via a thalamic relay, by activation of brain areas involved in the initiation of movement.	UNIV TORONTO,TORONTO WESTERN HOSP,DIV NEUROSURG,DEPT SURG,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,PET CTR,CLARKE INST PSYCHIAT,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,TORONTO WESTERN HOSP,DIV NEUROL,DEPT MED,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Lozano, Andres M/A-5058-2012; Lang, Anthony/ABF-8114-2021	Lozano, Andres M./0000-0001-8257-3694; Houle, Sylvain/0000-0002-4231-6316; Lang, Anthony/0000-0003-1229-3667				Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beric A, 1996, ADV NEUROL, V69, P123; CEBALLOSBAUMANN AO, 1994, LANCET, V344, P814, DOI 10.1016/S0140-6736(94)92369-8; COLEBATCH JG, 1990, LANCET, V336, P1028, DOI 10.1016/0140-6736(90)92489-5; CRIDLAND RA, 1988, BRAIN RES BULL, V20, P429, DOI 10.1016/0361-9230(88)90132-3; DEIBER MP, 1993, BRAIN, V116, P267, DOI 10.1093/brain/116.1.267; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Eidelberg D, 1996, ANN NEUROL, V39, P450, DOI 10.1002/ana.410390407; EIDELBERG D, 1994, J CEREBR BLOOD F MET, V14, P783, DOI 10.1038/jcbfm.1994.99; EKBLOM A, 1988, J NEUROL NEUROSUR PS, V51, P481, DOI 10.1136/jnnp.51.4.481; FILION M, 1991, BRAIN RES, V547, P142; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Galvez-Jimenez Nestor, 1996, Neurology, V46, pA402; GRAFTON ST, 1995, ANN NEUROL, V37, P776, DOI 10.1002/ana.410370611; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HUTCHISON WD, 1994, NEUROREPORT, V5, P1533, DOI 10.1097/00001756-199407000-00031; JENKINS IH, 1992, ANN NEUROL, V32, P749, DOI 10.1002/ana.410320608; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; Parent A., 1996, CARPENTERS HUMAN NEU, V9th; PLAYFORD ED, 1993, ADV NEUROL, V60, P506; RASCOL O, 1992, ARCH NEUROL-CHICAGO, V49, P144, DOI 10.1001/archneur.1992.00530260044017; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; Talairach J., 1988, CO PLANAR STEREOTAXI	29	167	173	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					671	674		10.1038/nm0697-671	http://dx.doi.org/10.1038/nm0697-671			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176495				2023-01-03	WOS:A1997XB97400038
J	Donahue, JG; Weiss, ST; Livingston, JM; Goetsch, MA; Greineder, DK; Platt, R				Donahue, JG; Weiss, ST; Livingston, JM; Goetsch, MA; Greineder, DK; Platt, R			Inhaled steroids and the risk of hospitalization for asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIRWAY HYPERRESPONSIVENESS; CORTICOSTEROID-THERAPY; CHILDHOOD ASTHMA; FATAL ASTHMA; BUDESONIDE; DISEASE; ADULTS	Objective.-To determine if anti-inflammatory treatment for asthma reduces the risk of asthma hospitalization. Design.-Retrospective cohort study. Setting.-A health maintenance organization (HMO) in eastern Massachusetts. Participants.-Members of the HMO who were identified during the period October 1991 through September 1994 as having a diagnosis of asthma using a computerized medical record system. Main Outcome.-Hospitalization for asthma. Results.-Of the 16941 eligible persons, 742 (4.4%) were hospitalized for asthma, The overall relative risk (RR) of hospitalization among those who received inhaled steroids was 0.5 (95% confidence interval [CI], 0.4-0.6) after adjustment for beta-agonist dispensing. Additional adjustment for age, race, other asthma medications, and amount and type of ambulatory care for asthma did not substantially affect the inverse relationship between use of inhaled steroids and hospitalization. Cromolyn was similarly associated with reduced risk, especially among children (RR,0.8; 95% CI, 0.7-0.9). In contrast, increasing beta-agonist use was associated with increasing hospitalization risk even after adjustment for other factors and medications. The steroid-associated protection was most marked among individuals who received the largest amount of beta-agonist. Conclusions.-Inhaled steroids and, to a lesser extent, cromolyn confer significant protection against exacerbations of asthma leading to hospitalization. These results support the use of inhaled steroids by individuals who require more than occasional beta-agonist use to control asthma symptoms.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD PILGRIM HLTH CTR,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care								BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; BARRETT TE, 1995, AM J RESP CRIT CARE, V151, P574, DOI 10.1164/ajrccm.151.2.7842223; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; CLARK TJH, 1985, J ALLERGY CLIN IMMUN, V76, P330, DOI 10.1016/0091-6749(85)90649-9; COLLET JP, 1994, PHARMACOEPIDEM DR S, P609; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; DONAHUE JG, IN PRESS J ASTHMA; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; *NAT ASTH ED PROGR, 1991, US DHHS PUBLICATION; OBRIENLADNER A, 1994, GERIATRICS, V49, P20; OBRIENLADNER A, 1994, GERIATRICS, V49, P30; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SHEFFER AL, 1996, MED CARE, V31, pMS20; SKORODIN MS, 1993, ARCH INTERN MED, V153, P814, DOI 10.1001/archinte.153.7.814; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3	35	425	428	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					887	891		10.1001/jama.277.11.887	http://dx.doi.org/10.1001/jama.277.11.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062326				2023-01-03	WOS:A1997WM77400031
J	Lesar, TS; Briceland, L; Stein, DS				Lesar, TS; Briceland, L; Stein, DS			Factors related to errors in medication prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS; PREVENTABILITY; SYSTEMS; DOCTORS	Objective.-To quantify the type and frequency of identifiable factors associated with medication prescribing errors. Design and Setting.-Systematic evaluation of every third prescribing error detected and averted by pharmacists in a 631-bed tertiary care teaching hospital between July 1, 1994, and June 30, 1995. Each error was concurrently evaluated for the potential to result in adverse patient consequences. Each error was retrospectively evaluated by a physician and 2 pharmacists and a factor likely related to the error was identified. Participants.--All physicians prescribing medications during the study period and all staff pharmacists involved in the routine review of medication orders. Main Outcome Measures.-Frequency of association of factors likely related to medication errors in general and specific to medication classes and prescribing services (needed for medical, pediatric, obstetric-gynecologic, surgical, or emergency department patients); and potential consequences of errors for negative patient outcomes. Results.-A total of 2103 errors thought to have potential clinical importance were detected during the 1-year study period. The overall rate of errors was 3.99 errors per 1000 medication orders, and the error rate varied among medication classes and prescribing services. A total of 696 errors met study criteria (ie, errors with the potential for adverse patient effects) and were evaluated for a likely related factor. The most common specific factors associated with errors were decline in renal or hepatic function requiring alteration of drug therapy (97 errors: 13.9%), patient history of allergy to the same medication class (84 errors, 12.1%): using the wrong drug name, dosage form, or abbreviation (total of 79 errors, 11.4%, for both brand name and generic name orders), incorrect dosage calculations (77 errors, 11.1%), and atypical or unusual and critical dosage frequency considerations (75 errors, 10.8%). The most common groups of factors associated with errors were those related to knowledge and the application of knowledge regarding drug therapy (209 errors, 30%); knowledge and use of knowledge regarding patient fac tors that affect drug therapy (203 errors, 29.2%); use of calculations, decimal points, or unit and rate expression factors (122 errors, 17.5%); and nomenclature factors (incorrect drug name, dosage form, or abbreviation) (93 errors, 13.4%). Conclusions.-Several easily identified factors are associated with a large proportion of medication prescribing errors. By improving the focus of organizational, technological, and risk management educational and training efforts using the factors commonly associated with prescribing errors, risk to patients from adverse drug events should be reduced.	ALBANY COLL PHARM, DEPT PHARM PRACTICE, ALBANY, NY USA; ALBANY MED COLL, DIV MED, ALBANY, NY 12208 USA	Albany College of Pharmacy & Health Sciences; Albany Medical College	Lesar, TS (corresponding author), ALBANY MED CTR HOSP, DEPT PHARM, 43 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.							*AM MED ASS, 1994, AMA BOARD TRUST REP; [Anonymous], 1992, Am J Hosp Pharm, V49, P640; Attilio RM, 1996, HOSP PHARM, V31, P17; BALDWIN L, 1995, BRIT MED J, V310, P1154, DOI 10.1136/bmj.310.6988.1154; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BEERS MH, 1990, J AM GERIATR SOC, V38, P1183, DOI 10.1111/j.1532-5415.1990.tb01496.x; BJORNSON DC, 1993, AM J HOSP PHARM, V50, P1875, DOI 10.1093/ajhp/50.9.1875; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; DAVIS N, 1987, MED ABBREVIATIONS 55; FOLLI HL, 1987, PEDIATRICS, V79, P718; HAIG GM, 1991, AM J HOSP PHARM, V48, P1457, DOI 10.1093/ajhp/48.7.1457; JICK H, 1977, AM J MED, V62, P514, DOI 10.1016/0002-9343(77)90406-5; KIRCHBAUM DW, 1988, DICP ANN PHARMAC, V22, P981; KOREN G, 1994, J CLIN PHARMACOL, V34, P1043, DOI 10.1002/j.1552-4604.1994.tb01978.x; LANDIS SJ, 1990, CAN MED ASSOC J, V143, P611; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEAPE LL, 1995, AM J HEALTH-SYST PH, V52, P379, DOI 10.1093/ajhp/52.4.379; LEBELLE MJ, 1993, CAN MED ASSOC J, V149, P941; Lesar T S, 1994, Hosp Pharm, V29, P935; Lesar TS, 1996, ANN PHARMACOTHER, V30, P31, DOI 10.1177/106002809603000105; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; LESAR TS, 1992, ANN INTERN MED, V117, P537, DOI 10.7326/0003-4819-117-6-537_2; LOMAESTRO BM, 1992, JAMA-J AM MED ASSOC, V268, P2031, DOI 10.1001/jama.1992.03490150083021; LOMAESTRO BM, 1994, ANN INTERN MED, V121, P818, DOI 10.7326/0003-4819-121-10-199411150-00034; MCKENNEY JM, 1979, AM J HOSP PHARM, V36, P1691, DOI 10.1093/ajhp/36.12.1691; MEYERSOHN MB, 1992, APPL PHARMACOKINETIC, P1; Potts MJ, 1996, ARCH PEDIAT ADOL MED, V150, P748, DOI 10.1001/archpedi.1996.02170320094016; Preston SL, 1995, ANN PHARMACOTHER, V29, P1202, DOI 10.1177/106002809502901202; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; VITILLO JA, 1991, DICP ANN PHARMAC, V25, P1388, DOI 10.1177/106002809102501221	35	466	481	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					312	317		10.1001/jama.277.4.312	http://dx.doi.org/10.1001/jama.277.4.312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002494				2023-01-03	WOS:A1997WC45800031
J	Larue, F; Fontaine, A; Colleau, SM				Larue, F; Fontaine, A; Colleau, SM			Underestimation and undertreatment of pain in HIV disease: Multicentre study	BRITISH MEDICAL JOURNAL			English	Article							CANCER PAIN; HOSPITALIZED-PATIENTS; FRANCE; ATTITUDES; MORPHINE; AIDS	Objectives: To measure the prevalence, severity, and impact of pain on quality of life for HIV patients; to identify factors associated with undertreatment of pain. Design: Multicentre cross sectional survey. Settings: 34 HIV treatment facilities, including inpatient hospital wards, day hospitals, and ambulatory care clinics, in 13 cities throughout France. Subjects: 315 HIV patients at different stages of the disease. Main outcome measures: Patients: recorded presence and severity of pain and rated quality of life, Doctors: reported disease status, estimate of pain severity, and analgesic treatment ordered. Results: From 30% (17/56) of outpatients to 62% (73/118) of inpatients reported pain due to HIV disease. Pain severity significantly decreased patients' quality of life. Doctors underestimated pain severity in 52% (70/135) of HIV patients reporting pain. Underestimation of pain severity was more likely for patients who reported moderate (odds ratio 24) or severe pain (165) and less likely for patients whose pain source was identified or who were perceived as more depressed, Of the patients reporting moderate or severe pain, 57% (61/107) did not receive any analgesic treatment; only 22% (23/107) received at least weak opioids. Likelihood of analgesic prescription increased when doctors estimated pain to be more severe and regarded patients as sicker. Conclusions: Pain is a common and debilitating symptom of HIV disease which is gravely underestimated and undertreated.	UNIV PARIS 07, FAC BICHAT, DEPT SANTE PUBL, F-75018 PARIS, FRANCE; UNIV WISCONSIN, SCH MED, WHO, COLLABORATING CTR SYMPTOM EVALUAT CANC CARE, MADISON, WI 53705 USA	UDICE-French Research Universities; Universite Paris Cite; University of Wisconsin System; University of Wisconsin Madison; World Health Organization	Larue, F (corresponding author), INST MUTUALISTE MONTSOURIS, 42 BLVD JOURDAN, F-75014 PARIS, FRANCE.							ANAND A, 1994, J ACQ IMMUN DEF SYND, V7, P52; BREITBART W, 1993, SYMP PAIN R, P49; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; DIXON P, 1991, POSTGRAD MED J, V67, pS92; DORMONT J, 1993, PRISE CHARGE PERSONN; Hoyt M J, 1994, J Assoc Nurses AIDS Care, V5, P33; JACOX A, 1994, 9 US DEP HLTH HUM SE; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LARUE F, 1995, CANCER, V76, P2375, DOI 10.1002/1097-0142(19951201)76:11<2375::AID-CNCR2820761129>3.0.CO;2-C; Larue F, 1996, J PAIN SYMPTOM MANAG, V12, P106; LARUE F, 1995, BRIT MED J, V310, P1034, DOI 10.1136/bmj.310.6986.1034; LEBOVITS AH, 1994, CLIN J PAIN, V10, P156, DOI 10.1097/00002508-199406000-00010; MCCORMACK JP, 1993, CLIN J PAIN, V9, P279, DOI 10.1097/00002508-199312000-00010; *MIN SOC AFF, 1994, HLTH CAR AIDS KEY FI; MOSS V, 1991, Palliative Medicine, V5, P112; Newshan G T, 1993, J Assoc Nurses AIDS Care, V4, P53; ONEILL WM, 1993, PAIN, V54, P3, DOI 10.1016/0304-3959(93)90093-5; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SHOFFERMAN J, 1988, J PALLIAT CARE, V4, P46; SINGER EJ, 1993, PAIN, V54, P15, DOI 10.1016/0304-3959(93)90094-6; VAINIO A, 1995, PAIN, V62, P155, DOI 10.1016/0304-3959(94)00264-F; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *WHO, 1990, WHO TECH REP SER, V804	27	141	146	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					23	28		10.1136/bmj.314.7073.23	http://dx.doi.org/10.1136/bmj.314.7073.23			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001475	Green Published			2023-01-03	WOS:A1997WB68400019
J	Alberts, DS; Liu, PY; Hannigan, EV; OToole, R; Williams, SD; Young, JA; Franklin, EW; ClarkePearson, DL; Malviya, VK; DuBeshter, B; Adelson, MD; Hoskins, WJ				Alberts, DS; Liu, PY; Hannigan, EV; OToole, R; Williams, SD; Young, JA; Franklin, EW; ClarkePearson, DL; Malviya, VK; DuBeshter, B; Adelson, MD; Hoskins, WJ			Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; CHEMOTHERAPY; CARCINOMA; THIOSULFATE; TUMORS	Background Intravenous platinum-based chemotherapy is the standard primary therapy for advanced ovarian cancer. We conducted a phase 3 trial to compare the effects of intraperitoneal and intravenous cisplatin on the survival of women with previously untreated, stage III, epithelial ovarian cancer. Methods The patients underwent an initial exploratory laparotomy and resection of all tumor masses larger than 2 cm. Within four weeks after surgery, six courses of intravenous cyclophosphamide (600 mg per square meter of body-surface area per course) plus either intraperitoneal cisplatin (100 mg per square meter) or intravenous cisplatin (100 mg per square meter) were administered at three-week intervals. Results Of 654 randomized patients, 546 were eligible for the study. The estimated median survival was significantly longer in the group receiving intraperitoneal cisplatin (49 months; 95 percent confidence interval, 42 to 56) than in the group receiving intravenous cisplatin (41 months; 95 percent confidence interval, 34 to 47). The risk of death was tower in the intraperitoneal group than in the intravenous group (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02). Moderate-to-severe tinnitus, clinical hearing loss, and neuromuscular toxic effects were significantly more frequent in the intravenous group. Conclusions As compared with intravenous cisplatin, intraperitoneal cisplatin significantly improves survival and has significantly fewer toxic effects in patients with stage ill ovarian cancer and residual tumor masses of 2 cm or less. (C) 1996, Massachusetts Medical Society.	UNIV ARIZONA,TUCSON,AZ; SW ONCOL GRP,CTR STAT,SEATTLE,WA; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; OHIO STATE UNIV,CTR HLTH,COLUMBUS,OH 43210; GYNECOL ONCOL GRP,PHILADELPHIA,PA 19107; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN; EASTERN COOPERAT ONCOL GRP,BOSTON,MA; CANC CARE ASSOCIATES,TULSA,OK; ATLANTA REG COMMUNITY CLIN ONCOL PROGRAM,ATLANTA,GA; WAYNE STATE UNIV,MED CTR,DETROIT,MI 48202; UNIV ROCHESTER,SCH MED,ROCHESTER,NY	University of Arizona; Southwest Oncology Group; University of Texas System; University of Texas Medical Branch Galveston; University System of Ohio; Ohio State University; Indiana University System; Indiana University-Purdue University Indianapolis; Detroit Medical Center; Wayne State University; University of Rochester					NATIONAL CANCER INSTITUTE [U10CA038926, U10CA032102, U10CA045450] Funding Source: NIH RePORTER; NCI NIH HHS [CA32102, CA45450, CA38926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COX DR, 1972, J R STAT SOC B, V34, P187; DEDRICK RL, 1978, CANCER TREAT REP, V62, P1; GOEL R, 1989, J NATL CANCER I, V81, P1552, DOI 10.1093/jnci/81.20.1552; HOWELL SB, 1982, ANN INTERN MED, V97, P845, DOI 10.7326/0003-4819-97-6-845; HOWELL SB, 1987, J CLIN ONCOL, V5, P1607, DOI 10.1200/JCO.1987.5.10.1607; KIRMANI S, 1991, J CLIN ONCOL, V9, P649, DOI 10.1200/JCO.1991.9.4.649; LOS G, 1989, CANCER RES, V49, P3380; MARKMAN M, 1986, CANCER TREAT REV, V13, P219, DOI 10.1016/0305-7372(86)90007-1; MARKMAN M, 1990, CHEMOTHERAPY GYNECOL, P375; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MILLER BA, 1993, NIH PUBLICATION; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; OMURA GA, 1989, J CLIN ONCOL, V7, P457, DOI 10.1200/JCO.1989.7.4.457; PICCART MJ, 1985, SEMIN ONCOL, V12, P90; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WINGO PA, 1995, CA-CANCER J CLIN, V45, P127	16	962	995	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1950	1955		10.1056/NEJM199612263352603	http://dx.doi.org/10.1056/NEJM199612263352603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960474				2023-01-03	WOS:A1996WA16000003
J	Holm, S; Evans, M				Holm, S; Evans, M			Product names, proper claims? More ethical issues in the marketing of drugs	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To analyse the explicit or implicit claims embodied in the proprietary names of pharmaceutical products. Design-Linguistic and ethical analysis of proprietary names of pharmaceutical products marketed in the UK and in Denmark. Results and conclusions-A number of drugs have names that allude to their indication or actions. Such names may be problematic, however, because they often promise more than the drug can deliver. Taking into account, firstly, the type of allusion and its degree of sophistication, and, secondly, the seriousness of the indication may help in identifying the most problematic drug names.	UNIV COLL SWANSEA,CTR PHILOSOPHY & HLTH CARE,SWANSEA SA2 8PP,W GLAM,WALES	Swansea University	Holm, S (corresponding author), UNIV COPENHAGEN,DEPT MED PHILOSOPHY & CLIN THEORY,DK-2200 COPENHAGEN N,DENMARK.			Holm, Soren/0000-0002-7200-5607				ARONSON JK, 1994, BRIT MED J, V308, P1140, DOI 10.1136/bmj.308.6937.1140; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; JACK DB, 1991, BRIT MED J, V303, P1606, DOI 10.1136/bmj.303.6817.1606; *LAEG FORL, 1995, LAEG MED; MCNULTY H, 1979, BRIT MED J, V2, P836, DOI 10.1136/bmj.2.6194.836; Spigset Olav, 1995, Tidsskrift for den Norske Laegeforening, V115, P380	7	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1627	1629		10.1136/bmj.313.7072.1627	http://dx.doi.org/10.1136/bmj.313.7072.1627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991014	Green Published			2023-01-03	WOS:A1996VZ81100046
J	Grimes, DA; Daley, J; Delbanco, TL				Grimes, DA; Daley, J; Delbanco, TL			A 17-year-old mother seeking contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PELVIC INFLAMMATORY DISEASE; MEDROXYPROGESTERONE ACETATE; BONE-DENSITY; PATIENT SATISFACTION; ADOLESCENT MOTHERS; DEPO-PROVERA; WOMEN; LEVONORGESTREL; TRIAL; RISK		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco								*A GUTTM I, 1994, SEX AM TEEN; ARROYO P, 1995, INT J GYNECOL OBSTET, V48, P269, DOI 10.1016/0020-7292(94)02284-6; BERENSON AB, 1993, PEDIATRICS, V92, P257; Brown S.S., 1995, BEST INTENTIONS UNIN; CORMIA FE, 1967, JAMA-J AM MED ASSOC, V201, P141; CUNDY T, 1994, BRIT MED J, V308, P247, DOI 10.1136/bmj.308.6923.247; CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; Davis AJ, 1996, J REPROD MED, V41, P407; DROEGEMUELLER W, 1989, AM J OBSTET GYNECOL, V161, P1407, DOI 10.1016/0002-9378(89)90705-9; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FORREST JD, 1990, FAM PLANN PERSPECT, V22, P206, DOI 10.2307/2135494; FORREST JD, 1989, NEED AVAILABILITY FI, P36; Gleicher N, 1979, Obstet Gynecol Surv, V34, P721, DOI 10.1097/00006254-197910000-00001; GRAY RH, 1985, LANCET, V1, P1046; GROU F, 1994, AM J OBSTET GYNECOL, V171, P1529, DOI 10.1016/0002-9378(94)90396-4; HAREL Z, 1995, J ADOLESCENT HEALTH, V16, P379, DOI 10.1016/S1054-139X(95)00094-9; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; JONES EF, 1992, FAM PLANN PERSPECT, V24, P12, DOI 10.2307/2135719; JONES KP, 1994, AM J OBSTET GYNECOL, V170, P1575; Kato K, 1995, Zentralbl Gynakol, V117, P260; KAUNITZ AM, 1994, AM J OBSTET GYNECOL, V170, P1548; KOOIKER CH, 1990, WESTERN J MED, V153, P279; MAINWARING R, 1995, CONTRACEPTION, V51, P149, DOI 10.1016/0010-7824(95)00011-X; MARX PA, 1996, AM SOC CLIN INV MAY; MASTROIANNI L, 1990, DEV NEW CONTRACEPTIV, P118; MCGREGOR JA, 1993, AM J OBSTET GYNECOL, V168, P2033, DOI 10.1016/S0002-9378(12)90946-1; MOORE KA, 1989, FAM PLANN PERSPECT, V21, P110, DOI 10.2307/2135660; NAESSEN T, 1995, CONTRACEPTION, V52, P35, DOI 10.1016/0010-7824(95)00121-P; PARIANI S, 1991, STUD FAMILY PLANN, V22, P384, DOI 10.2307/1966452; PETERSEN KR, 1994, AM J OBSTET GYNECOL, V171, P400, DOI 10.1016/S0002-9378(94)70041-9; POLANECZKY M, 1994, NEW ENGL J MED, V331, P1201, DOI 10.1056/NEJM199411033311806; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; REUBINOFF BE, 1995, FERTIL STERIL, V68, P516; ROSSNER S, 1995, OBES RES, V3, pS267; RYDEN G, 1979, CONTRACEPTION, V20, P149, DOI 10.1016/0010-7824(79)90087-8; SALEH WA, 1993, AM J OBSTET GYNECOL, V168, P1740, DOI 10.1016/0002-9378(93)90685-C; Sawaya GF, 1996, OBSTET GYNECOL, V87, P884; SEITZ V, 1993, AM J ORTHOPSYCHIAT, V63, P572, DOI 10.1037/h0079483; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; SMITH RD, 1995, ADOLESCENT PEDIAT G, V8, P24, DOI 10.1016/S0932-8610(12)80157-5; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; TRUSSELL J, 1995, AM J PUBLIC HEALTH, V85, P494, DOI 10.2105/AJPH.85.4.494; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; *US PREV SERV TASK, 1995, GUID CLIN PREV SERV; Virutamasen P, 1994, Asia Oceania J Obstet Gynaecol, V20, P269; WALSH TL, 1994, CONTRACEPTION, V50, P319, DOI 10.1016/0010-7824(94)90019-1; WOODS ER, 1992, AM J OBSTET GYNECOL, V166, P901, DOI 10.1016/0002-9378(92)91359-I; ZABIN LS, 1979, FAM PLANN PERSPECT, V11, P215, DOI 10.2307/2134252	49	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1163	1170		10.1001/jama.276.14.1163	http://dx.doi.org/10.1001/jama.276.14.1163			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL332	8827970				2023-01-03	WOS:A1996VL33200027
J	deVries, EGE; tenVergert, EM; Mastenbroek, CG; Dalesio, O; Rodenhuis, S				deVries, EGE; tenVergert, EM; Mastenbroek, CG; Dalesio, O; Rodenhuis, S			Breast cancer studies in the Netherlands	LANCET			English	Letter											deVries, EGE (corresponding author), UNIV GRONINGEN HOSP,DEPT MED ONCOL,DUTCH WORK PARTY AUT BONE MARROW TRANS SOLID TUM,NL-9700 RB GRONINGEN,NETHERLANDS.			de Vries, Elisabeth/0000-0002-8949-7425				McCarthy M, 1996, LANCET, V347, P1617, DOI 10.1016/S0140-6736(96)91102-2	1	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					407	408		10.1016/S0140-6736(05)65026-X	http://dx.doi.org/10.1016/S0140-6736(05)65026-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709754				2023-01-03	WOS:A1996VB42600047
J	Armstrong, D; Reyburn, H; Jones, R				Armstrong, D; Reyburn, H; Jones, R			A study of general practitioners' reasons for changing their prescribing behaviour	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To explore general practitioners' reasons for recent changes in their prescribing behaviour. Design - Qualitative analysis of semistructured interviews. Setting - General practice in south east London. Subjects - A heterogeneous sample of 18 general practitioners. Results - Interviewees were able to identify between two and five specific changes that had occurred in their prescribing in the preceding six months. The most frequently mentioned changes related to fluoxetine, angiotensin converting enzyme inhibitors, and the antibiotic treatment of Helicobacter pylori. Three models of change were identified: an accumulation model, in which the volume and authority of evidence were important; a challenge model, in which behaviour change followed a dramatic or conflictual clinical event; and a continuity model, in which change took place against a background of willingness to change, modulated by other factors such as cost pressures and the comprehensible therapeutic action of a drug. Behaviour change was reinforced and sustained by experiences with individual patients. Conclusions - Multiple factors are involved in general practitioners) decisions to change their prescribing habits. Three models of change can be identified which have important implications for the design and evaluation of interventions aimed at behaviour change.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London			Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				[Anonymous], 1995, LANCET, V346, P785; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; SMITH R, 1995, BRIT MED J, V311, P961; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244	7	120	122	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					949	952						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616310				2023-01-03	WOS:A1996UF65900022
J	Bradley, C; Blenkinsopp, A				Bradley, C; Blenkinsopp, A			Over the counter drugs - The future for self medication	BRITISH MEDICAL JOURNAL			English	Article								The increasing trend towards deregulation of more medicines to over the counter status has implications for the primary health care team as well as for consumers and patients. Better information for patients could improve the safety of over the counter medicines, but better systems need to be devised for reporting adverse reactions. ''Collaborative care'' could bring financial benefits. Doctors, nurses, and pharmacists need to discuss how they will respond to self medication practices, and ways of rewarding pharmacists for advising patients need to be found. Improved communication between doctors and pharmacists and the involvement of nurses could bring health care professionals into a new and more constructive interaction with each other and with the patient-or the changes required could split the professions as they each try to keep control of medicines.	UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Bradley, C (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				Blenkinsopp A, 1996, BRIT MED J, V312, P629; BRADLEY C, 1995, PRESCRIBER      0305, P75; DRIFE JO, 1993, BRIT MED J, V307, P695, DOI 10.1136/bmj.307.6906.695; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; *MED CONTR AG, 1992, CHANG LEG CLASS PRES; 1995, PHARM J, V254, P433; 1993, LANCET, V342, P565; 1992, OFFICIAL J EUROPEA L, P113	9	65	67	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					835	837						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608296				2023-01-03	WOS:A1996UD37800032
J	Pickering, WG				Pickering, WG			Does medical treatment mean patient benefit?	LANCET			English	Article																		BERN JL, 1988, BR J CLIN PHARM, V26, P679; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MEDAWAR C, 1992, POWER DEPENDENCE; PICKERING W, 1992, BRIT MED J, V304, P1516; Pickering W G, 1993, J Med Ethics, V19, P121, DOI 10.1136/jme.19.2.121-a; 1995, BRIT NATIONAL FORMUL, P219; 1994, PRESCRIPTION IMPROVE	8	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					379	380		10.1016/S0140-6736(96)90544-9	http://dx.doi.org/10.1016/S0140-6736(96)90544-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598708				2023-01-03	WOS:A1996TU69500016
J	Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH				Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH			Collaborative management of chronic illness	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIORAL MEDICINE INTERVENTIONS; ACUTE MYOCARDIAL-INFARCTION; ARTHRITIS SELF-MANAGEMENT; CONGESTIVE-HEART-FAILURE; QUALITY-OF-LIFE; PATIENT EDUCATION; PSYCHOSOCIAL INTERVENTIONS; DIABETES-MELLITUS; CONTROLLED TRIAL; CANCER-PATIENTS	In chronic illness, day-to-day care responsibilities fall most heavily on patients and their families. Effective collaborative relationships with health care providers can help patients and families better handle self-care tasks. Collaborative management is care that strengthens and supports self-care in chronic illness while assuring that effective medical, preventive, and health maintenance interventions take place. In this paper, the following essential elements of collaborative management developed in light of behavioral principles and empirical evidence about effective care in chronic illness are discussed: 1) collaborative definition of problems, in which patient-defined problems are identified along with medical problems diagnosed by physicians; 2) targeting, goal setting, and planning, in which patients and providers focus on a specific problem, set realistic objectives, and develop an action plan for attaining those objectives in the context of patient preferences and readiness; 3) creation of a continuum of selfmanagement training and support services, in which patients have access to services that teach skills needed to carry out medical regimens, guide health behavior changes, and provide emotional support; and 4) active and sustained follow-up, in which patients are contacted at specified intervals to monitor health status, identify potential complications, and check and reinforce progress in implementing the care plan. These elements make up a common core of services for chronic illness care that need not be reinvented for each disease.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Ctr Advancement Hlth, Washington, DC 20009 USA	Group Health Cooperative	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; VonKorff, Michael/0000-0001-5386-8477				ALARANTA H, 1994, SPINE, V19, P1339, DOI 10.1097/00007632-199406000-00007; ANDERSEN BL, 1992, J CONSULT CLIN PSYCH, V60, P552, DOI 10.1037/0022-006X.60.4.552; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAUM D, 1986, J ASTHMA, V23, P49, DOI 10.3109/02770908609077475; BERESFORD SAA, 1992, AM J PUBLIC HEALTH, V82, P79, DOI 10.2105/AJPH.82.1.79; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Burg MM., 1994, ANN BEHAV MED, V16, P109, DOI 10.1093/abm/16.2.109; CLARK NM, 1992, GERONTOLOGIST, V32, P438, DOI 10.1093/geront/32.4.438; CLARK NM, 1992, HEALTH EDUC QUART, V19, P341, DOI 10.1177/109019819201900306; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1994, J ASTHMA, V31, P427, DOI 10.3109/02770909409089484; CLARK NM, 1989, CHEST, V95, P1110, DOI 10.1378/chest.95.5.1110; Clark NM, 1991, J AGING HEALTH, V3, P3, DOI DOI 10.1177/089826439100300101; CURRY SJ, 1993, J CONSULT CLIN PSYCH, V61, P790, DOI 10.1037/0022-006X.61.5.790; CURRY SJ, 1994, ANNU REV PUBL HEALTH, V15, P345; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; FAWZY FI, 1995, ARCH GEN PSYCHIAT, V52, P100; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; Frasure-Smith N, 1995, J Cardiopulm Rehabil, V15, P103; GILOTH BE, 1990, PATIENT EDUC COUNS, V15, P29, DOI 10.1016/0738-3991(90)90005-6; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; GLASGOW RE, 1989, HEALTH PSYCHOL, V8, P285, DOI 10.1037/0278-6133.8.3.285; GLASGOW RE, 1992, PATIENT EDUC COUNS, V19, P61, DOI 10.1016/0738-3991(92)90102-O; GLASGOW RE, 1995, DIABETES CARE, V18, P117, DOI 10.2337/diacare.18.1.117; Glasgow RE, 1996, DIABETES CARE, V19, P835, DOI 10.2337/diacare.19.8.835; GLYNN TJ, 1990, HEALTH EDUC QUART, V17, P329, DOI 10.1177/109019819001700308; GOODALL TA, 1991, HEALTH PSYCHOL, V10, P1, DOI 10.1037/0278-6133.10.1.1; GREENE B, 1994, J CONSULT CLIN PSYCH, V62, P576, DOI 10.1037/0022-006X.62.3.576; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HELLER RF, 1993, AM J CARDIOL, V72, P759, DOI 10.1016/0002-9149(93)91058-P; HELLMAN CJC, 1990, BEHAV MED, V16, P165, DOI 10.1080/08964289.1990.9934605; HILTON S, 1986, LANCET, V1, P26; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Holman H, 1988, Trans Assoc Am Physicians, V101, P173; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; INUI TS, 1985, MED CARE, V23, P521, DOI 10.1097/00005650-198505000-00013; JAMES LD, 1993, BEHAV THER, V24, P305, DOI 10.1016/S0005-7894(05)80271-0; JENKINS CD, 1995, BEHAV MED, V21, P53, DOI 10.1080/08964289.1995.9933742; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLY JA, 1993, AM J PSYCHIAT, V150, P1679; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG K, 1984, GERONTOLOGIST, V24, P455; Lorig K, 1993, GENERATIONS, V17, P11; Lorig K., 1994, LIVING HLTH LIFE CHR; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MAZZE RS, 1994, DIABETES CARE, V17, P5; MAZZE RS, 1994, DIABETES CARE, V17, P56; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; MONTGOMERY EB, 1994, AM J MED, V97, P429, DOI 10.1016/0002-9343(94)90322-0; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; Patterson J.M., 1994, ANN BEHAV MED, V16, P131, DOI [DOI 10.1093/ABM/16.2.131, 10.1093/abm/16.2.131]; Payne T H, 1995, HMO Pract, V9, P101; PAYNE TJ, 1994, J PSYCHOSOM RES, V38, P409, DOI 10.1016/0022-3999(94)90102-3; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; Ruggiero L., 1993, DIABETES SPECTRUM, V6, P22; RUTTAN VW, 1988, GENERATION DIFFUSION, P69; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; Sikkema KJ, 1996, ANN BEHAV MED, V18, P40, DOI 10.1007/BF02903938; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; SPIEGEL D, 1989, LANCET, V2, P888; STEWART AL, 1994, J CLIN EPIDEMIOL, V47, P719, DOI 10.1016/0895-4356(94)90169-4; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; TOBIN D, 1986, HDB CLIN INTERVENTIO; Turner JA, 1996, SPINE, V21, P2851, DOI 10.1097/00007632-199612150-00010; *U CAL, 1996, CHRON CAR AM 21 CENT; VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/j.2044-8260.1994.tb01133.x; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227	85	838	845	2	81	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1097	1102		10.7326/0003-4819-127-12-199712150-00008	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL262	9412313				2023-01-03	WOS:000070936600007
J	Tallman, MS; Andersen, JW; Schiffer, CA; Appelbaum, FR; Feusner, JH; Ogden, A; Shepherd, L; Willman, C; Bloomfield, CD; Rowe, JM; Wiernik, PH				Tallman, MS; Andersen, JW; Schiffer, CA; Appelbaum, FR; Feusner, JH; Ogden, A; Shepherd, L; Willman, C; Bloomfield, CD; Rowe, JM; Wiernik, PH			All-trans-retinoic acid in acute promyelocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Meeting of the American-Society-of-Hematology	DEC 01-05, 1995	SEATTLE, WA	Amer soc Hematol			ACUTE MYELOID-LEUKEMIA; DIFFERENTIATION THERAPY; REMISSION INDUCTION; RESIDUAL DISEASE; RAR-ALPHA; TRANSLOCATION; CHEMOTHERAPY; EXPERIENCE; DIAGNOSIS; REDUCTION	Background All-trans-retinoic acid induces complete remission in acute promyelocytic leukemia. However, it is not clear whether induction therapy with all-trans-retinoic acid is superior to chemotherapy alone or whether maintenance treatment with all-trans-retinoic acid improves outcome. Methods Three hundred forty-six patients with previously untreated acute promyelocytic leukemia were randomly assigned to receive all-trans-retinoic acid or daunorubicin plus cytarabine as induction treatment. Patients who had a complete remission received consolidation therapy consisting of one cycle of treatment identical to the induction chemotherapy, then high-dose cytarabine plus daunorubicin. Patients still in complete remission after two cycles of consolidation therapy were then randomly assigned to maintenance treatment with all-trans-retinoic acid or to observation. Results Of the 174 patients treated with chemotherapy, 120 (69 percent) had a complete remission, as did 124 of the 172 (72 percent) given all-trans-retinoic acid (P=0.56). When both induction and maintenance treatments were taken into account, the estimated rates of disease-free survival at one, two, and three years were 77, 61, and 55 percent, respectively, for patients assigned to chemotherapy then all-trans-retinoic acid; 86, 75, and 75 percent for all-trans-retinoic acid then all-trans-retinoic acid; 75, 60, and 60 percent for all-trans-retinoic acid then observation; and 29, 18, and 18 percent for chemotherapy then observation. By intention-to-treat analysis, the rates of overall survival at one, two, and three years after entry into the study were 75, 57, and 50 percent, respectively, among patients assigned to chemotherapy, and 82, 72, and 67 percent among those assigned to all-trans-retinoic acid (P=0.003). Conclusions All-trans-retinoic acid as induction or maintenance treatment improves disease-free and overall survival as compared with chemotherapy alone and should be included in the treatment of acute promyelocytic leukemia. (C) 1997, Massachusetts Medical Society.	DANA FARBER CANC INST,BOSTON,MA 02115; UNIV MARYLAND,SCH MED,GREENEBAUM CANC CTR,BALTIMORE,MD 21201; UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195; CHILDRENS HOSP OAKLAND,OAKLAND,CA 94609; TEXAN CHILDRENS CANC CTR,HOUSTON,TX; NATL CANC INST,CANADA CLIN TRIALS GRP,KINGSTON,ON,CANADA; UNIV NEW MEXICO,ALBUQUERQUE,NM 87131; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,BUFFALO,NY 14263; UNIV ROCHESTER,ROCHESTER,NY; MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,BRONX,NY 10467	Harvard University; Dana-Farber Cancer Institute; University System of Maryland; University of Maryland Baltimore; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Texas Children's Cancer Center; Queens University - Canada; Canadian Cancer Trials Group; University of New Mexico; Roswell Park Cancer Institute; University of Rochester; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Tallman, MS (corresponding author), NORTHWESTERN UNIV,SCH MED,DIV HEMATOL ONCOL,ROBERT H LURIE CANC CTR,233 E ERIE ST,SUITE 700,CHICAGO,IL 60611, USA.							Avvisati G, 1996, BLOOD, V88, P1390, DOI 10.1182/blood.V88.4.1390.bloodjournal8841390; BENNETT JM, 1991, LEUKEMIA RES, V15, P223, DOI 10.1016/0145-2126(91)90124-C; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, LEUKEMIA, V10, P825; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CHOMIENNE C, 1990, BLOOD, V76, P1710; CORDONNIER C, 1985, CANCER-AM CANCER SOC, V55, P18, DOI 10.1002/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B; CUNNINGHAM I, 1989, BLOOD, V73, P1116; DETHE H, 1990, NATURE, V347, P358; EARDLEY AM, 1994, LEUKEMIA, V8, P934; ELLIOTT S, 1992, BLOOD, V79, P1916; Estey E, 1997, J CLIN ONCOL, V15, P483, DOI 10.1200/JCO.1997.15.2.483; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; Gallagher RE, 1997, BLOOD, V90, P1656; HEAD D, 1995, BLOOD, V86, P1717, DOI 10.1182/blood.V86.5.1717.bloodjournal8651717; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; KANTARJIAN HM, 1986, AM J MED, V80, P789, DOI 10.1016/0002-9343(86)90617-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORNINGER L, 1994, BRIT J HAEMATOL, V88, P427, DOI 10.1111/j.1365-2141.1994.tb05048.x; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; OHNO R, 1993, LEUKEMIA, V7, P1722; TAKESHITA A, 1995, CANCER-AM CANCER SOC, V76, P602, DOI 10.1002/1097-0142(19950815)76:4<602::AID-CNCR2820760410>3.0.CO;2-L; TALLMAN MS, 1992, BLOOD, V79, P543; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WIERNIK PH, 1996, NEOPLASTIC DIS BLOOD, P353; WILEY JS, 1995, LEUKEMIA, V9, P774	37	761	788	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1021	1028		10.1056/NEJM199710093371501	http://dx.doi.org/10.1056/NEJM199710093371501			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321529	Bronze			2023-01-03	WOS:A1997XZ84400001
J	Emanuel, EJ				Emanuel, EJ			Care for dying patients	LANCET			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Emanuel, EJ (corresponding author), DANA FARBER CANC INST,CTR OUTCOMES & POLICY RES,BOSTON,MA 02115, USA.							COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285	6	15	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1714	1714		10.1016/S0140-6736(05)62952-2	http://dx.doi.org/10.1016/S0140-6736(05)62952-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193379				2023-01-03	WOS:A1997XE06500006
J	Gemke, RJBJ				Gemke, RJBJ			Centralisation of paediatric intensive care to improve outcome	LANCET			English	Editorial Material							IMPACT				Gemke, RJBJ (corresponding author), UNIV UTRECHT,CHILDRENS HOSP WILHELMINA,NL-3501 CA UTRECHT,NETHERLANDS.							*BRIT PAED ASS, 1993, CAR CRIT ILL CHILDR; BRITTO J, 1995, BRIT MED J, V311, P836, DOI 10.1136/bmj.311.7009.836; GEMKE RJBJ, 1995, CRIT CARE MED, V23, P238, DOI 10.1097/00003246-199502000-00007; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Ryan DW, 1996, BRIT MED J, V312, P654; THOMPSON DR, 1994, CRIT CARE MED, V22, P1306, DOI 10.1097/00003246-199408000-00015	7	11	12	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1187	1188		10.1016/S0140-6736(05)62407-5	http://dx.doi.org/10.1016/S0140-6736(05)62407-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130935				2023-01-03	WOS:A1997WW71700003
J	Vassar, MJ; Kizer, KW				Vassar, MJ; Kizer, KW			Hospitalizations for firearm-related injuries - A population-based study of 9562 patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URBAN TRAUMA CENTER; HOMICIDE	Objective.-To determine the incidence, nature, demographics, severity, and hospital charges associated with inpatient treatment of firearm-related injuries. Design.-A retrospective, 1-year, population-based study of firearm-related hospitalizations based on the 1991 California Hospital Discharge Abstract Data Tapes. Setting.-California acute care hospitals that reported firearm-related discharges. Patients.-A total of 9562 patients discharged with firearm-related injuries. Main Outcome Measures.-Per capita hospital discharge rates, according to age, race, and sex. Results.-A total of 9562 firearm-injured persons were discharged from California hospitals in 1991, representing a rate of 32 discharges per 100 000 population, Males aged 15 to 24 years accounted for 72% of the hospitalizations. For all causes of firearm-related injury, the highest age- and race-specific discharge rate was 439 per 100 000 for black persons aged 15 to 24 years, The highest county discharge rate was 55 per 100 000 for Los Angeles County. Statewide, there were 1.8 hospital discharges per firearm-related fatality (both in the hospital and in the community). Assaults accounted for 74% of cases, Among black males aged 15 to 24 years, assaults accounted for 598 discharges per 100 000 population. Hospital charges for 9193 patients exceeded $164 million; mean and median charges per patient discharged were $17 888 and $8535, respectively, Publicly financed health insurance programs sponsored 56% of patients; 25% had private insurance, and 19% were uninsured, Fifty-three percent of the discharges occurred at 13 of the 371 hospitals that discharged patients with firearm-related injuries. Conclusions.-Firearm-related violence is a major cause of hospitalization of young urban black males and represents a significant cost to publicly financed health care, The impact on individual hospitals is highly disproportionate, While hospital discharge data can be used for population-based surveillance of firearm-related trauma, there is need for improvement in local, state, and national surveillance of these injuries.	UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; *CA DEP HLTH SERV, 1994, 4 EPIC CAL DEP HLTH; CLANCY TV, 1994, J TRAUMA, V37, P1, DOI 10.1097/00005373-199407000-00001; EASTMAN AB, 1994, J TRAUMA, V36, P835, DOI 10.1097/00005373-199406000-00014; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HUTSON HR, 1994, NEW ENGL J MED, V330, P324, DOI 10.1056/NEJM199402033300506; *J HOPK HLTH SERV, 1989, DET INJ SEV HOSP DIS; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; KLEIN SR, 1991, AM SURGEON, V57, P793; LANGLOIS JA, 1995, AM J PUBLIC HEALTH, V85, P1261, DOI 10.2105/AJPH.85.9.1261; MARGANITT B, 1990, AM J PUBLIC HEALTH, V10, P1463; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; ORDOG GJ, 1995, J TRAUMA, V38, P291, DOI 10.1097/00005373-199502000-00029; OZONOFF V, 1995, MMWR-MORBID MORTAL W, V44, P160; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; RIDDICK L, 1993, AM J FOREN MED PATH, V14, P216; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; RYAN M, 1993, AM SURGEON, V59, P831; SHELEY JF, 1995, PUBLIC HEALTH REP, V110, P18; SMITH RS, 1992, ARCH SURG-CHICAGO, V127, P668; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; TARDIFF K, 1995, PUBLIC HEALTH REP, V110, P13; *US BUR CENS, 1990, 1990 CENS POP; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US GEN ACC OFF, 1991, TRAUM CAR LIF SYST; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1994, MONTHLY VITAL STAT R, V43, P1; 1994, MMWR-MORBID MORTAL W, V43, P37	37	35	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1734	1739		10.1001/jama.275.22.1734	http://dx.doi.org/10.1001/jama.275.22.1734			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637170				2023-01-03	WOS:A1996UP30700026
J	Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M				Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M			Infection with hepatitis GB virus C in patients on maintenance hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FULMINANT-HEPATITIS; NON-A; PREVALENCE; REGION; RNA	Background. A recently discovered non-AE hepatitis virus has been designated hepatitis GB virus C (HGBV-C), but little is known about its mode of transmission and its clinical manifestations. We studied 519 patients on maintenance hemodialysis to determine whether they were infected with HGBV-C. Methods. HGBV-C RNA was identified in serum by a reverse-transcription-polymerase-chain-reaction assay with nested primers deduced from a nonstructural region. A nucleotide sequence of 100 bp in the nonstructural region was determined on HGBV-C clones. Results. HGBV-C RNA was detected in 3.1 percent of the patients on hemodialysis (16 of 519), as compared with 0.9 percent of healthy blood donors (4 of 448, P<0.03). None of the 16 patients had evidence of active liver disease, although 7 were also infected with hepatitis C virus. Eight patients with HGBV-C infection were followed for 7 to 16 years. In two patients the virus was present at the start of hemodialysis. One had a history of transfusion, and HGBV-C RNA persisted over a period of 16 years; the other became free of HGBV-C after 10 years. In five patients, HGBV-C RNA was first detected 3 to 20 weeks after blood transfusion and persisted for up to 13 years. One patient with no history of transfusion was infected with an HGBV-C variant with the same sequence as in two of the patients with post-transfusion HGBV-C infections. Conclusions. Patients on maintenance hemodialysis are at increased risk for HGBV-C infection. This virus produces persistent infections, which may be transmitted by transfusions but may also be transmitted by other means. (C) 1996, Massachusetts Medical Society.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; MASUKO HOSP, NAGOYA, AICHI, JAPAN; MASUKO INST MED RES, NAGOYA, AICHI, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO, JAPAN; MIYAKAWA MED RES FDN, TOKYO, JAPAN	Jichi Medical University; University of Yamanashi; Toshiba Corporation			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; CHAN TM, 1993, HEPATOLOGY, V17, P5, DOI 10.1002/hep.1840170103; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LONDON WT, 1969, NEW ENGL J MED, V281, P571, DOI 10.1056/NEJM196909112811101; Masuko K, 1994, J Viral Hepat, V1, P65, DOI 10.1111/j.1365-2893.1994.tb00063.x; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1002/hep.1840200505; SATO S, 1995, ANN INTERN MED, V122, P241, DOI 10.7326/0003-4819-122-4-199502150-00001; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SZMUNESS W, 1974, JAMA-J AM MED ASSOC, V227, P901, DOI 10.1001/jama.227.8.901; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	27	449	454	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1485	1490		10.1056/NEJM199606063342301	http://dx.doi.org/10.1056/NEJM199606063342301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618602	Bronze			2023-01-03	WOS:A1996UN79900001
J	Freeman, G; Hjortdahl, P				Freeman, G; Hjortdahl, P			What future for continuity of care in general practice?	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; PRACTITIONERS KNOWLEDGE; PATIENT SATISFACTION; PERSONAL CONTINUITY; DOCTOR; CONSULTATIONS; QUALITY; VIEWS; KEY		UNIV OSLO,DEPT GEN PRACTICE & COMMUNITY MED,N-0317 OSLO,NORWAY	University of Oslo	Freeman, G (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DEPT PUBL HLTH & PRIMARY CARE,LONDON SW10 9NH,ENGLAND.							BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BRESLAU N, 1982, MED CARE, V20, P347, DOI 10.1097/00005650-198204000-00001; CHACKO MR, 1987, J ADOLESCENT HEALTH, V8, P261, DOI 10.1016/0197-0070(87)90429-3; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; ETTLINGER PRA, 1981, BRIT MED J, V282, P1192, DOI 10.1136/bmj.282.6271.1192; FLYNN SP, 1985, J FAM PRACTICE, V21, P375; FREEDMAN R, 1987, ALCOHOL, V4, P249, DOI 10.1016/0741-8329(87)90019-X; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; Freeman G., 1985, J ROYAL COLL GEN PRA, V5, P423; FREEMAN GK, 1994, BRIT J GEN PRACT, V44, P395; FREEMAN GK, 1989, J ROY COLL GEN PRACT, V39, P145; FREEMAN GK, 1993, BRIT J GEN PRACT, V43, P493; Freidson E., 1970, PROFESSION MED STUDY; *GEN MED SERV COMM, 1995, COR GEN MED SERV CLA; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; Haig-Smith C, 1989, BRIT MED J, V299, P494; Harris MF, 1996, MED J AUSTRALIA, V164, P456, DOI 10.5694/j.1326-5377.1996.tb122119.x; Heath I., 1995, MYSTERY GEN PRACTICE; Hennen B K, 1975, J Fam Pract, V2, P371; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hjortdahl P, 1990, Fam Med, V22, P361; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; LEWIS JR, 1994, SOC SCI MED, V39, P655, DOI 10.1016/0277-9536(94)90022-1; MCWHINNEY IR, 1989, TXB FAMILY MED, P12; MILLER MH, 1973, J HEALTH SOC BEHAV, V14, P176, DOI 10.2307/2137067; MOREHEAD MA, 1974, MED CARE, V12, P301, DOI 10.1097/00005650-197404000-00002; PENDLETON DA, 1996, OXFORD GEN PRACTICE, V37; PHILLIPS DM, 1984, J FAM PRACTICE, V19, P793; PRATT J, 1995, PRACTITIONERS PRACTI, P60; ROOS LL, 1980, MED CARE, V18, P174, DOI 10.1097/00005650-198002000-00004; *ROYAL COLL GEN PR, 1985, EV ROYAL COMM NAT HL, P1; Schon Donald A., 1988, ED REFLECTIVE PRACTI; SMITH WG, 1985, EVAL HEALTH PROF, V8, P339, DOI 10.1177/016327878500800305; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; STARFIELD B, 1980, AM J PUBLIC HEALTH, V70, P117, DOI 10.2105/AJPH.70.2.117; VANDULMEN AM, 1995, PSYCHOL MED, V25, P1011, DOI 10.1017/S0033291700037508; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237; WILSON M, 1996, MED WORKFORCE	44	105	107	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1870	1873		10.1136/bmj.314.7098.1870	http://dx.doi.org/10.1136/bmj.314.7098.1870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224130	Green Published			2023-01-03	WOS:A1997XH73800025
J	Bullock, N				Bullock, N			Impotence after sclerotherapy of haemorrhoids: Case reports	BRITISH MEDICAL JOURNAL			English	Article											Bullock, N (corresponding author), ADDENBROOKES NHS TRUST,DEPT UROL,CAMBRIDGE CB2 2QQ,ENGLAND.							BENNANI S, 1994, ANN UROL, V28, P13; Goligher JC., 1984, SURG ANUS RECTUM COL, VVol. 5, P98; MITCHELL AB, 1903, BRIT MED J, V1, P482; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WRIGHT AD, 1950, P ROY SOC MED, V43, P263, DOI 10.1177/003591575004300409	5	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					419	419		10.1136/bmj.314.7078.419	http://dx.doi.org/10.1136/bmj.314.7078.419			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040388	Green Published			2023-01-03	WOS:A1997WH29500030
J	Lundeberg, T				Lundeberg, T			Electrical stimulation techniques	LANCET			English	Editorial Material							NERVE-STIMULATION		KAROLINSKA INST,DEPT REHABIL MED,STOCKHOLM,SWEDEN	Karolinska Institutet	Lundeberg, T (corresponding author), KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,STOCKHOLM,SWEDEN.							ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; Bosch JLHR, 1996, LANCET, V348, P717, DOI 10.1016/S0140-6736(96)04437-6; LUNDEBERG T, 1988, LANCET, V2, P712; LUNDEBERG TCM, 1992, ANN PLAS SURG, V29, P328, DOI 10.1097/00000637-199210000-00009; MEYERSON BA, 1996, PAIN 1996 UPDATED RE, P207	5	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1672	1673		10.1016/S0140-6736(05)65815-1	http://dx.doi.org/10.1016/S0140-6736(05)65815-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973423				2023-01-03	WOS:A1996VZ76600003
J	Saunders, C				Saunders, C			A personal therapeutic journey	BRITISH MEDICAL JOURNAL			English	Article											Saunders, C (corresponding author), ST CHRISTOPHERS HOSPICE,LONDON SE26 6DZ,ENGLAND.							Carter, 1976, SCI FDN ONCOLOGY, P673; KEARNEY M, 1992, Palliative Medicine, V6, P39, DOI 10.1177/026921639200600107; SAUNDERS C, 1963, P ROY SOC MED, V56, P195, DOI 10.1177/003591576305600322; SAUNDERS C, 1972, CONTACT, V38, P12; SEALE C, 1995, SOCIOLOGY, V29, P597, DOI 10.1177/0038038595029004003; TWYCROSS RG, 1977, PAIN, V3, P93, DOI 10.1016/0304-3959(77)90072-0; *WHO, 1990, REP CANC PAIN REL PA, P11; World Health Organization, 1996, CANC PAIN REL	8	76	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1599	1601		10.1136/bmj.313.7072.1599	http://dx.doi.org/10.1136/bmj.313.7072.1599			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991003	Green Published			2023-01-03	WOS:A1996VZ81100027
J	Hellman, S; Weichselbaum, RR				Hellman, S; Weichselbaum, RR			Radiation oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Hellman, S (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HANKS GE, 1995, CANCER, V75, P1972, DOI 10.1002/1097-0142(19950401)75:7+<1972::AID-CNCR2820751636>3.0.CO;2-P; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; SANDLER HM, 1995, INT J RADIAT ONCOL, V33, P797, DOI 10.1016/0360-3016(95)00219-7; Zelefsky M J, 1995, Cancer J Sci Am, V1, P142	7	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1852	1853		10.1001/jama.275.23.1852	http://dx.doi.org/10.1001/jama.275.23.1852			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642748				2023-01-03	WOS:A1996UQ15200047
J	Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN				Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN			The impact of aerosols on solar ultraviolet radiation and photochemical smog	SCIENCE			English	Article							NITROGEN-DIOXIDE PHOTOLYSIS; SKY BRIGHTNESS MEASUREMENTS; EASTERN-UNITED-STATES; AIR-POLLUTION; ACTINIC FLUX; ATMOSPHERE; OZONE; TROPOSPHERE; SCATTERING; CLOUDS	Photochemical smog, or ground-level ozone, has been the most recalcitrant of air pollution problems, but reductions in emissions of sulfur and hydrocarbons may yield unanticipated benefits in air quality. While sulfate and some organic aerosol particles scatter solar radiation back into space and can cool Earth's surface, they also change the actinic flux of ultraviolet (UV) radiation. Observations and numerical models show that UV-scattering particles in the boundary layer accelerate photochemical reactions and smog production, but UV-absorbing aerosols such as mineral dust and soot inhibit smog production. Results could have major implications for the control of air pollution.	NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20742	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Dickerson, RR (corresponding author), UNIV MARYLAND,DEPT METEOROL,COLLEGE PK,MD 20742, USA.		Kondragunta, Shobha/F-5601-2010; Dickerson, Russell/ABB-1512-2020; Stenchikov, Georgiy/AAA-4371-2022; Dickerson, Russell R/F-2857-2010; Georgiy, Stenchikov/J-8569-2013	Kondragunta, Shobha/0000-0001-8593-8046; Dickerson, Russell/0000-0003-0206-3083; Dickerson, Russell R/0000-0003-0206-3083; Stenchikov, Georgiy Lvovich/0000-0001-9033-4925				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; BLACKBURN TE, 1992, J GEOPHYS RES-ATMOS, V97, P10109, DOI 10.1029/92JD00504; Blindauer C, 1996, J ATMOS CHEM, V24, P1, DOI 10.1007/BF00053820; BRUEHL C, 1989, GEOPHYS RES LETT, V16, P703; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; CIVEROLO KL, 1996, THESIS U MARYLAND CO; DENTENER FJ, 1993, J GEOPHYS RES-ATMOS, V98, P7149, DOI 10.1029/92JD02979; DICKERSON RR, 1982, J GEOPHYS RES-OCEANS, V87, P4933, DOI 10.1029/JC087iC07p04933; FinlaysonPitts BJ, 1997, SCIENCE, V276, P1045, DOI 10.1126/science.276.5315.1045; Flowers EC, 1969, J APPL METEOROL, V8, P955, DOI [10.1175/1520-0450(1969)0082.0.CO;2, DOI 10.1175/1520-0450(1969)0082.0.CO;2]; FRASER RS, 1985, IEEE J GEOSCI REM GE, V23, P525; Hauglustaine DA, 1996, GEOPHYS RES LETT, V23, P2609, DOI 10.1029/96GL02474; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P16911, DOI 10.1029/96JD03680; HOLBEN BN, 1997, 6 INT S PHYS MEAS SI, P75; HUSAR RB, 1981, ATMOS ENVIRON, V15, P1919, DOI 10.1016/0004-6981(81)90226-2; HUSAR RB, 1993, ENVIRON SCI TECHNOL, V27, P12, DOI 10.1021/es00038a001; KAUFMAN YJ, 1986, J ATMOS SCI, V43, P1135, DOI 10.1175/1520-0469(1986)043<1135:FEFMOT>2.0.CO;2; KAUFMAN YJ, 1983, J CLIM APPL METEOROL, V22, P1694, DOI 10.1175/1520-0450(1983)022<1694:LEBADS>2.0.CO;2; KAUFMAN YJ, 1994, J GEOPHYS RES-ATMOS, V99, P10341, DOI 10.1029/94JD00229; KELLEY P, 1995, GEOPHYS RES LETT, V22, P2621, DOI 10.1029/95GL02563; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; KONDRAGUNTA S, 1997, THESIS U MARYLAND CO; Lary DJ, 1997, J GEOPHYS RES-ATMOS, V102, P3671, DOI 10.1029/96JD02969; LELIEVELD J, 1990, NATURE, V343, P277; Liang JY, 1997, J GEOPHYS RES-ATMOS, V102, P5993, DOI 10.1029/96JD02957; LIU S, 1901, GEOPHYS RES LETT, V18, P2265; Lu Y, 1996, CHEMOSPHERE, V32, P739, DOI 10.1016/0045-6535(96)00028-8; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; Meng Z, 1997, SCIENCE, V277, P116, DOI 10.1126/science.277.5322.116; Naja M, 1996, GEOPHYS RES LETT, V23, P81, DOI 10.1029/95GL03589; Nakajima T, 1996, APPL OPTICS, V35, P2672, DOI 10.1364/AO.35.002672; *NASA, 1994, CHEM KIN PHOT DAT US; National Academy of Sciences, 1991, RETH OZ PROBL URB RE; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; PETERSON JT, 1976, ATMOS ENVIRON, V10, P459, DOI 10.1016/0004-6981(76)90026-3; PETERSON JT, 1981, J APPL METEOROL, V20, P229, DOI 10.1175/1520-0450(1981)020<0229:ATOCNC>2.0.CO;2; PETERSON JT, 1977, ATMOS ENVIRON, V11, P689, DOI 10.1016/0004-6981(77)90177-9; PIELKE RA, 1992, METEOROL ATMOS PHYS, V49, P69, DOI 10.1007/BF01025401; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; Remer LA, 1997, J GEOPHYS RES-ATMOS, V102, P16849, DOI 10.1029/96JD01932; Rhoads KP, 1997, J GEOPHYS RES-ATMOS, V102, P18981, DOI 10.1029/97JD01078; RUGGABER A, 1994, J ATMOS CHEM, V18, P171, DOI 10.1007/BF00696813; RYAN W, IN PRESS J AIR WASTE; SEINFELD JH, 1989, SCIENCE, V243, P745, DOI 10.1126/science.243.4892.745; Shetter RE, 1996, J GEOPHYS RES-ATMOS, V101, P14631, DOI 10.1029/96JD00211; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; Systems Applications International (SAI), 1995, US GUID VAR GRID URB; *US EPA, 1996, EPA454R96005; US-EPA, 1991, EPA450491013; VARSHNEY CK, 1992, ATMOS ENVIRON B-URB, V26, P291, DOI 10.1016/0957-1272(92)90004-C; Walcek CJ, 1997, ATMOS ENVIRON, V31, P1221, DOI 10.1016/S1352-2310(96)00257-9; WISCOMBE WJ, 1980, APPL OPTICS, V19, P1505, DOI 10.1364/AO.19.001505; ZAFONTE L, 1977, ENVIRON SCI TECHNOL, V11, P483, DOI 10.1021/es60128a006	54	418	461	17	200	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					827	830		10.1126/science.278.5339.827	http://dx.doi.org/10.1126/science.278.5339.827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346474				2023-01-03	WOS:A1997YD47900036
J	Rankin, AC				Rankin, AC			Non-sedating antihistamines and cardiac arrhythmia	LANCET			English	Editorial Material							DE-POINTES; TERFENADINE; INTERVAL				Rankin, AC (corresponding author), ROYAL INFIRM,DEPT CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND.							HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; LINDQUIST EIR, 1997, LANCET, V39, P1322; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; SALATA JJ, 1995, CIRC RES, V76, P110, DOI 10.1161/01.RES.76.1.110; TAN HL, 1995, ANN INTERN MED, V122, P701, DOI 10.7326/0003-4819-122-9-199505010-00009; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313	11	23	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1115	1116		10.1016/S0140-6736(05)63783-X	http://dx.doi.org/10.1016/S0140-6736(05)63783-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343494				2023-01-03	WOS:A1997YB19900003
J	Glasier, A				Glasier, A			Drug therapy - Emergency postcoital contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POST-COITAL CONTRACEPTION; ETHINYLESTRADIOL-NORGESTREL COMBINATION; EARLY LUTEAL-PHASE; MIFEPRISTONE RU-486; YUZPE REGIMEN; MENSTRUAL-CYCLE; ENDOMETRIUM; ESTROGENS; DANAZOL; WOMEN		EDINBURGH HEALTHCARE TRUST FAMILY PLANNING & WELL, EDINBURGH, MIDLOTHIAN, SCOTLAND		Glasier, A (corresponding author), UNIV EDINBURGH, DEPT OBSTET & GYNAECOL, 18 DEAN TERR, EDINBURGH EH4 1NL, MIDLOTHIAN, SCOTLAND.		Dilek, Umut/AAP-6047-2021; dilek, umut Kutlu/E-4527-2016	Dilek, Umut/0000-0003-4297-3081; 				ALVAREZ F, 1988, FERTIL STERIL, V49, P768; Barnett AA, 1996, LANCET, V348, P53, DOI 10.1016/S0140-6736(05)64372-3; BRACKEN MB, 1990, OBSTET GYNECOL, V76, P552; CHANG MC, 1966, ENDOCRINOLOGY, V78, P860, DOI 10.1210/endo-78-4-860; COUZINET B, 1990, FERTIL STERIL, V54, P1039; DIXON GW, 1980, JAMA-J AM MED ASSOC, V244, P1336, DOI 10.1001/jama.244.12.1336; FASOLI M, 1989, CONTRACEPTION, V39, P459, DOI 10.1016/0010-7824(89)90123-6; FASOLI M, 1989, CONTRACEPTION, V39, P699; *FOOD DRUG ADM, 1997, FED REGISTER, V62, P8610; GEMZELLDANIELSSON K, 1993, HUM REPROD, V8, P870, DOI 10.1093/oxfordjournals.humrep.a138157; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; Glasier A, 1996, FAM PLANN PERSPECT, V28, P49, DOI 10.2307/2136123; GLASIER A, 1993, BRIT J OBSTET GYNAEC, V100, P611, DOI 10.1111/j.1471-0528.1993.tb14223.x; GLASIER A, 1995, PROVISION EMERGENCY, P16; Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; GROU F, 1994, AM J OBSTET GYNECOL, V171, P1529, DOI 10.1016/0002-9378(94)90396-4; Hagenfeldt K, 1972, Acta Endocrinol Suppl (Copenh), V169, P3; HARPER CC, 1995, AM J OBSTET GYNECOL, V173, P1438, DOI 10.1016/0002-9378(95)90630-4; HASPELS AA, 1976, CONTRACEPTION, V14, P375, DOI 10.1016/S0010-7824(76)80052-2; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; *INT PLANN PAR FED, 1994, IPPF MED B, V28, P1; JESPERSEN J, 1990, AM J OBSTET GYNECOL, V163, P396, DOI 10.1016/0002-9378(90)90590-4; KUBBA AA, 1986, FERTIL STERIL, V45, P512; LEDGER WL, 1992, HUM REPROD, V7, P945, DOI 10.1093/oxfordjournals.humrep.a137776; LEHMANN F, 1975, ACTA ENDOCRINOL-COP, V79, P329, DOI 10.1530/acta.0.0790329; LING WY, 1983, FERTIL STERIL, V39, P292; MORRIS JM, 1966, AM J OBSTET GYNECOL, V96, P804, DOI 10.1016/0002-9378(66)90676-4; MORRIS JM, 1973, AM J OBSTET GYNECOL, V115, P101, DOI 10.1016/0002-9378(73)90095-1; POULTER NR, 1995, LANCET, V346, P1575; RAMSAY S, 1995, LANCET, V345, P1169, DOI 10.1016/S0140-6736(95)90996-6; ROWLANDS S, 1986, CONTRACEPTION, V33, P539, DOI 10.1016/0010-7824(86)90042-9; SHIRLEY B, 1995, CONTRACEPTION, V52, P277, DOI 10.1016/0010-7824(95)00211-R; SIMPSON J L, 1990, Advances in Contraception, V6, P141, DOI 10.1007/BF01849490; Steiner M, 1994, INT FAMILY PLANNING, V20, P55; SWAHN ML, 1988, HUM REPROD, V3, P915, DOI 10.1093/oxfordjournals.humrep.a136809; Swahn ML, 1996, ACTA OBSTET GYN SCAN, V75, P738, DOI 10.3109/00016349609065738; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; Trussell J, 1996, FAM PLANN PERSPECT, V28, P58, DOI 10.2307/2136125; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P262, DOI 10.2307/2135855; TRUSSELL J, 1995, FERTILITY CONTROL RE, V4, P8; VANLOOK PFA, 1995, MODERN METHODS INDUC, P1; VANSANTEN MR, 1985, FERTIL STERIL, V43, P206; Webb A., 1993, Advances in Contraception, V9, P75, DOI 10.1007/BF02115904; WEBB AMC, 1992, BMJ-BRIT MED J, V305, P927, DOI 10.1136/bmj.305.6859.927; WEENINK GH, 1981, LANCET, V1, P1105; *WHO, 1996, WHOFRHFPP969, P31; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301; Williams C, 1996, BRIT MED J, V312, P463, DOI 10.1136/bmj.312.7029.463a; YUZPE AA, 1977, FERTIL STERIL, V28, P932; ZULIANI G, 1990, EUR J OBSTET GYN R B, V37, P253, DOI 10.1016/0028-2243(90)90032-V	51	193	197	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1058	1064		10.1056/NEJM199710093371507	http://dx.doi.org/10.1056/NEJM199710093371507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321535				2023-01-03	WOS:A1997XZ84400007
J	Sidney, S; Petitti, DB; Quesenberry, CP				Sidney, S; Petitti, DB; Quesenberry, CP			Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; menopause; estrogen replacement therapy; progestational hormones	HORMONE REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; HEART-DISEASE; FOLLOW-UP; MORTALITY; RISK; DEATH	Objective: To estimate the relative risk for incident acute myocardial infarction in relation to the current use of estrogen and estrogen-progestogen. Design: Retrospective case-control study. Setting: Medical centers of a large prepaid health care program, the Kaiser Permanente Medical Care Program (KPMCP), Northern California region. Participants: All women hospitalized at a KPMCP center for incident acute myocardial infarction during a 3-year period from 1991 to 1994. Controls were matched to case-patients for year of birth and KPMCP facility and were selected at random from among all female members of the KPMCP. Intervention: An in-person interview that included questions about current and lifetime use of estrogen and estrogen-progestogen; known cardiovascular risk factors; and other medical, sociodemographic, and behavioral factors that might affect risk for myocardial infarction. Main Outcome Measure: Odds ratios for myocardial infarction associated with use of estrogen and estrogen-progestogen. Results: The odds ratio for myocardial infarction in current users of estrogen or estrogen-progestogen compared with women who had never used these agents was 0.96 (95% CI, 0.66 to 1.40) after adjustment for confounders. The odds ratio for myocardial infarction in past users of estrogen or estrogen-progestogen was 1.07 (CI, 0.72 to 1.58). Duration of hormone use was unrelated to the odds ratio for myocardial infarction. Conclusions: This study did not show a statistically significant decrease in the odds ratio for myocardial infarction associated with current use of estrogen or estrogen-progestogen. it neither confirms nor refutes the hypothesis that hormone use prevents myocardial infarction in postmenopausal women.			Sidney, S (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3505 BROADWAY, OAKLAND, CA 94611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-47043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; AVILA MH, 1990, EPIDEMIOLOGY, V1, P128; BAIN C, 1981, CIRCULATION, V64, P42, DOI 10.1161/01.CIR.64.1.42; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; MACMAHON B, 1978, CORONARY HEART DISEA, P197; MANN RD, 1994, J CLIN EPIDEMIOL, V47, P307, DOI 10.1016/0895-4356(94)90014-0; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSS RK, 1981, LANCET, V1, P858; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; TALBOTT E, 1977, AM J CARDIOL, V39, P858, DOI 10.1016/S0002-9149(77)80040-4; 1995, OTABPH144 OFF TECHN	27	101	101	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					501	+		10.7326/0003-4819-127-7-199710010-00001	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313017				2023-01-03	WOS:A1997XY73300001
J	Connor, WE; Connor, SL				Connor, WE; Connor, SL			Should a low-fat, high-carbohydrate diet be recommended for everyone?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHOLESTEROL				Connor, WE (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,L465,PORTLAND,OR 97201, USA.							*AM CANC SOC 1996, 1996, CA CANC J CLIN, V43, P325; Anitschkow N.N., 1933, ARTERIOSCLEROSIS, P271; [Anonymous], 1988, CIRCULATION, V77, p721A; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; CONNOR WE, 1961, GERIATRICS, V16, P407; DE LANGEN C. D., 1922, Geneeskundig Tijdschrift voor Nederlandsche-Indie, V62, P1; *DEP AGR, 1995, IN PRESS STAT B; *DEP AGR AGR RES S, 1995, DAT TABL RES USDAS 1; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V269, P3015; Kennedy E, 1996, J AM DIET ASSOC, V96, P234, DOI 10.1016/S0002-8223(96)00072-7; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; SPADY DK, 1988, J CLIN INVEST, V81, P300, DOI 10.1172/JCI113321; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	15	122	125	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					562	563						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262503				2023-01-03	WOS:A1997XR54800011
J	Wright, J; Johns, R; Watt, I; Melville, A; Sheldon, T				Wright, J; Johns, R; Watt, I; Melville, A; Sheldon, T			Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: A systematic review of the research evidence	BRITISH MEDICAL JOURNAL			English	Review							LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR RISK-FACTORS; AMBULATORY BLOOD-PRESSURE; APNEA HYPOPNEA SYNDROME; NASAL CPAP TREATMENT; LONG-TERM COMPLIANCE; PULMONARY-HYPERTENSION; AUTOMOBILE ACCIDENTS; CARDIAC-ARRHYTHMIAS; APNOEA/HYPOPNOEA SYNDROME	Objective: To examine the research evidence for the health consequences of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure. Design: A systematic review of published research, studies being identified by searching Medline (1966-96), Embase (1974-96), and CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1982-95); scanning citations; and consulting experts. Studies in all languages were considered which either investigated the association between obstructive sleep apnoea in adults and key health outcomes or evaluated the effectiveness of treatment of obstructive sleep apnoea with continuous positive airways pressure in adults. Main outcome measures: Mortality, systematic hypertension, cardiac arrhythmias, ischaemic heart disease, left ventricular hypertrophy, pulmonary hypertension, stroke, vehicle accidents, measures of daytime sleepiness, and quality of life. Results: 54 epidemiological studies examined the association between sleep apnoea and health related outcomes. Most were poorly designed and only weak or contradictory evidence was found of an association with cardiac arrhythmias, ischaemic heart disease, cardiac failure, systemic or pulmonary hypertension, and stroke. Evidence of a link with sleepiness and road traffic accidents was stronger but inconclusive. Only one small randomised controlled trial evaluated continuous positive airways pressure. Five non-randomised controlled trials and 38 uncontrolled trials were identified. Small changes in objectively measured daytime sleepiness were consistently found, but improvements in morbidity, mortality, and quality of life indicators were not adequately assessed. Conclusions: The relevance of sleep apnoea to public health has been exaggerated. The effectiveness of continuous positive airways pressure in improving health outcomes has been poorly evaluated. There is enough evidence suggesting benefit in reducing daytime sleepiness in some patients to warrant large randomised placebo controlled trials of continuous positive airways pressure versus an effective weight reduction programme and other interventions.	N YORKSHIRE HLTH AUTHOR,YORK YO3 4XF,N YORKSHIRE,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YOU DD,N YORKSHIRE,ENGLAND	University of York - UK	Wright, J (corresponding author), BRADFORD ROYAL INFIRM,BRADFORD BD9 6RJ,W YORKSHIRE,ENGLAND.		Wright, John/H-1624-2012; Sheldon, Trevor/AAK-7088-2021	Wright, John/0000-0001-9572-7293; Sheldon, Trevor/0000-0002-7479-5913				ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; *AM SLEEP DIS ASS, 1992, SLEEP, V15, P268; ANCOLIISRAEL S, 1994, SLEEP, V17, P77, DOI 10.1093/sleep/17.1.77; ANCOLIISRAEL S, 1989, CHEST, V96, P1054, DOI 10.1378/chest.96.5.1054; BEARPARK H, 1987, SLEEP RES, V16, P303; BEDARD MA, 1993, J CLIN EXP NEUROPSYC, V15, P330, DOI 10.1080/01688639308402567; BLIWISE DL, 1988, AM J PUBLIC HEALTH, V78, P544, DOI 10.2105/AJPH.78.5.544; Borak J, 1993, Psychiatr Pol, V27, P43; BOUDOULAS H, 1983, J MED, V14, P223; BRADLEY TD, 1985, AM REV RESPIR DIS, V131, P835; CARLSON JT, 1994, AM J RESP CRIT CARE, V150, P72, DOI 10.1164/ajrccm.150.1.8025776; CHARBONNEAU M, 1992, American Review of Respiratory Disease, V145, pA168; COOK DJ, 1992, CHEST S4, V102, P305; DAVIES RJO, 1993, AM REV RESPIR DIS, V147, P630, DOI 10.1164/ajrccm/147.3.630; DAVIES RJO, 1994, CLIN SCI, V86, P417, DOI 10.1042/cs0860417; DEEKS J, 1996, 4 NHS CTR REV DISS; Denzel K, 1993, Pneumologie, V47 Suppl 1, P155; DERIDERIAN SS, 1988, CHEST, V94, P1023; DIPHILLIPO MA, 1988, SLEEP RES, V17, P167; DOUGLAS NJ, 1994, LANCET, V344, P653, DOI 10.1016/S0140-6736(94)92088-5; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; ELIGULASHVILI TS, 1994, ZH NEVROPATOL PSIKH, V94, P76; ENGLEMAN HM, 1994, THORAX, V49, P263, DOI 10.1136/thx.49.3.263; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; ENGLEMAN HM, 1993, THORAX, V48, P911, DOI 10.1136/thx.48.9.911; ENGLEMAN HM, 1993, SLEEP, V16, pS114, DOI 10.1093/sleep/16.suppl_8.S114; ENGLEMAN HM, 1996, SELF REPORTED USE CP; ESCOURROU P, 1990, CHEST, V98, P1362, DOI 10.1378/chest.98.6.1362; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FINDLEY LJ, 1989, NEW ENGL J MED, V320, P868; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; Fischer J, 1995, Pneumologie, V49 Suppl 1, P131; FLEMONS WW, 1993, SLEEP, V16, pS71, DOI 10.1093/sleep/16.suppl_8.S71; FLEMONS WW, 1993, AM REV RESPIR DIS, V148, P618, DOI 10.1164/ajrccm/148.3.618; FLETCHER EC, 1991, AM REV RESPIR DIS, V143, P936, DOI 10.1164/ajrccm/143.5_Pt_1.936; GADDY JR, 1991, SLEEP RES, V20, P245; GONZALEZROTHI RJ, 1988, CHEST, V94, P531, DOI 10.1378/chest.94.3.531; GRUNSTEIN R, 1993, INT J OBESITY, V17, P533; GUILLEMINAULT C, 1983, AM J CARDIOL, V52, P490, DOI 10.1016/0002-9149(83)90013-9; GUILLEMINAULT C, 1992, SLEEP, V15, pS20; HANLY P, 1992, CHEST, V102, P100, DOI 10.1378/chest.102.1.100; HARALDSSON PO, 1990, ACTA OTO-LARYNGOL, V110, P136, DOI 10.3109/00016489009122528; HARALDSSON PO, 1990, ORL J OTO-RHINO-LARY, V52, P57, DOI 10.1159/000276104; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HEDNER J, 1990, J HYPERTENS, V8, P941, DOI 10.1097/00004872-199010000-00009; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HOFFSTEIN V, 1994, CHEST, V106, P466, DOI 10.1378/chest.106.2.466; HOFFSTEIN V, 1992, AM REV RESPIR DIS, V145, P841, DOI 10.1164/ajrccm/145.4_Pt_1.841; HOFFSTEIN V, 1994, LANCET, V344, P643, DOI 10.1016/S0140-6736(94)92084-2; HOFFSTEIN V, 1992, CHEST, V101, P379, DOI 10.1378/chest.101.2.379; HOFFSTEIN V, 1988, LANCET, V2, P992; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; INGRAM F, 1994, SLEEP, V17, P248, DOI 10.1093/sleep/17.3.248; Jennum, 1992, J Sleep Res, V1, P240; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; JENNUM P, 1989, AM J HYPERTENS, V2, P847, DOI 10.1093/ajh/2.11.847; KATSANTONIS GP, 1988, LARYNGOSCOPE, V98, P304; KEENAU SP, 1991, AM REV RESPIR DIS, V143, pA603; KISELAK J, 1993, CHEST, V104, P775, DOI 10.1378/chest.104.3.775; KOEHLER U, 1994, KLIN WOCHENSCHR, V69, P474; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; KRIEGER J, 1989, CHEST, V96, P729, DOI 10.1378/chest.96.4.729; KRIEGER J, 1988, EUR RESPIR J, V1, P436; KRIEGER J, 1992, SLEEP, V15, pS42, DOI 10.1093/sleep/15.suppl_6.S42; KRIEGER J, 1991, CHEST, V100, P917, DOI 10.1378/chest.100.4.917; LAKS L, 1995, EUR RESPIR J, V8, P537; LAMPHERE J, 1989, CHEST, V96, P1364, DOI 10.1378/chest.96.6.1364; LAVIE P, 1993, CHEST, V103, P717, DOI 10.1378/chest.103.3.717; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; LEVINSON PD, 1993, CHEST, V103, P1336, DOI 10.1378/chest.103.5.1336; LEVINSON PD, 1991, ARCH INTERN MED, V151, P544; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; MAUT A, 1995, SLEEP, V18, P433; MAYER J, 1991, CARDIOLOGY, V79, P84, DOI 10.1159/000174864; MAYER J, 1993, CARDIOLOGY, V82, P69, DOI 10.1159/000175907; MAYER J, 1991, NIEREN HOCHDRUKKR, V10, P531; MENDELSON WB, 1992, CHEST, V101, P903, DOI 10.1378/chest.101.4.903; MENDELSON WB, 1995, CHEST, V108, P966, DOI 10.1378/chest.108.4.966; MEURICE JC, 1994, CHEST, V105, P429, DOI 10.1378/chest.105.2.429; MEURICE JC, 1995, REV MAL RESPIR, V12, P283; Miles PG, 1996, AM J ORTHOD DENTOFAC, V109, P163, DOI 10.1016/S0889-5406(96)70177-4; MILLER WP, 1982, AM J MED, V73, P317, DOI 10.1016/0002-9343(82)90716-1; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; MINEMURA H, 1993, JPN J THORAC MED, V31, P1103; MOHSENIN V, 1995, ARCH PHYS MED REHAB, V76, P71, DOI 10.1016/S0003-9993(95)80046-8; Mooe T, 1996, CHEST, V109, P659, DOI 10.1378/chest.109.3.659; NAUGHTON M, 1992, AUST NZ J MED, V21, P917; NINOMURCIA G, 1989, WESTERN J MED, V150, P165; NODA A, 1993, CHEST, V103, P1343, DOI 10.1378/chest.103.5.1343; NORUP PW, 1996, UGESKRIFT LAEGER, V157, P2315; OVESEN J, 1992, ACTA OTO-LARYNGOL, P119; PALOMAKI H, 1991, STROKE, V22, P1021, DOI 10.1161/01.STR.22.8.1021; PHILLIPS BA, 1990, CHEST, V98, P325, DOI 10.1378/chest.98.2.325; PHILLIPSON EA, 1993, NEW ENGL J MED, V328, P1271, DOI 10.1056/NEJM199304293281712; PINILLA CF, 1994, MED CLIN-BARCELONA, V103, P165; PRZYBYLOWSKI T, 1994, ATEMWEG LUNGENKRANK, V20, P358; RAJAGOPAL KR, 1986, CHEST, V90, P172, DOI 10.1378/chest.90.2.172; RAUSCHER H, 1993, THORAX, V48, P529, DOI 10.1136/thx.48.5.529; RAUSCHER H, 1991, CHEST, V100, P1019, DOI 10.1378/chest.100.4.1019; RAUSCHER H, 1992, CHEST, V102, P367, DOI 10.1378/chest.102.2.367; RAUSCHER H, 1993, CHEST, V103, P1675, DOI 10.1378/chest.103.6.1675; REEVESHOCHE MK, 1994, AM J RESP CRIT CARE, V149, P149, DOI 10.1164/ajrccm.149.1.8111574; ROLFE I, 1991, AM REV RESPIR DIS, V144, P1130, DOI 10.1164/ajrccm/144.5.1130; *ROYAL COLL PHYS, 1993, SLEEP APN REL COND R; RUFFIN JM, 1969, NEW ENGL J MED, V281, P16, DOI 10.1056/NEJM196907032810104; SAJKOV D, 1994, AM J RESP CRIT CARE, V149, P416, DOI 10.1164/ajrccm.149.2.8306039; SANGAL RB, 1992, CHEST, V102, P699, DOI 10.1378/chest.102.3.699; SCHECHTMAN KB, 1995, SLEEP, V18, P659, DOI 10.1093/sleep/18.8.659; SCHMIDTNOWARA WW, 1990, PROG CLIN BIOL RES, V345, P377; SFORZA E, 1992, J NEUROL SCI, V110, P21, DOI 10.1016/0022-510X(92)90004-5; SFORZA E, 1992, EUR RESPIR J, V5, P858; SFORZA E, 1995, SLEEP, V18, P195; SFORZA E, 1994, EUR RESPIR J, V7, P1765, DOI 10.1183/09031936.94.07101765; SFORZA E, 1990, AM REV RESPIR DIS, V141, P866, DOI 10.1164/ajrccm/141.4_Pt_1.866; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; Shinozaki T, 1995, Nihon Kyobu Shikkan Gakkai Zasshi, V33, P1073; SIMONDS AK, 1994, BRIT MED J, V309, P35, DOI 10.1136/bmj.309.6946.35; SIRELING LI, 1983, J ROY SOC MED, V76, P131, DOI 10.1177/014107688307600209; SMITH IE, 1995, J SLEEP RES, V4, P183, DOI 10.1111/j.1365-2869.1995.tb00167.x; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; STOOHS RA, 1994, SLEEP, V17, P619; STOOHS RA, 1993, SLEEP, V16, pS141, DOI 10.1093/sleep/16.suppl_8.S141; STOOHS RA, 1993, SLEEP, V16, P511; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; STRADLING JR, 1990, LANCET, V336, P1378, DOI 10.1016/0140-6736(90)92929-C; STROHL KP, 1994, SLEEP, V17, P614, DOI 10.1093/sleep/17.7.614; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; SUZUKI M, 1993, SLEEP, V16, P545, DOI 10.1093/sleep/16.6.545; Thalhofer S, 1991, Pneumologie, V45 Suppl 1, P293; TILKIAN AG, 1977, AM J MED, V63, P348, DOI 10.1016/0002-9343(77)90272-8; Vazquez Oliva R, 1995, ARCH BRONCONEUMOL, V31, P18; WALDHORN RE, 1990, CHEST, V97, P33, DOI 10.1378/chest.97.1.33; WALLER PC, 1989, LANCET, V1, P143; Weissenberg A, 1995, Wien Med Wochenschr, V145, P523; WEITZENBLUM E, 1988, AM REV RESPIR DIS, V138, P345, DOI 10.1164/ajrccm/138.2.345; WILCOX I, 1993, SLEEP, V16, P539, DOI 10.1093/sleep/16.6.539; WITTIG R, 1986, SLEEP RES, V15, P185; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZORICK FJ, 1990, H FORD HOSP MED J, V38, P233	144	322	342	1	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					851	860						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093094				2023-01-03	WOS:A1997WQ02800022
J	Griffiths, C; Sturdy, P; Naish, J; Omar, R; Dolan, S; Feder, G				Griffiths, C; Sturdy, P; Naish, J; Omar, R; Dolan, S; Feder, G			Hospital admissions for asthma in east London: Associations with characteristics of local general practices, prescribing, and population	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; RATES	Objective: To determine the relative importance of appropriate prescribing for asthma in explaining high rates of hospital admission for asthma among east London general practices. Design: Poisson regression analysis describing relation of each general practice's admission rates for asthma with prescribing for asthma and characteristics of general practitioners, practices, and practice populations. Setting: East London, a deprived inner city area with high admission rates for asthma Subjects: All 163 general practices in East London and the City Health Authority (complete data available for 124 practices). Main outcome measures: Admission rates for asthma, excluding readmissions, for ages 5-64 years; ratio of asthma prophylaxis to bronchodilator prescribing; selected characteristics of general practitioners, practices, and practice populations. Results: Median admission rate for asthma was 0.9 (range 0-3.6) per 1000 patients per year. Higher admission rates were most strongly associated with small size of practice partnership: admission rates of singlehanded and two partner practices were higher than those of practices with three or more principals by 1.7 times (95% confidence Interval 1.4 to 2.0, P<0.001) and 1.3 times (1.1 to 1.6, P=0.001) respectively. Practices with higher rates of night visits also had significantly higher admission rates: an increase in night visiting rate by 10 visits per 1000 patients over two years was associated with an increase in admission rates for asthma by 4% (1% to 7%). These associations were independent of asthma prescribing ratios, measures of practice resources, and characteristics of practice populations. Conclusions: Higher asthma admission rates in east London practices were most strongly associated with smaller partnership size and higher rates of night visiting. Evaluating ways of helping smaller partnerships develop structured proactive care for asthma patients at high risk of admission is a priority.	ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED STAT & EVALUAT,LONDON W12 0NN,ENGLAND; ST MARYS HOSP,SCH MED,IMPERIAL COLL,LONDON W2 1PG,ENGLAND	University of London; Queen Mary University London; Imperial College London; Imperial College London	Griffiths, C (corresponding author), ST BARTHOLOMEWS HOSP,CITY & E LONDON PRACTICE DATABASE PROJECT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.			Feder, Gene/0000-0002-7890-3926; Omar, Rumana/0000-0003-1483-1932				Altman DG, 1991, PRACTICAL STAT MED R; ANDERSON HR, 1995, THORAX, V50, P1188, DOI 10.1136/thx.50.11.1188; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; *CHART I PUBL FIN, 1993, HLTH DAT 1993; *CONS ASS, 1993, WHICH           0311, P735; Davidson AC, 1996, BRIT MED J, V312, P601; *DEP HLTH, 1995, ASTHM EP OV; *DEP HLTH, 1992, STAT B, V4, P2; *DEP HLTH, 1995, ID R D PRIOR NHS MAN; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; *E LOND CIT HLTH A, 1996, HLTH E END ANN PUBL; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GREEN JM, 1993, BRIT MED J, V307, P607, DOI 10.1136/bmj.307.6904.607; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; Hills, 1993, STAT MODELS EPIDEMIO; *HLTH EAST PROJ, 1996, HLTH EAST PROJ ANN R; HOWARD SA, 1996, ASTHMA GEN PRACT, V4, P11; Hull S, 1996, BRIT J GEN PRACT, V46, P375; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; JACKSON SHD, 1981, POSTGRAD MED J, V57, P777, DOI 10.1136/pgmj.57.674.777; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; *N THAM REG HLTH A, 1994, DEV ED LOND IN ZON E; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; ORMEROD LP, 1995, RESP MED, V89, P415, DOI 10.1016/0954-6111(95)90209-0; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Shahani A, 1996, BRIT MED J, V313, P1057; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; STORR J, 1988, ARCH DIS CHILD, V63, P778; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; Sturdy P, 1996, BRIT J GEN PRACT, V46, P375; VanSchayck CP, 1996, BRIT J GEN PRACT, V46, P193	34	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					482	486		10.1136/bmj.314.7079.482	http://dx.doi.org/10.1136/bmj.314.7079.482			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056800	Green Published			2023-01-03	WOS:A1997WJ41900028
J	Slome, LR; Mitchell, TF; Charlebois, E; Benevedes, JM; Abrams, DI				Slome, LR; Mitchell, TF; Charlebois, E; Benevedes, JM; Abrams, DI			Physician-assisted suicide and patients with human immunodeficiency virus disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS; EUTHANASIA; ATTITUDES; LIFE	Background Data are limited on the attitudes and practices of physicians regarding assisting the suicide of patients with human immunodeficiency virus (HIV) disease. Methods Between November 1994 and January 1995, we used an anonymous, self-administered questionnaire to survey all 228 physicians in the Community Consortium, an association of providers of health care to patients infected with HIV in the San Francisco Bay area. The responses were compared with those in a 1990 survey of consortium physicians. Physician-assisted suicide was defined as ''a physician providing a sufficient dose of narcotics to enable a patient to kill himself.'' Respondents were to ''assume that the patient is a mentally competent, severely ill individual facing imminent death.'' Results One hundred eighteen of the questionnaires were evaluated. Respondents reported a mean of 7.9 ''direct'' and 13.7 ''indirect'' requests from patients for assistance. In responses based on a case vignette, 48 percent of the physicians said they would be likely or very likely to grant the request of a patient with the acquired immunodeficiency syndrome (AIDS) for assistance in a suicide, as compared with 28 percent of the respondents in 1990. Asked to estimate the number of times they had granted the request of a patient with AIDS for assistance in committing suicide, 53 percent said they had done so at least once (mean number of times, 4.2; median, 1.0; range, 0 to 100). In a multivariate analysis, factors positively associated with a physician's having, in fact, assisted a suicide were having had a higher number of patients with AIDS who had died; having received a higher number of indirect requests from patients for assistance; having a stated gay, lesbian, or bisexual orientation him- or herself; and having a higher ''intention to assist'' score (as calculated from the physician's responses to the case vignette). Conclusions Within a group of physicians caring for patients with HIV disease, the acceptance of assisted suicide increased between 1990 and 1995. A majority of respondents in 1995 said they had granted a request for assisted suicide from a patient with AIDS at least once. (C) 1997, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,COMMUNITY CONSORTIUM,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco								Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Bindels PJE, 1996, LANCET, V347, P499, DOI 10.1016/S0140-6736(96)91138-1; Bruni Frank, 1996, N Y Times Web, pB5; Conover W. J., 1998, PRACTICAL NONPARAMET; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GOLDBLUM P, 1989, FACE FACE GUIDE AIDS, P152; HOLDING R, 1976, SAN FRANCISCO C 0307, pA1; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; NELSON B, 1996, HARPERS          MAR, P35; RUSSELL S, 1995, SAN FRANCISCO C 0329; SLOME L, 1992, J ACQ IMMUN DEF SYND, V5, P712; Solomon A., 1995, NEW YORKER      0522, pa154; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L	17	57	57	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					417	421		10.1056/NEJM199702063360606	http://dx.doi.org/10.1056/NEJM199702063360606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010149				2023-01-03	WOS:A1997WF85900006
J	Dorman, P; Sandercock, P				Dorman, P; Sandercock, P			TPA within 3 hours of acute ischaemic stroke?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; HEMORRHAGE; HEMATOMA; TRIAL				Dorman, P (corresponding author), UNIV EDINBURGH, NEUROSCI TRIALS UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				Adams HP, 1996, STROKE, V27, P1711; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HUNT D, 1992, LANCET, V339, P753; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V33, P1581; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SIX AJ, 1990, AM J CARDIOL, V65, P119, DOI 10.1016/0002-9149(90)90071-8; WARDLAW JM, 1996, COCHRANE DATABASE SY	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1996	348	9042					1600	1601		10.1016/S0140-6736(05)65688-7	http://dx.doi.org/10.1016/S0140-6736(05)65688-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961984				2023-01-03	WOS:A1996VX87600003
J	Bush, TL; Wells, HB; James, MK; BarrettConnor, E; Marcus, R; Greendale, G; Hunsberger, S; McGowan, J				Bush, TL; Wells, HB; James, MK; BarrettConnor, E; Marcus, R; Greendale, G; Hunsberger, S; McGowan, J			Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN REPLACEMENT THERAPY; HIP FRACTURE; PERCUTANEOUS ESTRADIOL; TRABECULAR BONE; ELDERLY WOMEN; RISK-FACTORS; OLDER WOMEN; OSTEOPOROSIS; MENOPAUSE; MASS	Objective.-To assess the effects of hormone therapy on bone mineral density (BMD) in the spine and hip of postmenopausal women. Design.-A 3-year, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Participants.-A total of 875 healthy women aged 45 to 64 years recruited at 7 clinical centers. Interventions.-Treatments were (1) placebo; (2) conjugated equine estrogens (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus MPA, 2.5 mg/d daily; or (5) GEE, 0.625 mg/d plus micronized progesterone (MP), 200 mg/d for 12 d/mo. Main Outcome Measures.-Bone mineral density at baseline, 12 months, and 36 months. Results.-Participants assigned to the placebo group lost an average of 1.8% of spine BMD and 1.7% of hip BMD by the 36-month visit, while those assigned to active regimens gained BMD at both sites, ranging from 3.5% to 5.0% mean total increases in spinal BMD and a mean total increase of 1.7% of BMD in the hip. Changes in BMD for women assigned to active regimens were significantly greater than those assigned to placebo. Women assigned to CEE plus continuous MPA had significantly greater increases in spinal BMD (increase of 5%) than those assigned to the other 3 active regimens (average increase, 3.8%). Findings were similar among those adhering to assigned therapy, although, among adherent participants, there were no significant differences in BMD changes among the 4 active treatment groups, Older women, women with low initial BMD, and those with no previous hormone use gained significantly more bone than younger women, women with higher initial BMD, and those who had used hormones previously. Conclusions.-Postmenopausal women assigned to placebo demonstrated decreased BMD at the spine and hip, whereas women assigned to estrogen therapy increased BMD during a 36-month period, These findings demonstrate that estrogen replacement therapy increases BMD at clinically important sites.	PARKE DAVIS & CO, MORRIS PLAINS, NJ USA; ELI LILLY & CO, INDIANAPOLIS, IN 46285 USA; ORTHO PHARMACEUT CORP, RARITAN, NJ 08869 USA; FOREST LABS INC, ST LOUIS, MO USA; ORGANON INC, W ORANGE, NJ USA	Pfizer; Eli Lilly					NHLBI NIH HHS [U01-HL40185, U01-HL40154, U01-HL40195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040154, U01HL040195, U01HL040185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMAMENTOVILLAREAL R, 1995, J CLIN ENDOCR METAB, V80, P776, DOI 10.1210/jc.80.3.776; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BLACK DM, 1992, J BONE MINER RES, V7, P633; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1990, MATURITAS, V12, P247, DOI 10.1016/0378-5122(90)90006-R; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; FROST HM, 1989, BONE MINER, V7, P47, DOI 10.1016/0169-6009(89)90062-7; GALLAGHER JC, 1991, AM J MED, V90, P171; GREENDALE GA, 1995, MENOPAUSE, V2, P27; GREENDALE GA, 1995, J WOMENS HEALTH, V4, P231; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; GRYNPAS M, 1993, CALCIFIED TISSUE INT, V53, P557; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; HOLLAND EFN, 1994, OBSTET GYNECOL, V83, P43; HOLLAND EFN, 1993, BRIT J OBSTET GYNAEC, V100, P966, DOI 10.1111/j.1471-0528.1993.tb15124.x; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1990, ANN NY ACAD SCI, V592, P326; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MARCUS R, 1994, J BONE MINER RES, V9, P1467, DOI 10.1002/jbmr.5650090920; MELTON LJ, 1995, J BONE MINER RES, V10, P175; NOTELOVITZ M, 1991, J BONE MINER RES, V6, P583, DOI 10.1002/jbmr.5650060609; ODELL WE, 1993, DIS MON, V19, P789; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; SARTORIS DJ, 1989, AM J ROENTGENOL, V152, P241, DOI 10.2214/ajr.152.2.241; *SAS I INC, 1992, P229 SAS; SAS&REG; Procedures, 1990, VERSION 6; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SESSION DR, 1993, FERTIL STERIL, V59, P277; Smith Everett L, 1982, Phys Sportsmed, V10, P72, DOI 10.1080/00913847.1982.11947184; SOWERS MR, 1993, OSTEOPOROSIS INT, V3, P314, DOI 10.1007/BF01637317; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; WIMALAWANSA SJ, 1995, AM J MED, V99, P36, DOI 10.1016/S0002-9343(99)80102-8; WOOD H, 1993, J GEN INTERN MED, V8, P451, DOI 10.1007/BF02599627; 1995, CONTROL CLIN TRIALS, V16, pS3; 1996, JAMA-J AM MED ASSOC, V274, P1676; 1995, JAMA-J AM MED ASSOC, V273, P199	49	576	584	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1389	1396		10.1001/jama.276.17.1389	http://dx.doi.org/10.1001/jama.276.17.1389			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892713				2023-01-03	WOS:A1996VQ46400024
J	Boersma, E; Maas, ACP; Deckers, JW; Simoons, ML				Boersma, E; Maas, ACP; Deckers, JW; Simoons, ML			Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; RANDOMIZED TRIAL; INTRACORONARY STREPTOKINASE; PREHOSPITAL THROMBOLYSIS; INTRAVENOUS STREPTOKINASE; IMPROVED SURVIVAL; HOSPITAL ARRIVAL; UNSTABLE ANGINA; THERAPY	Background There is conclusive evidence from clinical trials that reduction of mortality by fibrinolytic therapy in acute myocardial infarction is related to the time elapsing between onset of symptoms and commencement of treatment. However, the exact pattern of this relation continues to be debated. This paper discusses whether or not appreciable additional gain can be achieved with very early treatment. Methods The relation between treatment delay and shortterm mortality (up to 35 days) was evaluated using tabulated data from all randomised trials of at least 100 patients (n=22; 50 246 patients) that compared fibrinolytic therapy with placebo or control, reported between 1983 and 1993. Findings Benefit of fibrinolytic therapy was 65 (SD 14), 37 (9), 26 (6) and 29 (5) lives saved per 1000 treated patients in the 0-1, 1-2, 2-3, and 3-6 h intervals, respectively. Proportional mortality reduction was significantly higher in patients treated within 2 h compared to those treated later (44% [95% CI 32, 53] vs 20% [15, 25]; p=0.001). The relation between treatment delay and mortality reduction per 1000 treated patients was expressed significantly better by a non-linear (19.4-0.6x+29.3x(-1)) than a linear (34.7-1.6x) regression equation (p=0.03). Interpretation The beneficial effect of fibrinolytic therapy is substantially higher in patients presenting within 2 h after symptom onset compared to those presenting later.	ERASMUS UNIV ROTTERDAM, NL-3015 GD ROTTERDAM, NETHERLANDS; ACAD HOSP ROTTERDAM DIJKZIGT, NL-3015 GD ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC								[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1993, Lancet, V342, P767; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARMSTRONG PW, 1989, J AM COLL CARDIOL, V13, P1469, DOI 10.1016/0735-1097(89)90334-3; BAR FW, 1992, CIRCULATION, V86, P131, DOI 10.1161/01.CIR.86.1.131; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BRUNELLI C, 1988, Cardiologia (Rome), V33, P669; BRUNELLI C, 1991, AM J CARDIOL, V68, pB110, DOI 10.1016/0002-9149(91)90393-Y; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; DAVIES GJ, 1984, NEW ENGL J MED, V311, P1488, DOI 10.1056/NEJM198412063112306; DORADO DG, 1987, CARDIOVASC RES, V21, P537; FATHORDOUBAD F, 1994, CIRCULATION, V90, P325; FATHORDOUBADI F, 1994, LANCET, V343, P912, DOI 10.1016/S0140-6736(94)90029-9; FLAMENG W, 1990, BASIC RES CARDIOL, V85, P392, DOI 10.1007/BF01907131; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; HAMPTON J, 1993, LANCET, V342, P759; HERMENS WT, 1992, LANCET, V340, P1297, DOI 10.1016/0140-6736(92)93003-6; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; HUNT D, 1992, LANCET, V339, P753; IKRAM S, 1986, BRIT MED J, V293, P786, DOI 10.1136/bmj.293.6550.786; Julian DG, 1996, EUR HEART J, V17, P43; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MCALEER B, 1992, CARDIOVASC DRUG THER, V6, P369, DOI 10.1007/BF00054183; MCNEILL AJ, 1991, Q J MED, V79, P487; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; OROURKE M, 1988, CIRCULATION, V77, P1311, DOI 10.1161/01.CIR.77.6.1311; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; REIMER KA, 1993, AM J CARDIOL, V72, pG13, DOI 10.1016/0002-9149(93)90102-I; RENTROP KP, 1989, CIRCULATION, V80, P1166, DOI 10.1161/01.CIR.80.5.1166; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SCHAPER W, 1987, J MOL CELL CARDIOL, V19, P19, DOI 10.1016/S0022-2828(87)80542-4; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; SIMOONS ML, 1985, LANCET, V2, P578; THOMPSON PL, 1988, LANCET, V1, P203; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; VERSTRAETE M, 1985, LANCET, V2, P965; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WEAVER WD, 1995, J AM COLL CARDIOL, V25, pS3; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILCOX RG, 1988, LANCET, V2, P525; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4	52	832	886	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					771	775		10.1016/S0140-6736(96)02514-7	http://dx.doi.org/10.1016/S0140-6736(96)02514-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813982	Green Submitted			2023-01-03	WOS:A1996VH98900008
J	Jackson, MA; Lodwick, R; Hutchinson, SG				Jackson, MA; Lodwick, R; Hutchinson, SG			Lesson of the week - Hyperkalaemic cardiac arrest successfully treated with peritoneal dialysis	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ALEXANDRA HOSP,PORTSMOUTH,HANTS,ENGLAND	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Jackson, MA (corresponding author), NEW CROSS HOSP,DEPT GEN MED & NEPHROL,WOLVERHAMPTON WV10 0QP,W MIDLANDS,ENGLAND.							ETTINGER PO, 1974, AM J CARDIOL, V33, P876, DOI 10.1016/0002-9149(74)90635-3; GENEVER EE, 1971, BRIT J ANAESTH, V43, P984, DOI 10.1093/bja/43.10.984; LYNN JL, 1990, CRIT CARE MED, V18, P342; MATCH WE, 1982, AM J MED, V72, P536; MILLNER M, 1987, KLIN PADIATR, V199, P122, DOI 10.1055/s-2008-1026777; SMITH CL, 1983, BRIT J ANAESTH, V55, P923; TORRECILLA C, 1989, INTENS CARE MED, V15, P325, DOI 10.1007/BF00263870	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1289	1290		10.1136/bmj.312.7041.1289	http://dx.doi.org/10.1136/bmj.312.7041.1289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634622	Green Published			2023-01-03	WOS:A1996UM40400030
J	Stiell, IG; Hebert, PC; Wells, GA; Laupacis, A; Vandemheen, K; Dreyer, JF; Eisenhauer, MA; Gibson, J; Higginson, LAJ; Kirby, AS; Mahon, JL; Maloney, JP; Weitzman, BN				Stiell, IG; Hebert, PC; Wells, GA; Laupacis, A; Vandemheen, K; Dreyer, JF; Eisenhauer, MA; Gibson, J; Higginson, LAJ; Kirby, AS; Mahon, JL; Maloney, JP; Weitzman, BN			The Ontario trial of active compression-decompression cardiopulmonary resuscitation for in-hospital and prehospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DOSE EPINEPHRINE; CORONARY PERFUSION-PRESSURE; MYOCARDIAL BLOOD-FLOW; CPR; CHEST; AUGMENTATION; SWINE; VEST; PIGS	Objective.-To compare the impact of active compression-decompression (ACD) cardiopulmonary resuscitation (CPR) and standard CPR on the outcomes of in-hospital and prehospital victims of cardiac arrest. Design.-Randomized controlled trial with blinding of allocation using a sealed container. Settings.-(1) Emergency departments, wards, and intensive care units of 5 university hospitals and (2) all locations outside hospitals in 2 midsized cities. Patients.-A total of 1784 adults who had cardiac arrest, Intervention.-Patients received either standard or ACD CPR throughout resuscitation. Main Outcome Measures.-Survival for 1 hour and to hospital discharge and the modified Mini-Mental State Examination (MMSE). Results.-All characteristics were similar in the standard and ACD CPR groups for the 773 in-hospital patients and the 1011 prehospital patients. For in-hospital patients, there were no significant differences between the standard (n=368) and ACD (n=405) CPR groups in survival for 1 hour (35.1% vs 34.6%; P=.89), in survival until hospital discharge (11.4% vs 10.4%; P=.64), or in the median MMSE score of survivors (37 in both groups). For patients who collapsed outside the hospital, there were also no significant differences between the standard (n=510) and ACD (n=501) CPR groups in survival for 1 hour (16.5% vs 18.2%; P=.48), in survival to hospital discharge (3.7% vs 4.6%; P=.49), or in the median MMSE score of survivors (35 in both groups). Exploration of clinically important subgroups failed to identify any patients who appeared to benefit from ACD CPR. Conclusions.-ACD CPR did not improve survival or neurologic outcomes in any group of patients with cardiac arrest.	OTTAWA CIVIC HOSP,DIV EMERGENCY MED,OTTAWA,ON K1Y 4E9,CANADA; OTTAWA CIVIC HOSP,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV WESTERN ONTARIO,DIV EMERGENCY MED,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario); Western University (University of Western Ontario)	Stiell, IG (corresponding author), OTTAWA CIVIC HOSP,CLIN EPIDEMIOL UNIT,LOEB MED RES INST,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.		Mahon, Jeff/G-3324-2011	Stiell, Ian/0000-0002-2583-6408				BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CARLI PA, 1994, ANN EMERG MED, V24, P890, DOI 10.1016/S0196-0644(54)00211-9; CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9; CHANG MW, 1993, CIRCULATION, V88, P193; CHANG MW, 1994, CHEST, V106, P1250, DOI 10.1378/chest.106.4.1250; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1992, AM HEART J, V124, P1145, DOI 10.1016/0002-8703(92)90393-A; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; Fleiss JL, 1986, DESIGN ANAL CLIN EXP; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; GULY UM, 1994, RESUSCITATION, V28, pS27; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; HALPERIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2940, DOI 10.1001/jama.267.21.2940; HALPERIN HR, 1994, CIRCULATION, V90, P5; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; IDRIS AH, 1994, ACAD EMERG MED, V1, pA17; KERN KB, 1990, AM HEART J, V120, P324, DOI 10.1016/0002-8703(90)90076-A; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; LURIE KG, 1994, RESUSCITATION, V28, P115, DOI 10.1016/0300-9572(94)90083-3; MALZER R, 1994, RESUSCITATION, V28, pS5; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; ORLIAGUET GA, 1995, ANN EMERG MED, V25, P48, DOI 10.1016/S0196-0644(95)70354-3; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; PELL ACH, 1994, RESUSCITATION, V27, P137, DOI 10.1016/0300-9572(94)90006-X; RIVERS EP, 1994, ACAD EMERG MED, V1, pA19; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHULTZ JJ, 1995, RESUSCITATION, V29, P23, DOI 10.1016/0300-9572(94)00812-T; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STIELL IG, 1995, ACAD EMERG MED, V2, P264, DOI 10.1111/j.1553-2712.1995.tb03220.x; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TUCKER KJ, 1993, J AM COLL CARDIOL, V22, P1485, DOI 10.1016/0735-1097(93)90561-E; TUCKER KJ, 1993, RESUSCITATION, V26, P125, DOI 10.1016/0300-9572(93)90172-M; TUCKER KJ, 1994, ANN EMERG MED, V24, P895, DOI 10.1016/S0196-0644(54)00229-6; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; TUCKER KJ, 1994, RESUSCITATION, V28, P1, DOI 10.1016/0300-9572(94)90048-5; WIK L, 1994, RESUSCITATION, V28, P55, DOI 10.1016/0300-9572(94)90055-8; Zar JH, 2010, BIOSTAT ANAL; 1991, CONTROL CLIN TRIALS, V12, P525; 1992, JAMA-J AM MED ASSOC, V268, P2171	51	95	97	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1417	1423		10.1001/jama.275.18.1417	http://dx.doi.org/10.1001/jama.275.18.1417			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618367				2023-01-03	WOS:A1996UJ30300027
J	Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ				Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ			Manganese toxicity in children receiving long-term parenteral nutrition	LANCET			English	Article							CHOLESTASIS	Background In patients receiving long-term parenteral nutrition (PN), cholestatic disease acid nervous system disorders have been associated with high blood concentrations of manganese. In such patients, the normal homoeostatic mechanisms of the liver and gut ate bypassed and the requirement for this trace element is not known; nor has it been certain whether hypermanganesaemia causes the cholestasis or vice versa. We explored the direction of effect by serial tests of liver function after withdrawal of manganese supplements from children receiving long-term PN. We also examined the relation between blood manganese concentrations and brain lesions, as indicated by clinical examination and magnetic resonance imaging (MRI). Methods From a combined group of 57 children receiving PN we identified 11 with the combination of hypermanganesaemia and cholestasis; one also had a movement disorder. Manganese supplements were reduced in the first three and withdrawn in the remainder. MRI was done in two of these children. We also looked at manganese concentrations and MRI scans in six children who had received PN for more than 2 years without developing liver disease. Findings In the hypermanganesaemia/cholestasis group, four of the 11 patients died. In the seven survivors baseline whole-blood manganese was 615-1840 nmol/L, and after 4 months it had declined by a median of 643 nmol/L (p<0 . 01). Over the same interval total bilirubin declined by a median of 70 mu mol/L (p<0 . 05). Two of these children had movement disorders, one of whom survived to have an MRI scan; this showed, with T1 weighted images, bilateral symmetrically increased signal intensity in the globus pallidus and subthalamic nuclei. Such changes were also seen in five other children-one from the hypermanganesaemia/cholestasis group and four of six in the long-term PN group without liver disease (in all of whom blood manganese was above normal). Interpretation The cholestasis complicating PN is multifactorial, but these results add to the evidence that manganese contributes. In view of the additional hazard of basal ganglia damage from high manganese levels in children receiving long-term PN, we recommend a low dose regimen of not more than 0 . 018 mu mol/kg per 24 h together with regular examination of the nervous system.	GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT GASTROENTEROL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT CHEM PATHOL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT NEURORADIOL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Lalpour, Abdollah/0000-0002-7134-9395				AYOTTE P, 1985, BIOCHEM PHARMACOL, V34, P3857, DOI 10.1016/0006-2952(85)90435-6; BALL PA, 1994, PAEDIAT PARENTERAL N; DEVENYI AG, 1994, GASTROENTEROLOGY, V106, P1068, DOI 10.1016/0016-5085(94)90769-2; EJAMA A, 1992, LANCET, V339, P426; GRAEF JW, 1982, LEAD ABSORPTION CHIL, P153; HAMBIDGE KM, 1989, JPEN-PARENTER ENTER, V13, P168, DOI 10.1177/0148607189013002168; HUANG CC, 1989, ARCH NEUROL-CHICAGO, V46, P1104, DOI 10.1001/archneur.1989.00520460090018; KRIEGER D, 1995, LANCET, V346, P270, DOI 10.1016/S0140-6736(95)92164-8; LUSTIG S, 1982, ARCH INTERN MED, V142, P405, DOI 10.1001/archinte.142.2.405; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MIROWITZ SA, 1991, RADIOLOGY, V181, P117, DOI 10.1148/radiology.181.1.1909445; NELSON K, 1993, BRIT J IND MED, V50, P510; PLAA GL, 1982, BIOCHEM PHARMACOL, V31, P3698, DOI 10.1016/0006-2952(82)90602-5; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; REYNOLDS AP, 1994, ARCH DIS CHILD, V71, P527, DOI 10.1136/adc.71.6.527; SINGH J, 1974, ENVIRON PHYSIOL BIOC, V4, P16; UNDERWOOD EJ, 1977, TRACE ELEMENTS HUMAN, P170; 1988, AM J CLIN NUTR, V48, P1324; 1979, JAMA-J AM MED ASSOC, V241, P2051	19	227	230	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1218	1221		10.1016/S0140-6736(96)90735-7	http://dx.doi.org/10.1016/S0140-6736(96)90735-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622451				2023-01-03	WOS:A1996UJ59700010
J	Mason, JK; Mulligan, D				Mason, JK; Mulligan, D			Euthanasia by stages	LANCET			English	Article									VOLUNTARY EUTHANASIA SOC SCOTLAND,EDINBURGH,MIDLOTHIAN,SCOTLAND		Mason, JK (corresponding author), UNIV EDINBURGH,FAC LAW,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; CRANFORD RE, 1995, BRIT MED J, V311, P464, DOI 10.1136/bmj.311.7003.464; HARRIGAN P, 1995, LANCET, V346, P494, DOI 10.1016/S0140-6736(95)91332-7; *HM STAT OFF, 1994, GOV RESP REP SEL COM; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; WALL M, 1995, LANCET, V346, P368, DOI 10.1016/S0140-6736(95)92243-1; 1995, LANCET, V346, P259; [No title captured]	9	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					810	811		10.1016/S0140-6736(96)90875-2	http://dx.doi.org/10.1016/S0140-6736(96)90875-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622341				2023-01-03	WOS:A1996UB15300016
J	Allen, JP; Davis, RM; Genel, M; Howe, JP; Karlan, MS; Kennedy, WR; Numann, PA; Riggs, JA; Skelton, WD; Slanetz, PJ; Spillman, MA; Williams, MA; Young, DC; Allen, JR; Rinaldi, RC; Schwartzberg, JG				Allen, JP; Davis, RM; Genel, M; Howe, JP; Karlan, MS; Kennedy, WR; Numann, PA; Riggs, JA; Skelton, WD; Slanetz, PJ; Spillman, MA; Williams, MA; Young, DC; Allen, JR; Rinaldi, RC; Schwartzberg, JG			Good care of the dying patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ILL CANCER-PATIENTS; TERMINALLY ILL; CRITICALLY ILL; INTENSIVE-CARE; HOSPICE CARE; LIFE; PAIN; DEATH; MANAGEMENT; ATTITUDES				Allen, JP (corresponding author), AMER MED ASSOC, COUNCIL SCI AFFAIRS, GRP SCI TECHNOL & PUBL HLTH STAND, 515 N STATE ST, CHICAGO, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014; Slanetz, Priscilla/0000-0003-1248-5116				ACHTE KA, 1971, OMEGA-J DEATH DYING, V2, P46; [Anonymous], 1992, J Clin Oncol, V10, P1976; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BERRY ZS, 1992, CLIN RES, V40, pA552; BREITBART W, 1990, ADV PAIN RES THER, V16, P399; Breitbart W, 1987, Oncology (Williston Park), V1, P49; BROCK DB, 1987, P AM STAT ASS SOC ST, P306; BRODY H, 1984, NEW ENGL J MED, V310, P920; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; BRUERA E, 1993, OXFORD TXB PALLIATIV, P87; BUKBERG J, 1984, PSYCHOSOM MED, V46, P199, DOI 10.1097/00006842-198405000-00002; CARTWRIGHT A, 1973, LIFE DEATH; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DESBIENS NA, IN PRESS CRIT CARE M; Doyle D., 1993, OXFORD TXB PALLIATIV; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EXTONSMITH A, 1961, LANCET, V2, P305; FIELD MJ, 1994, SUMMARY COMMITTEE VI; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; Glaser BG, 1965, AWARENESS DYING; Gomez Carlos F., 1991, REGULATING DEATH EUT; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; KANE RL, 1984, LANCET, V1, P890; Katz J., 1984, SILENT WORLD DOCTOR; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOUHIVUORI KA, 1979, AM J EPIDEMIOL, V109, P59, DOI 10.1093/oxfordjournals.aje.a112659; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; LYNN J, 1991, THEOR MED, V12, P325, DOI 10.1007/BF00489892; LYNN J, 1993, NEW ENGL J MED, V328, P964; LYNN J, 1989, REV DAXS CASE ESSAYS, P63; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MASSIE MJ, 1990, J CLIN PSYCHIAT, V51, P12; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MELZACK R, 1976, CAN MED ASSOC J, V115, P125; MERRILL D, 1993, AGING HLTH, V5, P516; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; OSLER W, 1908, SCI IMMORTALITY, P18; PARKES CM, 1980, POSTGRAD MED J, V56, P685, DOI 10.1136/pgmj.56.660.685; PARKES CM, 1985, LANCET, V1, P155; PLUMB MM, 1977, PSYCHOSOM MED, V39, P264, DOI 10.1097/00006842-197707000-00007; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; PRITCHARD R, 1994, J GEN INTERN MED, V9, pA146; QUILL TE, 1993, NEW ENGL J MED, V328, P965; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; Roy D J, 1990, J Palliat Care, V6, P3; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SAUNDERS CM, 1978, MANAGEMENT TERMINAL, P194; SAUNDERS CM, 1981, THERAPY PAIN, P215; SCHMITZ P, 1994, PRINCIPLES GERIATRIC, P383; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEEMAN I, 1992, VITAL HLTH STAT, V19, P20; SILBERFARB PM, 1980, AM J PSYCHIAT, V137, P450; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SUDNOW D, 1965, PASSING ON SOCIAL OR; Sugarman J, 1993, Kennedy Inst Ethics J, V3, P387; Takeda F., 1986, PAIN CLINIC, V1, P83; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; TENO J, 1993, CLIN RES, V41, pA582; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, J CLIN ETHIC, V5, P23; Tomlinson Tom, 1990, Bioethics, V4, P253, DOI 10.1111/j.1467-8519.1990.tb00088.x; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Ventafridda V, 1990, J Palliat Care, V6, P7; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WILKES E, 1984, LANCET, V1, P950; 1989, PRINCIPLES ANAL USE; 1987, GUIDELINES TERMINATI; 1993, CHOOSING DEATH HLTH; 1990, WHO TECHNICAL REPORT, V809; 1995, POLICY COMPENDIUM, P292; 1993, CAMB Q HLTH ETHICS, V2, P275; [No title captured]; 1991, GUIDELINES STATE COU	93	171	171	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					474	478						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU638	8627970				2023-01-03	WOS:A1996TU63800037
J	Carolei, A; Marini, C; Motolese, M				Carolei, A; Marini, C; Motolese, M			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Carolei, A (corresponding author), UNIV LAQUILA,DIPARTIMENTO MED INTERNA & SANITA PUBL,I-67100 LAQUILA,ITALY.		Marini, Carla/AAC-2413-2022	Marini, Carla/0000-0002-9212-2691				[Anonymous], 1986, Lancet, V1, P397; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; TOGNONI G, 1995, LANCET, V346, P1515, DOI 10.1016/S0140-6736(95)92050-1; 1995, NEW ENGL J MED, V333, P1581	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					392	392						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598713				2023-01-03	WOS:A1996TU69500040
J	Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR				Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR			The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; MENOPAUSAL ESTROGEN; OLDER WOMEN; FOLLOW-UP; METAANALYSIS; DISEASE	Background: The risks and benefits of hormone replacement therapy (HRT) are of considerable interest and importance, especially in terms of whether they differ among subsets of women. Objective: To determine whether HRT is associated with increased risks for breast cancer and total mortality in women with a family history of breast cancer. Design: Prospective cohort study. Setting: Population-based sample of midwestern post-menopausal women enrolled in an observational study of risk factors for cancer. Participants: Random sample of 41 837 female Iowa residents 55 to 69 years of age. Measurements: Incidence rates of and relative risks for breast cancer (n = 1085) and total mortality (n = 2035) th rough 8 years of follow-up were calculated by using data from the State Health Registry of Iowa and the National Death Index. Results: A family history of breast cancer was reported by 12.2% of the cohort at risk. Among women with a family history of breast cancer, those who currently used HRT and had done so for at least 5 years developed breast cancer at an age-adjusted annual rate of 61 cases per 10 000 person-years (95% CI, 28 to 94 cases); this rate was not statistically significantly higher than the rate in women who had never used HRT (46 cases per 10 000 person-years ICI, 36 to 55 cases]). Among women with a family history, those who used HRT had a significantly lower risk for total mortality than did women who had never used HRT (relative risk, 0.67 [CI, 0.51 to 0.89]), including total cancer-related mortality (relative risk, 0.75 [CI, 0.50 to 1.12]). The age-adjusted annual mortality rate for women using HRT for at least 5 years was 46 deaths per 10 000 person-years (CI, 19 to 74 deaths); this is roughly half the rate seen in women who had never used HRT (80 deaths per In 000 person-years [CI, 69 to 92 deaths]). Conclusions: These data suggest that HRT use in women with a family history of breast cancer is not associated with a significantly increased incidence of breast cancer but is associated with a significantly reduced total mortality rate.	UNIV IOWA, IOWA CITY, IA 52242 USA	University of Iowa	Sellers, TA (corresponding author), UNIV MINNESOTA, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.		Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Kushi, Lawrence/0000-0001-9136-1175; Cerhan, James/0000-0002-7482-178X	NCI NIH HHS [R01 CA39742, T32CA09607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742, T32CA009607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, NIH PUBLICATION, V94-1447; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BLACKMAN JA, 1995, NEW ENGL J MED, V333, P1355; Breslow N., 1987, STATISTICAL METHODS; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GO RCP, 1983, J NATL CANCER I, V71, P455; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR, P1022; HOOVER R, 1981, J NATL CANCER I, V67, P815; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; *SAS I, 1985, SAS US GUID; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	40	146	150	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					973	980		10.7326/0003-4819-127-11-199712010-00004	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412302				2023-01-03	WOS:A1997YJ08000003
J	Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL				Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL			Effects of residence in Alzheimer disease special care units on functional outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; NURSING-HOME; DEMENTIA; IMPACT; PREDICTORS; STATE; MDS	Context.-Alzheimer disease special care units (SCUs) in nursing homes are increasingly prevalent, but little is known about their effects on residents' outcomes. Objective.-To analyze the effect of SCU residence on the rates at which residents decline in functional status. Design.-A cohort of nursing home residents assessed at multiple points during about 1 year. Facility staff completed all assessments using the Minimum Data Set for Nursing Home Resident Assessment and Care Screening (MDS). Setting.-Medicare-or Medicaid-certified nursing facilities. Patients or Other Participants.-All nursing home residents in 1993 and early 1994 in Kansas, Maine, Mississippi, and South Dakota. Serial MDS assessments of 77 337 residents in more than 800 facilities, including 1228 residents in 48 facilities with SCUs. Main Outcome Measures.-Decline in locomotion, transferring, toileting, eating, dressing, and a summary activities of daily living index; decline in urinary and bowel continence; and significant weight loss. Results.-No statistically significant difference was observed in the speed of decline for residents in SCUs and traditional units in any of the 9 outcomes. Residents were matched on a variety of characteristics, and subgroup analyses were performed. In none did we observe a pattern of better outcomes among SCU residents. Conclusions.-Although SCUs may have provided unmeasured benefits to families and residents, it does not appear that those benefits included any slowing in the rates of functional decline experienced by individuals with dementia.	UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC; RES TRIANGLE INST,DIV STAT RES,RES TRIANGLE PK,NC 27709; RES TRIANGLE INST,PROGRAM AGING & LONG TERM CARE,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Research Triangle Institute	Phillips, CD (corresponding author), MENORAH PK CTR AGING,MYERS RES INST,BEACHWOOD,OH 44122, USA.				NIA NIH HHS [5-U01-AG10313-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG010313] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON WE, 1994, GERONTOLOGIST, V34, P775, DOI 10.1093/geront/34.6.775; *ADV PAN ALZH DIS, 1991, DHHS PUBL; Allison PaulD., 1982, SOCIOL METHODOL, V13, P61, DOI [10.2307/270718, DOI 10.2307/270718]; *ALZH DIS REL DIS, 1992, GUID DIGN GOALS SPEC; BanaszakHoll J, 1996, HEALTH SERV RES, V31, P97; BENSON DM, 1987, J AM GERIATR SOC, V35, P319, DOI 10.1111/j.1532-5415.1987.tb04638.x; BOLING K, 1991, DEMENTIA UNITS LONG, P3; BRAUN BI, 1991, J AM GERIATR SOC, V39, P329, DOI 10.1111/j.1532-5415.1991.tb02896.x; CHAFETZ P K, 1991, Clinical Gerontologist, V11, P19, DOI 10.1300/J018v11n01_03; CLEARY TA, 1988, GERONTOLOGIST, V28, P511, DOI 10.1093/geront/28.4.511; GOLD DT, 1991, GERONTOLOGIST, V31, P467, DOI 10.1093/geront/31.4.467; GRANT LA, 1995, J AM GERIATR SOC, V43, P569, DOI 10.1111/j.1532-5415.1995.tb06108.x; GREEN CR, 1993, J AM GERIATR SOC, V41, P654, DOI 10.1111/j.1532-5415.1993.tb06740.x; Greene J A, 1985, J Tenn Med Assoc, V78, P559; HARDWICK S, 1994, STATES 1994 PROFILES; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; HAWES C, 1997, FAMILY MEMBERS VIEWS; HEINEMANN GD, 1985, RES AGING, V7, P363, DOI 10.1177/0164027585007003003; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOLMES D, 1990, GERONTOLOGIST, V30, P178, DOI 10.1093/geront/30.2.178; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; *I MED COMM NURS H, 1986, IMPR QUAL NURS HOM; *JOINT COMM ACCR H, 1993, STAND SURV PROT DEM; MATHEW L, 1988, AM J ALZHEIMERS CARE, V3, P16; MEHR DR, 1995, GERONTOLOGIST, V35, P179, DOI 10.1093/geront/35.2.179; MOR V, 1996, GENERATIONS, V19, P24; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS JN, 1991, RESIDENT ASSESSMENT; NORRISBAKER C, IN PRESS MEASURING E; *OFF TECHN ASS, 1992, PUBL OFF TECHN ASS; *OFF TECHN ASS, 1987, OTABA323; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PHILLIPS CD, IN PRESS ALZHEIMERS; RITER RN, 1992, GERONTOLOGIST, V32, P184, DOI 10.1093/geront/32.2.184; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rovner BW, 1996, J AM GERIATR SOC, V44, P7, DOI 10.1111/j.1532-5415.1996.tb05631.x; Shah BV, 1996, SUDAAN USERS MANUAL; SLOANE PD, 1991, JAMA-J AM MED ASSOC, V265, P1278, DOI 10.1001/jama.265.10.1278; SLOANE PD, 1995, GERONTOLOGIST, V35, P103, DOI 10.1093/geront/35.1.103; STARK AJ, 1995, GERONTOLOGIST, V35, P648, DOI 10.1093/geront/35.5.648; SWANSON EA, 1993, ARCH PSYCHIATR NURS, V5, P292; WELLS Y, 1987, AUST NZ J PSYCHIAT, V21, P524, DOI 10.3109/00048678709158920; ZINN JS, 1994, GERONTOLOGIST, V34, P371, DOI 10.1093/geront/34.3.371	44	58	58	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1340	1344		10.1001/jama.278.16.1340	http://dx.doi.org/10.1001/jama.278.16.1340			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343465				2023-01-03	WOS:A1997YA90500035
J	Beresford, SAA; Weiss, NS; Voigt, LF; McKnight, B				Beresford, SAA; Weiss, NS; Voigt, LF; McKnight, B			Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; MENOPAUSAL WOMEN; HORMONE USE; PROGESTERONE; RELIABILITY; RECALL	Background Postmenopausal oestrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of oestrogen with cyclic progestagen on risk of endometrial cancer for postmenopausal women. Methods We did a population-based case-control study of women aged 45-74 years in western Washington State, USA. Cases were identified from a regional cancer registry as having histologically confirmed endometrial cancer during 1985-91. 832 (72%) of 1154 eligible cases completed interviews. Controls were identified by random digit dialling, screened for intact uterus, frequency matched for age and county, and randomly assigned a reference date within 1985-91. Interviews with 1114 (73%) of 1526 eligible controls were done. The women provided information about use of hormone replacement therapy, and reproductive and medical history before diagnosis date (cases) or reference date (controls). Findings Relative to women who had never used hormones (for >6 months), women who had taken unopposed oestrogen had a four-fold increase (95% CI 3.1-5.1) in risk of endometrial cancer. Women who used a combined therapy of oestrogen with cyclic progestagen leg, medroxyprogesterone acetate) had a relative risk of 1.4 (1.0-1.9). Among women with fewer than 10 days of added progestagen per month, the relative risk was 3.1 (1.7-5.7), whereas that for women with 10-21 days of added progestagen was 1.3 (0.8-2.2). The use of these combined regimens for 5 or more years was associated with risks of 3.7 (1.7-8.2) and 2.5 (1.1-5.5), respectively, relative to non-users of hormones. Interpretation Postmenopausal women who use combined therapy of oestrogen with cyclic progestagen on a longterm basis have an increased risk of endometrial cancer compared with those who are not on hormone replacement, even when progestagen is added for 10 or more days per month. This increase is much smaller than that associated with unopposed oestrogen, but needs to be confirmed.	UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,PROGRAM EPIDEMIOL,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,PROGRAM BIOSTAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Beresford, SAA (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,BOX 357236,SEATTLE,WA 98195, USA.				NCI NIH HHS [R35CA39779, R01CA47749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047749, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERESFORD SAA, 1989, AM J EPIDEMIOL, V130, P202, DOI 10.1093/oxfordjournals.aje.a115313; BRESLOW NE, 1980, ANAL CASE CONTROL ST, V1; BRINTON LA, 1993, OBSTET GYNECOL, V81, P265; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; GAMBRELL RD, 1980, OBSTET GYNECOL, V55, P732; GENALO MA, 1988, P SECT SURV RES METH, P552; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; JICK SS, 1993, EPIDEMIOLOGY, V4, P20, DOI 10.1097/00001648-199301000-00005; JICK SS, 1993, EPIDEMIOLOGY, V4, P384, DOI 10.1097/00001648-199307000-00016; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PERSSON I, 1987, INT J EPIDEMIOL, V16, P222, DOI 10.1093/ije/16.2.222; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; STADEL BV, 1975, AM J EPIDEMIOL, V102, P209, DOI 10.1093/oxfordjournals.aje.a112149; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHITEHEAD MI, 1987, OBSTET GYN CLIN N AM, V14, P299; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1990, OBSTETRICS GYNECOL S, V75, P59; *WRIT GROUP PEPI T, 1996, JAMA-J AM MED ASSOC, V275, P370; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199	23	361	371	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					458	461		10.1016/S0140-6736(96)07365-5	http://dx.doi.org/10.1016/S0140-6736(96)07365-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040575				2023-01-03	WOS:A1997WH38900010
J	Julian, DG; Chamberlain, DA; Pocock, SJ				Julian, DG; Chamberlain, DA; Pocock, SJ			A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicentre unblinded randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction. Design-A multicentre unblinded randomised clinical trial. Setting-38 hospitals in six countries. Subjects-1036 patients who had been treated with anistreplase for myocardial infarction were randomly assigned to either aspirin (150 mg daily) or anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant). The trial was stopped earlier than originally intended because of the slowing rate of recruitment. Main outcome measure-Cardiac death or recurrent myocardial infarction at 30 days. Results-After 30 days cardiac death or reinfarction, occurred in 11.0% (57/517) of the patients treated with anticoagulation and 11.2% (58/519) of the patients treated with aspirin (odds ratio 1.02, 95% confidence interval 0.69 to 1.50, P=0.92). Corresponding findings at three months were 13.2% (68/517) and 12.1% (63/519) (0.91, 0.63 to 1.32, P=0.67). Patients receiving anticoagulation were more likely than patients receiving aspirin to have had severe bleeding or a stroke by three months (3.9% v 1.7% (0.44, 0.20 to 0.97, P=0.04)). Conclusion-No evidence of a difference in the incidence of cardiac events was found between the two treatment groups, though the trial is too small to claim treatment equivalence confidently. A higher incidence of severe bleeding events and strokes was detected in the group receiving anticoagulation, suggesting that aspirin may be the drug of choice for most patients in this context.	ROYAL SUSSEX CTY HOSP, BRIGHTON BN2 5BE, E SUSSEX, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	University of Brighton; University of London; London School of Hygiene & Tropical Medicine								ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CAIRNS JA, 1995, JAMA-J AM MED ASSOC, V273, P965; JONKER JJC, 1994, LANCET, V343, P499; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302	5	53	56	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1996	313	7070					1429	1431		10.1136/bmj.313.7070.1429	http://dx.doi.org/10.1136/bmj.313.7070.1429			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973228	Green Published			2023-01-03	WOS:A1996VX61200024
J	Lazard, T; Retel, O; Guidet, B; Maury, E; Valleron, AJ; Offenstadt, G				Lazard, T; Retel, O; Guidet, B; Maury, E; Valleron, AJ; Offenstadt, G			AIDS in a medical intensive care unit - Immediate prognosis and long-term survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-FAILURE; MECHANICAL VENTILATION; ADMISSION; INFECTION; MORTALITY; OUTCOMES; COUNT	Objective.-To help physicians decide whether to admit patients with acquired immunodeficiency syndrome (AIDS) to the medical intensive care unit (MICU). Design.-Case series study of AIDS patients admitted to the MICU between October 1990 and October 1992 and followed up until April 1993 (median follow-up, 1 year). Setting.-The MICU in a 970-bed teaching hospital in Paris, France. Patients.-A total of 120 consecutive AIDS patients with acute respiratory failure (50%), central nervous system dysfunction (22.5%), pneumothorax (12.5%), shock (10.8%), or miscellaneous conditions (4.2%), A fetal of 86 patients were discharged alive from the MICU. Main Outcome Measures.-Predictive factors for mortality during and after MICU stay. Results.-Multivariate analysis identified 3 factors predicting poor MICU outcome: Simplified Acute Physiology Score I (SAPS I) above 10 (relative risk [RR], 6.1, 95% confidence interval [CI]: 1.5-26.6), time between AIDS diagnosis and MICU admission more than 1 year(RR, 6.0; 95% CI, 2.1-17.5), serum albumin level less than 30 g/L (RR, 4.9; 95% CI, 1.3-18.2). The CD4 cell count, beta(2)-microglobulinemia, and previous opportunistic infections had no influence on MICU mortality. After MICU discharge, survival rates were 86% al 1 week, 82% at 1 month, 53% at 6 months, and 39% at 1 year, The Karnofsky scale score and the number of previous opportunistic infections were simultaneously associated with post-MICU outcome. Predictive factors for MICU survival did not influence post-MICU survival. Conclusion.-The MICU mortality was related to immediate severity (assessed within 48 hours of admission) and the time between AIDS diagnosis and MICU admission. Long-term survival after MICU discharge depended only on the severity of AIDS. We conclude that AIDS patients should be admitted to the MICU on the same basis as other patients.	HOP ST ANTOINE,UNITE BIOSTAT & INFORMAT MED,F-75571 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Lazard, T (corresponding author), HOP ST ANTOINE,SERV REANIMAT POLYVALENTE,184 RUE FAUBOURG ST ANTOINE,F-75012 PARIS,FRANCE.							BEDOS JP, 1995, JAMA-J AM MED ASSOC, V273, P35, DOI 10.1001/jama.273.1.35; DEAM R, 1988, ANAESTHESIA, V43, P150; DEPALO VA, 1995, CHEST, V107, P506, DOI 10.1378/chest.107.2.506; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; FRIEDMAN Y, 1990, CRIT CARE MED, V18, P346, DOI 10.1097/00003246-199003000-00027; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; HAWLEY PH, 1994, CHEST, V106, P1456, DOI 10.1378/chest.106.5.1456; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MILLS GD, 1993, AIDS, V7, P1383, DOI 10.1097/00002030-199310000-00013; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1993, CRIT CARE CLIN, V9, P107, DOI 10.1016/S0749-0704(18)30210-0; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; TEASDALE G, 1974, LANCET, V2, P81; TUCKER KJ, 1992, WESTERN J MED, V157, P637; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1995, JAMA-J AM MED ASSOC, V273, P230, DOI 10.1001/jama.273.3.230; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1986, REANIM SOINS INTENSI, V2, P219; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, B EPIDEMIOL HEBDOMAD, V7, P25	30	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1240	1245		10.1001/jama.276.15.1240	http://dx.doi.org/10.1001/jama.276.15.1240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849752				2023-01-03	WOS:A1996VL69100033
J	Ramos, R; Kennedy, KI; Visness, CM				Ramos, R; Kennedy, KI; Visness, CM			Effectiveness of lactational amenorrhoea in prevention of pregnancy in Manila, the Philippines: Non-comparative prospective trial	BRITISH MEDICAL JOURNAL			English	Article							CONTRACEPTIVE FAILURE	Objective-To determine the contraceptive efficacy of the lactational amenorrhoea method. Design-Non-comparative prospective trial. Setting-Urban Manila, the Philippines. Subjects-485 lower income, educated women with extensive experience of breast feeding. Intervention-Women were offered all available contraceptives for use after birth. Those who chose the lactational amenorrhoea method were taught the method, screened for the study, and followed for 12 months to determine the risk of pregnancy when the method was used. Main outcome measures-Life table pregnancy rates during correct and incorrect use of the method, censored monthly in the event of sexual abstinence or the use of another contraceptive method. Results-The lactational amenorrhoea method was 99% effective when used correctly (that is, during lactational amenorrhoea and full or nearly full breast feeding for up to six months). At 12 months the effectiveness during amenorrhoea dropped to 97%. Conclusions-The lactational amenorrhoea method provided as much protection from pregnancy as non-breast feeding women experience with non-medicated intrauterine devices and barrier methods. The contraceptive effect of lactation cannot be attributed to lactational or postpartum abstinence.	JOSE FABELLA MEM HOSP,COMPREHENS FAMILY PLANNING CTR,MANILA,PHILIPPINES; FAMILY HLTH INT,RES TRIANGLE PK,NC 27709									COX DR, 1984, ANAL SURVIVAL DATA, P2; Francis B., 1993, GLIM SYSTEM RELEASE; KAZI A, 1995, FERTIL STERIL, V64, P717, DOI 10.1016/S0015-0282(16)57845-5; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LABBOK M, 1994, GUIDELINES BREASFEED; MOGGIA AV, 1991, CONTRACEPTION, V44, P31, DOI 10.1016/0010-7824(91)90104-N; PEREZ A, 1992, LANCET, V339, P968, DOI 10.1016/0140-6736(92)91538-J; ROLLAND R, 1976, BIBLIO REPROD, V8, P1; ROLLAND R, 1976, BIBLIO REPROD, V8, P93; *SAS I, 1991, SAS STAT REL 6 07; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; TRUSSELL J, 1991, STAT MED, V10, P201, DOI 10.1002/sim.4780100206; VANGINNE.JK, 1974, STUD FAMILY PLANN, V5, P201, DOI 10.2307/1965371; 1988, LANCET, V2, P1204	15	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					909	912						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876092	Green Published			2023-01-03	WOS:A1996VM75400023
J	Topol, EJ; Califf, R; Granger, C; VandeWerf, F; Aylward, P; Simes, J; Col, J; Armstrong, P; Vahanian, A; Neuhaus, K; Rutsch, W; Ardissino, D; Simoons, M; White, H; Betriu, A; Emanuelsson, H; Pfisterer, M; Beatt, K; Bates, E; Cheseboro, J; Ellis, S; Fuster, V; Gibler, W; Gore, J; Guerci, A; Hochman, J; Holmes, D; Kleiman, N; Morris, D; Ohman, M; Phillips, H; Weaver, D; Lee, K; Woodleaf, L; Miller, G; Bahr, R; Worley, S; Schrading, W; Gilchrist, I; Ibarra, J; Krishnaswami, V; Nygaard, T; Dageforde, D; Puma, J; Palmeri, S; Rosing, D; Dale, H; Boyek, T; Morrice, B; Weinberg, S; Noble, W; VanGilder, J; OToole, J; Jesse, R; Loss, D; Wertheimer, J; Ferrari, D; Santer, M; Strahan, N; Schaeffer, J; Aveington, M; Miller, R; Eich, D; Vrobel, T; Kerieakes, D; Sharma, S; Beckwith, W; Micale, P; Polinski, W; Goodfield, P; Paraschos, A; Chandler, A; Talley, J; Morse, H; Sheridan, F; Silverman, M; Baga, V; Ware, J; Seagle, R; Maddox, W; Schrank, J; Gainey, P; Morris, D; Iwaoka, R; Schneider, R; Ingram, R; Hanger, K; Lane, G; Beeson, W; Williams, D; Beasley, C; Spriggs, D; Schlant, R; Sullebarger, J; Smith, J; Mishkel, D; Williams, C; Gibbs, K; Hearon, B; Gonzales, M; Sheikh, K; Dedonis, J; Long, T; Popio, K; Jamal, N; Lambrew, C; Labib, S; Vorchheimer, D; Weiss, R; Mercadante, N; Guerei, A; Rashkow, A; Balleli, L; Gacioch, G; Niles, N; Seidenstein, H; Hollander, G; Wallach, R; Khan, A; Graham, S; Simons, A; Ward, H; Parkes, R; Watkins, M; DeLuccia, W; Urbach, D; Grodman, R; McCord, D; Bleiberg, M; Corbelli, J; Pepe, A; Zwerner, P; Pinsky, L; Petrovich, L; Lindenberg, B; Therrien, M; Sands, M; Rosenfeld, A; Sheikh, S; Riba, A; Hanovich, G; Swenson, L; Holland, K; Schmidt, P; Besley, D; Hession, W; Ferrigni, F; Meyers, D; Duvernoy, W; Abramowitz, B; Stomel, R; Becker, J; Mooss, A; Thompson, J; Calli, L; Penilla, A; McCriskin, J; Millsaps, R; Heinsimer, J; Pfefferkorn, D; Saddin, M; Fintel, D; Harner, R; Kopecky, S; Andres, P; Cook, L; Wefald, F; Vanderlaan, R; Love, J; Zands, M; Santolin, C; Arnold, A; Oatfield, R; Jaeger, K; Dean, E; Swenson, R; Lancaster, L; Raskin, S; Fehrenbacher, G; Lombardo, T; Strunk, B; Perry, J; Lai, P; Rowe, W; Symkoviak, G; Lee, H; Kwee, H; Woolbert, S; Miller, R; Kaplan, J; Titus, B; Wolfe, C; Cislowski, D; Berndt, T; White, R; Brown, D; Hill, D; Hui, G; Spiegel, R; Wesley, G; Mattern, A; Lapin, E; Stern, M; Kraus, M; Olson, H; Scott, R; Mackenzie, B; Hui, W; Roth, S; Goode, E; Burton, J; Senaratne, M; Traboulsi, M; Greenwood, P; Morgan, C; Ervin, F; McDowell, J; Lefkowitz, C; Sauve, M; Turek, M; Finnie, K; Kuruvilla, G; Lange, A; Charles, J; Kells, C; Vizel, S; Baillie, H; Sahay, B; Roth, D; Lubelsky, B; Jablonsky, G; Lesoway, R; Kowk, K; MacMillan, C; Adelmlan, A; Labinaz, M; Guagliumi, G; Branzi, A; Galvani, M; Mafrici, A; Savonitto, S; Fornaro, G; Colombi, E; Zanuttini, D; Ottani, F; Cavallini, C; Camerini, F; Repetto, S; Vassanelli, C; Rovelli, E; Polese, A; Politi, A; Capucci, A; Mambelli, M; Sabate, X; Masia, R; Bescos, LL; Sendon, JL; Jodar, L; RodriquezLlorian, A; MartinLuengo, C; Saenz, L; FernandezAviles, F; Froufe, J; LomaOsorio, A; Bayon, J; Jeffrey, I; Nelson, G; Walsh, W; Leitch, J; Campbell, T; Healey, J; Owensby, D; Ramsey, D; Grigg, L; Ferderman, J; Newman, R; Strickland, J; Lim, P; Counsell, J; Cross, D; Garrahy, P; Coverdale, S; Bett, N; Aroncy, G; Brown, M; Simmons, G; Horowitz, J; Thompson, P; HOckings, B; Hendricks, R; Thomson, A; Rankin, R; Bouma, H; Cozynsen, L; Stolwijk, P; Drost, H; vanKalmthout, P; Engbers, J; Westendorp, P; Voorburg, J; Veerhoek, M; PaoHan, T; Bogerijen, L; Misier, AR; Bosker, H; Smits, W; Tan, T; Castadot, M; Installe, E; DeMeester, A; Boland, J; Legrand, V; Vanwelden, J; Pirenne, B; Emmerechts, C; Beeuwsaert, R; Thiels, H; Beckers, J; Lesseliers, H; Popeye, R; Quiret, J; Maroni, J; Farah, B; Etienne, Y; Funck, F; Thank, XT; Khalife, K; Leclercq, F; Vitoux, B; Cohen, A; Vacheron, A; Barreau, D; Simon, R; Kreft, H; Ditter, H; Zeiher, A; Weizner, M; Wacker, R; Marbach, M; Nast, H; MeyerHofmann, H; SchmitzHubner, U; Bode, M; Maisch, B; Topp, H; Rutsch, W; Lollgen, H; Williams, M; Durham, D; Bruns, B; Hayes, D; Leslie, P; Hart, H; Ikram, H; Mann, S; Kirk, A; Jardine, D; Rankin, R; Audeau, M; Anandaraja, S; Cooper, I; Hogan, J; Hackett, D; Travill, C; Bridgon, G; Burrell, C; Debelder, M; Rozkovec, A; Kooner, J; James, M; Garcia, E; Risenfors, M; Pfisterer, M; Baur, H; Urban, P; Mocetti, T; Angehrn, W; Bertel, O; Amann, F				Topol, EJ; Califf, R; Granger, C; VandeWerf, F; Aylward, P; Simes, J; Col, J; Armstrong, P; Vahanian, A; Neuhaus, K; Rutsch, W; Ardissino, D; Simoons, M; White, H; Betriu, A; Emanuelsson, H; Pfisterer, M; Beatt, K; Bates, E; Cheseboro, J; Ellis, S; Fuster, V; Gibler, W; Gore, J; Guerci, A; Hochman, J; Holmes, D; Kleiman, N; Morris, D; Ohman, M; Phillips, H; Weaver, D; Lee, K; Woodleaf, L; Miller, G; Bahr, R; Worley, S; Schrading, W; Gilchrist, I; Ibarra, J; Krishnaswami, V; Nygaard, T; Dageforde, D; Puma, J; Palmeri, S; Rosing, D; Dale, H; Boyek, T; Morrice, B; Weinberg, S; Noble, W; VanGilder, J; OToole, J; Jesse, R; Loss, D; Wertheimer, J; Ferrari, D; Santer, M; Strahan, N; Schaeffer, J; Aveington, M; Miller, R; Eich, D; Vrobel, T; Kerieakes, D; Sharma, S; Beckwith, W; Micale, P; Polinski, W; Goodfield, P; Paraschos, A; Chandler, A; Talley, J; Morse, H; Sheridan, F; Silverman, M; Baga, V; Ware, J; Seagle, R; Maddox, W; Schrank, J; Gainey, P; Morris, D; Iwaoka, R; Schneider, R; Ingram, R; Hanger, K; Lane, G; Beeson, W; Williams, D; Beasley, C; Spriggs, D; Schlant, R; Sullebarger, J; Smith, J; Mishkel, D; Williams, C; Gibbs, K; Hearon, B; Gonzales, M; Sheikh, K; Dedonis, J; Long, T; Popio, K; Jamal, N; Lambrew, C; Labib, S; Vorchheimer, D; Weiss, R; Mercadante, N; Guerei, A; Rashkow, A; Balleli, L; Gacioch, G; Niles, N; Seidenstein, H; Hollander, G; Wallach, R; Khan, A; Graham, S; Simons, A; Ward, H; Parkes, R; Watkins, M; DeLuccia, W; Urbach, D; Grodman, R; McCord, D; Bleiberg, M; Corbelli, J; Pepe, A; Zwerner, P; Pinsky, L; Petrovich, L; Lindenberg, B; Therrien, M; Sands, M; Rosenfeld, A; Sheikh, S; Riba, A; Hanovich, G; Swenson, L; Holland, K; Schmidt, P; Besley, D; Hession, W; Ferrigni, F; Meyers, D; Duvernoy, W; Abramowitz, B; Stomel, R; Becker, J; Mooss, A; Thompson, J; Calli, L; Penilla, A; McCriskin, J; Millsaps, R; Heinsimer, J; Pfefferkorn, D; Saddin, M; Fintel, D; Harner, R; Kopecky, S; Andres, P; Cook, L; Wefald, F; Vanderlaan, R; Love, J; Zands, M; Santolin, C; Arnold, A; Oatfield, R; Jaeger, K; Dean, E; Swenson, R; Lancaster, L; Raskin, S; Fehrenbacher, G; Lombardo, T; Strunk, B; Perry, J; Lai, P; Rowe, W; Symkoviak, G; Lee, H; Kwee, H; Woolbert, S; Miller, R; Kaplan, J; Titus, B; Wolfe, C; Cislowski, D; Berndt, T; White, R; Brown, D; Hill, D; Hui, G; Spiegel, R; Wesley, G; Mattern, A; Lapin, E; Stern, M; Kraus, M; Olson, H; Scott, R; Mackenzie, B; Hui, W; Roth, S; Goode, E; Burton, J; Senaratne, M; Traboulsi, M; Greenwood, P; Morgan, C; Ervin, F; McDowell, J; Lefkowitz, C; Sauve, M; Turek, M; Finnie, K; Kuruvilla, G; Lange, A; Charles, J; Kells, C; Vizel, S; Baillie, H; Sahay, B; Roth, D; Lubelsky, B; Jablonsky, G; Lesoway, R; Kowk, K; MacMillan, C; Adelmlan, A; Labinaz, M; Guagliumi, G; Branzi, A; Galvani, M; Mafrici, A; Savonitto, S; Fornaro, G; Colombi, E; Zanuttini, D; Ottani, F; Cavallini, C; Camerini, F; Repetto, S; Vassanelli, C; Rovelli, E; Polese, A; Politi, A; Capucci, A; Mambelli, M; Sabate, X; Masia, R; Bescos, LL; Sendon, JL; Jodar, L; RodriquezLlorian, A; MartinLuengo, C; Saenz, L; FernandezAviles, F; Froufe, J; LomaOsorio, A; Bayon, J; Jeffrey, I; Nelson, G; Walsh, W; Leitch, J; Campbell, T; Healey, J; Owensby, D; Ramsey, D; Grigg, L; Ferderman, J; Newman, R; Strickland, J; Lim, P; Counsell, J; Cross, D; Garrahy, P; Coverdale, S; Bett, N; Aroncy, G; Brown, M; Simmons, G; Horowitz, J; Thompson, P; HOckings, B; Hendricks, R; Thomson, A; Rankin, R; Bouma, H; Cozynsen, L; Stolwijk, P; Drost, H; vanKalmthout, P; Engbers, J; Westendorp, P; Voorburg, J; Veerhoek, M; PaoHan, T; Bogerijen, L; Misier, AR; Bosker, H; Smits, W; Tan, T; Castadot, M; Installe, E; DeMeester, A; Boland, J; Legrand, V; Vanwelden, J; Pirenne, B; Emmerechts, C; Beeuwsaert, R; Thiels, H; Beckers, J; Lesseliers, H; Popeye, R; Quiret, J; Maroni, J; Farah, B; Etienne, Y; Funck, F; Thank, XT; Khalife, K; Leclercq, F; Vitoux, B; Cohen, A; Vacheron, A; Barreau, D; Simon, R; Kreft, H; Ditter, H; Zeiher, A; Weizner, M; Wacker, R; Marbach, M; Nast, H; MeyerHofmann, H; SchmitzHubner, U; Bode, M; Maisch, B; Topp, H; Rutsch, W; Lollgen, H; Williams, M; Durham, D; Bruns, B; Hayes, D; Leslie, P; Hart, H; Ikram, H; Mann, S; Kirk, A; Jardine, D; Rankin, R; Audeau, M; Anandaraja, S; Cooper, I; Hogan, J; Hackett, D; Travill, C; Bridgon, G; Burrell, C; Debelder, M; Rozkovec, A; Kooner, J; James, M; Garcia, E; Risenfors, M; Pfisterer, M; Baur, H; Urban, P; Mocetti, T; Angehrn, W; Bertel, O; Amann, F			A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; THROMBOLYSIS; TRIAL; ANGIOPLASTY; INSIGHTS; ASPIRIN	Background Thrombin has a pivotal role in the pathogenesis of acute coronary thrombosis. We compared the clinical efficacy of a potent, direct thrombin inhibitor, recombinant hirudin, with that of heparin (an indirect antithrombin agent) in patients with unstable angina or acute myocardial infarction. Methods At 373 hospitals in 13 countries, 12,142 patients with acute coronary syndromes were randomly assigned to 72 hours of therapy with either intravenous heparin or hirudin. Patients were stratified according to the presence of ST-segment elevation on the base-line electrocardiogram (4131 patients) or its absence (8011 patients), with the latter characteristic considered to indicate unstable angina or non-Q-wave myocardial infarction. Results At 24 hours, the risk of death or myocardial infarction was significantly lower in the group assigned to hirudin therapy than in the group assigned to heparin (1.3 percent vs. 2.1 percent, P = 0.001). The primary end point of death or nonfatal myocardial infarction or reinfarction at 30 days was reached in 9.8 percent of the heparin group as compared with 8.9 percent of the hirudin group (odds ratio for the risk of the end point in the hirudin group, 0.89; 95 percent confidence interval, 0.79 to 1.00; P = 0.06), The predominant effect of hirudin was on myocardial infarction or reinfarction and was not influenced by ST-segment status. There were no significant differences in the incidence of serious or life-threatening bleeding complications, but hirudin therapy was associated with a higher incidence of moderate bleeding (8.8 percent vs. 7.7 percent, P = 0.03), Conclusions For acute coronary syndromes, recombinant hirudin provided a small advantage, as compared with heparin, principally related to a reduction in the risk of nonfatal myocardial infarction. The relative therapeutic effect was more pronounced early (at 24 hours) but dissipated over time, The small benefit was consistent across the spectrum of acute coronary syndromes and was not associated with a greater risk of major bleeding complications. (C) 1996, Massachusetts Medical Society.			Topol, EJ (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL F25, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Fuster, Valentin/H-4319-2015; Maisch, Bernhard/AAH-9198-2020; Ardissino, Diego/AAC-4041-2022; Guagliumi, Giulio/K-8006-2016; Smith, Jane/B-6254-2009; Schrading, Walter/AAA-4726-2021	Fuster, Valentin/0000-0002-9043-9986; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1994, Circulation, V90, P1631; [Anonymous], 1994, Circulation, V89, P1545; ANTMAN EM, 1995, 68 SCI SESS AM HEART; ASTER RH, 1995, NEW ENGL J MED, V332, P1374, DOI 10.1056/NEJM199505183322011; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CANNON CP, 1994, J AM COLL CARDIOL, V23, P993, DOI 10.1016/0735-1097(94)90581-9; Coller BS, 1995, EUR HEART J, V16, P11, DOI 10.1093/eurheartj/16.suppl_L.11; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEMETS DL, 1980, BIOMETRIKA, V67, P651; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FLATHER M, 1995, CIRCULATION, V92, P485; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; FUSTER V, 1995, CIRCULATION, V91, P256; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; GRANGER CB, 1995, CIRCULATION, V91, P1929, DOI 10.1161/01.CIR.91.7.1929; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; LEE LV, 1995, AM J CARDIOL, V75, P7, DOI 10.1016/S0002-9149(99)80517-7; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LINCOFF AM, 1996, AM COLL CARDIOLOGY S, V622; MANTEL N, 1959, J NATL CANCER I, V22, P719; MERLINI PA, 1995, CIRCULATION, V92, P623; NICOLINI FA, 1994, CIRCULATION, V89, P1802, DOI 10.1161/01.CIR.89.4.1802; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; SIMOONS ML, 1996, AM COLL CARDIOLOGY S, V602; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; Wallentin L, 1996, LANCET, V347, P561; ZOLDHELYI P, 1995, CIRCULATION, V92, P1405; 1995, CIRCULATION S1, V92, P416	33	656	668	2	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					775	782						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8778585				2023-01-03	WOS:A1996VF78600003
J	ToozsHobson, P; Cardozo, L				ToozsHobson, P; Cardozo, L			Controversies in management - Hormone replacement therapy for all? Universal prescription is desirable	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN THERAPY; BREAST-CANCER; DISEASE; METAANALYSIS; RISK		UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT OBSTET & GYNAECOL, UROGYNAECOL UNIT, LONDON SE5 8RX, ENGLAND	University of London; King's College London				Toozs-Hobson, Philip/0000-0002-1859-9934				ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; COWAN WK, 1991, BRIT J CANCER, V64, P780, DOI 10.1038/bjc.1991.398; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FERGUSON KJ, 1989, ARCH INTERN MED, V149, P133, DOI 10.1001/archinte.149.1.133; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRIFFITHS F, 1995, FAM PRACT, V12, P54, DOI 10.1093/fampra/12.1.54; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; Leather A. T., 1993, P291; LEATHER AT, 1990, BRIT J OBSTET GYNAEC, V97, P1071, DOI 10.1111/j.1471-0528.1990.tb02491.x; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P982, DOI 10.1016/0002-9378(95)90247-3; NACHIGALL RG, 1989, OBSTET GYNECOL, V75, P77; NORMAN SG, 1994, BRIT J OBSTET GYNAEC, V101, P879, DOI 10.1111/j.1471-0528.1994.tb13549.x; OHKURA T, 1995, DEMENTIA, V6, P99, DOI 10.1159/000106929; Paganini-Hill A, 1995, Int J Fertil Menopausal Stud, V40 Suppl 1, P54; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PURDIE DW, 1995, BRIT J OBSTET GYNAEC, V102, P735, DOI 10.1111/j.1471-0528.1995.tb11433.x; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; *US DEPT HHS, 1980, VIT STAT US	21	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					350	351		10.1136/bmj.313.7053.350	http://dx.doi.org/10.1136/bmj.313.7053.350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760747	Green Published			2023-01-03	WOS:A1996VC30000025
J	Townsend, J; Frank, A; Piper, M				Townsend, J; Frank, A; Piper, M			Continuing rise in emergency admissions - Visiting elderly patients at home immediately after discharge reduces emergency readmissions	BRITISH MEDICAL JOURNAL			English	Letter									NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; HM PRISON SERV,DIRECTORATE HLTH CARE,LONDON SW1P 4LN,ENGLAND	Imperial College London	Townsend, J (corresponding author), UNIV HERTFORDSHIRE,CTR RES PRIMARY & COMMUNITY CARE,HATFIELD AL10 9AB,HERTS,ENGLAND.							Capewell S, 1996, BRIT MED J, V312, P991; *N THAM REG HLTH A, 1994, N THAM RES DEV PLAN, P16; Townsend J, 1992, Health Trends, V24, P136; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					302	302		10.1136/bmj.313.7052.302	http://dx.doi.org/10.1136/bmj.313.7052.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704567	Green Published			2023-01-03	WOS:A1996VA90300068
J	Gilligan, T; Raffin, TA				Gilligan, T; Raffin, TA			Whose death is it, anyway?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									STANFORD UNIV, MED CTR, DIV PULM & CRIT CARE MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR BIOMED ETH, STANFORD, CA 94305 USA	Stanford University; Stanford University			Gilligan, Timothy/AAC-6693-2019; Gilligan, Timothy/HGA-7460-2022	Gilligan, Timothy/0000-0003-2308-9303; 				[Anonymous], 1990, CRIT CARE MED, V18, P1435; BELENKY MF, 1986, WOMENS WAYS KNOWING, P100; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; COWLEY LT, 1992, CRIT CARE MED, V20, P1473, DOI 10.1097/00003246-199210000-00018; Gilligan C., 1982, DIFFERENT VOICE; GILLIGAN T, 1996, CHEST, V108, P1047; Hansot E, 1996, ANN INTERN MED, V125, P149, DOI 10.7326/0003-4819-125-2-199607150-00016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MARSH FA, 1994, LEGAL MED, P283; Miles S H, 1990, Law Med Health Care, V18, P85; PAOLA FA, 1995, LEGAL MED LEGAL DYNA, P404; RAFFIN TA, 1995, JAMA-J AM MED ASSOC, V273, P738, DOI 10.1001/jama.273.9.738; REINES HD, 1992, CRIT CARE MED, V20, P316, DOI 10.1097/00003246-199203000-00002; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106	16	34	35	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					137	141		10.7326/0003-4819-125-2-199607150-00010	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678368				2023-01-03	WOS:A1996UV92100012
J	Hansot, E				Hansot, E			A letter from a patient's daughter	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hansot, E (corresponding author), STANFORD UNIV, DEPT POLIT SCI,MED CTR,DIV PULM & CRIT CARE MED, MC 5236,300 PASTEUR DR, ROOM H3151, STANFORD, CA 94305 USA.								0	26	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					149	151		10.7326/0003-4819-125-2-199607150-00016	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678372				2023-01-03	WOS:A1996UV92100017
J	Murphy, JJ				Murphy, JJ			Current practice and complications of temporary transvenous cardiac pacing	BRITISH MEDICAL JOURNAL			English	Article											Murphy, JJ (corresponding author), DARLINGTON MEM HOSP,DEPT MED,DARLINGTON DL3 6HX,DURHAM,ENGLAND.							ANDREWS R, 1992, BRIT HEART J, V68, P91; MURPHY JJ, 1995, BRIT J CLIN PRACT, V49, P126; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161	4	66	68	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1134	1134						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620131				2023-01-03	WOS:A1996UK06900025
J	Rothwell, P				Rothwell, P			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Rothwell, P (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,NEUROSCI TRIALS UNIT,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; 1995, NEW ENGL J MED, V333, P1581	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					392	393						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598714				2023-01-03	WOS:A1996TU69500041
J	Evans, RS; Pestotnik, SL; Classen, DC; Clemmer, TP; Weaver, LK; Orme, JF; Lloyd, JF; Burke, JP				Evans, RS; Pestotnik, SL; Classen, DC; Clemmer, TP; Weaver, LK; Orme, JF; Lloyd, JF; Burke, JP			A computer-assisted management program for antibiotics and other antiinfective agents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; QUALITY; SURVEILLANCE; SEVERITY; ILLNESS; SYSTEM; COSTS	Background and Methods Optimal decisions about the use of antibiotics and other antiinfective agents in critically ill patients require access to a large amount of complex information. We have developed a computerized decision-support program linked to computer-based patient records that can assist physicians in the use of antiinfective agents and improve the quality of care. This program presents epidemiologic information, along with detailed recommendations and warnings. The program recommends antiinfective regimens and courses of therapy for particular patients and provides immediate feedback. We prospectively studied the use of the computerized antiinfectives-management program for one year in a 12-bed intensive care unit. Results During the intervention period, all 545 patients admitted were cared for with the aid of the antiinfectives-management program. Measures of processes and outcomes were compared with those for the 1136 patients admitted to the same unit during the two years before the intervention period. The use of the program led to significant reductions in orders for drugs to which the patients had reported allergies (35, vs. 146 during the preintervention period; P<0.01), excess drug dosages (87 vs. 405, P<0.01), and antibiotic-susceptibility mismatches (12 vs. 206, P<0.01). There were also marked reductions in the mean number of days of excessive drug dosage (2.7 vs. 5.9, P<0.002) and in adverse events caused by antiinfective agents (4 vs. 28, P<0.02). In analyses of patients who received antiinfective agents, those treated during the intervention period who always received the regimens recommended by the computer program (n=203) had significant reductions, as compared with those who did not always receive the recommended regimens (n=195) and those in the preintervention cohort (n=766), in the cost of an tiinfective agents (adjusted mean, $102 vs. $427 and $340, respectively; P<0.001), in total hospital costs (adjusted mean, $26,315 vs. $44,865 and $35,283; P<0.001), and in the length of the hospital stay (adjusted mean, 10.0 vs. 16.7 and 12.9 days; P<0.001). Conclusions A computerized antiinfectives-management program can improve the quality of patient care and reduce costs. (C) 1998, Massachusetts Medical Society.	Latter Day St Hosp, Dept Clin Epidemiol, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Crit Care, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Med Informat, Salt Lake City, UT 84143 USA		Evans, RS (corresponding author), Latter Day St Hosp, Dept Clin Epidemiol, 8th Ave & C St, Salt Lake City, UT 84143 USA.							Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Burke JP, 1996, CURR OPIN INFECT DIS, V9, P253, DOI 10.1097/00001432-199608000-00008; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CLASSEN DC, 1992, JAMA-J AM MED ASSOC, V267, P1922; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans R S, 1995, Proc Annu Symp Comput Appl Med Care, P651; EVANS RS, 1993, M D COMPUT, V10, P17; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; EVANS RS, 1992, 15 ANN S COMP APPL M, P23; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; HULSE RK, 1976, AM J HOSP PHARM, V33, P1061, DOI 10.1093/ajhp/33.10.1061; Iezzoni LI, 1997, ANN INTERN MED, V126, P588, DOI 10.7326/0003-4819-126-5-199703010-00009; Iezzoni LI, 1997, ANN INTERN MED, V126, P391, DOI 10.7326/0003-4819-126-5-199703010-00009; Logan RL, 1996, LANCET, V347, P595, DOI 10.1016/S0140-6736(96)91284-2; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MAXWELL M, 1993, BRIT MED J, V307, P1470; McDonald CJ, 1996, ANN INTERN MED, V124, P170, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00018; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; STOLLEY PD, 1969, J CHRON DIS, V22, P395, DOI 10.1016/0021-9681(69)90003-4; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39	28	792	812	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					232	238		10.1056/NEJM199801223380406	http://dx.doi.org/10.1056/NEJM199801223380406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435330				2023-01-03	WOS:000071594100006
J	Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW				Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW			Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus	LANCET			English	Article							COMPLICATIONS; BEHAVIORS	Background Intensive insulin treatment effectively delays the onset and slows the progression of microvascular complications in insulin-dependent diabetes mellitus (IDDM). Variable adherence to insulin treatment is thought to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle diabetes in adolescents and young adults with IDDM. We assessed the association between the prescribed insulin dose and the amount dispensed from all community pharmacies with the Diabetes Audit and Research in Tayside Scotland (DARTS) database. Methods We studied 89 patients, mean age 16 (SD 7) years, diabetes duration 8 (4) years, and glycosylated haemoglobin (HbA(1c)) 8.4 (1.9)%, who attended a teaching hospital paediatric or young-adult diabetes clinic in 1993 and 1994. The medically recommended insulin dose and cumulative volume of insulin prescriptions supplied were used to calculate the days of maximum possible insulin coverage per annum, expressed as the adherence index. Associations between glycaemic control (HbA(1c)), episodes of diabetic ketoacidosis, and all hospital admissions for acute complications and the adherence index were modelled. Findings Insulin was prescribed at 48 (19) IU/day and mean insulin collected from pharmacies was 58 (25) IU/day. 25 (28%) of the 89 patients obtained less insulin than their prescribed dose (mean deficit 115 [68; range 9-246] insulin days/annum). There was a significant inverse association between HbA(1c) and the adherence index (R-2=0.39; p<0.001). In the top quartile (HbA(1c)>10%), 14 (64%) of individuals had an adherence index suggestive of a missed dose of insulin (mean deficit 55 insulin days/annum). There were 36 admissions for complications related to diabetes. The adherence index was inversely related to hospital admissions for diabetic ketoacidosis (p<0.001) and all hospital admissions related to acute diabetes complications (p=0.008). The deterioration in glycaemic control observed in patients aged 10-20 years was associated with a significant reduction (p=0.01) in the adherence index. Interpretation We found direct evidence of poor compliance with insulin therapy in young patients with IDDM. We suggest that poor adherence to insulin treatment is the major factor that contributes to long-term poor glycaemic control and diabetic ketoacidosis in this age group.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CTR DIABET, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; University of Dundee	Morris, AD (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND.		McMahon, Alex D/C-4304-2008; Morris, Andrew D/C-2837-2009; Boyle, Douglas/B-9193-2017	Boyle, Douglas/0000-0002-4779-7083; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acerini CL, 1997, LANCET, V350, P1199, DOI 10.1016/S0140-6736(97)06467-2; BEARDON PHG, 1988, PHARM MED, V3, P185; CERKONEY KAB, 1980, DIABETES CARE, V3, P594, DOI 10.2337/diacare.3.5.594; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; DeFronzo RA, 1994, DIABETES REV, V2, P209; DUNGER DB, 1995, PRACTICAL DIABETES I, V12, P63, DOI [10.1002/pdi.1960120205, DOI 10.1002/PDI.1960120205]; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; Gill GV, 1996, QJM-MON J ASSOC PHYS, V89, P839, DOI 10.1093/qjmed/89.11.839; GILL GV, 1991, BRIT MED J, V303, P285, DOI 10.1136/bmj.303.6797.285; GLASGOW RE, 1987, J CHRON DIS, V40, P399, DOI 10.1016/0021-9681(87)90173-1; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; McNabb WL, 1997, DIABETES CARE, V20, P215, DOI 10.2337/diacare.20.2.215; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; Pound N, 1996, DIABETIC MED, V13, P510, DOI 10.1002/(SICI)1096-9136(199606)13:6<510::AID-DIA122>3.0.CO;2-W; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C; Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; SCOBIE IN, 1981, LANCET, V2, P521; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1994, LANCET, V344, P765, DOI 10.1016/S0140-6736(94)92333-7; THOMPSON CJ, 1995, DIABETIC MED, V12, P429, DOI 10.1111/j.1464-5491.1995.tb00508.x; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	26	365	367	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1505	1510		10.1016/S0140-6736(97)06234-X	http://dx.doi.org/10.1016/S0140-6736(97)06234-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388398				2023-01-03	WOS:A1997YH11500009
J	Hemminki, E; McPherson, K				Hemminki, E; McPherson, K			Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT THERAPY; POST-MENOPAUSAL OSTEOPOROSIS; PLACEBO-CONTROLLED TRIAL; BONE LOSS; LONG-TERM; PROGESTIN THERAPY; WOMEN; PREVENTION; CALCIUM; 2-YEAR	Objective: To examine the incidence of cardiovascular diseases and cancer from published clinical trials that studied other outcomes of postmenopausal hormone therapy as some surveys have suggested that it may decrease the incidence of cardiovascular diseases and increase the incidence of hormone dependent cancers. Design: Trials that compared hormone therapy with placebo, no therapy, or vitamins and minerals in comparable groups of postmenopausal women and reported cardiovascular or cancer outcomes were searched from the literature. Subjects: 22 trials with 4124 women were identified. In each group, the numbers of women with cardiovascular and cancer events were summed and divided by the numbers of women originally allocated to the groups. Results: Data on cardiovascular events and cancer were usually given incidentally, either as a reason for dropping out of a study or in a list of adverse effects. The calculated odds ratios for women taking hormones versus those not taking hormones was 1.39 (95% confidence interval 0.48 to 3.95) for cardiovascular events without pulmonary embolus and deep vein thrombosis and 1.64 (0.65 to 4.18) with them. It is unlikely that such results would have occurred if the true odds ratio were 0.7 or less. For cancers, the numbers of reported events were too low for a useful conclusion. Conclusions: The results of these pooled data do not support the notion that postmenopausal hormone therapy prevents cardiovascular events.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Hemminki, E (corresponding author), NATL RES & DEV CTR WELF & HLTH,HLTH SERV RES UNIT,POB 220,HELSINKI 00531,FINLAND.							AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; ALOIA JF, 1995, AM J OBSTET GYNECOL, V172, P896, DOI 10.1016/0002-9378(95)90018-7; ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; BACKE B, 1992, Scandinavian Journal of Primary Health Care, V10, P179, DOI 10.3109/02813439209014058; BARRETTCONNOR E, 1986, WESTERN J MED, V144, P620; CHRISTENSEN MS, 1982, AM J OBSTET GYNECOL, V144, P873, DOI 10.1016/0002-9378(82)90176-4; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CHRISTIANSEN C, 1981, EUR J CLIN INVEST, V11, P305, DOI 10.1111/j.1365-2362.1981.tb02121.x; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Coope J, 1981, J R Coll Gen Pract, V31, P134; DERMAN RJ, 1995, INT J FERTIL MENOP S, V40, P73; DIXON WJ, 1988, BMDP STAT SOFTW MAN, P262; GALLAGHER JC, 1991, AM J MED, V90, P171; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HASSAGER C, 1989, METABOLISM, V38, P662, DOI 10.1016/0026-0495(89)90104-2; HASSAGER C, 1987, CIRCULATION, V76, P753, DOI 10.1161/01.CIR.76.4.753; HEMMINKI E, 1993, MATURITAS, V16, P163, DOI 10.1016/0378-5122(93)90062-M; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; JENSEN J, 1989, MATURITAS, V11, P117, DOI 10.1016/0378-5122(89)90004-2; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491, DOI 10.5694/j.1326-5377.1995.tb140014.x; MARSLEW U, 1992, OBSTET GYNECOL, V79, P202; MOLANDER U, 1990, MATURITAS, V12, P113, DOI 10.1016/0378-5122(90)90089-O; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; MUNKJENSEN N, 1994, AM J OBSTET GYNECOL, V171, P132, DOI 10.1016/0002-9378(94)90458-8; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; OBEL EB, 1993, MATURITAS, V16, P13, DOI 10.1016/0378-5122(93)90129-6; *OFF TECHN ASS, 1995, EFF COSTS OST SCREEN; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; RESCH H, 1990, ACTA ENDOCRINOL-COP, V123, P14, DOI 10.1530/acta.0.1230014; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, pB6165; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; SVENDSEN OL, 1992, SCAND J CLIN LAB INV, V52, P831, DOI 10.3109/00365519209088388; TONSTAD S, 1995, J INTERN MED, V238, P39, DOI 10.1111/j.1365-2796.1995.tb00897.x; TOPO P, 1995, MATURITAS, V22, P89, DOI 10.1016/0378-5122(95)00932-B; VANDENBROUCKE JP, 1995, EPIDEMIOLOGY, V6, P207; *WHO STUD GROUP, 1994, ASSESSMENT FRACTURE; WIMALAWANSA SJ, 1995, AM J MED, V99, P36, DOI 10.1016/S0002-9343(99)80102-8; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	47	198	206	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					149	153		10.1136/bmj.315.7101.149	http://dx.doi.org/10.1136/bmj.315.7101.149			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251544	Green Published			2023-01-03	WOS:A1997XM32100017
J	vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK				vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK			Retrospective study of doctors' ''end of life decisions'' in caring for mentally handicapped people in institutions in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To gain insight into the reasons behind and the prevalence of doctors' decisions at the end of life that might hasten a patient's death (''end of life decisions'') in institutions caring for mentally handicapped people in the Netherlands, and to describe important aspects of the decisions making process. Design: Survey of random sample of doctors caring for mentally handicapped people by means of self completed questionnaires and structured interviews. Subjects: 89 of the 101 selected doctors completed the questionnaire. 67 doctors had taken an end of life decision and were interviewed about their most recent case. Main outcome measures: Prevalence of end of life decisions; types of decisions; characteristics of patients; reasons why the decision was taken; and the decision making process. Results: The 89 doctors reported 222 deaths for 1995, An end of life decision was taken in 97 cases (44%); in 75 the decision was to withdraw or withhold treatment, and in 22 it was to relieve pain or symptoms with opiates in dosages that may have shortened life. In the 67 most recent cases with an end of life decision the patients were mostly incompetent (63) and under 65 years old (51). Only two patients explicitly asked to die, but in 23 cases there had been some communication with the patient In 60 cases the doctors discussed the decision with nursing staff and in 46 with a colleague. Conclusions: End of life decisions are an important aspect of the institutionalised care of mentally handicapped people. The proportion of such decisions in the total number of deaths is similar to that in other specialties. However, the discussion of such decisions is less open in the care of mental handicap than in other specialties. Because of distinctive features of care in this specialty an open debate about end of life decisions should not be postponed.	HEEREN LOO LOZENOORD,ERMELO,NETHERLANDS		vanThiel, GJMW (corresponding author), UNIV UTRECHT,CTR BIOETH & HLTH LAW,POB 80105,NL-3508 TC UTRECHT,NETHERLANDS.		Van Thiel, Ghislaine/R-8977-2019	van Thiel, Ghislaine/0000-0003-1799-1894				DRANE JF, 1985, HASTINGS CENT REP, V15, P17, DOI 10.2307/3560639; Jonsen A. R., 1992, CLIN ETHICS; *MIN VOLSG WELZ SP, 1995, PERK BUIT MEERJ INT; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIA MED DECIS; *VER GEH NED, 1996, JB VERST GEH DIC LRZ; *VER GEH NED, 1996, LAND REG ZORG DIENST	8	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					88	91		10.1136/bmj.315.7100.88	http://dx.doi.org/10.1136/bmj.315.7100.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240047	Green Published			2023-01-03	WOS:A1997XL25200020
J	Iskos, D; Lurie, KG; Sakaguchi, S; Benditt, DG				Iskos, D; Lurie, KG; Sakaguchi, S; Benditt, DG			Termination of implantable pacemaker therapy: Experience in five patients	ANNALS OF INTERNAL MEDICINE			English	Article							LYME CARDITIS; HEART-BLOCK	Background: Established guidelines direct the initial implantation of permanent pacemakers, Elective replacement of these devices is common. However, no guidelines exist for the removal of permanent pacemakers and the termination of long-term cardiac pacing. Objective: To describe the feasibility and safety of terminating cardiac pacing in carefully selected patients. Design: Case series, Setting: University hospital, Patients: Five adults with permanent pacemakers who were referred for pacemaker replacement or a complication related to cardiac pacing. All patients showed alleviation or reversal of the electric disturbance that originally led to the implantation of the device. The patients had received a pacemaker for a class I or II indication (that is, symptomatic bradycardia or asymptomatic, persistent third-degree atrioventricular block at the level of the atrioventricular node). Intervention: After an appropriate natural rhythm was documented, pacemakers were removed from all patients. Measurements: Time without recurrence of symptomatic bradycardia. Results: No patient had recurrent symptomatic bradycardia after 18 to 48 months of clinical follow-up. Conclusions: The presence of a permanent pacemaker does not necessarily imply a permanent need for cardiac pacing. Discontinuation of cardiac pacing may be considered in certain patients. Establishing consensus criteria about the potential indications, methods, and timing of the termination of cardiac pacing seems appropriate.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities								BLUHM GL, 1985, SCAND J THORAC CARD, V19, P231, DOI 10.3109/14017438509102724; BRENNAN JA, 1979, J TRAUMA, V19, P784, DOI 10.1097/00005373-197910000-00013; BRIGNOLE M, 1992, EUR J CPE, V2, P109; BUCKINGHAM TA, 1991, PACE, V14, P1437, DOI 10.1111/j.1540-8159.1991.tb04060.x; CLARKE M, 1991, BRIT HEART J, V66, P185; DREIFUS LS, 1991, CIRCULATION, V84, P455, DOI 10.1161/01.CIR.84.1.455; FLEG JL, 1983, ARCH INTERN MED, V143, P1821, DOI 10.1001/archinte.143.9.1821; GODMAN MJ, 1974, CIRCULATION, V49, P214, DOI 10.1161/01.CIR.49.2.214; Heimberger T S, 1989, Infect Dis Clin North Am, V3, P221; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P616; Kusumoto FM, 1996, NEW ENGL J MED, V334, P89, DOI 10.1056/NEJM199601113340206; KUTALEK SP, 1995, CLIN CARDIAC PACING, P523; LEWIS AB, 1985, J THORAC CARDIOV SUR, V89, P758; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MIYAMOTO Y, 1990, CIRCULATION, V82, P313; NAGI KS, 1995, CAN J CARDIOL, V11, P335; NIELSEN H, 1986, ACTA CARDIOL, V41, P451; OTSUJI Y, 1994, EUR HEART J, V15, P407, DOI 10.1093/oxfordjournals.eurheartj.a060514; Stegman SS, 1996, PACE, V19, P899, DOI 10.1111/j.1540-8159.1996.tb03385.x	19	15	15	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					787	790		10.7326/0003-4819-126-10-199705150-00007	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148652				2023-01-03	WOS:A1997WZ82300008
J	Schlozman, S				Schlozman, S			The Bard in his outcast state	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1118	1118						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087460				2023-01-03	WOS:A1997WR34200015
J	King, P				King, P			A partnership to resolve the conundrum	BRITISH MEDICAL JOURNAL			English	Article											King, P (corresponding author), ROCHE PROD LTD,POB 8,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					890	891						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093108				2023-01-03	WOS:A1997WQ02800039
J	Falany, CN				Falany, CN			Sulfation and sulfotransferases .3. Enzymology of human cytosolic sulfotransferases	FASEB JOURNAL			English	Review						sulfation; xenobiotics; steroid; drug metabolism; human	LIVER DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; HUMAN PHENOL SULFOTRANSFERASE; ESTROGEN SULFOTRANSFERASE; HYDROXYSTEROID SULFOTRANSFERASE; IMMUNOLOGICAL CHARACTERIZATION; HUMAN-PLATELET; CDNA CLONING; HUMAN-BRAIN; RAT-LIVER; FUNCTIONAL-CHARACTERIZATION	Conjugation of many xenobiotics, drugs, and endogenous compounds with a sulfonate moiety is an important reaction in their biotransformation. Sulfation of these compounds generally results in a decrease in biological activity and an increase in their urinary excretion. However, in certain instances, sulfation results in bioactivation to reactive electrophilic or therapeutically active forms. At least four cytosolic sulfotransferases (STs) have been identified and characterized from human tissues. These enzymes are two forms of phenol ST (PST), the phenol-sulfating and the monoamine-sulfating forms of PST (P-PST and M-PST, respectively), an estrogen sulfotransferase (EST), and a hydroxysteroid ST, dehydroepiandrosterone ST (DHEA-ST). Although four cytosolic STs have been well characterized in human tissues, evidence is accumulating for the presence of allelic forms or additional distinct forms of the STs in human tissues. The STs possess distinct but overlapping substrate specificities, and all of tile STs are capable of conjugating both xenobiotic and endogenous compounds. The individual forms of ST may display distinct patterns of tissue specific expression and different mechanisms of regulation. Although the role of sulfation in drug metabolism is well recognized, an increased understanding of the biochemistry and molecular biology of the STs should also provide additional information as to their functions in many normal physiologic processes.-Falany, C. N. Enzymology of human cytosolic sulfotransferases.			Falany, CN (corresponding author), UNIV ALABAMA, DEPT PHARMACOL & TOXICOL, 1670 UNIV BLVD, BIRMINGHAM, AL 35294 USA.				NIGMS NIH HHS [GM38953] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038953, R01GM038953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JB, 1979, BIOCHIM BIOPHYS ACTA, V567, P144, DOI 10.1016/0005-2744(79)90181-5; AKSOY IA, 1993, DRUG METAB DISPOS, V21, P268; AKSOY IA, 1993, CLIN PHARMACOL THER, V54, P498, DOI 10.1038/clpt.1993.181; AKSOY IA, 1993, BIOCHEM BIOPH RES CO, V4, P181; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BARKER EV, 1994, ENDOCRINOLOGY, V134, P982, DOI 10.1210/en.134.2.982; BARNES S, 1989, J LIPID RES, V30, P529; BARNES S, 1991, OXFORD TXB CLIN HEPA, P115; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; Baumann E, 1876, DTSCH CHEM GES, P54; Baxter JD, 1987, ENDOCRINOL METAB, P511; BROOKS SC, 1983, STEROIDS ENDOMETRIAL, P145; CAMPBELL NRC, 1987, BIOCHEM PHARMACOL, V36, P1435, DOI 10.1016/0006-2952(87)90108-0; CASEY ML, 1983, J STEROID BIOCHEM, V19, P1403, DOI 10.1016/0022-4731(83)91114-7; CLARKE CL, 1982, J CLIN ENDOCR METAB, V55, P70, DOI 10.1210/jcem-55-1-70; COMER KA, 1993, BIOCHEM J, V289, P233, DOI 10.1042/bj2890233; COMER KA, 1992, MOL PHARMACOL, V41, P645; DOOLEY TP, 1993, GENOMICS, V18, P440, DOI 10.1006/geno.1993.1494; DOOLEY TP, 1994, BIOCHEM BIOPH RES CO, V205, P482, DOI 10.1006/bbrc.1994.2691; Falany CN, 1995, ANN NY ACAD SCI, V774, P59, DOI 10.1111/j.1749-6632.1995.tb17372.x; FALANY CN, 1995, J STEROID BIOCHEM, V52, P529, DOI 10.1016/0960-0760(95)00015-R; FALANY CN, 1990, BIOCHEM PHARMACOL, V40, P1027, DOI 10.1016/0006-2952(90)90489-8; FALANY CN, 1990, ARCH BIOCHEM BIOPHYS, V278, P312, DOI 10.1016/0003-9861(90)90265-Z; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FALANY CN, 1992, J BIOCHEM TOXICOL, V7, P241, DOI 10.1002/jbt.2570070407; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Falany JL, 1996, ENDOCRINOLOGY, V137, P1395, DOI 10.1210/en.137.4.1395; Falany JL, 1996, CANCER RES, V56, P1551; FEHER T, 1975, CAN J BIOCHEM CELL B, V53, P215, DOI 10.1139/o75-030; FORBES KJ, 1995, MOL CELL ENDOCRINOL, V112, P53, DOI 10.1016/0303-7207(95)03585-U; FORBESBAMFORTH KJ, 1994, BIOCHEM BIOPH RES CO, V198, P707, DOI 10.1006/bbrc.1994.1102; GANGULY TC, 1995, DRUG METAB DISPOS, V23, P945; GLATT H, 1995, EUR J PHARM-ENVIRON, V293, P173, DOI 10.1016/0926-6917(95)90002-0; GLATT H, IN PRESS FASEB J, V11; GROSSO DS, 1984, J CLIN ENDOCR METAB, V59, P829, DOI 10.1210/jcem-59-5-829; GURPIDE E, 1982, AM J OBSTET GYNECOL, V144, P551, DOI 10.1016/0002-9378(82)90226-5; HART RF, 1979, LIFE SCI, V24, P125, DOI 10.1016/0024-3205(79)90121-8; HENDRIXTREACY S, 1986, EUR J CLIN PHARMACOL, V30, P273, DOI 10.1007/BF00541527; HER C, 1995, GENOMICS, V29, P16, DOI 10.1006/geno.1995.1210; HERNANDEZ JS, 1992, DRUG METAB DISPOS, V20, P413; HEROUX JA, 1988, MOL PHARMACOL, V34, P194; HEROUX JA, 1989, MOL PHARMACOL, V36, P29; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; HOMMA H, 1994, CHEM-BIOL INTERACT, V92, P15, DOI 10.1016/0009-2797(94)90049-3; Hornsby PJ, 1995, ANN NY ACAD SCI, V774, P29, DOI 10.1111/j.1749-6632.1995.tb17370.x; HUME R, 1994, HISTOCHEM J, V26, P850, DOI 10.1007/BF00162930; Hume R, 1996, HISTOCHEM CELL BIOL, V105, P147, DOI 10.1007/BF01696154; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; KENNERSON AR, 1983, J CLIN ENDOCR METAB, V56, P786, DOI 10.1210/jcem-56-4-786; KIEHLBAUCH CC, 1995, J BIOL CHEM, V270, P18941, DOI 10.1074/jbc.270.32.18941; KONG ANT, 1992, BIOCHEM BIOPH RES CO, V187, P448, DOI 10.1016/S0006-291X(05)81514-1; KUDLACEK PE, 1995, BIOCHEM BIOPH RES CO, V210, P363, DOI 10.1006/bbrc.1995.1670; LIU HC, 1979, ENDOCRINOLOGY, V104, P1674, DOI 10.1210/endo-104-6-1674; Longcope C, 1995, ANN NY ACAD SCI, V774, P143, DOI 10.1111/j.1749-6632.1995.tb17378.x; Majewska MD, 1995, ANN NY ACAD SCI, V774, P111, DOI 10.1111/j.1749-6632.1995.tb17375.x; MATSUI M, 1994, INT J BIOCHEM, V26, P1237; MCALLISTER JM, 1988, ENDOCRINOLOGY, V122, P2012, DOI 10.1210/endo-122-5-2012; MCCALL JM, 1983, J MED CHEM, V26, P1791, DOI 10.1021/jm00366a030; MEISHERI KD, 1988, J PHARMACOL EXP THER, V245, P751; MILLER EC, 1985, CARCINOGENESIS LOND, V11, P93; MORRIS ME, 1983, CLIN PHARMACOL THER, V33, P529, DOI 10.1038/clpt.1983.72; MORTOLA JF, 1990, J CLIN ENDOCR METAB, V71, P696, DOI 10.1210/jcem-71-3-696; MOUELHI M E, 1986, Hepatology, V6, P450, DOI 10.1002/hep.1840060322; Mulder G.J., 1990, CONJUGATION REACTION, P107; MULDER GJ, 1984, PROG DRUG METAB, V8, P35; OBINATA K, 1994, SCAND J CLIN LAB INV, V54, P285, DOI 10.3109/00365519409087524; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; OTTERNESS DM, 1995, CYTOGENET CELL GENET, V70, P45, DOI 10.1159/000133988; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; OZAWA S, 1995, PHARMACOGENETICS, V5, pS135, DOI 10.1097/00008571-199512001-00015; PACK BA, 1979, J CLIN ENDOCR METAB, V48, P420, DOI 10.1210/jcem-48-3-420; PANG KS, 1990, CONJUGATION REACTION, P5; PARKER CR, 1994, J CLIN ENDOCR METAB, V78, P234, DOI 10.1210/jc.78.1.234; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; REITER C, 1983, N-S ARCH PHARMACOL, V324, P140, DOI 10.1007/BF00497020; REVELEY AM, 1983, J PSYCHIAT RES, V17, P303, DOI 10.1016/0022-3956(82)90009-7; ROBBINS PW, 1956, J AM CHEM SOC, V78, P2652, DOI 10.1021/ja01592a097; ROTH JA, 1982, BIOCHEM PHARMACOL, V31, P3017, DOI 10.1016/0006-2952(82)90073-9; ROTH JA, 1986, TRENDS PHARMACOL SCI, V7, P404, DOI 10.1016/0165-6147(86)90402-5; ROY AK, 1992, P SOC EXP BIOL MED, V199, P265; RUNGEMORRIS M, 1991, BIOCHEM BIOPH RES CO, V175, P1051, DOI 10.1016/0006-291X(91)91671-X; SCHWARTZ AG, 1988, ADV CANCER RES, V51, P391, DOI 10.1016/S0065-230X(08)60227-4; SPAULDING SW, 1992, J CLIN ENDOCR METAB, V74, P1062, DOI 10.1210/jc.74.5.1062; STIEHL A, 1977, LIVER BILE, P129; SUNDARAM RS, 1989, CLIN PHARMACOL THER, V46, P501, DOI 10.1038/clpt.1989.178; TSENG L, 1983, J STEROID BIOCHEM, V19, P1413, DOI 10.1016/0022-4731(83)91116-0; TYCE GM, 1980, J NEUROCHEM, V34, P210, DOI 10.1111/j.1471-4159.1980.tb04642.x; VERONESE ME, 1994, BIOCHEM J, V302, P497, DOI 10.1042/bj3020497; Visser TJ, 1996, EUR J ENDOCRINOL, V134, P12, DOI 10.1530/eje.0.1340012; WALDON DJ, 1989, J INVEST DERMATOL, V92, P538; WALLE T, 1992, DRUG METAB DISPOS, V20, P333; WALLE T, 1993, DRUG METAB DISPOS, V21, P76; WALLE T, 1994, CHEM-BIOL INTERACT, V92, P47, DOI 10.1016/0009-2797(94)90052-3; WANG DY, 1967, J ENDOCRINOL, V38, P307, DOI 10.1677/joe.0.0380307; WEINSHILBOUM R, 1988, CELL MOL NEUROBIOL, V8, P27, DOI 10.1007/BF00712908; WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y; WEINSHILBOUM RM, 1986, FASEB J, V45, P2223; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; WOOD TC, 1994, BIOCHEM BIOPH RES CO, V198, P1119, DOI 10.1006/bbrc.1994.1159; YOUNG WF, 1988, ENDOCRINOLOGY, V122, P1816, DOI 10.1210/endo-122-5-1816; YOUNG WF, 1985, J NEUROCHEM, V44, P1131, DOI 10.1111/j.1471-4159.1985.tb08734.x; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018; ZOU JY, 1990, J NEUROCHEM, V55, P1154, DOI 10.1111/j.1471-4159.1990.tb03119.x	106	489	500	2	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1997	11	4					206	216		10.1096/fasebj.11.4.9068609	http://dx.doi.org/10.1096/fasebj.11.4.9068609			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068609				2023-01-03	WOS:A1997WM85000002
J	McMurdo, MET; Mole, PA; Paterson, CR				McMurdo, MET; Mole, PA; Paterson, CR			Controlled trial of weight bearing exercise in older women in relation to bone density and falls	BRITISH MEDICAL JOURNAL			English	Article								Studies of the effects of different exercise programmes on bone in postmenopausal women have produced different conclusions, but few have targeted elderly women specifically.(1) We report a controlled trial of weight bearing exercise in this clinically important population.			McMurdo, MET (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,SECT AGEING & HLTH,DUNDEE DD1 9SY,SCOTLAND.							FORWOOD MR, 1993, BONE MINER, V21, P89, DOI 10.1016/S0169-6009(08)80012-8; MCMURDO MET, 1992, GERONTOLOGY, V38, P292; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341	3	75	75	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					569	569		10.1136/bmj.314.7080.569	http://dx.doi.org/10.1136/bmj.314.7080.569			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055716	Green Published			2023-01-03	WOS:A1997WK21500025
J	Schneider, DL; BarrettConnor, EL; Morton, DJ				Schneider, DL; BarrettConnor, EL; Morton, DJ			Timing of postmenopausal estrogen for optimal bone mineral density - The Rancho Bernardo study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONAL REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; ELDERLY WOMEN; HIP FRACTURE; OSTEOPOROSIS; PREVENTION; CALCIUM; MASS; GESTAGEN; SPINE	Objective-To determine the effect of the timing of initiation and the duration of postmenopausal estrogen therapy on bone mineral density (BMD). Design.-Cross-sectional study. Setting.-White, middle-class to upper middle-class community-dwelling women, Participants.-A total of 740 women aged 60 to 98 years who participated in a study of osteoporosis. Measurements.-Questionnaire, validated medication use, and height and weight. Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry (SPA) and at the hip and lumbar spine using dual-energy x-ray absorptiometry (DEXA). Results-Of the 740 women, 69% had used oral estrogen after menopause and 30% were current users. Five groups of estrogen use were identified: never users, past users who started at menopause, past users who started after age 60 years, current users who started after age 60 years, and current users who started at menopause, At all 4 bone sites, current users who started at menopause had the highest BMD levels, which were significantly higher than never users or past users who started at menopause (with 10 years' duration of use). These differences persisted after controlling for all major risk factors for osteoporosis. Among current users, there was no significant difference in BMD levels at any site between those who started estrogen at menopause (with 20 years of use) and those who started after age 60 years (with 9 years of use), Conclusions.-Estrogen initiated in the menopausal period and continued into late life is associated with the highest bone density. Nevertheless, estrogen begun after age 60 years and continued appears to offer nearly equal bone-conserving benefit.	UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; BIRKENHAGER JC, 1992, BONE MINER, V18, P251, DOI 10.1016/0169-6009(92)90811-Q; BRODY JA, 1984, AM J PUBLIC HEALTH, V74, P1397, DOI 10.2105/AJPH.74.12.1397; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1981, LANCET, V1, P459; ERDTSIECK RJ, 1994, J BONE MINER RES, V9, P277; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; ETTINGER B, 1994, MENOPAUSE, V1, P19; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; ETTINGER B, 1994, CURRENT THERAPY ENDO, P596; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GREY AB, 1994, CLIN ENDOCRINOL, V40, P671, DOI 10.1111/j.1365-2265.1994.tb03020.x; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HUTCHINSON TA, 1979, LANCET, V2, P705; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOHRT WM, 1995, OSTEOPOROSIS INT, V5, P150, DOI 10.1007/BF02106093; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NGUYEN TV, 1995, J CLIN ENDOCR METAB, V80, P2709, DOI 10.1210/jc.80.9.2709; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; *SAS I INC, 1990, SAS STAT US GUID VER, P2; STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756-3282(89)90126-9; SZEJNFELD VL, 1994, SAO PAULO MED J, V112, P514; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	36	181	184	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					543	547		10.1001/jama.277.7.543	http://dx.doi.org/10.1001/jama.277.7.543			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032160				2023-01-03	WOS:A1997WH29700029
J	Pringle, M				Pringle, M			Interesting idea, but case not proved - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Pringle, M (corresponding author), QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; CAMPBELL LM, 1995, BRIT MED J, V311, P236, DOI 10.1136/bmj.311.6999.236; Kinnersley P, 1996, FAM PRACT, V13, P41, DOI 10.1093/fampra/13.1.41; POULTON B, 1995, BR J GEN PRACT, V46, P26	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					348	348		10.1136/bmj.314.7077.348	http://dx.doi.org/10.1136/bmj.314.7077.348			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040329	Green Published			2023-01-03	WOS:A1997WF86100035
J	Lynn, J; Teno, JM; Phillips, RS; Wu, AW; Desbiens, N; Harrold, J; Claessens, MT; Wenger, N; Kreling, B; Connors, AF				Lynn, J; Teno, JM; Phillips, RS; Wu, AW; Desbiens, N; Harrold, J; Claessens, MT; Wenger, N; Kreling, B; Connors, AF			Perceptions by family members of the dying experience of older and seriously ill patients	ANNALS OF INTERNAL MEDICINE			English	Article						terminal care; attitude to death; death; advance directives; decision making	RANDOMIZED CONTROLLED TRIAL; CANCER-PATIENTS; SUPPORT; DYSPNEA; PAIN	Background: Alleviating the problems faced by dying persons and their families has drawn substantial public attention, but little is known about the experience of dying. Objective: To characterize the experience of dying from the perspective of surrogate decision makers, usually close family members (89%). Design: Prospective cohort study. Setting: Five teaching hospitals. Patients: Persons who had one of nine serious medical conditions or were 80 years of age or older who died and for whom a surrogate decision maker completed an interview about the death. Measurements: Medical records were reviewed and surrogate decision makers were interviewed. Results: 4124 of 9105 seriously ill patients died (46%); 408 of 1176 elderly patients died (35%). The patients' family members were interviewed after 3357 persons (73%) had died. Of 1541 patients who survived the enrollment hospitalization, 46% died during a later hospitalization. In the last 3 days of life, 55% of patients were conscious. Among these patients, pain, dyspnea, and fatigue were prevalent. Four in 10 patients had severe pain most of the time. Severe fatigue affected almost 8 in 10 patients. More than 1 in 4 patients had moderate dysphoria. Sixty-three percent of patients had difficulty tolerating physical or emotional symptoms. Overall, 11% of patients had a final resuscitation attempt. A ventilator was used in one fourth of patients, and a feeding tube was used in four tenths of patients. Most patients (59%) were reported to prefer a treatment plan that focused on comfort, but care was reported to be contrary to the preferred approach in 10% of cases. Conclusions: Most elderly and seriously ill patients died in acute care hospitals. Pain and other symptoms were commonplace and troubling to patients. Family members believed that patients preferred comfort, but life-sustaining treatments were often used. These findings indicate important opportunities to improve the care of dying patients.	BETH ISRAEL HOSP, DEPT MED, DEPT CLIN EPIDEMIOL, BOSTON, MA 02215 USA; JOHNS HOPKINS UNIV, SERV RES CTR, BALTIMORE, MD 21205 USA; MARSHFIELD MED RES FDN, DEPT GEN INTERNAL MED, MARSHFIELD, WI 54449 USA; DEPT VET AFFAIRS HOSP, OUTCOMES RES GRP, WHITE RIVER JCT, VT 05009 USA; UNIV CALIF LOS ANGELES, SCH MED, CTR HLTH & ETH, LOS ANGELES, CA 90095 USA; METROHLTH MED CTR, DIV PULM DIS & CRIT CARE, CLEVELAND, OH 44109 USA	Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; MetroHealth System	Lynn, J (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, CTR IMPROVE CARE DYING, 100 22ND ST, SUITE 820, WASHINGTON, DC 20037 USA.		Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; [Anonymous], 1992, J Clin Oncol, V10, P1976; [Anonymous], YEAR DEATH; BROCK DB, 1987, P AM STAT ASS SOC ST, P306; BROWN D, 1994, WASHINGTON POST 1113, pA20; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P365, DOI 10.1016/0885-3924(92)90091-U; Carter Stephen L, 1996, N Y Times Mag, P28; CELLA DF, 1987, J CHRON DIS, V40, P939, DOI 10.1016/0021-9681(87)90143-3; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; COLBURN D, 1994, WASHINGTON POST 0510; Doyle D., 1993, OXFORD TXB PALLIATIV; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; KANE RL, 1984, LANCET, V1, P890; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KRELING B, 1990, J CLIN EPIDEMIOL, V43, pS5, DOI 10.1016/0895-4356(90)90212-8; Layde PM, 1996, J CLIN EPIDEMIOL, V49, P835, DOI 10.1016/0895-4356(96)00006-6; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; LYNN J, 1993, NEW ENGL J MED, V328, P964; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; OSLER W, 1908, SCI IMMORTALITY, P18; QUILL TE, 1993, NEW ENGL J MED, V328, P965; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; Rothman, 1995, LIVING SHADOW DEATH; SAUNDERS DC, 1989, TXB PAIN, P624; SCHROEDER SA, 1995, DYING AM, P7; TEASDALE G, 1974, LANCET, V2, P81; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; World Health Organization, 1990, CANC PAIN REL PALL C	36	537	546	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					97	+		10.7326/0003-4819-126-2-199701150-00001	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005760				2023-01-03	WOS:A1997WD29800004
J	Reynolds, F; Crowhurst, JA				Reynolds, F; Crowhurst, JA			Opioids in labour - No analgesic effect	LANCET			English	Editorial Material							PAIN		QUEEN CHARLOTTES & CHELSEA HOSP,LONDON W6 0XG,ENGLAND	Imperial College London	Reynolds, F (corresponding author), ST THOMAS HOSP,DEPT ANAESTHET,LONDON SE1 7EH,ENGLAND.							Chamberlain G, 1993, PAIN ITS RELIEF CHIL; HOLDCROFT A, 1974, J OBSTET GYN BR COMM, V81, P603; MOORE J, 1993, EFFECTS BABY MATERNA, P148; MORGAN BM, 1982, LANCET, V2, P808; NORVELL KT, 1987, PAIN, V31, P77, DOI 10.1016/0304-3959(87)90008-X; Olofsson C, 1996, Int J Obstet Anesth, V5, P176, DOI 10.1016/S0959-289X(96)80028-8; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; PAECH MJ, 1991, ANAESTH INTENS CARE, V19, P393, DOI 10.1177/0310057X9101900316; Ranta P, 1994, Int J Obstet Anesth, V3, P193, DOI 10.1016/0959-289X(94)90067-1; REYNOLDS F, 1989, BRIT MED J, V299, P751, DOI 10.1136/bmj.299.6702.751; WIENER PC, 1977, BRIT MED J, V2, P228, DOI 10.1136/bmj.2.6081.228	11	22	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					4	5		10.1016/S0140-6736(05)62156-3	http://dx.doi.org/10.1016/S0140-6736(05)62156-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988111				2023-01-03	WOS:A1997WA72500005
J	Kroon, AA; vanAsten, WNJC; Stalenhoef, AFH				Kroon, AA; vanAsten, WNJC; Stalenhoef, AFH			Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Article						lipoprotein, LDL cholesterol; hypercholesterolemia; blood component removal; coronary arteriosclerosis; hydroxymethylglutaryl CoA reductases	INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK-FACTORS; COLESTIPOL-NIACIN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; LDL-APHERESIS; FEMORAL ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; HEART-DISEASE; REGRESSION; ASSOCIATIONS	Background: Apheresis of low-density lipoprotein (LDL) is an effective lipid-lowering treatment in hypercholesterolemic patients who have coronary artery disease and are refractory to drugs. More aggressive lipid-lowering therapy may further slow the progression of atherosclerosis. Objective: To compare the effect of LDL apheresis and simvastatin therapy with the effect of simvastatin therapy alone on the progression of peripheral vascular disease. Design: Open, randomized, single-center study. Setting: University hospital. Patients: 42 men with primary hypercholesterolemia (total cholesterol level > 8.0 mmol/L) and extensive coronary atherosclerosis. Intervention: Biweekly apheresis of LDL plus simvastatin, 40 mg/d (n = 21), or simvastatin, 40 mg/d (n = 21), for 2 years. Measurements: Lipid and lipoprotein levels, changes in hemodynamically significant stenoses in the aortotibial tract (measured by ankle:arm systolic blood pressure ratio combined with Doppler spectrum analysis of the femoral artery), and changes in the mean intima-media thickness of three carotid artery segments. Results: Mean baseline LDL cholesterol levels decreased from 7.8 to 3.0 mmol/L in the apheresis and simvastatin group and from 7.9 to 4.1 mmol/L in the simvastatin-only group; mean lipoprotein(a) levels decreased from 57.0 to 44.5 mg/dL (change, -19%) in the former group and increased from 38.4 to 44.5 mg/dL (change, 15%) in the latter group. In the apheresis group, the number of patients with hemodynamically significant stenoses in the aortotibial tract decreased from 9 to 7; in the simvastatin-only group, the number increased from 6 to 13 (P = 0.002). Mean intima-media thickness decreased by a mean +/- SD of 0.05 +/- 0.34 mm in the apheresis group and increased by 0.06 +/- 0.38 mm in the simvastatin-only group (P < 0.001). According to multiple regression analysis, changes in apolipoprotein B, total cholesterol, and lipoprotein(a) levels accounted for changes in the aortotibial tract (R(2) = 0.36); changes in lipoprotein(a) and apolipoprotein Al levels accounted for changes in the intima-media thickness of the carotid artery (R(2) = 0.49). Conclusions: Aggressive lipid lowering with simvastatin and LDL apheresis decreased the intima-media thickness of the carotid artery and prevented an increase in the number of hemodynamically significant stenoses in the lower limbs. Therapy with simvastatin alone did not prevent progression of carotid or aortotibial vascular disease.	UNIV NIJMEGEN HOSP, DEPT INTERNAL MED, NL-6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, CLIN VASC LAB, NL-6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Stalenhoef, A.F.H./H-8094-2014					AGISHI T, 1993, ANGIOLOGY, V44, P222, DOI 10.1177/000331979304400308; APSTEIN CS, 1978, ATHEROSCLEROSIS, V31, P105, DOI 10.1016/0021-9150(78)90157-0; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BOTS ML, 1994, ARTERIOSCLER THROMB, V14, P1885, DOI 10.1161/01.ATV.14.12.1885; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; DEMACKER PNM, 1980, CLIN CHEM, V26, P1775; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FURBERG CD, 1994, J INTERN MED, V236, P575, DOI 10.1111/j.1365-2796.1994.tb00848.x; GORDON BR, 1992, AM J CARDIOL, V70, P1010, DOI 10.1016/0002-9149(92)90352-Y; Gordon Bruce R., 1994, Current Opinion in Lipidology, V5, P69, DOI 10.1097/00041433-199402000-00011; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HOMER D, 1991, MAYO CLIN PROC, V66, P259, DOI 10.1016/S0025-6196(12)61007-6; JURGENS G, 1989, LANCET, V1, P911; KARNEGIS JN, 1992, ATHEROSCLEROSIS, V92, P25, DOI 10.1016/0021-9150(92)90006-3; KELLER C, 1991, ATHEROSCLEROSIS, V86, P1, DOI 10.1016/0021-9150(91)90093-I; KNISEL W, 1993, J INTERN MED, V234, P479, DOI 10.1111/j.1365-2796.1993.tb00781.x; KOHLER TR, 1987, CIRCULATION, V76, P1074, DOI 10.1161/01.CIR.76.5.1074; KOIZUMI J, 1993, ATHEROSCLEROSIS, V100, P65, DOI 10.1016/0021-9150(93)90068-6; Kroon AA, 1996, CIRCULATION, V93, P1826, DOI 10.1161/01.CIR.93.10.1826; KROON AA, 1995, J INTERN MED, V238, P451, DOI 10.1111/j.1365-2796.1995.tb01223.x; KROON AA, 1996, LIPID LOWERING THERA, P193; LEGEMATE DA, 1991, ULTRASOUND MED BIOL, V17, P769, DOI 10.1016/0301-5629(91)90159-T; LOPESVIRELLA MFL, 1980, CLIN CHEM, V26, P1205; MABUCHI H, 1987, ATHEROSCLEROSIS, V68, P19, DOI 10.1016/0021-9150(87)90089-X; Mack Wendy J., 1993, Journal of the American College of Cardiology, V21, p166A; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OLSSON AG, 1990, J INTERN MED, V227, P381, DOI 10.1111/j.1365-2796.1990.tb00176.x; PEDERSEN TR, 1994, LANCET, V344, P1383; PFOHL M, 1994, J LIPID RES, V35, P1946; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; RUBBA P, 1990, CIRCULATION, V81, P610, DOI 10.1161/01.CIR.81.2.610; SALONEN JT, 1994, J INTERN MED, V236, P561, DOI 10.1111/j.1365-2796.1994.tb00846.x; SALONEN R, 1994, ARTERIOSCLER THROMB, V14, P1631, DOI 10.1161/01.ATV.14.10.1631; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SALONEN R, 1991, ULTRASOUND MED BIOL, V17, P225, DOI 10.1016/0301-5629(91)90043-V; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STALENHOEF AFH, 1989, AM J MED A, V4, pS39; SUPERKO HR, 1994, CIRCULATION, V90, P1056, DOI 10.1161/01.CIR.90.2.1056; TATAMI R, 1992, ATHEROSCLEROSIS, V95, P1, DOI 10.1016/0021-9150(92)90170-L; THOMPSON GR, 1995, LANCET, V345, P811, DOI 10.1016/S0140-6736(95)92961-4; VANASTEN WNJC, 1991, SURGERY, V109, P633; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WENDELHAG I, 1993, ARTERIOSCLER THROMB, V13, P1404, DOI 10.1161/01.ATV.13.10.1404; Widmann M D, 1993, Ann Vasc Surg, V7, P446, DOI 10.1007/BF02002128; WIKSTRAND J, 1992, ARTERIOSCLER THROMB, V12, P114, DOI 10.1161/01.ATV.12.1.114; WONG ML, 1993, ARTERIOSCLER THROMB, V13, P482, DOI 10.1161/01.ATV.13.4.482; YAMAMOTO A, 1991, ATHEROSCLEROSIS, V89, P1, DOI 10.1016/0021-9150(91)90002-K; YAMAMOTO K, 1995, NUTR METAB CARDIOVAS, V5, P181	54	81	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					945	+		10.7326/0003-4819-125-12-199612150-00001	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967704	Green Submitted			2023-01-03	WOS:A1996VX76800004
J	Bowman, RJC; Bennett, HGB; Houston, CA; Aitchison, TC; Dutton, GN				Bowman, RJC; Bennett, HGB; Houston, CA; Aitchison, TC; Dutton, GN			Waiting times for and attendance at paediatric ophthalmology outpatient appointments	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW EYE INFIRM,GLASGOW G3 8JE,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8AG,LANARK,SCOTLAND	University of Glasgow	Bowman, RJC (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,TENNENT INST OPHTHALMOL,GLASGOW G11 6NT,LANARK,SCOTLAND.							ALPERT JJ, 1964, PEDIATRICS, V34, P127; CARSTAIRS V, 1992, DEPRIVATION HLTH SCO; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481	3	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1244	1244		10.1136/bmj.313.7067.1244	http://dx.doi.org/10.1136/bmj.313.7067.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939117	Green Published			2023-01-03	WOS:A1996VU20800026
J	Roberts, I; Campbell, F; Hollis, S; Yates, D				Roberts, I; Campbell, F; Hollis, S; Yates, D			Reducing accident death rates in children and young adults: The contribution of hospital care	BRITISH MEDICAL JOURNAL			English	Article							INJURY SEVERITY SCORE; MAJOR TRAUMA	Objective-To assess the contribution of trauma care to the recent decline in accident death rates among children and young people. Design-Logistic regression modelling of temporal trends in the probability of death in patients admitted to hospital for the treatment of severe injury. Setting-Hospitals participating the United Kingdom major trauma outcome study. Subjects-3230 patients with an injury severity score of 16 or more, who were admitted for more than three days, transferred or admitted to intensive care, or died from their injuries. Main outcome measures-Death or survival in hospital within three months of injury. Results-Over the seven year period 1989-95 there was a substantial decline in the probability of death among children and young adults admitted to hospital after severe injury. The overall estimate of the reduction in the odds of death was 16% per year (odds ratio for the yearly trend 0.84; 95% cofidence interval 0.79 to 0.89). This decline did not differ significantly between age groups. (0-4 years 0.79; 5-14 years 0.87; 15-24 years 0.83). Conclusions-Reductions in hospital case fatality have made an important contribution to reaching the Health of the Nation targets. The contribution of hospital care in the reduction of accident mortality should be taken into account in decisions about the allocation of resources to preventive and curative services.	UNIV LONDON,INST CHILD HLTH,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND; UNIV MANCHESTER,MAJOR TRAUMA OUTCOME STUDY,SALFORD M6 8HD,LANCS,ENGLAND; UNIV LANCASTER,MED STAT UNIT,LANCASTER LA1 4YF,ENGLAND; UNIV MANCHESTER,MANCHESTER M6 8HD,LANCS,ENGLAND	University of London; University College London; University of Manchester; Lancaster University; University of Manchester				Hollis, Sally/0000-0003-0156-9189				BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHAMPION HR, 1987, J TRAUMA, V27, P370; *DEP HLTH, 1991, HLTH NATION; *DEP HLTH, 1995, FIT FUTURE 2 PROGR R; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090; ZOLTIE N, 1993, BMJ-BRIT MED J, V307, P906, DOI 10.1136/bmj.307.6909.906	9	66	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1239	1241		10.1136/bmj.313.7067.1239	http://dx.doi.org/10.1136/bmj.313.7067.1239			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939113	Green Published			2023-01-03	WOS:A1996VU20800022
J	Schindler, MB; Bohn, D; Cox, PN; McCrindle, BW; Jarvis, A; Edmonds, J; Barker, G				Schindler, MB; Bohn, D; Cox, PN; McCrindle, BW; Jarvis, A; Edmonds, J; Barker, G			Outcome of out-of-hospital cardiac or respiratory arrest in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC CARDIOPULMONARY-RESUSCITATION; HIGH-DOSE EPINEPHRINE; LIFE-SUPPORT; CARE; EMERGENCY; COST	Background Among adults who have a cardiac arrest outside the hospital, the survival rate is known to be poor. However, less information is available on out-of-hospital cardiac arrest among children. This study was performed to determine the survival rate among children after out-of-hospital cardiac arrest and to identify predictors of survival. Methods We reviewed the records of 101 children (median age, two years) with apnea or no palpable pulse (or both) who presented to the emergency department at the Hospital for Sick Children in Toronto. The characteristics of the patients and the outcomes ;of illness were analyzed. We assessed the functional outcome of the survivors using the Pediatric Cerebral and Overall Performance Category scores. Results Overall, there was a return of vital signs in 64 of the 101 patients; 15 survived to discharge from the hospital, and 13 were alive 12 months after discharge. Factors that predicted survival to hospital discharge included a short interval between the arrest and arrival at the hospital, a palpable pulse on presentation, a short duration of resuscitation in the emergency department, and the administration of fewer doses of epinephrine in the emergency department. No patients who required more than two doses of epinephrine or resuscitation for longer than 20 minutes in the emergency department survived to hospital discharge. The survivors who were neurologically normal after arrest had had a respiratory arrest only and were resuscitated within five minutes after arrival in the emergency department. Of the 80 patients who had had a cardiac arrest, only 6 survived to hospital discharge, and all had neurologic sequelae. Conclusions These results suggest that out-of-hospital cardiac arrest among children has a very poor prognosis, especially when efforts at resuscitation continue for longer than 20 minutes and require more than two doses of epinephrine. (C) 1996, Massachusetts Medical Society.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT CRIT CARE MED,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT CRIT CARE MED,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BARZILAY Z, 1988, J MED, V19, P229; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CORNELI HM, 1992, J PEDIATR-US, V120, P671, DOI 10.1016/S0022-3476(05)80226-4; Emergency Cardiac Care Committee and Subcommittees American Heart Association, 1992, JAMA-J AM MED ASSOC, V268, P2262; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; Fiser D H, 1987, Pediatr Emerg Care, V3, P235, DOI 10.1097/00006565-198712000-00004; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; FISER DH, 1994, CRIT CARE MED, V22, pA212; FRIESEN RM, 1982, CAN MED ASSOC J, V126, P1055; GILLIS J, 1986, CRIT CARE MED, V14, P469, DOI 10.1097/00003246-198605000-00007; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; INNES PA, 1993, ARCH DIS CHILD, V68, P487, DOI 10.1136/adc.68.4.487; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; Nichols D G, 1986, Pediatr Emerg Care, V2, P1, DOI 10.1097/00006565-198603000-00001; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; OMARCAIGH AS, 1993, MAYO CLIN PROC, V68, P332, DOI 10.1016/S0025-6196(12)60126-8; ORLOWSKI JP, 1987, PEDIATR CLIN N AM, V34, P75; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; QUAN L, 1990, PEDIATRICS, V86, P586; RONCO R, 1995, ARCH PEDIAT ADOL MED, V149, P210, DOI 10.1001/archpedi.1995.02170140092017; SHEIKH A, 1994, PEDIATRICS, V93, P392; THOMPSON JE, 1990, PEDIATRICS, V86, P302; WEAVER WD, 1991, NEW ENGL J MED, V325, P1437, DOI 10.1056/NEJM199111143252008; ZARITSKY A, 1987, ANN EMERG MED, V16, P1107, DOI 10.1016/S0196-0644(87)80465-1; ZARITSKY A, 1995, PEDIATRICS, V96, P765	27	195	199	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1473	1479		10.1056/NEJM199611143352001	http://dx.doi.org/10.1056/NEJM199611143352001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890097				2023-01-03	WOS:A1996VT34000001
J	Tao, JS; Sanghera, JS; Pelech, SL; Wong, G; Levy, JG				Tao, JS; Sanghera, JS; Pelech, SL; Wong, G; Levy, JG			Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; C-JUN; PORPHYRIN PHOTOSENSITIZATION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; MAPKAP KINASE-2; PHOSPHORYLATION; TRANSCRIPTION; INDUCTION	The activation state of the members of the mitogen-activated protein kinase family following photodynamic therapy (PDT) with benzoporphyrin derivative monoacid ring A was investigated using a naturally transformed murine keratinocyte cell line, Pam 212. PDT involves the use of photosensitizer molecules and a specific wavelength of visible light. The process of PDT generates singlet oxygen and other reactive oxygen intermediates (ROIs), and the cytotoxic effect of these ROIs is the basis for the use of PDT to treat cancer and psoriasis. PDT caused a strong dose- and time-dependent activation of both stress-activated protein kinase (SAPK) and p38 HOG1. The maximum activation of SAPK and p38 HOG1 occurred between 20 and 30 min following PDT treatment with 200 ng/ml benzoporphyrin derivative monoacid ring A and 2 J/cm(2) of red light at 690 nm. In our system, PDT did not cause significant activation of extracellularly regulated kinase (ERK) 1 and ERK2. Under the same experimental conditions, ultraviolet light irradiation caused strong activation of SAPK and p38 HOG1 and minimum activation of ERK1 and ERK2 in Pam212 cells. A number of ROI scavengers were tested for their effect on PDT-induced SAPK and p38 HOG1 activation. Both L-histidine and N-acetyl-L-cysteine showed a significant inhibitory effect on PDT-induced SAPK and p38 HOG1 activation. This indicated that PDT-induced SAPK and p38 HOG1 activation may be partially mediated by ROI.	UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA; QLT PHOTOTHERAPEUT INC, VANCOUVER, BC V5Z 4H5, CANADA; KINETEK PHARMACEUT INC, VANCOUVER, BC V5Z 1A1, CANADA; STRESSGEN BIOTECHNOL CORP, VICTORIA, BC V8Z 4B9, CANADA	University of British Columbia; University of British Columbia								AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CURRY PM, 1993, PHOTOCHEM PHOTOBIOL, V58, P374, DOI 10.1111/j.1751-1097.1993.tb09577.x; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EVANS S, 1990, J NATL CANCER I, V82, P34, DOI 10.1093/jnci/82.1.34; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GIROTTI A, 1990, PHOTODYNAMIC THERAPY, V1, P229; GOMER CJ, 1991, CANCER RES, V51, P6574; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; GOMER GJ, 1988, LASER SURG MED, V8, P450, DOI 10.1002/lsm.1900080503; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, PROTECTION OXIDANTS, P86; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HENDERSON BW, 1989, CANCER RES, V49, P6896; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRUTMANN J, 1989, J BIOL CHEM, V264, P11407; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LUNA MC, 1994, CANCER RES, V54, P1374; MAI S, 1989, J CELL SCI, V94, P609; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NICKOLOFF BJ, 1993, AM J PATHOL, V143, P325; PELECH SL, 1995, PROTEIN KINASE CIRCU; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND CL, 1996, IN PRESS J IMMUNOL; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27107	27115		10.1074/jbc.271.43.27107	http://dx.doi.org/10.1074/jbc.271.43.27107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900202	hybrid			2023-01-03	WOS:A1996VP23300096
J	Graham, A; Green, L; Glasier, AF				Graham, A; Green, L; Glasier, AF			Teenagers' knowledge of emergency contraception: Questionnaire survey in south east Scotland	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCIES	Objective-To determine the level of knowledge of emergency contraception among 14 and 15 year olds. Design-Confidential questionnaire survey. Setting-10 secondary schools in Lothian, south east Scotland. Subjects-1206 pupils predominantly (98.7%) aged 14 and 15 in the fourth year of secondary school. Main outcome measures-Knowledge of the existence of emergency contraception; of its safety, efficacy, and time limits; and of where to obtain it. Results-1121 (93.0%) fourth year pupils aged 14-16 had heard of emergency contraception. 194 girls (32.7%) and 168 boys (27.5%) had experienced sexual intercourse. Of girls who had experienced sexual intercourse, 61 (31.4%) had used emergency contraception. Knowledge of correct time limits was poor, sexually active girls being the most knowledgeable. Pupils attending schools ranked lower than the national average for academic attainment were less likely to have heard of emergency contraception and more likely to have been sexually active. 861 (76.8%) pupils knew they could obtain emergency contraception from their doctor. 925 (82.5%) pupils believed emergency contraception to be effective but 398 (35.5%) thought it more dangerous than the oral contraceptive pill. Conclusions-One third of sexually active girls aged under 16 in Lothian have used emergency contraception. This may help explain the fairly constant teenage pregnancy rates despite increasing sexual activity. Scottish teenagers are well informed about the existence of emergency contraception. However, many do not know when and how to access it properly. Health education initiatives should target teenagers from less academic schools as they are more likely to be sexually active at a young age and are less well informed about emergency contraception.	EDINBURGH HEALTHCARE NHS TRUST,FAMILY PLANNING & WELL WOMAN SERV,EDINBURGH EH4 1NL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh								ALLABY MAK, 1995, BRIT MED J, V310, P1641, DOI 10.1136/bmj.310.6995.1641; *AUD UN HER MAJ IN, 1995, EX RES SCOTT SCH 199; BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; BURTON R, 1990, BRIT J GEN PRACT, V40, P326; BURTON R, 1990, BR J FAM PLANN, V15, P119; Department of Health, 1992, GEN HOUS SURV; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; GEORGE J, 1994, BRIT J GEN PRACT, V44, P451; Johnson AM, 1994, SEXUAL ATTITUDES LIF; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; MELLANBY AR, 1995, BRIT MED J, V311, P414, DOI 10.1136/bmj.311.7002.414; PEARSON VAH, 1995, BRIT MED J, V310, P1644, DOI 10.1136/bmj.310.6995.1644; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SMITH T, 1993, BRIT MED J, V306, P1232, DOI 10.1136/bmj.306.6887.1232; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857	15	67	67	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1567	1569		10.1136/bmj.312.7046.1567	http://dx.doi.org/10.1136/bmj.312.7046.1567			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664665	Green Published			2023-01-03	WOS:A1996UU80600017
J	Asch, DA				Asch, DA			The role of critical care nurses in euthanasia and assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTARY EUTHANASIA; ATTITUDES	Background. Euthanasia and assisted suicide have received considerable attention recently in medical literature, public discussion, and proposed state legislation. Almost all the discussion in this area has focused on the role of physicians. However, nurses - especially critical care nurses - may be in a special position to understand the wishes of patients and to act on this understanding. Methods. I mailed a survey to 1600 critical care nurses in the United States, asking them to describe anonymously any requests from patients, family members or others acting for patients (surrogates), or physicians to perform euthanasia or assisted suicide, as well as their own practices. Results. Of the 1139 nurses who responded (71 percent), 852 said they practiced exclusively in intensive care units for adults in the United States. Of these 852 nurses, 141 (17 percent) reported that they had received requests from patients or family members to perform euthanasia or assist in suicide; 129 (16 percent of those for whom data were available) reported that they had engaged in such practices; and an additional 35 (4 percent) reported that they had hastened a patient's death by only pretending to provide life-sustaining treatment ordered by a physician. Some nurses reported engaging in these practices without the request or advance knowledge of physicians or others. The method of euthanasia most commonly described was the administration of a high dose of an opiate to a terminally ill patient. Conclusions. As public debate continues about euthanasia and assisted suicide, some critical care nurses in the United States are engaging in such practices. (C) 1995, Massachusetts Medical Society.	VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,CTR BIOETH,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania				Asch, David/0000-0002-7970-286X				*AM NURS ASS, 1994, POS STAT ACT EUTH; ANDERSON JG, 1993, SOC SCI MED, V37, P105, DOI 10.1016/0277-9536(93)90323-V; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ASCH DA, 1995, CRIT CARE MED, V151, P288; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BLACKSHER EA, 1995, HASTINGS CENT REP, V25, P47; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; KUHSE H, 1993, INT J NURS STUD, V30, P311, DOI 10.1016/0020-7489(93)90103-2; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; Kuhse H, 1992, Aust Nurses J, V21, P21; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Stevens C A, 1994, Med Law, V13, P541; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; Young A, 1993, Oncol Nurs Forum, V20, P445; 1988, JAMA-J AM MED ASSOC, V259, P272; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	174	178	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1374	1379		10.1056/NEJM199605233342106	http://dx.doi.org/10.1056/NEJM199605233342106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL251	8614424				2023-01-03	WOS:A1996UL25100006
J	Manome, Y; Wen, PY; Dong, YH; Tanaka, T; Mitchell, BS; Kufe, DW; Fine, HA				Manome, Y; Wen, PY; Dong, YH; Tanaka, T; Mitchell, BS; Kufe, DW; Fine, HA			Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo	NATURE MEDICINE			English	Article							HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ACUTE MYELOCYTIC-LEUKEMIA; HUMAN ADENOVIRUS TYPE-5; DNA POLYMERASE; GENE-TRANSFER; RAT MODEL; ARA-C; ADRIAMYCIN; TRANSPORT; TOXICITY	Cytosine arabinoside (ara-C) is a cytidine analog that incorporates into replicating DNA and induces lethal DNA strand breaks. Although ara-C is a potent antitumor agent for hematologic malignancies, it has only minimal activity against most solid tumors. The rate-limiting step in intracellular ara-C activation is phosphorylation of the prodrug by deoxycytidine kinase (dCK). The present results demonstrate that both retroviral and adenoviral vector-mediated transduction of the dCK cDNA results in marked sensitization of glioma cell lines to the cytotoxic effects of ara-C in vitro. We also demonstrate that ara-C treatment of established intradermal and intracerebral gliomas transduced with dCK results in significant antitumor effects in vivo. These data suggest that viral vector transduction of the dCK gene followed by treatment with ara-C represents a new chemosensitization strategy for cancer gene therapy.	DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27599	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Wen, Patrick/AAE-3776-2022	Manome, Yoshinobu/0000-0002-8755-8976				ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; CADMAN E, 1977, CANCER TREAT REP, V61, P1109; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; COLLY LP, 1984, LEUKEMIA RES, V8, P945, DOI 10.1016/0145-2126(84)90048-1; COLLY LP, 1986, CANCER RES, V46, P3825; COLLY LP, 1982, MED PEDIAT ONCOL S1, V209, P209; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; EARLY AP, 1982, CANCER RES, V42, P1587; ELLISON RR, 1968, BLOOD, V32, P507, DOI 10.1182/blood.V32.4.507.507; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FRAM RJ, 1983, LEUKEMIA RES, V7, P243, DOI 10.1016/0145-2126(83)90014-0; FREEMAN SM, 1993, CANCER RES, V53, P5274; GRAHAM FL, 1970, CANCER RES, V30, P2636; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KOBAYASHI N, 1980, J NEUROSURG, V53, P808, DOI 10.3171/jns.1980.53.6.0808; KUFE D, 1984, BLOOD, V64, P54; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MANOME Y, 1994, CANCER RES, V54, P5408; MANOME Y, 1993, BIOCHEM PHARMACOL, V45, P1677, DOI 10.1016/0006-2952(93)90309-K; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; OHNO Y, 1988, CANCER RES, V48, P1494; PLAGEMANN PGW, 1978, CANCER RES, V38, P978; TAPSCOTT SJ, 1994, P NATL ACAD SCI USA, V91, P8185, DOI 10.1073/pnas.91.17.8185; VAUGHAN WP, 1983, CANCER RES, V43, P2005; WILEY JS, 1982, J CLIN INVEST, V69, P479, DOI 10.1172/JCI110472	35	102	108	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1996	2	5					567	573		10.1038/nm0596-567	http://dx.doi.org/10.1038/nm0596-567			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UJ230	8616717				2023-01-03	WOS:A1996UJ23000041
J	Quill, TE; Lo, B; Brock, DW				Quill, TE; Lo, B; Brock, DW			Palliative options of last resort - A comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WASHINGTON-STATE; PATIENT REQUESTS; DEATH; NETHERLANDS; DOCTORS; OREGON; DIE; ATTITUDES; WILL; CARE	Palliative care is generally agreed to be the standard of care for the dying, but there remain some patients for whom intolerable suffering persists, In the face of ethical and legal controversy about the acceptability of physician-assisted suicide and voluntary active euthanasia, voluntarily stopping eating and drinking and terminal sedation have been proposed as ethically superior responses of last resort that do not require changes in professional standards or the law, The clinical and ethical differences and similarities between these 4 practices are critically compared in light of the doctrine of double effect, the active/passive distinction, patient voluntariness, proportionality between risks and benefits, and the physician's potential conflict of duties, Terminal sedation and voluntarily stopping eating and drinking would allow clinicians to remain responsive to a wide range of patient suffering, but they are ethically and clinically more complex and closer to physician-assisted suicide and voluntary active euthanasia than is ordinarily acknowledged, Safeguards are presented for any medical action that may hasten death, including determining that palliative care is ineffective, obtaining informed consent, ensuring diagnostic and prognostic clarity, obtaining an independent second opinion, and implementing reporting and monitoring processes, Explicit public policy about which of these practices are permissible would reassure the many patients who fear a bad death in their future and allow for a predictable response for the few whose suffering becomes intolerable in spite of optimal palliative care.	UNIV ROCHESTER, SCH MED & DENT, PROGRAM BIOPSYCHOSOCIAL STUDIES, ROCHESTER, NY USA; UNIV CALIF SAN FRANCISCO, PROGRAM MED ETH, SAN FRANCISCO, CA 94143 USA; BROWN UNIV, CTR BIOMED ETH, PROVIDENCE, RI 02912 USA	University of Rochester; University of California System; University of California San Francisco; Brown University					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Admiraal P V, 1995, Ned Tijdschr Geneeskd, V139, P265; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1993, J CLIN ETHIC, V4, P112; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; Byock I R, 1993, J Palliat Care, V9, P25; Cherny N I, 1994, J Palliat Care, V10, P31; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; ENCK RE, 1994, MED CARE TERMINALLY; EVANS JM, 1987, GEN ANESTHESIA, P184; FOLEY KM, 1995, PAIN FORUM, V4, P163; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; *HAST CTR REP, 1987, GUID TERM LIF SUST T; HENDIN H, 1994, ISSUES LAW MED, V10, P123; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; KAMM FM, 1991, J MED PHILOS, V16, P571, DOI 10.1093/jmp/16.5.571; KASTING GA, 1993, PHYSICIAN ASSISTED D, P25; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MARQUIS DB, 1991, J MED PHILOS, V16, P515, DOI 10.1093/jmp/16.5.515; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MOERMAN N, 1993, ANESTHESIOLOGY, V79, P454, DOI 10.1097/00000542-199309000-00007; Morrison R S, 1995, Trends Health Care Law Ethics, V10, P91; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; *PC STUD ETH PROBL, 1982, DEC FOR LIF SUST TRE; PRESTON TA, 1996, J PHARM CARE PAIN SY, V1, P183; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; QUILL TE, 1993, DEATH DIGNITY MAKING, P1; ROLLIN B, 1985, LAST WISH; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; Saunders C., 1993, MANAGEMENT TERMINAL, P1; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; UTTING JE, 1987, GEN ANESTHESIA, P171; van der Maas P. J., 1992, EUTHANASIA OTHER MED; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Ventafridda V, 1990, J Palliat Care, V6, P7; WELIE JVM, 1992, J MED PHILOS, V17, P419, DOI 10.1093/jmp/17.4.419	66	275	279	2	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2099	2104		10.1001/jama.278.23.2099	http://dx.doi.org/10.1001/jama.278.23.2099			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK987	9403426				2023-01-03	WOS:A1997YK98700041
J	Schott, GD				Schott, GD			Bisphosphonates for pain relief in reflex sympathetic dystrophy?	LANCET			English	Editorial Material											Schott, GD (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201; Cortet B, 1997, CLIN RHEUMATOL, V16, P51, DOI 10.1007/BF02238763; DEVOGELAER JP, 1988, J BONE MINER RES  S1, V3, pSI22; Dray A, 1996, PROG BRAIN RES, V110, P85; KOZIN F, 1992, CLIN EXP RHEUMATOL, V10, P401; MAILLEFERT JF, 1995, ANN RHEUM DIS, V54, P687, DOI 10.1136/ard.54.8.687-a; OYEN WJG, 1993, PAIN, V55, P151, DOI 10.1016/0304-3959(93)90144-E; REHMAN MTA, 1992, BONE, V13, P116; SCHOTT GD, 1995, LANCET, V345, P634, DOI 10.1016/S0140-6736(95)90528-6; SELBY PL, 1994, DIABETIC MED, V11, P28, DOI 10.1111/j.1464-5491.1994.tb00225.x; Strang P, 1996, ACTA ONCOL, V35, P50, DOI 10.3109/02841869609083968; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147	12	16	76	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1117	1117		10.1016/S0140-6736(05)63785-3	http://dx.doi.org/10.1016/S0140-6736(05)63785-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343496				2023-01-03	WOS:A1997YB19900005
J	Frank, SH; Stange, KC; Langa, D; Workings, M				Frank, SH; Stange, KC; Langa, D; Workings, M			Direct observation of community-based ambulatory encounters involving medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; PRODUCTIVITY; ATTITUDES; COSTS	Context.-The current shift of predoctoral medical education from inpatient tertiary settings to community-based, ambulatory practice has raised questions about the effect of the medical student on the process of patient care. Objective.-To determine how the presence of a medical student during the ambulatory medical encounter affects the use of clinical time and patient satisfaction. Design.-Cross-sectional, multimethod study using direct observation of ambulatory care by research-trained nurses. Setting.-A total of 16 community-based family practice offices accepting family practice clerkship students. Patients.-A total of 452 outpatient visits with and without student involvement. Main Outcome Measures.-Clinical time use as measured by the Davis Observation Code; patient satisfaction was assessed with the Medical Outcomes Study 9-item visit rating scale. Results.-When students were involved, physicians spent more time discussing visit expectations (P=.03) and less time in history taking (P=.007), providing assessment (P=.01), and answering questions (P=.04), Despite these differences, patients were equally satisfied with explanations received, and there was no change in the rank order of the 5 most commonly observed physician behaviors. There was no difference in time spent in treatment planning, physical examination, health education, or social chatting. The physician spent equal time with the patient with (10.3 minutes) and without (9.9 minutes, P=.6) student involvement, There was no decrease in patient satisfaction when students were involved. Physicians were more likely to discuss another family member's problems when a student was present (P=.001). Students were directed to care for minority patients at a disproportionate rate (P=.001), controlling for confounding variables. Conclusions.-Medical student involvement alters the content but not the duration of the ambulatory medical encounter. Application of validated measures indicate that students did not impair patient satisfaction or hinder the physicians' ability to ensure that patient expectations for the visit were met.	CASE WESTERN RESERVE UNIV, DEPT SOCIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR CANC RES, CLEVELAND, OH 44106 USA; HENRY FORD HLTH SYST, DEPT FAMILY MED, DETROIT, MI USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Henry Ford Health System; Henry Ford Hospital	Frank, SH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT FAMILY MED, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.		Frank, Scott/R-5727-2019	Frank, Scott/0000-0002-2303-5922	NCI NIH HHS [1R01 CA60862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM AC FAM PHYS, 1994, FACTS FAM PRACT; [Anonymous], 1993, ACAD MED, V68, P1; Bertakis K D, 1992, Fam Med, V24, P307; Bertakis K D, 1993, Fam Med, V25, P530; Callahan E J, 1993, Fam Pract Res J, V13, P171; Callahan E J, 1996, Fam Med, V28, P346; Callahan E J, 1991, Fam Med, V23, P19; Crandall L A, 1986, J Rural Health, V2, P7, DOI 10.1111/j.1748-0361.1986.tb00142.x; Delbanco T L, 1988, J Gen Intern Med, V3, pS34, DOI 10.1007/BF02600250; Doyle G A, 1997, Fam Med, V29, P12; FIELDS SA, 1994, ACAD MED, V69, pS87, DOI 10.1097/00001888-199410000-00052; FLOCKE SA, IN PRESS J FAM PRACT; GARG ML, 1991, ACAD MED, V66, P348, DOI 10.1097/00001888-199106000-00009; KEARL GW, 1993, ACAD MED, V68, P166, DOI 10.1097/00001888-199302000-00017; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; PAWLSON LG, 1980, J FAM PRACTICE, V10, P847; PERKOFF GT, 1986, NEW ENGL J MED, V314, P27, DOI 10.1056/NEJM198601023140105; PETERSDORF RG, 1989, JAMA-J AM MED ASSOC, V262, P826, DOI 10.1001/jama.262.6.826; Robbins J A, 1993, Fam Med, V25, P17; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SCHAPPERT SM, 1996, ADV DATA, V273, P1; SIMONS RJ, 1995, J GEN INTERN MED, V10, P251, DOI 10.1007/BF02599880; SOSTOK MA, 1995, ACAD MED, V70, P949, DOI 10.1097/00001888-199511000-00003; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; VINSON DC, 1994, ACAD MED, V69, P237, DOI 10.1097/00001888-199403000-00020; Vinson DC, 1996, J FAM PRACTICE, V42, P243; WARE JE, 1992, MEASURING FUNCTIONIN, P291; YORK NL, 1995, AM J SURG, V169, P421, DOI 10.1016/S0002-9610(99)80189-5	28	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					712	716		10.1001/jama.278.9.712	http://dx.doi.org/10.1001/jama.278.9.712			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286829				2023-01-03	WOS:A1997XT70900022
J	Sulmasy, DP; Lynn, J				Sulmasy, DP; Lynn, J			End-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Sulmasy, DP (corresponding author), GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AMA POLL, 1997, AM MED NEWS     0113, V40, P56; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BACON F, 1905, PHILOS WORKS F BACON, V2, P487; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; ENDE J, 1997, GRADUATE ED INTERNAL; JONES WHS, 1992, HIPPOCRATES, V2, P193; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; *US BUR CENS, 1995, STAT ABSTR US, P86; VITEZ M, 1997, PHILADELPHIA IN 0108, P3; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1996, C ED PHYS DYING APR; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	20	9	9	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1854	1855						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185798				2023-01-03	WOS:A1997XD54400017
J	Webster, NR				Webster, NR			Ventilation in the prone position	LANCET			English	Editorial Material											Webster, NR (corresponding author), UNIV ABERDEEN,ABERDEEN AB25 2ZD,SCOTLAND.							AMIS TC, 1984, RESP PHYSIOL, V56, P145, DOI 10.1016/0034-5687(84)90100-2; BECK KC, 1992, J APPL PHYSIOL, V72, P2292, DOI 10.1152/jappl.1992.72.6.2292; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; Fridrich P, 1996, ANESTH ANALG, V83, P1206, DOI 10.1097/00000539-199612000-00013; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; KRAYER S, 1989, ANESTHESIOLOGY, V70, P891, DOI 10.1097/00000542-198906000-00002; LAMM WJE, 1994, AM J RESP CRIT CARE, V150, P184, DOI 10.1164/ajrccm.150.1.8025748; LANGER M, 1988, CHEST, V94, P103, DOI 10.1378/chest.94.1.103; PAPPERT D, 1994, CHEST, V106, P1511, DOI 10.1378/chest.106.5.1511; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; WEINER CM, 1990, J APPL PHYSIOL, V68, P1386	13	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1638	1639		10.1016/S0140-6736(05)62630-X	http://dx.doi.org/10.1016/S0140-6736(05)62630-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186378				2023-01-03	WOS:A1997XD10000004
J	Busse, P				Busse, P			Strident, but essential: The voices of people with AIDS	BRITISH MEDICAL JOURNAL			English	Article											Busse, P (corresponding author), NAPWA S AFRICA,POB 27262,PO RHINE RD 8050,WESTERN CAPE,SOUTH AFRICA.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					888	889						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093105				2023-01-03	WOS:A1997WQ02800037
J	Emery, S; Cooper, DA				Emery, S; Cooper, DA			Drug companies have a duty to continue treatment	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW 2010,AUSTRALIA	University of New South Wales Sydney; Kirby Institute			Emery, Sean/O-9122-2019; Emery, Sean/J-3825-2017	Emery, Sean/0000-0001-6072-8309; Emery, Sean/0000-0001-6072-8309				*WORLD MED ASS, 1964, WORLD MED ASS HDB DE	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					889	889						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093106				2023-01-03	WOS:A1997WQ02800038
J	Kellett, JM				Kellett, JM			An ethical dilemma - A nurse is suspended	BRITISH MEDICAL JOURNAL			English	Article								A day hospital sister was suspended and given a final formal warning for obeying the request of her consultant to give a patient tranquillising medication in disguise. Though a disciplinary inquiry exonerated the consultant, the action on the nurse has not been rescinded. This case questions the authority of the multidisciplinary team and the role of nursing managers. We asked two geriatricians and forensic scientists to comment on the case.			Kellett, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT GERIATR MED,LONDON SW17 0RE,ENGLAND.								0	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1249	1250		10.1136/bmj.313.7067.1249	http://dx.doi.org/10.1136/bmj.313.7067.1249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939119	Green Published			2023-01-03	WOS:A1996VU20800029
J	Kirby, M				Kirby, M			Human rights and the HIV paradox	LANCET			English	Article								Faced with the grave challenge to public health posed by HIV infection, governments are obliged to ''do something''. One response, which often finds favour with the general public, is to enact laws that criminalise the activities of certain target groups. However, such laws maginalise individuals in these groups and have very little impact on containment of the epidemic. It is far better to introduce measures that protect the rights of people most at risk of infection and thereby encourage and sustain behaviour modification.	INT COMMISS JURISTS,GENEVA,SWITZERLAND		Kirby, M (corresponding author), HIGH COURT AUSTRALIA,POB E435 QUEEN VICTORIA TERRACE,CANBERRA,ACT 2600,AUSTRALIA.								0	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1217	1218		10.1016/S0140-6736(96)05468-2	http://dx.doi.org/10.1016/S0140-6736(96)05468-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ467	8898041				2023-01-03	WOS:A1996VQ46700015
J	Angus, DC; LindeZwirble, WT; Sirio, CA; Rotondi, AJ; Chelluri, L; Newbold, RC; Lave, JR; Pinsky, MR				Angus, DC; LindeZwirble, WT; Sirio, CA; Rotondi, AJ; Chelluri, L; Newbold, RC; Lave, JR; Pinsky, MR			The effect of managed care on ICU length of stay - Implications for Medicare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMPROVING INTENSIVE-CARE; UNITED-STATES; TRADITIONAL INSURANCE; INCEPTION COHORT; MORTALITY; SEVERITY; OUTCOMES; COSTS; PERFORMANCE	Objective.-To determine whether insurance status (managed care vs traditional commercial and Medicare) influences resource consumption (as measured by length of stay [LOS]) in the intensive care unit (ICU). Design.-Retrospective analysis of the 1992 Massachusetts state hospital discharge database, using prospectively developed and validated risk-stratification models. Setting.-All nonfederal hospitals in Massachusetts. Subjects.-Of all adult hospitalizations where an ICU stay was incurred (n=104 270), we selected those covered by 1 of 4 payer groups (n=88 050): (1) commercial fee-for-service (patients aged <65 years); (2) commercial managed care (patients aged <65 years); (3) traditional Medicare (patients aged greater than or equal to 65 years); and (4) Medicare-sponsored managed care (patients aged greater than or equal to 65 years). Main Outcome Measure.-Mean ICU LOS. Analysis.-The ICU LOS regression models were constructed using split-halves validation to adjust for differences in age, sex, severity of illness, diagnosis, discharge status, and payer. Separate models were constructed for those younger than 65 years and those aged 65 years or older. Robustness of the models was explored using goodness of fit and correlation. The effect of payer on hospital mortality was also explored using logistic regression. Observed minus predicted mean ICU LOS and mortality rates were correlated with managed care penetration at the hospital level. Results.-The ICU LOS models performed well (R(2)=0.84 and R(L)(2), [likelihood ratio statistic]=0.92 for the development set, and R(2)=0.83 and R(L)(2)=0.89 for the validation set). Significant covariables affecting LOS included age, severity of principal illness, comorbidity, reason for admission, and discharge status (P<.001 for each). Among the cohort younger than 65 years (n=27 805), although unadjusted mean ICU LOS was shorter (2.9 vs 3.43 days; P<.05) for those covered by managed care organizations, payer status had no independent effect on ICU LOS (P=.48). Among those older than 65 years, there was neither a difference in unadjusted ICU LOS (3.94 vs 3.88 days; P greater than or equal to.05) nor an independent effect of payer on ICU LOS (P=.35). Unadjusted mortality was lower among managed care patients (3.9% vs 5.1% in patients aged < 65 years [P<.05] and 8.7% vs 12.1% in patients aged greater than or equal to 65 years [P<.05]). Age, severity of principal diagnosis, comorbidity, and reason for admission significantly influenced mortality (P<.001), After controlling for these factors with the mortality model (R(L)(2)=0.92 and 0.89, C statistic [12 df]=8.45 and 17.58, and P=.75 and .13 [where a large P reflects good agreement] for the development and validation sets, respectively), payer continued to have a small but significant effect on mortality (odds ratios ranging from 1.67 at 0.1% probability of death to 1.11 at 30% probability of death). Managed care penetration among the commercially insured varied across hospitals (n=82) from 0% to 68%. There was no correlation between managed care penetration and either ICU LOS (R(2)=0.04; P=.09) or mortality (R(2)=0.0; P=.88). Conclusions.-Though patients covered under managed care consume fewer ICU resources, this appears to be primarily attributable to a difference in patient-related factors. Thus, as managed care case mix changes in the future to include sicker and older patients, the initial advantages of reduced resource consumption may diminish.	UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15213 USA; HLTH PROC MANAGEMENT INC, DOYLESTOWN, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Angus, DC (corresponding author), UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL & CRIT CARE MED, DIV CRIT CARE MED, PITTSBURGH, PA 15213 USA.		Angus, Derek C/E-9671-2012					*AG HLTH CAR POL R, 1992, COST FIN ISS HLTH CA, P93; ANGUS DC, 1995, AM J RESP CRIT CARE, V151, pA492; ANGUS DC, 1994, P ASS HLTH SERV RES, P7; ANGUS DC, 1995, CHEST, V108, pS105; ARNOULD RJ, 1984, INQUIRY-J HEALTH CAR, V21, P243; BECK M, 1995, NEWSWEEK        0918, P42; BRADBURY RC, 1991, INQUIRY-J HEALTH CAR, V28, P87; BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; CLERMONT G, 1995, P INT C HLTH POL RES; CLERMONT G, 1996, CRIT CARE MED S1, V24, pA52; DALEY J, 1994, RISK ADJUSTMENT MEAS, P239; DOWD BE, 1986, MED CARE, V24, P694, DOI 10.1097/00005650-198608000-00005; FETTER RB, 1981, NEW ICD 9 CM DIAGN R; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; HANLEY JA, 1988, RADIOLOGY, V168, P568, DOI 10.1148/radiology.168.2.3393683; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILBE J, 1995, XPLORE INTERACTIVE S, P195; HILBE JM, 1994, AM STAT, V48, P255, DOI 10.2307/2684732; IEZZONI L, 1994, P ASS HLTH SERV RES, P21; Iezzoni L I, 1994, Am J Med Qual, V9, P43, DOI 10.1177/0885713X9400900202; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P119; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JOHNSON AN, 1989, INQUIRY-J HEALTH CAR, V26, P388; KNAUS WA, 1982, LANCET, V2, P642; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LAVE JR, 1994, MED CARE, V32, pJS77; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LINDEZWIRBLE WT, 1995, P 155 ANN JOINT STAT; LUFT HS, 1981, HLTH MAINTENANCE ORG; *MA ASS HMOS, 1996, HMO ENR MASS RES 199, P1; MAKLAN CW, 1994, MED CARE, V32, pJS13; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McCullagh P., 1989, GEN LINEAR MODELS, V2nd, DOI [10.1007/978-1-4899-3242-6, DOI 10.1007/978-1-4899-3242-6]; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MITCHELL JB, 1994, MED CARE, V32, pJS38; NAESSENS JM, 1992, MAYO CLIN PROC, V67, P1140, DOI 10.1016/S0025-6196(12)61143-4; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; RAPOPORT J, 1994, CRIT CARE MED, V22, P1385, DOI 10.1097/00003246-199409000-00006; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; RAPOPORT J, 1995, CRIT CARE MED, V23, P1336, DOI 10.1097/00003246-199508000-00006; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; SPRAGGINS EE, 1995, NEWSWEEK        0619, P55; *STAT FL AG HLTH C, 1994, 1994 PAT DAT TAP; *STAT MD, 1993, NONC VERS MAR STAT I; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; *SYST INC, 1983, DIS STAG CLIN BAS AP; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEP HHS, 1988, INT CLASS DIS 9 REV; Wagner D P, 1989, Am Rev Respir Dis, V140, pS14; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005; ZIMMERMAN JE, 1988, CRIT CARE MED, V16, P318, DOI 10.1097/00003246-198804000-00003; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010; ZINNER MJ, 1995, ARCH SURG-CHICAGO, V130, P937; 1995, P INT C HLTH POL RES; 1986, ICU COST BENEFIT ANA, P101; 1994, FED REGISTER, V59, P1951; 1995, HLTH CARE FINANC R S, P24	67	92	93	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1075	1082		10.1001/jama.276.13.1075	http://dx.doi.org/10.1001/jama.276.13.1075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847771				2023-01-03	WOS:A1996VK03500030
J	Golzari, H; Cebul, RD; Bahler, RC				Golzari, H; Cebul, RD; Bahler, RC			Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy	ANNALS OF INTERNAL MEDICINE			English	Review							PARKINSON-WHITE SYNDROME; TACHYCARDIA-INDUCED CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; LEFT-VENTRICULAR DYSFUNCTION; DIRECT-CURRENT CARDIOVERSION; LOW-DOSE AMIODARONE; OPEN-HEART-SURGERY; ACUTE CONVERSION; ELECTRICAL CARDIOVERSION; INTRAVENOUS FLECAINIDE	Purpose: To review the efficacy and safety of electrical and pharmacologic conversion of atrial fibrillation, strategies for maintenance of sinus rhythm, and the importance of antithrombotic therapy. Data Sources: English-language trials were identified from the MEDLINE database through 1995, bibliographic references, Current Contents, textbooks, and recent abstracts. Study Selection: Randomized trials (including abstracts) were selected. Cohort studies were used if randomized trials were not available. Data Extraction: Study design and data were extracted from clinical trials. Statistical analysis of combined data was not appropriate, given the marked variations in study designs and study populations. Data Synthesis: Cardioversion restores sinus rhythm in more than 80% of patients. In atrial fibrillation of recent onset, pharmacologic regimens have a success rate of 40% to 90%. Sinus rhythm at 1 year is maintained in 30% of patients without antiarrhythmic therapy but in 50% of patients with such therapy. The efficacy and safety of antiarrhythmic drugs relative to one another are not established because trials done to date have been small and cases vary. Successful cardioversion and maintenance of sinus rhythm are most predictable when the duration of atrial fibrillation is brief. Warfarin reduces the incidence of ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per year. Aspirin (325 mg/d) appears to be equally effective in patients younger than 75 years of age who do not have hypertension or a history of thromboembolism or recent heart failure. Although warfarin is more effective than aspirin in preventing embolic strokes in patients older than 75 years of age, it may increase the incidence of hemorrhagic stroke and result in a similar rate of disabling stroke. Conclusion: Cardioversion remains the preferred method with which to re-establish sinus rhythm. Longterm antiarrhythmic therapy is warranted only if recurrences or initial clinical instability are seen; pro-arrhythmic concerns and potential side effects should guide drug selection. Antithrombotic therapy is indicated for all patients older than 60 years of age and in all patients younger than 60 yea rs of age who have clinical evidence of a primary cardiac disorder.	METROHLTH MED CTR, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA	MetroHealth System; Case Western Reserve University								ALTAMURA G, 1996, PACING CLIN ELECTR 2, V18, P194; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ASPLUND K, 1993, EUR HEART J, V14, P1427; ATWOOD JE, 1989, AM HEART J, V118, P913, DOI 10.1016/0002-8703(89)90223-8; ATWOOD JE, 1988, J AM COLL CARDIOL, V11, P508, DOI 10.1016/0735-1097(88)91524-0; ATWOOD JE, 1993, HERZ, V18, P27; BAILEY GWH, 1968, ANN INTERN MED, V69, P13, DOI 10.7326/0003-4819-69-1-13; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BIALY D, 1992, Journal of the American College of Cardiology, V19, p41A; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; Boissel J P, 1981, Eur Heart J, V2, P49; BORGGREFE M, 1991, CIRCULATION, V84, P412; BORIANI G, 1995, CHEST, V108, P355, DOI 10.1378/chest.108.2.355; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BRIGNOLE M, 1994, AM J CARDIOL, V74, P242, DOI 10.1016/0002-9149(94)90364-6; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CAMPBELL TJ, 1985, BRIT HEART J, V54, P86; CAMPBELL TJ, 1980, AUST NZ J MED, V10, P644, DOI 10.1111/j.1445-5994.1980.tb04246.x; CAPUCCI A, 1994, INT J CARDIOL, V43, P305, DOI 10.1016/0167-5273(94)90211-9; CAPUCCI A, 1992, AM J CARDIOL, V70, P69, DOI 10.1016/0002-9149(92)91392-H; CAPUCCI A, 1994, AM J CARDIOL, V74, P503, DOI 10.1016/0002-9149(94)90915-6; CASTELLANOS A, 1965, AM J MED SCI, V250, P254, DOI 10.1097/00000441-196509000-00002; CASTELLANOS A, 1965, ARCH INTERN MED, V115, P426, DOI 10.1001/archinte.1965.03860160052009; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1557, DOI 10.1056/NEJM199011293232209; CHUN PKC, 1981, CIRCULATION, V63, P220, DOI 10.1161/01.CIR.63.1.220; CHUN SH, 1995, AM J CARDIOL, V76, P47, DOI 10.1016/S0002-9149(99)80799-1; CIACCHERI M, 1981, ACTA CARDIOL, V36, P125; COLLINS LJ, 1995, CIRCULATION, V92, P160, DOI 10.1161/01.CIR.92.2.160; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CONNOLLY SJ, 1989, AM J CARDIOL, V63, P817, DOI 10.1016/0002-9149(89)90049-0; CONNOLLY SJ, 1987, J AM COLL CARDIOL, V10, P1145, DOI 10.1016/S0735-1097(87)80359-5; COOPER RAS, 1993, CIRCULATION, V87, P1673, DOI 10.1161/01.CIR.87.5.1673; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COUMEL P, 1990, CLIN CARDIOL, V13, P209, DOI 10.1002/clc.4960130311; COUMEL P, 1982, ATRIAL FIBRILLATION, P158; COWAN JC, 1986, J CARDIOVASC PHARM, V8, P252, DOI 10.1097/00005344-198603000-00005; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; CRIJNS HJGM, 1988, EUR HEART J, V9, P634, DOI 10.1093/oxfordjournals.eurheartj.a062553; DALZELL GWN, 1990, Q J MED, V76, P903; DAS G, 1981, PACE, V4, P487, DOI 10.1111/j.1540-8159.1981.tb06215.x; DAVIES MJ, 1972, BRIT HEART J, V34, P520; DAVIES P, 1965, BRIT MED J, V2, P517, DOI 10.1136/bmj.2.5460.517; DAVIS PH, 1987, ANN NEUROL, V22, P319, DOI 10.1002/ana.410220307; DESILVA RA, 1980, AM HEART J, V100, P881, DOI 10.1016/0002-8703(80)90071-X; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; DITTRICH HC, 1989, AM J CARDIOL, V63, P193, DOI 10.1016/0002-9149(89)90284-1; DONOVAN KD, 1995, AM J CARDIOL, V75, P693, DOI 10.1016/S0002-9149(99)80655-9; DONOVAN KD, 1991, AM J CARDIOL, V67, P137, DOI 10.1016/0002-9149(91)90435-N; EDHAG O, 1982, OPUSC MED, V27, P22; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FALK RH, 1991, ANN INTERN MED, V114, P573, DOI 10.7326/0003-4819-114-7-573; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; Feinberg M S, 1995, J Am Soc Echocardiogr, V8, P139, DOI 10.1016/S0894-7317(05)80403-1; FEINBERG WM, 1990, ARCH INTERN MED, V150, P2340, DOI 10.1001/archinte.150.11.2340; FELD GK, 1988, AM HEART J, V115, P102, DOI 10.1016/0002-8703(88)90524-8; FERGUSON TB, 1993, HERZ, V18, P39; FLEGEL KM, 1987, LANCET, V1, P526; FRIEDBER.CK, 1965, CIRCULATION, V32, P89; GARDNER JD, 1982, CHEST, V81, P429, DOI 10.1378/chest.81.4.429; GAVAGHAN TP, 1988, BRIT HEART J, V60, P497; GILLETTE PC, 1985, JAMA-J AM MED ASSOC, V253, P391, DOI 10.1001/jama.253.3.391; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRANDE P, 1986, CIRCULATION, V74, P101; GROGAN M, 1992, AM J CARDIOL, V69, P1570, DOI 10.1016/0002-9149(92)90705-4; GROGONO AW, 1963, LANCET, V2, P1039; GUARNIERI T, 1991, PACE, V14, P1007, DOI 10.1111/j.1540-8159.1991.tb04150.x; GUIRAUDON GM, 1993, HERZ, V18, P51; GUNNING JF, 1970, BRIT HEART J, V32, P462; GUSTAFSSON KS, 1986, CIRCULATION, V74, P101; HALINEN MO, 1995, AM J CARDIOL, V76, P495, DOI 10.1016/S0002-9149(99)80137-4; HALL JI, 1968, BRIT HEART J, V30, P84; HART RG, 1987, ARCH INTERN MED, V147, P636; HARTEL G, 1970, BRIT HEART J, V32, P57; HARTEL G, 1974, CLIN PHARMACOL THER, V15, P551; HEINZ G, 1992, AM J CARDIOL, V69, P489, DOI 10.1016/0002-9149(92)90991-7; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HILLESTAD L, 1972, BRIT HEART J, V34, P139; HJELMS E, 1992, SCAND J THORAC CARD, V26, P193, DOI 10.3109/14017439209099077; HOHNLOSER SH, 1994, ANN INTERN MED, V121, P529, DOI 10.7326/0003-4819-121-7-199410010-00009; HOLZMAN D, 1951, AM J MED SCI, V222, P644, DOI 10.1097/00000441-195112000-00005; HOU ZY, 1995, EUR HEART J, V16, P521, DOI 10.1093/oxfordjournals.eurheartj.a060945; JACK CM, 1987, IRISH J MED SCI, V156, P330, DOI 10.1007/BF02951266; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JANSSEN J, 1986, ANGIOLOGY, V37, P601, DOI 10.1177/000331978603700807; JATENE MB, 1994, CIRCULATION, V90, P595; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KALMAN JM, 1992, PACE, V15, P1332; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; KARLSON BW, 1988, EUR HEART J, V9, P284, DOI 10.1093/oxfordjournals.eurheartj.a062498; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KENNELLY BM, 1977, BRIT HEART J, V39, P540; KIENY JR, 1992, EUR HEART J, V13, P1290, DOI 10.1093/oxfordjournals.eurheartj.a060351; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KONDILI A, 1990, WIEN KLIN WOCHENSCHR, V102, P510; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOPELMAN HA, 1989, PROG CARDIOVASC DIS, V31, P355, DOI 10.1016/0033-0620(89)90030-3; KOSAKAI Y, 1994, CIRCULATION, V90, P587; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOWEY PR, 1992, AM J CARDIOL, V69, P963, DOI 10.1016/0002-9149(92)90802-6; KOWEY PR, 1979, CIRCULATION, V60, P253; KUMAGAI K, 1991, PACE, V14, P1571, DOI 10.1111/j.1540-8159.1991.tb02730.x; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEVINE PA, 1983, J AM COLL CARDIOL, V1, P1413, DOI 10.1016/S0735-1097(83)80044-8; LEVY S, 1988, J AM COLL CARDIOL, V12, P514, DOI 10.1016/0735-1097(88)90428-7; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; LEVY S, 1992, CLIN CARDIOL, V15, P445, DOI 10.1002/clc.4960150611; LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X; LINDSAY J, 1967, AM HEART J, V74, P434, DOI 10.1016/0002-8703(67)90086-5; LLOYD EA, 1984, S AFR MED J, V65, P367; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; LOWN B, 1967, BRIT HEART J, V29, P469; LOWN B, 1962, AM J CARDIOL, V10, P223, DOI 10.1016/0002-9149(62)90299-0; MADRID AH, 1993, EUR HEART J, V14, P1127, DOI 10.1093/eurheartj/14.8.1127; MANNING WJ, 1994, J AM COLL CARDIOL, V23, P1535, DOI 10.1016/0735-1097(94)90652-1; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1989, J AM COLL CARDIOL, V13, P617, DOI 10.1016/0735-1097(89)90602-5; MCALISTER HF, 1990, J THORAC CARDIOV SUR, V99, P911; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCARTHY C, 1969, BRIT HEART J, V31, P496; MCLARAN CJ, 1985, BRIT HEART J, V53, P323; MEIJLER FL, 1985, J AM COLL CARDIOL, V5, pB17, DOI 10.1016/S0735-1097(85)80520-9; MEIJLER FL, 1985, J AM COLL CARDIOL, V5, pA60, DOI 10.1016/S0735-1097(85)80464-2; MIDDLEKAUFF HR, 1992, ANN INTERN MED, V116, P1017, DOI 10.7326/0003-4819-116-12-1017; MOREIRA DAR, 1989, PACE, V12, P761, DOI 10.1111/j.1540-8159.1989.tb01898.x; MOREYRA E, 1995, AM HEART J, V129, P71, DOI 10.1016/0002-8703(95)90045-4; MOSTOW ND, 1990, AM HEART J, V120, P1356, DOI 10.1016/0002-8703(90)90248-V; MURGATROYD FD, 1995, J AM COLL CARDIOL, V25, P1347, DOI 10.1016/0735-1097(94)00555-5; Noble R J, 1973, Cardiovasc Clin, V5, P97; NOC M, 1990, AM J CARDIOL, V65, P679, DOI 10.1016/0002-9149(90)91053-9; NORMAND JP, 1976, BRIT HEART J, V38, P381; OKEEFFE DB, 1984, BRIT HEART J, V51, P103; OLSSON SB, 1980, ACTA MED SCAND, V207, P5; ORMEROD OJM, 1984, BRIT HEART J, V51, P618; PACKER DL, 1986, AM J CARDIOL, V57, P563, DOI 10.1016/0002-9149(86)90836-2; PAULK EA, 1965, AM HEART J, V70, P248, DOI 10.1016/0002-8703(65)90074-8; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PHILLIPS E, 1949, AM J MED, V7, P478, DOI 10.1016/0002-9343(49)90397-6; PILATI G, 1991, CURR THER RES CLIN E, V49, P140; PLATIA EV, 1989, AM J CARDIOL, V63, P925, DOI 10.1016/0002-9149(89)90141-0; PODRID PJ, 1993, HERZ, V18, P9; PORTERFIELD JG, 1989, AM J CARDIOL, V63, P114, DOI 10.1016/0002-9149(89)91091-6; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; PRITCHETT ELC, 1988, AM J CARDIOL, V62, pD1; RASMUSSEN K, 1988, European Heart Journal, V9, P52; RASMUSSEN K, 1981, ACTA MED SCAND, P23; RAWLES JM, 1990, BRIT HEART J, V63, P225; REIMOLD SC, 1993, AM J CARDIOL, V71, P558, DOI 10.1016/0002-9149(93)90511-A; RESNEKOV L, 1967, BRIT HEART J, V29, P700; RESNEKOV L, 1976, MED CLIN N AM, V60, P325, DOI 10.1016/S0025-7125(16)31913-7; RESNEKOV L, 1971, BRIT HEART J, V33, P339; ROBERTS SA, 1993, AM J CARDIOL, V72, P567, DOI 10.1016/0002-9149(93)90353-E; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; ROWLAND E, 1986, BRIT J CLIN PRACT, V40, P39; SANFILIPPO AJ, 1990, CIRCULATION, V82, P792, DOI 10.1161/01.CIR.82.3.792; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; Santos A L, 1979, Acta Med Port, V1, P15; SAREMBOCK IJ, 1988, S AFR MED J, V73, P484; Scott M E, 1968, Ulster Med J, V37, P155; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHAPIRO W, 1968, CIRCULATION, V38, P1074, DOI 10.1161/01.CIR.38.6.1074; SHAVER JA, 1965, AM J CARDIOL, V15, P146, DOI 10.1016/0002-9149(65)90677-6; SIMON RP, 1991, MED KNOWLEDGE SELF A, P104; SIMS BA, 1972, BRIT HEART J, V34, P336; SINGH S, 1991, AM J CARDIOL, V68, P1227, DOI 10.1016/0002-9149(91)90200-5; SODERMARK T, 1975, BRIT HEART J, V37, P486; SOMBERG JC, 1983, CIRCULATION, V68, P56; STODDARD MF, 1995, AM HEART J, V129, P1204, DOI 10.1016/0002-8703(95)90405-0; SUAREZ GS, 1991, CLIN CARDIOL, V14, P652, DOI 10.1002/clc.4960140806; SUN JP, 1988, J CARDIOVASC ULTRAS, V7, P247; SUTTON RB, 1970, CHEST, V57, P191, DOI 10.1378/chest.57.2.191; SUTTORP MJ, 1989, AM J CARDIOL, V63, P693, DOI 10.1016/0002-9149(89)90253-1; SUTTORP MJ, 1990, J AM COLL CARDIOL, V16, P1722, DOI 10.1016/0735-1097(90)90326-K; SWARTZ JF, 1994, CIRCULATION, V90, P335; SZEKELY P, 1964, BMJ-BRIT MED J, V1, P1209, DOI 10.1136/bmj.1.5392.1209; THOMSON GW, 1956, CIRCULATION, V14, P757, DOI 10.1161/01.CIR.14.5.757; TISCHLER MD, 1990, AM J CARDIOL, V66, P721, DOI 10.1016/0002-9149(90)91137-U; TOIVONEN LK, 1986, BRIT HEART J, V55, P176; TOUBOUL P, 1991, CIRCULATION, V84, P127; UESHIMA K, 1993, AM HEART J, V125, P1301, DOI 10.1016/0002-8703(93)90998-O; UPKIN DP, 1988, BRIT HEART J, V59, P572; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; VANGELDER IC, 1993, AM J CARDIOL, V72, P560, DOI 10.1016/0002-9149(93)90352-D; VANGELDER IC, 1989, AM J CARDIOL, V64, P1317, DOI 10.1016/0002-9149(89)90574-2; VITA JA, 1989, AM J CARDIOL, V63, P1275, DOI 10.1016/0002-9149(89)90191-4; VITOLO E, 1981, ACTA CARDIOL, V36, P431; WAFA SS, 1989, AM J CARDIOL, V63, P1058, DOI 10.1016/0002-9149(89)90078-7; WAGNER G S, 1969, Progress in Cardiovascular Diseases, V11, P431, DOI 10.1016/0033-0620(69)90030-9; WHEELDON NM, 1995, EUR HEART J, V16, P302, DOI 10.1093/oxfordjournals.eurheartj.a060911; WHITE HD, 1994, LANCET, V343, P683, DOI 10.1016/S0140-6736(94)91573-3; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; WOO KS, 1980, CIRCULATION, V62, P181; YIGITBASI O, 1967, CARDIOLOGIA, V51, P307, DOI 10.1159/000165826; 1993, LANCET, V342, P1255; 1983, STROKE, V14, P668	205	70	72	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					311	323		10.7326/0003-4819-125-4-199608150-00010	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678396				2023-01-03	WOS:A1996VB68000013
J	Kaiser, L; Lew, D; Hirschel, B; Auckenthaler, R; Morabia, A; Heald, A; Benedict, P; Terrier, F; Wunderli, W; Matter, L; Germann, D; Voegeli, J; Stalder, H				Kaiser, L; Lew, D; Hirschel, B; Auckenthaler, R; Morabia, A; Heald, A; Benedict, P; Terrier, F; Wunderli, W; Matter, L; Germann, D; Voegeli, J; Stalder, H			Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions	LANCET			English	Article							SINUSITIS; COMMUNITY	Background Upper-respiratory-tract infection is one of the main causes of overuse of antibiotics. We have found previously that bacteria such as Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae can be isolated from the nasopharyngeal secretions of a substantial proportion of adults with upper-respiratory-tract infections, We have assessed the efficacy of co-amoxiclav in patients with common colds but no clinical signs of sinusitis or other indications for antibiotics, Methods Between January, 1992, and March, 1994, 314 patients who presented to our outpatient clinic with common colds were enrolled in the double-blind, placebo-controlled study. They were randomly assigned 5 days' treatment with co-amoxiclav (375 mg three times daily) or identical placebo. Clinical examinations were done at enrolment and on day 5-7 to assess outcome (cured, persistent symptoms, worse symptoms). Seven patients were excluded after randomisation, seven did not have nasopharyngeal aspiration, and 12 did not return for followup assessment. Findings Of 300 patients with nasopharyngeal aspirates, 72 had negative bacterial cultures, 167 had cultures positive only for bacteria unrelated to respiratory infections, and 61 had cultures positive for H influenzae, M catarrhalis, or S pneumoniae. At 5-day follow-up of these culture-positive patients, the distribution of outcome was significantly better among co-amoxiclav-treated (n=30) than placebo-treated (n=28) patients (cured 27 vs 4%; persistent symptoms 70 vs 60%; worse symptoms 3 vs 36%; p=0.001). Patients on co-amoxiclav also scored their symptoms significantly lower than patients on placebo (p=0.008). Among culture-negative patients (n=230), the outcome distribution did not differ between the treatment groups(p=0.392). Interpretation The majority of patients with upper-respiratory-tract infection do not benefit from antibiotics and side-effects are frequent. However, for the subgroup whose nasopharyngeal secretions contain H influenzae, M catarrhalis, or S pneumoniae, antibiotics are clinically beneficial.	UNIV HOSP GENEVA,DIV CLIN EPIDEMIOL,CH-1211 GENEVA,SWITZERLAND; UNIV HOSP GENEVA,MED POLICLIN,CH-1211 GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DIV RADIODIAGNOST & INTERVENT RADIOL,CH-1211 GENEVA,SWITZERLAND; UNIV HOSP GENEVA,CENT LAB VIROL,CH-1211 GENEVA,SWITZERLAND; UNIV BERN,INST MED MICROBIOL,BERN,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Bern	Kaiser, L (corresponding author), UNIV HOSP GENEVA,DIV INFECT DIS,RUE MICHELI-DU-CREST 24,CH-1211 GENEVA,SWITZERLAND.							AGRESTI A, 1990, MULTINOMIAL RESPONSE, P315; DOUGLAS RG, 1986, NEW ENGL J MED, V314, P114, DOI 10.1056/NEJM198601093140209; DRUCE HM, 1994, MICROBIOLOGY SINUSIT, P41; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Gwaltney J.M., 1995, PRINCIPLES PRACTICE, V4th ed., P561; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HARDY LM, 1956, J PEDIATR-US, V48, P146, DOI 10.1016/S0022-3476(56)80160-1; HEALD A, 1993, J GEN INTERN MED, V8, P667, DOI 10.1007/BF02598283; HOAGLAND RJ, 1950, NEW ENGL J MED, V243, P773, DOI 10.1056/NEJM195011162432003; JONES PN, 1953, JAMA-J AM MED ASSOC, V153, P262, DOI 10.1001/jama.1953.02940210004002; JOUSIMIESSOMER HR, 1989, J CLIN MICROBIOL, V27, P2736, DOI 10.1128/JCM.27.12.2736-2743.1989; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SOYKA LF, 1975, PEDIATRICS, V55, P552; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; 1965, BRIT MED J, V2, P319	21	137	140	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1507	1510		10.1016/S0140-6736(96)90670-4	http://dx.doi.org/10.1016/S0140-6736(96)90670-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684101	Bronze			2023-01-03	WOS:A1996UN47300009
J	Chisholm, A; Mann, J; Sutherland, W; Duncan, A; Skeaff, M; Frampton, C				Chisholm, A; Mann, J; Sutherland, W; Duncan, A; Skeaff, M; Frampton, C			Effect on lipoprotein profile of replacing butter with margarine in a low fat diet: Randomised crossover study with hypercholesterolaemic subjects	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; SERUM-LIPIDS; ACIDS; PLASMA; CHOLESTEROL; DENSITY; HUMANS	Objective-To examine the effect on lipid and lipoprotein concentrations when butter or an unsaturated margarine is used for cooking or spreading in a reduced fat diet. Design-Randomised crossover study with two intervention periods of six weeks' duration separated by a five week washout. Setting-Community setting in New Zealand. Subjects-49 volunteers with polygenic hypercholesterolaemia and baseline total cholesterol concentration in the range 5.5-7.9 mmol/l. Main outcome measures-Concentrations of total and low density lipoprotein, Lp(a) lipoprotein, high density lipoprotein, apolipoprotein B 100, and apolipoprotein A I. Results-Concentrations of low density lipoprotein cholesterol and apolipoprotein B were about 10% lower with margarine than with butter. Lp(a) lipoprotein and high density lipoprotein cholesterol concentrations were similar with the two diets. Conclusion-Despite concerns about adverse effects on lipoproteins of trans fatty acids in margarines, the use of unsaturated margarine rather than butter by hypercholesterolaemic people is associated with a lipoprotein profile that would be expected to reduce cardiovascular risk.	UNIV OTAGO,DEPT HUMAN NUTR,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND; LINCOLN UNIV,CTR COMP & BIOMETR,CANTERBURY,NEW ZEALAND	University of Otago; University of Otago; Lincoln University - New Zealand			Skeaff, Clark/C-2713-2009					ASSMAN G, 1993, CLIN CHEM, V29, P2026; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROOK JG, 1989, EUR HEART J, V10, P702, DOI 10.1093/oxfordjournals.eurheartj.a059554; CONNOR WE, 1989, ARTERIOSCLEROSIS S, V1, P91; FOLEY M, 1992, EUR J CLIN NUTR, V46, P429; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUMERON F, 1991, AM J CLIN NUTR, V53, P655, DOI 10.1093/ajcn/53.3.655; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; SACKS FM, 1986, ARCH INTERN MED, V146, P1573, DOI 10.1001/archinte.146.8.1573; THOLSTRUP T, 1994, AM J CLIN NUTR, V60, P919, DOI 10.1093/ajcn/60.6.919; WAHLE KWJ, 1993, EUR J CLIN NUTR, V47, P828; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WOOD R, 1993, J LIPID RES, V34, P1; ZOCK PL, 1992, J LIPID RES, V33, P399; 1994, CIRCULATION, V89, P1336; 1991, ARCH INTERN MED, V151, P1071; 1992, NUTR METAB, V2, P113	22	40	41	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					931	934						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616303	Green Published			2023-01-03	WOS:A1996UF65900015
J	Pedrini, MT; Levey, AS; Lau, J; Chalmers, TC; Wang, PH				Pedrini, MT; Levey, AS; Lau, J; Chalmers, TC; Wang, PH			The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article						dietary proteins; meta-analysis; kidney failure, chronic; diabetic nephropathies; albuminuria	CLINICAL-TRIALS; NEPHROPATHY; FAILURE; INSUFFICIENCY; METAANALYSIS	Background: Dietary protein has long been thought to play a role in the progression of chronic renal disease, but clinical trials to date have not consistently shown that dietary protein restriction is beneficial. Purpose: To use meta-analysis to assess the efficacy of dietary protein restriction in previously published studies of diabetic and nondiabetic renal diseases, including the recently completed Modification of Diet in Renal Disease Study. Data Sources: The English-language medical literature published from January 1966 through December 1994 was searched for studies examining the effect of low-protein diets in humans with chronic renal disease. A total of 1413 patients in five studies of nondiabetic renal disease (mean length of follow-up, 18 to 36 months) and 108 patients in five studies of type I diabetes mellitus (mean length of follow-up, 9 to 35 months) were included. Study Selection: Randomized, controlled studies were selected for nondiabetic renal disease; randomized, controlled studies or time-controlled stud ies with non randomized crossover design were selected for diabetic nephropathy. Data Extraction: Data in tables, figures, or text were independently extracted by two of the authors. Data Synthesis: The relative risk for progression of renal disease in patients receiving a low-protein diet compared with patients receiving a usual-protein diet was calculated by using a random-effects model. In five studies of nondiabetic renal disease, a low-protein diet significantly reduced the risk for renal failure or death (relative risk, 0.67 [95% CI, 0.50 to 0.89]). In five studies of insulin-dependent diabetes mellitus, a low-protein diet significantly slowed the increase in urinary albumin level or the decline in glomerular filtration rate or creatinine clearance (relative risk, 0.56 [CI, 0.40 to 0.77]). Tests for heterogeneity showed no significant differences in relative risk among studies of either diabetic or nondiabetic renal disease. No significant differences were seen between diet groups in pooled mean arterial blood pressure (diabetic and nondiabetic patients) or glycosylated hemoglobin level (diabetic patients only). Conclusion: Dietary protein restriction effectively slows the progression of both diabetic and nondiabetic renal diseases.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV NEPHROL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DIV CLIN CARE RES, BOSTON, MA 02111 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA	Tufts Medical Center; Tufts Medical Center; University of California System; University of California Irvine								BARSOTTI G, 1988, CLIN NEPHROL, V29, P280; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; CLAVARELLA A, 1987, DIABETES CARE, V10, P407; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; DULLAART RPF, 1993, DIABETES CARE, V16, P483, DOI 10.2337/diacare.16.2.483; FOUQUE D, 1992, BMJ-BRIT MED J, V304, P216, DOI 10.1136/bmj.304.6821.216; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; JUNGERS P, 1987, KIDNEY INT, V32, pS67; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LEVEY AS, 1996, IN PRESS AM J KIDNEY; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; PARVING HH, 1985, HYPERTENSION, V7, P114; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROSMAN JB, 1989, KIDNEY INT, V36, pS96; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STRIKER G, 1995, J AM SOC NEPHROL, V5, P1537; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; WALKER JD, 1989, LANCET, V2, P1411; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WILLIAMS PS, 1991, Q J MED, V81, P837; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	25	488	520	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					627	+		10.7326/0003-4819-124-7-199604010-00002	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607590				2023-01-03	WOS:A1996UB51300002
J	Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Peramaki, E; Poussa, T; Saarelainen, S; Svahn, T				Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Peramaki, E; Poussa, T; Saarelainen, S; Svahn, T			Randomised comparison of guided self management and traditional treatment of asthma over one year	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ADULT ASTHMA; PEAK FLOW; EDUCATION; TRIAL	Objective-To compare the efficacy of self management of asthma with traditional treatment. Design-12 month prospective randomised trial. Setting-Outpatient clinics in Finland. Subjects-115 patients with mild to moderately severe asthma. Interventions-Patient education and adjustment of anti-inflammatory therapy guided by peak flow measurements. Main outcome measures-Unscheduled admissions to hospital and outpatient visits, days off work, courses of antibiotics and prednisolone, lung function, and quality of life. Results-The mean number of unscheduled visits to ambulatory care facilities (0.5 v 1.0), days off work (2.8 v 4.8), and courses of antibiotics (0.4 v 0.9) and prednisolone (0.4 v 1.0) per patient were lower and the quality of life score (16.6 v 8.4 at 12 months) higher in the self management group than in the traditionally treated group. In both groups admissions for asthma were rare. Conclusions-Self management reduces incidents caused by asthma and improves quality of life.	UNIV HELSINKI,CENT HOSP,SKIN & ALLERGY HOSP,SF-00250 HELSINKI,FINLAND; CENT HOSP NO KARELIA,DEPT PULM DIS,SF-80780 KONTIONIEMI,FINLAND; STAT CONSULTING,SF-33300 TAMPERE,FINLAND; SUOMEN ASTRA OY,SF-02430 MASALA,FINLAND	University of Helsinki; Helsinki University Central Hospital	Lahdensuo, A (corresponding author), TAMPERE UNIV HOSP,DEPT PULM DIS,SF-36280 PIKONLINNA,FINLAND.		Herrala, Jaakko/L-9797-2013	Herrala, Jaakko/0000-0002-6524-1759				[Anonymous], 1993, THORAX, V48, pS1; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BLAINEY AD, 1991, HLTH TRENDS, V22, P151; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; DSOUZA W, 1994, EUR RESPIR J, V7, P1260, DOI 10.1183/09031936.94.07071260; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HILTON S, 1986, LANCET, V1, P26; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; JAMISON JP, 1990, THORAX, V45, pP341; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; KINSMAN RA, 1980, J PSYCHOSOM RES, V24, P97, DOI 10.1016/0022-3999(80)90059-8; KLEIGER JH, 1979, J ASTHMA RES, V16, P93, DOI 10.3109/02770907909106618; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; *NAT HEART LUNG BL, 1992, NIH PUBL; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; PARTRIDGE MR, 1993, RES CLIN FORUMS, V15, P65; REEDER KP, 1990, J ASTHMA, V27, P219, DOI 10.3109/02770909009073330; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; 1994, BRIT MED J, V308, P564	27	257	264	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					748	752						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605463				2023-01-03	WOS:A1996UC16600030
J	Muir, KW				Muir, KW			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Muir, KW (corresponding author), SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,LANARK,SCOTLAND.		Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; Ciccone, Alfonso/0000-0002-4590-3575				MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7; TOGNONI G, 1995, LANCET, V346, P1515, DOI 10.1016/S0140-6736(95)92050-1; 1995, NEW ENGL J MED, V333, P1581	5	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					391	391		10.1016/S0140-6736(96)90568-1	http://dx.doi.org/10.1016/S0140-6736(96)90568-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598711				2023-01-03	WOS:A1996TU69500038
J	Barraclough, J				Barraclough, J			ABC of palliative care - Depression, anxiety, and confusion	BRITISH MEDICAL JOURNAL			English	Review											Barraclough, J (corresponding author), CHURCHILL HOSP,OXFORD RADCLIFFE NHS TRUST,OXFORD,ENGLAND.								0	33	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1365	1368		10.1136/bmj.315.7119.1365	http://dx.doi.org/10.1136/bmj.315.7119.1365			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402782	Green Published			2023-01-03	WOS:A1997YJ21800030
J	vanWeel, C; Michels, J				vanWeel, C; Michels, J			Dying, not old age, to blame for costs of health care	LANCET			English	Article											vanWeel, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				GREENBERG I, 1997, HLTH SERV RES, V31, P723; Perls TT, 1996, ARCH INTERN MED, V156, P754, DOI 10.1001/archinte.156.7.754; RUWAARD D, 1997, VOLKSGEZONDHEID TOEK; van Noordt M, 1992, Gesundheitswesen, V54, P173; *VAND HLTH STAT NE, 1996, STAT NETH; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17	6	27	27	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1159	1160		10.1016/S0140-6736(97)08312-8	http://dx.doi.org/10.1016/S0140-6736(97)08312-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343516	Green Submitted			2023-01-03	WOS:A1997YB19900044
J	Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD				Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD			Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: A thrombolytic predictive instrument	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-CARE-UNIT; TISSUE PLASMINOGEN-ACTIVATOR; ACUTE CARDIAC ISCHEMIA; QRS SCORING SYSTEM; RANDOMIZED TRIAL; CLINICAL-TRIAL; THERAPY; MULTICENTER; MORTALITY; STREPTOKINASE	Background: Thrombolytic therapy can be life-saving in patients with acute myocardial infarction. However, if given too late or insufficiently selectively, it may provide little benefit but still cause serious complications and incur substantial costs. Objective: To develop a thrombolytic predictive instrument for real-time use in emergency medical service settings that could 1) identify patients likely to benefit from thrombolysis and 2) facilitate the earliest possible use of this therapy. Design: Creation and validation of logistic regression-based predictive instruments based on secondary analysis of clinical data. Patients: 4911 patients who had acute myocardial infarction and ST-segment elevation on electrocardiogram; 3483 received thrombolytic therapy. Measurements: Data were obtained from 13 major clinical trials and registries and directly from medical records, including electrocardiograms obtained at presentation. Input variables include presenting clinical and electrocardiographic features; predictive models generate probabilities for acute (30-day) mortality if and if not treated with thrombolysis, 1-year mortality rates if and if not treated with thrombolysis, cardiac arrest if and if not treated with thrombolysis, thrombolysis-related intracranial hemorrhage, and thrombolysis-related major bleeding episode requiring transfusion. Together, these models constitute the thrombolytic predictive instrument. Results: The predictive models generated the following mean predictions for patients in the Thrombolytic Predictive Instrument Database: 30-day mortality rate, 7.1%; 1-year mortality rate, 10.9%; rate of cardiac arrest, 3.7%; rate of thrombolysis-related intracranial hemorrhage, 0.6%; and rate of other thrombolysis-related major bleeding episodes, 5.0%. They discriminated well between persons having and those not having the predicted outcome; areas under the receiver-operating characteristic (ROC) curve were between 0.77 and 0.84 for the five outcomes. Calibration between each instrument's predicted and observed rates was excellent. Validation of the predictive instruments for 30-day and 1-year mortality, done on a separate test dataset, yielded areas under the ROC curve of 0.76 for each. Conclusions: After the basic features of a clinical presentation are entered into a computerized electrocardiograph, the predictions of the thrombolytic predictive instrument can be printed on the electrocardiogram report. This decision aid may facilitate earlier and more appropriate use of thrombolytic therapy in patients with acute myocardial infarction.	BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DUKE UNIV, MED CTR, DURHAM, NC 27705 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, LOS ANGELES, CA 90024 USA	Boston University; Duke University; University of Washington; University of Washington Seattle; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Selker, HP (corresponding author), TUFTS UNIV, CTR CARDIOVASC HLTH SERV RES, DIV CLIN CARE RES, SCH MED, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA.		Maynard, Charles/N-3906-2015; Schmid, Christopher H./J-2398-2014	Maynard, Charles/0000-0002-1644-7814; Schmid, Christopher H./0000-0002-0855-5313	AHRQ HHS [R01 HS06208] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; ANDERSON WD, 1988, AM J CARDIOL, V61, P729, DOI 10.1016/0002-9149(88)91056-9; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CAIRNS CB, 1992, J ELECTROCARDIOL, V24, P46; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CENTOR RM, 1991, MED DECIS MAKING, V11, P102, DOI 10.1177/0272989X9101100205; CHAMBERS JM, 1992, STAT MODELS S, P249; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Gunnar R M, 1990, Circulation, V82, P664; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P95; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LAROSA JH, 1992, P NAT HEART LUNG BLO; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MAYNARD C, 1995, MED DECIS MAKING, V15, P38, DOI 10.1177/0272989X9501500107; Midgette AS, 1996, AM J CARDIOL, V78, P389, DOI 10.1016/S0002-9149(96)00325-6; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; *SAS I INC, 1989, SAS STAT US GUID VER, P1077; SCHMID CH, 1997, IN PRESS J CLIN EPID; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; SELKER HP, 1994, MED CARE, V32, P1040, DOI 10.1097/00005650-199410000-00005; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SELKER HP, 1995, J INVEST MED, V43, P468; SELKER HP, 1989, AM J MED, V87, P491; SELKER HP, 1994, CIRCULATION, V90, P1657, DOI 10.1161/01.CIR.90.4.1657; SELKER HP, 1992, THROMBOLYTIC PREDICT, P9; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Wall T C, 1989, N C Med J, V50, P363; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211	45	69	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					538	556		10.7326/0003-4819-127-7-199710010-00006	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00006			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313022				2023-01-03	WOS:A1997XY73300006
J	Gilbert, DN; Dworkin, RJ; Raber, SR; Leggett, JE				Gilbert, DN; Dworkin, RJ; Raber, SR; Leggett, JE			Outpatient parenteral antimicrobial-drug therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CENTRAL VENOUS CATHETERS; INTRAVENOUS ANTIBIOTIC-THERAPY; LUMEN SUBCLAVIAN CATHETERS; VENA-CAVA SYNDROME; STAPHYLOCOCCUS-EPIDERMIDIS; HOSPITALIZED-PATIENTS; POLYVINYL-CHLORIDE; RANDOMIZED TRIAL; INFECTION-RATE; INFUSION-PUMP		OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201	Oregon Health & Science University	Gilbert, DN (corresponding author), PROVIDENCE PORTLAND MED CTR,DEPT MED EDUC,EARLE A CHILES RES INST,5050 NE HOYT,SUITE 540,PORTLAND,OR 97213, USA.							ADAMS KS, 1993, AM J INFECT CONTROL, V21, P263, DOI 10.1016/0196-6553(93)90419-5; ANTONISKIS A, 1978, WESTERN J MED, V128, P203; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; ASHKENAZI S, 1986, J LAB CLIN MED, V107, P136; BAUCH TD, 1992, JPEN-PARENTER ENTER, V16, P175, DOI 10.1177/0148607192016002175; BIRDWELL BG, 1994, ARCH INTERN MED, V154, P808; BLACK MD, 1993, CHEST, V103, P1887, DOI 10.1378/chest.103.6.1887; *CDCP, 1995, FED REGISTER, V60, P49978; CLARKCHRISTOFF N, 1992, JPEN-PARENTER ENTER, V16, P403, DOI 10.1177/0148607192016005403; CONLY JM, 1989, J INFECT DIS, V159, P310, DOI 10.1093/infdis/159.2.310; COOPER GL, 1985, NEW ENGL J MED, V312, P1142, DOI 10.1056/NEJM198505023121802; CTANIA PN, 1996, KING GUIDE PARENTERA; DANZIG LE, 1995, JAMA-J AM MED ASSOC, V273, P1862, DOI 10.1001/jama.273.23.1862; DECICCO M, 1989, LANCET, V2, P1258, DOI 10.1016/S0140-6736(89)91861-8; DIMAYUGA E, 1995, INFECT DIS CLIN PRAC, V4, P468, DOI 10.1097/00019048-199511000-00031; EISENBERG JM, 1986, JAMA-J AM MED ASSOC, V255, P1584, DOI 10.1001/jama.255.12.1584; ENSMINGER WD, 1993, J INFUS CHEMOTHER, V3, P200; FARBER BF, 1990, J INFECT DIS, V161, P37, DOI 10.1093/infdis/161.1.37; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; GARRISON RN, 1994, SURG CLIN N AM, V74, P557, DOI 10.1016/S0039-6109(16)46329-2; GRAHAM DR, 1991, AM J MED S3B, V91; GRAY ED, 1984, LANCET, V1, P365; GRAYSON ML, 1995, MED J AUSTRALIA, V162, P249, DOI 10.5694/j.1326-5377.1995.tb139878.x; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HAIRE WD, 1994, THROMB HAEMOSTASIS, V72, P543; HINDES R, 1995, INFECT DIS CLIN PRAC, V4, P211, DOI 10.1097/00019048-199505000-00016; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; HOGR AH, 1983, FEMS MICROBIOL LETT, V18, P211; JENSEN BL, 1993, INTRAVENOUS THERAPY, P303; JOHNSON GM, 1986, INFECT IMMUN, V54, P13, DOI 10.1128/IAI.54.1.13-20.1986; KRAVITZ GR, 1993, HOSP PRACT, V28, P21, DOI 10.1080/21548331.1993.11442931; LaRue G D, 1995, J Intraven Nurs, V18, P24; LAWSON M, 1982, AM J IV THER CLIN NU, V9, P29; LEINHARDT DJ, 1992, JPEN-PARENTER ENTER, V16, P168, DOI 10.1177/0148607192016002168; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; LINDBECK G, 1993, HOSP PRACT, V28, P44, DOI 10.1080/21548331.1993.11442947; LINZ DN, 1994, JPEN-PARENTER ENTER, V18, P198; Maki Dennis G., 1994, P155; MAKI DG, 1994, CRIT CARE MED, V22, P1729; MAKI DG, 1995, ANN INTERN MED, V123, P884, DOI 10.7326/0003-4819-123-11-199512010-00013; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1991, IMPROVING CATHETER S; Mayhall C G, 1992, Curr Clin Top Infect Dis, V12, P83; MCCARTHY MC, 1987, JPEN-PARENTER ENTER, V11, P259, DOI 10.1177/0148607187011003259; MENNIM P, 1992, BRIT MED J, V305, P171, DOI 10.1136/bmj.305.6846.171; MERMEL LA, 1995, ANN INTERN MED, V123, P841, DOI 10.7326/0003-4819-123-11-199512010-00005; MILLER Z, 1993, HOSP PRACT, V28, P48, DOI 10.1080/21548331.1993.11442948; Ng PK, 1997, MAYO CLIN PROC, V72, P225, DOI 10.4065/72.3.225; OSULLIVAN TL, 1993, J INFECT DIS, V168, P773, DOI 10.1093/infdis/168.3.773; PARKER JW, 1995, J BONE JOINT SURG AM, V77A, P572, DOI 10.2106/00004623-199504000-00010; PERDUE M, 1993, INTRAVENOUS THERAPY, P419; PORETZ DM, 1993, HOSP PRACT, V28, P40, DOI 10.1080/21548331.1993.11442946; POWERS DL, 1982, J GRAPH THEOR, V6, P43, DOI 10.1002/jgt.3190060106; PRESS OW, 1984, MEDICINE, V63, P189, DOI 10.1097/00005792-198407000-00001; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; Raad I, 1993, J INFECT DIS, V168, P400; RANTIS PC, 1994, J VASC SURG, V20, P108, DOI 10.1016/0741-5214(94)90182-1; RAVIGLIONE MC, 1989, AM J MED, V86, P780, DOI 10.1016/0002-9343(89)90473-7; RUSSELL PB, 1987, J CLIN MICROBIOL, V25, P1083, DOI 10.1128/JCM.25.6.1083-1087.1987; RYDER MA, 1993, NURS CLIN N AM, V28, P937; SALADOW JM, 1995, INFUSION, V1, P17; Salzman M B, 1995, Adv Pediatr Infect Dis, V10, P337; SCHEIS TG, 1996, AM J HEALTH-SYST PH, V53, P868; SHETH NK, 1983, J CLIN MICROBIOL, V18, P1061, DOI 10.1128/JCM.18.5.1061-1063.1983; SIMMONS TC, 1991, JPEN-PARENTER ENTER, V15, P676, DOI 10.1177/0148607191015006676; Sing Ronald F., 1995, Journal of the American Osteopathic Association, V95, P204; STANLEY HD, 1994, J ACQ IMMUN DEF SYND, V7, P272; STILES ML, 1995, AM J HEALTH-SYST PH, V52, P70, DOI 10.1093/ajhp/52.1.70; STIVER HG, 1982, CAN MED ASSOC J, V127, P207; SUTCLIFFE AG, 1995, J ROY SOC MED, V88, pP173; SWANIKER F, 1995, AM SURGEON, V61, P877; TICE AD, 1995, EUR J CLIN MICROBIOL, V14, P655, DOI 10.1007/BF01690748; TICE AD, 1993, INFECT DIS CLIN PRAC, V2, P186, DOI 10.1097/00019048-199305000-00005; TICE AD, 1993, HOSP PRACT, V28, P6, DOI 10.1080/21548331.1993.11442928; TRISSEL L A, 1990, Cancer Bulletin (Houston), V42, P393; TRISSEL LA, 1994, HDB INJECTABLE DRUGS; VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546; WAGGONER SE, 1993, GYNECOL ONCOL, V48, P394, DOI 10.1006/gyno.1993.1068; WEINSTEIN SM, 1993, PRINCIPLES PRACTICE, P143; WEVER MLG, 1995, THROMB HAEMOSTASIS, V73, P180; WILLIAMS DN, 1989, ARCH INTERN MED, V149, P1157, DOI 10.1001/archinte.149.5.1157; WILLIAMS DN, 1994, AM J MED, V97, P50, DOI 10.1016/0002-9343(94)90288-7; WOODYARD TC, 1993, CANCER, V71, P2621, DOI 10.1002/1097-0142(19930415)71:8<2621::AID-CNCR2820710829>3.0.CO;2-V; YEUNG C, 1988, INFECT CONT HOSP EP, V9, P154; 1993, HOSP PRACT S1, V28, P1; 1996, MMWR-MORBID MORTAL W, V45, P101; 1993, HOSP PRACT S2, V28, P1; 1994, AM J MED S2A, V97, P1	89	75	76	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					829	838		10.1056/NEJM199709183371207	http://dx.doi.org/10.1056/NEJM199709183371207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9297114				2023-01-03	WOS:A1997XW28300007
J	Akhlynina, TV; Jans, DA; Rosenkranz, AA; Statsyuk, NV; Balashova, IY; Toth, G; Pavo, I; Rubin, AB; Sobolev, AS				Akhlynina, TV; Jans, DA; Rosenkranz, AA; Statsyuk, NV; Balashova, IY; Toth, G; Pavo, I; Rubin, AB; Sobolev, AS			Nuclear targeting of chlorin e(6) enhances its photosensitizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II SITE FLANKING; SV40 T-ANTIGEN; PHOTODYNAMIC THERAPY; PROTEIN-TRANSPORT; CARCINOMA-CELLS; PHOTOFRIN-II; INSULIN; PHOSPHORYLATION; LOCALIZATION; E6	Although photosensitizers, molecules that produce active oxygen species upon activation by visible light, are being extensively used in photodynamic therapy to treat cancer and other clinical conditions, problems include normal cell and tissue damage and associated side effects, which are attributable in part to the fact that cytotoxic effects are largely restricted to the plasma membrane, We have previously shown that the photosensitizer chlorin e(6) has significantly higher photosensitizing activity when present in conjugates containing specific ligands and thus able to be internalized by receptor-expressing cells. In this study we use insulin-containing conjugates to which variants of the simian virus SV40 large tumor antigen nuclear localization signal (NLS) were linked to target chlorin e(6) to the nucleus, a hypersensitive site for active oxygen species-induced damage. NLSs were either included as peptides crosslinked to the carrier bovine serum albumin or encoded within the sequence of a beta-galactosidase fusion protein carrier. The results for photosensitization demonstrate clearly for the first time that NLSs increase the photosensitizing activity of chlorin e(6), maximally reducing the EC50 by a factor of over 2000-fold. This has wide-reaching implications for achieving efficient cell type-specific photodynamic therapy.	MOSCOW MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT BIOPHYS,MOSCOW 119899,RUSSIA; RUSSIAN INST AGR BIOTECHNOL,BIOPHYS LAB,MOSCOW 127550,RUSSIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOL BIOL,NUCL SIGNALING LAB,CANBERRA,ACT 2601,AUSTRALIA; UNIV SZEGED,INST MED CHEM,H-6720 SZEGED,HUNGARY	Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Australian National University; John Curtin School of Medical Research; Szeged University			Rosenkranz, Andrey A/J-3514-2015; Andrei, Rubin/U-6451-2019; Pavo, Imre/AAZ-6421-2021; Statsyuk, Natalia V./P-6383-2014; Sobolev, Alexander S./P-6302-2015	Rosenkranz, Andrey A/0000-0001-9941-6118; Pavo, Imre/0000-0002-2016-7049; Statsyuk, Natalia V./0000-0001-6159-148X; Sobolev, Alexander S./0000-0001-8315-7764				AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; Alper T, 1979, CELLULAR RADIOBIOLOG; BACHOR R, 1991, P NATL ACAD SCI USA, V88, P1580, DOI 10.1073/pnas.88.4.1580; FINLAY GJ, 1984, ANAL BIOCHEM, V139, P272, DOI 10.1016/0003-2697(84)90002-2; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; LEVY JG, 1995, TRENDS BIOTECHNOL, V13, P14, DOI 10.1016/S0167-7799(00)88895-2; MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380; MONTIEL F, 1989, BIOCHEM J, V258, P147, DOI 10.1042/bj2580147; PATEL AK, 1987, BIOCHEM J, V248, P173, DOI 10.1042/bj2480173; POPOVIC EA, 1995, SEMIN SURG ONCOL, V11, P335, DOI 10.1002/ssu.2980110503; POZNANSKY MJ, 1984, SCIENCE, V223, P1304, DOI 10.1126/science.6367042; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS WG, 1989, LASER SURG MED, V9, P102, DOI 10.1002/lsm.1900090204; ROBERTS WG, 1989, LASER SURG MED, V9, P90, DOI 10.1002/lsm.1900090203; SHECHTER Y, 1978, P NATL ACAD SCI USA, V75, P2135, DOI 10.1073/pnas.75.5.2135; SOBOLEV AS, 1992, BIOCHEM INT, V26, P445; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Tsukagoshi S, 1995, Gan To Kagaku Ryoho, V22, P1271; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; YANO T, 1995, RES COMMUN MOL PATH, V87, P367	26	112	126	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20328	20331		10.1074/jbc.272.33.20328	http://dx.doi.org/10.1074/jbc.272.33.20328			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252335	hybrid			2023-01-03	WOS:A1997XR22100005
J	Fraser, J; Mok, Q; Tasker, R				Fraser, J; Mok, Q; Tasker, R			Survey of occupancy of paediatric intensive care units by children who are dependent on ventilators	BRITISH MEDICAL JOURNAL			English	Article											Fraser, J (corresponding author), HOSP SICK CHILDREN,PAEDIAT INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Mok, Quen/AAA-2648-2019; Tasker, Robert C/R-5837-2019	Mok, Quen/0000-0003-4807-9275; Tasker, Robert/0000-0003-3647-8113				British Paediatric Association, 1993, REP MULT WORK PART P; DEWITT PK, 1993, CHEST, V103, P1560, DOI 10.1378/chest.103.5.1560; James I, 1996, BRIT MED J, V312, P1476, DOI 10.1136/bmj.312.7044.1476b	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					347	348						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270456				2023-01-03	WOS:A1997XQ86400021
J	Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH				Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH			The safety of newborn early discharge - The Washington State experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL DISCHARGE; MOTHERS; POPULATION; INFANTS	Context.-While early discharge of newborns following routine vaginal delivery has become common practice, its safety has not been firmly established. Objective.-To assess the risk for rehospitalization following newborn early discharge. Design.-Population-based, case-control study. Setting.-Washington State linked birth certificate and hospital discharge abstracts covering 310 578 live births from 1991 through 1994. Patients.-Case patients were 2029 newborns rehospitalized in the first month of life. Control subjects were 8657 randomly selected newborns not rehospitalized and frequency matched to case patients on year of birth. Cesarean deliveries, multiple births, and births at less than 36 weeks' gestation were not included. Main Outcome Measure.-Stratified analyses and logistic regression were performed to assess the risk for rehospitalization within a month of birth after early discharge (<30 hours after birth) compared with later discharge (30-78 hours after birth). Results.-Seventeen percent of newborns were discharged early. Newborns discharged early were more likely to be rehospitalized within 7 days (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.11-1.47), 14 days (OR, 1.16; 95% CI, 1.03-1.32), and 28 days (OR, 1.12; 95% CI, 1.00-1.25) of discharge than newborns sent home later. Subgroups at increased risk for rehospitalization following early discharge included newborns born to primigravidas (OR,1.25; 95% CI, 1.07-1.45), mothers younger than 18 years (OR, 1.22; 95% CI, 0.79-1.91), and mothers with premature rupture of membranes (OR, 1.41;95% CI, 0.85-2.36). Early discharge was also associated with an increased risk of readmission for jaundice, dehydration, and sepsis. Conclusion.-Newborns discharged home early (<30 hours after birth) are at increased risk for rehospitalization during the first month of life.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; University of North Carolina; University of North Carolina Chapel Hill			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Shay, David/0000-0001-9619-4820	BHP HRSA HHS [5-T32-PE10002] Funding Source: Medline	BHP HRSA HHS		ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRESLOW NE, 1980, STATISTICAL METHODS, P1; BRITTON JR, 1994, PEDIATRICS, V94, P291; CARTY EM, 1990, BIRTH-ISS PERINAT C, V17, P199, DOI 10.1111/j.1523-536X.1990.tb00021.x; CLARK G, 1996, AAP NEWS, V12, P1; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505; Gauda EB, 1996, JAMA-J AM MED ASSOC, V275, P1823, DOI 10.1001/jama.275.23.1823; HELLMAN LM, 1962, LANCET, V1, P227; JANSSON P, 1985, AM J NURS, V85, P547, DOI 10.2307/3425241; KEMPER KJ, 1990, AM J DIS CHILD, V144, P238, DOI 10.1001/archpedi.1990.02150260118043; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; RHODES MK, 1994, MIL MED, V159, P227, DOI 10.1093/milmed/159.3.227; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCUPHOLME A, 1981, J NURSE-MIDWIFERY, V26, P19, DOI 10.1016/0091-2182(81)90171-3; SOLA A, 1996, SOC PED RES ANN M, V39, pA113; WALDENSTROM U, 1987, UPSALA J MED SCI, V92, P301, DOI 10.3109/03009738709178701; *WASH STAT DEP HLT, 1996, BIRA18M1 WASH STAT D; WELT SI, 1993, AM J PERINAT, V10, P384, DOI 10.1055/s-2007-994768; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; 1995, NY TIMES        1011, pC18; 1995, VITAL HLTH STAT, V13	29	129	134	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					293	298		10.1001/jama.278.4.293	http://dx.doi.org/10.1001/jama.278.4.293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL059	9228434				2023-01-03	WOS:A1997XL05900029
J	Weigner, MJ; Caulfield, TA; Danias, PG; Silverman, DI; Manning, WJ				Weigner, MJ; Caulfield, TA; Danias, PG; Silverman, DI; Manning, WJ			Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours	ANNALS OF INTERNAL MEDICINE			English	Article						atrial fibrillation; thromboembolism; electric countershock; time factors; cardiac output, low	DIRECT-CURRENT CARDIOVERSION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTITHROMBOTIC THERAPY; ANTICOAGULATION; COMPLICATIONS; RECOMMENDATIONS; MANAGEMENT; THROMBUS; TRIAL	Background: It has been assumed that cardioversion in patients with atrial fibrillation lasting less than 48 hours is associated with a low risk for thromboembolism. However, no clinical data support this assumption. Objective: To determine the incidence of cardioversion-related clinical thromboembolism among patients presenting with atrial fibrillation lasting less than 48 hours. Design: Patients were prospectively identified on admission, and clinical data on the duration of atrial fibrillation were recorded. Data on cardioversion and thromboembolism were obtained retrospectively from hospital and outpatient records. Setting: Academic medical center. Patients: 1822 consecutive patients admitted to the hospital for atrial fibrillation were screened. Three hundred seventy-five adults (mean age +/- SD, 68 +/- 16 years) with atrial fibrillation that had lasted less than 48 hours were identified. One hundred eighty-one patients (48.3%) had a history of atrial fibrillation; 23 (6.1%) had a history of thromboembolism. Results: 357 patients (95.2%) converted to sinus rhythm during the index admission; spontaneous conversion occurred in 250 patients (66.7%) and active pharmacologic or electrical conversion was done in 107 patients (28.5%). Three patients (0.8% [95% CI, 0.2% to 2.4%]), all of whom had converted spontaneously after ventricular rate control was begun, had a clinical thromboembolic event: One had a stroke, 1 had a transient ischemic attack, and 1 had a peripheral embolus. None of these 3 patients had a history of atrial fibrillation or thromboembolism, and all had normal left ventricular systolic function. Conclusion: Among patients presenting with atrial fibrillation that was clinically estimated to have lasted less than 48 hours, the likelihood of cardioversion-related clinical thromboembolism is low. These data support the current recommendation for early cardioversion in these patients.	BETH ISRAEL DEACONESS MED CTR, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; JOHN DEMPSEY HOSP, FARMINGTON, CT USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Connecticut					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RRO6192] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM HEART ASS, 1996, HEART STROK FACTS ST, P14; [Anonymous], 1995, J STROKE CEREBROVASC, V5, P147, DOI [DOI 10.1016/S1052-3057(10)80166-1, 10.1016/S10523057(10)80166-1]; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; ASPLUND K, 1993, EUR HEART J, V14, P1427; ATWOOD JE, 1987, J AM COLL CARDIOL, V10, P314; BAER M, 1995, GERIATRICS, V50, P22; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; COLLINS LJ, 1995, CIRCULATION, V92, P160, DOI 10.1161/01.CIR.92.2.160; DALY L, 1992, COMPUT BIOL MED, V22, P351, DOI 10.1016/0010-4825(92)90023-G; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FATKIN D, 1994, J AM COLL CARDIOL, V23, P307, DOI 10.1016/0735-1097(94)90412-X; GOLDMAN MJ, 1960, PROG CARDIOVASC DIS, V2, P465, DOI 10.1016/S0033-0620(60)80005-9; Golzari H, 1996, ANN INTERN MED, V125, P311, DOI 10.7326/0003-4819-125-4-199608150-00010; GRIMM RA, 1995, AM HEART J, V130, P174, DOI 10.1016/0002-8703(95)90253-8; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LOWN B, 1963, NEW ENGL J MED, V269, P325, DOI 10.1056/NEJM196308152690701; MANCINI GBJ, 1982, AM HEART J, V104, P617; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MANNING WJ, 1995, ARCH INTERN MED, V155, P2193, DOI 10.1001/archinte.155.20.2193; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SCHAMROTH L, 1971, CARDIOVASC RES, V5, P419, DOI 10.1093/cvr/5.4.419; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; STODDARD MF, 1995, AM HEART J, V129, P1204, DOI 10.1016/0002-8703(95)90405-0; THEISEN K, 1985, AM J CARDIOL, V55, P98, DOI 10.1016/0002-9149(85)90307-8; WEINBERG DM, 1989, AM J CARDIOL, V63, P745, DOI 10.1016/0002-9149(89)90264-6	35	166	167	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					615	+		10.7326/0003-4819-126-8-199704150-00005	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103128				2023-01-03	WOS:A1997WT58000007
J	Hanson, LC; Tulsky, JA; Danis, M				Hanson, LC; Tulsky, JA; Danis, M			Can clinical interventions change care at the end of life?	ANNALS OF INTERNAL MEDICINE			English	Review							CRITICALLY ILL PATIENTS; SELF-DETERMINATION ACT; RANDOMIZED CONTROLLED TRIAL; PROSPECTIVE PAYMENT SYSTEM; ADVANCE DIRECTIVES; SUSTAINING TREATMENTS; RESUSCITATION DECISIONS; RESOURCE UTILIZATION; ELDERLY PATIENTS; TERMINAL CARE	Purpose: To review clinical interventions designed to change care at the end of life. Data Sources: Published results of clinical trials identified by MEDLINE searches, review of abstracts from meetings, and selected bibliographies. Study Selection: Studies were included if data were presented on a clinical intervention designed to change medical care at the end of life. Studies done in nonclinical settings or outside the United States were excluded. Data Extraction: Interventions were classified as targeting patients, physicians, or both and were analyzed by their effect on four common clinical goals: increasing use of patient preferences, decreasing pain and suffering, reducing use of life-sustaining treatments, and reducing costs. Positive and negative trial results were compared for differences in intervention, target group, and strength of study methods. Data Synthesis: Educational interventions usually increased expression of patient treatment preferences. Success rates were higher when more severely ill patients were targeted and when written materials were combined with repeated discussions in clinical encounters. Educational interventions with physicians led to increased use of patient preferences, but sophisticated educational techniques were needed to motivate physicians to change their behavior. Three studies provided limited evidence that physician education reduced the use of life-sustaining treatments. No clinical intervention had an effect on pain, suffering, or cost of medical care. Conclusion: To change care at the end of life, intensive educational interventions for physicians and broad institutional programs seem more promising than advance directives. Future innovations should seek to change physician practices, reduce costs, and improve patient-centered out comes, such as pain control and satisfaction.	VET AFFAIRS MED CTR, DIV GEN MED, DURHAM, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hanson, LC (corresponding author), UNIV N CAROLINA, DIV GEN INTERNAL MED, CB 7110, 5035 OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.			Hanson, Laura/0000-0001-5120-6058	NATIONAL INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER; NIA NIH HHS [5-P60-AG11268] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATES DW, 1988, WESTERN J MED, V148, P471; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; DALY BJ, 1991, HEART LUNG, V20, P45; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Davila F, 1996, ARCH INTERN MED, V156, P405; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAWSON NJ, 1991, SOC SCI MED, V32, P83, DOI 10.1016/0277-9536(91)90131-U; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Fischer G. S., 1996, JGIM, V11, P115; FISCHER GS, 1996, J GEN INTERN MED S4, V10, P115; GAUMER GL, 1992, HEALTH SERV RES, V26, P725; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Hanson LC, 1996, ARCH INTERN MED, V156, P1018, DOI 10.1001/archinte.156.9.1018; HANSON LC, 1994, AM J MED, V97, P235, DOI 10.1016/0002-9343(94)90006-X; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HESSE KA, 1995, ARCH INTERN MED, V155, P1513, DOI 10.1001/archinte.155.14.1513; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HIGH DM, 1993, GERONTOLOGIST, V33, P342, DOI 10.1093/geront/33.3.342; HOLLORAN SD, 1995, SURGERY, V118, P294, DOI 10.1016/S0039-6060(05)80337-X; KANE RL, 1984, LANCET, V1, P890; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LAYSON RT, 1994, J CLIN ETHIC, V5, P195; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LUPTAK MK, 1994, GERONTOLOGIST, V34, P409; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MAYEROAKES SA, 1988, JAMA-J AM MED ASSOC, V260, P3146, DOI 10.1001/jama.260.21.3146; MCCLISH DK, 1989, MED DECIS MAKING, V9, P125, DOI 10.1177/0272989X8900900207; Meier DE, 1996, J AM GERIATR SOC, V44, P37, DOI 10.1111/j.1532-5415.1996.tb05635.x; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P947; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; NIGHTINGALE SD, 1991, J GEN INTERN MED, V6, P420, DOI 10.1007/BF02598163; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; QUILL TE, 1992, ARCH INTERN MED, V152, P569, DOI 10.1001/archinte.152.3.569; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; REILLY BM, 1995, ARCH INTERN MED, V155, P2317, DOI 10.1001/archinte.155.21.2317; Richter K P, 1995, Arch Fam Med, V4, P609, DOI 10.1001/archfami.4.7.609; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; Sullivan KE, 1996, CHEST, V109, P258, DOI 10.1378/chest.109.1.258; SULMASY DP, 1994, J GEN INTERN MED, V9, P622, DOI 10.1007/BF02600306; TENO JM, 1994, J CLIN ETHIC, V5, P23; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; VOLICER L, 1994, J AM GERIATR SOC, V42, P597, DOI 10.1111/j.1532-5415.1994.tb06856.x; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; YANO EM, 1995, ARCH INTERN MED, V155, P1146, DOI 10.1001/archinte.155.11.1146	65	130	132	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					381	388		10.7326/0003-4819-126-5-199703010-00007	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WL104	9054283				2023-01-03	WOS:A1997WL10400007
J	Farwell, B				Farwell, B			Health care in America: An intimate glimpse	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					1005	1006		10.7326/0003-4819-125-12-199612150-00014	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967689				2023-01-03	WOS:A1996VX76800014
J	Kelley, DJ; Shah, JP				Kelley, DJ; Shah, JP			Management of Barrett's oesophagus	LANCET			English	Editorial Material							PHOTODYNAMIC THERAPY; ESOPHAGEAL; ABLATION; MUCOSA				Kelley, DJ (corresponding author), MEM SLOAN KETTERING CANC CTR, HEAD & NECK SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; ERTAN A, 1995, AM J GASTROENTEROL, V90, P2201; FALK GW, 1994, GASTROINTEST ENDOSC, V40, P207, DOI 10.1016/S0016-5107(94)70168-7; MCBRIDE MA, 1995, AM J GASTROENTEROL, V90, P2029; OVERHOLT BF, 1995, SEMIN SURG ONCOL, V11, P372, DOI 10.1002/ssu.2980110508; Panjehpour M, 1996, GASTROENTEROLOGY, V111, P93, DOI 10.1053/gast.1996.v111.pm8698231; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67; SAMPLINER RE, 1993, AM J GASTROENTEROL, V88, P2092; Wang Kenneth K., 1994, Comprehensive Therapy, V20, P36	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					561	562		10.1016/S0140-6736(05)64794-0	http://dx.doi.org/10.1016/S0140-6736(05)64794-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774565				2023-01-03	WOS:A1996VF18600006
J	Dobson, M; Peel, D; Khallaf, N				Dobson, M; Peel, D; Khallaf, N			Field trial of oxygen concentrators in upper Egypt	LANCET			English	Article							DEVELOPING-COUNTRIES	Technical problems in developing countries often require more than just technological solutions. Many small hospitals in rural areas are without a reliable oxygen supply; small oxygen concentrators offer a solution, but simply sending out machines is ineffective. This account details the setting up and first year's operation of a project to test oxygen concentrations in a developing country. A co-ordinated strategy has been developed to include machines, supplies, education, training, and feedback. Initial results are encouraging, and support the idea that suitably installed and maintained concentrations can have a valuable role in bringing oxygen therapy to patients and hospitals in countries which have so far been denied it.	NATL ARI PROGRAM,CAIRO,EGYPT		Dobson, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT ANAESTHET,OXFORD OX3 9DU,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x; FENTON PM, 1989, ANAESTHESIA, V44, P498, DOI 10.1111/j.1365-2044.1989.tb11380.x; GOULD GA, 1985, THORAX, V40, P811, DOI 10.1136/thx.40.11.811; PEDERSEN J, 1991, BRIT J ANAESTH, V66, P264, DOI 10.1093/bja/66.2.264; *WHO, 1991, 912 WHO ARI	6	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1597	1599		10.1016/S0140-6736(96)91080-6	http://dx.doi.org/10.1016/S0140-6736(96)91080-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667871				2023-01-03	WOS:A1996UP66100014
J	Feldman, W; Feldman, ME				Feldman, W; Feldman, ME			The intelligence on infant feeding	LANCET			English	Editorial Material							COGNITIVE-DEVELOPMENT; LIFE		SCARBOROUGH GRACE HOSP,TORONTO,ON,CANADA	Scarborough Hospital	Feldman, W (corresponding author), UNIV TORONTO,HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO,ON M5G 1X8,CANADA.							DUV C, 1995, INT J EPIDMEIOL, V24, pS21; FERGUSSON DM, 1982, SOC SCI MED, V16, P1705, DOI 10.1016/0277-9536(82)90096-X; JACOBSON SW, 1992, LANCET, V339, P926, DOI 10.1016/0140-6736(92)90962-3; MORROWTLUCAK M, 1988, SOC SCI MED, V26, P635, DOI 10.1016/0277-9536(88)90028-7; SILVA PA, 1978, AUST PAEDIATR J, V4, P265; TAYLOR B, 1984, DEV MED CHILD NEUROL, V26, P73; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005; WRIGHT P, 1992, LANCET, V339, P612, DOI 10.1016/0140-6736(92)90898-D	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1057	1057		10.1016/S0140-6736(96)90270-6	http://dx.doi.org/10.1016/S0140-6736(96)90270-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG042	8602050				2023-01-03	WOS:A1996UG04200003
J	Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P				Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P			Inappropriate drug-donation practices in Bosnia and Herzegovina, 1992 to 1996	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EARTHQUAKE		EUROPEAN ASSOC HLTH & DEV,B-1000 BRUSSELS,BELGIUM; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)			Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321				ALI HM, 1988, LANCET, V333, P538; AUTIER P, 1990, LANCET, V335, P1388; BERCKMANS P, 1996, DRUG DONATION PRACTI; COHEN S, 1990, LANCET, V336, P745, DOI 10.1016/0140-6736(90)92233-8; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Hogerzeil HV, 1997, BRIT MED J, V314, P737, DOI 10.1136/bmj.314.7082.737; Michael M, 1996, JAMA-J AM MED ASSOC, V276, P364, DOI 10.1001/jama.276.5.364; OFFERHAUS L, 1992, LANCET, V339, P607; *RES MED DEV, 1996, ECH MED ENTR PAYS EU; SCHOUTEN E, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684; *UN INF MED ETH DE, 1994, MED UT EUR REC DESTR; United Nations Environment Programme, 1989, BAS CONV CONTR TRANS; VANDERHEIDE B, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684a; *WAR HLTH CROSS BR, 1996, EUR COR ANN REP 1995; *WEMOS PHARM PROJ, 1991, EXP DEADL EXP STOR E; *WHO, 1994, WHO MISS FORM YUG; *WHO, 1996, WHODAP962; *WHO, 1992, WHO TECH REP SER, V825, P1; *WHO, 1994, MED SUPPL DON GUID W; ZEBALLOS JL, 1986, DISASTERS, V10, P141, DOI 10.1111/j.1467-7717.1986.tb00579.x	20	24	26	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1842	1845		10.1056/NEJM199712183372512	http://dx.doi.org/10.1056/NEJM199712183372512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400045				2023-01-03	WOS:A1997YL85500012
J	McNagny, SE; Wenger, NK; Frank, E				McNagny, SE; Wenger, NK; Frank, E			Personal use of postmenopausal hormone replacement therapy by women physicians in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENT OSTEOPOROSIS; ESTROGEN REPLACEMENT; ATTITUDES; DISEASE	Background: Women physicians' use of postmenopausal hormone replacement therapy (HRT) is unknown. Objective: To study use of HRT by women physicians in the United States. Design: Stratified random-sample mail survey. Setting: United States. Participants: 1466 postmenopausal women U.S. physicians in the Women Physicians' Health Study. Measurements: Self-reported personal use of HRT and information on demographic, professional, and behavioral characteristics and medical history. Results: Overall, 47.4% of participants currently use HRT; the prevalence of use is 59.8% in women 40 to 49 years of age, 49.4% in women 50 to 59 years of age, and 36.4% in women 60 to 70 years of age (P < 0.001). In an adjusted logistic regression model, current users were significantly more likely to be gynecologists, to be younger, to be white, to be sexually active, to be previous users of oral contraceptives, to live in Pacific or Mountain states, to have had a hysterectomy, and to have no personal or family history of breast cancer. Conclusions: Women physicians have a higher rate of HRT use than that reported in cross-sectional U.S. surveys. This may presage greater use of HRT for U.S. women in the future.	Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA	Emory University	McNagny, SE (corresponding author), Emory Univ, Sch Med, Div Gen Med, 69 Butler St, Atlanta, GA 30303 USA.			Frank, Erica/0000-0001-7159-5417	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32-HL-07034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; *COMM TECHN B AM C, 1992, ACOG TECHN B, V166, P1; Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1997, WESTERN J MED, V166, P179; FRANK E, 1995, PREV MED, V24, P543, DOI 10.1006/pmed.1995.1086; FRANK E, IN PRESS ARCH INTERN; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; GRISSO JA, 1990, J BONE MINER RES, V5, P213, DOI 10.1002/jbmr.5650050303; Handa VL, 1996, J AM GERIATR SOC, V44, P1; HEMMINKI E, 1991, DICP ANN PHARMAC, V25, P418, DOI 10.1177/106002809102500416; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; *RES TRIANGL I, 1996, SUDAAN US MAN VERS 6; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; [No title captured]	19	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1093	1096		10.7326/0003-4819-127-12-199712150-00007	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412312				2023-01-03	WOS:000070936600006
J	Shu, SY; Plautz, GE; Krauss, JC; Chang, AE				Shu, SY; Plautz, GE; Krauss, JC; Chang, AE			Tumor immunology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFILTRATING LYMPHOCYTES; T-LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; IN-VIVO; THERAPEUTIC EFFICACY; CANCER-IMMUNOTHERAPY; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; MICE BEARING; CELLS	Malignant tumors express antigens that may stimulate and serve as targets for antitumor immunity. Virally induced tumors usually contain integrated proviral genomes in their cellular genomes and often express viral genome-encoded proteins that may stimulate specific host immune responses. Antigens unique to individual tumors that stimulate specific rejection of transplanted tumors have been demonstrated only in experimental animals. Other tumor antigens that potentially can stimulate immune responses are shared by different tumors. These include products of mutated or rearranged oncogenes or tumor-suppressor genes. Tumors may also overexpress tissue differentiation antigens or embryonic antigens, which also have the potential to be recognized by the immune system. The recent identification of tumor antigens recognized by cytotoxic T cells opens up new possibilities for constructing chemically defined antigens for specific immunotherapy. Treatment of malignant tumors in humans by immunologic approaches, although theoretically attractive, has not yet succeeded on a large scale. Important progress in immunotherapy of cancer is emerging with several different treatment modalities.	UNIV MICHIGAN, TAUBMAN CTR 2920K, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Shu, SY (corresponding author), CLEVELAND CLIN FDN FF50, DIV SURG, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							AALTOMAA S, 1992, EUR J CANCER, V28A, P859, DOI 10.1016/0959-8049(92)90134-N; BAST RC, 1974, NEW ENGL J MED, V290, P1413, DOI 10.1056/NEJM197406202902506; BAST RC, 1974, NEW ENGL J MED, V290, P1458, DOI 10.1056/NEJM197406272902605; Bocchia M, 1996, BLOOD, V87, P3587, DOI 10.1182/blood.V87.9.3587.bloodjournal8793587; BOON T, 1977, P NATL ACAD SCI USA, V74, P272, DOI 10.1073/pnas.74.1.272; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CANAANI E, 1991, CHRONIC MYELOGENOU 3; CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105; Chang AE, 1997, J CLIN ONCOL, V15, P796, DOI 10.1200/JCO.1997.15.2.796; CHANG AE, 1993, CANCER RES, V53, P1043; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN W, 1992, P NATL ACAD SCI USA, V89, P1468, DOI 10.1073/pnas.89.4.1468; CONNOR J, 1993, J EXP MED, V177, P1127, DOI 10.1084/jem.177.4.1127; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dudley ME, 1996, J EXP MED, V184, P441, DOI 10.1084/jem.184.2.441; FU YX, 1991, J IMMUNOL, V146, P783; GRIMM EA, 1983, J EXP MED, V158, P1356, DOI 10.1084/jem.158.4.1356; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HOUBIERS JGA, 1993, EUR J IMMUNOL, V23, P2072, DOI 10.1002/eji.1830230905; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Huang AYC, 1996, J EXP MED, V183, P769, DOI 10.1084/jem.183.3.769; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KLARNET JP, 1989, J EXP MED, V169, P457, DOI 10.1084/jem.169.2.457; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; MATSUMURA T, 1994, CANCER RES, V54, P2744; McLaughlin JP, 1996, CANCER RES, V56, P2361; MILLER AR, 1994, ANN SURG ONCOL, V1, P436, DOI 10.1007/BF02303818; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURRAY JL, 1985, CANCER RES, V45, P2376; NORTH RJ, 1985, ADV CANCER RES, V45, P1, DOI 10.1016/S0065-230X(08)60265-1; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PASTORFIDE GC, 1992, J CUTAN PATHOL, V19, P390, DOI 10.1111/j.1600-0560.1992.tb00611.x; PEACE DJ, 1993, J IMMUNOTHER, V14, P110, DOI 10.1097/00002371-199308000-00005; PORGADOR A, 1993, J IMMUNOL, V150, P1458; PREHN RT, 1957, J NATL CANCER I, V18, P769; ROSENBERG SA, 1986, ANNU REV IMMUNOL, V4, P681, DOI 10.1146/annurev.immunol.4.1.681; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; SHU S, 1987, J IMMUNOL, V139, P295; SHU S, 1989, J IMMUNOL, V143, P740; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; VIEWEG J, 1995, CANCER INVEST, V13, P193, DOI 10.3109/07357909509011690; VINUELA JE, 1991, INT J CANCER, V47, P86, DOI 10.1002/ijc.2910470116; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; YOSHIZAWA H, 1991, J IMMUNOL, V147, P729	53	56	59	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1972	1981		10.1001/jama.278.22.1972	http://dx.doi.org/10.1001/jama.278.22.1972			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396660				2023-01-03	WOS:A1997YK15500021
J	Arbuzova, A; Wang, JY; Murray, D; Jacob, J; Cafiso, DS; McLaughlin, S				Arbuzova, A; Wang, JY; Murray, D; Jacob, J; Cafiso, DS; McLaughlin, S			Kinetics of interaction of the myristoylated alanine-rich C kinase substrate, membranes, and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; MARCKS-RELATED PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPID-VESICLES; ELECTROSTATIC SWITCH; CALCIUM-CALMODULIN; DEPENDENT BINDING; ASSOCIATION; PHOSPHORYLATION; PEPTIDES	Membrane binding of the myristoylated alanine-rich C kinase substrate (MARCKS) requires both its myristate chain and basic ''effector'' region. Previous studies with a peptide corresponding to the effector region, MARCKS-(151-175), showed that the 13 basic residues interact electrostatically with acidic lipids and that the 5 hydrophobic phenylalanine residues penetrate the polar head group region of the bilayer, Here we describe the kinetics of the membrane binding of fluorescent (acrylodan-labeled) peptides measured with a stopped-flow technique, Even though the peptide penetrates the polar head group region, the association of MARCKS-(151-175) with membranes is extremely rapid; association occurs with a diffusion-limited association rate constant, For example, k(on) = 10(11) M-1 s(-1) for the peptide binding to 100-nm diameter phospholipid vesicles, As expected theoretically, k(on) is independent of factors that affect the molar partition coefficient, such as the mole fraction of acidic lipid in the vesicle and the salt concentration The dissociation rate constant (k(off)) is similar to 10 s(-1) (lifetime = 0.1 s) for vesicles with 10% acidic lipid in 100 mM KCl. Ca2+-calmodulin (Ca2+. CaM) decreases markedly the lifetime of the peptide on vesicles, e.g. from 0.1 to 0.01 s in the presence of 5 mu M Ca2+. CaM. Our results suggest that Ca2+. CaM collides with the membrane-bound MARCKS (151-175) peptide and pulls the peptide off rapidly, We discuss the biological implications of this switch mechanism, speculating that an increase in the level of Ca2+-calmodulin could rapidly release phosphatidylinositol 4,5-bisphosphate that previous work has suggested is sequestered in lateral domains formed by MARCKS and MARCKS-(151-175).	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,HLTH SCI CTR,STONY BROOK,NY 11794; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,BIOPHYS PROGRAM,CHARLOTTESVILLE,VA 22901	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Virginia; University of Virginia				Arbuzova, Anna/0000-0003-2462-147X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024971, R37GM024971, R01GM035215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24971, GM35215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BERG HC, 1983, RANDOM WALKS BIOL, P17; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COBURN C, 1993, BIOPHYS J, V64, P60; DIEBLER H, 1969, Pure and Applied Chemistry, V20, P93, DOI 10.1351/pac196920010093; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KOELCHENS S, 1993, CHEM PHYS LIPIDSA, V65, P1; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; KUZELOVA K, 1994, BIOCHEMISTRY-US, V33, P9447, DOI 10.1021/bi00198a010; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LU Y, 1995, BIOCHEMISTRY-US, V34, P10777, DOI 10.1021/bi00034a010; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOYES RM, 1961, PROG REACT KINET MEC, V1, P129; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROUX M, 1988, EUR BIOPHYS J BIOPHY, V16, P267, DOI 10.1007/BF00254062; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; SCHWARZ G, 1989, BIOCHIM BIOPHYS ACTA, V979, P82, DOI 10.1016/0005-2736(89)90526-9; SCHWARZ G, 1987, BIOPHYS CHEM, V26, P163, DOI 10.1016/0301-4622(87)80019-4; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361	53	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27167	27177		10.1074/jbc.272.43.27167	http://dx.doi.org/10.1074/jbc.272.43.27167			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341159	hybrid			2023-01-03	WOS:A1997YC65900055
J	Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G				Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G			Case-control study of oestrogen replacement therapy and risk of cervical cancer	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUSES; ORAL-CONTRACEPTIVES; ONCOGENIC TRANSFORMATION; GENITAL-TRACT; PROGESTERONE; NEOPLASIA; ESTROGEN; TYPE-16; WOMEN	Objective : To examine the relation between use of oestrogen replacement therapy and risk of cervical cancer. Design : Case-control study. Setting : Northern Italy. Subjects : 645 women aged 40-75 years with cervical cancer admitted between 1981 and 1993 to university and general hospitals. The control group consisted of 749 women aged 40-75 years admitted to the same hospitals with acute conditions judged to be unrelated to any of the known or suspected risk factors for cervical cancer. Main outcome measures : Use of oestrogen replacement therapy and risk of cervical cancer. Results : 40 cases versus 86 controls had ever used oestrogens, and the corresponding multivariate odds ratio was 0.5 (95% confidence interval 0.3 to 0.8). The odds ratios of cervical cancer decreased with duration of use, being 0.6 (0.4 to 1.1) for less than 12 months' use and 0.5 (0.2 to 1.0) for use for 12 months or more compared with never users. The protection tended to be somewhat stronger for women reporting first oestrogen use before age 50. The odds ratio was 0.9 (0.5 to 1.7) for women who had taken oestrogens within the past 10 years and 0.4 (0.2 to 0.7) for those who had taken them 10 or more years ago. Conclusion :These findings suggest that exogenous oestrogens do not increase the risk of cervical cancer and may decrease the risk.	MARIO NEGRI INST PHARMACOL RES,UNIT EPIDEMIOL METHODOL,I-20157 MILAN,ITALY; UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; CTR RIFERIMENTO ONCOL,DIV EPIDEMIOL,I-33081 AVIANO,PN,ITALY; UNIV MILAN,IST CLIN OSTETR GINECOL,I-20129 MILAN,ITALY; IST NAZL TUMORI,DIV GYNECOL ONCOL,I-20133 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; IRCCS Aviano (CRO); University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Parazzini, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,ANALYT EPIDEMIOL UNIT,VIA ERITREA 62,I-20157 MILAN,ITALY.		Chatenoud, Liliane/AAA-6377-2020; franceschi, silvia/M-2452-2014; Negri, Eva/B-7244-2013; Negri, Eva Vanna Lorenza/AAC-5698-2019	Chatenoud, Liliane/0000-0001-9599-8229; franceschi, silvia/0000-0003-4181-8071; Negri, Eva/0000-0001-9712-8526; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; parazzini, fabio/0000-0001-5624-4854; Bolis, Giorgio/0000-0001-8216-0080; La Vecchia, Carlo/0000-0003-1441-897X				ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; BAKER RJ, 1978, GLIM SYSTEM; BERRY G, 1993, INT J CANCER, V55, P228; BRINTON LA, 1987, J NATL CANCER I, V79, P23; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; HILDESHEIM A, 1990, INT J CANCER, V45, P860, DOI 10.1002/ijc.2910450513; LAVECCHIA C, 1986, BRIT J CANCER, V54, P311, DOI 10.1038/bjc.1986.178; MANTEL N, 1959, J NATL CANCER I, V22, P719; MONSONEGO J, 1991, INT J CANCER, V48, P533, DOI 10.1002/ijc.2910480410; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PARAZZINI F, 1993, REV EPIDEMIOL SANTE, V41, P53; PARAZZINI F, 1991, GYNECOL ONCOL, V41, P1, DOI 10.1016/0090-8258(91)90246-2; PARAZZINI F, 1989, BRIT J CANCER, V59, P805, DOI 10.1038/bjc.1989.168; PARAZZINI F, 1992, CANCER-AM CANCER SOC, V69, P2276, DOI 10.1002/1097-0142(19920501)69:9<2276::AID-CNCR2820690912>3.0.CO;2-Q; PATER A, 1990, AM J OBSTET GYNECOL, V162, P1099, DOI 10.1016/0002-9378(90)91323-5; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; SCHNEIDER A, 1987, INT J CANCER, V40, P198, DOI 10.1002/ijc.2910400212; SERRA GB, 1992, TERAPIA ORMONALE NEL	19	42	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					85	88		10.1136/bmj.315.7100.85	http://dx.doi.org/10.1136/bmj.315.7100.85			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240046	Green Published			2023-01-03	WOS:A1997XL25200019
J	Groenewoud, JH; van der Maas, PJ; vanderWal, G; Hengeveld, MW; Tholen, AJ; Schudel, WJ; vanderHeide, A				Groenewoud, JH; van der Maas, PJ; vanderWal, G; Hengeveld, MW; Tholen, AJ; Schudel, WJ; vanderHeide, A			Physician-assisted death in psychiatric practice in the Netherlands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; CONSULTATION; SUICIDE	Background In 1994 the Dutch Supreme Court ruled that in exceptional instances, physician-assist ed suicide might be justifiable for patients with unbearable mental suffering but no physical illness. We studied physician-assisted suicide and euthanasia in psychiatric practice in the Netherlands. Methods In 1996, we sent questionnaires to 673 Dutch psychiatrists - about half of all such special ists in the country - and received 552 responses from the 667 who met the study criteria (response rate, 83 percent). We estimated the annual frequencies of requests for physician-assisted suicide by psychiatrists and actual instances of assistance. Results Of the respondents, 205 (37 percent) had at least once received an explicit, persistent request for physician-assisted suicide and 12 had complied. We estimate there are 320 requests a year in psychiatric practice and 2 to 5 assisted suicides. Excluding those who had ever assisted, 345 of the respondents (64 percent) thought physician-assisted suicide because of a mental disorder could be acceptable, including 241 who said they could conceive of instances in which they themselves would be willing to assist. The most frequent reasons for refusing were the belief that the patient had a treatable mental disorder, opposition to assisted suicide in principle, and doubt that the suffering was unbearable or hopeless. Most, but not all, patients who had been assisted by their psychiatrists in suicide had both a mental disorder and a serious physical illness, often in a terminal phase. Thirty percent of the respondents had been consulted at least once by a physician in another specialty about a patient's request for assisted death. The annual number of such consultations was estimated at 310, about 3 percent of the estimated 9700 requests for euthanasia or physician-assisted suicide in medical practice. Conclusions Explicit requests for physician-assisted suicide are not uncommon in psychiatric practice in the Netherlands, but these requests are rarely granted. Psychiatric consultation for medical patients who request physician-assisted death is relatively rare. (C)1997, Massachusetts Medical Society.	ERASMUS UNIV ROTTERDAM, DEPT PSYCHIAT, NL-3000 DR ROTTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; LEIDEN UNIV, DEPT PSYCHIAT, LEIDEN, NETHERLANDS; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT PSYCHIAT, GRONINGEN, NETHERLANDS	Erasmus University Rotterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University - Excl LUMC; University of Groningen	Groenewoud, JH (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BAILE WF, 1993, CANCER, V72, P2786, DOI 10.1002/1097-0142(19931101)72:9<2786::AID-CNCR2820720942>3.0.CO;2-2; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; Bokhove J., 1996, BALANS REKENONDERWIJ; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; *COMM AANV LEV HAN, 1993, DISC NOT HULP BIJ ZE; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; GEVERS S, 1995, BIOETHICS, V9, P309, DOI 10.1111/j.1467-8519.1995.tb00366.x; Griffiths J., 1995, MOD LAW REV, V58, P232, DOI [10.1111/j.1468-2230.1995.tb02006.x, DOI 10.1111/J.1468-2230.1995.TB02006.X]; Humphrey D., 1991, FINAL EXIT PRACTICAL; HUYSE FJ, 1993, HOSP COMMUNITY PSYCH, V44, P733; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; 1994, NED JURISPRUDENTIE, V656, P3142	14	77	78	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1795	1801		10.1056/NEJM199706193362506	http://dx.doi.org/10.1056/NEJM199706193362506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE485	9187071	Green Published			2023-01-03	WOS:A1997XE48500006
J	Thompson, MS				Thompson, MS			Contraceptive implants: Long acting and provider dependent contraception raises concerns about freedom of choice	BMJ-BRITISH MEDICAL JOURNAL			English	Article								David Bromham's editorial on contraceptive implants ignores the wider issues to voice concern that trial by media could limit contraceptive choice by jeopardising research into new methods. However, it is more beneficial to the public for points of conflict to be debated openly. Furthermore, the impetus for research into new contraceptive technology is driven by profit and political motives and is only marginally affected by the media. Implanted contraceptives may increase the choice of contraceptive methods, but they put control of fertility increasingly into the hands of the medical profession. Herein lies their greatest problem: their potential to increase providers' control over clients) choice. There is the danger that certain groups of women may be targeted for their use: in the United States the coercive use of Norplant for mothers receiving welfare benefit has been suggested. Long acting contraceptives are a contraceptive of choice only when they are available without pressure, as part of a wider menu; when instant removal on request is guaranteed; and when there is an open and free flow of information and opinions between users, health professionals, and special interest groups.	UNIV DURHAM, DURHAM DH1 3HP, ENGLAND	Durham University								Bromham DR, 1996, BRIT MED J, V312, P1555, DOI 10.1136/bmj.312.7046.1555; COCKBURN A, 1994, NATION          0725, P116; DUNN CDR, 1993, SCRIPS 1993 REV FERT; FRASER IS, 1989, CONTRACEPTION SCI PR, P109; GARCIA G, 1992, WOMENS PERSPECTIVES, P29; Hardee K., 1994, International Family Planning Perspectives, V20, P59, DOI 10.2307/2133436; HARTMANN B, 1995, REPRODUCTIVE RIGHTS; MORSY S, 1993, NORPLANT HER SKIN, P89; ODLIND V, 1986, ACTA OBSTET GYN SCAN, P15; OLLILA E, 1993, NORPLANT SKIN, P47; WHELAN R, 1992, CHOICES CHILDBEARING; ZIMMERMAN M, 1990, STUD FAMILY PLANN, V21, P92, DOI 10.2307/1966670; 1993, CONTRACEPTIVE TECHNO, V14, P149	13	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1393	1395		10.1136/bmj.313.7069.1393	http://dx.doi.org/10.1136/bmj.313.7069.1393			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VW685	8956712	Green Published			2023-01-03	WOS:A1996VW68500039
J	Morgan, CL; Donnelly, PD; Lester, CA; Assar, DH				Morgan, CL; Donnelly, PD; Lester, CA; Assar, DH			Effectiveness of the BBC's 999 training roadshows on cardiopulmonary resuscitation: Video performance of cohort of unforewarned participants at home six months afterwards	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; CPR SKILLS; RETENTION; SURVIVAL; IMPACT	Objective-To examine the competence of a cohort trained in cardiopulmonary resuscitation by the BBC's 999 training roadshows. Design-Descriptive cohort study applying an innovative testing procedure to a nationwide systematic sample. The test sample received an unsolicited home visit and without warning were required to perform cardiopulmonary resuscitation on a manikin while being videoed. The videos were then analysed for effectiveness and safety using the new test. Setting-Nine cities and surrounding areas in the United Kingdom, Subjects-280 people aged between 11 and 72. Results-Thirty three (12%) trainees were able to perform effective cardiopulmonary resuscitation, but of these 14 (5%) performed one or more elements in a way that was deemed to be potentially injurious, Thus only 19 (7%) trainees were able at six months to provide safe cardiopulmonary resuscitation, In addition, large numbers of subjects failed to shout for help, effectively assess the status of the patient, or alert an ambulance, Significantly better performances were recorded by those under 45 years old (31 (14%) v 2 (4%) gave effective performances respectively, P<0.05), those who had attended a subsequent cardiopulmonary resuscitation course (8 (40%) v 25 (10%) gave effective performances respectively, P<0.0001), and those confident in their initial ability (26 (20%) v 7 (6%) gave effective performances respectively, P<0.005). Females were significantly less likely than males to perform procedures in a harmful way (117 (62%) v 10 (12%) performed safely respectively, P<0.005). Conclusion-Television is an effective means of generating large training cohorts, Volunteers will cooperate with unsolicited testing in their home, such testing being a realistic simulation of the stress and lack of forewarning that would surround a real event, Under such conditions the performance of cardiopulmonary resuscitation was disappointing. However, retraining greatly improves performance.	UNIV WALES COLL CARDIFF,COLL MED,CTR APPL PUBL HLTH MED,CARDIFF F1 8UL,S GLAM,WALES	Cardiff University								ASSAR D, 1995, SHOULD S GLAMORGAN H, P41; BASKETT PJF, 1985, ANAESTHAESIA, V37, P74; BERDEN HJJM, 1993, BRIT MED J, V306, P1576, DOI 10.1136/bmj.306.6892.1576; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1980, ANNU REV MED, V31, P453, DOI 10.1146/annurev.me.31.020180.002321; CUMMINS RO, 1985, BRIT MED J, V291, P1401, DOI 10.1136/bmj.291.6506.1401; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; CUMMINS RO, 1991, CIRCULATION, V83, P1833; DAVID J, 1993, BRIT MED J, V306, P1578, DOI 10.1136/bmj.306.6892.1578; DELIERE DM, 1980, EMT J, V4, P57; FOSSEL M, 1983, J MED EDUC, V58, P568; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GASS DA, 1983, CAN MED ASSOC J, V128, P550; GOMBESKI WR, 1982, AM J PUBLIC HEALTH, V72, P849, DOI 10.2105/AJPH.72.8.849; HEARNE TR, 1988, PACING CLIN ELECTROP, V2, P1968; Hughes R J, 1988, Health Educ J, V47, P53, DOI 10.1177/001789698804700205; JONES J, 1994, AM J EMERG MED, V12, P687, DOI 10.1016/0735-6757(94)90042-6; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; KORTTILA K, 1979, ACTA ANAESTH SCAND, V23, P235, DOI 10.1111/j.1399-6576.1979.tb01445.x; KOWALSKI R, 1984, ANN EMERG MED, V13, P1016, DOI 10.1016/S0196-0644(84)80061-X; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; MARTIN WJ, 1983, AM J PUBLIC HEALTH, V73, P1310, DOI 10.2105/AJPH.73.11.1310; MCKENNA SP, 1985, J OCCUP PSYCHOL, V58, P109, DOI 10.1111/j.2044-8325.1985.tb00186.x; MOSER DK, 1992, HEART LUNG, V21, P372; WEAVER FJ, 1979, JAMA-J AM MED ASSOC, V241, P901, DOI 10.1001/jama.241.9.901; WESTON CFM, 1994, J ROY COLL PHYS LOND, V28, P402; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; 1992, RESUSCITATION, V24, P103	29	53	53	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					912	916						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876093				2023-01-03	WOS:A1996VM75400024
J	Kuhl, PR; GriffithCima, LG				Kuhl, PR; GriffithCima, LG			Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase	NATURE MEDICINE			English	Article							FACTOR RECEPTOR; TYROSINE KINASE; RAT HEPATOCYTES; CELLS; MITOGENESIS; CULTURE; ADULT; INTERNALIZATION; TRANSIENT; BINDING	We have tethered epidermal growth factor (EGF) to a solid substrate in a manner permitting the factor to retain its biological activity as assessed by both mitogenic and morphological assays. Mouse EGF was covalently coupled to aminosilane-modified glass via star poly(ethylene oxide) (PEG), which allows the ligand to retain significant mobility and active conformation. Tethered EGF was as effective as soluble EGF in eliciting DNA synthesis and cell rounding responses of primary rat hepatocytes under different surface conditions. In contrast, physically adsorbed EGF at comparable surface concentrations showed no activity. Presentation of growth factors in this manner may help to expedite their clinical use by permitting greater control of temporal and spatial availability in the extracellular environment.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,CTR BIOMED ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Griffith, Linda/0000-0002-1801-5548	NIGMS NIH HHS [GM 50047] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050047] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHARONOV A, 1978, J BIOL CHEM, V253, P3970; ALLGOR SS, 1996, THESIS MIT; BLANC P, 1992, GASTROENTEROLOGY, V102, P1340; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CIMA LG, 1991, BIOTECHNOL BIOENG, V38, P145, DOI 10.1002/bit.260380207; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; GLADHAUG IP, 1987, EUR J BIOCHEM, V164, P267, DOI 10.1111/j.1432-1033.1987.tb11054.x; KNAUER DJ, 1984, J BIOL CHEM, V269, P5623; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Lopina ST, 1996, BIOMATERIALS, V17, P559, DOI 10.1016/0142-9612(96)88706-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MEYERINGOLD W, 1993, TRENDS BIOTECHNOL, V11, P387, DOI 10.1016/0167-7799(93)90098-T; MORIARITY DM, 1980, ARCH BIOCHEM BIOPHYS, V203, P506, DOI 10.1016/0003-9861(80)90208-8; PIERCE GF, 1995, ANNU REV MED, V46, P467; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; SCHAUDIES RP, 1985, J CELL PHYSIOL, V124, P493, DOI 10.1002/jcp.1041240320; SMITH KA, 1988, INTERLEUKIN, V2, P1; STENGER DA, 1992, J AM CHEM SOC, V114, P8435, DOI 10.1021/ja00048a013; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; TOMOMURA A, 1987, J CELL PHYSIOL, V130, P221, DOI 10.1002/jcp.1041300208; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; WILEY HS, 1989, J BIOL CHEM, V264, P912	28	260	269	0	26	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1996	2	9					1022	1027		10.1038/nm0996-1022	http://dx.doi.org/10.1038/nm0996-1022			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VF497	8782461				2023-01-03	WOS:A1996VF49700038
J	Nageotte, MP; Larson, D; Rumney, PJ; Sidhu, M; Hollenbach, K				Nageotte, MP; Larson, D; Rumney, PJ; Sidhu, M; Hollenbach, K			Epidural analgesia compared with combined spinal-epidural analgesia during labor in nulliparous women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CESAREAN-SECTION; RISK-FACTORS; BIRTH; TRIAL; SUFENTANIL; MANAGEMENT; DYSTOCIA; DELIVERY; PROGRESS; FENTANYL	Background Among nulliparous women, there appears to be an association between the use of epidural analgesia during labor and an increased risk of dystocia. We tested the hypothesis that combined spinal-epidural analgesia, which permits ambulation during labor, is associated with a lower incidence of dystocia than continuous lumbar epidural analgesia. Methods Between July 1995 and September 1996, we randomly assigned 761 nulliparous women in spontaneous labor at term who requested epidural analgesia to receive either continuous lumbar epidural analgesia or a combination of spinal and epidural analgesia. Among the women who received combined spinal-epidural analgesia, some were discouraged from walking and others were encouraged to walk. Maternal and neonatal outcomes, the incidence of dystocia necessitating cesarean section, and measures of patients' satisfaction were compared in the two groups. Results There were no significant differences in the overall rate of cesarean section, the incidence of dystocia, the frequency of maternal or fetal complications, the patients' or nursing staff's assessment of the adequacy of analgesia, or the degree of overall satisfaction between the two groups. Significantly more women receiving combined spinal-epidural analgesia had pruritus (P<0.001) and requested additional epidural bolus doses of local anesthetic (P=0.01). For all the women, dystocia necessitating cesarean section was significantly more likely when analgesia was administered with the fetal vertex at a negative station (odds ratio, 2.5; P<0.001) or at less than 4 cm of cervical dilatation (odds ratio, 2.2; P<0.001). Conclusions As compared with continuous lumbar epidural analgesia, the combination of spinal and epidural analgesia is not associated with an overall decrease in the incidence of cesarean delivery. (C) 1997, Massachusetts Medical Society.	WOMENS HOSP MED CTR,LONG BEACH MEM MED CTR,LONG BEACH,CA; UNIV CALIF SAN DIEGO,DEPT FAMILY PREVENT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego								BREEN TW, 1993, ANESTH ANALG, V77, P919; BUTLER J, 1993, AM J OBSTET GYNECOL, V168, P1407, DOI 10.1016/S0002-9378(11)90773-X; CAMANN WR, 1992, ANESTHESIOLOGY, V77, P884, DOI 10.1097/00000542-199211000-00008; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1193, DOI 10.1097/00000542-199406000-00005; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; DIRO M, 1985, J NATL MED ASSOC, V78, P569; FRIGOLETTO FD, 1995, NEW ENGL J MED, V333, P1163; FRIGOLETTO FD, 1995, NEW ENGL J MED, V333, P745, DOI 10.1056/NEJM199509213331201; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; GRIBBLE RK, 1991, OBSTET GYNECOL, V78, P231; HONET JE, 1992, ANESTH ANALG, V75, P734; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; Lieberman E, 1996, OBSTET GYNECOL, V88, P993, DOI 10.1016/S0029-7844(96)00359-6; LUPE PJ, 1986, OBSTET GYNECOL, V67, P727, DOI 10.1097/00006250-198605000-00023; Mendez-Bauer C, 1975, J Perinat Med, V3, P89, DOI 10.1515/jpme.1975.3.2.89; MITRE IN, 1974, INT J GYNECOL OBSTET, V12, P181; MORGAN MA, 1992, AM J OBSTET GYNECOL, V166, P810, DOI 10.1016/0002-9378(92)91338-B; NEUHOFF D, 1989, OBSTET GYNECOL, V73, P915; PEACEMAN AM, 1993, AM J OBSTET GYNECOL, V169, P940, DOI 10.1016/0002-9378(93)90031-D; PEISERT JF, 1993, OBSTET GYNECOL, V81, P200; PHILIPSEN T, 1989, EUR J OBSTET GYN R B, V30, P27, DOI 10.1016/0028-2243(89)90090-7; RADIN TG, 1993, BIRTH-ISS PERINAT C, V20, P14, DOI 10.1111/j.1523-536X.1993.tb00174.x; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; READ JA, 1981, AM J OBSTET GYNECOL, V139, P669, DOI 10.1016/0002-9378(81)90482-8; SCOTT RT, 1989, MIL MED, V154, P365; SOSA R, 1980, NEW ENGL J MED, V303, P597, DOI 10.1056/NEJM198009113031101; THORP JA, 1991, AM J PERINAT, V8, P402, DOI 10.1055/s-2007-999426; THORP JA, 1989, AM J OBSTET GYNECOL, V161, P670, DOI 10.1016/0002-9378(89)90377-3; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; TURNER MJ, 1990, OBSTET GYNECOL, V76, P159; WUITCHIK M, 1989, OBSTET GYNECOL, V73, P35	33	138	148	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1715	1719		10.1056/NEJM199712113372402	http://dx.doi.org/10.1056/NEJM199712113372402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392696				2023-01-03	WOS:A1997YK65300002
J	Bruera, E				Bruera, E			ABC of palliative care - Anorexia, cachexia, and nutrition	BRITISH MEDICAL JOURNAL			English	Review									GREY NUNS HOSP,EDMONTON,AB,CANADA		Bruera, E (corresponding author), UNIV ALBERTA,EDMONTON,AB T6G 2M7,CANADA.		Bruera, Eduardo/AAA-1550-2022						0	189	199	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1219	1222		10.1136/bmj.315.7117.1219	http://dx.doi.org/10.1136/bmj.315.7117.1219			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393230	Green Published			2023-01-03	WOS:A1997YF25200030
J	Baines, MJ				Baines, MJ			ABC of palliative care - Nausea, vomiting, and intestinal obstruction	BRITISH MEDICAL JOURNAL			English	Review											Baines, MJ (corresponding author), ELLENOR FDN,DARTFORD,KENT,ENGLAND.								0	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1148	1150						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374893				2023-01-03	WOS:A1997YE61500034
J	Hofmann, JC; Wenger, NS; Davis, RB; Teno, J; Connors, AF; Desbiens, N; Lynn, J; Phillips, RS				Hofmann, JC; Wenger, NS; Davis, RB; Teno, J; Connors, AF; Desbiens, N; Lynn, J; Phillips, RS			Patient preferences for communication with physicians about end-of-life decisions	ANNALS OF INTERNAL MEDICINE			English	Article						decision making; cardiopulmonary resuscitation; respiration, artificial	ILL HOSPITALIZED ADULTS; NOT-RESUSCITATE ORDERS; SUPPORT PROGNOSTIC MODEL; MEDICAL INTENSIVE-CARE; NURSING-HOME RESIDENTS; ADVANCE DIRECTIVES; HEALTH-CARE; SUSTAINING TREATMENT; CARDIOPULMONARY-RESUSCITATION; PROMOTING COMPLETION	Background: Physicians are frequently unaware of patient preferences for end-of-life care. Identifying and exploring barriers to patient-physician communication about end-of-life issues may help guide physicians and their patients toward more effective discussions. Objective: To examine correlates and associated outcomes of patient communication and patient preferences for communication with physicians about cardiopulmonary resuscitation and prolonged mechanical ventilation. Design: Prospective cohort study. Setting: Five tertiary care hospitals. Patients: 1832 (85%) of 2162 eligible patients completed interviews. Measurements: Surveys of patient characteristics and preferences for end-of-life care; perceptions of prognosis, decision making, and quality of life; and patient preferences for communication with physicians about end-of-life decisions. Results: Fewer than one fourth (23%) of seriously ill patients had discussed preferences for cardiopulmonary resuscitation with their physicians. Of patients who had not discussed their preferences for resuscitation, 58% were not interested in doing so. Of patients who had not discussed and did not want to discuss their preferences, 25% did not want resuscitation. In multivariable analyses, patient factors independently associated with not wanting to discuss preferences for cardiopulmonary resuscitation included being of an ethnicity other than black (adjusted odds ratio [OR]I 1.48 [95% CI, 1.10 to 1.99), not having an advance directive (OR, 1.35 [CI, 1.04 to 1.76]), estimating an excellent prognosis (OR, 1.72 [Cl, 1.32 to 2.59]), reporting fair to excellent quality of life (OR, 1.36 [CI, 1.05 to 1.76]), and not desiring active involvement in medical decisions (OR, 1.33 [Ci, 1.07 to 1.65]). Factors independently associated with wanting to discuss preferences for resuscitation but not doing so included being black (OR, 1.53 [CI, 1.11 to 2.11]) and being younger (OR, 1.14 per 10-year interval younger [CI, 1.04 to 1.25]). Conclusions: Among seriously ill hospitalized adults, communication about preferences for cardiopulmonary resuscitation is uncommon. A majority of patients who have not discussed preferences for end-of-life care do not want to do so. For patients who do not want to discuss their preferences, as well as patients with an unmet need for such discussions, failure to discuss preferences for cardiopulmonary resuscitation and mechanical ventilation may result in unwanted interventions.	BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; GEORGE WASHINGTON UNIV, MED CTR, CTR IMPROVE CARE DYING, WASHINGTON, DC 20037 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA; UNIV VIRGINIA, SCH MED, DEPT HLTH EVALUAT SCI, CHARLOTTESVILLE, VA 22908 USA; DUKE UNIV, MED CTR, DURHAM, NC 27706 USA; MARSHFIELD CLIN FDN MED RES & EDUC, MARSHFIELD, WI 54449 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; George Washington University; Case Western Reserve University; University of Virginia; Duke University; Marshfield Clinic				Connors, Alfred F./0000-0001-7123-3360	BHP HRSA HHS [5T32PE11001] Funding Source: Medline	BHP HRSA HHS		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BROWN D, 1994, GYNECOL ONCOL, V55, P355, DOI 10.1006/gyno.1994.1306; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; COULTON CJ, 1990, J CLIN EPIDEMIOL, V43, pS51, DOI 10.1016/0895-4356(90)90219-F; CUGLIARI AM, 1995, ARCH INTERN MED, V155, P1893, DOI 10.1001/archinte.155.17.1893; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; ELPERN EH, 1992, CRIT CARE MED, V20, P43, DOI 10.1097/00003246-199201000-00014; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; HEAP MJ, 1993, ANAESTHESIA, V48, P1027; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; LANDEFELD CS, 1990, J CLIN EPIDEMIOL, V43, pS37, DOI 10.1016/0895-4356(90)90216-C; Layde P M, 1995, Arch Fam Med, V4, P518, DOI 10.1001/archfami.4.6.518; LEVY MR, 1984, WESTERN J MED, V140, P111; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MIRVIS DM, 1994, J AM COLL CARDIOL, V24, P1297, DOI 10.1016/0735-1097(94)90112-0; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS15; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS33, DOI 10.1016/0895-4356(90)90215-B; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; REILLY BM, 1995, ARCH INTERN MED, V155, P2317, DOI 10.1001/archinte.155.21.2317; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SATARIANO ER, 1992, AM J PUBLIC HEALTH, V82, P195, DOI 10.2105/AJPH.82.2.195; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SOLOMON MZ, 1995, COMMUNICATING EFFECT, P8; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; Terry M, 1994, Arch Fam Med, V3, P141, DOI 10.1001/archfami.3.2.141; TUNIS SR, 1993, ARCH INTERN MED, V153, P991, DOI 10.1001/archinte.153.8.991; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; UHLMANN RF, 1989, WESTERN J MED, V150, P705; UHLMANN RF, 1984, WESTERN J MED, V140, P114; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351	71	351	353	0	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					1	+		10.7326/0003-4819-127-1-199707010-00001	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214246				2023-01-03	WOS:A1997XG91400001
J	Casarett, D; Ross, LF				Casarett, D; Ross, LF			Overriding a patient's refusal of treatment after an iatrogenic complication	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NOT-RESUSCITATE ORDERS; ADVERSE EVENTS; HOSPITALIZED-PATIENTS; PHYSICIANS; ANESTHESIA; SURGERY				Casarett, D (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							APPLEGATE WB, 1986, ARCH INTERN MED, V146, P2249, DOI 10.1001/archinte.146.11.2249; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERNAT JL, 1993, SURG NEUROL, V40, P7, DOI 10.1016/0090-3019(93)90161-S; BOSK CL, 1979, FORGIVE REMEMBER; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P104; BURGIO GR, 1994, INT CONGR SER, V1071, P1; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; COHEN CB, 1991, NEW ENGL J MED, V325, P1879, DOI 10.1056/NEJM199112263252611; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Engelhardt H. T., 1989, DAXS CASE ESSAYS MED, P79; Feinberg, 1984, HARM OTHERS, VI; Jonsen AR., 1977, PHILOS MED ETHICS IT, P27; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MACKINNON B, 1988, J MED PHILOS, V13, P313, DOI 10.1093/jmp/13.3.313; Nightingale F., 1863, NOTES ON HOSP; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; 1982, STEDMANS MED DICT	25	38	38	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1908	1910		10.1056/NEJM199706263362611	http://dx.doi.org/10.1056/NEJM199706263362611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197222				2023-01-03	WOS:A1997XF75600011
J	Poulter, NR; Chang, CL; Farley, TMM; Kelaghan, J; Meirlk, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; He, S; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumchinda, K; Koetsawang, S; PiyaAnant, M; Vessey, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Vessey, MP; Petitti, D; Perlman, J; Kelaghan, J; Holck, S; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M				Poulter, NR; Chang, CL; Farley, TMM; Kelaghan, J; Meirlk, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; He, S; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumchinda, K; Koetsawang, S; PiyaAnant, M; Vessey, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Vessey, MP; Petitti, D; Perlman, J; Kelaghan, J; Holck, S; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M			Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study	LANCET			English	Article							YOUNG-WOMEN; CARDIOVASCULAR-DISEASE; RISK-FACTORS; DEATH	Background The association between oral contraceptive (OC) use and acute myocardial infarction (AMI) was established in studies from northern Europe and the USA, which took place during the 1960s and 1970s. Few data are available to quantify the risk worldwide of AMI associated with use of OCs introduced since those early studies. This hospital-based case-control study examined the association between a first AMI and current OC use in women from Africa, Asia, Europe, and Latin America (21 centres). Methods Cases were women aged 20-44 years who had definite or possible AMI (classified by history, electrocardiographic, and cardiac-enzyme criteria), who were admitted to hospital, and who survived for at least 24 h. Up to three hospital controls matched by 5-year age-band were recruited for each of the 368 cases (941 controls). All participants were interviewed while in hospital with the same questionnaire, which included information on medical and personal history, lifetime contraceptive use, and blood-pressure screening before the most recent episode of OC use. Odds ratios compared the risk of AMI in current OC users and in non-users (past users and never-users combined). Findings The overall odds ratio for AMI was 5.01 (95% CI 2.54-9.90) in Europe and 4.78 (2.52-9.07) in the non-European (developing) countries; however, these risk estimates reflect the frequent coexistence of other risk factors among OC users who have AMI. Very few AMIs were identified among women who had no cardiovascular risk factors and who reported that their blood pressure had been checked before OC use; odds ratios associated with OC use in such women were not increased in either Europe or the developing countries. Among OC users who smoked ten or more cigarettes per day, the odds ratios in Europe and in the developing countries were over 20. Similarly, among OC users with a history of hypertension (during pregnancy or at any other time), odds ratios were at least ten in both groups of countries, No consistent association between odds ratios for AMI and age of OC users or oestrogen dose was apparent in either group of countries, No significant increase in odds ratios was apparent with increasing duration of OC use among current users, and odds ratios were not significantly increased in women who had stopped using OCs, even after long exposure. The study had insufficient power to examine whether progestagen dose or type had any effect on AMI risk. Interpretation Current use of combined OCs is associated with an increased risk of AMI among women with known cardiovascular risk factors and among those who have not been effectively screened, particularly for blood pressure, AMI is extremely rare in younger (<35 years) non-smoking women who use OCs, and the estimated excess risk of AMI in such women in the European centres is about 3 per 10(6) woman-years. The risk is likely to be even lower if blood pressure is screened before, and presumably during, OC use. Only among older women who smoke is the degree of excess risk associated with OCs substantial (about 400 per 10(6) woman-years).	ESCOLA PAULISTA MED, BR-04023 SAO PAULO, BRAZIL; UNIV CHILE, ESCUELA SALUD PUBL, SANTIAGO, CHILE; NATL RES INST FAMILY PLANNING, BEIJING, PEOPLES R CHINA; SICHUAN FAMILY PLANNING RES INST, CHENGDU, PEOPLES R CHINA; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; ZENTRUM EPIDEMIOL & GESUNDHEITSFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, SHATIN 100083, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, H-6701 SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REPROD, DURANGO, MEXICO; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; ESCUELA MED, VALPARAISO, CHILE; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, BANGKOK, THAILAND; SIRIRAJ HOSP, BANGKOK, THAILAND; UNIV OXFORD, OXFORD, ENGLAND; UNIV BELGRADE, SCH MED, YU-11001 BELGRADE, YUGOSLAVIA; UNIV TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, HARARE, ZIMBABWE; UNIV OXFORD, OXFORD OX1 2JD, ENGLAND; KAISER PERMANENTE, PASADENA, CA USA; NICHHD, BETHESDA, MD USA; AARHUS UNIV, DANISH EPIDMEIOL SCI CTR, DK-8000 AARHUS C, DENMARK; LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND	Universidade Federal de Sao Paulo (UNIFESP); Universidad de Chile; National Research Institute for Family Planning - China; Universidad del Valle; Chinese University of Hong Kong; Szeged University; University of Indonesia; Kenya Medical Research Institute; University West Indies Mona Jamaica; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Oxford; University of Belgrade; University of Zambia; University of Zimbabwe; University of Oxford; Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Poulter, NR (corresponding author), UNIV LONDON UNIV COLL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, TORRINGTON PL, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002914] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAM SA, 1981, BRIT J OBSTET GYNAEC, V88, P838, DOI 10.1111/j.1471-0528.1981.tb01311.x; ANANIJEVICPANDEY J, 1989, INT J EPIDEMIOL, V18, P585, DOI 10.1093/ije/18.3.585; [Anonymous], 1995, J Clin Epidemiol, V48, P1513; BOYCE J, 1963, LANCET, V1, P111, DOI 10.1016/S0140-6736(63)91117-6; Breslow N.E., 1980, STAT METHODS CANC RE, P192; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; FARLEY TMM, 1995, LANCET, V346, P1582; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JAIN AK, 1976, AM J OBSTET GYNECOL, V126, P301, DOI 10.1016/0002-9378(76)90539-1; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1403, DOI 10.1001/jama.239.14.1403; KRUEGER DE, 1980, AM J EPIDEMIOL, V125, P832; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; Lewis MA, 1996, BRIT MED J, V312, P88; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MANN JI, 1975, BRIT MED J, V3, P631, DOI 10.1136/bmj.3.5984.631; MANT D, 1987, J EPIDEMIOL COMMUN H, V41, P215, DOI 10.1136/jech.41.3.215; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; Poulter NR, 1996, J EPIDEMIOL COMMUN H, V50, P674, DOI 10.1136/jech.50.6.674; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; ROSENBERG L, 1980, AM J EPIDEMIOL, V111, P59, DOI 10.1093/oxfordjournals.aje.a112874; SHAPIRO S, 1979, LANCET, V1, P743; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; SLONE D, 1981, NEW ENGL J MED, V305, P420, DOI 10.1056/NEJM198108203050802; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TALBOTT EO, 1989, INT J EPIDEMIOL, V18, P589, DOI 10.1093/ije/18.3.589; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; *WHO COLL STUD CAR, 1996, LANCET, V38, P505; *WHO MONICA PROJ, 1990, MONICA MAN, P11	37	290	290	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	1997	349	9060					1202	1209						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130941				2023-01-03	WOS:A1997WW71700009
J	Doyal, L				Doyal, L			The rationing debate: Rationing within the NHS should be explicit - The case for	BRITISH MEDICAL JOURNAL			English	Article							CARE											*AUD COMM, 1993, WHAT SEEMS MATTER CO, P1; BEAUCHAMP TC, 1994, PRINCIPLES BIOMEDICA, P395; Coast J, 1997, BRIT MED J, V314, P1118, DOI 10.1136/bmj.314.7087.1118; CURTIS S, 1995, HLTH SOC, P138; DAVEY B, 1993, DILEMMAS HLTH CARE, P27; DAVIS H, 1991, COUNSELLING COMMUNIC, P3; DOYAL L, 1990, J LAW SOC, V17, P1, DOI 10.2307/1409951; Doyal L, 1995, Qual Health Care, V4, P273, DOI 10.1136/qshc.4.4.273; DOYAL L, 1991, THEORY HUMAN NEED, P49; EVANS JG, 1993, RATIONING HLTH CARE; FRANKEL S, 1993, RATIONING RATIONALIT, P115; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GRIMSHAW J, 1995, RATIONING HLTH CARE; GUTMAN A, 1980, LIBERAL EQUALITY, P48; HOFFENBERG R, 1993, BRIT MED J, V306, P198; *HOUS COMM HLTH CO, 1995, PRIOR SETT NHS PURCH, P57; HUNTER D, 1995, RATIONING HLTH CARE, P877; KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309; Klein R, 1992, Health Manage Q, V14, P2; KLEIN R, 1996, MANAGING SCARCITY, P83; Maxwell R., 1995, RATIONING HLTH CARE; MECHANIC D, 1995, BRIT MED J, V310, P1655, DOI 10.1136/bmj.310.6995.1655; MOONEY G, 1993, SOC SCI MED, V37, P873, DOI 10.1016/0277-9536(93)90140-Y; NEW B, 1996, RATIONING NHS, P63; Pfeffer N, 1991, IS QUALITY GOOD YOU, P45; Winslow GR, 1982, TRIAGE JUSTICE	26	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1114	1118		10.1136/bmj.314.7087.1114	http://dx.doi.org/10.1136/bmj.314.7087.1114			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133899	Green Published			2023-01-03	WOS:A1997WU23600036
J	Costello, A				Costello, A			Should mother and child health services in developing countries be free? Comment	BRITISH MEDICAL JOURNAL			English	Editorial Material											Costello, A (corresponding author), INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							Abel-Smith B., 1993, NU Nytt om U-landshalsovard, V7, P8; CARRHILL RA, 1994, SOC SCI MED, V39, P1189, DOI 10.1016/0277-9536(94)90351-4; COSTELLO A, 1994, HUMAN FACE HUMAN F 2; COSTELLO A, 1994, HUMAN FACE HUMAN F 1; MCPAKE B, 1993, SOC SCI MED, V36, P1397, DOI 10.1016/0277-9536(93)90382-E; World Bank, 1993, INV HLTH WORLD DEV R	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					941	941		10.1136/bmj.314.7085.941	http://dx.doi.org/10.1136/bmj.314.7085.941			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WQ169	9099119	Green Published			2023-01-03	WOS:A1997WQ16900027
J	Hogerzeil, HV; Couper, MR; Gray, R				Hogerzeil, HV; Couper, MR; Gray, R			Guidelines for drug donations	BRITISH MEDICAL JOURNAL			English	Article								Drug donations are usually given in response to acute emergencies, but they can also be part of development aid. Donations may be given directly by governments, by non-governmental organisations, as corporate donations (direct or through private voluntary organisations), or as private donations to single health facilities. Although there are legitimate differences between these donations, basic rules should apply to them all. This common core of ''good donation practice'' is the basis for new guidelines which have recently been issued by the World Health Organisation after consultation with all relevant United Nations agencies, the Red Cross, and other major international agencies active in humanitarian emergency relief. This article summarises the need for such guidelines, the development process, the core principles, and the guidelines themselves and gives practical advice to recipients and donor agencies.	WHO,DIV DRUG MANAGEMENT & POLICIES,CH-1211 GENEVA,SWITZERLAND; WHO,DIV EMERGENCY & HUMANITARIAN ACT,CH-1211 GENEVA,SWITZERLAND	World Health Organization; World Health Organization	Hogerzeil, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA,SWITZERLAND.							AUTIER P, 1990, LANCET, V335, P1388; *CHRIST MED COMM, 1990, GUID DON REC PHARM D; COHEN S, 1990, LANCET, V335, P745; FORTE GB, 1994, OUNCE PREVENTION WOR; HOEN E, 1993, LANCET, V342, P308; HOGERZEIL HV, 1990, LANCET, V336, P1194, DOI 10.1016/0140-6736(90)92812-V; *WHO, 1990, NEW EM HLTH KIT, P5; *WHO, 1992, WHO TECH REP SER, V825, P13; *WHO, 1996, GUID DRUG DON; *WHO, 1994, MED SUPPL DON GUID W; WOLDEYESUS K, 1994, LANCET, V344, P879, DOI 10.1016/S0140-6736(94)92845-2	11	22	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					737	740		10.1136/bmj.314.7082.737	http://dx.doi.org/10.1136/bmj.314.7082.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116555	Green Published			2023-01-03	WOS:A1997WM77600032
J	Slepushkin, VA; Simoes, S; Dazin, P; Newman, MS; Guo, LS; deLima, MCP; Duzgunes, N				Slepushkin, VA; Simoes, S; Dazin, P; Newman, MS; Guo, LS; deLima, MCP; Duzgunes, N			Sterically stabilized pH-sensitive liposomes - Intracellular delivery of aqueous contents and prolonged circulation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DELIVERY; DRUG-DELIVERY; OLEIC-ACID; PLASMA; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; VESICLES; CELLS; MACROMOLECULES; SYSTEM; INVIVO	Liposomes that destabilize at mildly acidic pH are efficient tools for delivering water-soluble drugs into the cell cytoplasm. However, their use in vivo is limited because of their rapid uptake from circulation by the reticuloendothelial system. Lipid-anchored polyethylene glycol (PEG-PE) prolongs the circulation time of liposomes by steric stabilization. We have found that addition of PEG-PE to the membrane of pH-sensitive liposomes composed of cholesteryl hemisuccinate (CHEMS) and dioleoylphosphatidylethanolamine (DOPE) confers steric stability to these vesicles. This modification significantly decreases the pH-dependent release of a charged water-soluble fluorophore, calcein, from liposomes suspended in buffer or cell culture medium. However, the ability of such liposomes to release calcein intracellularly, measured by a novel flow cytometry technique involving dual fluorescence labeling, remains unaltered. As expected, the release of calcein from liposomes endocytosed by cells is inhibited upon pretreatment of the cells with NH4Cl, an inhibitor of endosome acidification. The unique properties of these liposomes were also demonstrated in vivo. The distribution kinetics of In-111-containing CHEMS/DOPE/PEG-PE liposomes injected intravenously into rats has pharmacokinetic parameters similar to control, non-pH-sensitive, sterically stabilized CHEMS/distearoylphosphatidylcholine/PEG-PE liposomes. In contrast, regular pH-sensitive liposomes lacking the PEG-PE component are cleared rapidly. Sterically stabilized pH-sensitive liposomes may therefore be useful, for the intracellular delivery in vivo of highly negatively charged molecules such as genes, antisense oligonucleotides, and ribozymes for the treatment of various diseases.	UNIV PACIFIC,SCH DENT,DEPT MICROBIOL,SAN FRANCISCO,CA 94115; DI IVANOVSKII INST VIROL,MOSCOW 123098,RUSSIA; UNIV COIMBRA,FAC PHARM,P-3000 COIMBRA,PORTUGAL; UNIV COIMBRA,DEPT BIOCHEM,P-3000 COIMBRA,PORTUGAL; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; SEQUUS PHARMACEUT,MENLO PK,CA 94025	University of the Pacific; Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS; Universidade de Coimbra; Universidade de Coimbra; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Duzgunes, Nejat/V-5058-2019; Simoes, Sergio/A-3798-2012; de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Duzgunes, Nejat/T-5478-2019	de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; Simoes, Sergio/0000-0002-8898-7625	NIAID NIH HHS [AI 32399, AI 33833, AI 35231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032399, R01AI033833, U01AI035231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TM, 1993, BIOCHIM BIOPHYS ACTA, V1150, P9, DOI 10.1016/0005-2736(93)90115-G; ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7; ALLEN TM, 1992, CANCER RES, V52, P2431; ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; BAKKERWOUDENBERG IAJM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P318, DOI 10.1016/0925-4439(92)90010-K; BANGHAM AD, 1964, J MOL BIOL, V8, P660, DOI 10.1016/S0022-2836(64)80115-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; CHONN A, 1995, CURR OPIN BIOTECH, V6, P698, DOI 10.1016/0958-1669(95)80115-4; CHU CJ, 1990, PHARM RES-DORDR, V7, P824, DOI 10.1023/A:1015908831507; Collins D., 1995, LIPOSOMES TOOLS BASI, P201; CONNOR J, 1985, J CELL BIOL, V101, P582, DOI 10.1083/jcb.101.2.582; DUZGUNES N, 1991, MEMBRANE FUSION, P713; ELLENS H, 1984, BIOCHEMISTRY-US, V23, P1532, DOI 10.1021/bi00302a029; GRANT CWM, 1989, MAGNET RESON MED, V11, P236, DOI 10.1002/mrm.1910110211; KHIBANOV AL, 1990, FEBS LETT, V268, P235; KONO K, 1994, BBA-BIOMEMBRANES, V1193, P1, DOI 10.1016/0005-2736(94)90325-5; KONOPKA K, 1993, VIROLOGY, V193, P877, DOI 10.1006/viro.1993.1197; Lasic D.D., 1995, STEALTH LIPOSOMES; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LEE KD, 1993, BIOCHEMISTRY-US, V32, P889, DOI 10.1021/bi00054a021; LESERMAN L, 1995, LIPOSOMES TOOLS BASI, P215; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1127, P249, DOI 10.1016/0005-2760(92)90228-N; LIU D, 1989, BIOCHEM BIOPH RES CO, V162, P326, DOI 10.1016/0006-291X(89)91999-2; LIU DX, 1990, BIOCHIM BIOPHYS ACTA, V1022, P348, DOI 10.1016/0005-2736(90)90284-U; LIU DX, 1989, BIOCHEMISTRY-US, V28, P7700, DOI 10.1021/bi00445a027; Lurquin P.F., 1993, LIPOSOME TECHNOLOGY, V2, P129; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; New R. R. C., 1990, LIPOSOMES PRACTICAL, P71; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; Singhal A., 1994, GENE THERAPEUTICS ME, P118, DOI 10.1007/978-1-4684-6822-9_7; Slepushkin V. A., 1995, Biophysical Journal, V68, pA216; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; STEWART CC, 1990, FLOW CYTOMETRY, P427; STRAUBINGER RM, 1985, FEBS LETT, V179, P148, DOI 10.1016/0014-5793(85)80210-6; STRAUBINGER RM, 1993, METHOD ENZYMOL, V221, P361, DOI 10.1016/0076-6879(93)21030-C; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Torchilin VP, 1993, J LIPOSOME RES, V3, P201, DOI DOI 10.3109/08982109309148213]; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VAAGE J, 1994, CANCER, V73, P2366, DOI 10.1002/1097-0142(19940501)73:9<2366::AID-CNCR2820730920>3.0.CO;2-6; VIANI P, 1993, BIOCHIM BIOPHYS ACTA, V1147, P73, DOI 10.1016/0005-2736(93)90317-S; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1105, P193, DOI 10.1016/0005-2736(92)90194-Q; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C	47	215	231	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2382	2388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	8999949				2023-01-03	WOS:A1997WD67900055
J	Stradling, J				Stradling, J			Sleep apnoea and the misuse of evidence-based medicine	LANCET			English	Editorial Material							AIRWAY PRESSURE TREATMENT; APNEA; PERFORMANCE				Stradling, J (corresponding author), CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD RADCLIFFE TRUST,OXFORD OX3 7LJ,ENGLAND.							CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; FERGUSON KA, 1995, THORAX, V50, P998, DOI 10.1136/thx.50.9.998; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GRUNSTEIN RR, 1995, THORAX, V50, P1106, DOI 10.1136/thx.50.10.1106; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SMITH IE, 1995, J SLEEP RES, V4, P183, DOI 10.1111/j.1365-2869.1995.tb00167.x; SULLIVAN CE, 1981, LANCET, V1, P862; WRIGHT J, 1996, SYSTEMATIC REV OBSTR	14	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					201	202		10.1016/S0140-6736(96)08166-4	http://dx.doi.org/10.1016/S0140-6736(96)08166-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111558				2023-01-03	WOS:A1997WC86100047
J	Corlett, AJ				Corlett, AJ			Aids to compliance with medication	BRITISH MEDICAL JOURNAL			English	Article								Elderly people may need to take several forms of medication, including tablets and capsules, inhalers, insulin, and eye drops. This article describes various aids that are designed to facilitate compliance.			Corlett, AJ (corresponding author), ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							MORRISON J, 1993, HOSP PHARM PRACTICE, V3, P413; *ROYAL PHARM SOC G, 1994, MED ETH PRACT GUID P, V12, P9; WALKER R, 1992, PHARM J, V249, P608; 1989, DRUGS THERAPEUTICS B, V27, P66; 1992, DRUGS THERAPEUTICS B, V30, P3	5	37	38	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					926	929						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876101				2023-01-03	WOS:A1996VM75400033
J	Leach, CL; Greenspan, JS; Rubenstein, SD; Shaffer, TH; Wolfson, MR; Jackson, JC; DeLemos, R; Fuhrman, BP				Leach, CL; Greenspan, JS; Rubenstein, SD; Shaffer, TH; Wolfson, MR; Jackson, JC; DeLemos, R; Fuhrman, BP			Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL DIAPHRAGMATIC-HERNIA; GAS-EXCHANGE; EXOGENOUS SURFACTANT; LAMBS; LUNG; OXYGENATION; THERAPY; BIRTH	Background The intratracheal administration of a perfluorocarbon liquid during continuous positive-pressure ventilation (partial liquid ventilation) improves lung function in animals with surfactant deficiency. Whether partial liquid ventilation is effective in the treatment of infants with severe respiratory distress syndrome is not known. Methods We studied the efficacy of partial liquid ventilation with perflubron in 13 premature infants with severe respiratory distress syndrome in whom conventional treatment, including surfactant therapy, had failed. Partial liquid ventilation was initiated by instilling perflubron during conventional mechanical ventilation to a volume approximating the functional residual capacity. Infants were considered to have completed the study if they received partial liquid ventilation for at least 24 hours. Results Ten infants received partial liquid ventilation for 24 to 76 hours. In the other th ree infants, partial liquid ventilation was discontinued within four hours in favor of high-frequency ventilation, which was not permitted by the protocol, and the data from these infants were excluded from the analysis. Within one hour after the instillation of perflubron, the arterial oxygen tension increased by 138 percent and the dynamic compliance increased by 61 percent; the mean (+/-SD) oxygenation index was reduced from 49+/-60 to 17+/-16. Chest radiographs showed symmetric filling, with patchy clearing during the return from partial liquid to gas ventilation. There were no adverse events clearly attributable to partial liquid ventilation, Infants were weaned from partial liquid to gas ventilation without complications. Eight infants survived to 36 weeks' corrected gestational age. Conclusions Partial liquid ventilation leads to clinical improvement and survival in some infants with severe respiratory distress syndrome who are not predicted to survive. (C) 1996, Massachusetts Medical Society.	SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PEDIAT,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19122; TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19122; ST CHRISTOPHERS HOSP CHILDREN,PHILADELPHIA,PA 19133; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105; UNIV SO CALIF,MED CTR,DEPT PEDIAT,LOS ANGELES,CA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	Leach, CL (corresponding author), CHILDRENS HOSP BUFFALO,DIV NEONATOL,219 BRYANT ST,BUFFALO,NY 14222, USA.							AVERY ME, 1991, NEW ENGL J MED, V324, P910, DOI 10.1056/NEJM199103283241308; CHARON A, 1989, PEDIATRICS, V83, P348; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; CURTIS SE, 1993, J APPL PHYSIOL, V75, P2696, DOI 10.1152/jappl.1993.75.6.2696; DELEMOS R, 1994, PEDIATR RES, V35, pA330; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; Haycock KH, 1992, STATVIEW; IKEGAMI M, 1984, J APPL PHYSIOL, V57, P1134, DOI 10.1152/jappl.1984.57.4.1134; IKEGAMI M, 1987, AM REV RESPIR DIS, V136, P892, DOI 10.1164/ajrccm/136.4.892; JOBE A, 1984, J CLIN INVEST, V73, P848, DOI 10.1172/JCI111280; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; KOBAYASHI T, 1991, PEDIATR RES, V29, P353, DOI 10.1203/00006450-199104000-00005; KYLSTRA JA, 1972, J APPL PHYSIOL, V33, P32, DOI 10.1152/jappl.1972.33.1.32; LEACH CL, 1995, J PEDIATR-US, V126, P412, DOI 10.1016/S0022-3476(95)70461-2; LEACH CL, 1993, CRIT CARE MED, V21, P1270, DOI 10.1097/00003246-199309000-00008; LEACH CL, 1995, PEDIATR RES, V37, pA220; LEACH CL, 1994, PEDIATR RES, V35, pA394; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; MAJOR D, 1995, J PEDIATR SURG, V30, P1178, DOI 10.1016/0022-3468(95)90016-0; Papo MC, 1996, CRIT CARE MED, V24, P466, DOI 10.1097/00003246-199603000-00017; SALMAN NH, 1995, CRIT CARE MED, V23, P919, DOI 10.1097/00003246-199505000-00021; SEGERER H, 1991, PEDIATR RES, V30, P591, DOI 10.1203/00006450-199112000-00022; SHAFFER TH, 1976, PEDIATR RES, V10, P227, DOI 10.1203/00006450-197604000-00005; SHAFFER TH, 1995, FASEB J, V9, pA17; Steinhorn DM, 1996, CRIT CARE MED, V24, P1252, DOI 10.1097/00003246-199607000-00031; Volpe JJ, 1995, NEUROLOGY NEWBORN, P403; WILCOX DT, 1995, CRIT CARE MED, V23, P1858, DOI 10.1097/00003246-199511000-00012; WOLFSON MR, 1995, PEDIATR RES, V37, pA246	29	327	334	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					761	767		10.1056/NEJM199609123351101	http://dx.doi.org/10.1056/NEJM199609123351101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8778584				2023-01-03	WOS:A1996VF78600001
J	Jacobs, HS				Jacobs, HS			Controversies in management - Hormone replacement therapy for all? Universal prescription is desirable - Not for everybody	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; ESTROGEN				Jacobs, HS (corresponding author), MIDDLESEX HOSP,COBBOLD LABS,LONDON W1N 8AA,ENGLAND.		Jacobs, Howard/A-9845-2009					BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; JACOBS HS, 1992, BMJ-BRIT MED J, V305, P1403, DOI 10.1136/bmj.305.6866.1403; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; Stampfer Meir J., 1994, P223	9	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					351	352		10.1136/bmj.313.7053.351	http://dx.doi.org/10.1136/bmj.313.7053.351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760748	Green Published			2023-01-03	WOS:A1996VC30000026
J	Davies, RH				Davies, RH			A difficult case - Home ventilation of a child with motor and sensory neuropathy	BRITISH MEDICAL JOURNAL			English	Article											Davies, RH (corresponding author), GWYNEDD COMMUNITY HLTH TRUST,WOMEN & CHILDRENS BUSINESS UNIT HEADQUARTERS,CAERNARVON LL55 1BH,GWYNEDD,WALES.							KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309	1	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					153	154		10.1136/bmj.313.7050.153	http://dx.doi.org/10.1136/bmj.313.7050.153			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688778	Green Published			2023-01-03	WOS:A1996UY92100022
J	Nightingale, SL				Nightingale, SL			New cancer therapy initiatives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2023-01-03	WOS:A1996UF47800009
J	Thomas, DHV; Noyce, PR				Thomas, DHV; Noyce, PR			Over the counter drugs - The interface between self medication and the NHS	BRITISH MEDICAL JOURNAL			English	Article								Cost and convenience seem to be major factors in determining whether, given the choice, patients purchase a medicine over the counter or obtain it on prescription. With current arrangements, exemption from prescription charges provides an incentive to continue to obtain products on NHS prescription even when they are available over the counter. There is therefore no simple relation between the availability of over the counter medicines and the level of prescribing of deregulated products. The appropriate use of over the counter medicines-particularly those that have only recently been deregulated-places a burden of care on community pharmacists and calls for closer working relationships with general practitioners. In particular, systems for referral and for recording details of both prescribed and over the counter medicines need to be developed, and a direct route needs to be established for community pharmacists to report adverse drug reactions to over the counter products.	UNIV MANCHESTER,DEPT PHARM,MANCHESTER M13 9PL,LANCS,ENGLAND; ST JOHNS HLTH CTR,WOKING GU21 1TD,SURREY,ENGLAND	University of Manchester								BAHRA MS, 1994, PHARM J, V253, pR10; BLENKINSOPP A, 1991, BRIT J GEN PRACT, V41, P116; BRADLEY C, 1995, PRESCRIBER      0305, P75; *BRIT MARK RES BUR, 1987, EVERYDAY HLTH CARE C; COLWELL J, 1993, PHARM J, V251, P194; Consumers' Association, 1991, WHICH WAY HLTH, P191; HEAD S, 1994, BRIT MED J, V309, P957, DOI 10.1136/bmj.309.6959.957a; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; NOYCE PR, 1992, INT J PHARM PRACT, V1, P122; NOYCE PR, 1995, PARLIAMENTARY BREIF, V3, P85; *PROPR ASS GREAT B, 1995, OTC DIR 1995 6; Rogers PJ, 1994, INT J PHARM PRACT, V3, P6; ROGERS PJ, 1992, PHARM J, V248, P193; RYAN M, 1990, HEALTH POLICY, V16, P233, DOI 10.1016/0168-8510(90)90424-C; SCHAFHEUTLE EL, 1994, THESIS U MANCHESTER; TERMIN P, 1983, J HLTH EC, V2, P187; THOM C, 1994, PHARM J, V253, P616; 1994, OTG BUSINESS NE 0706, P13; 1994, READERS DIGEST	19	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					688	691						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597739				2023-01-03	WOS:A1996UB11000032
J	Hillberg, RE; Johnson, DC				Hillberg, RE; Johnson, DC			Current concepts - Noninvasive ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITIVE-PRESSURE VENTILATION; ACUTE RESPIRATORY-FAILURE; CONGESTIVE-HEART-FAILURE; OBSTRUCTIVE PULMONARY-DISEASE; NOCTURNAL NASAL VENTILATION; CHEYNE-STOKES RESPIRATION; TERM FOLLOW-UP; MECHANICAL VENTILATION; AIRWAY PRESSURE; SUPPORT VENTILATION		HARVARD UNIV,SCH MED,BOSTON,MA 02138; MASSACHUSETTS GEN HOSP,DEPT MED,PULM & CRIT CARE UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Hillberg, RE (corresponding author), SPAULDING REHABIL HOSP,DEPT RESP SERV,BOSTON,MA 02114, USA.							AbouShala N, 1996, CRIT CARE MED, V24, P705, DOI 10.1097/00003246-199604000-00025; Ambrosino N, 1996, EUR RESPIR J, V9, P795, DOI 10.1183/09031936.96.09040795; AMBROSINO N, 1992, CHEST, V101, P385, DOI 10.1378/chest.101.2.385; AMBROSINO N, 1992, EUR RESPIR REV, V2, P353; APPENDINI L, 1994, AM J RESP CRIT CARE, V149, P1069, DOI 10.1164/ajrccm.149.5.8173743; Bach J R, 1995, Monaldi Arch Chest Dis, V50, P223; BACH JR, 1987, CHEST, V92, P168, DOI 10.1378/chest.92.1.168; BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BERGOFSKY EH, 1979, AM REV RESPIR DIS, V119, P643; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BLACK JW, 1988, CHEST, V93, P333, DOI 10.1378/chest.93.2.333; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BRADLEY TD, 1992, AM REV RESPIR DIS, V145, P377, DOI 10.1164/ajrccm/145.2_Pt_1.377; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Claman DM, 1996, CHEST, V110, P1581, DOI 10.1378/chest.110.6.1581; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; CONFALONIERI M, 1994, RESPIRATION, V61, P310; Confalonieri M, 1996, EUR RESPIR J, V9, P422, DOI 10.1183/09031936.96.09030422; Corrado A, 1996, EUR RESPIR J, V9, P1531, DOI 10.1183/09031936.96.09071531; CURRAN FJ, 1981, ARCH PHYS MED REHAB, V62, P270; ELLIOTT MW, 1993, ANAESTHESIA, V48, P8; ELLIS ER, 1988, CHEST, V94, P811, DOI 10.1378/chest.94.4.811; FERGUSON GT, 1995, AM J RESP CRIT CARE, V151, P1126; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; GARAY SM, 1981, AM J MED, V70, P269, DOI 10.1016/0002-9343(81)90761-0; GAY PC, 1991, MAYO CLIN PROC, V66, P695, DOI 10.1016/S0025-6196(12)62081-3; GOLDBERG P, 1995, EUR RESPIR J, V8, P1894, DOI 10.1183/09031936.95.08111894; GOLDSTEIN RS, 1987, AM REV RESPIR DIS, V135, P1049; Hanly PJ, 1996, AM J RESP CRIT CARE, V153, P272, DOI 10.1164/ajrccm.153.1.8542128; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; HILL NS, 1992, AM REV RESPIR DIS, V145, P365, DOI 10.1164/ajrccm/145.2_Pt_1.365; HILL NS, 1986, CHEST, V90, P897, DOI 10.1378/chest.90.6.897; HOO GWS, 1994, CRIT CARE MED, V22, P1253, DOI 10.1097/00003246-199408000-00009; HORMANN C, 1994, EUR J ANAESTH, V11, P37; JAVAHERI S, 1995, ANN INTERN MED, V123, P77; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; JUBRAN A, 1995, AM J RESP CRIT CARE, V152, P129, DOI 10.1164/ajrccm.152.1.7599811; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LAPINSKY SE, 1994, CHEST, V105, P229, DOI 10.1378/chest.105.1.229; LEGER P, 1989, Respiratory Care, V34, P73; LEGER P, 1994, CHEST, V105, P100, DOI 10.1378/chest.105.1.100; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; LOFASO F, 1995, CHEST, V108, P772, DOI 10.1378/chest.108.3.772; Lofaso F, 1996, AM J RESP CRIT CARE, V153, P1591, DOI 10.1164/ajrccm.153.5.8630607; MARINO W, 1991, CHEST, V99, P681, DOI 10.1378/chest.99.3.681; Masa JF, 1997, CHEST, V112, P207, DOI 10.1378/chest.112.1.207; Meduri GU, 1996, CHEST, V110, P767, DOI 10.1378/chest.110.3.767; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; Meduri GU, 1996, CLIN CHEST MED, V17, P513, DOI 10.1016/S0272-5231(05)70330-0; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; MEYER TJ, 1994, ANN INTERN MED, V120, P760, DOI 10.7326/0003-4819-120-9-199405010-00008; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V151, P92, DOI 10.1164/ajrccm.151.1.7812579; NAVA S, 1990, CHEST, V98, P857, DOI 10.1378/chest.98.4.857; PINTO AC, 1995, J NEUROL SCI, V129, P19, DOI 10.1016/0022-510X(95)00052-4; Pollack CV, 1996, ANN EMERG MED, V27, P189, DOI 10.1016/S0196-0644(96)70321-9; Quaranta AJ, 1997, CHEST, V111, P467, DOI 10.1378/chest.111.2.467; RENSTON JP, 1994, CHEST, V105, P1053, DOI 10.1378/chest.105.4.1053; SACCHETTI AD, 1995, ACAD EMERG MED, V2, P714, DOI 10.1111/j.1553-2712.1995.tb03623.x; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; Soudon P, 1995, Monaldi Arch Chest Dis, V50, P228; Spessert C K, 1993, Am J Crit Care, V2, P54; STRUMPF DA, 1991, AM REV RESPIR DIS, V144, P1234, DOI 10.1164/ajrccm/144.6.1234; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; UNTERBORN JN, 1994, CLIN CHEST MED, V15, P765; Vitacca M, 1996, INTENS CARE MED, V22, P94, DOI 10.1007/BF01720714	70	102	107	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1746	1752		10.1056/NEJM199712113372407	http://dx.doi.org/10.1056/NEJM199712113372407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392701				2023-01-03	WOS:A1997YK65300007
J	Marais, R; Spooner, RA; Stribbling, SM; Light, Y; Martin, J; Springer, CJ				Marais, R; Spooner, RA; Stribbling, SM; Light, Y; Martin, J; Springer, CJ			A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy	NATURE BIOTECHNOLOGY			English	Article						drug delivery; enzyme engineering; bystander effect; cancer therapy	TISSUE-SPECIFIC EXPRESSION; THYMIDINE KINASE GENE; BRAIN-TUMORS; CANCER; TRANSDUCTION; REGRESSION; COMPONENT; G2	The potential for expressing the bacterial enzyme carboxypeptidase G2 (CPG2) tethered to the outer surface of mammalian cells was examined for use in gene-directed enzyme prodrug therapy, The affinity of CPG2 for the substrate methotrexate was unaffected by three mutations required to prevent N-linked glycosylation. Breast carcinoma MDA MB 361 cells expressing CPG2 internally showed only a very modest increase in sensitivity to the prodrug CMDA because the prodrug did not enter the cells. Cells expressing surface-tethered CPG2, however, became 16-24-fold more sensitive to CMDA and could mount a good bystander effect. Systemic administration of CMDA to mice bearing established xenografts of the transfected cells led to sustained tumor regressions or cures.	INST CANC RES,CRC,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND; INST CANC RES,CRC,CTR CANC THERAPEUT,SUTTON SM2 5NG,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK			Spooner, Robert/A-9870-2010	Spooner, Robert/0000-0001-9593-0195; Marais, Richard/0000-0001-7484-4183; Stribbling, Stephen/0000-0001-6820-4630				BARBA D, 1993, J NEUROSURG, V79, P729, DOI 10.3171/jns.1993.79.5.0729; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BORELLI E, 1988, P NATL ACAD SCI USA, V85, P7572; Bridgewater JA, 1995, EUR J CANCER, V31A, P2362, DOI 10.1016/0959-8049(95)00436-X; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; CHANSON M, 1989, J CELL PHYSIOL, V139, P147, DOI 10.1002/jcp.1041390121; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gagandeep S, 1996, CANCER GENE THER, V3, P83; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P8302, DOI 10.1073/pnas.91.17.8302; HUGHES BW, 1995, CANCER RES, V55, P3339; Marais R, 1996, CANCER RES, V56, P4735; MOOLTEN FL, 1986, CANCER RES, V46, P5276; NABEL GJ, 1994, HUM GENE THER, V5, P57, DOI 10.1089/hum.1994.5.1-57; Niculescu-Duvaz I, 1997, Expert Opin Investig Drugs, V6, P685, DOI 10.1517/13543784.6.6.685; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; OMALLEY BW, 1995, CANCER RES, V55, P1080; Pavlovic J, 1996, GENE THER, V3, P635; RAMASH R, 1996, CANCER GENE THER, V3, P373; RAMASH R, 1996, EXP HEMATOL, V24, P829; RAPTIS I, 1995, ELECTROPORATION ADHE, P93; RAPTIS L, 1990, DNA CELL BIOL, V9, P615, DOI 10.1089/dna.1990.9.615; SHERWOOD RF, 1985, EUR J BIOCHEM, V148, P447, DOI 10.1111/j.1432-1033.1985.tb08860.x; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Springer C. J., 1993, Drugs of the Future, V18, P212; SPRINGER CJ, 1990, J MED CHEM, V33, P677, DOI 10.1021/jm00164a034; Stribbling SM, 1997, CANCER CHEMOTH PHARM, V40, P277, DOI 10.1007/s002800050659; Tanaka T, 1996, CANCER RES, V56, P1341; VILE RG, 1994, CANCER RES, V54, P6228; VILE RG, 1993, CANCER RES, V53, P3860; [No title captured]	32	66	76	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1373	1377		10.1038/nbt1297-1373	http://dx.doi.org/10.1038/nbt1297-1373			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415889				2023-01-03	WOS:A1997YK36100028
J	Wood, CGA; Whittet, S; Bradbeer, CS				Wood, CGA; Whittet, S; Bradbeer, CS			ABC of palliative care - HIV infection and AIDS	BRITISH MEDICAL JOURNAL			English	Review									GUYS & ST THOMASS HOSP TRUST,LONDON,ENGLAND		Wood, CGA (corresponding author), N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND.								0	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1433	1436		10.1136/bmj.315.7120.1433	http://dx.doi.org/10.1136/bmj.315.7120.1433			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418094	Green Published			2023-01-03	WOS:A1997YJ67200030
J	Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W				Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NEUROL INST,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	Caplan, LR (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT NEUROL,314,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Mohr, J/AAO-9694-2020					Adams HP, 1996, STROKE, V27, P1711; [Anonymous], 1996, NEUROLOGY, V47, P835; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; PESSIN MS, 1995, CEREBROVASCULAR DISEASES, P409; SLOAN MA, 1987, ARCH NEUROL-CHICAGO, V44, P748, DOI 10.1001/archneur.1987.00520190052017; YAMAGUCHI T, 1995, THROMBOLYTIC THERAPY, P111	7	147	151	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1309	1310						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345084				2023-01-03	WOS:A1997YC92000012
J	Lange, S; Nussler, F; Kauschke, E; Lutsch, G; Cooper, EL; Herrmann, A				Lange, S; Nussler, F; Kauschke, E; Lutsch, G; Cooper, EL; Herrmann, A			Interaction of earthworm hemolysin with lipid membranes requires sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SEMLIKI-FOREST-VIRUS; PORE-FORMING DOMAIN; CELOMIC FLUID; LUMBRICUS-TERRESTRIS; EISENIA-FOETIDA; CATALYZED OXIDATION; COLICIN-A; CHOLESTEROL; TOXIN	Lytic activity in the coelomic fluid of earthworm (Eisenia fetida fetida) has been ascribed to eiseniapore, a hemolytic protein of 38 kDa. Since receptors for eiseniapore on target cell membranes are not known, we used lipid vesicles of various composition to determine whether specific lipids may serve as receptors, Lytic activity of eiseniapore was probed by the relief of fluorescence dequenching from the fluorophore 8-aminonaphthalene-1,3,6-trisulfonic acid originally incorporated into the vesicle lumen as a complex with p-xylene-bis-pyridinium bromide, Hemolysin binds to and disturbs the lipid bilayer only when distinct sphingolipids consisting of a hydrophilic head group as phosphorylcholine or galactosyl as well as the ceramide backbone, e,g. sphingomyelin, are present. Cholesterol enhances eiseniapore lytic activity toward sphingomyelin-containing vesicles probably due to interaction with sphingomyelin. Leakage of vesicles was most efficient when the lipid composition resembled that of the outer leaflet of human erythrocytes. Presumably, an oligomeric protein pore formed by six monomers is responsible for leakage of sphingomyelin-containing vesicles. The secondary structure of eiseniapore did not change upon binding to lipid membranes. The lytic activity of eiseniapore was completely abolished after its denaturation or after preincubation with polyclonal antibodies. Our results suggest that the presence of specific sphingolipids is sufficient to mediate lytic activity of eiseniapore, This action contributes to our understanding of earthworm immune responses.	HUMBOLDT UNIV BERLIN, MATH NAT WISSENSCH FAK 1, INST BIOL BIOPHYS, D-10115 BERLIN, GERMANY; MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY; UNIV GREIFSWALD, ZOOL INST & MUSEUM, D-17489 GREIFSWALD, GERMANY; UNIV CALIF LOS ANGELES, MED CTR, DEPT NEUROBIOL, LAB COMPARAT IMMUNOL, LOS ANGELES, CA 90095 USA	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ernst Moritz Arndt Universitat Greifswald; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								ALBRO PW, 1992, LIPIDS, V27, P136, DOI 10.1007/BF02535813; ANDRE FRANCIS, 1963, BULL BIOL FRANCE ET BELGIQUE, V97, P3; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bouche M.B., 1972, LOMBRICIENS FRANCE E; CANICATTI C, 1987, DEV COMP IMMUNOL, V11, P29, DOI 10.1016/0145-305X(87)90005-X; CANICATTI C, 1990, EXPERIENTIA, V46, P239, DOI 10.1007/BF01951753; CHITWOOD DJ, 1995, LIPIDS, V30, P567, DOI 10.1007/BF02537032; COOPER EL, 1995, CELL IMMUNOL, V166, P113, DOI 10.1006/cimm.1995.0013; Cossarizza A, 1996, EXP CELL RES, V224, P174, DOI 10.1006/excr.1996.0125; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; EUE I, 1991, DEV COMP IMMUNOL S1, V15, P75; GRONBERG L, 1990, BIOCHEMISTRY-US, V29, P3173, DOI 10.1021/bi00465a003; HORI T, 1993, PROG LIPID RES, V32, P25, DOI 10.1016/0163-7827(93)90003-F; KANESHIRO ES, 1987, J LIPID RES, V28, P1241; KARNOVSKY ML, 1969, CHEM ZOOL, V4, P205; KAUSCHKE E, 1987, DEV COMP IMMUNOL, V11, P331, DOI 10.1016/0145-305X(87)90077-2; KAUSCHKE E, 1987, J COMP PHYSIOL B, V157, P77, DOI 10.1007/BF00702731; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LANGE S, 1995, 23 M FEBS BAS AUG 13, P285; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MALONEY MD, 1991, PARASITOL RES, V77, P294, DOI 10.1007/BF00930904; Marsh D, 1981, Mol Biol Biochem Biophys, V31, P51; MCLAUGHIN J, 1970, COMP BIOCH PHYSL B, V38, P147; MEINARDI E, 1995, BIOCHEM BIOPH RES CO, V216, P348, DOI 10.1006/bbrc.1995.2630; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; Mohrig W, 1996, COMP BIOCHEM PHYS A, V115, P19, DOI 10.1016/0300-9629(95)02100-0; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; NISHIMURA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P141, DOI 10.1016/0005-2760(91)90001-X; OKAMURA N, 1985, J NEUROCHEM, V45, P1875, DOI 10.1111/j.1471-4159.1985.tb10546.x; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PARRINELLO N, 1995, DEV COMP IMMUNOL, V19, P31, DOI 10.1016/0145-305X(94)00046-I; PODACK ER, 1982, J BIOL CHEM, V257, P5204; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; POMORSKI T, 1994, MOL MEMBR BIOL, V11, P39, DOI 10.3109/09687689409161028; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Quaglino D, 1996, EUR J CELL BIOL, V70, P278; Roch P, 1996, ITAL J ZOOL, V63, P311, DOI 10.1080/11250009609356151; ROCH P, 1991, DEV COMP IMMUNOL, V15, P27, DOI 10.1016/0145-305X(91)90044-Y; ROCH P, 1981, COMP BIOCHEM PHYS B, V69, P829, DOI 10.1016/0305-0491(81)90390-4; ROCH P, 1989, BIOCHIM BIOPHYS ACTA, V983, P193, DOI 10.1016/0005-2736(89)90233-2; SATOUCHI K, 1993, LIPIDS, V28, P837, DOI 10.1007/BF02536239; SCHREIER S, 1978, BIOCHIM BIOPHYS ACTA, V515, P395, DOI DOI 10.1016/0304-4157(78)90011-4; SCHWOCH G, 1973, MOL CELL BIOCHEM, V2, P197, DOI 10.1007/BF01795474; SIMA P, 1993, CRIT REV IMMUNOL, V13, P83; SLOTTE JP, 1993, BIOCHEMISTRY-US, V32, P7886, DOI 10.1021/bi00082a008; SLOTTE JP, 1992, BIOCHEMISTRY-US, V31, P5472, DOI 10.1021/bi00139a008; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1994, NATO ASI SERIES 82, V2, P181; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	60	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20884	20892		10.1074/jbc.272.33.20884	http://dx.doi.org/10.1074/jbc.272.33.20884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252415	hybrid			2023-01-03	WOS:A1997XR22100085
J	Ohno, K; Sawai, K; Iijima, Y; Levin, B; Meruelo, D				Ohno, K; Sawai, K; Iijima, Y; Levin, B; Meruelo, D			Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A	NATURE BIOTECHNOLOGY			English	Article						gene therapy vector; alphavirus; targeting; protein A	RETROVIRAL VECTORS; EXPRESSION VECTORS; GENE-EXPRESSION; RECEPTOR; ANTIBODIES; NEUROVIRULENCE; PATHOGENESIS; GENERATION; MICE; RNA	Sindbis virus can infect a broad range of insect and vertebrate cell types due to the widespread distribution of the cellular receptor for the virus. The development of Sindbis virus vectors that target specific cell types could have important implications for the design of gene therapy strategies. To achieve this goal we have designed and constructed Sindbis virus particles displaying the IgG-binding domain of protein A. The protein A-envelope chimeric Sindbis virus vector has minimal infectivities against baby hamster kidney and human cell lines. When used in conjunction with monoclonal antibodies that react with cell-surface antigens, however, the protein A-envelope chimeric virus was able to infect human cell lines with high efficiency. Infection rates were 90% or higher for human lymphoblastoid cells. A variety of cells could be targeted by changing the monoclonal antibody without generating a new recombinant virus.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [CA68498, CA22247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022247, R01CA068498, R01CA022247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; BREDENBEEK PJ, 1992, SEMIN VIROL, V3, P297; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; DUBUISSON J, 1993, J VIROL, V67, P3363, DOI 10.1128/JVI.67.6.3363-3374.1993; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LEVINE B, 1992, J VIROL, V66, P6429, DOI 10.1128/JVI.66.11.6429-6435.1992; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988; Marin M, 1996, J VIROL, V70, P2957, DOI 10.1128/JVI.70.5.2957-2962.1996; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; OLMSTED RA, 1986, VIROLOGY, V148, P245, DOI 10.1016/0042-6822(86)90322-3; POLO JM, 1988, J VIROL, V62, P2124, DOI 10.1128/JVI.62.6.2124-2133.1988; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; STANLEY J, 1985, J VIROL, V56, P110, DOI 10.1128/JVI.56.1.110-119.1985; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; SURCLIA A, 1982, TRENDS BIOCHEM SCI, V7, P74; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607	25	133	166	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					763	767		10.1038/nbt0897-763	http://dx.doi.org/10.1038/nbt0897-763			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255791				2023-01-03	WOS:A1997XM70700028
J	Hesketh, T; Zhu, WX				Hesketh, T; Zhu, WX			Health in China - Traditional Chinese medicine: One country, two systems	BRITISH MEDICAL JOURNAL			English	Article								China is the only country in the world where Western medicine and traditional medicine are practised alongside each ether at every level of the healthcare system, Traditional Chinese medicine has a unique theoretical and practical approach to the treatment of disease, which has developed over thousands of years. Traditional treatments include herbal remedies, acupuncture, acupressure and massage, and moxibustion. They account for around 40% of all health care delivered in China, The current government policy of expansion of traditional facilities and manpower is being questioned because many hospitals using traditional Chinese medicine are already underutilised and depend on government subsidies for survival, Research priorities include randomised controlled trials of common treatments and analysis of the active agents in herbal remedies, As more studies show the clinical effectiveness of traditional Chinese medicine, an integrated approach to disease using a combination of Western medicine and traditional approaches becomes a possibility for the future.	HLTH UNLIMITED,LONDON SE1 9NT,ENGLAND		Hesketh, T (corresponding author), CTR INT CHILD HLTH,LONDON WC1 N1EH,ENGLAND.			Hesketh, Therese/0000-0002-7564-9221				Chen R, 1966, CHINA REV, V3, P24; HESKETH T, 1994, BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441; HIEN TT, 1993, LANCET, V341, P603; Kaptchuk T, 1983, WEB HAS NO WEAVER; World Bank, 1992, CHIN LONG TERM ISS O; ZHENG X, 1995, SOC SCI MED, V41, P1057, DOI 10.1016/0277-9536(94)00431-R; 1992, CHINA DAILY     1104	7	147	155	5	52	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					115	117		10.1136/bmj.315.7100.115	http://dx.doi.org/10.1136/bmj.315.7100.115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240055	Green Published			2023-01-03	WOS:A1997XL25200033
J	Alpers, A; Lo, B				Alpers, A; Lo, B			Does it make clinical sense to equate terminally ill patients who require life-sustaining interventions with those who do not?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; DEATH	Two US courts of appeals have ruled that competent, terminally ill patients have a constitutional right to physician-assisted suicide. The cases are now before the US Supreme Court, which is expected to issue a ruling later this year. This article analyzes the keystone of the courts' ruling: their assertion that competent, terminally ill patients who are being kept alive on life support are equivalent to competent, terminally ill patients who do not require such support. Because the former are permitted to end their lives by refusing treatment, the courts found that the latter also have a right to determine the time and manner of their death, through prescriptions for lethal doses of medication. This article analyzes whether the courts' thinking is premised on a clinically plausible view of the care of terminally ill patients, Based on a discussion of common situations involving terminal illness, we argue that the courts' reasoning is deeply flawed. The article also analyzes how the implications of the courts' reasoning might undermine the care of terminally ill patients.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ALPERS A, 1995, JAMA-J AM MED ASSOC, V273, P156, DOI 10.1001/jama.273.2.156; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BRODY H, 1996, BIOLAW, V2, P154; Cantor NL., 1993, CIVILIZATION MIDDLE; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; JECKER N, 1995, J AM GERONTOL, V46, P696; KADISH SH, 1992, CALIF LAW REV, V80, P857, DOI 10.2307/3480699; Kamisar Y, 1996, Duquesne Law Rev, V35, P481; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; LO B, 1995, RESOLVING ETHICAL DI, P24; MEISEL A, 1995, LIMITATIONS DECISION, P470; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; 1996, DUQUESNE LAW REV, V35, P1; 1996, JAMA-J AM MED ASSOC, V275, P1232; 1996, BIOLAW           JUL, V2, P119; 1995, JAMA-J AM MED ASSOC, V274, P1591	25	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1705	1708		10.1001/jama.277.21.1705	http://dx.doi.org/10.1001/jama.277.21.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169898				2023-01-03	WOS:A1997XB08800032
J	Mackenzie, PA; Smith, EA; Wallace, PGM				Mackenzie, PA; Smith, EA; Wallace, PGM			Transfer of adults between intensive care units in the United Kingdom: Postal survey	BRITISH MEDICAL JOURNAL			English	Article							ILL PATIENTS; AUDIT		UNIV GLASGOW,GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,LANARK,SCOTLAND	University of Glasgow	Mackenzie, PA (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DIRECTORATE ANAESTHESIA,GLASGOW G11 6NT,LANARK,SCOTLAND.							*ASS AN GB IR, 1994, REC STAND MON AN REC; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; OAKLEY PA, 1994, ANAESTHESIA, V49, P565; WRIGHT IH, 1988, BRIT MED J, V296, P543, DOI 10.1136/bmj.296.6621.543	5	39	40	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1455	1456		10.1136/bmj.314.7092.1455	http://dx.doi.org/10.1136/bmj.314.7092.1455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167562	Green Published			2023-01-03	WOS:A1997XA20200023
J	Creed, F; Mbaya, P; Lancashire, S; Tomenson, B; Williams, B; Holme, S				Creed, F; Mbaya, P; Lancashire, S; Tomenson, B; Williams, B; Holme, S			Cost effectiveness of day and inpatient psychiatric treatment: Results of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SERIOUS MENTAL-ILLNESS; COMMUNITY CARE; HOSPITAL-CARE; PEOPLE; OUTPATIENT; DISORDERS; BENEFITS; SERVICE	Objective: To compare direct and indirect costs of day and inpatient treatment of acute psychiatric illness. Design: Randomised controlled trial with outcome and costs assessed over 12 months after the date of admission. Setting: Teaching hospital in an inner city area. Subjects: 179 patients with acute psychiatric illness referred for admission who were suitable for random allocation to day hospital or inpatient treatment. 77 (43%) patients had schizophrenia. Interventions: Routine inpatient or day hospital treatment. Main outcome measures: Direct and indirect costs over 12 months; clinical symptoms, social functioning, and burden on relatives over the follow up period. Results: Clinical and social outcomes were similar at 12 months, except that inpatients improved significantly faster than day patients and burden on relatives was significantly less in the day hospital group at one year. Median direct costs to the hospital were pound 1923 (95% confidence interval pound 750 to pound 3174) per patient less for day hospital treatment than inpatient treatment Indirect costs were greater for day patients; when these were included, overall day hospital treatment was pound 2165 cheaper than inpatient treatment (95% confidence interval of median difference pound 737 to pound 3593). Including costs to informants when appropriate meant that day hospital treatment was pound 1994 per patient cheaper (95% confidence interval pound 600 to pound 3543). Conclusions: Day patient treatment is cheaper for the 30-40% of potential admissions that can be treated in this way. Carers of day hospital patients may bear additional costs. Carers of all patients with acute psychiatric illness are often themselves severely distressed at the time of admission, but day hospital treatment leads to less burden on carers in the long term.			Creed, F (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT PSYCHIAT,RAWNSLEY BLDG,MANCHESTER M13 9WL,LANCS,ENGLAND.		Lancashire, Stuart/D-1791-2010					ASBERG M, 1978, ACTA PSYCHIATR SCA S, V271; AUDINI B, 1994, BRIT J PSYCHIAT, V165, P204, DOI 10.1192/bjp.165.2.204; BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; CREED F, 1989, BRIT J PSYCHIAT, V154, P341, DOI 10.1192/bjp.154.3.341; CREED F, 1989, BRIT J PSYCHIAT, V154, P300, DOI 10.1192/bjp.154.3.300; CREED F, 1991, BRIT J PSYCHIAT, V158, P183, DOI 10.1192/bjp.158.2.183; CREED F, 1990, BMJ-BRIT MED J, V300, P1033, DOI 10.1136/bmj.300.6731.1033; CREED F, 1995, COMMUNITY PSYCHIAT A, P11; DEAN C, 1993, BRIT MED J, V307, P473, DOI 10.1136/bmj.307.6902.473; DICK P, 1985, BRIT J PSYCHIAT, V147, P246, DOI 10.1192/bjp.147.3.246; Goldberg DP., 1972, DETECTION PSYCHIATRI; HOLLOWAY F, 1995, COMMUNITY PSYCHIAT A, P85; KLUITER H, 1992, AM J PSYCHIAT, V149, P1192; KNAPP M, 1994, BRIT J PSYCHIAT, V165, P195, DOI 10.1192/bjp.165.2.195; MBAYA P, 1995, THESIS U MANCHESTER; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; NETTEN A, 1994, UNIT COSTS COMMUNITY; ONYETT S, 1990, PSYCHIAT B, V124, P267; PLATT SD, 1981, ACTA PSYCHIAT SCAND, V63, P117, DOI 10.1111/j.1600-0447.1981.tb00658.x; Rosen A., 1992, CURRENT OPINION PSYC, V5, P257; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCHENE AH, 1993, ACTA PSYCHIAT SCAND, V87, P427, DOI 10.1111/j.1600-0447.1993.tb03400.x; TEST MA, 1980, ARCH GEN PSYCHIAT, V37, P409; TYRER P, 1987, BRIT J PSYCHIAT, V151, P57, DOI 10.1192/bjp.151.1.57; TYRER PJ, 1979, LANCET, V1, P714; WIERSMA D, 1995, BRIT J PSYCHIAT, V166, P52, DOI 10.1192/S0007125000293409; WIERSMA D, 1991, SCHIZOPHRENIA BULL, V17, P411, DOI 10.1093/schbul/17.3.411; Wing JK, 1972, MEASUREMENT CLASSIFI; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1; Wykes T, 1995, COMMUNITY PSYCHIAT A, P97; ZWERLING I, 1964, ISR J PSYCHIAT REL D, V2, P162	31	62	63	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1381	1385						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WZ169	9161310				2023-01-03	WOS:A1997WZ16900025
J	Metkus, AP; Trabulsy, PP; Schlobohm, RS; Hickey, MS				Metkus, AP; Trabulsy, PP; Schlobohm, RS; Hickey, MS			A firefighter with pancreatitis	LANCET			English	Article							CRITICALLY ILL PATIENTS; SEDATION; PROPOFOL		SAN FRANCISCO GEN HOSP,DEPT SURG,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center								BOYLE W A, 1990, Anesthesiology (Hagerstown), V73, pA245; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; GOTTARDIS M, 1989, BRIT J ANAESTH, V62, P393, DOI 10.1093/bja/62.4.393; LESIURE GS, 1996, ANESTHESIOLOGY, V84, P224; LEVINE RL, 1994, CRIT CARE CLIN, V10, P709, DOI 10.1016/S0749-0704(18)30102-7	5	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1702	1702		10.1016/S0140-6736(96)06205-8	http://dx.doi.org/10.1016/S0140-6736(96)06205-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973434				2023-01-03	WOS:A1996VZ76600014
J	Tobin, MJ; Luce, JM				Tobin, MJ; Luce, JM			Update in critical care medicine	ANNALS OF INTERNAL MEDICINE			English	Article									SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA	San Francisco General Hospital Medical Center	Tobin, MJ (corresponding author), LOYOLA UNIV, DIV PULM MED, 2160 1ST AVE, MAYWOOD, IL 60153 USA.							BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; ESTEBAN A, 1994, CHEST, V106, P1188, DOI 10.1378/chest.106.4.1188; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463	5	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					909	916		10.7326/0003-4819-125-11-199612010-00007	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967672				2023-01-03	WOS:A1996VV54100007
J	Beach, RC				Beach, RC			Management of childhood constipation	LANCET			English	Editorial Material											Beach, RC (corresponding author), NORFOLK & NORWICH HLTH CARE NHS TRUST, JENNY LIND CHILDRENS DEPT, NORFOLK NR1 3SR, ENGLAND.							CLADEN G, 1991, CONSTIPATION CHILDHO; GLEGHORN EE, 1991, CLIN PEDIATR, V30, P669, DOI 10.1177/000992289103001203; PARTIN JC, 1992, PEDIATRICS, V89, P1007; Sprague-McRae J M, 1993, Nurse Pract, V18, P52; Sprague-McRae JM, 1993, NURSE PRACT, V18, P56	5	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					766	767		10.1016/S0140-6736(05)65203-8	http://dx.doi.org/10.1016/S0140-6736(05)65203-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813977				2023-01-03	WOS:A1996VH98900003
J	Richmond, J; Berman, BM; Docherty, JP; Goldstein, LB; Kaplan, G; Keil, JE; Krippner, S; Lyne, S; Mosteller, F; OConnor, BB; Rudy, EB; Schatzberg, AF; Friedman, R; Altman, F; Benson, H; Elliott, JM; Ferguson, JH; Gracely, R; Greene, A; Haddox, JD; Hall, WH; Hauri, PJ; Helzner, EC; Kaufmann, PG; Kiley, JP; Leveck, MD; McCutchen, CB; Monjan, AA; Pillemer, SR; MacArthur, JD; Sherman, C; Spencer, J; Varricchio, CG				Richmond, J; Berman, BM; Docherty, JP; Goldstein, LB; Kaplan, G; Keil, JE; Krippner, S; Lyne, S; Mosteller, F; OConnor, BB; Rudy, EB; Schatzberg, AF; Friedman, R; Altman, F; Benson, H; Elliott, JM; Ferguson, JH; Gracely, R; Greene, A; Haddox, JD; Hall, WH; Hauri, PJ; Helzner, EC; Kaufmann, PG; Kiley, JP; Leveck, MD; McCutchen, CB; Monjan, AA; Pillemer, SR; MacArthur, JD; Sherman, C; Spencer, J; Varricchio, CG			Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To provide physicians with a responsible assessment of the integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. Participants.-A nonfederal, nonadvocate, 12-member panel representing the fields of family medicine, social medicine, psychiatry, psychology, public health, nursing, and epidemiology. In addition, 23 experts in behavioral medicine, pain medicine, sleep medicine, psychiatry, nursing, psychology, neurology, and behavioral and neurosciences presented data to the panel and a conference audience of 528 during a 1 1/2-day public session. Questions and statements from conference attendees were considered during the open session. Closed deliberations by the panel occurred during the remainder of the second day and the morning of the third day. Evidence.-The literature was searched through MEDLINE, and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience. Assessment Process.-The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. Conclusions.-A number of well-defined behavioral and relaxation interventions now exist and are effective in the treatment of chronic pain and insomnia. The panel found strong evidence for the use of relaxation techniques in reducing chronic pain in a variety of medical conditions as well as strong evidence for the use of hypnosis in alleviating pain associated with cancer. The evidence was moderate for the effectiveness of cognitive-behavioral techniques and biofeedback in relieving chronic pain. Regarding insomnia, behavioral techniques, particularly relaxation and biofeedback, produce improvements in some aspects of sleep, but it is questionable whether the magnitude of the improvement in sleep onset and total sleep time are clinically significant.	UNIV MARYLAND,SCH MED,DEPT FAMILY MED,DIV COMPLEMENTARY MED,BALTIMORE,MD 21201; CORNELL UNIV,NEW YORK HOSP,WHITE PLAINS,NY 10605; CORNELL UNIV,COLL MED,DEPT PSYCHIAT,WHITE PLAINS,NY 10605; DUKE UNIV,MED CTR,DURHAM VA MED CTR,DEPT MED,DIV NEUROL,DURHAM,NC; DUKE UNIV,MED CTR,DURHAM VA MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC; GEORGETOWN UNIV,SCH MED,DEPT FAMILY & COMMUNITY MED,WASHINGTON,DC 20057; FAMILY PRACTICE ASSOCIATES,ARLINGTON,VA; MED UNIV S CAROLINA,DEPT BIOSTAT EPIDEMIOL & SYST SCI,CHARLESTON,SC 29425; SAYBROOK INST GRAD SCH & RES CTR,SAN FRANCISCO,CA; CHICAGO DEPT PUBL HLTH,CHICAGO,IL; HARVARD UNIV,DEPT STAT,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT HLTH POLICY & MANAGEMENT,CAMBRIDGE,MA 02138; MED COLL PENN & HAHNEMANN UNIV,SCH MED,DEPT COMMUNITY & PREVENT MED,PHILADELPHIA,PA 19102; UNIV PITTSBURGH,SCH NURSING,PITTSBURGH,PA 15261; STANFORD UNIV,SCH MED,DEPT PSYCHIAT,STANFORD,CA 94305; SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794; NIMH,MED RES BRANCH,DIV EPIDEMIOL & SERV RES,NIH,BETHESDA,MD 20892; DEACONESS HOSP,DIV BEHAV MED,BOSTON,MA; MIND BODY MED INST,BOSTON,MA; NIH,OFF MED APPLICAT RES,BETHESDA,MD 20892; NIDR,NEUROPATH & PAIN MEASUREMENT SECT,NEUROBIOL & ANESTHESIOL BRANCH,NIH,BETHESDA,MD 20892; NIH,OFF ALTERNAT MED,BETHESDA,MD 20892; EMORY UNIV,SCH MED,ATLANTA,GA; NIH,OFF MED APPLICAT RES,BETHESDA,MD 20892; MAYO CLIN & MAYO FDN,MAYO MED SCH,ROCHESTER,MN 55905; MAYO CLIN,INSOMNIA PROGRAM,DEPT PSYCHOL,SLEEP DISORDERS CTR,ROCHESTER,MI; NHLBI,BEHAV MED SCI RES GRP,BETHESDA,MD 20892; NHLBI,NATL CTR SLEEP DISORDERS CTR,NIH,BETHESDA,MD 20892; NINR,DIV EXTRAMURAL PROGRAMS,NIH,BETHESDA,MD; NINCDS,EPILEPSY BRANCH,DIV CONVULS DEV & NEUROMUSCULAR DISORDERS,NIH,BETHESDA,MD 20892; NIA,NEUROBIOL AGING PROGRAM,NIH,BETHESDA,MD 20892; NIA,NEUROSCI & NEUROPSYCHOL AGING PROGRAM,NIH,BETHESDA,MD 20892; NIAMSD,OFF PREVENT EPIDEMIOL & CLIN APPLICAT,NIH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; NIH,OFF MED APPLICAT RES,BETHESDA,MD 20892; NIH,OFF ALTERNAT MED,BETHESDA,MD 20892; NCI,COMMUNITY ONCOL & REHABIL BRANCH,DIV CANC PREVENT & CONTROL,NIH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; Cornell University; NewYork-Presbyterian Hospital; Cornell University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Georgetown University; Medical University of South Carolina; Chicago Department of Public Health; Harvard University; Harvard University; Drexel University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; Emory University; National Institutes of Health (NIH) - USA; Mayo Clinic; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Nursing Research (NINR); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Richmond, J (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115, USA.			Bradley, Laurence/0000-0002-1206-2263					0	213	217	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1996	276	4					313	318						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX583	8656544				2023-01-03	WOS:A1996UX58300037
J	Kujala, UM; Sarna, S; Kaprio, J; Koskenvuo, M				Kujala, UM; Sarna, S; Kaprio, J; Koskenvuo, M			Hospital care in later life among former world-class Finnish athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; EXPECTANCY; MORTALITY; LONGEVITY; HEALTH	Objective.-To investigate the use of hospital care from all causes among former top-level athletes from different vigorous sports to determine whether health benefits or adverse effects have the greater influence. Design.-National, population-based cohort study with a 21-year follow-up. Setting.-Finland. Subjects.-A total of 2049 male athletes who had represented Finland during 1920 to 1965, and 1403 male controls classified healthy at 20 years of age. Main Outcome Measure.-In-hospital care from all causes was extracted from the national hospital discharge registry for the period 1970 through 1990 expressed as hospital days per person-yeats of exposure, Results.-Compared with controls, the rate ratios (RRs) for all-cause hospital days per person-years of exposure were lower in athletes from endurance sports (RR, 0.71; 95% confidence interval [CI], 0.70-0.73), mixed sports (including endurance and weight training) (RR, 0.86; 95% CI, 0.85-0.87), and power sports(RR, 0.95; 95% CI, 0.94-0.96) (P<.001 for all comparisons) after adjustment for age and occupational group. The lower RR among athletes from endurance sports and other sports involving aerobic activity was largely explained by lower rates of hospital care for heart disease, respiratory disease, and neoplasms, but not for musculoskeletal disorders, Conclusions.-Former elite athletes, particularly those in aerobic sports, use less hospital care. Other beneficial health habits are known to be associated with a physically active lifestyle.	UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20500 TURKU,FINLAND	University of Helsinki; University of Turku	Kujala, UM (corresponding author), UNIV HELSINKI,INST BIOMED,UNIT SPORTS & EXERCISE MED,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,FIN-00250 HELSINKI,FINLAND.		Kaprio, Jaakko/A-1820-2008; Kujala, Urho/AAP-2547-2020	Kaprio, Jaakko/0000-0002-3716-2455; Kujala, Urho/0000-0002-9262-1992; Sarna, Seppo/0000-0003-3458-1627				ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; Astrand P.O., 1986, TXB WORK PHYSL PHYSL; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; *FINLAND CENTR STA, 1972, ALPH LIST OCC CLASS; FOGELHOLM M, 1994, MED SCI SPORT EXER, V26, P224, DOI 10.1249/00005768-199402000-00013; GORNICK M, 1993, HLTH AFF, V12, P999; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Howard D.R., 1992, J SPORT MANAGE, V6, DOI [10.1123/jsm.6.3.191, DOI 10.1123/JSM.6.3.191]; KAPRIO J, 1988, J CLIN EPIDEMIOL, V41, P139, DOI 10.1016/0895-4356(88)90088-1; KARVONEN MJ, 1974, MED SCI SPORT EXER, V6, P49; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KOSKENVUO M, 1979, SOC SCI MED-MED SOC, V13, P691, DOI 10.1016/0271-7123(79)90114-7; KUJALA UM, 1995, ARTHRITIS RHEUM, V38, P539, DOI 10.1002/art.1780380413; KUJALA UM, 1994, BRIT MED J, V308, P231, DOI 10.1136/bmj.308.6923.231; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SARNA S, 1994, SPORTS MED, V17, P149, DOI 10.2165/00007256-199417030-00001; SARNA S, 1993, MED SCI SPORT EXER, V25, P237; SCHNOHR P, 1971, LANCET, V2, P1364; *WHO, 1977, WHO ICD9; *WHO, 1969, WHO ICD8; YAMAJI K, 1977, Journal of Human Ergology, V6, P15; 1990, EGRET STAT SOFTWARE	28	58	58	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					216	220		10.1001/jama.276.3.216	http://dx.doi.org/10.1001/jama.276.3.216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667566				2023-01-03	WOS:A1996UW46900033
J	Lindner, KH; Prengel, AW; Brinkmann, A; Strohmenger, HU; Lindner, IM; Lurie, KG				Lindner, KH; Prengel, AW; Brinkmann, A; Strohmenger, HU; Lindner, IM; Lurie, KG			Vasopressin administration in refractory cardiac arrest	ANNALS OF INTERNAL MEDICINE			English	Article							HIGH-DOSE EPINEPHRINE; CARDIOPULMONARY-RESUSCITATION; BLOOD-FLOW	Background: Successful outcomes after cardiopulmonary resuscitation remain disappointingly infrequent. In animal studies, administration of exogenous vasopressin during closed- and open-chest cardiopulmonary resuscitation has recently been shown to be more effective than optimal doses of epinephrine in improving vital organ blood flow. Objective: To describe the clinical effects and outcomes of administering vasopressin to patients in cardiac arrest refractory to current medical therapies. Design: Case reports. Setting: University hospital. Patients: 8 adults with in-hospital cardiac arrest. Interventions: After intravenous epinephrine (administered according to American Heart Association guidelines) and defibrillation efforts had failed, patients in cardiac arrest who were having cardiopulmonary resuscitation received 40 U of vasopressin intravenously and then defibrillation. Measurements: Return of spontaneous circulation and hospital discharge rates. Results: After administration of vasopressin, spontaneous circulation was promptly restored in all patients. Three patients were discharged from the hospital with intact neurologic function; the other five lived for between 30 minutes and 82 hours. Conclusion: In the presence of ventricular fibrillation with severe hypoxia and acidosis, vasopressin seems to be more potent and effective than adrenergic vasopressors for restoring spontaneous cardiovascular function. These results do not justify the widespread use of vasopressin for refractory cardiac arrest. However, on the basis of these cases, further studies comparing vasopressin with epinephrine are warranted in an effort to improve the currently dismal prognosis of patients after cardiac arrest.	UNIV ULM KLINIKUM, ANASTHESIOL KLIN, D-89075 ULM, GERMANY; UNIV MINNESOTA, SCH MED, CARDIAC ARRHYTHMIA CTR, MINNEAPOLIS, MN 55455 USA	Ulm University; University of Minnesota System; University of Minnesota Twin Cities								BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; FOREMAN BW, 1991, CIRC RES, V69, P657, DOI 10.1161/01.RES.69.3.657; LINDNER KH, 1993, ANESTH ANALG, V77, P427; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; LINDNER KH, 1996, BRIT HEART J, V75, P145; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Woodhouse SP, 1995, RESUSCITATION, V30, P243, DOI 10.1016/0300-9572(95)00890-X	10	154	162	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1061	1064		10.7326/0003-4819-124-12-199606150-00006	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633820				2023-01-03	WOS:A1996UQ65800006
J	Roberts, RR; Zalenski, RJ; Mensah, EK; Rydman, RJ; Ciavarella, G; Gussow, L; Das, K; Kampe, LM; Dickover, B; McDermott, MF; Hart, A; Straus, HE; Murphy, DG; Rao, R				Roberts, RR; Zalenski, RJ; Mensah, EK; Rydman, RJ; Ciavarella, G; Gussow, L; Das, K; Kampe, LM; Dickover, B; McDermott, MF; Hart, A; Straus, HE; Murphy, DG; Rao, R			Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 05-08, 1996	DENVER, CO	Soc Acad Emergency Med			ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; UNSTABLE ANGINA-PECTORIS; CREATINE-KINASE MB; LOW-RISK PATIENTS; HEART-DISEASE; ROOM PATIENTS; STAY; ISCHEMIA; MEDICINE	Context.-More than 3 million patients are hospitalized yearly in the United states for chest pain, The cost is over $3 billion just for those found to be free of acute disease, New rapid diagnostic tests for acute myocardial infarction (AMI) have resulted in the proliferation of accelerated diagnostic protocols (ADPs) and chest pain observation units. Objective.-To determine whether use of an emergency department (ED)-based ADP can reduce hospital admission rate, total cost, and length of stay (LOS) for patients needing admission for evaluation of chest pain. Design.-Prospective randomized controlled trial comparing admission rate, total cost, and LOS for patients treated using ADP vs inpatient controls, Total costs were determined using empirically measured resource utilization and microcosting techniques. Setting.-A large urban public teaching hospital serving a predominantly African American and Hispanic population. Patients.-A sample of 165 patients was randomly selected from a larger consecutive sample of 429 patients with chest pain concurrently enrolled in an ADP diagnostic cohort trial, Eligible patients presented to the ED with clinical findings suggestive of AMI or acute cardiac ischemia (ACI) but at low risk using a validated predictive algorithm. Main Outcome Measures.-Primary outcomes measured for each subject were LOS and total cost of treatment. Results.-The hospital admission rate for ADP vs control patients was 45.2% vs 100% (P<.001). The mean total cost per patient for ADP vs control patients was $1528 vs $2095 (P<.001), The mean LOS measured in hours for ADP vs control patients was 33.1 hours vs 44.8 hours (P<.01). Conclusions.-In this trial, ADP saved $567 in total hospital costs per patient treated, Use of ED-based ADPs can reduce hospitalization rates, LOS, and total cost for low-risk patients with chest pain needing evaluation for possible AMI or ACI.	UNIV ILLINOIS,SCH PUBL HLTH,CTR HLTH SERV RES,CHICAGO,IL 60680; COOK CTY HOSP,DEPT INTERNAL MED,CHICAGO,IL; UNIV ILLINOIS,SCH PUBL HLTH,DIV HLTH POLICY & ADM,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roberts, RR (corresponding author), RUSH UNIV,COOK CTY HOSP,DEPT EMERGENCY MED,1900 W POLK ST,10TH FLOOR,CHICAGO,IL 60612, USA.		McDermott, Michael Francis/GZM-5330-2022	McDermott, Michael F./0000-0002-1015-0745	AHRQ HHS [R01HS-07103] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABBOTT JA, 1973, AM J MED, V55, P608, DOI 10.1016/0002-9343(73)90182-4; Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; APPLE FS, 1992, AM J CLIN PATHOL, V97, P217, DOI 10.1093/ajcp/97.2.217; BERKI SE, 1984, MED CARE, V22, P126, DOI 10.1097/00005650-198402000-00004; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; COLLINSON PO, 1992, ANN CLIN BIOCHEM, V29, P43, DOI 10.1177/000456329202900105; DELEON AC, 1989, SOUTHERN MED J, V82, P1083, DOI 10.1097/00007611-198909000-00006; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; FINKLER SA, 1994, ESSENTIALS COST ACCO, P43; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBLER WB, 1992, ANN EMERG MED, V21, P504; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; Gibler WB, 1997, ANN EMERG MED, V29, P168; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; GRAFF LG, 1993, OBSERVATION MED, P83; GRAFF LG, 1993, OBSERVATION MED, P99; HEDGES JR, 1993, OBSERVATION MED, P133; HERLITZ J, 1988, CLIN CARDIOL, V11, P209, DOI 10.1002/clc.4960110404; HILL M, 1989, QRC ADVISOR, V6, P2; Hoekstra J W, 1994, Acad Emerg Med, V1, P103; JONES KR, 1985, MED CARE, V23, P220, DOI 10.1097/00005650-198503000-00004; JOSEPHSON RA, 1990, CIRCULATION, V81, P20, DOI 10.1161/01.CIR.81.1.20; KARCZ A, 1993, ANN EMERG MED, V22, P553, DOI 10.1016/S0196-0644(05)81941-9; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; KASSIRER JP, 1995, NEW ENGL J MED, V333, P1348, DOI 10.1056/NEJM199511163332009; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KERNS JR, 1993, ANN EMERG MED, V22, P36; Lambrew CT, 1997, ANN EMERG MED, V29, P163; LAVE JR, 1984, ANNU REV PUBL HEALTH, V5, P193; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEMROW N, 1991, HCFA PUBLICATION; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; LINDBERG K, 1985, ACTA MED SCAND, V217, P559; LOWE RA, 1991, ANN EMERG MED, V20, P790, DOI 10.1016/S0196-0644(05)80844-3; MAIR J, 1995, CLIN CHEM, V41, P1266; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; MENSAH EK, 1995, AM PUBL HLTH ASS ANN; *NAT HEART ATT AL, 1993, NIH PUBL; *NAT HEART LUNG BL, 1994, REP WORK GROUP RES C; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; ROBERTS R, 1994, CIRCULATION, V89, P872, DOI 10.1161/01.CIR.89.2.872; RUSNAK RA, 1989, ANN EMERG MED, V18, P1029, DOI 10.1016/S0196-0644(89)80924-2; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Rydman RJ, 1997, ANN EMERG MED, V29, P109, DOI 10.1016/S0196-0644(97)70316-0; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SHESSER R, 1994, ANN EMERG MED, V23, P334, DOI 10.1016/S0196-0644(94)70047-8; SOX HC, 1989, ANN INTERN MED, V110, P456, DOI 10.7326/0003-4819-110-6-456; Steinbrook R, 1996, NEW ENGL J MED, V334, P657, DOI 10.1056/NEJM199603073341010; SUVER JD, 1992, MANAGE ACCOUNTING, P205; SUVER JD, 1992, MANAGE ACCOUNTING, P278; TANDBERG D, 1994, ANN EMERG MED, V23, P299, DOI 10.1016/S0196-0644(94)70044-3; Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2; TIERNEY WM, 1986, MED DECIS MAKING, V6, P12, DOI 10.1177/0272989X8600600103; TOPOL EJ, 1987, AM J CARDIOL, V60, P958, DOI 10.1016/0002-9149(87)90332-8; Torrance GW, 1987, METHODS EC EVALUATIO; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; WEARS R L, 1989, Annals of Emergency Medicine, V18, P953, DOI 10.1016/S0196-0644(89)80460-3; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C; WILCOX I, 1991, AM J CARDIOL, V67, P89, DOI 10.1016/0002-9149(91)90106-U; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007; Zalenski RJ, 1997, ARCH INTERN MED, V157, P1085, DOI 10.1001/archinte.157.10.1085; Zalenski RJ, 1997, ANN EMERG MED, V29, P99, DOI 10.1016/S0196-0644(97)70315-9	73	259	260	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1670	1676		10.1001/jama.278.20.1670	http://dx.doi.org/10.1001/jama.278.20.1670			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388086				2023-01-03	WOS:A1997YG85900028
J	ONeill, B; Fallon, M				ONeill, B; Fallon, M			ABC of palliative care - Principles of palliative care and pain control	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,WESTERN INFIRM,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND	Beatson Oncology Centre; University of Glasgow	ONeill, B (corresponding author), BRITISH MED ASSOC,BMA HOUSE,LONDON,ENGLAND.			Fallon, Marie/0000-0001-9214-0091					0	45	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					801	804		10.1136/bmj.315.7111.801	http://dx.doi.org/10.1136/bmj.315.7111.801			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345176	Green Published			2023-01-03	WOS:A1997XY91100028
J	Chattergoon, M; Boyer, J; Weiner, DB				Chattergoon, M; Boyer, J; Weiner, DB			Genetic immunization: a new era in vaccines and immune therapeutics	FASEB JOURNAL			English	Review						infectious diseases; immunotherapy; DNA vaccine; cancer; human vaccines; genetic immunization	DNA-BASED IMMUNIZATION; PROTECTIVE IMMUNITY; SKELETAL-MUSCLE; SURFACE-ANTIGEN; VIRUS; HEPATITIS; VACCINATION; INFLUENZA; INJECTION; RESPONSES	DNA inoculation represents a novel approach to vaccine and immune therapeutic develop ment, The direct injection of gene expression cassettes into a living host transforms a number of cells into factories for production of the introduced gene products, Expression of these delivered genes has important immunological consequences and may result in the specific immune activation of the host against the novel expressed antigens, The recent demonstration by laboratories that these immune responses are protective in some infectious disease experimental models as well as cancers is viewed with cautious optimism, Further, the relatively short development times, ease of large-scale production, low development, manufacturing, and distribution costs all combine with immunological effectiveness to suggest that this technology will dramatically influence the production of a new generation of experimental vaccines and immune therapies, It is hoped that DNA inoculation will ultimately lead to new vaccines that are immunologically effective and economically accessible to all nations.	UNIV PENN,DEPT PATHOL & LAB MED,STELLAR CHANCE LABS 505,PHILADELPHIA,PA 19104	University of Pennsylvania			Weiner, David B/H-8579-2014					Atanasiu P., 1962, ACAD SCI, V254, P4228; Bright RK, 1995, ANN NY ACAD SCI, V772, P241, DOI 10.1111/j.1749-6632.1995.tb44750.x; CAMPO MS, 1994, CIBA F SYMP, V187, P61; CONRY RM, 1995, CANCER GENE THER, V2, P33; Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; DEBENSKY T, 1984, P NATL ACAD SCI USA, V81, P7529; Donnelly JJ, 1996, J INFECT DIS, V173, P314, DOI 10.1093/infdis/173.2.314; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Gaukroger JM, 1996, J GEN VIROL, V77, P1577, DOI 10.1099/0022-1317-77-7-1577; HUYGEN K, 1996, NTURE MED, V2, P983; ISRAEL MA, 1979, J VIROL, V29, P990, DOI 10.1128/JVI.29.3.990-996.1979; ITO Y, 1960, VIROLOGY, V12, P596, DOI 10.1016/0042-6822(60)90182-3; Khanna R, 1995, VIROLOGY, V214, P633, DOI 10.1006/viro.1995.0076; Kim JJ, 1997, J IMMUNOL, V158, P816; Kirnbauer R, 1996, VIROLOGY, V219, P37, DOI 10.1006/viro.1996.0220; Mancini M, 1996, J BIOTECHNOL, V44, P47, DOI 10.1016/0168-1656(95)00098-4; ORTH G, 1964, P SOC EXP BIOL MED, V115, P1090; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Regimbald LH, 1996, CANCER RES, V56, P4244; Roth J, 1996, P NATL ACAD SCI USA, V93, P4781, DOI 10.1073/pnas.93.10.4781; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; STASNEY J, 1950, CANCER RES, V10, P775; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; ULMER JB, 1994, VACCINE, V12, P1541, DOI 10.1016/0264-410X(94)90081-7; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WANG B, 1994, VACCINES, V94, P83; WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996	42	102	138	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					753	763		10.1096/fasebj.11.10.9271360	http://dx.doi.org/10.1096/fasebj.11.10.9271360			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271360				2023-01-03	WOS:A1997XR10500005
J	Goldstein, B; Hammond, M				Goldstein, B; Hammond, M			Physical medicine and rehabilitation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV WASHINGTON,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Goldstein, B (corresponding author), VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA 98195, USA.							Baker JG, 1996, AM J PHYS MED REHAB, V75, P356, DOI 10.1097/00002060-199609000-00011; BATTERHAUM RW, 1996, ARCH PHS MED REHABIL, V77, P219; Bowling A., 1991, MEASURING HLTH REV Q; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Granger C. V., 1996, PHYS MED REHABILITAT, P239; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HAYS RM, 1994, CHRONIC DIS DISABILI, P215; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; *HLTH INS ASS AM, 1992, RES STAT B HLTH INS, V287; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; *MED ETH SER, 1995, AM J PHYS MED REHABI, V74, pS3; MULCAHY C, 1994, NATL UNDERWRITE 0509, P17; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	15	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1891	1892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185820				2023-01-03	WOS:A1997XD54400039
J	Chung, SSC; Lau, JYW; Sung, JJY; Chan, ACW; Lai, CW; Ng, EKW; Chan, FKL; Yung, MY; Li, AKC				Chung, SSC; Lau, JYW; Sung, JJY; Chan, ACW; Lai, CW; Ng, EKW; Chan, FKL; Yung, MY; Li, AKC			Randomised comparison between adrenaline injection alone and adrenaline injection plus heat probe treatment for actively bleeding ulcers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL HEMORRHAGE; ND-YAG LASER; PEPTIC-ULCERS; CONTROLLED TRIAL; ENDOSCOPIC INJECTION; MULTIPOLAR ELECTROCOAGULATION; THERAPY; PHOTOCOAGULATION; EPINEPHRINE; HEMOSTASIS	Objective: To compare endoscopic adrenaline injection alone and adrenaline injection plus heat probe for the treatment of actively bleeding peptic ulcers. Design: Randomised prospective study of patients admitted with actively bleeding peptic ulcers. Setting: One university hospital. Subjects: 276 patients with actively bleeding ulcers detected by endoscopy within 24 hours of admission: 136 patients were randomised to endoscopic adrenaline injection atone and 140 to adrenaline injection plus heat probe treatment. Main outcome measures: Initial endoscopic haemostasis; clinical rebleeding; requirement for operation; requirement for blood transfusion; hospital stay, ulcer healing at four weeks; and mortality in hospital. Results:Initial haemostasis was achieved in 131/134 patients (98%) who received adrenaline injection alone and 135/136 patients (99%) who received additional heat probe treatment (P = 0.33). Outcome as measured by clinical rebleeding (12 v 5), requirement for emergency operation (14 v 8), blood transfusion (2 v 3 units), hospital stay (4 v 4 days), ulcer healing at four weeks (79.1% v 74%), and in hospital mortality (7 v 8) were not significantly different in the two groups. In the subgroup of patients with spurting haemorrhage 8/27 (29.6%; 14.5% to 50.3%) patients from the adrenaline injection alone group and 2/31 (6.5%; 1.1% to 22.9%) patients from the dual treatment group required operative intervention. The relative risk of this was lower in the dual treatment group (0.17; 0.03 to 0.87). Hospital stay was significantly shorter in the dual treatment group than the adrenaline injection alone group (4 v 6 days, P = 0.01). Conclusion: The addition of heat probe treatment after endoscopic adrenaline injection confers an advantage in ulcers with spurting haemorrhage.	CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT SURG, SHATIN, NEW TERRITORIES, HONG KONG; CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT MED, SHATIN, NEW TERRITORIES, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Sung, Joseph J. Y./R-3203-2018; Chan, Francis K. L./F-4851-2010; Lau, James Y. W./O-2612-2016; Ng, Enders Kwok-wai/E-8276-2016	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436; Lau, James Y. W./0000-0003-0122-4068; Ng, Enders Kwok-wai/0000-0001-7219-5810				BALZNO J, 1988, ENDOSCOPY, V20, P289; CHUNG SCS, 1987, ENDOSCOPY, V19, P47, DOI 10.1055/s-2007-1018229; CHUNG SCS, 1988, BRIT MED J, V296, P1631, DOI 10.1136/bmj.296.6637.1631; CHUNG SCS, 1991, GASTROENTEROLOGY, V100, P33, DOI 10.1016/0016-5085(91)90579-A; CHUNG SCS, 1993, GASTROINTEST ENDOSC, V39, P611; Chung SCS, 1996, GASTROINTEST ENDOSC, V43, P591, DOI 10.1016/S0016-5107(96)70197-9; CHUNG SCS, 1988, GASTROINTEST ENDOSC, V34, P174; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; FULLARTON GM, 1989, BRIT J SURG, V76, P541, DOI 10.1002/bjs.1800760606; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; KREJS GJ, 1987, NEW ENGL J MED, V316, P1618, DOI 10.1056/NEJM198706253162602; LAI KH, 1994, ENDOSCOPY, V26, P338, DOI 10.1055/s-2007-1008987; LAINE L, 1990, GASTROENTEROLOGY, V99, P1303, DOI 10.1016/0016-5085(90)91154-X; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; LAU JYW, 1995, GASTROINTEST ENDOSC, V41, P368, DOI 10.1016/S0016-5107(05)80326-8; LEUNG JWC, 1987, GASTROINTEST ENDOSC, V33, P73, DOI 10.1016/S0016-5107(87)71512-0; LOIZOU LA, 1991, GUT, V32, P1100, DOI 10.1136/gut.32.10.1100; MATTHEWSON K, 1990, GASTROENTEROLOGY, V98, P1239, DOI 10.1016/0016-5085(90)90339-3; OBRIEN JD, 1986, LANCET, V1, P464; PANES J, 1987, LANCET, V2, P1292; RUTGEERTS P, 1989, GASTROENTEROLOGY, V97, P610, DOI 10.1016/0016-5085(89)90632-X; RUTGEERTS P, 1989, LANCET, V1, P1164; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; STEELE RJC, 1991, BRIT J SURG, V78, P477, DOI 10.1002/bjs.1800780428; SUNG JY, 1993, GASTROINTEST ENDOSC, V39, P20, DOI 10.1016/S0016-5107(93)70004-8; SWAIN CP, 1986, LANCET, V1, P1113; TEDESCO FJ, 1981, DIGEST DIS SCI, V26, pS102, DOI 10.1007/BF01300816; ULRICH CD, 1994, GASTROINTEST ENDOSC, V40, P89; WARING JP, 1991, GASTROINTEST ENDOSC, V37, P295	29	155	159	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1307	1311		10.1136/bmj.314.7090.1307	http://dx.doi.org/10.1136/bmj.314.7090.1307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158465	Green Published			2023-01-03	WOS:A1997WX97500021
J	Ferrucci, L; Guralnik, JM; Pahor, M; Corti, MC; Havlik, RJ				Ferrucci, L; Guralnik, JM; Pahor, M; Corti, MC; Havlik, RJ			Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; MAINTAINING MOBILITY; CORONARY ANGIOPLASTY; PHYSICAL-DISABILITY; BYPASS-SURGERY; LATE-LIFE; AGE; CARE; SURVIVAL	Objective.-To characterize hospital diagnoses, procedures and charges, and nursing home admissions in the year when older persons become severely disabled, comparing those in whom severe disability develops rapidly with those in whom disability develops gradually. Design.-A prospective, population-based cohort study with at least 6 annual interviews beginning in 1982. Setting.-A total of 3 communities: East Boston, Mass, New Haven, Conn, and Iowa and Washington counties in Iowa. Subjects.-A total of 6070 persons at least 70 years old with at least 1 interview after the fourth annual follow-up and without evidence of previous severe disability, defined as disability in 3 or more activities of daily living (ADLs). Main Outcome Measures.-Characteristics associated with development of severe disability after the fourth annual follow-up, in which the disability is classified as catastrophic disability if the individual did not report any ADL disability in the 2 interviews prior to severe disability onset or as progressive disability if the individual had previous disability in 1 or 2 ADLs. Results.-In the year during which severe disability developed, hospitalizations were documented for 72.1% of those developing catastrophic disability and for 48.6% of those developing progressive disability. In the corresponding year, only 14.7% of those who were stable with no disability and 22.3% of those with some disability were hospitalized, The 6 most frequent principal discharge diagnoses included stroke, hip fracture, congestive heart failure, and pneumonia in both severe disability subsets; coronary heart disease and cancer in catastrophic disability; and diabetes and dehydration in progressive disability. These diagnoses occurred in 49% of those with catastrophic disability and 25% of those with progressive disability. In both severe disability subsets, the oldest patients received less intensive hospital care as indicated by charges for surgery, diagnostics, and rehabilitation and by the percentage who received major diagnostic procedures; they were also more often admitted to nursing homes. Conclusions.-In the year when they become severely disabled, a large proportion of older persons are hospitalized for a small group of diseases. Hospital-based interventions aimed at reducing the severity and functional consequences of these diseases could have a large impact on reduction of severe disability.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; NATL RES INST INRCA,DEPT GERIATR,FLORENCE,ITALY; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; University of Tennessee System; University of Tennessee Health Science Center								ACKERMANN RJ, 1995, J FAM PRACTICE, V40, P129; BEARDEN D, 1994, J AM GERIATR SOC, V42, P1143, DOI 10.1111/j.1532-5415.1994.tb06979.x; BERGMAN L, 1991, BREAST CANCER RES TR, V18, P189, DOI 10.1007/BF01990035; BINSTOCK R, 1991, TOO OLD HLTH CARE; BOULT C, 1994, J GERONTOL, V49, pM28, DOI 10.1093/geronj/49.1.M28; BRACH LG, 1984, AM J PUBLIC HEALTH, V74, P266; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DEGARA CJ, 1995, HEPATO-GASTROENTEROL, V42, P73; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FALCONER JA, 1994, J AM GERIATR SOC, V42, P39, DOI 10.1111/j.1532-5415.1994.tb06071.x; Ferrucci L, 1996, J GERONTOL A-BIOL, V51, pM123, DOI 10.1093/gerona/51A.3.M123; FRIED LP, 1992, AGING-CLIN EXP RES, V4, P251, DOI 10.1007/BF03324099; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; GURALNIK JM, 1993, J GERONTOL, V48, P3, DOI 10.1093/geronj/48.Special_Issue.3; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P720; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KOWALSKI LP, 1994, AM J SURG, V168, P485, DOI 10.1016/S0002-9610(05)80107-2; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MARCHIONNI N, 1995, J AM GERIATR SOC, V43, P389, DOI 10.1111/j.1532-5415.1995.tb05813.x; OKEEFE JH, 1994, J AM COLL CARDIOL, V24, P425, DOI 10.1016/0735-1097(94)90299-2; PALMER RM, 1994, J AM GERIATR SOC, V42, P545, DOI 10.1111/j.1532-5415.1994.tb04978.x; PERLER BA, 1994, SURGERY, V116, P479; ROSENTHAL GE, 1994, J AM GERIATR SOC, V42, P826, DOI 10.1111/j.1532-5415.1994.tb06553.x; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; THOMAS DR, 1995, J AM GERIATR SOC, V43, P811, DOI 10.1111/j.1532-5415.1995.tb07058.x; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P259, DOI 10.1001/jama.274.3.259	36	201	205	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					728	734						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK026	9042845				2023-01-03	WOS:A1997WK02600032
J	McKinley, RK; Cragg, DK; Hastings, AM; French, DP; MankuScott, TK; Campbell, SM; Van, F; Roland, MO; Roberts, C				McKinley, RK; Cragg, DK; Hastings, AM; French, DP; MankuScott, TK; Campbell, SM; Van, F; Roland, MO; Roberts, C			Comparison of out of hours care provided by patients' own general practitioners and commercial deputising services: A randomised controlled trial .1. The outcome of care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; SATISFACTION	Objective: To compare the outcome of out of hours care given by general practitioners from patients' own practices and by commercial deputising services. Design: Randomised controlled trial. Setting: Four urban areas in Manchester, Salford, Stockport, and Leicester. Subjects: 2152 patients who requested out of hours care, and 49 practice doctors and 183 deputising doctors (61% local principals in general practice) who responded to the requests. Main outcome measures: Health status outcome, patient satisfaction, and subsequent health sen ice use. Results: Patients seen by deputising doctors were less satisfied with the care they received. The mean overall satisfaction score for practice doctors was 70.7 (95% confidence interval 68.1 to 73.2) and for deputising doctors 61.8 (59.9 to 63.7), The greatest difference in satisfaction was with the delay in visiting. There were no differences in the change in health or overall health status measured 24 to 120 hours after the out of hours call or subsequent use of the health service in the two groups. Conclusions: Patients are more satisfied with the out of hours care provided by practice doctors than that provided by deputising doctors, Organisation of doctors into large groups ma) produce lower levels of patient satisfaction, especially when associated with increased delays in the time taken to visit There seem to be no appreciable differences in health outcome between the two types of service.	UNIV MANCHESTER, RUSHOLME HLTH CTR, DEPT GEN PRACTICE, MANCHESTER M14 5NP, LANCS, ENGLAND; UNIV MANCHESTER, NATL PRIMARY CARE RES & DEV CTR, MANCHESTER M13 9PL, LANCS, ENGLAND	University of Manchester; University of Manchester	McKinley, RK (corresponding author), UNIV LEICESTER, LEICESTER GEN HOSP, DEPT GEN PRACTICE & PRIMARY HLTH CARE, LEICESTER LE5 4PW, LEICS, ENGLAND.		French, David P/K-7283-2012; McKinley, Robert Kee/H-9211-2013	French, David P/0000-0002-7663-7804; McKinley, Robert Kee/0000-0002-3684-3435; Campbell, Stephen/0000-0002-2328-4136				BAKER R, 1995, BRIT J GEN PRACT, V45, P654; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BAKER R, 1995, BRIT MED J, V310, P533, DOI 10.1136/bmj.310.6978.533c; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Cragg DK, 1997, BMJ-BRIT MED J, V314, P187, DOI 10.1136/bmj.314.7075.187; CREIGHTON PA, 1982, BRIT MED J, V284, P1090, DOI 10.1136/bmj.284.6322.1090; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; FITZPATRICK R, 1993, BRIT J RHEUMATOL, V32, P807; Garratt A M, 1994, Qual Health Care, V3, P186, DOI 10.1136/qshc.3.4.186; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; MAXWELL RBH, 1993, BRIT J GEN PRACT, V43, P226; McKinley RK, 1997, BMJ-BRIT MED J, V314, P193, DOI 10.1136/bmj.314.7075.193; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PRINGLE M, 1990, BRIT J GEN PRACT, V40, P455; PRUDHOE RH, 1984, BRIT MED J, V288, P718, DOI 10.1136/bmj.288.6418.718-a; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; STEVENSON JSK, 1982, BRIT MED J, V284, P947, DOI 10.1136/bmj.284.6320.947; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; Ware J. E., 1993, SF36 HLTH SURVEY MAN	25	43	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					190	193		10.1136/bmj.314.7075.190	http://dx.doi.org/10.1136/bmj.314.7075.190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022435	Green Published			2023-01-03	WOS:A1997WD91100030
J	Russell, SCS; Doyle, E				Russell, SCS; Doyle, E			Recent advances - Paediatric anaesthesia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CAUDAL ANALGESIA; VENOUS CANNULATION; EMLA CREAM; TOPICAL ANESTHESIA; CHILDREN; HALOTHANE; SEVOFLURANE; BUPIVACAINE; CLONIDINE; KETAMINE		ROYAL HOSP SICK CHILDREN, DEPT ANAESTHESIA, EDINBURGH EH9 1LF, MIDLOTHIAN, SCOTLAND									BJERRING P, 1989, BRIT J ANAESTH, V63, P655, DOI 10.1093/bja/63.6.655; BJERRING P, 1990, BRIT J ANAESTH, V64, P173, DOI 10.1093/bja/64.2.173; Black A, 1996, ANAESTHESIA, V51, P539, DOI 10.1111/j.1365-2044.1996.tb12559.x; BROCKMEYER DM, 1995, BRIT J ANAESTH, V74, P79, DOI 10.1093/bja/74.1.79; COOK B, 1995, BRIT J ANAESTH, V75, P698, DOI 10.1093/bja/75.6.698; DOI M, 1987, ANESTH ANALG, V66, P241; DOYLE E, 1993, ANAESTHESIA, V48, P1050; Eger Edmond I. Ii, 1993, Canadian Journal of Anaesthesia, V40, pR3; EHRENSTROMREIZ G, 1983, ACTA ANAESTH SCAND, V27, P510, DOI 10.1111/j.1399-6576.1983.tb01997.x; FISHER DM, 1985, ANESTHESIOLOGY, V63, P647, DOI 10.1097/00000542-198512000-00015; FRINK EJ, 1994, ANAESTH PHARM REV, V2, P61; HALLEN B, 1984, ANAESTHESIA, V39, P969, DOI 10.1111/j.1365-2044.1984.tb08884.x; Imamura S, 1987, J Anesth, V1, P62; JAMALI S, 1994, ANESTH ANALG, V78, P663; KAMAL RS, 1995, PAEDIATR ANAESTH, V5, P101, DOI 10.1111/j.1460-9592.1995.tb00253.x; KENNA JG, 1987, BRIT MED J, V294, P1209, DOI 10.1136/bmj.294.6581.1209; KRISTENSEN JD, 1995, BRIT J ANAESTH, V74, P193, DOI 10.1093/bja/74.2.193; LANDAIS A, 1995, PAEDIATR ANAESTH, V5, P297, DOI 10.1111/j.1460-9592.1995.tb00309.x; LAWSON RA, 1995, BRIT J ANAESTH, V75, P282, DOI 10.1093/bja/75.3.282; LEE JJ, 1994, BRIT J ANAESTH, V72, P258, DOI 10.1093/bja/72.3.258; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; MANNER T, 1987, ACTA ANAESTH SCAND, V31, P735, DOI 10.1111/j.1399-6576.1987.tb02655.x; Mori N, 1996, PAEDIATR ANAESTH, V6, P95, DOI 10.1111/j.1460-9592.1996.tb00368.x; NAGUIB M, 1991, BRIT J ANAESTH, V67, P559, DOI 10.1093/bja/67.5.559; NAITO Y, 1991, BRIT J ANAESTH, V67, P387, DOI 10.1093/bja/67.4.387; PHILLIPS AJ, 1988, ANAESTHESIA, V43, P927, DOI 10.1111/j.1365-2044.1988.tb05653.x; PIAT V, 1994, ANESTH ANALG, V79, P840; Ray DC, 1996, BRIT J ANAESTH, V77, P404, DOI 10.1093/bja/77.3.404; SARNER JB, 1995, ANESTHESIOLOGY, V82, P38, DOI 10.1097/00000542-199501000-00006; SEMPLE D, IN PRESS ANAESTHESIA; Shiraishi Y, 1990, J Clin Anesth, V2, P381, DOI 10.1016/0952-8180(90)90024-W; Sury MRJ, 1996, ANAESTHESIA, V51, P543, DOI 10.1111/j.1365-2044.1996.tb12560.x; WARK HJ, 1983, ANAESTHESIA, V38, P237, DOI 10.1111/j.1365-2044.1983.tb13983.x; WARNER LO, 1984, ANESTH ANALG, V63, P838; WOLF AR, 1990, BRIT J ANAESTH, V64, P430, DOI 10.1093/bja/64.4.430	35	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					201	203		10.1136/bmj.314.7075.201	http://dx.doi.org/10.1136/bmj.314.7075.201			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022439	Green Published			2023-01-03	WOS:A1997WD91100035
J	King, AC; Oman, RF; Brassington, GS; Bliwise, DL; Haskell, WL				King, AC; Oman, RF; Brassington, GS; Bliwise, DL; Haskell, WL			Moderate-intensity exercise and self-rated quality of sleep in older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; INSOMNIA; MEN; HEALTH; INDEX; WOMEN	Objective.-To determine the effects of moderate-intensity exercise training on serf-rated (subjective) sleep quality among healthy, sedentary older adults reporting moderate sleep complaints, Design.-Randomized controlled trial of 16 weeks' duration, Setting.-General community, Participants.-Volunteer sample of 29 women and 14 men (of 67 eligible subjects) aged 50 to 76 years who were sedentary, free of cardiovascular disease, and reported moderate sleep complaints. No participant was withdrawn for adverse effects. Intervention.-Randomized to 16 weeks of community-based, moderate-intensity exercise training or to a wait-listed control condition, Exercise consisted primarily of four 30- to 40-minute endurance training sessions (low-impact aerobics; brisk walking) prescribed per week at 60% to 75% of heart rate reserve based on peak treadmill exercise heart rate. Main Outcome Measure.-Pittsburgh Sleep Quality index (PSQI). Results.-Compared with controls (C), subjects in the exercise training condition (E) showed significant improvement in the PSQI global steep score at 16 weeks (baseline and posttest values in mean [SD] for C=8.93 [3.1] and 8.8 [2.6]; baseline and posttest Values for E=8,7 [3.0] and 5.4 [2.8]; mean posttest difference between conditions=3.4; P<.001; 95% confidence interval, 1.9-5.4), as well as in the steep parameters of rated sleep quality, sleep-onset latency (baseline and posttest values for C=26.1 [20,0] and 23.8 [15.3]; for E=28.4 [20,2] and 14.6 [13.0]; net improvement=11.5 minutes), and sleep duration baseline and posttest scores for C=5.8 [1.1] and 6.0 [1,0]; for E=6.0 [1,1] and 6.8 [1.2]; net improvement=42 minutes) assessed via PSQI and sleep diaries (P=.05). Conclusions.-Older adults with moderate sleep complaints can improve self-rated sleep quality by initiating a regular moderate-intensity exercise program.	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT MED,STANFORD CTR RES DIS PREVENT,PALO ALTO,CA 94304; UNIV OKLAHOMA,COLL PUBL HLTH,DEPT HLTH PROMOT SCI,OKLAHOMA CITY,OK; EMORY UNIV,SCH MED,DEPT NEUROL,ATLANTA,GA 30322	Stanford University; Stanford University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Emory University	King, AC (corresponding author), STANFORD UNIV,SCH MED,DEPT HLTH RES & POLICY,DIV EPIDEMIOL,730 WELCH RD,SUITE B,PALO ALTO,CA 94304, USA.		Winwood, Peter/A-6363-2008	King, Abby/0000-0002-7949-8811	NIA NIH HHS [AG-12358, AG-09991] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009991, R55AG012358, R01AG012358, R55AG009991] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI CA, 1995, J AM GERIATR SOC, V43, P1098, DOI 10.1111/j.1532-5415.1995.tb07007.x; American College of Sports Medicine, 1986, GUID EX TEST PRESCR; [Anonymous], 1995, GUID EX TEST PRESCR; BANNERMAN C, 1988, POSTGRAD MED, V84, P265; BECK AT, 1974, PSYCHOL MEASUREMENTS, P151; BLIWISE DL, 1993, SLEEP, V16, P40, DOI 10.1093/sleep/16.1.40; BLUMENTHAL JA, 1991, JAMA-J AM MED ASSOC, V266, P2098, DOI 10.1001/jama.266.15.2098; BOOTZIN RR, 1981, BEHAV ASSESS, V3, P107; BUYSSE DJ, 1991, SLEEP, V14, P331; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CARSKADON MA, 1976, AM J PSYCHIAT, V133, P1382; COATES TJ, 1982, J CONSULT CLIN PSYCH, V50, P345, DOI 10.1037/0022-006X.50.3.345; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.1093/biomet/58.3.403; GOSSARD D, 1986, AM J CARDIOL, V57, P446, DOI 10.1016/0002-9149(86)90770-8; HORNE JA, 1983, SLEEP, V6, P36, DOI 10.1093/sleep/6.1.36; KING AC, 1991, JAMA-J AM MED ASSOC, V266, P1535, DOI 10.1001/jama.266.11.1535; KING AC, 1993, HEALTH PSYCHOL, V12, P292, DOI 10.1037/0278-6133.12.4.292; KING AC, 1989, HEALTH PSYCHOL, V8, P305, DOI 10.1037/0278-6133.8.3.305; KRIPKE DF, 1979, ARCH GEN PSYCHIAT, V36, P103; Miles L. E., 1982, SLEEPING WAKING DISO, P383; MONK TH, 1991, J GERONTOL, V46, pM171, DOI 10.1093/geronj/46.5.M171; MORAN MG, 1988, AM J PSYCHIAT, V145, P1369; MORIN CM, 1988, J CONSULT CLIN PSYCH, V56, P748, DOI 10.1037/0022-006X.56.5.748; MUELLER JK, 1986, AM J CARDIOL, V57, P441, DOI 10.1016/0002-9149(86)90769-1; National Commission on Sleep Disorders Research, 1993, WAK AM NAT SLEEP AL, P1; O'Connor P J, 1995, Exerc Sport Sci Rev, V23, P105; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PHILLIPS WT, 1995, J AGING PHYS ACTIV, V3, P261, DOI 10.1123/japa.3.3.261; PUDER R, 1983, BEHAV THER, V14, P424, DOI 10.1016/S0005-7894(83)80104-X; SPECTOR PC, 1985, SAS USERS GUIDE STAT, P433; STEVENSON JS, 1990, RES NURS HEALTH, V13, P209, DOI 10.1002/nur.4770130403; VITIELLO M, 1989, GERONTOLOGIST, V29, pA258; Vitiello M.V., 1994, SLEEP RES, V23, P149; Vitiello MV, 1994, SLEEP RES, V23, P148	34	420	424	2	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					32	37		10.1001/jama.277.1.32	http://dx.doi.org/10.1001/jama.277.1.32			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ767	8980207				2023-01-03	WOS:A1997VZ76700026
J	van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL				van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL			Euthanasia, physician-assisted suicide, and other medical practices involving the end of life in the Netherlands, 1990-1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATTITUDES	Background In 1991 a new procedure for reporting physician-assisted deaths was introduced in the Netherlands that led to a tripling in the number of reported cases. In 1995, as part of an evaluation of this procedure, a nationwide study of euthanasia and other medical practices concerning the end of life was begun that was identical to a study conducted in 1990. Methods We conducted two studies, the first involving interviews with 405 physicians (general practitioners, nursing home physicians, and clinical specialists) and the second involving questionnaires mailed to the physicians attending 6060 deaths that were identified from death certificates. The response rates were 89 percent and 77 percent, respectively. Results Among the deaths studied, 2.3 percent of those in the interview study and 2.4 percent of those in the death-certificate study were estimated to have resulted from euthanasia, and 0.4 percent and 0.2 percent, respectively, resulted from physician-assisted suicide. In 0.7 percent of cases, life was ended without the explicit, concurrent request of the patient. Pain and symptoms were alleviated with doses of opioids that may have shortened life in 14.7 to 19.1 percent of cases, and decisions to withhold or withdraw life-prolonging treatment were made in 20.2 percent. Euthanasia seems to have increased in incidence since 1990, and the ending of life without the patient's explicit request seems to have decreased slightly. For each type of medical decision except those in which life-prolonging treatment was withheld or withdrawn, cancer was the most frequently reported diagnosis. Conclusions Since the notification procedure was introduced, end-of-life decision making in the Netherlands has changed only slightly, in an anticipated direction. Close monitoring of such decisions is possible, and we found no signs of an unacceptable increase in the number of decisions or of less careful decision making. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BLACK AL, 1996, JAMA-J AM MED ASSOC, V275, P919; Bokhove J., 1996, BALANS REKENONDERWIJ; Cochran WG, 1963, PREIS S BIOM J, V2nd, DOI [DOI 10.1002/BIMJ.19650070312, 10.1002/bimj.19650070312]; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; *ROYAL DUTCH MED A, 1995, POS PAP EUTH; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERMAAS PJ, 1992, HLTH POLICY, V22; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	14	386	386	2	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1699	1705		10.1056/NEJM199611283352227	http://dx.doi.org/10.1056/NEJM199611283352227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV936	8929370	Green Published, Bronze			2023-01-03	WOS:A1996VV93600034
J	Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP				Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP			The use of empiric clinical data in the evaluation of practice guidelines for unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ACUTE CARDIAC ISCHEMIA; CORONARY-CARE-UNIT; MEDICAL-PRACTICE GUIDELINES; PREDICTIVE INSTRUMENT; CHEST PAIN; PROSPECTIVE MULTICENTER; HEART-DISEASE; EMERGENCY; PECTORIS	Objective.-To determine the applicability to emergency department (ED) clinical practice of a nationally disseminated practice guideline on the disposition of patients with a diagnosis of unstable angina, and to determine the potential impact of the guideline on hospital admissions and demand for intensive care beds. Design.-Application of guideline criteria for ED disposition decisions to a validation sample derived from a prospective clinical trial. Setting.-Five hospitals, including 2 urban general teaching hospitals, 2 urban tertiary care university hospitals, and 1 suburban university-affiliated community hospital. Patients.-A consecutive sample of 457 patients who presented with symptoms suggestive of acute cardiac ischemia and who had ''unstable angina'' or ''rule out unstable angina'' diagnosed by ED physicians. Greater than 90% of eligible patients were enrolled in the clinical trial, follow-up data sufficient for assignment of a definitive diagnosis were obtained for 99% of subjects. Main outcome Measures.-Acute myocardial infarction and unstable angina, based on blind review of initial and follow-up clinical data, including cardiac enzyme levels and electrocardiograms. After completion of the trial, without knowledge of final diagnosis or outcome, the investigators classified patients into risk groups specified by the unstable angina guideline. Results.-Of subjects with an ED diagnosis of unstable angina, only 6% (n=28) met the guideline's criteria corresponding to low risk for adverse events and were therefore suitable for discharge directly to home. Fifty-four percent (n=247) mel the intermediate-risk criteria; 40% (n=182) met the high-risk criteria and were identified as requiring admission to an intensive care unit. Actual ED disposition differed from guideline recommendations in 2 major areas: only 4% (1/28) of low-risk patients were discharged to home with outpatient follow-up, and only 40% (72/182) of high-risk patients were admitted to an intensive care unit. Conclusions.-Although the guideline was intended to reduce hospitalization by identifying a low-risk group, the small size of this group among ED patients suggests that little reduction in hospitalization can be expected. Indeed, the guideline may increase demand for the limited number of intensive care beds to accommodate patients with unstable angina considered high-risk but currently placed elsewhere. These results emphasize the need to use empiric data from target clinical settings to assess the likely actual impact of guidelines on clinical care prior to national dissemination.	TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN CARE RES, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University				Katz, David/0000-0001-5348-6532	AHRQ HHS [R01-HS07360] Funding Source: Medline; NLM NIH HHS [LM7092] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007360] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ATKINS J, 1995, AM J EMERG MED, V13, P188; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BERTINI G, 1991, Journal of Emergency Medicine, V9, P57, DOI 10.1016/0736-4679(91)90589-8; BRAUNWALD E, 1994, CLIN PRACTICE GUIDEL, V10; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CANNON CP, 1995, AM J CARDIOL, V75, P977, DOI 10.1016/S0002-9149(99)80707-3; CANTRILL S, 1992, EMERG MED CLIN N AM, V8, P507; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Field MJ., 1992, GUIDELINES CLIN PRAC; FUCHS R, 1981, JAMA-J AM MED ASSOC, V246, P2037, DOI 10.1001/jama.246.18.2037; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAVES E, 1993, NATL CTR HLTH STAT S, V13; GRIJSEELS EWM, 1995, EUR HEART J, V16, P325; JAYES RL, 1992, J GEN INTERN MED, V7, P387, DOI 10.1007/BF02599153; KARCZ A, 1990, ANN EMERG MED, V19, P865, DOI 10.1016/S0196-0644(05)81559-8; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCDONALD C, 1994, CLIN PRACTICE GUIDEL, P71; MCNUTT RA, 1988, MED DECIS MAKING, V8, P90, DOI 10.1177/0272989X8800800204; NATTEL S, 1980, CAN MED ASSOC J, V122, P180; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RIZIK DG, 1995, AM J CARDIOL, V75, P993, DOI 10.1016/S0002-9149(99)80710-3; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; SAS, 2021, SAS PROC KAPP COEFF; Selker H. P., 1995, Journal of Investigative Medicine, V43, p497A; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; VANDERDOES E, 1976, HEART B, V7, P91; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C	35	60	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1568	1574						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918854				2023-01-03	WOS:A1996VT02500029
J	Cassel, CK; Vladeck, BC				Cassel, CK; Vladeck, BC			ICD-9 code for palliative or terminal care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US HLTH CARE FINANCING ADM,WASHINGTON,DC 20201		Cassel, CK (corresponding author), MT SINAI MED CTR,NEW YORK,NY 10029, USA.							Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; *NAT CTR HLTH STAT, 1991, VIT STAT US, V2; 1996, FED REGISTER, V61, P27451; 1996, FED REGISTER, V61, P27542; 1995, JAMA-J AM MED ASSOC, V274, P1591	5	58	58	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1232	1234		10.1056/NEJM199610173351612	http://dx.doi.org/10.1056/NEJM199610173351612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815949				2023-01-03	WOS:A1996VN40100012
J	Robinson, JC				Robinson, JC			Decline in hospital utilization and cost inflation under managed care in California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPETITION; CONTAINMENT; CAPITATION; SERVICES; MARKET	Objective.-To measure the impact of health maintenance organizations (HMOs) on hospital capacity, utilization, and expenditures between 1983 and 1993. Design.-Multivariate regression analysis. Setting.-Private nonprofit and for-profit hospitals in California with 25 or more beds. Patients.-Patient discharge abstract data were used to measure growth of HMO penetration of local hospital markets. Interventions.-None. Main Outcome Measures.-Hospital closures, changes in bed capacity, changes in acute care admissions and length of stay, psychiatric inpatient days, subacute inpatient days, inpatient and outpatient surgical procedures, ambulatory patient visits, and hospital expenditures. Results.-Between 1983 and 1993 hospital expenditures grew 44% less rapidly in markets with high HMO penetration than in markets with low HMO penetration. Of this, 28% was due to reductions in the volume and mix of services, 6% was due to reductions in bed capacity, and 10% was due to changes in the intensity of services provided. Health maintenance organizations accelerated the substitution of outpatient for inpatient surgery, the shift from acute to subacute inpatient days, and the reduction of psychiatric hospitalization. Conclusion.-Managed care is shifting the acute care hospital from the center toward the periphery of the health care system.			Robinson, JC (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA.							*AM HOSP ASS, 1994, HOSP STAT AHA PROF A; BERGTHOLD L, 1984, J HEALTH POLIT POLIC, V9, P203, DOI 10.1215/03616878-9-2-203; Coulam R F, 1991, Health Care Financ Rev Annu Suppl, P45; DOW MM, 1994, MANAGED CARE DIGEST; *GOV COMM, 1993, GRAND ALL VERT INT S; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Helbing C, 1992, Health Care Financ Rev Annu Suppl, P55; JOSKOW PL, 1980, BELL J ECON, V11, P421, DOI 10.2307/3003372; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LUFT HS, 1986, INQUIRY-J HEALTH CAR, V23, P83; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MELNICK GA, 1988, JAMA-J AM MED ASSOC, V260, P2669, DOI 10.1001/jama.260.18.2669; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Robinson JC, 1996, J LAW ECON, V39, P357, DOI 10.1086/467352; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; ROBINSON JC, 1994, MILBANK Q, V72, P259, DOI 10.2307/3350296; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; ROBINSON JC, 1987, JAMA-J AM MED ASSOC, V257, P3241, DOI 10.1001/jama.257.23.3241; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; Rosenberg Charles E., 1987, CARE STRANGERS RISE; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; Starr P., 1982, SOCIAL TRANSFORMATIO; Stevens Rosemary, 1989, SICKNESS WEALTH AM H	26	104	104	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1060	1064		10.1001/jama.276.13.1060	http://dx.doi.org/10.1001/jama.276.13.1060			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847768	Green Submitted			2023-01-03	WOS:A1996VK03500027
J	Turnbull, D; Holmes, A; Shields, N; Cheyne, H; Twaddle, S; Gilmour, WH; McGinley, M; Reid, M; Johnstone, I; Geer, I; McIlwaine, G; Lunan, CB				Turnbull, D; Holmes, A; Shields, N; Cheyne, H; Twaddle, S; Gilmour, WH; McGinley, M; Reid, M; Johnstone, I; Geer, I; McIlwaine, G; Lunan, CB			Randomised, controlled trial of efficacy of midwife-managed care	LANCET			English	Article							DELIVERY	Background Midwife-managed programmes of care are being widely implemented although there has been little investigation of their efficacy. We have compared midwife-managed care with shared care (ie, care divided among midwives, hospital doctors, and general practitioners) in terms of clinical efficacy and women's satisfaction. Methods We carried out a randomised controlled trial of 1299 pregnant women who had no adverse characteristics at booking (consent rate 81.9%). 648 women were assigned midwife-managed care and 651 shared care. The research hypothesis was that compared with shared care, midwife-managed care would produce fewer interventions, similar (or more favourable) outcomes, similar complications, and greater satisfaction with care. Data were collected by retrospective review of case records and self-report questionnaires. Analysis was by intention to treat. Findings Interventions were similar in the two groups or lower with midwife-managed care. For example, women in the midwife-managed group were less likely than women in shared care to have induction of labour (146 [23.9%] vs 199 [33.3%]; 95% Cl for difference 4.4-14.5). Women in the midwife-managed group were more likely to have an intact perineum and less likely to have had an episiotomy (p=0.02), with no significant difference in perineal tears. Complication rates were similar. Overall, 32.8% of women were permanently transferred from midwife-managed care (28.7% for clinical reasons, 3.7% for non-clinical reasons). Women in both groups reported satisfaction with their care but the midwife-managed group were significantly more satisfied with their antenatal (difference in mean scores 0.48 [95% Cl 0.41-0.55]), intrapartum (0.28 [0.18-0.37]), hospital-based postnatal care (0.57 [0.45-0.70]), and home-based postnatal care (0.33 [0.25-0.42]). Interpretation We conclude that midwife-managed care for healthy women, integrated within existing services, is clinically effective and enhances women's satisfaction with maternity care.	GLASGOW ROYAL MATERN HOSP,MIDWIFERY DEV UNIT,GLASGOW G4 ONA,LANARK,SCOTLAND; GLASGOW ROYAL MATERN HOSP,MIDWIFERY SERV,GLASGOW G4 ONA,LANARK,SCOTLAND; GLASGOW ROYAL MATERN HOSP,GYNECOL & PERINATAL DIRECTORATE,GLASGOW G4 ONA,LANARK,SCOTLAND; GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT OBSTET & GYNAECOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow				Cheyne, Helen/0000-0001-5738-8390				CAMPBELL R, 1994, WHERE TO BE BORN DEB; Carstairs V., 1991, DEPRIVATION HLTH SCO; COCKBURN J, 1991, EUR J CANCER, V27, P827, DOI 10.1016/0277-5379(91)90126-X; Department of Health (DoH), 1993, CHANGING CHILDBIRTH; *GREAT GLASG HLTH, 1992, 1991 1992 DEP PUBL H; *HOUS COMM SEL COM, 1992, 2 HOUS COMM SEL COMM; HUNDLEY VA, 1994, BRIT MED J, V309, P1400, DOI 10.1136/bmj.309.6966.1400; Likert R., 1932, ARCH PSYCHOL, V140, P1, DOI DOI 10.1111/J.1540-5834.2010.00585.X; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; Mason V., 1989, WOMENS EXPERIENCE MA; *MED RES COUNC, 1979, NORM BOYS GIRLS; *MIN REV BIRTH SER, 1990, FIN REP STUD GROUP R; *MIN TASK FORC OBS, 1989, FIN REP MIN TASK FOR; Murphy-Black T, 1992, Midwifery, V8, P113, DOI 10.1016/S0266-6138(05)80079-8; NEILSON JP, 1995, PREGNANCY CHILDBIRTH; Renfrew MJ, 1995, PREGNANCY CHILDBIRTH; *ROYAL COLL OBST G, 1982, REP RCOG WORK PART A; *SCOTT OFF HOM HLT, 1993, PROV MAT SERV SCOTL; *SCOTT PER MORT RE, 1990, IN DEPTH ENQ CERT CA; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; TURNBULL D, 1995, MIDWIFERY, V11, P110, DOI 10.1016/0266-6138(95)90025-X; WRAIGHT A, 1993, I MANPOWER STUDIES R, V242; [No title captured]; [No title captured]	24	139	143	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					213	218						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684197				2023-01-03	WOS:A1996UZ28600008
J	Diem, SJ; Lantos, JD; Tulsky, JA				Diem, SJ; Lantos, JD; Tulsky, JA			Cardiopulmonary resuscitation on television - Miracles and misinformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; PARAMEDIC SERVICES; METROPOLITAN-AREA; SURVIVAL; OUTCOMES; YOUNGER; OLDER; AGE	Background. Responsible, shared decision making on the part of physicians and patients about the potential use of cardiopulmonary resuscitation (CPR) requires patients who are educated about the procedure's risks and benefits, Television is an important source of information about CPR for patients, We analyzed how three popular television programs depict CPR, Methods. We watched all the episodes of the television programs ER and Chicago Hope during the 1994-1995 viewing season and 50 consecutive episodes of Rescue 911 broadcast over a three-month period in 1995, We identified all occurrences of CPR in each episode and recorded the causes of cardiac arrest, the identifiable demographic characteristics of the patients, the underlying illnesses, and the outcomes. Results. There were 60 occurrences of CPR in the 97 television episodes - 31 on ER, 11 on Chicago Hope, and 18 on Rescue 911, In the majority of cases, cardiac arrest was caused by trauma; only 28 percent were due to primary cardiac causes, Sixty-five percent of the cardiac arrests occurred in children, teenagers, or young adults, Seventy-five percent of the patients survived the immediate arrest, and 67 percent appeared to have survived to hospital discharge. Conclusions. The survival rates in our study are significantly higher than the most optimistic survival rates in the medical literature, and the portrayal of CPR on television may lead the viewing public to have an unrealistic impression of CPR and its chances for success, Physicians discussing the use of CPR with patients and families should be aware of the images of CPR depicted on television and the misperceptions these images may foster. (C) 1996, Massachusetts Medical Society.	DUKE UNIV,MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC; DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DURHAM,NC; UNIV CHICAGO,MACLEAN CTR MED ETH,CHICAGO,IL	Duke University; Duke University; University of Chicago	Diem, SJ (corresponding author), VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,508 FULTON ST,DURHAM,NC 27705, USA.		Diem, Susan/B-6479-2013					ANNAS GJ, 1995, HASTINGS CENT REP, V25, P40, DOI 10.2307/3562794; APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, LANCET, V1, P812; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; KARETZKY M, 1995, ARCH INTERN MED, V155, P1277, DOI 10.1001/archinte.155.12.1277; LAVELLE JM, 1993, CRIT CARE MED, V21, P368, DOI 10.1097/00003246-199303000-00013; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; Turow Joseph, 1989, PLAYING DOCTOR TELEV; VERTESI L, 1983, CAN MED ASSOC J, V128, P809; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	315	323	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1578	1582		10.1056/NEJM199606133342406	http://dx.doi.org/10.1056/NEJM199606133342406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP663	8628340				2023-01-03	WOS:A1996UP66300006
J	Boxma, H; Broekhuizen, T; Patka, P; Oosting, H				Boxma, H; Broekhuizen, T; Patka, P; Oosting, H			Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: The Dutch Trauma Trial	LANCET			English	Article							WOUND-INFECTION; MULTICENTER; CEFAZOLIN	Background The efficacy of prophylactic antibiotics in fracture surgery remains controversial for lack of well-documented prospective studies. We report here the findings of the Dutch Trauma Trial, a prospective, randomised, double-blind, placebo-controlled study of antibiotic prophylaxis in the primary operative treatment of limb fractures. Ceftriaxone was chosen because of its broad spectrum of activity and because its pharmacokinetic profile, including high serum levels, high tissue penetration, and long elimination half-life, makes it suitable for single-dose prophylaxis. Methods Patients aged 18 years or more, attending one of fourteen Dutch centres for acute treatment of closed fractures, were randomly allocated to a single preoperative dose of ceftriaxone 2 g or placebo, and evaluated for development of wound infection and nosocomial infection at 10 days, 30 days, and 120 days, To assess the effects of drop-outs and withdrawals, best-case and worst-case analyses were performed. Findings A total of 2195 patients were included, The incidence of superficial and deep wound infections after placebo was 8.3%, compared with 3.6% in the ceftriaxone group (p<0.001, Pearson chi(2)-test), The rate of nosocomial infection in the first month was 10.2% with placebo and 2.3% with ceftriaxone (p<0.001, Pearson chi(2)-test). Gram-positive bacteria were found in 74.5% of wound infections and 13.4% of nosocomial infections. Interpretation Adequate single-dose prophylaxis with a long-acting broad-spectrum antibiotic substantially reduces the incidence of wound infection and early nosocomial infection after surgery for closed fractures.	UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT SURG,1081 HV AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Boxma, H (corresponding author), ZUIDERZIEKENHUIS,DEPT SURG,GROENE HILLEDIJK 315,3075 EA ROTTERDAM,NETHERLANDS.							ALBERS BA, 1994, UNFALLCHIRURG, V97, P625; ALLGOWER M, 1980, SURG CLIN N AM, V60, P133; ARENS S, 1994, HYG MED, V19, P85; BERGAN T, 1988, INSIGHTS TREAT SERIO, V2, P15; BODOKY A, 1993, J BONE JOINT SURG AM, V75A, P61, DOI 10.2106/00004623-199301000-00009; BOYD RJ, 1973, J BONE JOINT SURG AM, VA 55, P1251, DOI 10.2106/00004623-197355060-00012; BUCKLEY R, 1990, CAN J SURG, V33, P122; BURKE JF, 1961, SURGERY, V50, P161; BURNETT JW, 1980, J BONE JOINT SURG AM, V62, P457, DOI 10.2106/00004623-198062030-00017; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; CUSHING RD, 1977, SURG CLIN N AM, V57, P165; DIPIRO JT, 1986, AM J SURG, V152, P552, DOI 10.1016/0002-9610(86)90228-X; ERICSON C, 1973, J BONE JOINT SURG AM, VA 55, P808, DOI 10.2106/00004623-197355040-00015; GATELL JM, 1984, J BONE JOINT SURG AM, V66A, P1219, DOI 10.2106/00004623-198466080-00009; GATELL JM, 1987, J BONE JOINT SURG AM, V69A, P1189, DOI 10.2106/00004623-198769080-00012; HENLEY MB, 1986, CLIN ORTHOP RELAT R, V209, P249; HILL C, 1981, LANCET, V1, P795; MCQUEEN MM, 1990, INJURY, V21, P104, DOI 10.1016/0020-1383(90)90065-3; NICHOLS RL, 1991, AM J MED, V91, pS54, DOI 10.1016/0002-9343(91)90344-W; OESTERN HJ, 1983, ORTHOPADE, V2, P2; PAIEMENT GD, 1994, J ORTHOP TRAUMA, V8, P64, DOI 10.1097/00005131-199402000-00014; PATZAKIS MJ, 1974, J BONE JOINT SURG AM, VA 56, P532, DOI 10.2106/00004623-197456030-00010; PAVEL A, 1974, J BONE JOINT SURG AM, VA 56, P777, DOI 10.2106/00004623-197456040-00011; POLLOCK AA, 1982, ANTIMICROB AGENTS CH, V22, P816, DOI 10.1128/AAC.22.5.816; ROTH AI, 1986, J TRAUMA, V26, P757, DOI 10.1097/00005373-198608000-00013; Stolle D, 1980, Hefte Unfallheilkd, V143, P1; WITTMANN DH, 1985, RECENT ADV CHEMOTHER, P189; WYMENGA A, 1992, ACTA ORTHOP SCAND, V63, P19, DOI 10.3109/17453679209154842; 1964, ANN SURG S2, V160, P1	29	178	181	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1133	1137		10.1016/S0140-6736(96)90606-6	http://dx.doi.org/10.1016/S0140-6736(96)90606-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609746				2023-01-03	WOS:A1996UG75500008
J	Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B				Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B			Hormone replacement therapy and risk of non-fatal stroke	LANCET			English	Article							POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; FOLLOW-UP; WOMEN; USERS; COPENHAGEN; MORTALITY; COHORT	Background The effect of postmenopausal hormone replacement therapy (HRT) on the risk of subtypes of stroke is as yet unclear. To investigate the effect of oestrogen and combined oestrogen-progestagen therapy on the risk of nonfatal haemorrhagic and thromboembolic stroke, we carried out a case-control study. Methods From the Danish National Patient Register we identified all Danish women aged 45-64 years who had a non-fatal, first-ever cerebrovascular attack during 1990-92. Two age-matched controls were randomly selected for each case from the Danish National Person Register. Important correlates of hormone use and stroke, on which information was obtained from postal questionnaires, were controlled for by multivariate analyses based on log-linear graphical models. The analyses included data on 1422 cases classified in four subtypes of stroke (160 subarachnoid haemorrhage, 95 intracerebral haemorrhage, 846 thromboembolic infarction, 321 transient ischaemic attack) and 3171 controls. Findings After adjustment for confounding variables and correction for the trend in sales of HRT preparations, no significant associations were detected between current use of unopposed oestrogen replacement therapy and non-fatal subarachnoid haemorrhage (odds ratio 0.52 [95% CI 0.23-1.22]), intracerebral haemorrhage (0.15 [0.02-1.09]), or thromboembolic infarction (1.16 [0.86-1.58]), respectively, compared with never use. Current use of combined oestrogen-progestagen replacement therapy had no significant influence on the risk of subarachnoid haemorrhage (1.22 [0.79-1.89]), intracerebral haemorrhage (1.17 [0.64-2.13]), or thromboembolic infarction (1.17 [0.92-1.47]). A significantly increased incidence of transient ischaemic attacks among former users of HRT and among current users of unopposed oestrogen may to some extent be explained by selection-HRT users being more aware of symptoms than non-users. Interpretation Unopposed oestrogen and combined oestrogen-progestagen replacement therapy have no influence on the risk of non-fatal thromboembolic or haemorrhagic stroke in women aged 45-64 years.	UNIV COPENHAGEN, INST SOCIOL, COPENHAGEN, DENMARK; HERLEV HOSP, DEPT OBSTET & GYNAECOL, DK-2730 HERLEV, DENMARK	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Pedersen, AT (corresponding author), UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT OBSTET & GYNAECOL 537, KETTEGARDS ALLEE 30, DK-2650 HVIDOVRE, DENMARK.							[Anonymous], [No title captured]; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DARROCH JN, 1980, ANN STAT, V8, P522, DOI 10.1214/aos/1176345006; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Falkeborn M, 1996, EPIDEMIOLOGY, V7, P67, DOI 10.1097/00001648-199601000-00012; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KLEIN JP, 1995, STAT MED, V14, P1265, DOI 10.1002/sim.4780141202; LINDEGAARD O, 1993, BRIT MED J, V306, P956; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; SALOMAA V, 1995, ARTERIOSCL THROM VAS, V15, P1549, DOI 10.1161/01.ATV.15.10.1549; SPEROFF L, 1996, EUR MENOPAUSE J, V3, P151; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WERMUTH N, 1990, J ROY STAT SOC B MET, V52, P21; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; ZHANG XH, 1995, STROKE, V26, P1774, DOI 10.1161/01.STR.26.10.1774	33	122	122	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1277	1283		10.1016/S0140-6736(97)06005-4	http://dx.doi.org/10.1016/S0140-6736(97)06005-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357407				2023-01-03	WOS:A1997YD68900009
J	Katan, MB; Grundy, SM; Willett, WC				Katan, MB; Grundy, SM; Willett, WC			Beyond low-fat diets	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED TRIAL; LIPOPROTEINS; ACIDS; WOMEN; CHOLESTEROL		UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health	Katan, MB (corresponding author), AGR UNIV WAGENINGEN, DIV HUMAN NUTR & EPIDEMIOL, BOMENWEG 2, NL-6703 HD WAGENINGEN, NETHERLANDS.							BLACK HS, 1994, NEW ENGL J MED, V330, P1272, DOI 10.1056/NEJM199405053301804; ERNST N, 1980, CIRCULATION, V62, P41; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; HYEWON LH, 1988, AM J CLIN NUTR, V48, P575, DOI 10.1093/ajcn/48.3.575; JEFFERY RW, 1995, INT J OBESITY, V19, P132; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KEYS A, 1957, LANCET, V2, P959; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; *NAT DIET HEART ST, 1968, CIRCULATION S1, V37, P170; SACKS RM, 1994, J CARDIOVASC RISK, V1, P3; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; Vega GL, 1996, CURR OPIN LIPIDOL, V7, P209, DOI 10.1097/00041433-199608000-00007; Willett Walter C., 1997, P559; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WILLETT WC, IN PRESS AM J CLIN N	16	206	209	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					563	566						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262504				2023-01-03	WOS:A1997XR54800012
J	Dajani, AS; Taubert, KA; Wilson, W; Bolger, AF; Bayer, A; Ferrieri, P; Gewitz, MH; Shulman, ST; Nouri, S; Newburger, JW; Hutto, C; Pallasch, TJ; Gage, TW; Levison, ME; Peter, G; Zuccaro, G				Dajani, AS; Taubert, KA; Wilson, W; Bolger, AF; Bayer, A; Ferrieri, P; Gewitz, MH; Shulman, ST; Nouri, S; Newburger, JW; Hutto, C; Pallasch, TJ; Gage, TW; Levison, ME; Peter, G; Zuccaro, G			Prevention of bacterial endocarditis - Recommendations by the American Heart Association	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MITRAL-VALVE PROLAPSE; UPPER GASTROINTESTINAL ENDOSCOPY; BENIGN ESOPHAGEAL STRICTURE; ORAL IRRIGATION DEVICE; INFECTIVE ENDOCARDITIS; HURST BOUGIENAGE; BACTEREMIA; PROPHYLAXIS; RISK; SIGMOIDOSCOPY	Objective.-To update recommendations issued by the American Heart Association last published in 1990 for the prevention of bacterial endocarditis in individuals at risk for this disease. Participants.-An ad hoc writing group appointed by the American Heart Association for their expertise in endocarditis and treatment with liaison members representing the American Dental Association, the Infectious Diseases Society of America, the American Academy of Pediatrics, and the American Society for Gastrointestinal Endoscopy. Evidence.-The recommendations in this article reflect analyses of relevant literature regarding procedure-related endocarditis, in vitro susceptibility data of pathogens causing endocarditis, results of prophylactic studies in animal models of endocarditis, and retrospective analyses of human endocarditis cases in terms of antibiotic prophylaxis usage patterns and apparent prophylaxis failures. MEDLINE database searches from 1936 through 1996 were done using the root words endocarditis, bacteremia, and antibiotic prophylaxis. Recommendations in this document fall into evidence level III of the US Preventive Services Task Force categories of evidence. Consensus Process.-The recommendations were formulated by the writing group after specific therapeutic regimens were discussed. The consensus statement was subsequently reviewed by outside experts not affiliated with the writing group and by the Science Advisory and Coordinating Committee of the American Heart Association. These guidelines are meant to aid practitioners but are not intended as the standard of care or as a substitute for clinical judgment. Conclusions.-Major changes in the updated recommendations include the following: (1) emphasis that most cases of endocarditis are not attributable to an invasive procedure; (2) cardiac conditions are stratified into high-, moderate-, and negligible-risk categories based on potential outcome if endocarditis develops; (3) procedures that may cause bacteremia and for which prophylaxis is recommended are more clearly specified; (4) an algorithm was developed to more clearly define when prophylaxis is recommended for patients with mitral valve prolapse; (5) for oral or dental procedures the initial amoxicillin dose is reduced to 2 g, a follow-up antibiotic dose is no longer recommended, erythromycin is no longer recommended for penicillin-allergic individuals, but clindamycin and other alternatives are offered; and (6) for gastrointestinal or genitourinary procedures, the prophylactic regimens have been simplified. These changes were instituted to more clearly define when prophylaxis is or is not recommended, improve practitioner and patient compliance, reduce cost and potential gastrointestinal adverse effects, and approach more uniform worldwide recommendations.	AMER HEART ASSOC,OFF SCI & MED,DALLAS,TX 75231; AMER DENT ASSOC,CHICAGO,IL; INFECT DIS SOC AMER,ALEXANDRIA,EGYPT; AMER ACAD PEDIAT,ELK GROVE VILLAGE,IL; AMER SOC GASTROINTESTINAL ENDOSCOPY,MANCHESTER,MA	American Academy of Pediatrics								AWADALLAH SM, 1991, AM J CARDIOL, V68, P90, DOI 10.1016/0002-9149(91)90717-Y; BASKIN G, 1989, AM J GASTROENTEROL, V84, P311; BAYER AS, 1990, CHEST, V97, P1203, DOI 10.1378/chest.97.5.1203; BENDER IB, 1984, J AM DENT ASSOC, V109, P415, DOI 10.14219/jada.archive.1984.0432; BERGER SA, 1974, ANN INTERN MED, V80, P510, DOI 10.7326/0003-4819-80-4-510; BERNEY P, 1990, J INFECT DIS, V161, P281; BOTOMAN VA, 1986, GASTROINTEST ENDOSC, V32, P342, DOI 10.1016/S0016-5107(86)71880-4; BOUDOULAS H, 1995, MOSS ADAMS HEART DIS, P1068; BRYNE W, 1982, J PEDIAT GASTROENTER, V1, P551; Carabello B A, 1993, Curr Probl Cardiol, V18, P423; Cheitlin MD, 1997, CIRCULATION, V95, P1686; Child John S., 1996, Cardiology Clinics, V14, P327, DOI 10.1016/S0733-8651(05)70287-3; COHEN LB, 1983, GASTROINTEST ENDOSC, V29, P198, DOI 10.1016/S0016-5107(83)72584-8; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DAJANI AS, 1994, CLIN INFECT DIS, V18, P157, DOI 10.1093/clinids/18.2.157; DANCHIN N, 1989, LANCET, V1, P743; DEVEREUX RB, 1989, ANN INTERN MED, V111, P305, DOI 10.7326/0003-4819-111-4-305; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DEVEREUX RB, 1986, AM J MED, V81, P751, DOI 10.1016/0002-9343(86)90339-6; DURACK DT, 1995, NEW ENGL J MED, V332, P38, DOI 10.1056/NEJM199501053320107; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; FELIX JE, 1971, J PERIODONTOL, V42, P785, DOI 10.1902/jop.1971.42.12.785; FLUCKIGER U, 1994, J INFECT DIS, V169, P397; GERSONY WM, 1993, CIRCULATION, V87, P121; GUNTHEROTH WG, 1984, AM J CARDIOL, V54, P797, DOI 10.1016/S0002-9149(84)80211-8; HO H, 1991, GASTROENTEROLOGY, V101, P1642, DOI 10.1016/0016-5085(91)90403-8; HUNTER KM, 1989, BRIT DENT J, V167, P275, DOI 10.1038/sj.bdj.4806998; KAYE D, 1986, ANN INTERN MED, V104, P419, DOI 10.7326/0003-4819-104-3-419; LEVINER E, 1987, ORAL SURG ORAL MED O, V64, P417, DOI 10.1016/0030-4220(87)90145-9; LOGAN RF, 1988, BRIT MED J, V296, P1107, DOI 10.1136/bmj.296.6629.1107; LOW DE, 1987, CAN J SURG, V30, P421; LOW DE, 1987, DIGEST DIS SCI, V32, P1239, DOI 10.1007/BF01296372; MACMAHON SW, 1987, AM HEART J, V113, P1291, DOI 10.1016/0002-8703(87)90957-4; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; MORALES AR, 1992, HUM PATHOL, V23, P129, DOI 10.1016/0046-8177(92)90233-S; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; NIV Y, 1985, GASTROINTEST ENDOSC, V31, P265, DOI 10.1016/S0016-5107(85)72179-7; NORFLEET RG, 1991, J CLIN GASTROENTEROL, V13, P448, DOI 10.1097/00004836-199108000-00017; Pallasch TJ, 1996, PERIODONTOL 2000, V10, P107, DOI 10.1111/j.1600-0757.1996.tb00071.x; PRABHU SD, 1997, ATLAS HEART DIS VALV, V11; PRITCHARD TM, 1991, AM J MED, V90, P516; RAINES DR, 1977, AUST N Z J MED, V7, P22; RIGILANO J, 1984, ARCH INTERN MED, V144, P850, DOI 10.1001/archinte.144.4.850; RODRIGUEZ W, 1984, WESTERN J MED, V140, P951; ROMANS AR, 1971, J PERIODONTOL, V42, P757, DOI 10.1902/jop.1971.42.12.757; ROUSE MS, IN PRESS ANTIMICROB; SAIMAN L, 1993, J PEDIATR-US, V122, P847, DOI 10.1016/S0022-3476(09)90006-3; SANDE M A, 1990, P1117; SHULL HJ, 1975, ANN INTERN MED, V83, P212, DOI 10.7326/0003-4819-83-2-212; SIMMONS NA, 1986, LANCET, V1, P1267; STARKEBAUM M, 1977, YALE J BIOL MED, V50, P49; STECKELBERG JM, 1993, INFECT DIS CLIN N AM, V7, P9; STEPHENSON PM, 1977, AUST NZ J MED, V7, P32, DOI 10.1111/j.1445-5994.1977.tb03353.x; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P693, DOI 10.1016/0735-1097(94)00408-I; STROM BL, 1996, J INVEST MED, V44, P229; SUGRUE D, 1980, BRIT HEART J, V44, P499, DOI 10.1136/hrt.44.5.499; SULLIVAN NM, 1973, J INFECT DIS, V127, P49, DOI 10.1093/infdis/127.1.49; TSENG CC, 1992, GASTROINTEST ENDOSC, V38, P336, DOI 10.1016/S0016-5107(92)70427-1; WATANAKUNAKORN C, 1988, AM HEART J, V116, P1115, DOI 10.1016/0002-8703(88)90173-1; WEISSMAN NJ, 1994, AM J CARDIOL, V73, P1080, DOI 10.1016/0002-9149(94)90287-9; WELSH JD, 1983, J CLIN GASTROENTEROL, V5, P109, DOI 10.1097/00004836-198304000-00003; WOOLEY CF, 1991, PROG CARDIOVASC DIS, V33, P397, DOI 10.1016/0033-0620(91)90005-7; YIN TP, 1983, ENDOSCOPY, V15, P27, DOI 10.1055/s-2007-1018601; Yin TP, 1983, ENDOSCOPY, V31, P265; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	66	705	732	1	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1794	1801		10.1001/jama.277.22.1794	http://dx.doi.org/10.1001/jama.277.22.1794			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178793				2023-01-03	WOS:A1997XC49900033
J	Lan, RS; Lo, SK; Chuang, ML; Yang, CT; Tsao, TCY; Lee, CH				Lan, RS; Lo, SK; Chuang, ML; Yang, CT; Tsao, TCY; Lee, CH			Elastance of the pleural space: A predictor for the outcome of pleurodesis in patients with malignant pleural effusion	ANNALS OF INTERNAL MEDICINE			English	Article						pleurodesis; pleural effusion, malignant; bleomycin; thoracostomy; elastance	TETRACYCLINE PLEURODESIS; INTRACAVITARY BLEOMYCIN; LOW GLUCOSE; MANAGEMENT; PH; ROTATION; FLUID; TERM	Background: In patients who have malignant pleural effusion, it is difficult to diagnose trapped lung before thoracoscopy, thoracostomy, and drainage of the effusion. Predicting the outcome of pleurodesis in patients who have malignant pleural effusion without trapped lung is also difficult. Objective: To investigate the factors that may be useful in diagnosing trapped lung and predicting the outcome of pleurodesis. Design: Prospective cohort study. Setting: University medical center. Patients: 65 patients with symptomatic malignant pleural effusion. Intervention: A chest tube was inserted for drainage of the effusion, and pleurodesis was done using bleomycin as the sclerosant. Measurements: The pH and glucose levels of the effusion and the elastance of the pleural space (defined as the decline in pleural fluid pressure in cm H2O after removal of 500 mt of effusion) were measured. The outcome of pleurodesis was evaluated 1 month after the chest tube was removed. Results: Patients with an elastance of 19 cm H2O or more had a higher incidence of trapped lung (11 of 14 patients) than did those with an elastance less than 19 cm H2O (3 of 51 patients) (P < 0.001). None of the 14 patients with an elastance of 19 cm H2O or more and none of the 14 patients with a trapped lung had successful pleurodesis. Forty-two of 43 patients with an elastance less than 19 cm H2O who did not have a trapped lung had successful pleurodesis. Elastance seemed to be the best predictor for trapped lung and outcome of pleurodesis, although outcome was also correlated with pH and glucose levels of the effusion. Low-dose bleomycin (30 mg) is as effective as the usual dose of bleomycin (60 mg) for pleurodesis. Conclusion: In patients with symptomatic malignant pleural effusion, measurement of the elastance of the pleural space is a simple and effective method for the diagnosis of trapped lung and prediction of the outcome of chemical pleurodesis with bleomycin.	DEAKIN UNIV, BURWOOD, VIC 3125, AUSTRALIA	Deakin University	Lan, RS (corresponding author), CHANG GUNG MEM HOSP, DEPT CHEST MED, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.			LO, Sing Kai/0000-0001-8401-1759; Yang, Cheng-Ta/0000-0003-1846-1027				AELONY Y, 1995, CHEST S, V108, pS111; CHERNOW B, 1977, AM J MED, V63, P695, DOI 10.1016/0002-9343(77)90154-1; DRYZER SR, 1993, CHEST, V104, P1763, DOI 10.1378/chest.104.6.1763; GOOD JT, 1978, CHEST, V74, P602, DOI 10.1378/chest.74.5.602a; GOOD JT, 1985, AM REV RESPIR DIS, V131, P737; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; LIGHT RW, 1980, AM REV RESPIR DIS, V121, P799; LIGHT RW, 1995, PLEURAL DISEASES; Moffett M J, 1992, Semin Oncol, V19, P59; OSTROWSKI MJ, 1982, CANCER TREAT REP, V66, P1903; OSTROWSKI MJ, 1986, CANCER, V57, P721, DOI 10.1002/1097-0142(19860215)57:4<721::AID-CNCR2820570407>3.0.CO;2-5; PALADINE W, 1976, CANCER, V38, P1903, DOI 10.1002/1097-0142(197611)38:5<1903::AID-CNCR2820380506>3.0.CO;2-A; RODRIGUEZPANADE.F, 1990, EUR RESP J S10, V3, pS247; RODRIGUEZPANADERO F, 1989, AM REV RESPIR DIS, V139, P663, DOI 10.1164/ajrccm/139.3.663; RUCKDESCHEL JC, 1995, SEMIN ONCOL, V22, P58; RUCKDESCHEL JC, 1992, MALIGNANT PLEURAL EF; SAHN SA, 1985, CLIN CHEST MED, V6, P113; SAHN SA, 1988, ANN INTERN MED, V108, P345, DOI 10.7326/0003-4819-108-3-345; SANCHEZARMENGOL A, 1993, CHEST, V104, P1482, DOI 10.1378/chest.104.5.1482; VARGAS FS, 1994, CHEST, V106, P1246, DOI 10.1378/chest.106.4.1246; VILLANUEVA AG, 1994, THORAX, V49, P23, DOI 10.1136/thx.49.1.23; WALKERRENARD PB, 1994, ANN INTERN MED, V120, P56, DOI 10.7326/0003-4819-120-1-199401010-00010	22	91	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					768	+		10.7326/0003-4819-126-10-199705150-00003	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148649				2023-01-03	WOS:A1997WZ82300005
J	Virchis, AE; Patel, RK; Contreras, M; Navarrete, C; Kaczmarksi, RS; JanMohamed, R				Virchis, AE; Patel, RK; Contreras, M; Navarrete, C; Kaczmarksi, RS; JanMohamed, R			Lesson of the week - Acute non-cardiogenic lung oedema after platelet transfusion	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY; ANTIBODY; INJURY		HILLINGDON HOSP,NHS TRUST,DEPT HAEMATOL MED,UXBRIDGE UB8 3NN,MIDDX,ENGLAND									ANDREWS AT, 1976, AM J CLIN PATHOL, V66, P483; BARNARD RD, 1951, NEW YORK STATE J MED, V51, P2399; Bux J, 1996, BRIT J HAEMATOL, V93, P707, DOI 10.1046/j.1365-2141.1996.d01-1703.x; LEVY GJ, 1986, TRANSFUSION, V26, P278, DOI 10.1046/j.1537-2995.1986.26386209388.x; NORDHAGEN R, 1986, VOX SANG, V51, P102, DOI 10.1111/j.1423-0410.1986.tb00223.x; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; VANBUREN NL, 1990, TRANSFUSION, V30, P42; WARD HN, 1970, ANN INTERN MED, V73, P689, DOI 10.7326/0003-4819-73-5-689; YOMTOVIAN R, 1984, LANCET, V1, P244	10	22	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					880	882						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093102				2023-01-03	WOS:A1997WQ02800033
J	Gutthann, SP; Rodriguez, LAG; Castellsague, J; Oliart, AD				Gutthann, SP; Rodriguez, LAG; Castellsague, J; Oliart, AD			Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To evaluate the association between use of hormone replacement therapy and the risk of idiopathic venous thromboembolism. Design: Population based case-control study. Setting: Population enrolled in the General Practice Research Database, United Kingdom. Subjects: A cohort of 347 253 women aged 50 to 79 without major risk factors for venous thromboembolism was identified. Cases were 292 women admitted to hospital for a first episode of pulmonary embolism or deep venous thrombosis; 10 000 controls were randomly selected from the source cohort. Main outcome measures: Adjusted relative risks estimated from unconditional logistic regression. Results: The adjusted odds ratio of venous thromboembolism for current use of hormone replacement therapy compared with non-users, with odds ratios of 4.6 (2.5 to 8.4) during the first six months and 3.0 (1.4 to 6.5) 6-12 months after starting treatment. No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations. The risk of idiopathic venous thromboembolism among non-users, idiopathic venous thromboembolism occurs at two to three times the rate in non-users, resulting in one to two additional cases per 10 000 women per year. Conclusions: Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use.	UNIV COMPLUTENSE MADRID, CTR ESPANOL INVEST FARMACOEPIDEMIOL, MADRID 28003, SPAIN	Complutense University of Madrid	Gutthann, SP (corresponding author), NOVARTIS PHARMACEUT, DEPT MED, GRAN VIA CORTS CATALANES 764, BARCELONA 08013, SPAIN.			Perez-Gutthann, Susana/0000-0001-5798-3691				[Anonymous], 1974, NEW ENGL J MED, V290, P15; *COMM SAF MED, 1996, CURRENT PROBLEMS PHA, V22, P9; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; FEINSTEIN AR, 1978, CANCER RES, V38, P4001; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; *SAS I, 1992, SAS SYST PERS COMP R; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; Walker A., 1991, OBSERVATION INFERENC	18	288	293	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					796	800		10.1136/bmj.314.7083.796	http://dx.doi.org/10.1136/bmj.314.7083.796			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081000	Green Published			2023-01-03	WOS:A1997WN64600029
J	Aebischer, P; Schluep, M; Deglon, N; Joseph, JM; Hirt, L; Heyd, B; Goddard, M; Hammang, JP; Zurn, AD; Kato, AC; Regli, F; Baetge, EE				Aebischer, P; Schluep, M; Deglon, N; Joseph, JM; Hirt, L; Heyd, B; Goddard, M; Hammang, JP; Zurn, AD; Kato, AC; Regli, F; Baetge, EE			Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients	NATURE MEDICINE			English	Article							NEUROTROPHIC FACTOR PREVENTS; MOTOR-NEURONS; MOTONEURONS	Neuronal growth factors hold promise for providing therapeutic benefits in various neurological disorders. As a means of ensuring adequate central nervous system delivery of growth factors and minimizing significant adverse side effects associated with systemic delivery methods, we have developed an ex vivo gene therapy approach for protein delivery using encapsulated genetically modified xenogeneic cells. Ciliary neurotrophic factor (CNTF) has been shown in various rodent models to reduce the motor neuron cell death similar to that seen in amyotrophic lateral sclerosis (ALS)(1-3). The initial trials focusing on the systemic administration of CNTF for ALS have been discontinued as a result of major side effects, thus preventing determination of the potential efficacy of the molecule(4,5). In order to deliver CNTF directly to the nervous system, we conducted a phase I study in which six ALS patients were implanted with polymer capsules containing genetically engineered baby hamster kidney cells releasing approximately 0.5 mu g of human CNTF per day in vitro. The CNTF-releasing implants were surgically placed within the lumbar intrathecal space. Nanogram levels of CNTF were measured within the patients' cerebrospinal fluid (CSF) for at least 17 weeks post-transplantation, whereas it was undetectable before implantation. Intrathecal delivery of CNTF was not associated with the limiting side effects observed with systemic delivery. These results demonstrate that neurotrophic factors can be continuously delivered within the CSF of humans by an ex vivo gene therapy approach, opening new avenues for the treatment of neurological diseases.	UNIV LAUSANNE,CHU VAUDOIS,SCH MED,DIV SURG RES,CH-1011 LAUSANNE,SWITZERLAND; UNIV LAUSANNE,CHU VAUDOIS,SCH MED,DEPT NEUROL,CH-1011 LAUSANNE,SWITZERLAND; CYTOTHERAPEUT INC,PROVIDENCE,RI 02906; CTR MED UNIV GENEVA,DEPT PHARMACOL,CH-1211 GENEVA,SWITZERLAND; CTR MED UNIV GENEVA,DIV CLIN NEUROMUSCULAR RES,CH-1211 GENEVA,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva	Aebischer, P (corresponding author), UNIV LAUSANNE,CHU VAUDOIS,SCH MED,GENE THERAPY CTR,CH-1011 LAUSANNE,SWITZERLAND.		Hirt, Lorenz/G-3553-2010; Deglon, Nicole/A-2265-2012; Aebischer, Patrick/E-1387-2013	Hirt, Lorenz/0000-0002-2921-5000; Deglon, Nicole/0000-0003-4475-9476; 				Aebischer P, 1996, HUM GENE THER, V7, P851, DOI 10.1089/hum.1996.7.7-851; AEBISCHER P, 1995, XENO, V3, P43; ANDRES PL, 1986, NEUROLOGY, V36, P937, DOI 10.1212/WNL.36.7.937; CEDERBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P500; CEDERBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; KATO AC, 1994, EXP NEUROL, V130, P196, DOI 10.1006/exnr.1994.1198; LEWIS ME, 1993, EXP NEUROL, V124, P73, DOI 10.1006/exnr.1993.1177; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; NORRIS FH, 1974, NEUROLOGY, V24, P721, DOI 10.1212/WNL.24.8.721; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; ZURN AD, 1994, NEUROREPORT, V6, P133	17	365	393	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1996	2	6					696	699		10.1038/nm0696-696	http://dx.doi.org/10.1038/nm0696-696			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UN691	8640564				2023-01-03	WOS:A1996UN69100041
J	Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI				Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI			Preserved acute pain and reduced neuropathic pain in mice lacking PKC gamma	SCIENCE			English	Article							PROTEIN-KINASE-C; RAT SPINAL-CORD; SENSORY NEURONS; DORSAL HORN; MUTANT MICE; NERVE INJURY; SUBSTANTIA GELATINOSA; JOINT INFLAMMATION; PERSISTENT PAIN; INCREASES	In normal animals, peripheral nerve injury produces a persistent, neuropathic pain state in which pain is exaggerated and can be produced by nonpainful stimuli. Here, mice that lack protein kinase C gamma (PKC gamma) displayed normal responses to acute pain stimuli, but they almost completely failed to develop a neuropathic pain syndrome after partial sciatic nerve section, and the neurochemical changes that occurred in the spinal cord after nerve injury were blunted. Also, PKC gamma was shown to be restricted to a small subset of dorsal horn neurons, thus identifying a potential biochemical target for the prevention and therapy of persistent pain.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 92143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 92143 USA; MIT, CTR CANC RES, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Malmberg, AB (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 92143 USA.				NIDA NIH HHS [DA08377] Funding Source: Medline; NINDS NIH HHS [NS 21445, NS 14627] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS021445, R01NS014627, P50NS021445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008377] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BENNETT GJ, 1980, J COMP NEUROL, V194, P809, DOI 10.1002/cne.901940407; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CODERRE TJ, 1992, NEUROSCI LETT, V140, P181, DOI 10.1016/0304-3940(92)90097-Q; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CODERRE TJ, 1989, J NEUROPHYSIOL, V62, P48, DOI 10.1152/jn.1989.62.1.48; Dubner R, 1994, TXB PAIN, P225; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNT SP, 1992, SENSORY NEURONS DIVE, P60; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KNYIHARCSILLIK E, 1981, PROG HISTOCHEM CYTOC, V14, P1; LANGFORD LA, 1979, J COMP NEUROL, V184, P193, DOI 10.1002/cne.901840111; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; Lin Q, 1996, J NEUROSCI, V16, P3026; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; Malmberg AB, 1997, J NEUROSCI, V17, P7462; MAO J, 1993, J NEUROPHYSIOL, V70, P470, DOI 10.1152/jn.1993.70.2.470; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; MAO JR, 1992, BRAIN RES, V588, P144, DOI 10.1016/0006-8993(92)91354-H; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; NAHIN RL, 1994, PAIN, V58, P95, DOI 10.1016/0304-3959(94)90189-9; PALECEK J, 1994, J NEUROPHYSIOL, V71, P529, DOI 10.1152/jn.1994.71.2.529; REES H, 1995, J PHYSIOL-LONDON, V484, P437, DOI 10.1113/jphysiol.1995.sp020676; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; SLUKA KA, 1993, NEUROREPORT, V5, P109, DOI 10.1097/00001756-199311180-00003; SLUKA KA, 1993, PAIN, V55, P217, DOI 10.1016/0304-3959(93)90150-N; WAKISAKA S, 1991, NEUROSCI LETT, V124, P200, DOI 10.1016/0304-3940(91)90093-9; WOOLF CJ, 1983, J COMP NEUROL, V221, P313, DOI 10.1002/cne.902210307	39	530	565	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					279	283		10.1126/science.278.5336.279	http://dx.doi.org/10.1126/science.278.5336.279			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323205				2023-01-03	WOS:A1997YA56400042
J	Gattinoni, L; Tognoni, G; Brazzi, L; Latini, R				Gattinoni, L; Tognoni, G; Brazzi, L; Latini, R			Ventilation in the prone position	LANCET			English	Letter									IRCCS,OSPED MAGGIORE POLICLIN,IST ANESTESIA & RIANIMAZ,I-20122 MILAN,ITALY; IST MARIO NEGRI,DIPARTIMENTO RIC CARDIOVASC,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Brazzi, Luca/AAS-4978-2020; Latini, Roberto/AAB-1410-2020	Brazzi, Luca/0000-0001-7059-0622; Latini, Roberto/0000-0002-3729-4650; Gattinoni, Luciano/0000-0001-5380-2494				Webster NR, 1997, LANCET, V349, P1638, DOI 10.1016/S0140-6736(05)62630-X	1	14	14	2	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					815	815		10.1016/S0140-6736(05)62612-8	http://dx.doi.org/10.1016/S0140-6736(05)62612-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298030	Bronze			2023-01-03	WOS:A1997XW28200068
J	Ballew, KA				Ballew, KA			Recent advances - Cardiopulmonary resuscitation	BRITISH MEDICAL JOURNAL			English	Review							HOSPITAL CARDIAC-ARREST; ACTIVE COMPRESSION-DECOMPRESSION; HIGH-DOSE EPINEPHRINE; AUTOMATIC EXTERNAL DEFIBRILLATOR; AMERICAN-HEART-ASSOCIATION; BYSTANDER CPR; CLINICAL-TRIAL; BLOOD-FLOW; SURVIVAL; EXPERIENCE				Ballew, KA (corresponding author), UNIV VIRGINIA,SCH MED,DIV GEN INTERNAL MED,2955 IVY RD,SUITE 205,CHARLOTTESVILLE,VA 22908, USA.							AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BALLEW KA, 1994, ARCH INTERN MED, V154, P2426, DOI 10.1001/archinte.154.21.2426; Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERG RA, 1995, ANN EMERG MED, V26, P342, DOI 10.1016/S0196-0644(95)70084-6; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; Callaham M, 1996, ANN EMERG MED, V27, P638, DOI 10.1016/S0196-0644(96)70169-5; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CRONE PD, 1995, NEW ZEAL MED J, V108, P297; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DITCHEY RV, 1982, CIRCULATION, V66, P297, DOI 10.1161/01.CIR.66.2.297; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; HERLITZ J, 1994, BRIT HEART J, V72, P408; KERBER RE, 1991, CIRCULATION, V83, P2233; Kuisma M, 1996, HEART, V76, P18, DOI 10.1136/hrt.76.1.18; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; Martens P, 1996, RESUSCITATION, V31, P25, DOI 10.1016/0300-9572(95)00909-4; MILLER B, 1995, RESUSCITATION, V30, P3, DOI 10.1016/0300-9572(95)00868-T; MURPHY DM, 1987, J EMERG MED SERV, V12, P67; *NAT CTR HLTH STAT, 1993, ADV REP FIN MORT S S, V47; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SMITH DL, 1995, J AM COLL SURGEONS, V180, P402; SPAITE DW, 1990, ANN EMERG MED, V19, P1264, DOI 10.1016/S0196-0644(05)82285-1; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7	42	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1462	1465		10.1136/bmj.314.7092.1462	http://dx.doi.org/10.1136/bmj.314.7092.1462			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167565	Green Published			2023-01-03	WOS:A1997XA20200027
J	Coulehan, J				Coulehan, J			The man with stars inside	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Public opinion polls show that a large percentage of persons in the United States currently favor the legalization of professionally assisted death. This support reflects widespread fear and confusion over the tortuously prolonged and painful process of dying countenanced by contemporary medicine. Physician-assisted suicide and euthanasia are complex moral issues. The current drive to translate them into debates about ''rights'' and public policy is curious: Does the energy directed toward ''palliation-by-death'' mean that our society is more compassionate now, or more just, than in the past? To the contrary, I believe that the movement toward assisted death reflects inadequate palliative care, poor patient-physician communication, great confusion about the right to refuse treatment, and profound inequity in U.S. health care. Legalization of assisted death diverts us from addressing these problems. Palliation-by-death will drive us farther apart, not closer together.			Coulehan, J (corresponding author), SUNY STONY BROOK, HLTH SCI CTR L3 092, INST MED CONTEMPORARY SOC, STONY BROOK, NY 11794 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					799	802		10.7326/0003-4819-126-10-199705150-00010	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148654				2023-01-03	WOS:A1997WZ82300010
J	Sano, M; Ernesto, C; Thomas, RG; Klauber, MR; Schafer, K; Grundman, M; Woodbury, P; Growdon, J; Cotman, DW; Pfeiffer, E; Schneider, LS; Thal, LJ				Sano, M; Ernesto, C; Thomas, RG; Klauber, MR; Schafer, K; Grundman, M; Woodbury, P; Growdon, J; Cotman, DW; Pfeiffer, E; Schneider, LS; Thal, LJ			A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RATING-SCALE; L-DEPRENYL; VITAMIN-E; DEMENTIA; TACRINE; CANCER	Background There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. Methods We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). Results Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental Stale Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001), or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). Conclusions In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease. (C) 1997, Massachusetts Medical Society.	COLUMBIA UNIV, COLL PHYS & SURG, GERTRUDE H SERGIEVSKY CTR, DEPT NEUROL, NEW YORK, NY USA; UNIV CALIF SAN DIEGO, ALZHEIMERS DIS COOPERAT STUDY, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV S FLORIDA, TAMPA, FL USA; UNIV SO CALIF, LOS ANGELES, CA USA	Columbia University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Harvard Medical School; University of California System; University of California Irvine; State University System of Florida; University of South Florida; University of Southern California					NATIONAL INSTITUTE ON AGING [U19AG010483, U01AG010483] Funding Source: NIH RePORTER; NIA NIH HHS [U01-AG10483, U19 AG010483] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson DK, 1988, J NEUROTRAUM, V5, P61, DOI 10.1089/neu.1988.5.61; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRAAK H, 1994, NEURODEGENER DIS, P585; BURKE WJ, 1993, J AM GERIATR SOC, V41, P1219, DOI 10.1111/j.1532-5415.1993.tb07306.x; DAVIES P, 1983, DEMENTIAS, V38, P75; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FLAGG EW, 1995, J AM COLL NUTR, V14, P419; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; HARMAN D, 1982, FREE RADICAL BIO MED, V5, P255; HOLM S, 1979, SCAND J STAT, V6, P65; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KNOLL J, 1983, ACTA NEUROL SCAND, V68, P57, DOI 10.1111/j.1600-0404.1983.tb01517.x; MACHLIN LJ, 1995, CRIT REV FOOD SCI, V35, P41, DOI 10.1080/10408399509527684; MANGONI, 1991, EUR NEUROL, V31, P434; MANGONI A, 1991, EUR NEUROL, V31, P100, DOI 10.1159/000116655; MEYDANI SN, 1995, AM J CLIN NUTR, V62, P1462; MILLER RG, 1983, BIOMETRICS, V39, P1077, DOI 10.2307/2531341; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; PEYSER CE, 1995, AM J PSYCHIAT, V152, P1771; PICCININ GL, 1990, CLIN NEUROPHARMACOL, V13, P147, DOI 10.1097/00002826-199004000-00004; PORTA EA, 1988, CELLULAR ANTIOXIDANT, V3, P1; RICHARDS M, 1991, ARCH NEUROL-CHICAGO, V48, P1147, DOI 10.1001/archneur.1991.00530230055021; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Sano M, 1996, ALZ DIS ASSOC DIS, V10, P132, DOI 10.1097/00002093-199601030-00004; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; STERN Y, 1994, J GERONTOL, V49, pM216, DOI 10.1093/geronj/49.5.M216; TARIOT PN, 1995, AM J PSYCHIAT, V152, P1349; Thal LJ, 1996, NEUROLOGY, V47, P705, DOI 10.1212/WNL.47.3.705; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x	35	1890	1994	1	161	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1216	1222		10.1056/NEJM199704243361704	http://dx.doi.org/10.1056/NEJM199704243361704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110909				2023-01-03	WOS:A1997WV33200004
J	Stern, RS; Nichols, KT; Vakeva, LH				Stern, RS; Nichols, KT; Vakeva, LH			Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							8-YEAR FOLLOW-UP; PLUS ULTRAVIOLET; ORAL METHOXSALEN; A RADIATION; PHOTOCHEMOTHERAPY; PATHOLOGISTS; TUMORS	Background Photochemotherapy with oral methoxsalen (psoralen) and ultraviolet A radiation (PUVA) is an effective treatment for psoriasis. However, PUVA is mutagenic, increases the risk of squamous-cell skin cancer, and can cause irregular, pigmented skin lesions. We studied the occurrence of melanoma among patients treated with PUVA. Methods We prospectively identified cases of melanoma and documented the extent of exposure to PUVA among 1380 patients with psoriasis who were first treated with PUVA in 1975 or 1976. Using incidence data, we calculated the expected incidence of melanoma in this cohort and compared it with the observed incidence. Using regression models, we assessed the risks of melanoma associated with a long time (greater than or equal to 15 years) since the first treatment and with a large number of PUVA treatments (greater than or equal to 250). Results From 1975 through 1990, we detected four malignant melanomas, about the number expected in the overall population (relative risk, 1.1). From 1991 through 1996, we detected seven malignant melanomas (relative risk, 5.4; 95 percent confidence interval, 2.2 to 11.1). The risk of melanoma was higher in the later period than in the earlier one (incidence-rate ratio, 3.8) and higher among patients who received at least 250 PUVA treatments than among those who received fewer treatments (incidence-rate ratio, 3.1). Conclusions About 15 years after the first treatment with PUVA, the risk of malignant melanoma increases, especially among patients who receive 250 treatments or more. (C) 1997, Massachusetts Medical Society.	BETH ISRAEL DEACONESS MED CTR,DEPT DERMATOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIAMS NIH HHS [N01-AR-2214] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEL EA, 1985, J AM ACAD DERMATOL, V13, P761, DOI 10.1016/S0190-9622(85)70219-8; ALCALAY J, 1990, PHOTODERMATOL PHOTO, V7, P28; AUBIN F, 1991, CANCER RES, V51, P5893; BERGNER T, 1992, DERMATOLOGY, V184, P59, DOI 10.1159/000247501; BINET O, 1985, PRESSE MED, V14, P1842; *CANC STAT BRANCH, 1995, SURV EP END RES SEER; Corona R, 1996, J CLIN ONCOL, V14, P1218, DOI 10.1200/JCO.1996.14.4.1218; COX NH, 1987, BRIT J DERMATOL, V116, P145, DOI 10.1111/j.1365-2133.1987.tb05805.x; ELWOOD JM, 1987, J NATL CANCER I, V78, P37, DOI 10.1093/jnci/78.1.37; FRENK E, 1983, DERMATOLOGICA, V167, P152, DOI 10.1159/000249771; Gahlinger PM, 1993, COMPUTER PROGRAMS EP; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; GUPTA AK, 1988, J AM ACAD DERMATOL, V19, P67, DOI 10.1016/S0190-9622(88)70153-X; HEENAN PJ, 1984, HISTOPATHOLOGY, V8, P717, DOI 10.1111/j.1365-2559.1984.tb02388.x; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; KEMMETT D, 1984, BRIT MED J, V289, P1498, DOI 10.1136/bmj.289.6457.1498; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KRIEGER N, 1994, J CLIN EPIDEMIOL, V47, P897, DOI 10.1016/0895-4356(94)90193-7; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; MACDONALD KJS, 1986, BRIT J DERMATOL, V114, P395, DOI 10.1111/j.1365-2133.1986.tb02838.x; MOSELEY HS, 1979, CANCER, V43, P939, DOI 10.1002/1097-0142(197903)43:3<939::AID-CNCR2820430323>3.0.CO;2-N; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P47, DOI 10.1016/S0190-9622(83)70106-4; RHODES AR, 1983, J INVEST DERMATOL, V81, P459, DOI 10.1111/1523-1747.ep12522663; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1994, CANCER-AM CANCER SOC, V73, P2759, DOI 10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C; WHITE E, 1994, AM J EPIDEMIOL, V139, P857, DOI 10.1093/oxfordjournals.aje.a117092; 1997, STATA REFERENCE MANU	30	486	497	3	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1041	1045		10.1056/NEJM199704103361501	http://dx.doi.org/10.1056/NEJM199704103361501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091799				2023-01-03	WOS:A1997WT16100001
J	Koh, KK; Mincemoyer, R; Bui, MN; Csako, G; Pucino, F; Guetta, V; Waclawiw, M; Cannon, RO				Koh, KK; Mincemoyer, R; Bui, MN; Csako, G; Pucino, F; Guetta, V; Waclawiw, M; Cannon, RO			Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; LOW-DENSITY-LIPOPROTEIN; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; MYOCARDIAL-INFARCTION; ESTROGEN REPLACEMENT; ENDOTHELIAL-CELLS; HEART-DISEASE; FOLLOW-UP; TYPE-1; PLASMA	Background Plasma levels of plasminogen-activator inhibitor type 1 (PAI-1), an essential inhibitor of fibrinolysis in humans, increase in women after menopause, and this may contribute to the risk of cardiovascular disease. We studied the effects of hormone-replacement therapy on PAI-1 levels. Methods In a randomized, crossover study, we investigated the effects of oral conjugated estrogen (0.625 mg per day) in 30 postmenopausal women and transdermal estradiol (0.1 mg per day) in 20 postmenopausal women, either alone or in combination with medroxyprogesterone acetate (2.5 mg daily) for one month, on plasma PAI-1 antigen levels. Degradation products of cross-linked fibrin (D-dimer) were measured in serum as an index of fibrinolysis. Results PAI-1 levels were inversely associated with D-dimer levels at base line (r=-0.540, P=0.002). Conjugated estrogen, both alone and in combination with medroxyprogesterone acetate, reduced mean (+/-SD) plasma levels of PAI-1 from 32+/-34 ng per milliliter to 14+/-10 ng per milliliter (P<0.001) and from 31+/-29 ng per milliliter to 15+/-11 ng per milliliter (P=0.003), respectively; there was a significant inverse correlation between pretreatment PAI-1 levels and the degree of reduction in these levels during therapy (r=-0.631, P<0.001 for conjugated estrogen; r=-0.507, P=0.004 for combined therapy). The degree of reduction in PAI-1 levels was associated with increases in D-dimer levels both when conjugated estrogen was given alone (r=-0.572, P=0.001) and when combined hormone therapy was given (r=-0.541, P=0.002). Transdermal estradiol caused no significant changes in PAI-1 levels from base-line values. Conclusions Conjugated estrogen, alone or combined with progestin therapy, reduced PAI-1 levels by approximately 50 percent in postmenopausal women and was associated with enhanced systemic fibrinolysis. These findings may partly explain the protective effect of hormone-replacement therapy with respect to coronary artery disease. (C) 1997, Massachusetts Medical Society.	NHLBI, CARDIOL BRANCH, NIH, BETHESDA, MD 20892 USA; NIH, DEPT CLIN PATHOL, CTR CLIN, BETHESDA, MD 20892 USA; NIH, DEPT PHARMACOL, CTR CLIN, BETHESDA, MD 20892 USA; NHLBI, OFF BIOSTAT RES, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BEEBE DP, 1986, THROMB RES, V43, P663, DOI 10.1016/0049-3848(86)90103-9; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; CORTELLARO M, 1993, ARTERIOSCLER THROMB, V13, P1412, DOI 10.1161/01.ATV.13.10.1412; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DECLERCK PJ, 1988, BLOOD, V71, P220; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEBARA OCE, 1995, CIRCULATION, V91, P1952, DOI 10.1161/01.CIR.91.7.1952; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMSTEN A, 1987, LANCET, V2, P3; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KEBER I, 1992, HAEMOSTASIS, V22, P187; KOOISTRA T, 1990, FIBRINOLYSIS, V4, P33, DOI 10.1016/0268-9499(90)90352-K; KORNINGER C, 1981, THROMB HAEMOSTASIS, V46, P658; KROON UB, 1994, THROMB HAEMOSTASIS, V71, P420; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; LEVINE DM, 1992, INT J CLIN LAB RES, V22, P173, DOI 10.1007/BF02591419; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLOFSSON BO, 1989, EUR HEART J, V10, P77; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCARABIN PY, 1993, THROMB HAEMOSTASIS, V70, P584; SCHNEIDER DJ, 1991, P NATL ACAD SCI USA, V88, P9959, DOI 10.1073/pnas.88.22.9959; SCHNEIDER DJ, 1992, P NATL ACAD SCI USA, V89, P1148; Shahar E, 1996, CIRCULATION, V93, P1970, DOI 10.1161/01.CIR.93.11.1970; SPORRONG T, 1990, BRIT J OBSTET GYNAEC, V97, P939, DOI 10.1111/j.1471-0528.1990.tb02451.x; SPRENGERS ED, 1987, BLOOD, V69, P381; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; VANWERSCH JWJ, 1994, EUR J CLIN CHEM CLIN, V32, P449; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WINDLER EET, 1980, J BIOL CHEM, V255, P464	46	321	331	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					683	690		10.1056/NEJM199703063361002	http://dx.doi.org/10.1056/NEJM199703063361002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041098				2023-01-03	WOS:A1997WL41900002
J	Cantekin, EI				Cantekin, EI			Treatment of glue ear in general practice	LANCET			English	Letter							OTITIS-MEDIA; EFFUSION				Cantekin, EI (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213, USA.							BAILAR JC, 1995, J CLIN EPIDEMIOL, V48, P149, DOI 10.1016/0895-4356(94)00149-K; CANTEKIN EI, 1991, JAMA-J AM MED ASSOC, V266, P3309; CANTEKIN EI, 1994, JAMA-J AM MED ASSOC, V272, P203, DOI 10.1001/jama.1994.03520030043025; MANDEL EM, 1991, PEDIATR INFECT DIS J, V10, P899, DOI 10.1097/00006454-199112000-00004; vanBalen FAM, 1996, LANCET, V348, P713, DOI 10.1016/S0140-6736(96)02511-1	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					133	134		10.1016/S0140-6736(05)60917-8	http://dx.doi.org/10.1016/S0140-6736(05)60917-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996444				2023-01-03	WOS:A1997WB80000056
J	Ely, EW; Baker, AM; Dunagan, DP; Burke, HL; Smith, AC; Kelly, PT; Johnson, MM; Browder, RW; Bowton, DL; Haponik, EF				Ely, EW; Baker, AM; Dunagan, DP; Burke, HL; Smith, AC; Kelly, PT; Johnson, MM; Browder, RW; Bowton, DL; Haponik, EF			Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEANING PATIENTS; INSPIRATORY PRESSURE; OCCLUSION PRESSURE; PREDICTORS; EXTUBATION; SUPPORT; RATIO; PARAMETERS; FAILURE; TRIALS	Background Prompt recognition of the reversal of respiratory failure may permit earlier discontinuation of mechanical ventilation, without harm to the patient. Methods We conducted a randomized, controlled trial in 300 adult patients receiving mechanical ventilation in medical and coronary intensive care units. In the intervention group, patients underwent daily screening of respiratory function by physicians, respiratory therapists, and nurses to identify those possibly capable of breathing spontaneously; successful tests were followed by two-hour trials of spontaneous breathing in those who met the criteria. Physicians were notified when their patients successfully completed the trials of spontaneous breathing. The control subjects had daily screening but no other interventions. In both groups, all clinical decisions, including the decision to discontinue mechanical ventilation, were made by the attending physicians. Results Although the 149 patients randomly assigned to the intervention group had more severe disease, they received mechanical ventilation for a median of 4.5 days, as compared with 6 days in the 151 patients in the control group (P=0.003). The median interval between the time a patient met the screening criteria and the discontinuation of mechanical ventilation was one day in the intervention group and three days in the control group (P<0.001). Complications - removal of the breathing tube by the patient, reintubation, tracheostomy, and mechanical ventilation for more than 21 days - occurred in 20 percent of the intervention group and 41 percent of the control group (P=0.001). The number of days of intensive care and hospital care was similar in the two groups. Total costs for the intensive care unit were lower in the intervention group (median, $15,740, vs. $20,890 in the controls; P=0.03); hospital costs were lower, though not significantly so (median, $26,229 and $29,048, respectively; P=0.3). Conclusions Daily screening of the respiratory function of adults receiving mechanical ventilation, followed by trials of spontaneous breathing in appropriate patients and notification of their physicians when the trials were successful, can reduce the duration of mechanical ventilation and the cost of intensive care and is associated with fewer complications than usual care.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,PULM & CRIT CARE MED SECT,WINSTON SALEM,NC 27103; LYNCHBURG PULM ASSOCIATES,LYNCHBURG,VA; MAYO CLIN,JACKSONVILLE,FL 32224	Wake Forest University; Wake Forest Baptist Medical Center; Mayo Clinic			Bowton, David/AAZ-2916-2020; Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172				Bland M, 1987, INTRO MED STAT; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; CAPDEVILA XJ, 1995, CHEST, V108, P482, DOI 10.1378/chest.108.2.482; COHEN IL, 1991, CRIT CARE MED, V19, P1278, DOI 10.1097/00003246-199110000-00010; COHEN IL, 1994, INTENS CARE MED, V20, P317, DOI 10.1007/BF01720902; COX DR, 1972, J R STAT SOC B, V34, P187; Dojat M, 1996, AM J RESP CRIT CARE, V153, P997, DOI 10.1164/ajrccm.153.3.8630586; EPSTEIN SK, 1995, AM J RESP CRIT CARE, V152, P545, DOI 10.1164/ajrccm.152.2.7633705; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; GANDIA F, 1992, INTENS CARE MED, V18, P327, DOI 10.1007/BF01694360; GLUCK EH, 1995, CRIT CARE MED, V23, P504, DOI 10.1097/00003246-199503000-00015; HALL JB, 1987, JAMA-J AM MED ASSOC, V257, P1621, DOI 10.1001/jama.257.12.1621; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LISTELLO D, 1994, CHEST, V105, P1496, DOI 10.1378/chest.105.5.1496; MADOR MJ, 1992, CHEST, V102, P1642, DOI 10.1378/chest.102.6.1642; MOHSENIFAR Z, 1993, ANN INTERN MED, V119, P794, DOI 10.7326/0003-4819-119-8-199310150-00004; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; SAHN SA, 1973, CHEST, V63, P1002, DOI 10.1378/chest.63.6.1002; SASSOON CSH, 1993, AM REV RESPIR DIS, V148, P860, DOI 10.1164/ajrccm/148.4_Pt_1.860; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHIKORA SA, 1994, ARCH SURG-CHICAGO, V129, P269; STRICKLAND JH, 1993, CHEST, V103, P1220, DOI 10.1378/chest.103.4.1220; STROETZ RW, 1995, AM J RESP CRIT CARE, V152, P1034, DOI 10.1164/ajrccm.152.3.7663780; TINDOL GA, 1994, CHEST, V105, P1804, DOI 10.1378/chest.105.6.1804; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; WEINBERGER SE, 1995, NEW ENGL J MED, V332, P388, DOI 10.1056/NEJM199502093320609; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101; YANG KL, 1993, INTENS CARE MED, V19, P204, DOI 10.1007/BF01694771; YANG KL, 1992, CHEST, V102, P1829, DOI 10.1378/chest.102.6.1829	31	897	937	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1864	1869		10.1056/NEJM199612193352502	http://dx.doi.org/10.1056/NEJM199612193352502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948561				2023-01-03	WOS:A1996VX87400002
J	Verdine, GL				Verdine, GL			The combinatorial chemistry of nature	NATURE			English	Article							MODULAR POLYKETIDE SYNTHASE; POLYMERASE CHAIN-REACTION; RECOMBINANT PROTEINS; BIOSYNTHESIS; OVERPRODUCTION; RAPAMYCIN; PRODUCTS; COMPLEX; DOMAIN				Verdine, GL (corresponding author), HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138, USA.							ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; Blundell TL, 1996, NATURE, V384, P23; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Corey E.J., 1989, LOGIC CHEM SYNTHESIS; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; FANTEANY G, 1995, SCIENCE, V268, P726; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Hogan JC, 1996, NATURE, V384, P17; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; LEE JC, 1995, CHEM BIOL, V2, P721, DOI 10.1016/1074-5521(95)90100-0; LIU J, 1991, CELL, V66, P1; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Nicolaou K. C., 1995, CLASSICS TOTAL SYNTH; Roessner C A, 1994, Chem Biol, V1, P119; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSOI CJ, 1995, CHEM BIOL, V2, P355; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	28	105	114	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			11	13						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895593				2023-01-03	WOS:A1996VR39200004
J	Jick, H; Derby, LE; Myers, MW; Vasilakis, C; Newton, KM				Jick, H; Derby, LE; Myers, MW; Vasilakis, C; Newton, KM			Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens	LANCET			English	Article							ENDOMETRIAL CANCER; ESTROGENS	Background At the request of researchers in the UK, we conducted a case-control study to explore the relation between use of postmenopausal oestrogen hormone replacement therapy (HRT) and idiopathic venous thromboembolism (VTE). Methods The study was based on information derived from Group Health Cooperative of Puget Sound for the period 1980 to 1994. Women aged 50-74 years admitted to hospital for idiopathic VTE were identified from hospital records. The diagnosis of idiopathic VTE was validated from the clinical record. Women who had medical conditions predisposing to VTE (a history of VTE or cancer, recent trauma, or surgery) were excluded as cases. Four control subjects matched to each case by age, duration of Cooperative membership, and calendar time were identified from the base population. Various potential risk factors were recorded based on record review. Findings An initial analysis of 42 cases and 168 matched controls yielded a matched relative risk estimate of 3 . 6 (95% CI 1 . 6-7 . 8) for current users of oestrogens compared with non-users. There was a substantial effect of daily oestrogen dose. The matched relative risk estimates for oestrogen users of 0 . 325 mg, 0 . 625 mg, and 1 . 25 mg or more daily were 2 . 1, 3 . 3, and 6 . 9, respectively. Body-mass index was independently associated with the risk of VTE but did not materially confound the relation of oestrogen and VTE. The absolute risk of idiopathic VTE is estimated to be low (0 . 9x10(-4) woman-years) in non-users of oestrogen; the risk in current users is estimated at 3 . 2x10(-4) woman-years. Interpretation The risk of idiopathic VTE is about three times higher among current users of replacement oestrogens than among non-users. However, the absolute risk is low for both groups and accounts for only a modest increase in morbidity.	GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	Group Health Cooperative	Jick, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,244 WOOD ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992				Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1984, PHARMACOTHERAPY, V4, P99; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK SS, 1993, EPIDEMIOLOGY, V4, P20, DOI 10.1097/00001648-199301000-00005	5	499	506	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					981	983		10.1016/S0140-6736(96)07114-0	http://dx.doi.org/10.1016/S0140-6736(96)07114-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855853	hybrid			2023-01-03	WOS:A1996VM02700009
J	Key, TJA; Thorogood, M; Appleby, PN; Burr, ML				Key, TJA; Thorogood, M; Appleby, PN; Burr, ML			Dietary habits and mortality in 11000 vegetarians and health conscious people: Results of a 17 year follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; 7TH-DAY ADVENTISTS; BREAST-CANCER; RISK; ASSOCIATION; CONSUMPTION; POPULATION; VEGETABLES; STROKE; CHOLESTEROL	Objective-To investigate the association of dietary habits with mortality in a cohort of vegetarians and other health conscious people. Design-Observational study. Setting-United Kingdom. Subjects-4336 men and 6435 women recruited through health food shops, vegetarian societies, and magazines. Main outcome measures-Mortality ratios for vegetarianism and for daily versus less than daily consumption of wholemeal bread, bran cereals, nuts or dried fruit, fresh fruit, and raw salad in relation to all cause mortality and mortality fi om ischaemic heart disease, cerebrovascular disease, all malignant neoplasms, lung cancer, colorectal cancer, and breast cancer. Results-2064 (19%) subjects smoked, 4627 (43%) were vegetarian, 6699 (62%) ate wholemeal bread daily, 2948 (27%) ate bran cereals daily, 4091 (38%) ate nuts or dried fruit daily, 8304 (77%) ate fresh fruit daily, and 4105 (38%) ate raw salad daily. After a mean of 16.8 years follow up there were 1343 deaths before age 80. Overall the cohort had a mortality about half that of the general population. Within the cohort, daily consumption of fresh fruit was associated with significantly reduced mortality from ischaemic heart disease (rate ratio adjusted for smoking 0.76 (95% confidence interval 0.60 to 0.97)), cerebrovascular disease (0.68 (0.47 to 0.98)), and for all causes combined (0.79 (0.70 to 0.90)). Conclusions-In this cohort of health conscious individuals, daily consumption of fresh fruit is associated with a reduced mortality from ischaemic heart disease, cerebrovascular disease, and all causes combined.	LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 6HT, ENGLAND; UNIV WALES COLL CARDIFF, COLL MED, CTR APPL PUBL HLTH MED, CARDIFF CF1 3NW, S GLAM, WALES	University of London; London School of Hygiene & Tropical Medicine; Cardiff University	Key, TJA (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND.							ACHESON RM, 1983, LANCET, V1, P1191; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BURKITT DP, 1973, BMJ-BRIT MED J, V1, P274, DOI 10.1136/bmj.1.5848.274; BURR ML, 1988, AM J CLIN NUTR, V48, P830, DOI 10.1093/ajcn/48.3.830; BURR ML, 1981, J HUM NUTR, V35, P437; BURR ML, 1982, AM J CLIN NUTR, V36, P873, DOI 10.1093/ajcn/36.5.873; CHANGCLAUDE J, 1992, EPIDEMIOLOGY, V3, P395, DOI 10.1097/00001648-199209000-00003; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KAHN HA, 1984, AM J EPIDEMIOL, V119, P775, DOI 10.1093/oxfordjournals.aje.a113798; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MILLS PK, 1988, AM J EPIDEMIOL, V127, P440, DOI 10.1093/oxfordjournals.aje.a114821; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; PHILLIPS RL, 1980, JNCI-J NATL CANCER I, V65, P1097; POTTER JD, 1995, EUR J CANCER, V31A, P1033, DOI 10.1016/0959-8049(95)00125-3; RAO DN, 1994, BRIT J CANCER, V70, P129, DOI 10.1038/bjc.1994.261; SNOWDON DA, 1984, PREV MED, V13, P490, DOI 10.1016/0091-7435(84)90017-3; THOROGOOD M, 1994, BMJ-BRIT MED J, V308, P1667, DOI 10.1136/bmj.308.6945.1667; White A, 1993, HLTH SURVEY ENGLAND; World Health Organization, 1967, INT CLASS DIS; World Health Organization, 1977, INT CLASS DIS	28	220	223	1	71	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1996	313	7060					775	779						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842068	Green Published			2023-01-03	WOS:A1996VK56600020
J	Bloor, K; Freemantle, N				Bloor, K; Freemantle, N			Lessons from international experience in controlling pharmaceutical expenditure .2. Influencing doctors	BRITISH MEDICAL JOURNAL			English	Article							COSTS	This is the second of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies influencing doctors' prescribing of drugs-particularly the use of budgetary restrictions, information and feedback, and guidelines-and evaluates the impact of these policies. Studies evaluating incentive systems are Limited, but evidence suggests that providing information on its own will not lead to substantial changes in practice and that more active strategies should be evaluated.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	Bloor, K (corresponding author), UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Freemantle, Nick/0000-0001-5807-5740; Bloor, Karen/0000-0003-4852-9854				*AG HLTH CAR POL R, 1992, CLIN PRACT GUID, V3; *AG HLTH CAR POL R, 1994, CLIN PRACT GUID, V8; [Anonymous], 1994, EFF HLTH CAR B; Bloor K, 1993, PURCHASING PROVIDING; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BROWN SS, 1995, BRIT MED J, V311, P1543; Cook T.D., 1979, QUASIEXPERIMENTATION; MALING TJB, 1994, PHARMACOECONOMICS, V6, P5, DOI 10.2165/00019053-199406010-00002; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; Maynard A, 1996, NEW ENGL J MED, V334, P604, DOI 10.1056/NEJM199602293340918; *MIN WELF HLTH CUL, 1994, V8E MIN WELF HLTH CU; PELC A, 1994, PHARMACOECONOMICS, V6, P28, DOI 10.2165/00019053-199400061-00009; SCHULENBURG JM, 1994, HEALTH ECON, V3, P301; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; SOUMERAI SB, 1989, MILBANK Q, V67, P296; Stryer D. B., 1995, JGIM, V10, P114; *U LEEDS, 1993, EFF HLTH CAR B, V5; 1994, SCRIP           1129, P3; 1995, SCRIP           0314, P3; 1995, SCRIP           0310, P3; 1995, SCRIP           0530, P16	22	77	78	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1525	1527		10.1136/bmj.312.7045.1525	http://dx.doi.org/10.1136/bmj.312.7045.1525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646148	Green Published			2023-01-03	WOS:A1996UR82300026
J	Malacrida, R; Genoni, M; Maggioni, AP; Spataro, V; Parish, S; Palmer, A; Collins, R; Moccetti, T				Malacrida, R; Genoni, M; Maggioni, AP; Spataro, V; Parish, S; Palmer, A; Collins, R; Moccetti, T		Third Int Study Infarct Survival Collaborative	A comparison of the early outcome of acute myocardial infarction in women and men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; THROMBOLYTIC THERAPY; SEX-DIFFERENCES; MORTALITY; GENDER; STROKE; TRIAL; TERM; BASE	Background In previous studies, unadjusted comparisons of mortality and major morbidity after acute myocardial infarction have generally indicated that women have a poorer outcome than men. Much larger studies are needed, with more complete adjustment for coexisting conditions, to determine whether this difference is explained by the older age of the women studied or by the presence of other unfavorable prognostic factors, or both. Methods As part of the Third International Study of lnfarct Survival (ISIS-3), information was collected on deaths during days 0 to 35 and on major clinical events during hospitalization up to day 35 for 9600 women and 26,480 men with suspected acute myo cardial infarction who were considered to have a clear indication for fibrinolytic therapy, We compared the outcome among women and men, first without adjustment, then with adjustment for age, and finally with adjustment for other recorded baseline characteristics by means of multiple logistic regression. Results The unadjusted odds ratio for death among women as compared with men was 1.73 (95 percent confidence interval, 1.61 to 1.86). The women were significantly older than the men, and after adjustment for age the odds ratio was reduced markedly to 1.20 (95 percent confidence interval, 1.11 to 1.29), Adjustment for other differences in base-line clinical features further reduced the odds ratio to 1.14 (95 percent confidence interval, 1.05 to 1.23), Excesses in other major clinical events among women were generally reduced to a similar extent by adjustment. Conclusions It seems likely that there is at most only a small independent association between female sex and early mortality and morbidity after suspected acute myocardial infarction. (C) 1998, Massachusetts Medical Society.	Civic Hosp, Dept Med, CH-6900 Lugano, Switzerland; Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, I-20157 Milan, Italy; Univ Oxford, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford, England	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Oxford; University of Oxford	Moccetti, T (corresponding author), Civic Hosp, Dept Med, Via Tesserete 46, CH-6900 Lugano, Switzerland.		Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				ARMITAGE P, 1994, STAT METHODS MED RES, P422; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; HUNT D, 1992, LANCET, V339, P753; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; STONE GW, 1995, AM J CARDIOL, V75, P987, DOI 10.1016/S0002-9149(99)80709-7; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4; Woods KL, 1996, LANCET, V347, P1203, DOI 10.1016/S0140-6736(96)90732-1; Yarzebski J, 1996, AM HEART J, V131, P43, DOI 10.1016/S0002-8703(96)90049-6	19	217	223	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					8	14		10.1056/NEJM199801013380102	http://dx.doi.org/10.1056/NEJM199801013380102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414325				2023-01-03	WOS:000071209200002
J	Subbarayappa, BV				Subbarayappa, BV			Siddha medicine: an overview	LANCET			English	Article									Indian Inst World Culture, Ctr Hist & Philosophy Sci, Bangalore 56004, Karnataka, India		Subbarayappa, BV (corresponding author), Indian Inst World Culture, Ctr Hist & Philosophy Sci, Bangalore 56004, Karnataka, India.							Bagchi, 1931, INDIAN HIST Q, V7, P1; BALARAMAIAH V, 1980, VADAVAIDYATTUKKI A 1, P6; BALARAMAIAH V, 1980, VADAVAIDYATTUKKI A 1, P22; BHATTACHARYA C, 1933, MATRKABHEDATANTRAM; CHAKRAVARTHY C, 1963, TANTRAS STUDIES THEI; GANAPATHI AG, 1995, SIDDA SEYAL; IYER KCV, 1932, ACHARYA PCR COMMEMOR, P466; IYER KCV, 1932, STUDY ALCHEMY TAMILA, P460; JOSEPH JT, 1984, HERITAGE TAMILS SIDD, P89; *MIN HLTH FAM WELF, 1993, IND SYST MED HOM IND, P66; MUDALIYAR K, 1987, SIDDBA MARUTTUVUM, P40; NEEDHAM J, 1974, SCI CIVILISATION CHI, V5, P128; NEEDHAM J, 1974, SCI CIVILIZATION CHI, V5, P109; NEEDHAM J, 1974, SCI CIVILIZATION CHI, V5, P13; RAJAN MC, 1989, MACCHAMUNI NAYANAR, P72; Roy M, 1976, RASARNAVAKALPA; ROYAN CSU, 1978, SIDDHA PHARMACOPOEIA; Royan CU, 1957, SIDDHA HOSP PHARMACO, P45; SAHIB PMA, 1975, AGASTYAR PALLU 200; SUBBARAYAPPA BV, 1971, CONCISE HIST SCI IND, P335; SUBRAMANIAN SV, 1984, HERITAGE TAMILS SIDD, P238; SUBRAMANIAN SV, 1984, HERITAGE TAMILS SIDD, P562; THEVAR VG, 1975, BHOGAR YELAIRAM YIRA; THYAGARAJAN R, 1974, THERAIER VENBA, P136; VAIDYACINTAMANI Y, 1980, VADAVAIDYATTUKKI A 1, P13; VELAN AS, 1963, SIDDHARS SCI LONGEVI, P202; VELAN AS, 1963, SIDDHARS SCI LONGEVI, V4, P67; VELAN AS, 1963, SIDDHARS SCI LONGEVI, P95; VLAENTINE DE, 1984, FLUID SIGNS, P173; 1989, FORMULARY SIDDHA MED, P1; 1953, PATANJALI YOGA SUTRA; 1975, AGASTYAR KANDAM, P4; 1980, YUGIMUNIVAR VAIDYA 1, P4; 1976, YUGIMUNIVAR VAIDYA 1, P47; 1976, THERAIER YEMAKA VE 1, P13; 1953, PANTAJALI YOGA SUTRA, V4, P1; 1976, THERAIER YEMAKA VE 1, P63	37	41	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1841	1844		10.1016/S0140-6736(97)04223-2	http://dx.doi.org/10.1016/S0140-6736(97)04223-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428267				2023-01-03	WOS:000071102500046
J	Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA				Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA			Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor	SCIENCE			English	Article							SPINOTHALAMIC TRACT NEURONS; EXCITATORY AMINO-ACIDS; GENE-RELATED PEPTIDE; DORSAL HORN NEURONS; MEDIATED INTERNALIZATION; NEUROKININ-1 RECEPTORS; TRIGEMINAL NUCLEUS; AXONAL-TRANSPORT; SENSORY NEURONS; DOWN-REGULATION	Substance P is released in the spinal cord in response to painful stimuli, but its role in nociceptive signaling remains unclear, When a conjugate of substance P and the ribosome-inactivating protein saporin was infused into the spinal cord, it was internalized and cytotoxic to lamina I spinal cord neurons that express the substance P receptor. This treatment left responses to mild noxious stimuli unchanged, but markedly attenuated responses to highly noxious stimuli and mechanical and thermal hyperalgesia. Thus, lamina I spinal cord neurons that express the substance P receptor play a pivotal role in the transmission of highly noxious stimuli and the maintenance of hyperalgesia.	UNIV MINNESOTA, SCH DENT, DEPT PREVENT SCI, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; ADV TARGETING SYST, CARLSBAD, CA 92008 USA; VET ADM MED CTR, NEUROL SERV 147, NASHVILLE, TN 37212 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mantyh, PW (corresponding author), VET ADM MED CTR, MOL NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.			Lappi, Douglas/0000-0003-4239-7387	NIMH NIH HHS [MH56368] Funding Source: Medline; NINDS NIH HHS [NS23970, NS31223] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R44MH056368, R43MH056368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS023970, R01NS023970, R29NS031223] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; BENYA RV, 1994, J BIOL CHEM, V269, P11721; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; COX BM, 1993, HDB EXPT PHARM OPIOI, V1, P145; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DELFIACCO M, 1994, NEUROREPORT, V5, P2349, DOI 10.1097/00001756-199411000-00035; DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; DOUGHERTY PM, 1995, PAIN, V61, P411, DOI 10.1016/0304-3959(94)00222-Z; DOUGHERTY PM, 1993, BRAIN RES REV, V18, P227, DOI 10.1016/0165-0173(93)90003-I; DOUGHERTY PM, 1994, J NEUROPHYSIOL, V72, P1464, DOI 10.1152/jn.1994.72.4.1464; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; Iversen LL, 1996, NATURE, V383, P759, DOI 10.1038/383759a0; IWASHITA T, 1992, BRAIN RES, V581, P59, DOI 10.1016/0006-8993(92)90344-9; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; KAR S, 1994, EUR J NEUROSCI, V6, P345, DOI 10.1111/j.1460-9568.1994.tb00277.x; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MUNGLANI R, 1995, BRIT J ANAESTH, V75, P186, DOI 10.1093/bja/75.2.186; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAGY I, 1994, NEUROREPORT, V5, P2105, DOI 10.1097/00001756-199410270-00029; NAGY I, 1993, NEUROSCIENCE, V52, P1029, DOI 10.1016/0306-4522(93)90549-U; NICOL GD, 1992, J NEUROSCI, V12, P1917; QUARTU M, 1992, J CHEM NEUROANAT, V5, P143, DOI 10.1016/0891-0618(92)90040-W; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; Simone D A, 1992, Curr Opin Neurobiol, V2, P479, DOI 10.1016/0959-4388(92)90183-L; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Traub RJ, 1996, PAIN, V67, P151, DOI 10.1016/0304-3959(96)03076-X; URBAN L, 1994, TRENDS NEUROSCI, V17, P432, DOI 10.1016/0166-2236(94)90018-3; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WUWONG JR, 1995, J PHARMACOL EXP THER, V274, P499; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; YAMAMOTO T, 1993, ANESTHESIOLOGY, V79, P1042, DOI 10.1097/00000542-199311000-00023	52	499	513	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					275	279		10.1126/science.278.5336.275	http://dx.doi.org/10.1126/science.278.5336.275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323204				2023-01-03	WOS:A1997YA56400041
J	Tamblyn, R; Berkson, L; Dauphinee, WD; Gayton, D; Grad, R; Huang, A; Isaac, L; McLeod, P; Snell, L				Tamblyn, R; Berkson, L; Dauphinee, WD; Gayton, D; Grad, R; Huang, A; Isaac, L; McLeod, P; Snell, L			Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER DISEASE; LONGITUDINAL DATA-ANALYSIS; ANTI-INFLAMMATORY DRUGS; GASTROINTESTINAL COMPLICATIONS; STANDARDIZED PATIENTS; COST-EFFECTIVENESS; ELDERLY PERSONS; PHYSICIANS; RISK	Background: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk for hospitalization and death from gastrointestinal bleeding and perforation. Objectives: To 1) estimate the extent to which NSAIDs are prescribed unnecessarily and NSAID-related side effects are inaccurately diagnosed and inappropriately managed and 2) identify the physician and visit characteristics associated with suboptimal use of NSAIDs. Design: Prospective cohort study. Setting: Montreal, Canada. Participants: 112 physicians representing academically affiliated general practitioners, community-based general practitioners, and residents in family medicine and internal medicine. Interventions: Blinded, office-based assessment of the management of two clinical cases (chronic hip pain due to early osteoarthritis and NSAID-related gastropathy) using elderly standardized patients. Measurements: Quality of drug management and potential predictors of suboptimal drug management. Results: Unnecessary prescriptions for NSAIDs or other drugs were written during 41.7% of visits. Gastropathy related to NSAID use was correctly diagnosed in 93.4% of visits and was acceptably managed in 77.4% of visits. The risk for an unnecessary NSAID prescription was greater when the contraindications to NSAID therapy were incompletely assessed (odds ratio, 2.3 [95% CI, 1.0 to 5.21) and when the case was managed by residents in internal medicine (odds ratio, 4.1 [CI, 1.2 to 14.7]). The risk for suboptimal management of NSAID-related side effects was increased by incorrect diagnosis (odds ratio, 16.6 [Cl, 3.6 to 76.5]) and shorter visits. Conclusions: Unnecessary NSAID prescribing and suboptimal management of NSAID-related side effects were sufficiently common to raise questions about the appropriateness of NSAID use in the general population. If these results reflect current practice, prescribing patterns may contribute to avoidable gastrointestinal morbidity in elderly persons.	MCGILL UNIV, DEPT FAMILY MED, HERZL FAMILY PRACTICE CTR, MONTREAL, PQ H3T 1E2, CANADA; MED COUNCIL CANADA, OTTAWA, ON K1G 3H7, CANADA; KAISER PERMANENTE, SAN FRANCISCO, CA USA	McGill University; Kaiser Permanente			Tamblyn, Robyn/L-6010-2016					ALFIREVIC Z, 1995, BRIT J OBSTET GYNAEC, V102, P638, DOI 10.1111/j.1471-0528.1995.tb11402.x; BAUMANN AO, 1991, SOC SCI MED, V32, P167, DOI 10.1016/0277-9536(91)90057-J; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; BLOOM BS, 1991, ANN INTERN MED, V114, P558, DOI 10.7326/0003-4819-114-7-558; CAFFERATA GL, 1990, MED CARE, V28, P285; *COMM SAF MED, 1986, BMJ-BRIT MED J, V292, P614; COX J, 1993, BRIT MED J, V306, P1043, DOI 10.1136/bmj.306.6884.1043; DAVIDSON W, 1995, CAN MED ASSOC J, V152, P1227; DAVIDSON W, 1994, CAN MED ASSOC J, V151, P142; DAVIDSON W, 1994, CAN MED ASSOC J, V150, P917; Demlo L K, 1983, Eval Health Prof, V6, P161, DOI 10.1177/016327878300600204; FENNER H, 1992, J RHEUMATOL, V19, P98; FERGUSON JA, 1990, CAN J AGING, V9, P278, DOI 10.1017/S0714980800010710; FERRY ME, 1985, J AM GERIATR SOC, V33, P616, DOI 10.1111/j.1532-5415.1985.tb06318.x; FRIES JF, 1992, SCAND J RHEUMATOL, P21; GABRIEL SE, 1993, ARTHRITIS RHEUM-US, V36, P447, DOI 10.1002/art.1780360404; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GILLEY J, 1994, BRIT MED J, V308, P731, DOI 10.1136/bmj.308.6931.731; GOEREE R, 1995, CAN MED ASSOC J, V152, P1445; Grad R, 1997, MED EDUC, V31, P132, DOI 10.1111/j.1365-2923.1997.tb02472.x; GREENE JM, 1992, ARCH INTERN MED, V152, P1995, DOI 10.1001/archinte.152.10.1995; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HARDO PG, 1993, BRIT J CLIN PRACT, V47, P241; HARTZEMA AG, 1983, MED CARE, V21, P990, DOI 10.1097/00005650-198310000-00005; HAWKEY CJ, 1994, SCAND J GASTROENTERO, V29, P42, DOI 10.3109/00365529409105361; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HENRY DA, 1987, BRIT MED J, V295, P1227, DOI 10.1136/bmj.295.6608.1227; HOCHBERG MC, 1992, J RHEUMATOL, V19, P63; HOGAN DB, 1994, CAN MED ASSOC J, V151, P315; Holt W S Jr, 1992, Fam Med, V24, P524; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KEYS J, 1992, J ROY SOC MED, V85, P442; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVINE JS, 1995, ANN INTERN MED, V123, P309, DOI 10.7326/0003-4819-123-4-199508150-00010; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; MILES DL, 1977, HEALTH SERV RES, V12, P3; Monette J, 1997, EVAL HEALTH PROF, V20, P115, DOI 10.1177/016327879702000201; NUMO R, 1992, SCAND J RHEUMATOL, P25; PEL M, 1995, EUR J OBSTET GYN R B, V61, P129, DOI 10.1016/0301-2115(95)02129-U; PITTS J, 1989, J ROY COLL GEN PRACT, V39, P65; RENAUD M, 1980, AM J PUBLIC HEALTH, V70, P1068, DOI 10.2105/AJPH.70.10.1068; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUCIE J, 1994, CAN MED ASSOC J, V151, P139; Tamblyn R M, 1997, Clin Perform Qual Health Care, V5, P104; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; Tamblyn RM, 1997, TEACH LEARN MED, V9, P25, DOI 10.1080/10401339709539809; Tannenbaum H, 1996, CAN MED ASSOC J, V155, P77; TUGWELL P, 1979, CLIN INVEST MED, V2, P113; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; VERHULST SJ, 1993, ACAD MED, V68, pS61, DOI 10.1097/00001888-199302000-00033; WALT RP, 1992, NEW ENGL J MED, V327, P1575; WHEELER B, 1994, CAN MED ASSOC J, V151, P139; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	77	121	125	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					429	438		10.7326/0003-4819-127-6-199709150-00003	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312999				2023-01-03	WOS:A1997XV77900003
J	Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M				Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M			Reliability of health information for the public on the world wide web: Systematic survey of advice on managing fever in children at home	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECTAL TEMPERATURE; PARENTS; INFANTS	Objective: To assess the reliability of healthcare information on the world wide web and therefore how it may help lay people cope with common health problems. Methods: Systematic search by means of two search engines, Yahoo and Excite, of parent oriented web pages relating to home management of feverish children. Reliability of information on the web sites was checked by comparison with published guidelines. Main outcome measures: Minimum temperature of child that should be considered as fever, optimal sites for measuring temperature, pharmacological and physical treatment of fever, conditions that may warrant a doctor's visit. Results: 41 web pages were retrieved and considered. 28 web pages gave a temperature above which a child is feverish; 26 pages indicated the optimal site for taking temperature, most recommending rectal measurement; 31 of the 34 pages that mentioned drug treatment recommended paracetamol as an antipyretic; 38 pages recommended non-drug measures, most commonly tepid sponging, dressing lightly, and increasing fluid intake; and 36 pages gave some indication of when a doctor should be called. Only four web pages adhered closely to the main recommendations in the guidelines. The largest deviations were in sponging procedures and how to take a child's temperature, whereas there was a general agreement in the use of paracetamol. Conclusions: Only a few web sites provided complete and accurate information for this common and widely discussed condition. This suggests an urgent need to check public oriented healthcare information on the internet for accuracy, completeness, and consistency.	MARIO NEGRI INST PHARMACOL RES, LAB MOTHER & CHILD HLTH, I-20157 MILAN, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Bonati, Maurizio/K-8980-2016; Pandolfini, Chiara/K-5693-2016	Bonati, Maurizio/0000-0003-3997-3726; Pandolfini, Chiara/0000-0001-9809-2991				ADAM D, 1994, EUR J PEDIATR, V153, P394; CASEY R, 1984, PEDIATRICS, V73, P600; Coeira E., 1996, BRIT MED J, V312, P3; DEAN AG, 1994, EPI INFO VERSION 6; ELRADHI AS, 1994, FEVER PAEDIAT PRACTI, P229; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; GRIBETZ B, 1987, PEDIATRICS, V80, P630; Impicciatore P, 1997, BRIT MED J, V314, P373, DOI 10.1136/bmj.314.7077.373a; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; KLUGER MJ, 1992, PEDIATRICS, V90, P846; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; KRAMER MS, 1985, PEDIATRICS, V75, P1110; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; LAPORTE RE, 1994, BRIT MED J, V308, P1651, DOI 10.1136/bmj.308.6945.1651; LaPorte RE, 1996, ANN EPIDEMIOL, V6, P162, DOI 10.1016/1047-2797(95)00133-6; LESKO SM, 1995, JAMA-J AM MED ASSOC, V273, P929, DOI 10.1001/jama.273.12.929; McIntyre J, 1996, ARCH DIS CHILD, V74, P164, DOI 10.1136/adc.74.2.164; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MOSS MH, 1970, PEDIATRICS, V46, P445; PALLEN M, 1995, BRIT MED J, V311, P1552, DOI 10.1136/bmj.311.7019.1552; PENNA A, 1991, BRIT J CLIN PHARMACO, V32, P143, DOI 10.1111/j.1365-2125.1991.tb03873.x; ROBINSON JS, 1989, AM J DIS CHILD, V143, P698, DOI 10.1001/archpedi.1989.02150180076024; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039; Spooner SA, 1996, PEDIATRICS, V98, P1185; TARLOW M, 1986, BRIT MED J, V292, P1543, DOI 10.1136/bmj.292.6535.1543; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; 1991, LANCET, V338, P1049	33	414	421	1	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1875	1879		10.1136/bmj.314.7098.1875	http://dx.doi.org/10.1136/bmj.314.7098.1875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224132	Green Published			2023-01-03	WOS:A1997XH73800028
J	Jeng, AY; Fujimoto, RA; Chou, M; Tan, J; Erion, MD				Jeng, AY; Fujimoto, RA; Chou, M; Tan, J; Erion, MD			Suppression of substance P biosynthesis in sensory neurons of dorsal root ganglion by prodrug esters of potent peptidylglycine alpha-amidating monooxygenase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-EXTENDED PEPTIDES; DOPAMINE BETA-MONOOXYGENASE; HYDROXYLATING MONOOXYGENASE; NEUROGENIC INFLAMMATION; SECRETORY GRANULES; COPPER ATOMS; ENZYME; RAT; INACTIVATION; PITUITARY	Substance P as well as many other neuropeptides are synthesized as glycine-extended precursors and converted to the biologically active C-terminal amides by posttranslational modification. The final step of posttranslational processing is catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM), In a previous study, N-substituted homocysteine analogs were found to be potent inhibitors of PAM partially purified from conditioned medium of cultured rat medullary thyroid carcinoma CA-77 cells, These compounds, however, were only modest inhibitors of substance P production in cultured dorsal root ganglion cells, possibly because of poor cell penetration, Several ester derivatives of hydrocinnamoyl-phenylalanyl-homocysteine, one of the most potent PAM inhibitors, were prepared to increase the intracellular accessibility of these compounds, Hydrocinnamoyl-phenylalanyl-(S-benzoyl-homocysteine) benzyl ester was identified as the most potent compound, inhibiting substance P biosynthesis in dorsal root ganglion cells with an IC50 of 2 mu M. Inhibition of PAM resulted in a concomitant increase in the glycine-extended substance p (substance P-Gly) precursor peptide. In the presence of 3 mu M benzyl ester derivative, the intracellular substance P-Gly level was 2.4-fold higher while the substance P level was 2.1-fold lower than the corresponding peptides in control cells. These results suggest that PAM inhibition represents an effective method for suppression of substance P biosynthesis and, therefore, may have therapeutic utility in conditions associated with elevated substance P levels. Furthermore, PAM inhibition may also prove useful in decreasing other amidated peptides.			Jeng, AY (corresponding author), NOVARTIS PHARMACEUT CORP, RES DEPT, LSB-3129, 556 MORRIS AVE, SUMMIT, NJ 07901 USA.							BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; Casara P, 1996, BIOORG MED CHEM LETT, V6, P393, DOI 10.1016/0960-894X(96)00041-8; COLOMBO G, 1987, ARCH BIOCHEM BIOPHYS, V252, P71, DOI 10.1016/0003-9861(87)90009-9; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; EIPPER BA, 1985, ENDOCRINOLOGY, V116, P2497, DOI 10.1210/endo-116-6-2497; ERION MD, 1994, J MED CHEM, V37, P4430, DOI 10.1021/jm00052a002; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GILLIGAN JP, 1994, INFLAMMATION, V18, P285, DOI 10.1007/BF01534269; GLEMBOTSKI CC, 1985, ARCH BIOCHEM BIOPHYS, V241, P673, DOI 10.1016/0003-9861(85)90594-6; HELME RD, 1986, NEUROSCI LETT, V66, P333, DOI 10.1016/0304-3940(86)90041-8; HILSTED L, 1986, FEBS LETT, V196, P151, DOI 10.1016/0014-5793(86)80231-9; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JENG AY, 1990, ANAL BIOCHEM, V185, P213, DOI 10.1016/0003-2697(90)90282-E; Kagan HM, 1995, CIBA F SYMP, V192, P100; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIZER JS, 1986, ENDOCRINOLOGY, V118, P2262, DOI 10.1210/endo-118-6-2262; KLINGE M, 1994, J CHEM SOC CHEM COMM, P1379, DOI 10.1039/c39940001379; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; LEVINE JD, 1985, J RHEUMATOL, V12, P406; LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609; LI AC, 1988, J LIPID RES, V29, P781; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; MAINS RE, 1986, J BIOL CHEM, V261, P1938; MARCHAND JE, 1990, J BIOL CHEM, V265, P264; MERKLER DJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P93, DOI 10.1006/abbi.1995.1140; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; MERKLER DJ, 1995, FEBS LETT, V366, P165, DOI 10.1016/0014-5793(95)00516-C; MUELLER GP, 1995, NEUROPEPTIDES, V28, P333, DOI 10.1016/0143-4179(95)90098-5; OKU R, 1987, NEUROSCI LETT, V74, P315, DOI 10.1016/0304-3940(87)90316-8; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; RAYCHAUDHURI A, 1991, AGENTS ACTIONS, V34, P251, DOI 10.1007/BF01993295; RHODES CH, 1993, ANN NY ACAD SCI, V689, P663, DOI 10.1111/j.1749-6632.1993.tb55622.x; TAMBURINI PP, 1988, ARCH BIOCHEM BIOPHYS, V267, P623, DOI 10.1016/0003-9861(88)90070-7; THAYER SA, 1988, J NEUROSCI, V8, P4089; TISSOT M, 1988, INFLAMMATION, V12, P25, DOI 10.1007/BF00915889; WIESENFELDHALLIN Z, 1993, REGUL PEPTIDES, V46, P165, DOI 10.1016/0167-0115(93)90027-6; WONG M, 1994, J NEUROSCI RES, V37, P97, DOI 10.1002/jnr.490370113; ZABRISKIE TM, 1992, J AM CHEM SOC, V114, P2270, DOI 10.1021/ja00032a058	44	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14666	14671		10.1074/jbc.272.23.14666	http://dx.doi.org/10.1074/jbc.272.23.14666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169429	hybrid			2023-01-03	WOS:A1997XC32700026
J	Wingen, AM; FabianBach, C; Schaefer, F; Mehls, O				Wingen, AM; FabianBach, C; Schaefer, F; Mehls, O			Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children	LANCET			English	Article							BLOOD-PRESSURE; RESTRICTION; INSUFFICIENCY; DISEASE; TRIAL	Background Some studies have suggested that a low-protein diet slows the deterioration of renal function in patients with chronic renal failure (CRF). The effects of a low-protein diet on renal function and growth, have not been assessed in a large, prospective randomised trial in children with CRF. Methods A 2-year prospective, stratified, and randomised multicentre study recruited 191 patients aged 2-18 years. After a run-in period of at least 6 months, patients were stratified into either a progressive or non-progressive category based on the change in creatinine clearance in this period. The patients were also stratified into three renal-disease categories and then randomly assigned to a control or diet group. In the diet group, the protein intake was the lowest, safe WHO recommendation-ie, 0.8-1.1 g/kg daily adjusted for age. All patients were advised to have a calorie intake of at least 70% of the WHO recommendations. Glomerular filtration rate (GFR) was measured every 2 months by creatinine clearance; dietary compliance was checked by urinary urea-nitrogen excretion and dietary diaries (weighing method). 112 patients completed an optional third year of the study. Findings The low-protein diet did not affect growth. However, there was no effect of diet on the mean decline in creatinine clearance over 2 years (diet vs control: progressive group -9.7 [SD 8.0] vs -10.7 [11.8] mL/min per 1.73m(2); non-progressive group -2.5 [7.5] vs -4.3 [10.0] mL/min per 1.73 m(2)). Patients classified as having progressive disease were older and had a lower creatinine clearance and a higher blood pressure at randomisation, and had a greater decrease in creatinine clearance than non-progressive patients. On multivariate regression analysis proteinuria (partial R-2=0.259) and systolic blood pressure (partial R-2=0.087) were independent predictors of the change in GFR. Similar results were found after the study was extended for a third year. Interpretation A low-protein diet for 3 years did not affect the decrease in renal function in children with CRF. Proteinuria and blood pressure explain a large part of the variability of, and may be causally related to the decline in the GFR.			Wingen, AM (corresponding author), UNIV ESSEN GESAMTHSCH,CHILDRENS HOSP,HUFELANDSTR 55,D-45122 ESSEN,GERMANY.		Schaefer, Franz/G-4365-2010					BAUDOIN P, 1993, PEDIATR NEPHROL, V7, P536, DOI 10.1007/BF00852539; *COMM DIET ALL, 1989, REC DIET ALL; DAMICO G, 1994, NEPHROL DIAL TRANSPL, V9, P1590; DEMAN SA, 1991, J HYPERTENS, V9, P109, DOI 10.1097/00004872-199102000-00002; ECHTEN JEKT, 1993, ARCH DIS CHILD, V68, P371, DOI 10.1136/adc.68.3.371; *FAO WHO, 1973, WHO TECHNICAL REPORT, V522; FAO/WHO, 1985, TECHNICAL REPORT SER, V724; FOUQUE D, 1992, BMJ-BRIT MED J, V304, P216, DOI 10.1136/bmj.304.6821.216; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; JUREIDINI KF, 1990, PEDIATR NEPHROL, V4, P1; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levey AS, 1996, AM J KIDNEY DIS, V27, P652, DOI 10.1016/S0272-6386(96)90099-2; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LOCATELLI F, 1992, MINER ELECTROL METAB, V18, P295; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MEHLS O, 1989, NUTR TREATMENT CHRON, P299; MOTOMURA K, 1988, NEPHRON, V49, P144, DOI 10.1159/000185041; Parving HH, 1996, KIDNEY INT, V49, P1778, DOI 10.1038/ki.1996.266; PELAYO JC, 1991, J CLIN INVEST, V88, P101, DOI 10.1172/JCI115264; Perna A, 1996, AM J KIDNEY DIS, V27, P34, DOI 10.1016/S0272-6386(96)90028-1; Prader A, 1989, Helv Paediatr Acta Suppl, V52, P1; ROSMAN JB, 1989, KIDNEY INT, V36, pS96; SALUSKY I, 1981, J LAB CLIN MED, V97, P21; SCHWARTZ GJ, 1992, PEDIATR NEPHROL, V6, P512, DOI 10.1007/BF00866487; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; SIMONS JL, 1994, KIDNEY INT, V46, P396, DOI 10.1038/ki.1994.287; WALKER JD, 1989, LANCET, V2, P1411; WINGEN AM, 1993, CLIN NEPHROL, V40, P208	29	168	176	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1117	1123		10.1016/S0140-6736(96)09260-4	http://dx.doi.org/10.1016/S0140-6736(96)09260-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113009				2023-01-03	WOS:A1997WU54400007
J	Goodnough, LT; Monk, TG; Andriole, GL				Goodnough, LT; Monk, TG; Andriole, GL			Current concepts: Erythropoietin therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AUTOLOGOUS BLOOD DONATION; RADICAL RETROPUBIC PROSTATECTOMY; ACUTE NORMOVOLEMIC HEMODILUTION; ELECTIVE ORTHOPEDIC OPERATION; STAGE RENAL-DISEASE; COST-EFFECTIVENESS; MATHEMATICAL-ANALYSIS; SURGERY PATIENTS; TOTAL HIP		WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANESTHESIA, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT SURG, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Goodnough, LT (corresponding author), WASHINGTON UNIV, SCH MED,DEPT MED,DIV LAB MED,BOX 8118, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.							ADAMSON JW, 1994, SURGERY, V115, P7; ANDRIOLE GL, 1994, J UROLOGY, V152, P1858, DOI 10.1016/S0022-5347(17)32400-X; BAILEY W, 1993, LANCET, V341, P1227; BERIS P, 1993, VOX SANG, V65, P212, DOI 10.1111/j.1423-0410.1993.tb02152.x; BESARAB A, 1992, J AM SOC NEPHROL, V2, P1405; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BRECHER ME, 1994, TRANSFUSION, V34, P176, DOI 10.1046/j.1537-2995.1994.34294143950.x; COHEN JA, 1995, TRANSFUSION, V35, P640, DOI 10.1046/j.1537-2995.1995.35895357894.x; DOOLITTLE RF, 1991, NEW ENGL J MED, V324, P1360, DOI 10.1056/NEJM199105093241910; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; Faris PM, 1996, J BONE JOINT SURG AM, V78A, P62, DOI 10.2106/00004623-199601000-00009; Goldberg M A, 1996, Am J Orthop (Belle Mead NJ), V25, P544; Goodnough L T, 1994, Am J Med Qual, V9, P172, DOI 10.1177/0885713X9400900408; GOODNOUGH LT, 1995, J LAB CLIN MED, V126, P57; GOODNOUGH LT, 1993, TRANSFUSION, V33, P944, DOI 10.1046/j.1537-2995.1993.331194082388.x; GOODNOUGH LT, 1993, SURG GYNECOL OBSTET, V176, P235; GOODNOUGH LT, 1994, TRANSFUSION, V34, P66, DOI 10.1046/j.1537-2995.1994.34194098608.x; GOODNOUGH LT, 1994, UROLOGY, V44, P226; GOODNOUGH LT, 1992, VOX SANG, V63, P90, DOI 10.1111/j.1423-0410.1992.tb02492.x; GOODNOUGH LT, 1992, TRANSFUSION, V32, P441, DOI 10.1046/j.1537-2995.1992.32592327718.x; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GOODNOUGH LT, 1994, AM J CLIN PATHOL, V101, P354; Goodnough LT, 1996, VOX SANG, V71, P133, DOI 10.1046/j.1423-0410.1996.7130133.x; GOODNOUGH LT, 1990, J LAB CLIN MED, V115, P28; GOODNOUGH LT, 1989, TRANSFUSION, V29, P821, DOI 10.1046/j.1537-2995.1989.29990070188.x; GOODNOUGH LT, 1994, J AM COLL SURGEONS, V179, P171; GOODNOUGH LT, 1990, VOX SANG, V59, P65, DOI 10.1111/j.1423-0410.1990.tb05010.x; GOODNOUGH LT, 1994, ANESTH ANALG, V78, P932; *JOINT COUNC AM RE, 1994, CIRC INF US HUM BLOO, P6; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; KRANTZ SB, 1991, BLOOD, V77, P419; MCMAHON FG, 1990, BLOOD, V76, P1718; MERCURIALI F, 1993, TRANSFUSION, V33, P55, DOI 10.1046/j.1537-2995.1993.33193142311.x; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; Monk T. G., 1995, Anesthesia and Analgesia, V80, pS320; MONK TG, 1995, TRANSFUSION, V35, P559, DOI 10.1046/j.1537-2995.1995.35795357877.x; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; Price TH, 1996, TRANSFUSION, V36, P29, DOI 10.1046/j.1537-2995.1996.36196190512.x; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; ROGUS SD, 1990, JAMA-J AM MED ASSOC, V263, P414; Sans T, 1996, TRANSFUSION, V36, P822, DOI 10.1046/j.1537-2995.1996.36996420762.x; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SISK JE, 1991, JAMA-J AM MED ASSOC, V266, P247, DOI 10.1001/jama.266.2.247; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P698, DOI 10.1001/jama.268.6.698; Sowade O, 1997, BLOOD, V89, P411, DOI 10.1182/blood.V89.2.411; TOY PTCY, 1993, TRANSFUSION, V33, P721, DOI 10.1046/j.1537-2995.1993.33994025020.x; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WEISKOPF RB, 1995, TRANSFUSION, V35, P37, DOI 10.1046/j.1537-2995.1995.35195090657.x; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; WINSLOW RM, 1989, TRANSFUSION, V29, P753, DOI 10.1046/j.1537-2995.1989.29990070175.x	56	157	164	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					933	938		10.1056/NEJM199703273361307	http://dx.doi.org/10.1056/NEJM199703273361307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070475				2023-01-03	WOS:A1997WP83200007
J	Katz, J				Katz, J			Prevention of phantom limb pain by regional anaesthesia	LANCET			English	Editorial Material							POSTOPERATIVE PAIN; AMPUTATION; ANALGESIA; NEUROPLASTICITY; SURGERY; BLOCK		TORONTO HOSP,ACUTE PAIN RES UNIT,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT BEHAV SCI,TORONTO,ON,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Katz, J (corresponding author), TORONTO HOSP,DEPT PSYCHOL,TORONTO,ON M5T 2S8,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; Bonn D, 1996, LANCET, V347, P530, DOI 10.1016/S0140-6736(96)91154-X; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Devor M, 1994, TXB PAIN, P79; ELIZAGA AM, 1994, J REHABIL RES DEV, V31, P179; FISHER A, 1991, ANESTH ANALG, V72, P300; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; MALAWER MM, 1991, CLIN ORTHOPAEDICS, V266, P227; Pinzur MS, 1996, J BONE JOINT SURG AM, V78A, P1501, DOI 10.2106/00004623-199610000-00007; SCHUG SA, 1995, REGION ANESTH, V20, P256; Sherman RA, 1997, PHANTOM PAIN	13	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					519	520		10.1016/S0140-6736(97)80081-5	http://dx.doi.org/10.1016/S0140-6736(97)80081-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048786	Green Submitted			2023-01-03	WOS:A1997WJ51200005
J	Vale, L; Silcock, J; Rawles, J				Vale, L; Silcock, J; Rawles, J			An economic evaluation of thrombolysis in a remote rural community	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To assess the cost effectiveness of community thrombolysis relative to hospital thrombolysis by investigating the extra costs and benefits of a policy of community thrombolysis. Design: Economic evaluation based an the results of the Grampian region early anistreplase trial. Setting: 29 rural general practices and one secondary care provider in Grampian, Scotland. Subjects: 311 patients recruited to the Grampian region early anistreplase trial. Interventions: Intravenous anistreplase given either by general practitioners or secondary care clinicians. Main outcome measures: Survival at 4 years and costs of administration of thrombolysis. Results: Relative to hospital thrombolysis, community thrombolysis gives an additional probability of survival at 4 years of 11% (95% confidence Interval 1% to 22%) at an additional cost of f425 per patient. This gives a marginal cost of life saved at 4 years of f3890 (f1990 to f42 820). Conclusions: The cost per life saved by community thrombolysis is modest compared with for example, the cost of changing the thrombolytic drug used in hospital from streptokinase to alteplase.	UNIV ABERDEEN,MED ASSESSMENT RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	Vale, L (corresponding author), UNIV ABERDEEN,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND.		Silcock, Jonathan/AAB-1856-2020	Silcock, Jonathan/0000-0002-4920-9249; Vale, Luke/0000-0001-8574-8429				BARRADELL LB, 1995, PHARMACOECONOMICS, V8, P428, DOI 10.2165/00019053-199508050-00006; *BRIT HEART FDN WO, 1994, BRIT MED J, V308, P767; *FIBR THER TRIAL C, 1994, LANCET, V343, P311; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; Rawles J, 1996, BMJ-BRIT MED J, V312, P212; RAWLES J, 1994, HLTH B, V52, P106	6	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					570	572		10.1136/bmj.314.7080.570	http://dx.doi.org/10.1136/bmj.314.7080.570			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055717	Green Published			2023-01-03	WOS:A1997WK21500026
J	Jessopp, L; Beck, I; Hollins, L; Shipman, C; Reynolds, M; Dale, J				Jessopp, L; Beck, I; Hollins, L; Shipman, C; Reynolds, M; Dale, J			Changing the pattern out of hours: A survey of general practice cooperatives	BRITISH MEDICAL JOURNAL			English	Article							CARE		MAIDDOC,NATL ASSOC GEN PRACTICE COOPERAT,AYLESFORD ME20 7SE,KENT,ENGLAND		Jessopp, L (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,LAMBETH SOUTHWARK & LEWISHAM OUT HOURS PROJECT,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553				Court BV, 1996, BRIT MED J, V312, P1401; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; Hallam L, 1996, BRIT MED J, V312, P1402; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; REYNOLDS M, 1995, GUIDANCE NATL ASS GP, P6	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					199	200		10.1136/bmj.314.7075.199	http://dx.doi.org/10.1136/bmj.314.7075.199			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022438	Green Published			2023-01-03	WOS:A1997WD91100033
J	Eastman, N				Eastman, N			Inquiry into homicides by psychiatric patients: Systematic audit should replace mandatory inquiries	BRITISH MEDICAL JOURNAL			English	Article								Inquiries into homicides committed by psychiatric patients are currently mandatory under Department of Health guidance. They are often broadly defined in their terms of reference and almost always address not only the cause of the incident but also professional skill, practice, and culpability. Concurrent pursuit of both purposes is unlikely to maximise ''learning from experience.'' Also, since inquiries can set their own thresholds for culpability, doctors can potentially be judged to a higher standard than would be required by the General Medical Council or negligence law. Lack of strict legal process increases the inherent potential unfairness to doctors. Investigation of cause and culpability should be separated and inquiries restricted to the former. There should also be a standing secretariat for inquiries to set terms of reference and to collate and distribute findings of inquiries. Widespread mandatory systematic audit of professional practice and service efficiency concerning risk assessment and management should largely replace costly ad hoc mandatory inquiries after homicides.			Eastman, N (corresponding author), ST GEORGE HOSP,SCH MED,SECT FORENS PSYCHIAT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							BLOMCOOPER L, 1993, CURRENT LEGAL PROBLE; CARSON D, 1996, INQUIRIES HOMICIDE; CLOTHIER C, 1996, INQUIRIES HOMICIDE; *DEP HLTH, 1994, HSG9427 NHS DOH; Department of Health and Social Security (DoHSS), 1974, REP COMM INQ CAR SUP; EASTMAN N, 1996, INQUIRIES HOMICIDE; House A, 1996, BRIT MED J, V312, P135; MARTIN J, 1984, HOSP TROUBLE; PEAY J, 1996, INQUIRIES HOMOCIDE; Reder P, 1996, INQUIRIES HOMICIDE; Ritchie J., 1994, REPORT INQUIRY CARE; *ROYAL COLL PSYCH, 1996, REP CONF INQ HOM SUI; Sheppard D, 1995, LEARNING LESSONS MEN; THOROLD O, 1996, INQUIRIES HOMOCIDE; VINESTOCK MD, 1996, ADV PSYCHIAT TREATME, V2, P3	15	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1069	1071						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898603				2023-01-03	WOS:A1996VP74200037
J	Lacasse, Y; Wong, E; Guyatt, GH; King, D; Cook, DJ; Goldstein, RS				Lacasse, Y; Wong, E; Guyatt, GH; King, D; Cook, DJ; Goldstein, RS			Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; QUALITY-OF-LIFE; AIR-FLOW LIMITATION; LUNG-DISEASE; EXERCISE CAPACITY; COPD; DYSPNEA; HOME; INDEXES; PROGRAM	Background Respiratory rehabilitation is increasingly recognised as an important part of the management of patients with chronic obstructive pulmonary disease (COPD), The widespread application of such programmes should be preceded by evidence of directly attributable improvements in function. We assessed the effect of respiratory rehabilitation on exercise capacity and health-related quality of life (HRQL) in patients with COPD. Methods We carried out a meta-analysis of randomised controlled trials of respiratory rehabilitation in patients with COPD that assessed functional or maximal exercise capacity, HRQL, or both. Respiratory rehabilitation was defined as exercise training (for at least 4 weeks) with or without education, psychological support, or both. The most commonly used measure for HRQL was the chronic respiratory questionnaire, in which responses were presented on a 7-point scale. The control groups received no rehabilitation. Within each trial and for each outcome an effect size was calculated; the effect sizes were then pooled by a random-effects model. The overall effect of treatment was compared with its minimum clinically important difference (MCID)-defined as the smallest difference perceived as important by the average patient. Findings We included 14 trials. Significant improvements were found for all the outcomes. For two important features of HRQL, dyspnoea and mastery, the overall treatment effect was larger than the MCID: 1 . 0 (95% CI 0 . 6-1 . 5) and 0 . 8 (0 . 5-1 . 2), respectively, compared with an MCID of 0 . 5. For functional exercise capacity (g-min walk test), the overall effect was 55 . 7 m (27 . 8-92 . 8), and for maximum exercise capacity (incremental cycle ergometer test), 8 . 3 W (2 . 8-16 . 5). Functional exercise capacity showed heterogeneity that could not be explained by the sensitivity analyses. Interpretation Respiratory rehabilitation relieves dyspnoea and improves control over COPD. These improvements are clinically important. The value of the improvement in exercise capacity is not clear. Respiratory rehabilitation is an effective part of care in patients with COPD.	UNIV TORONTO,DEPT MED,DIV RESP MED,W PK HOSP,TORONTO,ON M6M 25J,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA	University of Toronto; McMaster University; McMaster University								Booker H A, 1984, Physiotherapy, V70, P258; BUSCH AJ, 1988, PHYS THER, V68, P469, DOI 10.1093/ptj/68.4.469; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; COCKCROFT A, 1982, THORAX, V37, P413, DOI 10.1136/thx.37.6.413; DONNER CF, 1992, EUR RESPIR J, V5, P266; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GOLDSTEIN RS, 1995, P 5 INT C PULM REH H, P99; Guell R, 1995, EUR RESPIR J, V8, P356; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAESCHKE R, 1994, THORAX, V49, P479, DOI 10.1136/thx.49.5.479; JONES DT, 1985, EUR J RESPIR DIS, V67, P159; Jones NL, 1988, CLIN EXERCISE TESTIN, P123; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; LAKE FR, 1990, CHEST, V97, P1077, DOI 10.1378/chest.97.5.1077; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MCGAVIN CR, 1977, THORAX, V32, P307, DOI 10.1136/thx.32.3.307; MCKAY SE, 1993, THORAX, V48, P227, DOI 10.1136/thx.48.3.227; REARDON J, 1994, CHEST, V105, P1046, DOI 10.1378/chest.105.4.1046; REID WD, 1984, PHYSIOTHER CAN, V36, P305; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMPSON K, 1992, THORAX, V47, P70, DOI 10.1136/thx.47.2.70; Stanton M., 1995, JGIM, V10, P50; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; VALLET G, 1994, REV MAL RESPIR, V11, P493; WEINER P, 1992, CHEST, V102, P1351, DOI 10.1378/chest.102.5.1351; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; WIJKSTRA PJ, 1994, THORAX, V49, P468, DOI 10.1136/thx.49.5.468; 1981, AM REV RESPIR DIS, V124, P663	35	482	506	2	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1115	1119		10.1016/S0140-6736(96)04201-8	http://dx.doi.org/10.1016/S0140-6736(96)04201-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888163				2023-01-03	WOS:A1996VP10600007
J	Donnan, GA; Davis, SM; Chambers, BR; Gates, PC; Hankey, GJ; McNeil, JJ; Rosen, D; StewartWynne, EG; Tuck, RR				Donnan, GA; Davis, SM; Chambers, BR; Gates, PC; Hankey, GJ; McNeil, JJ; Rosen, D; StewartWynne, EG; Tuck, RR			Streptokinase for acute ischemic stroke with relationship to time of administration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; INTRACAROTID UROKINASE; FIBRINOLYTIC THERAPY; CEREBRAL INFARCTION; TERRITORY STROKE; EMBOLIC STROKE; URGENT THERAPY; OCCLUSION; ARTERY	Objectives.-To determine whether the administration of 1.5 million units of streptokinase intravenously within 4 hours of the onset of acute ischemic stroke would reduce morbidity and mortality at 3 months and whether outcomes may be better for those receiving therapy with in 3 hours of stroke onset compared with those receiving it after 3 hours. Design.-Randomized, double-blind, placebo-controlled trial with 3-month follow-up. Participants.-A total of 340 patients, aged 18 to 85 years, with moderate to severe strokes were randomized from 40 centers throughout Australia from June 1992 to November 1994. Intervention.-Administration of 1.5 million units of streptokinase or placebo intravenously in 100 mt of normal saline over 1 hour. Main Outcome Measure.-Combined death and disability score (Barthel index <60) 3 months after the stroke. Results.-Using an intention-to-treat analysis with a combined death and disability score at 3 months after stroke as the primary end point, we found a nonsignificant overall trend toward unfavorable outcomes for streptokinase vs placebo (relative risk [RR] of unfavorable outcome, 1.08; 95% confidence interval [CI], 0.74-1.58) and an excess of hematomas (13.2% [12.6% symptomatic] in the treated group, 3% [2.4% symptomatic] for placebo [P<.01]). However, poor outcomes were confined to patients receiving therapy more than 3 hours after stroke onset (RR of unfavorable outcome, 1.22; 95% CI, 0.80-1.86). In contrast, among the 70 patients who were entered into the trial within 3 hours of stroke onset, there was a trend toward improved outcomes for those who received streptokinase (FIR of unfavorable outcome, 0.66; 95% CI, 0.28-1.58), and this outcome pattern was significantly better than for those receiving therapy after 3 hours (P=.04). Streptokinase administration resulted in excess deaths in the group treated after 3 hours (RR, 1.98; 95% CI, 1.18-3.35), but not among those treated within 3 hours (RR, 1.11; 95% CI, 0.38-3.21). Conclusion.-The administration of streptokinase within 4 hours of acute ischemic stroke increased morbidity and mortality at 3 months. While treatment within 3 hours of stroke was safer and associated with significantly better outcomes than later treatment, it showed no significant benefit over placebo, The timing of thrombolytic therapy for acute stroke is critical.	ROYAL MELBOURNE HOSP, MELBOURNE, VIC, AUSTRALIA; GEELONG HOSP, GEELONG, VIC, AUSTRALIA; ROYAL PERTH HOSP, PERTH, WA, AUSTRALIA; ALFRED HOSP, VICTORIA, BC, CANADA; ROYAL PRINCE ALFRED HOSP, SYDNEY, NSW, AUSTRALIA; WODEN VALLEY HOSP, CANBERRA, ACT, AUSTRALIA	Royal Melbourne Hospital; Geelong Hospital; Royal Perth Hospital; University of Western Australia; University of Sydney; Australian National University; Canberra Hospital	Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR, HEIDELBERG, VIC, AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008; Hankey, Graeme J/H-4968-2014; McNeil, John/L-6440-2019; Simes, Robert John/P-1497-2014; Davis, Stephen M/L-5260-2013	Hankey, Graeme J/0000-0002-6044-7328; McNeil, John/0000-0002-1049-5129; Davis, Stephen M/0000-0003-0962-2300; Donnan, Geoffrey/0000-0001-6324-3403				[Anonymous], 1988, LANCET, V2, P349; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BELL BA, 1985, J NEUROSURG, V62, P31, DOI 10.3171/jns.1985.62.1.0031; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; CANDELISE L, 1995, LANCET, V346, P1509; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; Crowell RM, 1970, STROKE, V1, P439, DOI 10.1161/01.STR.1.6.439; del Zoppo GJ, 1993, THROMBOLYTIC THERAPY, P80; DELZOPPO G, 1993, THROMBOLYTIC THERAPY, V2; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DELZOPPO GJ, 1986, STROKE, V17, P638, DOI 10.1161/01.STR.17.4.638; DONNAN GA, 1995, LANCET, V345, P578; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HAIN RF, 1952, J NEUROPATH EXP NEUR, V11, P34, DOI 10.1097/00005072-195201000-00004; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALLENBECK JM, 1990, ARCH NEUROL-CHICAGO, V47, P1245, DOI 10.1001/archneur.1990.00530110107027; HENZE T, 1987, LANCET, V2, P1391; Hommel M, 1996, NEW ENGL J MED, V335, P145; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; JORGENSEN L, 1969, J NEUROL SCI, V9, P285, DOI 10.1016/0022-510X(69)90078-1; KAMIJYO Y, 1977, J NEUROPATH EXP NEUR, V36, P338, DOI 10.1097/00005072-197703000-00008; LEFTOVITZ J, 1992, AUST NZ J MED, V22, P30; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; SLIVKA A, 1987, STROKE, V18, P1148, DOI 10.1161/01.STR.18.6.1148; VERSTRAETE M, 1986, BLOOD, V67, P1529; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714; ZEUMER H, 1984, NEURORADIOLOGY, V26, P315; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754; ZIVIN JA, 1988, ARCH NEUROL-CHICAGO, V45, P387, DOI 10.1001/archneur.1988.00520280033012	34	315	321	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					961	966		10.1001/jama.276.12.961	http://dx.doi.org/10.1001/jama.276.12.961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805730				2023-01-03	WOS:A1996VH99000036
J	Haynes, RB; McKibbon, KA; Kanani, R				Haynes, RB; McKibbon, KA; Kanani, R			Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications	LANCET			English	Review							SCHIZOPHRENIC-PATIENTS; IMPROVE COMPLIANCE; HYPERTENSION; PUBLICATION; STRATEGIES; MANAGEMENT; DETECT	Background Low adherence of patients to prescribed, self-administered medical interventions is ubiquitous. Low adherence limits the benefits of current medical care. Efforts to assist patients to follow treatments might improve the efficiency of care and substantially enhance benefits. Our objective was to summarise the results of randomised controlled trials (RCTs) of interventions to help patients follow prescriptions for medications. Methods A previous systematic review was updated through computerised searches in Medline, International Pharmaceutical Abstracts, Psychinfo, and HSTAR online databases; bibliographies in articles on patient adherence; articles in the reviewers' personal collections; and contact with authors. Articles were judged of interest if they reported original data concerning an unconfounded RCT of an intervention to improve adherence with prescribed medications, with one or more measure of medication adherence, one or more measure of treatment outcome, at least 80% follow-up of each group studied, and, for longterm treatments, at least 6 months of follow-up for studies with positive initial findings. Information on study design features, interventions and controls, and findings were extracted by one reviewer (RK) and checked by the other two reviewers. Findings 1553 relevant citations and abstracts were screened, 252 full text articles were reviewed in detail, and 13 RCTs met all criteria. The studies were too disparate in clinical problems, adherence interventions, measures and reporting of adherence, and the clinical outcomes studied to warrant meta-analysis. Seven of 15 interventions were associated with improvements in adherence and six interventions led to improvements in treatment outcomes. For short-term treatments, one study showed an effect on adherence and outcome of counselling and written information. The interventions that were effective for long term care were complex, including various combinations of more convenient care, information, counselling, reminders, self-monitoring, reinforcement, family therapy, and other forms of additional supervision or attention. Even the most effective interventions did not lead to substantial improvements in adherence. Interpretation Although adherence and treatment outcomes can be improved by certain-usually complex-interventions, full benefits of medications cannot be realised at currently achievable levels of adherence. It is time that additional efforts be directed towards developing and testing innovative approaches to assist patients to follow treatment prescriptions.			Haynes, RB (corresponding author), MCMASTER UNIV, HLTH SCI CTR, HLTH INFORMAT RES UNIT, 3H7, 1200 MAIN ST W, HAMILTON, ON L8N 3Z5, CANADA.			Haynes, Robert Brian/0000-0002-1453-3196				BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAIRD MG, 1984, CLIN INVEST MED, V7, P95; BASS MJ, 1986, CAN MED ASSOC J, V134, P1247; BECKER LA, 1986, J FAM PRACTICE, V22, P357; COLCHER IS, 1972, J AMER MED ASSOC, V222, P657, DOI 10.1001/jama.222.6.657; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Gordis L, 1979, COMPLIANCE HLTH CARE, P23; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HAYNES RB, 1976, LANCET, V1, P1265; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HAYNES RB, 1982, HYPERTENSION, V4, P415; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; HOWLAND JS, 1990, J FAM PRACTICE, V31, P62; JOHNSON AL, 1978, CAN MED ASSOC J, V119, P1034; LOGAN AG, 1981, HYPERTENSION, V3, P211, DOI 10.1161/01.HYP.3.2.211; LOGAN AG, 1979, LANCET, V2, P1175; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; PETERSON GM, 1984, EPILEPSIA, V25, P412, DOI 10.1111/j.1528-1157.1984.tb03436.x; SACKETT DL, 1975, LANCET, V1, P1205; Sackett DL, 1979, COMPLIANCE HLTH CARE; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; STRANG J S, 1981, Psychopharmacology Bulletin, V17, P87; XIONG W, 1994, BRIT J PSYCHIAT, V165, P239, DOI 10.1192/bjp.165.2.239; ZHANG ML, 1994, BRIT J PSYCHIAT, V165, P96, DOI 10.1192/S0007125000293045	26	468	485	0	36	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1996	348	9024					383	386						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709739				2023-01-03	WOS:A1996VB42600015
J	Tibbles, PM; Edelsberg, JS				Tibbles, PM; Edelsberg, JS			Medical progress - Hyperbaric-oxygen therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARBON-MONOXIDE; NECROTIZING FASCIITIS; AIR-EMBOLISM; RADIATION NECROSIS; SKELETAL-MUSCLE; BRAIN; OSTEOMYELITIS; BIOSYNTHESIS; INHIBITION; TOXICITY				Tibbles, PM (corresponding author), UNIV MASSACHUSETTS, MED CTR, DEPT EMERGENCY MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.							BASKIN SE, 1975, NEW ENGL J MED, V293, P184, DOI 10.1056/NEJM197507242930407; Bernard C., 1857, LECONS EFFETS SUBSTA; BLUMEN IJ, 1992, CRIT CARE CLIN, V8, P597, DOI 10.1016/S0749-0704(18)30243-4; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; Boerema I, 1960, J CARDIOVASC SURG TO, V1, P133; Bowersox J.C., 1986, J HYPERBARIC MED, V1, P141; BRANNEN AL, 1995, UNDERSEA HYPERB ME S, V22, P11; BROWN DR, 1994, AM J SURG, V167, P485, DOI 10.1016/0002-9610(94)90240-2; BROWN OR, 1972, MICROBIOS, V5, P7; BROWN SD, 1990, J APPL PHYSIOL, V68, P604, DOI 10.1152/jappl.1990.68.2.604; Cianci P, 1988, J HYPERBAR MED, V3, P97; CLARK JM, 1971, PHARMACOL REV, V23, P37; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; DAVIS JC, 1986, J BONE JOINT SURG AM, V68A, P1210, DOI 10.2106/00004623-198668080-00010; DEMELLO FJ, 1973, SURGERY, V73, P936; Doctor N, 1992, J Postgrad Med, V38, P112; DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9; *DUK U MED CTR, 1995, DIV AL NETW REP 1993; ESTERHAI JL, 1987, J TRAUMA, V27, P763, DOI 10.1097/00005373-198707000-00013; Euing J, 1926, ACTA RADIOL, V6, P399; Francis TJR, 1993, PHYSL MED DIVING, P454; FYKE FE, 1985, AM J MED, V78, P333; GABB G, 1987, CHEST, V92, P1074, DOI 10.1378/chest.92.6.1074; GOLDBAUM LR, 1975, AVIAT SPACE ENVIR MD, V46, P1289; GOZAL D, 1986, ARCH SURG-CHICAGO, V121, P233; Haapaniemi T, 1996, PLAST RECONSTR SURG, V97, P602, DOI 10.1097/00006534-199603000-00017; HAMMARLUND C, 1994, PLAST RECONSTR SURG, V93, P829, DOI 10.1097/00006534-199404000-00026; HART GB, 1974, SURG GYNECOL OBSTET, V139, P693; HART GB, 1976, CANCER-AM CANCER SOC, V37, P2580, DOI 10.1002/1097-0142(197606)37:6<2580::AID-CNCR2820370603>3.0.CO;2-H; HART GB, 1994, HYPERBARIC MED PRACT, P57; HART GB, 1994, HYPERBARIC MED PRACT, P517; HARWARD TRS, 1985, J VASC SURG, V2, P220, DOI 10.1067/mva.1985.avs0020220; Heimbach RD, 1994, HYPERBARIC MED PRACT, P373; HILL GB, 1972, J INFECT DIS, V125, P17, DOI 10.1093/infdis/125.1.17; HUNT TK, 1988, ANN EMERG MED, V17, P1265, DOI 10.1016/S0196-0644(88)80351-2; HUNT TK, 1972, SURG GYNECOL OBSTETR, V135, P561; JURELL G, 1973, SCAND J PLAST RECONS, V7, P25, DOI 10.3109/02844317309072414; KAYE D, 1967, P SOC EXP BIOL MED, V124, P360; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KINDWALL EP, 1993, CLIN PLAST SURG, V20, P473; KNIGHTON DR, 1981, SURGERY, V90, P262; KNIGHTON DR, 1986, ARCH SURG-CHICAGO, V121, P191; KULONEN E, 1968, ACTA PHYSIOL SCAND, V73, P383, DOI 10.1111/j.1748-1716.1968.tb04116.x; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; Lee H.C., 1987, J HYPERBARIC MED, V2, P75; MADER JT, 1978, J INFECT DIS, V138, P312, DOI 10.1093/infdis/138.3.312; MADER JT, 1980, J INFECT DIS, V142, P915, DOI 10.1093/infdis/142.6.915; MAINOUS EG, 1974, INT J ORAL MAXILLOF, V3, P297, DOI 10.1016/S0300-9785(74)80066-9; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; MARX RE, 1982, J ORAL MAXIL SURG, V40, P412, DOI 10.1016/0278-2391(82)90076-3; MARX RE, 1987, ORAL SURG ORAL MED O, V64, P379, DOI 10.1016/0030-4220(87)90136-8; MARX RE, 1985, J AM DENT ASSOC, V111, P49, DOI 10.14219/jada.archive.1985.0074; Marx RE, 1994, HYPERBARIC MED PRACT, P447; Marx RE, 1988, PROBLEM WOUNDS ROLE, P65; Moon RE, 1993, PHYSL MED DIVING, P506; MURPHY BP, 1985, ANN SURG, V201, P242, DOI 10.1097/00000658-198502000-00019; MUSTOE TA, 1993, CLIN PLAST SURG, V20, P465; *NAT CTR HLTH STAT, 1994, VIT STAT US 1990, V2; NYLANDER G, 1984, BURNS, V10, P193, DOI 10.1016/0305-4179(84)90026-3; Oriani G, 1990, J HYPERB MED, V5, P171; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; PALMQUIST BM, 1984, BRIT J OPHTHALMOL, V68, P113, DOI 10.1136/bjo.68.2.113; PARK MK, 1991, ANTIMICROB AGENTS CH, V35, P691, DOI 10.1128/AAC.35.4.691; PECORARO RE, 1991, DIABETES, V40, P1305, DOI 10.2337/diabetes.40.10.1305; PERRINS DJD, 1967, LANCET, V1, P868; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; RAPHAEL JC, 1989, LANCET, V2, P414; RISEMAN JA, 1990, SURGERY, V108, P847; ROTH RN, 1994, CLIN DERMATOL, V12, P141, DOI 10.1016/0738-081X(94)90265-8; SHULMAN AG, 1967, SURGERY, V62, P1051; SKYHAR MJ, 1986, J BONE JOINT SURG AM, V68A, P1218, DOI 10.2106/00004623-198668080-00011; STRAUSS MB, 1983, J BONE JOINT SURG AM, V65, P656, DOI 10.2106/00004623-198365050-00011; Strauss MB, 1994, HYPERBARIC MED PRACT, P525; TEHRANI MA, 1977, POSTGRAD MED J, V53, P237, DOI 10.1136/pgmj.53.619.237; THOM SR, 1992, J APPL PHYSIOL, V73, P1584, DOI 10.1152/jappl.1992.73.4.1584; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; THOM SR, 1993, TOXICOL APPL PHARM, V123, P234, DOI 10.1006/taap.1993.1242; THOM SR, 1994, TOXICOL APPL PHARM, V128, P105, DOI 10.1006/taap.1994.1186; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; TIBBLES PM, 1994, ANN EMERG MED, V24, P269, DOI 10.1016/S0196-0644(94)70141-5; UHL E, 1994, PLAST RECONSTR SURG, V93, P835, DOI 10.1097/00006534-199404000-00028; *UND HYP MED SOC, 1996, DIR HYP CHAMB US CAN; *UND HYP MED SOC, 1992, HYP OX THER COMM REP; Van UNNIK A. J. M., 1965, ANTONIE LEEUWENHOEK J MICROBIOL SEROL, V31, P181; WATTEL F, 1990, ANGIOLOGY, V41, P59, DOI 10.1177/000331979004100109; Weaver LK, 1995, UNDERSEA HYPERB ME S, V22, P14; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; ZAMBONI W A, 1989, Journal of Reconstructive Microsurgery, V5, P343, DOI 10.1055/s-2007-1006884; ZAMBONI WA, 1993, PLAST RECONSTR SURG, V91, P1110, DOI 10.1097/00006534-199305000-00022	90	618	639	0	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1642	1648		10.1056/NEJM199606203342506	http://dx.doi.org/10.1056/NEJM199606203342506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628361				2023-01-03	WOS:A1996UQ70600006
J	Friedman, EA				Friedman, EA			End-stage renal disease therapy - An American success story	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEMODIALYSIS; ADEQUACY; SURVIVAL				Friedman, EA (corresponding author), SUNY HLTH SCI CTR, DEPT MED, 450 CLARKSON AVE, BROOKLYN, NY 11203 USA.							ALTER MJ, 1991, T AM SOC ART INT ORG, V37, P97; BERLYNE GM, 1982, NEPHRON, V31, P189, DOI 10.1159/000182644; BERNHEIM J, 1995, NEPHROL DIAL TRANSPL, V10, P431, DOI 10.1093/ndt/10.4.431; BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177; CHAZAN JA, 1992, AM J KIDNEY DIS, V19, P523, DOI 10.1016/S0272-6386(12)80829-8; CIESLINSKI DA, 1994, BIOTECHNOL BIOENG, V43, P678, DOI 10.1002/bit.260430718; FRIEDMAN EA, 1994, DEV NEPHROL, V35, P1; FRIEDMAN EA, 1994, NEPHROL DIAL TRANSPL, V9, P242; HAKIM RM, 1992, AM J KIDNEY DIS, V20, P107, DOI 10.1016/S0272-6386(12)80538-5; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; IKEGAMI N, 1995, NEW ENGL J MED, V333, P1295, DOI 10.1056/NEJM199511093331922; KJELLSTRAND CM, 1994, DEV NEPHROL, V35, P55; KJELLSTRAND CM, 1994, CAN MED ASSOC J, V150, P1067; KJELLSTRAND CM, 1988, ACTA MED SCAND, V224, P149; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levin N, 1991, ANNA J, V18, P269; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; LOWRIE EG, 1983, KIDNEY INT, pS113; MAKOWKA L, 1987, ANN SURG, V206, P482, DOI 10.1097/00000658-198710000-00009; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P10; MESSANA A, 1994, AM J KIDNEY DIS, V24, P334, DOI 10.1016/S0272-6386(12)80199-5; NEUMANN M, 1994, NEPHROL NEWS ISSUES, V8, P9; POWE NR, 1994, J AM SOC NEPHROL, V4, P1455; Rettig RA, 1991, KIDNEY FAILURE FEDER; SETALA K, 1978, KIDNEY INT S, V8, pS194; SHALDON S, 1994, DEV NEPHROL, V35, P95; SHALDON S, 1991, NEPHRON, V59, P353, DOI 10.1159/000186591; SHALDON S, 1993, KIDNEY NT S, V41, P5274; TEEHAN BP, 1995, J AM SOC NEPHROL, V6, P139; THOMAS B, 1995, JAMA-J AM MED ASSOC, V274, P276; THOMAS WM, 1995, ROLL CALL       0619, P1; *US REN DAT SYST, 1993, 1993 USRDS NIH NAT I; *US REN DAT SYST, 1995, 1995 USRDS NIH NAT I; WILLIAMSON K, 1965, Hospitals, V39, P39; 1993, NIH CONSENSUS STATE, V11, P1; 1995, DIABETES CARE S1, V18, P8; 1995, NEPHROL DIAL TRAN S5, V10, P1; 1995, ANN INTERN MED, V121, P62	40	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1118	1122		10.1001/jama.275.14.1118	http://dx.doi.org/10.1001/jama.275.14.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601932				2023-01-03	WOS:A1996UD02700029
J	Orentlicher, D				Orentlicher, D			The Supreme Court and physician-assisted suicide - Rejecting assisted suicide but embracing euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TERMINALLY ILL; CANCER		INDIANA UNIV,SCH LAW,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis								Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P206; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; Cherny N I, 1994, J Palliat Care, V10, P31; ENCK RE, 1994, MED CARE TERMINALLY, P166; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; Ramani S, 1996, SOUTH MED J, V89, P1101, DOI 10.1097/00007611-199611000-00017; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311	14	100	100	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1236	1239		10.1056/NEJM199710233371713	http://dx.doi.org/10.1056/NEJM199710233371713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9340517				2023-01-03	WOS:A1997YB71800013
J	Davis, CL				Davis, CL			ABC of palliative care - Breathlessness, cough, and other respiratory problems	BRITISH MEDICAL JOURNAL			English	Article											Davis, CL (corresponding author), COUNTESS MOUNTBATTEN HOUSE,SOUTHAMPTON,HANTS,ENGLAND.								0	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					931	934						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361545				2023-01-03	WOS:A1997YB07300032
J	Ross, D; Rees, M; Godfree, V; Cooper, A; Hart, D; Kingsland, C; Whitehead, M				Ross, D; Rees, M; Godfree, V; Cooper, A; Hart, D; Kingsland, C; Whitehead, M			Randomised crossover comparison of skin irritation with two transdermal oestradiol patches	BRITISH MEDICAL JOURNAL			English	Article							ESTRADIOL		JOHN RADCLIFFE HOSP,MENOPAUSE CLIN,OXFORD OX3 9DU,ENGLAND; AMARANT CTR,LONDON SE1 7PW,ENGLAND; QUEEN CHARLOTTES & CHELSEA HOSP,MENOPAUSE CLIN,LONDON W6 0XG,ENGLAND; STOBHILL GEN HOSP,MENOPAUSE CLIN,GLASGOW G21 3UW,LANARK,SCOTLAND; LIVERPOOL WOMENS HOSP,MENOPAUSE CLIN,LIVERPOOL L8 7SS,MERSEYSIDE,ENGLAND	University of Oxford; Imperial College London; University of Liverpool	Ross, D (corresponding author), UNIV LONDON KINGS COLL HOSP,MENOPAUSE CLIN,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							HILLARD TC, 1994, OSTEOPOROSIS INT, V4, P341, DOI 10.1007/BF01622195; HOWIE H, 1995, MENOPAUSE, V2, P43; PADWICK ML, 1985, AM J OBSTET GYNECOL, V152, P1085, DOI 10.1016/0002-9378(85)90567-8; STEVENSON JC, 1995, BRIT J CLIN PRACT, V49, P87; *TRANSD HRT INV GR, 1993, INT J FERTIL, V38, P5	5	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					288	288		10.1136/bmj.315.7103.288	http://dx.doi.org/10.1136/bmj.315.7103.288			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274549	Green Published			2023-01-03	WOS:A1997XP75000023
J	Rolfs, RT; Joesoef, R; Hendershot, EF; Rompalo, AM; Augenbraun, MH; Chiu, M; Bolan, G; Johnson, SC; French, P; Steen, E; Radolf, JD; Larsen, S				Rolfs, RT; Joesoef, R; Hendershot, EF; Rompalo, AM; Augenbraun, MH; Chiu, M; Bolan, G; Johnson, SC; French, P; Steen, E; Radolf, JD; Larsen, S			A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TREPONEMA-PALLIDUM; CEREBROSPINAL-FLUID; HIV-INFECTION; SECONDARY SYPHILIS; MEMBRANE IMMUNOGEN; PENICILLIN LEVELS; LATENT SYPHILIS; NEUROSYPHILIS; AIDS	Background Reports of neurosyphilis and invasion of cerebrospinal fluid by Treponema pallidum in patients with human immunodeficiency virus (HIV) infection have led to doubts about the adequacy of the recommended penicillin G benzathine therapy for early syphilis. Methods In a multicenter, randomized, double-blind trial, we assessed two treatments for early syphilis: 2.4 million units of penicillin G benzathine and that therapy enhanced with a 10-day course of amoxicillin and probenecid. The serologic and clinical responses of patients with and without HIV infection were studied during one year of follow-up. Results From 1991 through 1994, 541 patients were enrolled, including 101 patients (19 percent) who had HIV infection but differed little from the uninfected patients in their clinical presentations. The rates at which chancres and rashes resolved did not differ significantly according to treatment assignment or HIV status. Serologically defined treatment failures were more common among the HIV-infected patients. The single clinically defined treatment failure was in an HIV-infected patient. Rates of serologically defined treatment failure did not differ according to treatment group (18 percent at six months with usual therapy; 17 percent with enhanced therapy). T. pallidum was found at enrollment in the cerebrospinal fluid of 32 of 131 patients (24 percent) and after therapy in 7 of 35 patients tested. None had clinically evident neurosyphilis, and the rate of detection of T. pallidum did not differ according to HIV status. Conclusions After treatment for primary or secondary syphilis, the HIV-infected patients responded less well serologically than the patients without HIV infection, but clinically defined failure was uncommon in both groups. Enhanced treatment with amoxicillin and probenecid did not improve the outcomes. Although T. pallidum was detected in cerebrospinal fluid before therapy in a quarter of the patients tested, such a finding did not predict treatment failure. The current recommendations for treating early syphilis appear adequate for most patients, whether or not they have HIV infection. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, DIV STD LAB RES, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; BALTIMORE HLTH DEPT, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, MED CTR, BALTIMORE, MD 21218 USA; SUNY HLTH SCI CTR, BROOKLYN, NY 11203 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX USA; SAN FRANCISCO DEPT PUBL HLTH, SAN FRANCISCO, CA USA; WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA; NATL NAVAL MED CTR, PULM DIS SECT, BETHESDA, MD 20889 USA; MED COLL PENN & HAHNEMANN UNIV, PHILADELPHIA, PA USA; PHILADELPHIA DEPT PUBL HLTH, PHILADELPHIA, PA USA	Centers for Disease Control & Prevention - USA; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; San Francisco Department of Public Health; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Walter Reed National Military Medical Center; Drexel University	Rolfs, RT (corresponding author), CTR DIS CONTROL & PREVENT, COMMUN OFF, DIV STD PREVENT, NATL CTR HIV STD & TB PREVENT, MAILSTOP E-06, ATLANTA, GA 30333 USA.							AKINS DR, 1993, INFECT IMMUN, V61, P1202, DOI 10.1128/IAI.61.4.1202-1210.1993; Altman DG, 1991, PRACTICAL STAT MED R; [Anonymous], 1993, MMWR MORB MORTAL WKL, V42, pRR; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; BYRNE TN, 1991, J NEUROL SCI, V103, P48, DOI 10.1016/0022-510X(91)90282-C; CHEMOUILLI P, 1989, REV MED INTERNE, V10, P503; DOWELL ME, 1992, AM J MED, V93, P481, DOI 10.1016/0002-9343(92)90574-U; DUCAS J, 1981, JAMA-J AM MED ASSOC, V246, P2583, DOI 10.1001/jama.246.22.2583; FABER WR, 1983, SEX TRANSM DIS, V10, P148, DOI 10.1097/00007435-198307000-00011; FERARU ER, 1990, NEUROLOGY, V40, P541, DOI 10.1212/WNL.40.3_Part_1.541; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P92, DOI 10.1097/00007435-197707000-00004; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; GOODMAN SN, 1995, ANN INTERN MED, V122, P4781; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; GOUREVITCH MN, 1993, ANN INTERN MED, V118, P350, DOI 10.7326/0003-4819-118-5-199303010-00005; GRAMAN PS, 1987, SEX TRANSM DIS, V14, P205, DOI 10.1097/00007435-198710000-00005; GUINAN ME, 1987, JAMA-J AM MED ASSOC, V257, P359, DOI 10.1001/jama.257.3.359; HIRA SK, 1987, INT J DERMATOL, V26, P103, DOI 10.1111/j.1365-4362.1987.tb00532.x; HOOK EW, 1992, AM J MED, V93, P477, DOI 10.1016/0002-9343(92)90573-T; HSU PL, 1989, INFECT IMMUN, V57, P196, DOI 10.1128/IAI.57.1.196-203.1989; HUTCHINSON CM, 1994, ANN INTERN MED, V121, P94, DOI 10.7326/0003-4819-121-2-199407150-00003; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KASE CS, 1988, ARCH NEUROL-CHICAGO, V45, P832, DOI 10.1001/archneur.1988.00520320018007; KIDD PG, 1989, CLIN IMMUNOL IMMUNOP, V52, P3, DOI 10.1016/0090-1229(89)90187-6; LANDAY AL, 1989, CLIN IMMUNOL IMMUNOP, V52, P48, DOI 10.1016/0090-1229(89)90192-X; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; LARSEN S, 1990, MANUAL TESTS SYPHILI; LITTELL R. C., 1996, SAS SYSTEM MIXED MOD, P87; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MOHR JA, 1976, JAMA-J AM MED ASSOC, V236, P2208, DOI 10.1001/jama.236.19.2208; MORRISON RE, 1985, GENITOURIN MED, V61, P359; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; MUSHER DM, 1988, ANN INTERN MED, V109, P849, DOI 10.7326/0003-4819-109-11-849; POLNIKORN N, 1980, BRIT J VENER DIS, V56, P363; Radolf Justin D., 1993, P224; ROLFS RT, 1995, CLIN INFECT DIS, V20, pS23, DOI 10.1093/clinids/20.Supplement_1.S23; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; SANCHEZ PJ, 1993, J INFECT DIS, V167, P148, DOI 10.1093/infdis/167.1.148; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; TELZAK EE, 1991, AIDS, V5, P591, DOI 10.1097/00002030-199105000-00020; TRAMONT EC, 1976, JAMA-J AM MED ASSOC, V236, P2206, DOI 10.1001/jama.236.19.2206; TRAMONT EC, 1987, NEW ENGL J MED, V316, P1600, DOI 10.1056/NEJM198706183162510; WEIGEL LM, 1992, INFECT IMMUN, V60, P1568, DOI 10.1128/IAI.60.4.1568-1576.1992; Yinnon AM, 1996, ARCH INTERN MED, V156, P321, DOI 10.1001/archinte.156.3.321; YODER FW, 1975, JAMA-J AM MED ASSOC, V232, P270, DOI 10.1001/jama.232.3.270; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZENKER PN, 1990, REV INFECT DIS, V12, pS590; 1988, MMWR-MORBID MORTAL W, V36, P833; 1988, MMWR-MORBID MORTAL W, V37, P600; 1988, MMWR-MORBID MORTAL W, V37, P607; 1988, MMWR-MORBID MORTAL W, V33, P845; 1992, MMWR MORB MORTAL WLD, V41, P1	55	335	353	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					307	314		10.1056/NEJM199707313370504	http://dx.doi.org/10.1056/NEJM199707313370504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9235493	Bronze			2023-01-03	WOS:A1997XN11900004
J	Batavia, AI				Batavia, AI			Disability and physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE				Batavia, AI (corresponding author), MCDERMOTT WILL & EMERY,MIAMI,FL 33131, USA.							Angell M, 1996, NEW ENGL J MED, V335, P1676, DOI 10.1056/NEJM199611283352209; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; BATAVIA AI, 1993, HEALTH AFFAIR, V12, P40, DOI 10.1377/hlthaff.12.1.40; BATAVIA AI, 1990, M HLTH CARE NEEDS PH; BOWE F, 1980, REHABILITATING AM; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; CORBET B, 1997, NEW MOBILITY     APR, P48; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; Gallagher H.G., 1995, TRUST BETRAYED PATIE; NAGLER M, 1993, PERSPECTIVES DISABIL; *NAT COUNC HAND, 1986, THRESH IND; PFLUEGER SS, 1977, INDEPENDENT LIVING; TINDALL B, 1993, J ACQ IMMUN DEF SYND, V6, P1069; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VNADERMAAS PJ, 1996, NEW ENGL J MED, V335, P1699; WEST J, 1991, AM DISABILITES ACT P	16	19	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1671	1673		10.1056/NEJM199706053362310	http://dx.doi.org/10.1056/NEJM199706053362310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC086	9171072				2023-01-03	WOS:A1997XC08600010
J	Ellis, PA; Smith, IE; McCarthy, K; Detre, S; Salter, J; Dowsett, M				Ellis, PA; Smith, IE; McCarthy, K; Detre, S; Salter, J; Dowsett, M			Preoperative chemotherapy induces apoptosis in early breast cancer	LANCET			English	Article									ROYAL MARSDEN HOSP,DEPT ACAD BIOCHEM,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT PATHOL,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,BREAST UNIT,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Ellis, PA (corresponding author), ROYAL MARSDEN HOSP,DEPT MED,LONDON SW3 6JJ,ENGLAND.							HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; SMITH IE, 1995, J CLIN ONCOL, V13, P424, DOI 10.1200/JCO.1995.13.2.424; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025	5	118	125	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					849	849		10.1016/S0140-6736(05)61752-7	http://dx.doi.org/10.1016/S0140-6736(05)61752-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121265				2023-01-03	WOS:A1997WP40300018
J	Marinker, M				Marinker, M			Personal paper: Writing prescriptions is easy	BRITISH MEDICAL JOURNAL			English	Article											Marinker, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,LONDON SE1 7EH,ENGLAND.							HAYNES RB, 1976, LANCET, V1, P1265; HORNE R, 1997, PERCEPTIONS HLTH ILL, P115; MCGAVOCK HA, 1996, REV LIT DRUG ADHEREN; ROVELLI M, 1989, TRANSPLANT P, V21, P833; *ROYAL PHARM SOC G, 1997, COMPL CONC SHAR GOAL; Sackett DL, 1979, COMPLIANCE HLTH CARE	6	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					747	748		10.1136/bmj.314.7082.747	http://dx.doi.org/10.1136/bmj.314.7082.747			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116558	Green Published			2023-01-03	WOS:A1997WM77600036
J	Perry, G; Brown, E; Thornton, R; Shiva, T; Hubbard, J; Reddy, KR; Doherty, JE; Cardello, FP; Fast, A; Radford, MJ; Folger, JS; Bhaskar, G; Zoble, RG; Sridharan, V; Sridharan, MR; Loungani, RR; Gheorghiade, M; Hsieh, A; Tommaso, C; Mansuri, M; Guess, MA; Akhtar, S; Wagner, S; Hagan, K; McIntyre, KM; Ruble, P; Moten, M; Riley, A; Pierpont, G; Anand, I; Patel, G; Puram, BS; Eladasari, BR; Karnegis, J; Gillie, E; Crawford, MH; Graettinger, WF; Shah, A; Sacco, J; Chaudhry, MA; Dolen, D; ElSherif, N; BekheitSaad, S; Campos, EE; Greene, JG; Khanijo, V; Kumar, U; Mallis, GI; Mookherjee, S; DibnerDunlap, M; Gupta, SC; Danisa, K; Thadani, U; Tan, A; Rajachar, M; Amidi, M; OReilly, MV; Hassapoyannes, CA; Davies, ML; Kumar, VA; Okerson, D; Ramanathan, KB; Putatunda, B; Gollapudi, A; Montero, A; Mohanty, PK; Lui, C; Thagirisa, S; Lee, RW; Glatter, TR; Bodine, K; Roberts, D; Bertoglio, M; Dennish, GW; Sarma, RJ; Gregoratos, G; Rausch, DC; Pitt, WA; Kennelly, BM; Fahrenholtz, D; Gordon, R; Horwitz, L; Rothbart, R; Nutting, P; Lutz, L; Copen, DL; Rashkow, A; Babb, J; VanVoorhees, L; Silverman, A; Stillabower, ME; Miller, AB; NguyenPho, HT; Safford, RE; Fishman, S; Neiman, JC; Stein, M; Dominguez, JC; Abernathy, GT; Nair, PH; Goodman, LS; Cook, TH; Wickemeyer, WJ; Berkson, DM; Mathew, J; Richman, HG; Lubell, DL; Lang, R; Zajac, EJ; Rosenstein, R; Silver, MA; Shanes, JG; Kelly, KJ; Pequignot, MH; Campbell, R; Kirlin, PC; Ziperman, DB; Denny, DM; Gamble, L; Weiss, M; Kaimal, PK; Dhurandhar, RW; Ventura, H; Godley, ML; Pu, C; Schick, EC; Barbour, DJ; Salmon, D; Goldstein, M; Effron, MB; Fleg, JL; Baughman, KL; Weiss, R; Ericson, K; Sturrock, WA; Heinsimer, J; Timmis, GC; Smith, S; Shrestha, DD; Duvernoy, WFC; Hickner, J; Lewis, BK; OBrien, TK; Yarows, SA; Willens, HJ; Mast, DJ; Johnson, TH; Rodeheffer, RJ; Siefert, M; Swenson, L; Denes, P; Gudapati, R; Charles, FR; Rich, MW; Beckham, V; Hamilton, WP; Abele, PB; Harper, DM; OKelly, RL; Forker, AD; Kahl, FR; Garrou, BW; Klang, TE; Popio, K; Mohiuddin, S; Pollak, EM; Chiaramida, A; Gregory, JJ; Papa, LA; Abrams, J; Ung, S; Jutila, CK; Croke, RP; Chiaramida, S; Lucariello, R; Rim, DA; Goldberger, MH; Kohn, RM; Graham, S; Philbin, EF; Sheesley, K; Nafziger, A; Macina, G; Hsueh, JT; Zoneraich, S; Binder, A; Weinstein, C; Morrison, J; Cameron, A; Vanderbush, E; Brown, J; Pande, PN; Lader, E; Kay, R; Bloomfield, D; Costantino, T; Heiselman, DE; Radwany, S; Smith, MR; Hobbs, RE; Fraker, TD; Frerking, TR; DeLeon, AC; Christie, LG; Toren, M; Grover, J; McBarron, FD; Harris, DE; McLean, RW; Morris, L; Zatuchni, J; Boehmer, JP; Clemson, BS; Lipshutz, H; Small, RS; Ufret, R; LugoRodriquez, JE; Khan, AH; Yousefian, M; Friesinger, GC; Ely, D; Farmer, JA; Young, JB; Payne, RM; Fowles, RE; Lee, AB; Shalev, Y; AlBitar, I; Schroeder, GS; Radant, L; Hankey, TL; Rezkalla, S; Groden, DL; Teo, KK; Humen, DP; Wong, D; Greenwood, PV; Talibi, T; Hui, W; Klinke, WP; Senaratne, MPJ; Goeres, M; Hughes, DF; Sayeed, MAR; Roth, DL; Belenkie, I; Manyari, DE; Borgersen, K; Read, L; Kinloch, D; Reid, R; Barber, NC; Horner, BA; Kenefick, G; Kuritzky, RA; Imrie, JR; Wagner, KR; Rabkin, SW; Mizgala, HF; Tarry, L; Dodek, A; Kornder, JM; Ashton, T; Barr, D; Dufton, J; Sweeny, R; Morris, A; Bessoudo, R; Marr, D; Milton, JR; Thompson, B; Robinson, V; Sussex, BA; Tobin, M; McMahon, DP; Folkins, D; Crowell, R; Lalonde, LD; Koilpillai, C; Hatheway, RJ; OReilly, MG; Machel, T; Hack, I; Stewart, JW; Tanser, PH; Sullivan, B; Hagar, S; Quinn, B; Davies, RA; Baird, MG; Williams, WL; LeMay, M; Higginson, L; Turek, M; Sochowski, RA; Weeks, A; Jacobs, MH; Baigrie, R; DeVilla, MA; Vertes, G; Bozek, B; Goode, JE; Ricci, AJ; Swan, J; Fell, DA; LevinoffRoth, SN; Arnold, JMO; Patrick, L; Southern, RF; Rinne, C; Brisbin, D; DeYoung, JP; Baitz, T; Vizel, S; Minkowitz, J; Letarte, P; Chan, YK; Kwok, KK; Nawaz, S; Ganjavi, F; Yao, L; Misterski, J; Raco, DL; Hess, AR; Kuruvilla, G; Silverberg, L; Borts, D; Fulop, JC; Weingert, ME; Carter, RP; Sahay, BM; Hickey, JE; Lalonde, G; Gosselin, G; Bourassa, MG; Goulet, C; Joyal, M; Methe, M; Honos, G; Fitchett, D; Serpa, A; Sestier, F; Roberge, G; Latour, Y; Rondeau, C; Gossard, D; Lenis, JHF; Brossoit, R; Simard, L; Delage, F; Auger, P; Saulnier, D; Talbot, P; Beaudoin, J; Campeau, J; Pruneau, G; Tamilia, M; Boutros, G; Comeau, B; Starra, R; StHilaire, R; Veilleux, J; Mercier, M; Poulin, JF; Maclellan, K; Lepage, S; Rouleau, JL; Bruinsma, N; Levesque, C; DeLarochelliere, R; LeBlanc, M; Kouz, S; Kiwan, GS; Laforest, M; Brooks, J; Bouchard, G; Gervais, PB; Brophy, J; Gagnon, J; Habib, N; Basu, AK; Lutterodt, AT; Khouri, M; Gorlin, R; Egan, D; Garg, R; Yusuf, S; Montague, T; Smith, TW; Cohn, JN; Dagenais, GR; Davies, R; Johnstone, DE; Fye, C; Sather, MR; Deykin, D; Francis, G; Collins, JF; Williford, WO; Singh, BN				Perry, G; Brown, E; Thornton, R; Shiva, T; Hubbard, J; Reddy, KR; Doherty, JE; Cardello, FP; Fast, A; Radford, MJ; Folger, JS; Bhaskar, G; Zoble, RG; Sridharan, V; Sridharan, MR; Loungani, RR; Gheorghiade, M; Hsieh, A; Tommaso, C; Mansuri, M; Guess, MA; Akhtar, S; Wagner, S; Hagan, K; McIntyre, KM; Ruble, P; Moten, M; Riley, A; Pierpont, G; Anand, I; Patel, G; Puram, BS; Eladasari, BR; Karnegis, J; Gillie, E; Crawford, MH; Graettinger, WF; Shah, A; Sacco, J; Chaudhry, MA; Dolen, D; ElSherif, N; BekheitSaad, S; Campos, EE; Greene, JG; Khanijo, V; Kumar, U; Mallis, GI; Mookherjee, S; DibnerDunlap, M; Gupta, SC; Danisa, K; Thadani, U; Tan, A; Rajachar, M; Amidi, M; OReilly, MV; Hassapoyannes, CA; Davies, ML; Kumar, VA; Okerson, D; Ramanathan, KB; Putatunda, B; Gollapudi, A; Montero, A; Mohanty, PK; Lui, C; Thagirisa, S; Lee, RW; Glatter, TR; Bodine, K; Roberts, D; Bertoglio, M; Dennish, GW; Sarma, RJ; Gregoratos, G; Rausch, DC; Pitt, WA; Kennelly, BM; Fahrenholtz, D; Gordon, R; Horwitz, L; Rothbart, R; Nutting, P; Lutz, L; Copen, DL; Rashkow, A; Babb, J; VanVoorhees, L; Silverman, A; Stillabower, ME; Miller, AB; NguyenPho, HT; Safford, RE; Fishman, S; Neiman, JC; Stein, M; Dominguez, JC; Abernathy, GT; Nair, PH; Goodman, LS; Cook, TH; Wickemeyer, WJ; Berkson, DM; Mathew, J; Richman, HG; Lubell, DL; Lang, R; Zajac, EJ; Rosenstein, R; Silver, MA; Shanes, JG; Kelly, KJ; Pequignot, MH; Campbell, R; Kirlin, PC; Ziperman, DB; Denny, DM; Gamble, L; Weiss, M; Kaimal, PK; Dhurandhar, RW; Ventura, H; Godley, ML; Pu, C; Schick, EC; Barbour, DJ; Salmon, D; Goldstein, M; Effron, MB; Fleg, JL; Baughman, KL; Weiss, R; Ericson, K; Sturrock, WA; Heinsimer, J; Timmis, GC; Smith, S; Shrestha, DD; Duvernoy, WFC; Hickner, J; Lewis, BK; OBrien, TK; Yarows, SA; Willens, HJ; Mast, DJ; Johnson, TH; Rodeheffer, RJ; Siefert, M; Swenson, L; Denes, P; Gudapati, R; Charles, FR; Rich, MW; Beckham, V; Hamilton, WP; Abele, PB; Harper, DM; OKelly, RL; Forker, AD; Kahl, FR; Garrou, BW; Klang, TE; Popio, K; Mohiuddin, S; Pollak, EM; Chiaramida, A; Gregory, JJ; Papa, LA; Abrams, J; Ung, S; Jutila, CK; Croke, RP; Chiaramida, S; Lucariello, R; Rim, DA; Goldberger, MH; Kohn, RM; Graham, S; Philbin, EF; Sheesley, K; Nafziger, A; Macina, G; Hsueh, JT; Zoneraich, S; Binder, A; Weinstein, C; Morrison, J; Cameron, A; Vanderbush, E; Brown, J; Pande, PN; Lader, E; Kay, R; Bloomfield, D; Costantino, T; Heiselman, DE; Radwany, S; Smith, MR; Hobbs, RE; Fraker, TD; Frerking, TR; DeLeon, AC; Christie, LG; Toren, M; Grover, J; McBarron, FD; Harris, DE; McLean, RW; Morris, L; Zatuchni, J; Boehmer, JP; Clemson, BS; Lipshutz, H; Small, RS; Ufret, R; LugoRodriquez, JE; Khan, AH; Yousefian, M; Friesinger, GC; Ely, D; Farmer, JA; Young, JB; Payne, RM; Fowles, RE; Lee, AB; Shalev, Y; AlBitar, I; Schroeder, GS; Radant, L; Hankey, TL; Rezkalla, S; Groden, DL; Teo, KK; Humen, DP; Wong, D; Greenwood, PV; Talibi, T; Hui, W; Klinke, WP; Senaratne, MPJ; Goeres, M; Hughes, DF; Sayeed, MAR; Roth, DL; Belenkie, I; Manyari, DE; Borgersen, K; Read, L; Kinloch, D; Reid, R; Barber, NC; Horner, BA; Kenefick, G; Kuritzky, RA; Imrie, JR; Wagner, KR; Rabkin, SW; Mizgala, HF; Tarry, L; Dodek, A; Kornder, JM; Ashton, T; Barr, D; Dufton, J; Sweeny, R; Morris, A; Bessoudo, R; Marr, D; Milton, JR; Thompson, B; Robinson, V; Sussex, BA; Tobin, M; McMahon, DP; Folkins, D; Crowell, R; Lalonde, LD; Koilpillai, C; Hatheway, RJ; OReilly, MG; Machel, T; Hack, I; Stewart, JW; Tanser, PH; Sullivan, B; Hagar, S; Quinn, B; Davies, RA; Baird, MG; Williams, WL; LeMay, M; Higginson, L; Turek, M; Sochowski, RA; Weeks, A; Jacobs, MH; Baigrie, R; DeVilla, MA; Vertes, G; Bozek, B; Goode, JE; Ricci, AJ; Swan, J; Fell, DA; LevinoffRoth, SN; Arnold, JMO; Patrick, L; Southern, RF; Rinne, C; Brisbin, D; DeYoung, JP; Baitz, T; Vizel, S; Minkowitz, J; Letarte, P; Chan, YK; Kwok, KK; Nawaz, S; Ganjavi, F; Yao, L; Misterski, J; Raco, DL; Hess, AR; Kuruvilla, G; Silverberg, L; Borts, D; Fulop, JC; Weingert, ME; Carter, RP; Sahay, BM; Hickey, JE; Lalonde, G; Gosselin, G; Bourassa, MG; Goulet, C; Joyal, M; Methe, M; Honos, G; Fitchett, D; Serpa, A; Sestier, F; Roberge, G; Latour, Y; Rondeau, C; Gossard, D; Lenis, JHF; Brossoit, R; Simard, L; Delage, F; Auger, P; Saulnier, D; Talbot, P; Beaudoin, J; Campeau, J; Pruneau, G; Tamilia, M; Boutros, G; Comeau, B; Starra, R; StHilaire, R; Veilleux, J; Mercier, M; Poulin, JF; Maclellan, K; Lepage, S; Rouleau, JL; Bruinsma, N; Levesque, C; DeLarochelliere, R; LeBlanc, M; Kouz, S; Kiwan, GS; Laforest, M; Brooks, J; Bouchard, G; Gervais, PB; Brophy, J; Gagnon, J; Habib, N; Basu, AK; Lutterodt, AT; Khouri, M; Gorlin, R; Egan, D; Garg, R; Yusuf, S; Montague, T; Smith, TW; Cohn, JN; Dagenais, GR; Davies, R; Johnstone, DE; Fye, C; Sather, MR; Deykin, D; Francis, G; Collins, JF; Williford, WO; Singh, BN			The effect of digoxin on mortality and morbidity in patients with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WITHDRAWAL; DIGITALIS; TRIAL	Background The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and hospitalization in a randomized, double-blind clinical trial. Methods In the main trial, patients with left ventricular ejection fractions of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo. Results In the main trial, mortality was unaffected. There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P = 0.80). In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95 percent confidence interval, 0.77 to 1.01; P = 0.06). There were 6 percent fewer hospitalizations overall in that group than in the placebo group, and fewer patients were hospitalized for worsening heart failure (26.8 percent vs. 34.7 percent; risk ratio, 0.72; 95 percent confidence interval, 0.66 to 0.79; P < 0.001). In the ancillary trial, the findings regarding the primary combined outcome of death or hospitalization due to worsening heart failure were consistent with the results of the main trial. Conclusions Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure. These findings define more precisely the role of digoxin in the management of chronic heart failure. (C) 1997, Massachusetts Medical Society.	MT SINAI MED CTR,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai			brophy, james/H-6673-2019; Arnold, Malcolm/G-2869-2011; Rich, Michael/AAD-6167-2022; Effron, Mark B./P-9300-2015; Harper, Diane M./I-2180-2014; Sarma, Radha/AAK-1026-2020	brophy, james/0000-0001-8049-6875; Rich, Michael/0000-0002-4243-9391; Effron, Mark B./0000-0003-4050-5030; Harper, Diane M./0000-0001-7648-883X; 				*DIG INV GROUP, 1996, CONTROLLED CLIN TRIA, V17, P77; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; JELLIFFE RW, 1974, AM J MED, V57, P63, DOI 10.1016/0002-9343(74)90769-4; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; YUSUF S, 1990, CIRCULATION, V82, P673; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3; YUSUF S, 1986, CIRCULATION, V73, P14, DOI 10.1161/01.CIR.73.1.14; YUSUF S, 1990, HEART FAILURE ARRHYT, P147	11	1963	2031	1	72	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					525	533						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9036306				2023-01-03	WOS:A1997WJ24000001
J	Aurigemma, G				Aurigemma, G			Has thrombolytic therapy changed the equation for postinfarction risk stratification?	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION				Aurigemma, G (corresponding author), UNIV MASSACHUSETTS,DIV CARDIOVASC MED,WORCESTER,MA 01655, USA.							Basu S, 1996, BMJ-BRIT MED J, V313, P844; DIAMOND GA, 1993, JAMA-J AM MED ASSOC, V269, P2418, DOI 10.1001/jama.269.18.2418; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; MARX BE, 1995, AM J MED, V98, P550; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; RYAN TJ, REPORT AM COLEGE CAR; SHAW IJ, 1996, AM J CARDIOL, V78, P1327; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					298	299		10.1016/S0140-6736(05)62820-6	http://dx.doi.org/10.1016/S0140-6736(05)62820-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024369				2023-01-03	WOS:A1997WF79400004
J	Ginsburg, ES; Mello, NK; Mendelson, JH; Barbieri, RL; Teoh, SK; Rothman, M; Gao, XY; Sholar, JW				Ginsburg, ES; Mello, NK; Mendelson, JH; Barbieri, RL; Teoh, SK; Rothman, M; Gao, XY; Sholar, JW			Effects of alcohol ingestion on estrogens in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; PITUITARY-GONADAL-HORMONES; BREAST-CANCER; CARDIOVASCULAR-DISEASE; TRANSDERMAL ESTRADIOL; MENOPAUSAL ESTROGENS; LUTEINIZING-HORMONE; RISK; CONSUMPTION; ETHANOL	Objective.-To determine if moderate alcohol drinking increases circulating estradiol levels in postmenopausal women who are taking estrogen replacement. Design.-Randomized, double-blind, placebo-controlled crossover study of the effects of alcohol ingestion on plasma estradiol and estrone. Setting.-Inpatient Clinical Research Center. Participants.-Twelve healthy postmenopausal women receiving oral estrogen (estradiol, 1 mg/day) and progestin (medroxyprogesterone acetate) replacement therapy were compared with 12 postmenopausal women who were not using estrogen replacement therapy (ERT). Intervention.-Each group drank alcohol (0.7 g/kg) and an isoenergetic (isocaloric) placebo (randomized sequence) on consecutive days. Women who were taking ERT were studied during the estrogen-only portion of their replacement cycle, and estrogen was administered each evening at 2100 hours. Main Outcome Measure.-The impact of alcohol ingestion on plasma estradiol and estrone levels. Results.-Alcohol ingestion lead to a 3-fold increase in circulating estradiol in women on ERT; however, alcohol did not change estradiol significantly in control women who were not on ERT. In women using ERT, estradiol levels increased from 297 to 973 pmol/L (81 to 265 pg/ml) within 50 minutes (P<.001) during the ascending limb of the blood alcohol curve and remained significantly above baseline for 5 hours (P<.001). No significant increase in circulating estrone was detected in either group, However, estrone levels decreased after alcohol and placebo in women on ERT (P<.05). Blood alcohol levels did not differ significantly in women who used ERT and those who did not. Peak blood alcohol levels of 21 mmol/L were attained in each of the 2 groups within 50 to 60 minutes after drinking began. Changes in estradiol were significantly correlated with changes in blood alcohol levels on both the ascending (P<.001) and descending (P<.001) limb of the blood alcohol curve. Conclusions.-Acute alcohol ingestion may lead to significant and sustained elevations in circulating estradiol to levels 300% higher than those targeted in clinical use of ERT, Potential health risks and benefits of the interactions between acute alcohol ingestion and ERT should be further evaluated.	MCLEAN HOSP, DRUG & ALCOHOL ABUSE RES CTR, BELMONT, MA 02178 USA	Harvard University; McLean Hospital	Ginsburg, ES (corresponding author), BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000064] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 10040] Funding Source: Medline; NIDA NIH HHS [K05 DA001011, K05 DA0064] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1974, NEW ENGL J MED, V290, P15; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; *BUR CENS, 1995, CURR POP REP P25, V1104; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; CRONHOLM T, 1982, BIOCHIM BIOPHYS ACTA, V711, P159, DOI 10.1016/0005-2760(82)90022-4; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FISHMAN J, 1965, J CLIN ENDOCR METAB, V25, P365, DOI 10.1210/jcem-25-3-365; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GAVALER JS, 1993, ALCOHOL CLIN EXP RES, V17, P786, DOI 10.1111/j.1530-0277.1993.tb00842.x; GAVALER JS, 1987, J STUD ALCOHOL, V48, P295, DOI 10.15288/jsa.1987.48.295; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; GINSBURG ES, 1995, J SOC GYNECOL INVEST, V2, P26, DOI 10.1016/1071-5576(94)00048-6; GINSBURG ES, 1995, FERTIL STERIL, V63, P1227, DOI 10.1016/S0015-0282(16)57602-X; GOLDSTEIN DB, 1992, MED DIAGNOSIS TREATM, P25; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; LONGNECKER MP, 1993, JNCI-J NATL CANCER I, V85, P692, DOI 10.1093/jnci/85.9.692; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARTINS OO, 1982, J STEROID BIOCHEM, V16, P265, DOI 10.1016/0022-4731(82)90174-1; MCNAMEE B, 1979, BRIT J ADDICT, V74, P316; MENDELSON J H, 1984, Alcohol, V1, P417, DOI 10.1016/0741-8329(84)90014-4; MENDELSON JH, 1989, J PHARMACOL EXP THER, V250, P902; MENDELSON JH, 1987, J STUD ALCOHOL, V48, P287, DOI 10.15288/jsa.1987.48.287; MENDELSON JH, 1988, PSYCHOPHARMACOLOGY, V94, P464, DOI 10.1007/BF00212838; MENDELSON JH, 1981, J PHARMACOL EXP THER, V218, P23; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; SELBY PL, 1989, CLIN ENDOCRINOL, V30, P241, DOI 10.1111/j.1365-2265.1989.tb02232.x; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; TEOH SK, 1990, J PHARMACOL EXP THER, V254, P407; Van Thiel D H, 1988, Adv Alcohol Subst Abuse, V7, P131; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; YEN SSC, 1975, J CLIN ENDOCR METAB, V40, P518, DOI 10.1210/jcem-40-3-518; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613	47	169	171	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1747	1751		10.1001/jama.276.21.1747	http://dx.doi.org/10.1001/jama.276.21.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940324				2023-01-03	WOS:A1996VV56600033
J	Clark, CJ				Clark, CJ			Is pulmonary rehabilitation effective for patients with COPD?	LANCET			English	Editorial Material							DISEASE				Clark, CJ (corresponding author), HAIRMYRES HOSP,DEPT RESP MED,GLASGOW G75 8RG,LANARK,SCOTLAND.							CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; CELLI B, 1996, MED CLIN N AM; CLARK CJ, 1994, THORAX, V49, P270, DOI 10.1136/thx.49.3.270; CLARK CJ, 1995, CHRONIC OBSTRUCTIVE; CURTIS JR, 1994, THORAX, V49, P162, DOI 10.1136/thx.49.2.162; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; Maltais F, 1996, AM J RESP CRIT CARE, V154, P442, DOI 10.1164/ajrccm.154.2.8756820; 1995, J CARDIOPULMONARY RE, V15, P394; 1994, AM REV RESPIR DIS, V49, P825	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1111	1112		10.1016/S0140-6736(05)65266-X	http://dx.doi.org/10.1016/S0140-6736(05)65266-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888159				2023-01-03	WOS:A1996VP10600003
J	Langer, R				Langer, R			Controlled release of a therapeutic protein	NATURE MEDICINE			English	Editorial Material							DELIVERY		GENENTECH INC,SAN FRANCISCO,CA 94080	Roche Holding; Genentech	Langer, R (corresponding author), MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02134, USA.							COSTANTINO HR, 1994, J PHARM SCI-US, V83, P1662, DOI 10.1002/jps.2600831205; HAGEMAN MJ, 1992, J AGR FOOD CHEM, V40, P348, DOI 10.1021/jf00014a036; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; LANGER R, 1995, ANN BIOMED ENG, V23, P101, DOI 10.1007/BF02368317; OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; SCHOR AM, 1979, INT J CANCER, V245, P225; Stannett V. T., 1979, RECENT ADV MEMBRANE, P69	10	22	22	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1996	2	7					742	743		10.1038/nm0796-742	http://dx.doi.org/10.1038/nm0796-742			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UU680	8673913				2023-01-03	WOS:A1996UU68000023
J	Weinberger, M; Oddone, EZ; Henderson, WG				Weinberger, M; Oddone, EZ; Henderson, WG			Does increased access to primary care reduce hospital readmissions?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH SURVEY SF-36; MEDICARE POPULATION; RISK-FACTORS; COST	Background. For chronically ill patients, readmission to the hospital can be frequent and costly, We studied the effect of an intervention designed to increase access to primary care after discharge from the hospital, with the goals of reducing readmissions and emergency department visits and increasing patients' quality of life and satisfaction with care. Methods. In a multicenter randomized, controlled trial at nine Veterans Affairs Medical Centers, we randomly assigned 1396 veterans hospitalized with diabetes, chronic obstructive pulmonary disease, or congestive heart failure to receive either usual care or an intensive primary care intervention, The intervention involved close follow-up by a nurse and a primary care physician, beginning before discharge and continuing for the next six months. Results. The patients were severely ill, Half of those with congestive heart failure (504 patients) had disease in New York Heart Association class III or IV; 30 percent of those with diabetes (751 patients) had end-organ damage; and a quarter of those with chronic obstructive pulmonary disease (583 patients) required home oxygen treatment or oral corticosteroids, The patients had extremely poor quality-of-life scores, Although they received more intensive primary care than the controls, the patients in the intervention group had significantly higher rates of readmission (0.19 vs, 0.14 per month, P=0.005) and more days of rehospitalization (10.2 vs, 8.8, P=0.041), The patients in the intervention group were more satisfied with their care (P<0.001), but there was no difference between the study groups in quality-of-life scores, which remained very low (P=0.53). Conclusions. For veterans discharged from Veterans Affairs hospitals, the primary care intervention we studied increased rather than decreased the rate of rehospitalization, although patients in the intervention group were more satisfied with their care. (C) 1996, Massachusetts Medical Society.	VAMC, CTR HLTH SERV RES PRIMARY CARE, DURHAM, NC USA; VAMC, CTR COOPERAT STUDIES HLTH SERV, HINES, IL USA		Weinberger, M (corresponding author), RICHARD L ROUDEBUSH VET ADM MED CTR, 1481 W 10TH ST, INDIANAPOLIS, IN 46202 USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ANDERSON GF, 1985, INQUIRY-J HEALTH CAR, V22, P251; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; DAVIES AR, 1988, HEALTH AFFAIR, V7, P33, DOI 10.1377/hlthaff.7.1.33; EVANS RL, 1993, MED CARE, V31, P358, DOI 10.1097/00005650-199304000-00007; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; HOLLOWAY JJ, 1990, HEALTH SERV RES, V25, P213; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAZIS LE, 1993, 11 ANN HSR D SERV M, P57; LUDKE RL, 1990, HEALTH SERV RES, V25, P501; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; ODDONE EZ, 1993, CLIN RES, V41, pA819; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; SAFRAN C, 1989, MED CARE, V27, P204, DOI 10.1097/00005650-198902000-00010; SMITH DM, 1985, J CHRON DIS, V38, P213, DOI 10.1016/0021-9681(85)90064-5; SMITH DM, 1987, J GEN INTERN MED, V2, P168, DOI 10.1007/BF02596146; SMITH DM, 1988, MED CARE, V26, P699, DOI 10.1097/00005650-198807000-00005; Starfield B., 1992, PRIMARY CARE CONCEPT; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; WAITE K, 1994, J CLIN EPIDEMIOL, V47, P1229, DOI 10.1016/0895-4356(94)90127-9; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; Weinberger M, 1989, QRB Qual Rev Bull, V15, P255; Weinberger M, 1996, J CLIN EPIDEMIOL, V49, P135, DOI 10.1016/0895-4356(95)00556-0; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; ZOOK CJ, 1980, MILBANK FUND Q, V58, P454, DOI 10.2307/3349734; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804; 1995, HLTH CARE FINANC R S, V16, P159; [No title captured]	35	559	562	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1441	1447		10.1056/NEJM199605303342206	http://dx.doi.org/10.1056/NEJM199605303342206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM493	8618584				2023-01-03	WOS:A1996UM49300006
J	Nightingale, SL				Nightingale, SL			Important new safety information for tramadol hydrochloride	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2023-01-03	WOS:A1996UF47800008
J	Rudd, AG; Wolfe, CDA; Tilling, K; Beech, R				Rudd, AG; Wolfe, CDA; Tilling, K; Beech, R			Randomised controlled trial to evaluate early discharge scheme for patients with stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DISCHARGE; CARE; MANAGEMENT; COMMUNITY; SERVICES; COSTS; STAY	Objective: To assess the clinical effectiveness of an early discharge policy for patients with stroke by using a community based rehabilitation team. Design: Randomised controlled trial to compare conventional care with an early discharge policy. Setting Two teaching hospitals in inner London. Subjects: 331 medically stable patients with stroke (mean age 71) who lived alone and were able to transfer independently or who lived with a resident carer and were able to transfer with help. Interventions: 167 patients received specialist community rehabilitation for up to 3 months after randomisation. 164 patients continued with conventional hospital and community care. Main outcome measures: Barthel score at 12 months. Secondary outcomes measured impairment with motoricity index, minimental state examination, and Frenchay aphasia screening test; disability with the Rivermead activity of daily living scales, hospital anxiety and depression scale, and 5 m walk; handicap with the Nottingham health profile; carer stress with caregiver strain index and patient and carer satisfaction. The main process measure was length of stay after randomisation. Results: One year after randomisation no significant differences in clinical outcomes were found apart from increased satisfaction with hospital care in the community therapy group. Length of stay after randomisation in the community therapy group was significantly reduced (12 v 18 days; P < 0.0001). Patients with impairments were more likely to receive treatment in the community therapy group. Conclusions: Early discharge with specialist community rehabilitation after stroke is feasible, as clinically effective as conventional care, and acceptable to patients. Considerable reductions in use of hospital beds are achievable.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, ST THOMAS HOSP, DIV PUBL HLTH SCI, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Rudd, AG (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, ST THOMAS HOSP, ELDERLY CARE UNIT, LONDON SE1 7EH, ENGLAND.		Tilling, Kate/AAY-1578-2021	Wolfe, Charles/0000-0001-8264-0981; Tilling, Kate/0000-0002-1010-8926				Aboderin I, 1996, J INTERN MED, V240, P173, DOI 10.1046/j.1365-2796.1996.39861000.x; ADLER MW, 1974, MED CARE, V12, P541, DOI 10.1097/00005650-197406000-00007; ADLER MW, 1978, J EPIDEMIOL COMMUN H, V32, P136, DOI 10.1136/jech.32.2.136; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Beech R, 1996, STROKE, V27, P1958, DOI 10.1161/01.STR.27.11.1958; BERGMAN L, 1995, STROKE, V26, P1830, DOI 10.1161/01.STR.26.10.1830; BROOTEN D, 1994, OBSTET GYNECOL, V84, P832; Clarke A, 1996, QUAL HEALTH CARE, V5, P172, DOI 10.1136/qshc.5.3.172; FORSTER A, 1992, BRIT MED J, V305, P1446, DOI 10.1136/bmj.305.6867.1446; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; LINDLEY RI, 1995, AGE AGEING, V24, P525, DOI 10.1093/ageing/24.6.525; MARTIN F, 1994, AGE AGEING, V23, P228, DOI 10.1093/ageing/23.3.228; POUND P, 1995, BMJ-BRIT MED J, V311, P18, DOI 10.1136/bmj.311.6996.18; STOJCEVIC N, 1996, STROKE SERVICES RES; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WADE DT, 1986, HOSP UPDATE, P427; WADE DT, 1994, HLTH CARE NEEDS ASSE, V1, P111; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P144, DOI 10.1136/jech.47.2.144; YOUNG J, 1994, BRIT MED J, V309, P1356, DOI 10.1136/bmj.309.6965.1356	23	141	144	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1039	1044		10.1136/bmj.315.7115.1039	http://dx.doi.org/10.1136/bmj.315.7115.1039			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366727	Green Published			2023-01-03	WOS:A1997YD44500015
J	MacCoun, R; Reuter, P				MacCoun, R; Reuter, P			Interpreting Dutch cannabis policy: Reasoning by analogy in the legalization debate	SCIENCE			English	Article							DRUG PROHIBITION	The Dutch depenalization and subsequent de facto legalization of cannabis since 1976 is used here to highlight the strengths and limitations of reasoning by analogy as a guide for projecting the effects of relaxing drug prohibitions. While the Dutch case and other analogies have flaws, they appear to converge in suggesting that reductions in criminal penalties have limited effects on drug use-at least for marijuana-but that commercial access is associated with growth in the drug-using population.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742; UNIV MARYLAND,DEPT CRIMINOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MacCoun, R (corresponding author), UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720, USA.		MacCoun, Robert/N-1765-2019; MacCoun, Robert/D-1702-2011	MacCoun, Robert/0000-0003-0929-4423; 				Brown Jodi M., 1996, CORRECTIONAL POPULAT; COHEN P, 1997, CANNABIS USE AMSTERD; Cohen P., 1996, CANNABIS USE STEPPIN; COHEN P, COMMUNICATION; Cook T.D., 1979, QUASIEXPERIMENTATION; DEZWART WM, 1997, KERNGEGEVENS ROKEN D; DRIESSEN FM, 1989, ALCOHOL DRUGS ANDERE, V15, P2; *DRUG ENF ADM, ILL DRUG WHOL RET PR; DUKE SB, 1993, LONGEST RUNNING WAR; *EUR MON CTR DRUG, 1996, 1995 EUR MON CTR DRU; EVERINGHAM S, UNPUB 1993 NATL HOUS; *GEN ACC OFF, 1997, TGGD977 GAO; Goldstein A., 1994, ADDICTION BIOL DRUG; Hartnoll R., 1994, MULTICITY STUDY DRUG; Jansen A.C.M., 1991, CANNABIS AMSTERDAM G; Johnston LD, 1981, MARIJUANA DECRIMINAL; Johnston LD, 1995, NATL SURVEY RESULTS; KANDEL DB, 1991, MILBANK Q, V69, P365, DOI 10.2307/3350102; Kaplan J., 1970, MARIJUANA NEW PROHIB; KLEBER HD, 1994, NEW ENGL J MED, V330, P361, DOI 10.1056/NEJM199402033300514; Kleiman M, 1992, EXCESS DRUG POLICY R; KORF DJ, 1988, TIJDSCHR ALCOHOL DRU, V14, P81; LANGEMEIJER MPS, IN PRESS ILLICIT DRU; Leuw E, 1994, PROHIBITION LEGALIZA, P23; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MACCOUN R, IN PRESS DRUG WAR LE; MACCOUN RJ, 1993, PSYCHOL BULL, V113, P497, DOI 10.1037/0033-2909.113.3.497; MACCOUN RJ, 1993, J DRUG ISSUES, V23, P615, DOI 10.1177/002204269302300404; MACCOUN RJ, 1993, PSYCHOACTIVE DRUGS H, P103; MACCOUN RJ, 1995, POLICIES STRATEGIES; MEYENFELDT LH, 1996, EUROPEAN DRUG POLICI, P97; *MIN FOR AFF MIN H, 1995, DRUGS POL NETH CONT; *MIN JUST, DUTCH DRUGS POL; MIRON JA, 1995, J ECON PERSPECT, V9, P175, DOI 10.1257/jep.9.4.175; MIRON JA, 1991, AM ECON REV, V81, P242; NADELMANN E, 1989, SCIENCE, V245, P739; *NORW MIN HLTH SOC, 1997, NEW TRENDS DRUG AB N; *OFF NAT DRUG CONT, 1997, NAT DRUG CONTR STRAT; *OFF NAT DRUG CONT, 1993, STAT LOC SPEND DRUG; RHODES W, 1995, WHAT AM USERS SPEND; SANDWIJK JP, 1995, LICIT ILLICIT DRUG U, V2; SANDWIJK JP, 1991, LICIT ILLICIT DRUG U; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; *SUBST AB MENT HLT, 1994, MED EX DAT STAT 1 B, V14; *SUBST AB MENT HLT, NAT HOUS SURV DRUG A; UCHTENHAGEN A, 1997, PROGRAMME MED PRESCR; *UN, 1981, 2 UN SURV CRIME TREN; WILSON JQ, 1991, COMMENTARY, V89, P21; Wisotsky Steven., 1992, SOC SUSPECTS WAR DRU; 1997, MMWR-MORBID MORTAL W, V45, P392	50	91	94	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					47	52		10.1126/science.278.5335.47	http://dx.doi.org/10.1126/science.278.5335.47			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311925				2023-01-03	WOS:A1997XZ12400030
J	Mercer, BM; Miodovnik, M; Thurnau, GR; Goldenberg, RL; Das, AF; Ramsey, RD; Rabello, YA; Meis, PJ; Moawad, AH; Iams, JD; VanDorsten, JP; Paul, RH; Bottoms, SF; Merenstein, G; Thom, EA; Roberts, JM; McNellis, D				Mercer, BM; Miodovnik, M; Thurnau, GR; Goldenberg, RL; Das, AF; Ramsey, RD; Rabello, YA; Meis, PJ; Moawad, AH; Iams, JD; VanDorsten, JP; Paul, RH; Bottoms, SF; Merenstein, G; Thom, EA; Roberts, JM; McNellis, D			Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; ANTIMICROBIAL THERAPY; DOUBLE-BLIND; INTRAAMNIOTIC INFECTION; EXPECTANT MANAGEMENT; CLINICAL-TRIALS; GRAM STAIN; AMNIOCENTESIS; PROPHYLAXIS; AMPICILLIN	Context.-Intrauterine infection is thought to be one cause of preterm premature rupture of the membranes (PPROM). Antibiotic therapy has been shown to prolong pregnancy, but the effect on infant morbidity has been inconsistent. Objective.-To determine if antibiotic treatment during expectant management of PPROM will reduce infant morbidity. Design.-Randomized, double-blind, placebo-controlled trial. Setting.-University hospitals of the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Patients.-A total of 614 of 804 eligible gravidas with PPROM between 24 weeks' and 0 days' and 32 weeks' and 0 days' gestation who were considered candidates for pregnancy prolongation and had not received corticosteroids for fetal maturation or antibiotic treatment within 1 week of randomization. Interventions.-Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days vs a matching placebo regimen, Group B streptococcus (GBS) carriers were identified and treated, Tocolysis and corticosteroids were prohibited after randomization. Main Outcome Measures.-The composite primary outcome included pregnancies complicated by at least one of the following: fetal or infant death, respiratory distress, severe intraventricular hemorrhage, stage 2 or 3 necrotizing enterocolitis, or sepsis within 72 hours of birth, These perinatal morbidities were also evaluated individually and pregnancy prolongation was assessed. Results.-In the total study population, the primary outcome (44.1% vs 52.9%; P=.04), respiratory distress (40.5% vs 48.7%; P=.04), and necrotizing enterocolitis (2.3% vs 5.8%; P=.03) were less frequent with antibiotics. In the GBS-negative cohort, the antibiotic group had less frequent primary outcome (44.5% vs 54.5%; P=.03), respiratory distress (40.8% vs 50.6%; P=.03), overall sepsis (8.4% vs 15.6%; P=.01), pneumonia (2.9% vs 7.0%; P=.04), and other morbidities. Among GBS-negative women, significant pregnancy prolongation was seen with antibiotics (P<.001). Conclusions.-We recommend that women with expectantly managed PPROM remote from term receive antibiotics to reduce infant morbidity.	UNIV CINCINNATI,CINCINNATI,OH 45221; UNIV OKLAHOMA,OKLAHOMA CITY,OK; UNIV ALABAMA,BIRMINGHAM,AL; GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052; UNIV SO CALIF,LOS ANGELES,CA 90089; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; UNIV CHICAGO,CHICAGO,IL 60637; OHIO STATE UNIV,COLUMBUS,OH 43210; MED UNIV S CAROLINA,CHARLESTON,SC 29425; WAYNE STATE UNIV,DETROIT,MI 48202; UNIV COLORADO,DENVER,CO 80202; UNIV PITTSBURGH,PITTSBURGH,PA 15260; NICHHD,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Alabama System; University of Alabama Birmingham; George Washington University; University of Southern California; Wake Forest University; Wake Forest Baptist Medical Center; University of Chicago; University System of Ohio; Ohio State University; Medical University of South Carolina; Wayne State University; University of Colorado System; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mercer, BM (corresponding author), UNIV TENNESSEE,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,853 JEFFERSON AVE,SUITE E102,MEMPHIS,TN 38103, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207	NICHD NIH HHS [U10-HD-21434, U10-HD-27915, U10-HD-27917] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027917, U10HD027915] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021434] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALGER LS, 1988, AM J OBSTET GYNECOL, V159, P397, DOI 10.1016/S0002-9378(88)80093-0; AMON E, 1988, AM J OBSTET GYNECOL, V159, P539, DOI 10.1016/S0002-9378(88)80002-4; Blanco J., 1993, American Journal of Obstetrics and Gynecology, V168, P378; BROEKHUIZEN FF, 1985, OBSTET GYNECOL, V66, P316; CHRISTMAS JT, 1992, OBSTET GYNECOL, V80, P759; *COMM INF DIS COMM, 1992, PEDIATRICS, V90, P775; COTTON DB, 1984, OBSTET GYNECOL, V63, P38; DEBODINANCE P, 1990, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V19, P533; DUNLOP PDM, 1986, J OBSTET GYNAECOL, V7, P92, DOI 10.3109/01443618609112279; ERNEST JM, 1994, AM J OBSTET GYNECOL, V170, P516, DOI 10.1016/S0002-9378(94)70220-9; GARITE TJ, 1982, OBSTET GYNECOL, V59, P539; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GOCHAY DW, 1992, OBSTET GYNECOL, V80, P102; GORDON M, 1974, CONTROVERSY OBSTETRI, V2, P42; HILLIER SL, 1993, OBSTET GYNECOL, V81, P941; JOHNSTON MM, 1990, AM J OBSTET GYNECOL, V163, P743, DOI 10.1016/0002-9378(90)91060-P; KURKI T, 1992, AM J PERINAT, V9, P11, DOI 10.1055/s-2007-994661; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEWIS DF, 1995, OBSTET GYNECOL, V86, P392, DOI 10.1016/0029-7844(95)00181-P; LOCKWOOD CJ, 1993, AM J OBSTET GYNECOL, V169, P970, DOI 10.1016/0002-9378(93)90037-J; MCCAUL JF, 1992, INT J GYNECOL OBSTET, V38, P19, DOI 10.1016/0020-7292(92)90724-W; MCGREGOR J A, 1988, Obstetrical and Gynecological Survey, V43, P1; MCGREGOR JA, 1991, AM J OBSTET GYNECOL, V165, P632, DOI 10.1016/0002-9378(91)90299-7; MEIS PJ, 1987, AM J OBSTET GYNECOL, V156, P1165, DOI 10.1016/0002-9378(87)90133-5; MERCER BM, 1992, AM J OBSTET GYNECOL, V166, P794, DOI 10.1016/0002-9378(92)91336-9; MERCER BM, 1995, LANCET, V346, P1271, DOI 10.1016/S0140-6736(95)91868-X; MORALES WJ, 1989, OBSTET GYNECOL, V73, P721; *NIH, 1995, AM J OBSTET GYNECOL, V173, P246; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OWEN J, 1993, AM J OBSTET GYNECOL, V169, P976, DOI 10.1016/0002-9378(93)90038-K; *PREV EARL ONS GRO, 1996, COMM OP ACOG COMM OB, P1; ROMERO R, 1991, CLIN OBSTET GYNECOL, V34, P769, DOI 10.1097/00003081-199112000-00013; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P114, DOI 10.1016/0002-9378(88)90503-0; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P661, DOI 10.1016/S0002-9378(88)80030-9; Schuchat A., 1996, MMWR RECOMM REP, V45, P1; VINTZILEOS AM, 1986, OBSTET GYNECOL, V67, P579; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7	37	348	377	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					989	995		10.1001/jama.278.12.989	http://dx.doi.org/10.1001/jama.278.12.989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307346				2023-01-03	WOS:A1997XX01200029
J	Darling, GM; Johns, JA; McCloud, PI; Davis, SR				Darling, GM; Johns, JA; McCloud, PI; Davis, SR			Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; HORMONE-REPLACEMENT THERAPY; DENSITY LIPOPROTEIN CHOLESTEROL; RISK-FACTORS; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PLASMA-LIPOPROTEINS; ARTERY DISEASE; LIPIDS; LP(A)	Background Postmenopausal estrogen therapy has favorable effects on serum lipoproteins in women with normal serum lipid levels, but the effect of combined estrogen and progestin therapy on lipoproteins in women with hypercholesterolemia has not been determined, nor has it been directly compared with the effect of conventional lipid-lowering therapy. Methods In a randomized crossover trial, we studied 58 postmenopausal women with fasting serum total cholesterol levels greater than 250 mg per deciliter. Each woman received simvastatin (10 mg dally) for eight weeks and postmenopausal hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily) for eight weeks, with an eight-week washout period between the two treatment phases. Results At base line, the mean (+/-SD) cholesterol values were as follows: total cholesterol, 305+/-39 mg per deciliter; high-density lipoprotein (HDL) cholesterol, 62+/-19 mg per deciliter; and low-density lipoprotein (LDL) cholesterol, 217+/-39 mg per deciliter. For total cholesterol, the mean decrease with hormone therapy was 14 percent (95 percent confidence interval, 11 to 16 percent) and the mean decrease with simvastatin was 26 percent (95 percent confidence interval, 23 to 29 percent). For LDL cholesterol, the mean decrease was 24 percent (95 percent confidence interval, 20 to 28 percent) with hormone therapy and 36 percent (95 percent confidence interval, 32 to 40 percent) with simvastatin. The effect of simvastatin was significantly greater than that of hormone therapy (P<0.001). HDL cholesterol increased similarly with hormone therapy (mean increase, 7 percent; 95 percent confidence interval, 2 to 12 percent) and simvastatin (mean increase, 7 percent; 95 percent confidence interval, 4 to 10 percent). Triglyceride levels increased with hormone therapy (mean increase, 29 percent; 95 percent confidence interval, 15 to 42 percent) but decreased with simvastatin (mean decrease, 14 percent; 95 percent confidence interval, 8 to 20 percent). Lp(a) lipoprotein decreased with hormone therapy (mean decrease, 27 percent; 95 percent confidence interval, 20 to 34 percent), but not with simvastatin. Conclusions In postmenopausal women with hypercholesterolemia, therapy with estrogen plus progestin has beneficial effects on lipoprotein levels. Hormone therapy may be an effective alternative to treatment with simvastatin, especially in women with normal triglyceride levels. (C) 1997, Massachusetts Medical Society.	JEAN HAILES FDN, MELBOURNE, VIC, AUSTRALIA; AUSTIN & REPATRIAT MED CTR, DEPT CARDIOL, MELBOURNE, VIC, AUSTRALIA; MONASH UNIV, DEPT MATH, MELBOURNE, VIC 3004, AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University			Davis, Susan R/A-3111-2009; Davis, Susan D/GZL-2361-2022	Davis, Susan R/0000-0002-2955-0415; 				ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BLOMQVIST N, 1977, J AM STAT ASSOC, V72, P746, DOI 10.2307/2286454; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COLEMAN MP, 1992, ATHEROSCLEROSIS, V92, P177, DOI 10.1016/0021-9150(92)90276-M; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; CUTTER GR, 1976, AM STAT, V30, P194, DOI 10.2307/2683763; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAUBRESSE JC, 1993, AM J CARDIOL, V71, P1408; Davidson M. H., 1996, Journal of the American College of Cardiology, V27, p412A; DEEG R, 1983, CLIN CHEM, V29, P1798; DEMACKER PNM, 1980, CLIN CHEM, V26, P1775; DENKE MA, 1995, AM J MED, V99, P29, DOI 10.1016/S0002-9343(99)80101-6; FARISH E, 1991, BRIT MED J, V303, P694, DOI 10.1136/bmj.303.6804.694; FARISH E, 1989, BRIT J OBSTET GYNAEC, V96, P358, DOI 10.1111/j.1471-0528.1989.tb02398.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRANFONE A, 1992, METABOLISM, V41, P1193, DOI 10.1016/0026-0495(92)90008-X; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JENSEN J, 1990, MATURITAS, V12, P321, DOI 10.1016/0378-5122(90)90012-U; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KIM CJ, 1994, ARTERIOSCLER THROMB, V14, P275, DOI 10.1161/01.ATV.14.2.275; LEUS FR, 1994, CLIN BIOCHEM, V27, P449, DOI 10.1016/0009-9120(94)00052-W; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MENDOZA S, 1994, J LAB CLIN MED, V123, P837; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; PEDERSEN TR, 1994, LANCET, V344, P1383; SACKS FM, 1994, ARCH INTERN MED, V154, P1106, DOI 10.1001/archinte.154.10.1106; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHRAPNEL WS, 1992, MED J AUSTRALIA, V156, pS9; SOMA MR, 1993, ARCH INTERN MED, V153, P1462, DOI 10.1001/archinte.153.12.1462; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; TONSTAD S, 1995, J INTERN MED, V238, P39, DOI 10.1111/j.1365-2796.1995.tb00897.x; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702	40	163	165	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					595	601		10.1056/NEJM199708283370903	http://dx.doi.org/10.1056/NEJM199708283370903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271481				2023-01-03	WOS:A1997XT39400003
J	Lindsay, R; Nieves, J; Formica, C; Henneman, E; Woelfert, L; Shen, V; Dempster, D; Cosman, F				Lindsay, R; Nieves, J; Formica, C; Henneman, E; Woelfert, L; Shen, V; Dempster, D; Cosman, F			Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis	LANCET			English	Article							SODIUM-FLUORIDE; CALCITONIN; RESORPTION; ESTROGEN; THERAPY	Background Small increases in bone mass are commonly seen with existing treatments for osteoporosis, which reduce bone remodelling and primarily prevent bone loss. Since these drugs reduce but do not eliminate risk of fractures, an anabolic agent that would increase bone mass and potentially cure the underlying skeletal problem is needed. Methods We did a 3-year randomised controlled trial to find out the effects of 1-34 human parathyroid hormone (hPTH [1-34], 400 U/25 mu g daily subcutaneously) in postmenopausal women with osteoporosis taking hormone-replacement therapy (n=17). The controls were women taking hormone-replacement therapy only (n=17). The primary outcome was bone-mineral density of the lumbar vertebrae, with bone-mineral density at other sites and vertebral fractures as secondary endpoints. Findings Patients taking hormone-replacement therapy and PTH (1-34) had continuous increase in vertebral bone-mineral density during the 3 years, whereas there was no significant change in the control group. The total increase in vertebral bone-mineral density was 13.0% (p<0.001); 2.7% at the hip (p=0.05); and 8.0% in total-body bone mineral (p=0.002). No loss of bone mass was found at any skeletal site. Increased bone mass was associated with a reduction in the rate of vertebral fractures, which was significant when fractures were taken as a 15% reduction in vertebral height (p=0.04). During the first 6 months of treatment, serum osteocalcin concentration, which reflects bone formation, increased by more than 55%, whereas excretion of crosslinked n-telopeptide, which reflects bone resorption, increased by only 20%, which suggests some uncoupling of bone formation and resorption. By 6 months, there were similar increases in gradually returned towards baseline progressed. Vertebral bone-mineral density increased most during the first year of PTH treatment. Interpretation We found that PTH has a pronouned anabolic effect on the central skeleton in patients on hormone- replacement therapy. PTH also Increases total-body bone mineral, with no detrimental effects at any skeletal site. The increased vertebral mass was associated with a reduced rate of vertebral fracture, despite increased bone turnover. Bone-mass changes may be consistent with a reduction in all osteoporotic fractures. If confirmed in larger studies, these data have important implications for the treatment of postmenopausal osteoporosis.	HELEN HAYES HOSP, REG BONE CTR, W HAVERSTRAW, NY 10993 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT EPIDEMIOL, NEW YORK, NY USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY USA	Columbia University; Columbia University; Columbia University	Lindsay, R (corresponding author), HELEN HAYES HOSP, CLIN RES CTR, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.			Nieves, Jeri/0000-0001-8593-343X	NIAMS NIH HHS [AR39191] Funding Source: Medline; NIDDK NIH HHS [DK42892, DK4631] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COSMAN F, 1994, J CLIN ENDOCR METAB, V78, P939, DOI 10.1210/jc.78.4.939; Cosman F, 1997, J BONE MINER RES, V12, P958, DOI 10.1359/jbmr.1997.12.6.958; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140-6736(93)90570-7; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; Gallagher J. Christopher, 1996, P1191; HOCK JM, 1989, J BONE MINER RES, V4, P449; HODSMAN AB, 1991, BONE MINER, V14, P67, DOI 10.1016/0169-6009(91)90103-7; HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273; JEROME CP, 1995, EFFECT TREATMENT 3 S, V17, P4158; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KLEEREKOPER M, 1984, OSTEOPOROSIS, V1, P103; KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x; Libanati Cesar, 1996, P1259; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Meng XW, 1996, J BONE MINER RES, V11, P421; NEER M, 1993, OSTEOPOROSIS INT, V3, pS204; OVERGAARD K, 1989, CLIN ENDOCRINOL, V30, P435, DOI 10.1111/j.1365-2265.1989.tb00443.x; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; PARISIEN M, 1990, ENDOCRIN METAB CLIN, V19, P19, DOI 10.1016/S0889-8529(18)30337-2; REEVE J, 1990, BRIT MED J, V301, P314, DOI 10.1136/bmj.301.6747.314; Reeve J, 1991, Osteoporos Int, V1, P162, DOI 10.1007/BF01625448; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; Salamone LM, 1996, J BONE MINER RES, V11, P1557, DOI 10.1002/jbmr.5650111024; SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044	27	558	575	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	1997	350	9077					550	555		10.1016/S0140-6736(97)02342-8	http://dx.doi.org/10.1016/S0140-6736(97)02342-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284777	hybrid			2023-01-03	WOS:A1997XT22100010
J	Sessler, DI				Sessler, DI			Mild perioperative hypothermia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHIVERING THRESHOLDS; EPIDURAL-ANESTHESIA; INTRAOPERATIVE HYPOTHERMIA; ISOFLURANE ANESTHESIA; TEMPERATURE-CHANGES; SLIGHTLY INCREASES; SWEATING THRESHOLD; GENERAL-ANESTHESIA; SPINAL-ANESTHESIA; ELDERLY PATIENTS		UNIV VIENNA, DEPT ANESTHESIA & GEN INTENS CARE, OUTCOMES RES LAB, VIENNA, AUSTRIA	University of Vienna	Sessler, DI (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA.		Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHS [GM49670] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNADATA R, 1995, ANESTHESIOLOGY, V83, P1205, DOI 10.1097/00000542-199512000-00011; BREDAHL C, 1991, ACTA ANAESTH SCAND, V35, P548, DOI 10.1111/j.1399-6576.1991.tb03346.x; BRUCK K, 1976, PFLUG ARCH EUR J PHY, V363, P125, DOI 10.1007/BF01062280; BUONO MJ, 1988, J APPL PHYSIOL, V65, P811, DOI 10.1152/jappl.1988.65.2.811; CAPOGNA G, 1993, BRIT J ANAESTH, V71, P294, DOI 10.1093/bja/71.2.294; CARLI F, 1989, BRIT J ANAESTH, V63, P276, DOI 10.1093/bja/63.3.276; CORK RC, 1983, ANESTH ANALG, V62, P211; DAWKINS MJR, 1965, NATURE, V206, P201, DOI 10.1038/206201b0; DERIAZ H, 1992, ANN FR ANESTH, V11, P145, DOI 10.1016/S0750-7658(05)80005-X; DETRY JMR, 1972, J APPL PHYSIOL, V32, P506, DOI 10.1152/jappl.1972.32.4.506; Eilers H, 1996, ANESTHESIOLOGY, V85, P600, DOI 10.1097/00000542-199609000-00020; EMERICK TH, 1994, ANESTHESIOLOGY, V81, P289, DOI 10.1097/00000542-199408000-00005; FLAVAHAN NA, 1991, NEWS PHYSIOL SCI, V6, P251; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; GLOSTEN B, 1992, ANESTHESIOLOGY, V77, P10, DOI 10.1097/00000542-199207000-00003; Guffin A, 1987, J Cardiothorac Anesth, V1, P24, DOI 10.1016/S0888-6296(87)92593-2; GUFFIN A, 1987, J CARDIOTHORAC ANEST, V1, pA501; Hales J.R.S., 1985, CARD SHUNTS A BENZ S, P433; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; HYNSON JM, 1993, ANESTHESIOLOGY, V79, P695; Iaizzo PA, 1996, ANESTH ANALG, V82, P803, DOI 10.1097/00000539-199604000-00022; JESSEN C, 1984, AM J PHYSIOL, V247, pR456, DOI 10.1152/ajpregu.1984.247.3.R456; JUST B, 1992, ANESTHESIOLOGY, V76, P60, DOI 10.1097/00000542-199201000-00009; KURZ A, 1995, ANESTHESIOLOGY, V83, P1212, DOI 10.1097/00000542-199512000-00012; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; KURZ A, 1995, J CLIN ANESTH, V7, P359, DOI 10.1016/0952-8180(95)00028-G; KURZ A, 1995, ANESTHESIOLOGY, V83, P293, DOI 10.1097/00000542-199508000-00009; KURZ A, 1993, ANESTH ANALG, V77, P721; KURZ A, 1993, ANESTH ANALG, V77, P89; KURZ A, 1995, ANESTHESIOLOGY, V83, P491, DOI 10.1097/00000542-199509000-00007; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; LENHARDT R, 1995, ANESTHESIOLOGY, V83, pA1114; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Leslie K, 1996, ANESTHESIOLOGY, V84, P1327, DOI 10.1097/00000542-199606000-00008; LOPEZ M, 1994, ANESTHESIOLOGY, V80, P780, DOI 10.1097/00000542-199404000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARKS LE, 1974, NATURE, V247, P473, DOI 10.1038/247473a0; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; MATSUKAWA T, 1995, ANESTHESIOLOGY, V83, P961, DOI 10.1097/00000542-199511000-00008; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; Plattner O, 1997, ANESTHESIOLOGY, V86, P772, DOI 10.1097/00000542-199704000-00006; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; ROE CF, 1971, AM J SURG, V122, P13, DOI 10.1016/0002-9610(71)90338-2; SATINOFF E, 1978, SCIENCE, V201, P16, DOI 10.1126/science.351802; SCHELLER MS, 1992, J THORAC CARDIOV SUR, V104, P1396; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; SESSLER DI, 1990, ANESTHESIOLOGY, V72, P816, DOI 10.1097/00000542-199005000-00008; SESSLER DI, 1993, ANESTH ANALG, V77, P73; Sessler DI., 1994, ANESTHESIOL CLIN, V12, P425; SHARKEY A, 1987, ANESTHESIOLOGY, V66, P249, DOI 10.1097/00000542-198702000-00029; SHIMOSATO S, 1969, ANESTHESIOLOGY, V30, P619, DOI 10.1097/00000542-196906000-00009; SIMON E, 1974, REV PHYSIOL BIOCH P, V71, P1, DOI 10.1007/BFb0027660; TAKAHASHI H, 1994, CLIN EXP PHARMACOL P, V21, P539, DOI 10.1111/j.1440-1681.1994.tb02553.x; VASSILIEFF N, 1995, ANESTHESIOLOGY, V83, P1162, DOI 10.1097/00000542-199512000-00005; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; WASHINGTON DE, 1993, J APPL PHYSIOL, V74, P82, DOI 10.1152/jappl.1993.74.1.82; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Xiong JY, 1996, ANESTHESIOLOGY, V85, P240, DOI 10.1097/00000542-199608000-00003	61	398	472	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1730	1737		10.1056/NEJM199706123362407	http://dx.doi.org/10.1056/NEJM199706123362407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180091				2023-01-03	WOS:A1997XD54300007
J	Collins, R; Peto, R; Baigent, C; Sleight, P				Collins, R; Peto, R; Baigent, C; Sleight, P			Drug therapy: Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TISSUE-PLASMINOGEN-ACTIVATOR; RANDOMIZED CLINICAL-TRIALS; THROMBOLYTIC THERAPY; ANTITHROMBOTIC THERAPY; CORONARY THROMBOLYSIS; INTRAVENOUS HEPARIN; UNSTABLE ANGINA; PLATELET ACTIVATION; GUSTO TRIAL; STREPTOKINASE		RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, EPIDEMIOL STUDIES UNIT, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; [Anonymous], 1987, Eur Heart J, V8, P634; [Anonymous], 1988, Lancet, V1, P545; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1993, Lancet, V342, P767; *ANT SEC PREV EV C, 1994, MEIJ, V343, P499; Antiplatelet Trialists' Collaboration, 1994, BMJ, V308, P81; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARNOUT J, 1992, J AM COLL CARDIOL, V20, P513, DOI 10.1016/0735-1097(92)90001-4; BAIGENT C, 1993, CIRCULATION, V88, P291; BATES ER, 1991, J AM COLL CARDIOL, V18, P1077, DOI 10.1016/0735-1097(91)90770-A; BERGLUND U, 1991, EUR HEART J, V12, P428, DOI 10.1093/oxfordjournals.eurheartj.a059912; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; CAIRNS JA, 1994, LANCET, V343, P497, DOI 10.1016/S0140-6736(94)91457-5; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COHEN M, 1990, AM J CARDIOL, V66, P1287, DOI 10.1016/0002-9149(90)91155-Y; COL J, 1992, CIRCULATION, V86, P259; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1993, AM J CARDIOL, V71, P1127, DOI 10.1016/0002-9149(93)90591-Y; Collins R, 1996, BMJ-BRIT MED J, V313, P652; COLLINS R, 1996, OXFORD TXB MED, V1, P21; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DEBONO DP, 1992, BRIT HEART J, V67, P122; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; ELLIS S, 1996, AM COLL CARD SCI SES; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD DJ, 1989, CIRC RES, V65, P83, DOI 10.1161/01.RES.65.1.83; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; GRANGER CB, 1994, AM J CARDIOL, V74, P1220, DOI 10.1016/0002-9149(94)90552-5; GRANGER CB, 1992, CIRCULATION, V86, P258; Grines C L, 1991, J Interv Cardiol, V4, P149; GRINES CL, 1991, CIRCULATION, V84, P540, DOI 10.1161/01.CIR.84.2.540; GRINES CL, 1995, BRIT HEART J, V73, P405; GURFINKEL EP, 1995, J AM COLL CARDIOL, V26, P313, DOI 10.1016/0735-1097(95)80001-W; HAMPTON J, 1993, LANCET, V342, P759; HENNEKENS CH, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_D.2; HOLDRIGHT D, 1994, J AM COLL CARDIOL, V24, P39, DOI 10.1016/0735-1097(94)90539-8; HOLMES DR, 1995, J AM COLL CARDIOL, V25, pS10; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; HUNT D, 1992, LANCET, V339, P753; *INT JOINT EFF COM, 1995, LANCET, V346, P980; *INT JOINT EFF COM, 1995, LANCET, V346, P329; KERINS DM, 1989, CIRCULATION, V80, P1718, DOI 10.1161/01.CIR.80.6.1718; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LANGE RA, 1993, NEW ENGL J MED, V328, P726, DOI 10.1056/NEJM199303113281010; Leizorovicz A, 1996, BRIT MED J, V312, P215; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; Mahaffey KW, 1996, AM J CARDIOL, V77, P551, DOI 10.1016/S0002-9149(97)89305-8; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MARK DB, 1995, NEW ENGL J MED, V333, P267; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; NEUHAUS KL, 1994, CIRCULATION, V90, P1638, DOI 10.1161/01.CIR.90.4.1638; OCONNOR CM, 1994, J AM COLL CARDIOL, V23, P11, DOI 10.1016/0735-1097(94)90496-0; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRINS MH, 1991, AM J CARDIOL, V67, pA3; REILLY IAG, 1987, BLOOD, V69, P180; RIDKER PM, 1993, LANCET, V341, P1574, DOI 10.1016/0140-6736(93)90707-N; ROBERTS R, 1991, CLIN CHALLENGES ACUT, V1, P1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROSS AM, 1994, J MYOCARDIAL ISCHEMI, V6, P11; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SCHEIDT S, 1991, CVR R            SEP, P37; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Sleight Peter, 1995, Am J Ther, V2, P128, DOI 10.1097/00045391-199502000-00009; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SOBEL BE, 1992, AM J CARDIOL, V70, P385, DOI 10.1016/0002-9149(92)90624-8; SOBEL BE, 1991, AM J CARDIOL, V68, P382, DOI 10.1016/0002-9149(91)90836-A; Speizer, 1976, NATURAL HIST CHRONIC, P218; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TIEFENBRUNN AJ, 1991, FIBRINOLYSIS, V5, P1, DOI 10.1016/0268-9499(91)90073-D; TOPOL E, 1994, CIRCULATION, V90, P1631; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1995, EUR HEART J, V16, P1024; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; Wallentin L, 1996, LANCET, V347, P561; WALLENTIN L, 1990, LANCET, V336, P827; WARREN KS, 1993, ANN NY ACAD SCI, V703, P1, DOI 10.1111/j.1749-6632.1993.tb26327.x; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WILCOX RG, 1988, LANCET, V2, P525; Woods KL, 1996, LANCET, V347, P1203, DOI 10.1016/S0140-6736(96)90732-1; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	102	235	241	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					847	860		10.1056/NEJM199703203361207	http://dx.doi.org/10.1056/NEJM199703203361207			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062095				2023-01-03	WOS:A1997WN37100007
J	Drickamer, MA; Lee, MA; Ganzini, L				Drickamer, MA; Lee, MA; Ganzini, L			Practical issues in physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LIFE-SUSTAINING THERAPY; ILL HOSPITALIZED ADULTS; TERMINALLY ILL; EUTHANASIA; DEPRESSION; DEATH; PREFERENCES; ATTITUDES; DESIRE	Support for the participation of physicians in the suicides of terminally ill patients is increasing, and the concrete effects on physician practice of a policy change with regard to physician-assisted suicide must be carefully considered. If physician-assisted suicide is legalized, physicians will need to gain expertise in understanding patients' motivations for requesting physician-assisted suicide, assessing mental status, diagnosing and treating depression, maximizing palliative interventions, and evaluating the external pressures on the patient. They will be asked to prognosticate not only about life expectancy but also about the onset of functional and cognitive decline. They will need access to reliable information about effective medications and dosages. The physician's position on physician-assisted suicide must be open to discussion between practitioner and patient. Protection of the patient's right to confidentiality must be balanced against the need of health care professionals and institutions to know about the patient's choice. Insurance coverage and managed care options may be affected. All of these issues need to be further explored through research, education, decision making by individual practitioners, and ongoing societal debate.	PORTLAND VET AFFAIRS MED CTR, PORTLAND, OR 97207 USA; YALE UNIV, SCH MED, NEW HAVEN, CT USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; VA Portland Health Care System; Yale University; Oregon Health & Science University	Drickamer, MA (corresponding author), W HAVEN VET AFFAIRS MED CTR, 111C, 950 CAMPBELL AVE, W HAVEN, CT 06516 USA.							*AM NURS ASS, 1994, POS STAT ASS SUIC; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; *COUNC ETH JUD AFF, 1994, COD MED ETH REP COUN, P274; EMANUEL EJ, 1995, J CLIN ETHIC, V6, P158; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; *HAST CTR, 1987, GUID TERM LIF SUST T; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEE M, 1994, J GERONTOL, V49, pM15, DOI 10.1093/geronj/49.1.M15; LEE MA, 1992, J AM GERIATR SOC, V40, P983, DOI 10.1111/j.1532-5415.1992.tb04473.x; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lipowski Z.J, 1990, DELIRIUM ACUTE CONFU; LYNN J, 1995, WESTERN J MED, V163, P250; MCDANIEL JS, 1993, CURRENT EMERGING ISS; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Owen C., 1992, PSYCHO-ONCOLOGY, V1, P79, DOI [10.1002/pon.2960010205, DOI 10.1002/PON.2960010205]; PHAIR JP, 1994, AIDS RES HUM RETROV, V10, P883, DOI 10.1089/aid.1994.10.883; POPKIN MK, 1985, ARCH GEN PSYCHIAT, V42, P1160; *PUBL HLTH SERV CT, 1993, HLTH US 1993; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; ROHDE K, 1995, J AM GERIATR SOC, V43, P187, DOI 10.1111/j.1532-5415.1995.tb06388.x; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDONGEN CJ, 1991, J FAM PRACTICE, V33, P375; 1995, J AM GERIATR SOC, V43, P579	37	35	35	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					146	151		10.7326/0003-4819-126-2-199701150-00009	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WD298	9005749				2023-01-03	WOS:A1997WD29800010
J	Haynes, BF				Haynes, BF			New frontiers of immunotherapy for HIV	LANCET			English	Editorial Material											Haynes, BF (corresponding author), DUKE UNIV,MED CTR,DUKE CTR AIDS RES,DURHAM,NC 27710, USA.							Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Moss RB, 1996, J CLIN IMMUNOL, V16, P266, DOI 10.1007/BF01541391; PELLETIER E, 1996, J NIH RES, V8, P45; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1531	1532		10.1016/S0140-6736(05)66165-X	http://dx.doi.org/10.1016/S0140-6736(05)66165-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950876				2023-01-03	WOS:A1996VX02300004
J	Bosch, JLHR; Groen, J				Bosch, JLHR; Groen, J			Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients	LANCET			English	Article							ELECTRICAL-STIMULATION; BLADDER	Background Urge urinary incontinence in multiple sclerosis patients is usually due to detrusor hyperreflexia. Patients who do not respond to conservative measures such as anticholinergics, with or without clean intermittent catheterisation, are difficult to manage. Methods We applied electrical stimulation to the S3 sacral spinal nerves with the aim of activating afferent somatic nerve fibres. Stimulation of these fibres can inhibit the micturition reflex. An S3 electrode coupled to a subcutaneously placed pulse generator was implanted in four women who had shown a good response during temporary stimulation via a percutaneously placed wire electrode. All patients were followed for at least 2 years. Findings The number of leakage episodes decreased from a mean of 4 to 0.3 per 24 h. Two patients were completely dry. The hyperreflexia disappeared in one, improved in two, and got worse in one patient. The urodynamic result in the last patient may be explained by clinical progression of the multiple sclerosis. Interpretation Chronic stimulation of the S3 sacral spinal nerve by an implantable neuroprosthesis is a promising treatment option for selected multiple sclerosis patients with refractory urge incontinence.	ERASMUS UNIV ROTTERDAM,DEPT UROL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Bosch, JLHR (corresponding author), ACAD ZIEKENHUIS ROTTERDAM DIJKZIGT,DEPT UROL,H-1073,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							ABRAMS P, 1991, CLIN NEUROUROLOGY, P651; *AG HLTH CAR POL R, 1992, 920038 AG HLTH CAR P, P38; BETTS CD, 1993, J NEUROL NEUROSUR PS, V56, P245, DOI 10.1136/jnnp.56.3.245; BOSCH JLHR, 1995, J UROLOGY, V154, P504, DOI 10.1016/S0022-5347(01)67086-1; DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R; FALL M, 1991, UROL CLIN N AM, V18, P393; FOWLER CJ, 1994, J NEUROL NEUROSUR PS, V57, P169, DOI 10.1136/jnnp.57.2.169; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lindstrom S, 1989, NEUROUROL URODYNAM, V8, P392; MUNDY AR, 1985, UROL CLIN N AM, V12, P317; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHMIDT RA, 1990, UROLOGY, V35, P388, DOI 10.1016/0090-4295(90)80078-2; VODUSEK DB, 1986, NEUROUROL URODYNAM, V5, P381, DOI 10.1002/nau.1930050404; VODUSEK DB, 1988, NEUROUROL URODYNAM, V6, P389	14	71	75	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					717	719		10.1016/S0140-6736(96)04437-6	http://dx.doi.org/10.1016/S0140-6736(96)04437-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806291	Green Submitted			2023-01-03	WOS:A1996VG37400011
J	Brough, RJ; OFlynn, K				Brough, RJ; OFlynn, K			Lesson of the week - Recurrent pelvic endometriosis and bilateral ureteric obstruction associated with hormone replacement therapy	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; UROPATHY				Brough, RJ (corresponding author), MANCHESTER ROYAL INFIRM,DEPT UROL,MANCHESTER M13 9WL,LANCS,ENGLAND.							BALL TL, 1963, AM J OBSTET GYNECOL, V84, P1516; BARBIERI RL, 1990, AM J OBSTET GYNECOL, V162, P565, DOI 10.1016/0002-9378(90)90430-F; Dick A L, 1973, Br J Urol, V45, P153, DOI 10.1111/j.1464-410X.1973.tb12132.x; KANE C, 1985, AM J OBSTET GYNECOL, V151, P207, DOI 10.1016/0002-9378(85)90013-4; LAM AM, 1992, AUST NZ J OBSTET GYN, V32, P83, DOI 10.1111/j.1479-828X.1992.tb01910.x; LANGMADE CF, 1975, AM J OBSTET GYNECOL, V122, P463, DOI 10.1016/S0002-9378(16)33538-4; MANYONDA IT, 1989, EUR J OBSTET GYN R B, V31, P195, DOI 10.1016/0028-2243(89)90182-2; MOORE JG, 1979, AM J OBSTET GYNECOL, V134, P162, DOI 10.1016/0002-9378(79)90881-0; RIVLIN ME, 1985, FERTIL STERIL, V44, P274; WHEELER JM, 1983, AM J OBSTET GYNECOL, V146, P247, DOI 10.1016/0002-9378(83)90744-5	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1221	1222						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634571				2023-01-03	WOS:A1996UL05800028
J	Blackstone, MO				Blackstone, MO			Hospital admission for low-risk acute upper gastrointestinal bleeding	LANCET			English	Editorial Material							HEMORRHAGE				Blackstone, MO (corresponding author), UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637, USA.							GRIFFITHS WJ, 1979, NEW ENGL J MED, V300, P1411, DOI 10.1056/NEJM197906213002503; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; WARA P, 1985, GASTROENTEROLOGY, V88, P1209, DOI 10.1016/S0016-5085(85)80081-0; ZIMMERMAN J, 1995, SCAND J GASTROENTERO, V30, P327, DOI 10.3109/00365529509093285	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1130	1130		10.1016/S0140-6736(96)90602-9	http://dx.doi.org/10.1016/S0140-6736(96)90602-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609742				2023-01-03	WOS:A1996UG75500004
